data_1pjw_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1pjw _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.539 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 74.1 mtp . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.204 0.526 . . . . 50.0 110.263 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.76 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 8.6 p -149.01 108.06 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.608 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.583 ' HB ' HG22 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -161.57 41.96 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.611 -1.305 . . . . 99.989999999999995 110.678 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.7 tm-20 -70.03 -3.78 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.122 -0.986 . . . . 99.989999999999995 110.075 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.535 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -79.71 62.45 3.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.315 -0.866 . . . . 50.0 110.206 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.585 ' CD2' HG11 ' A' ' 94' ' ' VAL . 0.3 OUTLIER -102.64 140.87 36.34 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.188 -0.945 . . . . 50.0 110.431 -179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.647 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.4 t -125.53 119.69 28.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 50.0 109.81 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -73.62 108.41 6.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.125 -0.985 . . . . 50.0 110.298 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -94.87 -33.49 12.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 50.0 109.916 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.474 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 17.3 mtmt -144.78 150.29 36.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.288 -0.882 . . . . 50.0 110.202 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.467 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 11.2 m-20 -69.23 165.15 42.0 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.291 -0.881 . . . . 50.0 110.107 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD2' ' HB3' ' A' ' 22' ' ' ASN . 45.1 Cg_endo -72.84 122.53 8.24 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.946 1.498 . . . . 50.0 110.31 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.37 141.71 51.28 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.905 . . . . 50.0 110.287 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 30' ' ' THR . 2.7 p30 -81.89 131.65 35.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 50.0 110.312 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.501 HG22 ' CG2' ' A' ' 32' ' ' VAL . 1.2 p -123.54 52.46 1.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.312 -0.868 . . . . 50.0 110.137 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.57 -129.2 2.85 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.435 -1.466 . . . . 50.0 109.435 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -116.54 95.79 5.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.206 -1.173 . . . . 50.0 110.243 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.58 23.04 63.27 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -117.87 107.71 14.43 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -1.16 . . . . 50.0 110.219 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.448 HG21 ' HD2' ' A' ' 85' ' ' PRO . 11.8 t -103.58 137.3 32.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.307 -0.87 . . . . 50.0 110.208 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.501 ' CG2' HG22 ' A' ' 26' ' ' THR . 0.7 OUTLIER -110.82 136.46 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.224 -0.923 . . . . 50.0 110.294 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.536 HG22 ' CD1' ' A' ' 35' ' ' LEU . 12.7 tt -130.62 144.49 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.413 -0.805 . . . . 50.0 109.68 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.441 ' O ' ' HB2' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -122.62 105.26 9.94 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.982 . . . . 50.0 110.639 -179.495 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.647 ' HA ' ' O ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -123.12 141.63 51.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.238 -0.914 . . . . 50.0 109.511 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 78' ' ' LYS . 0.7 OUTLIER -90.74 128.93 36.84 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.102 -0.999 . . . . 50.0 109.855 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.535 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 11.4 t80 -91.44 98.58 11.77 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 118.935 -1.106 . . . . 50.0 109.679 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.77 69.6 8.69 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.291 -0.881 . . . . 50.0 109.711 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.499 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -124.24 119.85 3.87 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.634 -1.386 . . . . 99.989999999999995 109.634 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.1 m -86.22 20.04 2.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.327 -1.101 . . . . 99.989999999999995 110.278 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -97.47 -0.85 45.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 99.989999999999995 110.105 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.71 -158.3 26.05 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.411 -1.475 . . . . 99.989999999999995 109.411 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.529 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -73.06 151.32 49.75 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.959 1.505 . . . . 99.989999999999995 110.222 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.76 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -170.23 161.48 8.34 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -0.907 . . . . 50.0 109.784 -179.402 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.583 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 5.0 mmtt -79.48 114.39 18.37 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.979 -1.076 . . . . 50.0 110.125 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.583 HG22 ' HB ' ' A' ' 14' ' ' THR . 2.6 mt -75.06 113.58 26.42 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 50.0 110.194 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.497 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 46.5 Cg_endo -74.13 88.79 1.08 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 124.043 1.549 . . . . 50.0 110.013 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.573 ' CD1' HG21 ' A' ' 46' ' ' ILE . 79.4 mt -125.54 151.79 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 50.0 110.741 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.508 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 32.4 m -133.12 137.29 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.499 -0.751 . . . . 50.0 109.337 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -116.48 108.81 16.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.003 -1.061 . . . . 50.0 110.313 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 91' ' ' TYR . 14.8 m -131.58 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 50.0 110.113 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.48 163.6 1.7 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.31 -0.869 . . . . 50.0 110.184 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.665 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -62.85 120.46 11.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -0.887 . . . . 50.0 110.545 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.665 ' CB ' ' O ' ' A' ' 53' ' ' SER . 3.8 tp 81.47 29.96 0.15 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.582 -0.699 . . . . 50.0 110.725 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.518 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 64.6 m-80 -137.38 84.75 2.08 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 50.0 110.101 179.247 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -105.36 11.13 33.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 50.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.4 tpt -109.04 -14.15 14.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 50.0 110.211 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.3 p -136.04 142.84 41.71 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.289 -0.882 . . . . 50.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.457 ' O ' HG22 ' A' ' 60' ' ' VAL . 46.1 Cg_endo -72.68 137.2 27.01 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.006 1.53 . . . . 50.0 110.321 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.492 ' CG1' ' HG3' ' A' ' 86' ' ' PRO . 4.0 t -143.89 -49.08 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.305 -0.872 . . . . 50.0 110.079 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -86.29 147.22 21.43 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.085 -1.606 . . . . 50.0 109.085 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.448 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 10.1 mtp180 -138.66 156.38 47.48 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.057 -1.261 . . . . 50.0 110.686 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.505 ' HA ' ' HG2' ' A' ' 83' ' ' MET . 5.0 mp -91.91 109.62 20.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.32 -0.863 . . . . 50.0 110.051 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.545 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 77.9 t -55.93 -42.89 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.218 -0.926 . . . . 50.0 110.51 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.48 ' OG1' ' HB2' ' A' ' 82' ' ' GLU . 1.4 m -73.76 169.49 17.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.162 -0.961 . . . . 50.0 110.173 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 23.3 t -44.65 170.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.236 -0.915 . . . . 50.0 110.114 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.646 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . 60.7 m-80 -47.08 157.7 0.48 Allowed Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.243 -0.91 . . . . 50.0 109.979 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.525 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 45.4 Cg_endo -73.32 66.36 4.42 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 123.955 1.503 . . . . 50.0 110.58 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE2' ' CB ' ' A' ' 67' ' ' ASN . 16.7 m-30 -120.8 121.7 38.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 50.0 109.878 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.532 HG22 ' CG1' ' A' ' 46' ' ' ILE . 80.8 t -79.91 60.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 50.0 110.096 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.529 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -83.31 61.6 6.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.082 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.453 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -142.65 164.41 30.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.253 -0.905 . . . . 50.0 110.335 -179.758 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 p -94.08 -10.79 32.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 50.0 109.874 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 67.4 m -120.95 18.24 11.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -0.872 . . . . 99.989999999999995 110.253 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.523 ' CB ' HG11 ' A' ' 70' ' ' VAL . . . -81.98 11.44 5.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.136 -0.977 . . . . 99.989999999999995 110.073 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.1 m-20 -85.22 15.06 4.51 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.253 -0.904 . . . . 99.989999999999995 109.337 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 36' ' ' SER . 9.3 p -124.27 -171.98 2.45 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.464 -0.773 . . . . 99.989999999999995 109.574 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 11.8 pttt -62.87 88.86 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.559 -0.856 . . . . 99.989999999999995 109.115 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.534 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 22.2 m -76.52 174.42 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.41 -0.806 . . . . 99.989999999999995 109.651 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.461 HD21 ' O ' ' A' ' 33' ' ' ILE . 1.6 tt -138.8 120.39 15.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.977 -1.077 . . . . 50.0 110.942 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.402 ' N ' HD21 ' A' ' 80' ' ' LEU . 2.0 t -116.91 172.69 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 50.0 109.9 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.545 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 83.7 mt-10 -120.69 154.75 35.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.142 -0.974 . . . . 50.0 110.339 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.505 ' HG2' ' HA ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -146.14 140.39 26.64 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.332 -0.855 . . . . 50.0 110.027 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.434 ' HG2' HG21 ' A' ' 64' ' ' VAL . 0.4 OUTLIER -113.43 62.87 0.92 Allowed Pre-proline 0 C--N 1.306 -1.315 0 O-C-N 121.258 -0.901 . . . . 50.0 110.712 -179.864 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.494 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.4 Cg_endo -72.7 148.44 46.89 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 123.848 1.447 . . . . 50.0 110.357 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.492 ' HG3' ' CG1' ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.66 152.51 59.19 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 123.963 1.507 . . . . 50.0 110.413 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -52.8 133.63 37.13 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.19 -0.944 . . . . 50.0 110.136 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.53 161.68 11.41 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.532 -1.427 . . . . 50.0 109.532 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.522 ' CB ' ' HB2' ' A' ' 53' ' ' SER . 5.4 p30 -53.01 155.24 2.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 50.0 110.108 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.479 ' HA ' ' N ' ' A' ' 53' ' ' SER . 17.6 p -143.03 137.98 29.65 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.229 -0.919 . . . . 50.0 110.387 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 1.2 m-30 -101.56 103.34 14.18 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.88 . . . . 50.0 110.275 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.475 HD12 ' O ' ' A' ' 90' ' ' SER . 3.2 mp -101.5 138.95 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.201 -0.937 . . . . 50.0 109.871 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.508 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 75.5 t -125.37 113.73 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 50.0 110.785 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.585 HG11 ' CD2' ' A' ' 17' ' ' PHE . 41.3 t -101.97 91.54 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.958 . . . . 50.0 109.785 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.55 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.59 167.83 33.14 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.774 -1.33 . . . . 50.0 109.774 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.472 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ptp -108.38 -150.77 0.46 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -1.113 . . . . 50.0 110.08 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -73.7 -44.12 33.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.729 -1.348 . . . . 50.0 109.729 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 99' ' ' LYS . 39.5 t0 -74.98 -105.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.205 -1.174 . . . . 50.0 110.293 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.489 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 8.5 tttp -79.61 136.1 36.75 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.048 -1.032 . . . . 50.0 110.352 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.778 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -140.1 150.13 43.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.197 -0.939 . . . . 49.57 110.07 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 7.5 mt -115.72 146.98 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.856 -1.153 . . . . 49.57 110.182 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 24.0 p-10 -130.67 129.76 43.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -0.904 . . . . 49.57 110.469 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -135.48 163.79 29.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.442 -0.786 . . . . 49.57 110.018 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.627 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 10.3 p80 -134.39 164.15 28.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.931 . . . . 49.57 110.221 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 58.8 m95 . . . . . 0 C--N 1.305 -1.327 0 O-C-N 121.257 -0.902 . . . . 49.57 110.236 179.925 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.547 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 121.123 0.487 . . . . 50.0 110.208 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.661 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.7 p -148.6 107.53 3.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.112 -0.992 . . . . 99.989999999999995 110.567 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.482 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 6.7 m -160.84 42.12 0.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.679 -1.263 . . . . 99.989999999999995 110.602 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -65.14 -5.95 7.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.14 -0.975 . . . . 99.989999999999995 109.906 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 mmtm -83.44 61.21 6.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 50.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.584 ' CZ ' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -101.44 142.44 32.82 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.204 -0.935 . . . . 50.0 109.668 179.45 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 t -127.13 97.58 4.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.154 -0.966 . . . . 50.0 110.197 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 11.4 p90 -63.0 118.06 7.3 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.36 -0.837 . . . . 50.0 110.04 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -102.22 -22.41 14.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.093 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.491 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -138.06 145.99 42.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 50.0 110.137 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.425 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 22.9 p30 -66.83 162.62 50.74 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 50.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.425 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 45.0 Cg_endo -72.14 114.48 3.99 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.966 1.509 . . . . 50.0 110.37 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -105.02 140.13 38.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.284 -0.885 . . . . 50.0 110.368 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -90.53 111.24 22.45 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.36 -0.837 . . . . 50.0 110.184 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.5 59.02 5.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.228 -0.92 . . . . 50.0 110.158 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 128.31 -128.16 5.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -132.59 89.21 2.61 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -1.205 . . . . 50.0 110.138 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.68 31.05 2.43 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.521 -1.431 . . . . 50.0 109.521 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -154.95 111.19 3.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.214 -1.168 . . . . 50.0 110.343 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.499 ' HB ' ' O ' ' A' ' 83' ' ' MET . 57.7 t -109.27 147.88 13.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.295 -0.878 . . . . 50.0 110.253 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.92 118.26 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 50.0 110.318 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.446 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.6 OUTLIER -116.04 149.54 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.311 -0.868 . . . . 50.0 109.785 179.64 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.491 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.7 OUTLIER -126.69 104.87 8.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.207 -0.933 . . . . 50.0 110.534 -179.653 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.594 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -123.78 144.52 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.319 -0.863 . . . . 50.0 109.302 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.23 133.51 39.02 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.031 -1.043 . . . . 50.0 110.028 -179.688 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.507 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 6.8 t80 -94.0 97.56 10.42 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.065 -1.054 . . . . 50.0 109.863 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 59.1 p -95.41 70.06 3.11 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.27 -0.894 . . . . 50.0 110.14 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -122.39 129.38 7.53 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.575 -1.41 . . . . 99.989999999999995 109.575 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.0 p -92.86 24.78 3.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.274 -1.133 . . . . 99.989999999999995 110.244 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.452 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.2 p30 -98.43 -1.32 41.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.084 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -168.63 24.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.461 -1.456 . . . . 99.989999999999995 109.461 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.566 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.7 Cg_endo -73.56 153.4 49.39 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.976 1.513 . . . . 99.989999999999995 110.324 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.661 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.29 161.33 8.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.34 -0.85 . . . . 50.0 110.002 -179.378 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.547 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.0 OUTLIER -76.04 133.86 40.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.095 -1.003 . . . . 50.0 109.305 178.951 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.584 ' CD1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 mt -89.25 108.41 24.26 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 120.996 -1.065 . . . . 50.0 110.157 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.52 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 47.6 Cg_endo -74.49 99.99 1.27 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 124.043 1.549 . . . . 50.0 110.7 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.562 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 2.6 mt -126.55 150.34 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 50.0 110.172 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 93' ' ' VAL . 2.7 p -128.21 130.43 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.416 -0.802 . . . . 50.0 109.983 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.498 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.1 OUTLIER -115.35 106.47 14.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 50.0 109.931 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.548 HG12 ' CB ' ' A' ' 55' ' ' ASN . 2.9 t -132.78 163.09 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.187 -0.946 . . . . 50.0 110.698 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.459 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.24 164.43 1.31 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.485 -0.759 . . . . 50.0 110.393 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.647 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -58.69 122.28 13.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.441 -0.787 . . . . 50.0 110.598 -179.602 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.647 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 81.17 29.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.594 -0.691 . . . . 50.0 110.906 179.627 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.548 ' CB ' HG12 ' A' ' 51' ' ' VAL . 14.7 m120 -132.99 84.35 2.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 50.0 109.995 178.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 56' ' ' ASP . 10.4 m-20 -106.7 18.09 22.34 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.164 -0.96 . . . . 50.0 110.349 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 18.4 mtt -125.0 -8.93 7.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 50.0 110.474 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.542 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -136.2 144.29 47.33 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.151 -0.968 . . . . 50.0 110.391 -179.854 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.48 125.8 9.85 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.036 1.545 . . . . 50.0 110.239 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.0 t -139.2 -36.22 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 50.0 110.093 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -79.49 161.65 46.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.023 -1.631 . . . . 50.0 109.023 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.459 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -123.63 156.92 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 50.0 110.532 -179.527 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.446 ' HA ' ' HG3' ' A' ' 83' ' ' MET . 1.2 mt -107.16 132.75 52.69 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.314 -0.866 . . . . 50.0 109.944 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.495 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 27.2 t -63.71 -17.27 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -0.946 . . . . 50.0 110.451 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 66' ' ' VAL . 6.2 t -147.11 167.42 24.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 50.0 110.193 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.474 HG12 ' OD1' ' A' ' 67' ' ' ASN . 21.2 t -47.16 173.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 50.0 110.02 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.566 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 5.4 p30 -46.73 138.26 7.05 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.202 -0.936 . . . . 50.0 110.239 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.473 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 46.7 Cg_endo -74.01 103.05 1.6 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.934 1.492 . . . . 50.0 110.38 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.566 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -113.8 134.01 55.04 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.18 -0.95 . . . . 50.0 110.495 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.526 HG22 ' CD1' ' A' ' 46' ' ' ILE . 61.9 t -87.63 60.46 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 50.0 109.684 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.9 57.42 4.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.295 -0.878 . . . . 50.0 110.021 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.43 169.01 18.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 50.0 110.424 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.87 -7.15 34.19 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.872 . . . . 50.0 109.909 179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.11 12.59 11.12 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.31 -0.869 . . . . 99.989999999999995 110.242 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.509 ' CB ' HG12 ' A' ' 70' ' ' VAL . . . -77.15 6.82 5.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.079 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.507 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 8.2 m-80 -84.62 19.56 1.97 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.333 -0.855 . . . . 99.989999999999995 109.384 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 36' ' ' SER . 31.0 m -121.09 -172.54 2.42 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.414 -0.804 . . . . 99.989999999999995 109.177 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.459 ' HB3' ' OE2' ' A' ' 34' ' ' GLU . 6.8 mttp -63.21 88.06 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.235 -0.915 . . . . 99.989999999999995 109.064 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.573 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 11.2 m -76.95 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.331 -0.856 . . . . 99.989999999999995 109.318 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.44 ' CD2' ' O ' ' A' ' 33' ' ' ILE . 0.4 OUTLIER -133.87 130.36 37.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.785 -1.197 . . . . 50.0 111.1 -179.66 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.5 t -120.45 168.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.476 -0.765 . . . . 50.0 109.947 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.495 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 4.0 mt-10 -132.96 147.99 52.28 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.179 -0.951 . . . . 50.0 110.176 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.499 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -146.83 143.17 28.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.214 -0.929 . . . . 50.0 110.393 -179.853 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 62' ' ' ARG . 0.2 OUTLIER -117.95 68.56 6.65 Favored Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.115 -0.991 . . . . 50.0 110.477 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.86 161.44 41.48 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 O-C-N 123.975 1.513 . . . . 50.0 110.358 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.43 146.7 40.12 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 124.003 1.528 . . . . 50.0 110.446 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 87' ' ' PHE . 0.8 OUTLIER -52.74 135.18 35.82 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.281 -0.887 . . . . 50.0 110.07 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 124.81 165.63 12.19 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 53' ' ' SER . 92.8 m-20 -62.2 135.42 57.48 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -1.193 . . . . 50.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.551 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.7 OUTLIER -132.27 145.27 51.18 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.308 -0.87 . . . . 50.0 110.138 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.599 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.9 m-30 -100.74 113.16 25.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.081 -1.012 . . . . 50.0 110.026 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.426 HD13 ' HB2' ' A' ' 90' ' ' SER . 3.5 mp -109.06 131.1 60.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 50.0 110.108 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.506 ' HB ' ' CG1' ' A' ' 49' ' ' VAL . 71.3 t -124.89 118.86 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.17 -0.956 . . . . 50.0 110.437 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.513 ' HB ' ' CG1' ' A' ' 101' ' ' ILE . 21.7 t -101.41 93.78 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 50.0 109.88 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.481 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -156.15 170.73 33.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.784 -1.326 . . . . 50.0 109.784 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.535 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 15.9 ptp -112.2 -28.33 7.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.262 -1.14 . . . . 50.0 109.919 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . 0.535 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 171.3 -61.56 0.17 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -64.0 -108.41 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.232 -1.158 . . . . 50.0 110.268 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -79.62 127.98 32.83 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.093 -1.004 . . . . 50.0 110.182 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.77 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.8 pp0? -136.16 150.2 48.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.231 -0.918 . . . . 49.57 110.226 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.513 ' CG1' ' HB ' ' A' ' 94' ' ' VAL . 32.4 pt -102.95 148.94 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.974 -1.079 . . . . 49.57 110.186 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -132.27 142.39 49.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 49.57 110.397 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -128.46 166.74 18.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 49.57 110.193 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.586 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 8.8 p80 -118.61 85.36 2.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.327 -0.858 . . . . 49.57 110.346 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.494 ' C ' ' CD1' ' A' ' 105' ' ' TRP . 1.7 t-105 . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.156 -0.965 . . . . 49.57 110.051 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.551 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.107 0.479 . . . . 50.0 110.016 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.646 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.83 108.01 3.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 110.655 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.476 ' OG1' ' O ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -161.43 44.04 0.16 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.876 -1.14 . . . . 99.989999999999995 110.489 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.419 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.4 OUTLIER -76.83 10.43 2.25 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.147 -0.97 . . . . 99.989999999999995 110.615 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.463 ' HE2' ' HA2' ' A' ' 39' ' ' GLY . 0.0 OUTLIER -111.48 61.85 0.61 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.028 -1.045 . . . . 50.0 110.59 -179.964 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.547 ' CZ ' HD11 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -94.68 148.74 21.96 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.093 -1.004 . . . . 50.0 109.994 179.603 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.576 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 28.6 t -125.15 114.31 18.85 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 50.0 110.153 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.601 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 9.7 m-85 -64.94 112.92 3.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.26 -0.9 . . . . 50.0 110.188 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.48 ' C ' ' HG2' ' A' ' 21' ' ' LYS . . . -96.51 -32.94 12.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.19 -0.944 . . . . 50.0 110.152 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.48 ' HG2' ' C ' ' A' ' 20' ' ' ALA . 0.5 OUTLIER -138.96 163.03 33.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 50.0 110.229 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.446 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 36.7 p-10 -76.89 164.3 60.06 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 50.0 110.134 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.446 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.19 126.78 12.7 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.431 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -121.53 148.83 43.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.22 -0.925 . . . . 50.0 110.344 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 10.3 t70 -94.62 122.07 36.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 50.0 110.203 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.1 p -79.35 -51.33 9.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.166 -0.959 . . . . 50.0 110.278 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.425 ' O ' ' OD1' ' A' ' 25' ' ' ASP . . . -128.59 -108.1 1.38 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.641 -1.384 . . . . 50.0 109.641 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -127.11 108.37 10.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.127 . . . . 50.0 110.296 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.48 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 85.19 31.28 23.14 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.632 -1.387 . . . . 50.0 109.632 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.434 ' HA ' HG22 ' A' ' 64' ' ' VAL . 1.1 p -145.36 107.92 4.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.149 -1.207 . . . . 50.0 110.361 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.469 HG22 ' HD2' ' A' ' 85' ' ' PRO . 21.4 t -104.24 148.59 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 O-C-N 121.342 -0.849 . . . . 50.0 110.175 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -122.65 132.81 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 50.0 110.406 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.516 HG22 ' CD1' ' A' ' 35' ' ' LEU . 8.4 tp -128.49 133.6 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.335 -0.853 . . . . 50.0 109.781 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.479 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 8.9 tt0 -108.54 111.34 23.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.187 -0.946 . . . . 50.0 110.572 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.582 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 0.4 OUTLIER -125.2 143.12 51.1 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.32 -0.862 . . . . 50.0 109.183 179.299 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.465 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -89.45 126.01 35.4 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.98 -1.075 . . . . 50.0 109.925 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.59 ' CE1' ' HA3' ' A' ' 39' ' ' GLY . 1.3 t80 -93.56 101.77 13.96 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.987 -1.085 . . . . 50.0 109.357 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 79.5 p -96.36 69.73 2.66 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.281 -0.887 . . . . 50.0 110.261 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.59 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -117.47 130.77 9.01 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.334 -1.506 . . . . 99.989999999999995 109.334 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 36.9 m -84.42 25.55 0.86 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -1.176 . . . . 99.989999999999995 110.539 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.08 -0.91 26.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.077 -1.014 . . . . 99.989999999999995 110.219 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.33 -157.99 28.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.409 -1.477 . . . . 99.989999999999995 109.409 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.22 137.24 28.29 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.923 1.486 . . . . 99.989999999999995 110.265 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.642 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -153.02 161.18 42.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.855 . . . . 50.0 110.107 -179.432 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.551 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 26.8 mmtt -75.68 130.93 39.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 50.0 109.157 178.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.595 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 20.1 mt -89.71 107.31 18.0 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.088 -1.007 . . . . 50.0 110.672 -179.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.551 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.2 Cg_endo -74.84 100.7 1.37 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.031 1.543 . . . . 50.0 110.078 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.595 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 66.1 mt -135.87 146.83 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.165 -0.96 . . . . 50.0 110.563 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.438 HG21 ' HB ' ' A' ' 93' ' ' VAL . 15.7 m -121.41 161.7 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.353 -0.842 . . . . 50.0 109.664 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -132.72 104.33 6.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.127 -0.983 . . . . 50.0 110.119 -179.846 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.558 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.4 m -127.22 158.96 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.295 -0.878 . . . . 50.0 110.017 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.41 ' HB2' ' CG ' ' A' ' 55' ' ' ASN . . . -55.83 163.35 1.46 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.361 -0.837 . . . . 50.0 110.054 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.632 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.0 OUTLIER -59.53 118.53 6.16 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.255 -0.903 . . . . 50.0 110.454 -179.534 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.632 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.2 tp 79.53 30.51 0.29 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.568 -0.707 . . . . 50.0 110.673 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.41 ' CG ' ' HB2' ' A' ' 52' ' ' ALA . 6.5 m120 -124.51 84.87 2.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.284 -0.885 . . . . 50.0 110.341 179.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.442 ' OD1' ' HE1' ' A' ' 57' ' ' MET . 2.8 p30 -101.77 9.82 40.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 50.0 109.88 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.442 ' HE1' ' OD1' ' A' ' 56' ' ' ASP . 3.8 mtt -123.44 -12.88 7.7 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 50.0 110.106 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.6 m -130.26 119.02 18.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.378 -0.826 . . . . 50.0 110.035 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.55 136.94 29.42 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.922 1.485 . . . . 50.0 110.162 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.473 HG12 ' HG3' ' A' ' 86' ' ' PRO . 44.7 t -148.24 -37.37 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.176 -0.953 . . . . 50.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.81 145.18 37.95 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.817 -1.713 . . . . 50.0 108.817 179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.45 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.1 mmp_? -124.06 157.26 34.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.991 -1.3 . . . . 50.0 110.53 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.4 mt -101.67 127.43 48.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.298 -0.876 . . . . 50.0 109.731 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.51 ' CB ' ' HG2' ' A' ' 82' ' ' GLU . 22.8 t -64.5 -13.19 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 50.0 110.262 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' VAL . 14.0 t -140.8 165.97 26.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.215 -0.928 . . . . 50.0 110.215 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.442 ' CG1' ' H ' ' A' ' 67' ' ' ASN . 3.8 t -55.07 -170.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 50.0 109.881 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.612 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 3.0 t30 -46.31 132.66 7.62 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.023 -1.048 . . . . 50.0 110.08 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.524 ' O ' ' CD1' ' A' ' 46' ' ' ILE . 46.9 Cg_endo -73.51 75.36 3.01 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.042 1.549 . . . . 50.0 110.554 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.612 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.8 p90 -95.15 136.94 34.87 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.239 -0.913 . . . . 50.0 110.141 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.591 ' CG1' ' CB ' ' A' ' 75' ' ' ALA . 2.3 t -97.12 60.58 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 50.0 109.649 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -71.33 59.48 0.28 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.341 -0.849 . . . . 50.0 110.238 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 t -142.62 164.66 29.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 50.0 110.257 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.7 t -84.26 11.25 8.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.137 -0.977 . . . . 50.0 110.081 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -121.63 13.64 10.87 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 99.989999999999995 110.358 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.591 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -61.9 -10.98 10.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.18 -0.95 . . . . 99.989999999999995 110.172 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 63.5 m-20 -86.49 20.91 2.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.143 -0.973 . . . . 99.989999999999995 109.351 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.5 OUTLIER -132.69 -173.24 3.12 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.725 -179.872 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.463 ' HG3' ' OG ' ' A' ' 36' ' ' SER . 0.8 OUTLIER -64.34 89.56 0.06 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.196 179.256 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.582 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 27.0 m -75.74 174.83 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.221 -0.924 . . . . 99.989999999999995 109.165 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.69 134.29 44.61 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.764 -1.21 . . . . 50.0 111.432 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 t -121.03 178.25 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.736 . . . . 50.0 109.696 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.51 ' HG2' ' CB ' ' A' ' 64' ' ' VAL . 10.5 tt0 -143.69 138.78 29.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.172 -0.955 . . . . 50.0 110.342 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.4 mtm -147.25 145.44 29.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.151 -0.968 . . . . 50.0 110.383 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.48 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -118.07 70.05 7.66 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 121.341 -0.849 . . . . 50.0 110.563 -179.999 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.469 ' HD2' HG22 ' A' ' 31' ' ' VAL . 46.0 Cg_endo -74.11 162.28 39.16 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.012 1.533 . . . . 50.0 110.126 179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.473 ' HG3' HG12 ' A' ' 60' ' ' VAL . 47.1 Cg_endo -72.7 150.28 50.15 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 123.896 1.472 . . . . 50.0 110.335 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.54 120.56 5.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.197 -0.94 . . . . 50.0 110.029 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 134.64 178.31 15.56 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.562 -1.415 . . . . 50.0 109.562 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.412 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 25.3 p-10 -77.17 141.05 40.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -1.14 . . . . 50.0 110.208 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.536 ' HA ' ' N ' ' A' ' 53' ' ' SER . 53.6 p -135.11 150.62 50.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 50.0 110.164 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.588 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 0.5 OUTLIER -96.94 105.02 17.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 50.0 110.275 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.567 HG23 ' CE3' ' A' ' 105' ' ' TRP . 0.0 OUTLIER -96.06 136.4 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.226 -0.921 . . . . 50.0 109.505 179.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.506 ' N ' HD11 ' A' ' 92' ' ' ILE . 33.5 t -123.84 117.54 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.131 -0.98 . . . . 50.0 110.88 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.542 ' HA ' HG12 ' A' ' 48' ' ' ILE . 97.0 t -106.14 95.03 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.328 -0.857 . . . . 50.0 109.893 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.59 170.3 33.51 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.665 -1.374 . . . . 50.0 109.665 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 9.2 mtm -80.4 -63.52 1.39 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -1.157 . . . . 50.0 110.178 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -156.06 -68.48 0.01 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.561 -1.416 . . . . 50.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -71.14 -75.58 0.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -1.11 . . . . 50.0 110.279 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -79.67 119.62 22.86 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.289 -0.882 . . . . 50.0 110.305 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.607 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.54 148.72 41.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 49.57 110.091 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.7 mm -98.69 111.46 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.12 -0.988 . . . . 49.57 110.039 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.416 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 36.7 p-10 -101.57 130.37 47.86 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.154 -0.966 . . . . 49.57 110.275 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.601 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -128.93 170.62 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.355 -0.841 . . . . 49.57 110.324 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.454 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 50.0 p-80 -123.7 125.33 44.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.33 -0.857 . . . . 49.57 110.127 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.567 ' CE3' HG23 ' A' ' 92' ' ' ILE . 9.1 m0 . . . . . 0 C--N 1.304 -1.397 0 O-C-N 121.182 -0.949 . . . . 49.57 110.328 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 3.4 mtm . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.157 0.503 . . . . 50.0 110.37 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.548 ' HB3' ' O ' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -112.24 -175.5 2.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 99.989999999999995 109.929 179.674 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.619 ' HA ' ' HG3' ' A' ' 47' ' ' PRO . 21.8 p -158.24 -76.55 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.342 -0.849 . . . . 99.989999999999995 110.307 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.538 ' O ' ' CG ' ' A' ' 15' ' ' GLU . 20.6 tt0 -118.76 8.46 11.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 110.351 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.529 ' HB3' ' CD1' ' A' ' 37' ' ' TYR . 0.9 OUTLIER -56.04 81.97 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.349 -0.845 . . . . 50.0 111.021 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.26 142.06 12.7 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.174 -0.954 . . . . 50.0 110.205 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.477 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 m -127.75 97.46 4.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -0.892 . . . . 50.0 110.267 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p90 -57.12 119.55 6.53 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.25 -0.906 . . . . 50.0 110.249 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -107.15 -21.94 12.8 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.33 -0.856 . . . . 50.0 110.101 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.475 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 14.8 mttm -145.02 149.69 35.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.968 . . . . 50.0 110.278 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -67.66 159.45 78.48 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.849 . . . . 50.0 110.279 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.475 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.7 Cg_endo -72.93 134.16 21.13 Favored 'Trans proline' 0 C--N 1.303 -1.818 0 O-C-N 124.013 1.533 . . . . 50.0 110.401 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -130.51 155.32 46.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.231 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -83.69 148.46 27.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.232 -0.917 . . . . 50.0 110.122 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.488 HG22 HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -136.62 22.22 3.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.193 -0.942 . . . . 50.0 110.207 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.28 -133.71 3.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.577 -1.409 . . . . 50.0 109.577 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -104.77 92.78 4.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -1.129 . . . . 50.0 110.343 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 84' ' ' GLU . . . 80.41 30.83 39.46 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.627 -1.389 . . . . 50.0 109.627 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 p -122.59 107.62 12.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.2 -1.176 . . . . 50.0 110.275 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.475 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -100.11 145.19 11.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.276 -0.89 . . . . 50.0 110.099 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.488 HG22 HG22 ' A' ' 26' ' ' THR . 0.0 OUTLIER -122.42 148.9 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.147 -0.971 . . . . 50.0 110.388 -179.73 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.496 ' O ' ' CD2' ' A' ' 80' ' ' LEU . 6.1 tt -148.17 156.37 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 50.0 109.65 179.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.475 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 17.3 tt0 -126.09 103.81 7.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.117 -0.989 . . . . 50.0 110.696 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.568 ' HB2' ' CE1' ' A' ' 17' ' ' PHE . 0.2 OUTLIER -121.84 140.17 52.72 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.349 -0.845 . . . . 50.0 109.263 179.4 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.518 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -92.7 132.84 36.58 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.044 -1.035 . . . . 50.0 110.107 -179.563 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.529 ' CD1' ' HB3' ' A' ' 16' ' ' LYS . 9.4 t80 -94.88 103.05 14.92 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.088 -1.045 . . . . 50.0 109.742 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 t -96.48 69.7 2.6 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.313 -0.867 . . . . 50.0 109.929 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.488 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -112.89 130.57 9.58 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.661 -1.376 . . . . 99.989999999999995 109.661 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.52 5.72 10.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 99.989999999999995 110.344 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.27 -1.35 42.1 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.213 -0.93 . . . . 99.989999999999995 110.116 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' CE2' ' A' ' 37' ' ' TYR . . . 80.93 -131.91 10.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.457 -1.457 . . . . 99.989999999999995 109.457 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.541 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 45.6 Cg_endo -73.0 131.01 16.21 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.888 1.467 . . . . 99.989999999999995 110.441 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.484 ' SG ' ' CE1' ' A' ' 37' ' ' TYR . 30.5 p -147.81 161.84 40.45 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.323 -0.861 . . . . 50.0 110.126 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.548 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 17.2 mmtt -87.23 108.67 19.04 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 50.0 109.929 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.619 ' CD1' ' CE2' ' A' ' 17' ' ' PHE . 4.2 mt -84.51 116.48 65.33 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 50.0 110.353 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.619 ' HG3' ' HA ' ' A' ' 14' ' ' THR . 47.2 Cg_endo -71.94 104.7 1.68 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 124.117 1.588 . . . . 50.0 110.344 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.539 HG12 ' CG2' ' A' ' 94' ' ' VAL . 1.2 mt -125.86 151.15 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 50.0 110.233 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 49' ' ' VAL . 5.8 p -132.99 141.29 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.913 . . . . 50.0 110.051 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 61' ' ' GLY . 3.5 m -115.64 104.79 12.05 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.311 -0.868 . . . . 50.0 109.887 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.474 ' HB ' ' O ' ' A' ' 55' ' ' ASN . 30.4 m -131.78 162.94 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.265 -0.897 . . . . 50.0 110.322 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -55.58 163.97 1.17 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.422 -0.799 . . . . 50.0 110.18 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.636 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 10.2 t -63.15 118.26 7.68 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 50.0 110.711 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.599 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 77.21 30.76 0.52 Allowed 'General case' 0 N--CA 1.496 1.829 0 C-N-CA 119.876 -0.73 . . . . 50.0 110.765 179.485 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.474 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 10.5 m120 -134.9 84.95 2.14 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 50.0 110.032 179.124 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -104.53 18.54 22.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.273 -0.892 . . . . 50.0 110.373 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 ttt -102.87 -24.98 13.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -0.961 . . . . 50.0 110.136 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.41 138.59 27.28 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.462 -0.774 . . . . 50.0 110.196 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.431 ' C ' HG23 ' A' ' 60' ' ' VAL . 47.0 Cg_endo -72.37 133.23 20.51 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.997 1.525 . . . . 50.0 110.361 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.431 HG23 ' C ' ' A' ' 59' ' ' PRO . 21.7 t -143.86 -36.41 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.158 -0.964 . . . . 50.0 110.277 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.11 159.21 50.3 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.052 -1.619 . . . . 50.0 109.052 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.483 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 14.8 mtt-85 -129.36 156.22 44.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.049 -1.265 . . . . 50.0 110.372 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.6 mt -94.89 124.67 39.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.276 -0.89 . . . . 50.0 110.132 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.518 HG22 ' N ' ' A' ' 84' ' ' GLU . 54.5 t -70.54 -38.93 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.198 -0.939 . . . . 50.0 110.122 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.73 175.72 6.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.317 -0.864 . . . . 50.0 110.086 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.6 m -57.92 -175.02 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.217 -0.927 . . . . 50.0 110.315 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.478 ' HB2' ' CD1' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.93 156.91 0.51 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.264 -0.897 . . . . 50.0 110.045 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.533 ' HB2' ' CD1' ' A' ' 48' ' ' ILE . 48.1 Cg_endo -74.61 65.61 5.68 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.931 1.49 . . . . 50.0 110.9 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.604 ' CD2' ' O ' ' A' ' 69' ' ' PHE . 49.0 p90 -132.45 121.79 23.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.114 -0.991 . . . . 50.0 110.187 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.544 ' HB ' ' CB ' ' A' ' 75' ' ' ALA . 6.8 m -88.19 60.85 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.061 -1.024 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.541 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -66.09 65.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.3 -0.875 . . . . 50.0 110.307 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.455 ' N ' ' O ' ' A' ' 70' ' ' VAL . 1.5 m -142.49 159.26 42.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.2 -0.937 . . . . 50.0 110.244 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -86.16 -13.23 47.67 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.296 -0.878 . . . . 50.0 109.908 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.1 p -114.79 15.81 17.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.381 -0.824 . . . . 99.989999999999995 110.057 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.544 ' CB ' ' HB ' ' A' ' 70' ' ' VAL . . . -81.13 9.79 6.27 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 109.959 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 84.5 m-20 -85.2 16.86 3.31 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.335 -0.853 . . . . 99.989999999999995 109.441 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.518 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.0 t -121.66 -172.44 2.43 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.412 -0.805 . . . . 99.989999999999995 109.352 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 2.4 mttp -62.96 88.33 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.442 -0.903 . . . . 99.989999999999995 109.068 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.566 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 24.3 m -76.68 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.391 -0.818 . . . . 99.989999999999995 109.832 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.496 ' CD2' ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -123.51 129.65 51.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.971 -1.08 . . . . 50.0 110.953 -179.642 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.512 HG22 ' CD1' ' A' ' 35' ' ' LEU . 2.0 t -116.35 178.03 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.388 -0.82 . . . . 50.0 109.872 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.48 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 66.2 mt-10 -153.3 151.0 29.5 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.069 -1.02 . . . . 50.0 110.354 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' CD ' ' A' ' 85' ' ' PRO . 0.4 OUTLIER -149.54 130.86 14.65 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.236 -0.915 . . . . 50.0 110.267 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.518 ' N ' HG22 ' A' ' 64' ' ' VAL . 0.1 OUTLIER -106.57 72.72 0.3 Allowed Pre-proline 0 C--N 1.306 -1.285 0 O-C-N 121.255 -0.903 . . . . 50.0 110.802 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.49 ' CD ' ' O ' ' A' ' 83' ' ' MET . 47.1 Cg_endo -73.0 170.36 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.842 1.443 . . . . 50.0 110.089 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.35 157.0 57.83 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 123.974 1.513 . . . . 50.0 110.479 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -52.84 125.45 17.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.275 -0.891 . . . . 50.0 110.136 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 129.25 -161.15 22.68 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.51 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 15.3 p-10 -99.4 129.47 45.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.202 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.535 ' HA ' ' N ' ' A' ' 53' ' ' SER . 65.3 p -122.12 152.06 40.28 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.391 -0.818 . . . . 50.0 110.092 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.676 ' CZ ' ' CD2' ' A' ' 104' ' ' HIS . 1.8 m-30 -106.2 118.83 37.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 50.0 110.27 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.512 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.7 mp -109.08 133.32 54.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.259 -0.901 . . . . 50.0 109.83 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.525 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 18.7 t -123.61 128.21 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.038 -1.039 . . . . 50.0 110.769 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.539 ' CG2' HG12 ' A' ' 48' ' ' ILE . 35.5 t -107.82 88.77 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 50.0 109.98 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.492 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.84 -179.8 31.19 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.841 -1.304 . . . . 50.0 109.841 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.556 ' CE ' ' HB ' ' A' ' 14' ' ' THR . 3.8 ptp -99.05 -32.64 11.17 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -1.131 . . . . 50.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 175.86 -72.03 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.534 -1.427 . . . . 50.0 109.534 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -65.97 -82.82 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.239 -1.154 . . . . 50.0 110.102 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 118.24 21.32 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.209 -0.932 . . . . 50.0 110.182 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.61 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.32 148.77 41.86 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 49.57 110.308 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 66.2 mt -93.06 105.84 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.116 -0.99 . . . . 49.57 109.926 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -93.83 136.37 34.18 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.14 -0.975 . . . . 49.57 110.536 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.53 159.7 35.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.251 -0.905 . . . . 49.57 110.165 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.676 ' CD2' ' CZ ' ' A' ' 91' ' ' TYR . 7.1 m170 -118.98 106.84 12.84 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.351 -0.843 . . . . 49.57 110.589 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.415 ' CE3' ' HG2' ' A' ' 23' ' ' PRO . 1.3 t-105 . . . . . 0 N--CA 1.486 1.34 0 O-C-N 121.221 -0.924 . . . . 49.57 110.146 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.535 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.7 mtt . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 121.217 0.532 . . . . 50.0 110.334 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.652 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 10.7 p -148.71 108.2 3.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.312 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.598 HG23 ' CD1' ' A' ' 37' ' ' TYR . 0.3 OUTLIER -160.54 61.7 0.32 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.888 -1.133 . . . . 99.989999999999995 110.55 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.427 ' HG3' ' HD2' ' A' ' 16' ' ' LYS . 0.5 OUTLIER -89.68 28.27 1.35 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.161 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.545 ' CD ' ' N ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -133.36 67.06 1.54 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 50.0 110.829 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.646 ' CZ ' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -102.78 142.12 34.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.15 -0.969 . . . . 50.0 110.024 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -127.93 97.88 4.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.27 -0.894 . . . . 50.0 110.542 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.625 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 24.5 p90 -57.33 116.92 3.61 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.058 -1.026 . . . . 50.0 110.241 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.54 -18.05 14.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 50.0 109.994 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.47 ' HE2' ' HB2' ' A' ' 34' ' ' GLU . 21.1 mtmt -137.97 141.78 40.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.194 -0.941 . . . . 50.0 110.286 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.505 ' N ' ' OD1' ' A' ' 22' ' ' ASN . 16.0 p-10 -66.57 164.86 28.59 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.305 -0.872 . . . . 50.0 110.034 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.53 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 43.5 Cg_endo -71.09 136.46 29.56 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.983 1.517 . . . . 50.0 110.505 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' CG2' ' A' ' 32' ' ' VAL . . . -132.53 126.27 32.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.318 -0.864 . . . . 50.0 110.181 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 30' ' ' THR . 26.6 t0 -70.37 111.26 5.81 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.264 -0.898 . . . . 50.0 110.171 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.433 HG21 HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -88.3 22.94 2.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -0.959 . . . . 50.0 110.243 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.04 -117.41 0.67 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.567 -1.413 . . . . 50.0 109.567 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 1.1 p80 -129.72 89.42 2.82 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.256 -1.144 . . . . 50.0 110.322 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 101.25 -2.67 54.5 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.609 -1.396 . . . . 50.0 109.609 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.463 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 16.5 p -102.17 107.83 19.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.17 -1.194 . . . . 50.0 110.242 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.53 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 16.0 t -102.59 135.88 37.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.233 -0.917 . . . . 50.0 110.081 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -120.98 132.83 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.184 -0.947 . . . . 50.0 110.208 -179.885 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.593 HG23 ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -134.73 144.16 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 50.0 109.682 179.734 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.538 ' N ' ' CD1' ' A' ' 33' ' ' ILE . 6.4 tt0 -109.68 130.8 55.48 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.201 -0.937 . . . . 50.0 110.872 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.564 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 1.1 mp -135.39 134.49 39.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.357 -0.84 . . . . 50.0 109.237 179.233 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.531 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -79.89 121.84 25.92 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.991 -1.068 . . . . 50.0 109.236 -179.822 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.598 ' CD1' HG23 ' A' ' 14' ' ' THR . 10.1 t80 -91.61 106.16 18.27 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.584 -1.247 . . . . 50.0 109.458 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.79 69.84 3.41 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.367 -0.833 . . . . 50.0 110.09 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.589 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -121.62 127.86 7.06 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.541 -1.424 . . . . 99.989999999999995 109.541 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.3 p -87.96 28.28 1.06 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -1.117 . . . . 99.989999999999995 110.272 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.463 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.9 p-10 -110.28 -0.92 17.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -0.917 . . . . 99.989999999999995 110.247 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.37 -157.41 23.94 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.408 -1.477 . . . . 99.989999999999995 109.408 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.72 153.82 54.04 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.034 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.652 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.18 157.48 6.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.144 -0.973 . . . . 50.0 110.126 -179.489 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.535 ' CG ' ' HG2' ' A' ' 12' ' ' MET . 0.4 OUTLIER -70.56 125.76 27.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 50.0 109.256 179.171 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 mt -80.98 110.48 17.81 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.164 -0.96 . . . . 50.0 110.481 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.535 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.6 Cg_endo -75.33 84.43 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.034 1.544 . . . . 50.0 110.204 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.575 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 71.2 mt -124.29 149.26 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.917 . . . . 50.0 110.457 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.473 HG21 ' HB ' ' A' ' 93' ' ' VAL . 4.1 m -116.81 142.88 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 50.0 109.844 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 61' ' ' GLY . 22.8 m -122.56 100.88 7.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 50.0 110.016 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.536 ' O ' ' N ' ' A' ' 91' ' ' TYR . 36.0 m -129.02 157.49 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.334 -0.854 . . . . 50.0 110.238 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.21 163.95 1.45 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.389 -0.82 . . . . 50.0 109.998 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 12.7 t -62.12 121.3 12.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.167 -0.958 . . . . 50.0 110.491 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.644 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 80.07 30.39 0.24 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.61 -0.681 . . . . 50.0 110.738 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.497 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 11.4 m120 -135.41 84.29 2.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.144 -0.972 . . . . 50.0 110.182 179.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -106.75 8.57 30.99 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 50.0 110.471 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.07 -18.01 14.72 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.134 -0.979 . . . . 50.0 110.424 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 p -136.18 146.42 56.28 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.372 -0.83 . . . . 50.0 110.15 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.57 132.67 17.76 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.108 1.583 . . . . 50.0 110.496 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.83 -59.42 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -0.866 . . . . 50.0 109.817 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.3 154.12 51.45 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.69 -1.764 . . . . 50.0 108.69 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.418 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 6.2 mtt180 -142.83 156.71 45.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.963 -1.316 . . . . 50.0 110.681 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 1.1 mt -86.23 138.41 31.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.193 -0.942 . . . . 50.0 109.998 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.529 HG21 ' N ' ' A' ' 84' ' ' GLU . 76.2 t -91.64 -29.79 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 50.0 110.458 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.472 ' O ' ' O ' ' A' ' 66' ' ' VAL . 10.1 t -95.1 176.11 6.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 50.0 110.219 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' A' ' 65' ' ' THR . 53.8 t -44.34 171.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.294 -0.879 . . . . 50.0 110.225 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.448 ' OD1' HG11 ' A' ' 66' ' ' VAL . 7.4 p-10 -46.86 162.2 0.27 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 50.0 109.973 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.507 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.66 90.89 0.8 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.97 1.51 . . . . 50.0 110.319 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.648 ' CE2' ' CB ' ' A' ' 71' ' ' ALA . 2.2 t80 -149.6 121.79 8.34 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 50.0 110.366 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.537 HG12 ' CB ' ' A' ' 75' ' ' ALA . 2.2 t -88.27 63.42 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.232 -0.918 . . . . 50.0 110.064 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.648 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . . . -70.56 64.78 0.29 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.233 -0.917 . . . . 50.0 110.251 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.473 HG23 ' HB2' ' A' ' 75' ' ' ALA . 6.5 t -142.62 154.82 44.73 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.233 -0.917 . . . . 50.0 110.256 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 t -77.82 -2.83 38.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 50.0 110.082 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -117.93 23.14 11.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.247 -0.908 . . . . 99.989999999999995 110.187 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.569 ' O ' ' HB3' ' A' ' 37' ' ' TYR . . . -65.3 -5.61 7.67 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.267 -0.896 . . . . 99.989999999999995 110.418 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -85.23 22.86 1.38 Allowed 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.032 -1.043 . . . . 99.989999999999995 109.339 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.531 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.6 OUTLIER -131.59 -173.24 3.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.291 -0.88 . . . . 99.989999999999995 109.635 -179.802 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.466 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 17.3 pttt -63.92 89.11 0.05 Allowed 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.705 -0.798 . . . . 99.989999999999995 109.103 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 15.4 m -76.07 176.31 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.317 -0.864 . . . . 99.989999999999995 109.358 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.21 145.02 47.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.84 -1.162 . . . . 50.0 111.019 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.593 ' CG1' HG23 ' A' ' 33' ' ' ILE . 14.5 p -132.52 175.7 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.359 -0.838 . . . . 50.0 109.861 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 81' ' ' VAL . 3.9 mt-10 -140.29 144.87 36.63 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.085 -1.009 . . . . 50.0 110.605 -179.705 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.485 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -160.24 136.64 8.81 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.265 -0.897 . . . . 50.0 110.165 179.758 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.529 ' N ' HG21 ' A' ' 64' ' ' VAL . 2.9 pt-20 -106.13 73.96 0.31 Allowed Pre-proline 0 C--N 1.305 -1.343 0 O-C-N 121.263 -0.898 . . . . 50.0 110.579 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.7 Cg_endo -72.41 169.9 20.59 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.166 179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.18 136.93 27.79 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 123.983 1.517 . . . . 50.0 110.097 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -53.71 103.49 0.08 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.236 -0.915 . . . . 50.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.17 -173.04 33.46 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.421 -1.471 . . . . 50.0 109.421 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.487 ' N ' ' OD1' ' A' ' 89' ' ' ASP . 35.0 p-10 -69.34 145.52 52.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.275 -1.132 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.556 ' HA ' ' N ' ' A' ' 53' ' ' SER . 1.4 p -143.0 140.85 31.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.276 -0.89 . . . . 50.0 110.368 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.536 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -97.13 119.94 36.56 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.217 -0.927 . . . . 50.0 109.532 179.567 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 2.4 tt -114.96 132.08 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.141 -0.975 . . . . 50.0 110.38 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.473 ' HB ' HG21 ' A' ' 49' ' ' VAL . 45.3 t -120.74 120.81 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.054 -1.029 . . . . 50.0 110.405 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.518 ' CG1' HG12 ' A' ' 48' ' ' ILE . 62.0 t -109.0 99.64 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 50.0 110.107 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -153.64 160.44 29.28 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.616 -1.394 . . . . 50.0 109.616 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.459 ' SD ' ' HA ' ' A' ' 13' ' ' CYS . 4.4 ttm -115.5 -44.36 2.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -1.16 . . . . 50.0 110.271 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -115.32 -115.17 2.99 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.805 -1.318 . . . . 50.0 109.805 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.34 -35.07 17.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -1.133 . . . . 50.0 110.504 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -79.51 116.12 19.54 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.139 -0.976 . . . . 50.0 110.248 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.798 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.76 150.21 44.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.281 -0.887 . . . . 49.57 110.287 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.517 HD11 ' N ' ' A' ' 101' ' ' ILE . 4.4 mp -111.36 106.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.005 -1.059 . . . . 49.57 109.905 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.461 ' O ' ' OD1' ' A' ' 102' ' ' ASN . 16.3 p30 -95.32 130.17 42.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 49.57 110.523 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.605 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -115.38 160.79 19.41 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.373 -0.83 . . . . 49.57 109.834 179.812 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.528 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 7.4 p80 -121.6 86.64 2.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.198 -0.939 . . . . 49.57 110.386 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.485 ' O ' ' HA ' ' A' ' 89' ' ' ASP . 15.5 t-105 . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 49.57 110.051 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.538 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.8 ptm . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.281 0.562 . . . . 50.0 110.236 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.715 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.4 p -149.06 107.89 3.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.229 -0.919 . . . . 99.989999999999995 110.485 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.554 ' CG2' HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.32 51.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.629 -1.294 . . . . 99.989999999999995 110.759 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 2.0 pt-20 -78.9 12.19 2.29 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.084 -1.01 . . . . 99.989999999999995 110.005 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mptt -101.48 61.29 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.243 -0.911 . . . . 50.0 110.388 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.425 ' CE1' HD12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -100.41 144.17 29.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.11 -0.994 . . . . 50.0 109.66 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 30.6 t -127.28 100.13 5.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.065 -1.022 . . . . 50.0 110.658 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.588 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 10.2 p90 -59.02 107.94 0.6 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.202 -0.936 . . . . 50.0 110.258 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -94.58 -23.51 17.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.907 . . . . 50.0 109.824 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.463 ' HE3' ' OE1' ' A' ' 34' ' ' GLU . 13.0 mttt -142.11 143.81 33.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 50.0 110.084 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 43.9 p-10 -66.77 162.82 48.49 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 50.0 110.209 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 46.5 Cg_endo -73.0 135.07 22.52 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.947 1.498 . . . . 50.0 110.285 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.486 ' O ' HG21 ' A' ' 32' ' ' VAL . . . -136.55 156.83 48.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.191 -0.943 . . . . 50.0 110.317 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -85.53 148.53 25.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 50.0 110.043 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.492 HG21 HG13 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -116.91 -5.89 11.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.251 -0.905 . . . . 50.0 110.194 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -172.67 -105.77 0.19 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.318 -1.513 . . . . 50.0 109.318 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.59 88.8 2.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 50.0 110.024 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.407 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 97.93 31.23 6.72 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.557 -1.417 . . . . 50.0 109.557 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -136.62 107.85 6.82 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.22 -1.164 . . . . 50.0 110.431 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.445 HG21 ' CD ' ' A' ' 85' ' ' PRO . 21.7 t -97.01 145.48 8.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.253 -0.905 . . . . 50.0 110.118 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.492 HG13 HG21 ' A' ' 26' ' ' THR . 0.0 OUTLIER -126.27 137.74 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.236 -0.915 . . . . 50.0 110.486 -179.834 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 3.3 tt -140.33 152.86 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 50.0 109.893 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.463 ' OE1' ' HE3' ' A' ' 21' ' ' LYS . 2.0 tt0 -127.02 108.04 10.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.154 -0.966 . . . . 50.0 110.304 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.584 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 0.2 OUTLIER -122.7 138.97 54.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.252 -0.905 . . . . 50.0 109.544 179.588 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.635 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.9 OUTLIER -91.77 132.07 36.67 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.086 -1.009 . . . . 50.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.464 ' CE1' HG22 ' A' ' 14' ' ' THR . 8.3 t80 -93.87 95.7 9.26 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.911 -1.115 . . . . 50.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 81.8 p -96.11 69.52 2.76 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.305 -0.872 . . . . 50.0 109.977 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -119.3 131.0 8.8 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.318 -1.513 . . . . 99.989999999999995 109.318 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.1 m -84.71 21.93 1.44 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -1.135 . . . . 99.989999999999995 110.227 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.01 -2.09 44.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.918 . . . . 99.989999999999995 109.984 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.69 -159.39 31.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.597 -1.401 . . . . 99.989999999999995 109.597 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.559 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.6 Cg_endo -72.85 148.64 46.35 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.137 1.598 . . . . 99.989999999999995 110.497 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.715 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -170.42 161.43 7.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.924 . . . . 50.0 110.129 -179.582 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.562 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -74.81 128.3 35.24 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.091 -1.006 . . . . 50.0 109.563 179.35 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.577 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 9.6 mt -87.73 114.31 58.44 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.118 -0.989 . . . . 50.0 110.52 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.51 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 48.1 Cg_endo -76.88 101.72 1.54 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.063 1.56 . . . . 50.0 110.398 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.577 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 2.4 mp -129.04 155.11 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -0.927 . . . . 50.0 110.302 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 92' ' ' ILE . 14.8 p -130.65 145.32 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.294 -0.879 . . . . 50.0 109.814 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.445 ' O ' ' N ' ' A' ' 61' ' ' GLY . 61.5 m -122.76 111.25 16.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.134 -0.979 . . . . 50.0 109.895 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.529 ' HA ' HG22 ' A' ' 60' ' ' VAL . 35.9 m -135.91 161.49 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 50.0 110.561 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -56.2 164.44 1.29 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.471 -0.768 . . . . 50.0 110.097 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.655 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 1.3 m -60.31 114.64 3.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 50.0 110.292 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 79.72 30.49 0.27 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.548 -0.72 . . . . 50.0 110.498 179.776 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.446 ' O ' HG23 ' A' ' 51' ' ' VAL . 7.6 m-20 -122.5 85.02 2.35 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 50.0 110.302 179.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.66 16.81 24.62 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.945 . . . . 50.0 110.059 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 ttt -126.12 -10.23 6.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.314 -0.866 . . . . 50.0 110.348 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.14 115.65 14.12 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.226 -0.921 . . . . 50.0 110.212 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.64 127.77 12.75 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.96 1.505 . . . . 50.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.529 HG22 ' HA ' ' A' ' 51' ' ' VAL . 2.2 m -148.07 -33.67 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.253 -0.904 . . . . 50.0 110.294 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.64 146.35 40.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.479 ' O ' ' HB2' ' A' ' 83' ' ' MET . 4.6 mtt180 -139.12 156.95 46.77 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.071 -1.252 . . . . 50.0 110.736 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.405 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 5.9 mt -88.34 141.5 28.5 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 50.0 109.975 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.528 ' CG1' ' OE1' ' A' ' 82' ' ' GLU . 92.5 t -85.42 -12.76 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 50.0 110.213 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.526 ' OG1' ' CG ' ' A' ' 82' ' ' GLU . 0.0 OUTLIER -111.54 175.74 5.3 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.23 -0.919 . . . . 50.0 110.152 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.2 m -58.14 176.16 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.296 -0.877 . . . . 50.0 110.067 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.62 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 75.3 m-20 -46.83 141.92 5.24 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.208 -0.932 . . . . 50.0 109.992 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.472 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 50.2 Cg_endo -76.81 70.04 6.65 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.93 1.489 . . . . 50.0 110.896 -179.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 11.2 p90 -110.11 129.67 55.66 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.057 -1.027 . . . . 50.0 110.269 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.576 ' CG2' ' CD1' ' A' ' 46' ' ' ILE . 94.0 t -85.65 60.84 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 50.0 110.097 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.559 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.77 57.4 4.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.172 -0.955 . . . . 50.0 110.006 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.71 169.63 17.39 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.269 -0.894 . . . . 50.0 110.288 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 p -97.43 -4.34 38.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 50.0 109.833 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 93.2 p -121.19 9.47 10.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.324 -0.86 . . . . 99.989999999999995 110.538 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.551 ' HB2' ' CG1' ' A' ' 70' ' ' VAL . . . -78.51 8.11 5.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.047 -1.033 . . . . 99.989999999999995 109.941 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.436 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 20.1 m-80 -86.11 20.03 2.44 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 109.281 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.635 ' O ' ' HA ' ' A' ' 36' ' ' SER . 3.7 m -124.41 -173.08 2.69 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.386 -0.821 . . . . 99.989999999999995 109.359 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.545 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.0 OUTLIER -63.19 88.62 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.42 -0.8 . . . . 99.989999999999995 109.267 179.564 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.556 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 10.3 m -76.68 174.62 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.359 -0.838 . . . . 99.989999999999995 109.658 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.74 131.74 52.47 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.933 -1.104 . . . . 50.0 110.786 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.452 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -125.46 176.62 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 109.917 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.528 ' OE1' ' CG1' ' A' ' 64' ' ' VAL . 8.4 pt-20 -160.22 156.26 26.25 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -0.998 . . . . 50.0 110.354 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.531 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.8 OUTLIER -160.05 140.12 11.56 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -0.875 . . . . 50.0 110.291 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.407 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -104.11 86.36 1.28 Allowed Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.386 -0.821 . . . . 50.0 110.466 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 83' ' ' MET . 45.4 Cg_endo -71.44 170.16 19.11 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.818 1.431 . . . . 50.0 110.409 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.13 163.2 39.44 Favored 'Trans proline' 0 C--N 1.304 -1.814 0 O-C-N 124.036 1.545 . . . . 50.0 110.414 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.56 127.68 23.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.301 -0.874 . . . . 50.0 110.036 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.94 152.95 12.83 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 89' ' ' ASP . 13.8 p30 -53.05 155.12 2.64 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 50.0 110.195 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.602 ' HA ' ' N ' ' A' ' 53' ' ' SER . 11.9 p -141.47 153.32 44.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.254 -0.904 . . . . 50.0 110.386 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.592 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.5 m-30 -104.72 119.72 39.67 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.253 -0.905 . . . . 50.0 110.119 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.535 HG21 HD12 ' A' ' 92' ' ' ILE . 0.0 OUTLIER -110.91 129.7 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.166 -0.959 . . . . 50.0 110.027 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 21.2 t -115.56 139.19 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.157 -0.965 . . . . 50.0 110.536 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.55 ' CG2' HG12 ' A' ' 48' ' ' ILE . 53.8 t -120.91 104.03 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.409 -0.807 . . . . 50.0 110.081 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.515 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.95 168.55 33.46 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.708 -1.357 . . . . 50.0 109.708 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.51 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 26.5 ttm -98.36 -71.41 0.69 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.244 -1.151 . . . . 50.0 110.296 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.95 36.38 0.3 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.508 -1.437 . . . . 50.0 109.508 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.44 ' OD1' ' OE1' ' A' ' 15' ' ' GLU . 0.9 OUTLIER -162.18 -46.96 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.328 -1.101 . . . . 50.0 109.823 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.53 129.93 39.72 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.364 -0.835 . . . . 50.0 109.709 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.783 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.96 150.42 44.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.12 -0.987 . . . . 49.57 110.707 -179.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 1.4 mp -112.08 123.91 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.131 -0.98 . . . . 49.57 109.761 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -101.0 139.44 36.68 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.17 -0.956 . . . . 49.57 110.686 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.486 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 5.6 m-70 -120.41 160.93 22.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.416 -0.802 . . . . 49.57 109.856 179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' A' ' 104' ' ' HIS . 51.7 p-80 -118.38 92.28 3.78 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.204 -0.935 . . . . 49.57 110.509 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 2.3 t-105 . . . . . 0 N--CA 1.488 1.457 0 O-C-N 121.158 -0.964 . . . . 49.57 110.035 179.668 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.506 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.4 mtt . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 121.149 0.499 . . . . 50.0 110.241 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.644 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.75 107.55 3.84 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.054 -1.029 . . . . 99.989999999999995 110.558 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.482 HG23 HG12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -161.75 35.84 0.13 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.006 -1.059 . . . . 99.989999999999995 110.213 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.466 ' HG2' ' CE ' ' A' ' 96' ' ' MET . 1.1 pp20? -66.52 -5.44 11.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.451 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.567 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 8.8 mmtm -89.28 61.51 5.73 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 50.0 110.542 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.593 ' CZ ' HD11 ' A' ' 46' ' ' ILE . 0.0 OUTLIER -95.02 141.78 28.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.102 -0.999 . . . . 50.0 110.128 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.12 97.9 4.93 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 50.0 110.035 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.67 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 10.5 p90 -59.53 123.92 18.41 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.021 -1.049 . . . . 50.0 110.457 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.4 -23.96 12.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.335 -0.853 . . . . 50.0 109.969 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.477 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 11.8 mtmt -142.33 151.5 42.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 50.0 110.105 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -67.53 162.31 57.75 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 50.0 110.153 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.559 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.1 Cg_endo -71.86 127.79 13.39 Favored 'Trans proline' 0 C--N 1.303 -1.816 0 O-C-N 124.052 1.554 . . . . 50.0 110.3 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.98 147.83 46.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.257 -0.902 . . . . 50.0 110.37 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.474 ' HA ' ' O ' ' A' ' 30' ' ' THR . 18.5 t0 -87.75 148.11 24.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.885 . . . . 50.0 110.143 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.16 -69.55 0.86 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.125 -0.984 . . . . 50.0 110.237 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.41 -101.81 1.58 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.533 -1.427 . . . . 50.0 109.533 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 34.0 t60 -131.96 89.01 2.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -1.152 . . . . 50.0 110.342 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.496 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 100.15 5.92 54.18 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.661 -1.375 . . . . 50.0 109.661 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 14.4 p -101.9 107.67 18.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -1.169 . . . . 50.0 110.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.559 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 39.0 t -102.53 139.85 22.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.177 -0.952 . . . . 50.0 110.19 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.13 150.69 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -0.95 . . . . 50.0 110.319 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.57 HG12 ' CD1' ' A' ' 35' ' ' LEU . 0.6 OUTLIER -136.96 154.03 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.399 -0.813 . . . . 50.0 109.75 179.689 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.477 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 2.1 tp10 -119.55 91.44 3.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.129 -0.982 . . . . 50.0 110.9 -179.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.583 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 0.1 OUTLIER -119.03 138.79 52.6 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.289 -0.882 . . . . 50.0 109.081 179.274 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.568 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -93.78 135.16 35.37 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.06 -1.025 . . . . 50.0 110.175 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.567 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 5.8 t80 -94.38 103.34 15.33 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.964 -1.094 . . . . 50.0 109.558 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.82 69.6 3.38 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.22 -0.925 . . . . 50.0 110.038 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.491 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -118.46 139.33 14.47 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.439 -1.464 . . . . 99.989999999999995 109.439 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 40' ' ' SER . 2.6 t -82.95 31.08 0.43 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -1.124 . . . . 99.989999999999995 110.298 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.463 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -108.33 -11.96 15.12 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 99.989999999999995 110.243 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 -139.84 19.31 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.488 -1.445 . . . . 99.989999999999995 109.488 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.421 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -71.16 139.67 35.92 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.987 1.52 . . . . 99.989999999999995 110.248 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.601 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -169.38 157.57 7.51 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -0.867 . . . . 50.0 110.014 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.556 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.3 mmtt -76.34 129.15 36.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 50.0 109.178 178.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.615 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 10.3 mt -86.34 109.36 22.75 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 50.0 110.714 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 52.3 Cg_endo -78.98 99.42 1.26 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 O-C-N 124.056 1.556 . . . . 50.0 110.129 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.615 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 6.9 mt -136.11 144.01 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.072 -1.018 . . . . 50.0 110.471 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 23.0 m -116.19 148.54 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.399 -0.813 . . . . 50.0 109.835 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.5 OUTLIER -124.19 105.8 9.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.146 -0.971 . . . . 50.0 109.86 -179.932 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.489 ' O ' ' N ' ' A' ' 91' ' ' TYR . 4.3 m -129.7 159.49 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.281 -0.887 . . . . 50.0 110.34 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.435 ' HB1' ' CG ' ' A' ' 55' ' ' ASN . . . -55.94 163.72 1.41 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.856 . . . . 50.0 110.027 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.602 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 37.6 t -58.44 122.25 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.26 -0.9 . . . . 50.0 110.739 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.602 ' CB ' ' O ' ' A' ' 53' ' ' SER . 1.2 tp 78.32 30.56 0.41 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.919 -0.712 . . . . 50.0 110.827 179.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.435 ' CG ' ' HB1' ' A' ' 52' ' ' ALA . 10.3 m120 -126.66 84.11 2.23 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -0.957 . . . . 50.0 110.198 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -106.42 8.61 31.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.279 -0.888 . . . . 50.0 109.917 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.7 ttm -116.11 -13.26 11.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.418 -0.801 . . . . 50.0 110.131 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.16 134.06 19.96 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.368 -0.832 . . . . 50.0 110.104 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.79 134.75 22.41 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.941 1.495 . . . . 50.0 110.258 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 55.3 t -139.31 -46.87 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.237 -0.914 . . . . 50.0 109.848 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -75.43 156.35 48.27 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.67 -1.772 . . . . 50.0 108.67 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.434 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 15.3 mtp180 -138.04 157.15 46.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.881 -1.364 . . . . 50.0 110.722 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mp -91.3 134.65 34.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 50.0 109.737 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.499 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 4.0 t -72.83 -40.91 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.167 -0.958 . . . . 50.0 110.147 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.432 ' CG2' ' OE1' ' A' ' 82' ' ' GLU . 14.9 t -103.43 175.79 5.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.17 -0.956 . . . . 50.0 110.165 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.5 m -54.76 -172.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.394 -0.816 . . . . 50.0 110.098 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.603 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 1.8 m-20 -47.45 137.78 8.96 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.952 . . . . 50.0 110.073 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.553 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 48.0 Cg_endo -75.14 74.32 4.11 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.974 1.513 . . . . 50.0 110.707 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.603 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -107.27 141.32 38.78 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.141 -0.974 . . . . 50.0 110.282 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -103.69 60.26 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 50.0 109.358 179.398 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.421 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -69.67 57.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.359 -0.838 . . . . 50.0 110.364 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.38 165.09 28.37 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 50.0 110.104 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.68 7.32 17.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.151 -0.968 . . . . 50.0 110.117 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 8.0 t -121.47 17.62 11.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.26 -0.9 . . . . 99.989999999999995 110.488 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -69.03 -4.11 15.68 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.153 -0.967 . . . . 99.989999999999995 109.93 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.436 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 64.1 m-80 -88.58 24.01 2.09 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.364 -0.835 . . . . 99.989999999999995 109.416 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.568 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.3 OUTLIER -129.31 -173.19 2.93 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.368 -0.832 . . . . 99.989999999999995 109.442 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.52 ' N ' ' OG ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -63.7 88.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.114 179.507 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.583 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 15.8 m -76.45 174.35 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.292 -0.88 . . . . 99.989999999999995 109.199 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.3 tt -134.71 136.6 42.84 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.736 -1.227 . . . . 50.0 111.084 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.485 ' C ' ' HG3' ' A' ' 82' ' ' GLU . 2.1 t -117.33 166.73 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.456 -0.777 . . . . 50.0 109.751 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.499 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 5.6 mt-10 -134.75 146.34 49.29 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.071 -1.018 . . . . 50.0 110.271 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.468 ' HE1' ' HB ' ' A' ' 33' ' ' ILE . 0.0 OUTLIER -159.95 151.64 20.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.18 -0.95 . . . . 50.0 110.347 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.496 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -120.93 60.94 9.11 Favored Pre-proline 0 C--N 1.306 -1.286 0 O-C-N 121.239 -0.913 . . . . 50.0 110.509 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -73.34 158.78 47.94 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.073 1.565 . . . . 50.0 110.201 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.88 146.76 48.42 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.044 1.549 . . . . 50.0 110.453 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -52.97 146.89 10.14 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.269 -0.894 . . . . 50.0 110.062 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 122.71 172.75 14.03 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.394 -1.482 . . . . 50.0 109.394 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 11.4 m-20 -71.73 128.55 36.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.208 -1.171 . . . . 50.0 110.161 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.533 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.6 p -124.82 141.86 51.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 50.0 110.157 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.605 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -99.69 116.66 32.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.221 -0.924 . . . . 50.0 110.035 179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.494 ' C ' ' CD1' ' A' ' 92' ' ' ILE . 0.0 OUTLIER -103.83 133.88 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 50.0 109.947 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.467 ' N ' HD13 ' A' ' 92' ' ' ILE . 11.1 t -118.33 119.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.572 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.427 ' CG2' HG12 ' A' ' 48' ' ' ILE . 33.6 t -100.6 103.34 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 50.0 109.958 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.445 ' O ' ' HB2' ' A' ' 47' ' ' PRO . . . -155.25 147.78 17.2 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.484 -1.446 . . . . 50.0 109.484 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.535 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 12.3 ptp -102.28 1.71 36.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.257 -1.143 . . . . 50.0 110.224 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.89 -60.05 0.55 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.38 -77.61 0.23 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.23 -1.159 . . . . 50.0 110.205 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.5 mmtt -79.57 124.0 28.11 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.221 -0.925 . . . . 50.0 110.313 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.603 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.19 148.56 41.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.267 -0.895 . . . . 49.57 110.249 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.466 HG21 HD12 ' A' ' 101' ' ' ILE . 11.1 pt -137.29 130.13 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.243 -0.91 . . . . 49.57 110.232 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 34.0 p-10 -109.46 132.31 54.25 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.21 -0.932 . . . . 49.57 110.394 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.67 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -122.12 169.9 10.4 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.24 -0.912 . . . . 49.57 110.061 179.866 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.605 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 45.5 p-80 -118.68 123.89 46.03 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.213 -0.929 . . . . 49.57 110.4 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.538 ' CH2' HD11 ' A' ' 33' ' ' ILE . 26.1 m0 . . . . . 0 C--N 1.304 -1.375 0 O-C-N 121.294 -0.879 . . . . 49.57 110.23 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.509 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 1.1 mtm . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.041 0.448 . . . . 50.0 110.025 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.707 ' O ' ' CB ' ' A' ' 44' ' ' CYS . 12.0 p -148.89 107.23 3.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.067 -1.021 . . . . 99.989999999999995 110.785 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.494 ' HB ' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.76 31.8 0.15 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.672 -1.267 . . . . 99.989999999999995 110.489 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.458 ' HG3' ' HA2' ' A' ' 95' ' ' GLY . 10.3 tm-20 -71.01 -0.38 9.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -0.976 . . . . 99.989999999999995 110.106 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -87.94 61.68 6.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 50.0 110.403 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -94.72 146.28 24.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.894 . . . . 50.0 109.887 179.632 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 57.8 m -127.4 100.17 5.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.043 . . . . 50.0 110.659 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 103' ' ' HIS . 16.1 m-85 -57.2 115.24 2.55 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.193 -0.942 . . . . 50.0 109.802 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.455 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -102.81 -27.0 12.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.24 -0.912 . . . . 50.0 110.476 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 4.9 mttt -145.53 151.43 38.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.183 -0.948 . . . . 50.0 110.23 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.406 ' HA ' ' CH2' ' A' ' 105' ' ' TRP . 13.1 p30 -67.09 154.97 91.53 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 50.0 110.232 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.528 ' HD2' ' CE3' ' A' ' 105' ' ' TRP . 46.6 Cg_endo -73.24 141.2 31.91 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 O-C-N 124.097 1.577 . . . . 50.0 110.419 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.456 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -146.63 168.07 22.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.274 -0.891 . . . . 50.0 110.29 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -89.07 154.62 20.04 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 50.0 110.341 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.63 -48.06 1.4 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.307 -0.87 . . . . 50.0 110.074 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.52 -101.48 2.32 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.453 -1.459 . . . . 50.0 109.453 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -133.15 93.69 3.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -1.155 . . . . 50.0 110.23 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.6 19.75 57.68 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 50.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 70.7 p -115.35 107.83 15.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.28 -1.129 . . . . 50.0 110.283 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.457 HG22 ' HD2' ' A' ' 85' ' ' PRO . 98.7 t -85.32 143.82 10.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.251 -0.906 . . . . 50.0 110.174 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -125.14 149.32 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.213 -0.929 . . . . 50.0 110.409 -179.884 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.499 HG23 ' CD1' ' A' ' 35' ' ' LEU . 2.0 tt -152.51 163.4 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -0.851 . . . . 50.0 109.906 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.472 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.6 OUTLIER -132.46 102.07 5.59 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.12 -0.988 . . . . 50.0 110.502 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.567 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 0.2 OUTLIER -119.12 139.91 51.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.314 -0.867 . . . . 50.0 109.165 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.556 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -92.46 131.44 37.61 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.041 -1.037 . . . . 50.0 110.068 -179.457 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.476 ' HB3' ' O ' ' A' ' 75' ' ' ALA . 6.6 t80 -92.12 98.79 11.76 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.984 -1.086 . . . . 50.0 109.497 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 t -96.11 69.76 2.77 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.318 -0.864 . . . . 50.0 110.028 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -118.46 132.22 9.63 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.631 -1.388 . . . . 99.989999999999995 109.631 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 45.3 m -83.95 18.5 2.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.231 -1.158 . . . . 99.989999999999995 110.317 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -99.92 -1.08 38.17 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.241 -0.912 . . . . 99.989999999999995 110.225 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.6 -149.93 29.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.105 -1.598 . . . . 99.989999999999995 109.105 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.551 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.9 Cg_endo -73.35 150.67 47.19 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.916 1.482 . . . . 99.989999999999995 110.406 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.707 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -169.87 161.48 9.0 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.377 -0.827 . . . . 50.0 109.96 -179.487 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.629 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 24.0 mmtt -75.61 111.03 10.51 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.018 -1.051 . . . . 50.0 109.229 178.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.622 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 2.2 mt -72.29 110.66 8.5 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.966 . . . . 50.0 110.423 -179.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 50.3 Cg_endo -84.54 97.67 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.026 1.54 . . . . 50.0 110.652 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.622 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 24.2 mt -133.33 153.76 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 50.0 110.243 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 49' ' ' VAL . 11.2 p -125.78 110.97 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 50.0 110.23 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.478 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -91.52 100.74 13.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 50.0 109.751 179.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.536 ' CG1' ' O ' ' A' ' 58' ' ' THR . 24.8 t -122.2 155.2 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 50.0 110.223 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.517 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -60.92 164.36 4.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.204 -0.935 . . . . 50.0 109.208 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.619 ' N ' ' HA ' ' A' ' 90' ' ' SER . 16.8 t -71.53 101.27 2.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.721 -1.237 . . . . 50.0 108.936 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.542 ' HB2' ' O ' ' A' ' 53' ' ' SER . 5.0 tp 170.68 -61.67 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 C-N-CA 118.071 -1.451 . . . . 50.0 111.661 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.465 ' HB3' ' HB ' ' A' ' 58' ' ' THR . 60.4 m-20 -92.92 149.92 20.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.904 -1.123 . . . . 50.0 110.273 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -106.12 -20.61 13.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.226 -0.921 . . . . 50.0 110.187 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.9 ttp -126.55 31.31 5.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.282 -0.886 . . . . 50.0 110.27 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.536 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 59.6 m -126.87 120.62 22.81 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 50.0 110.171 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.5 126.0 11.16 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.968 1.509 . . . . 50.0 110.212 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.41 HG23 HG12 ' A' ' 51' ' ' VAL . 24.4 t -135.02 -47.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.91 . . . . 50.0 110.05 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.43 158.8 49.45 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.133 -1.587 . . . . 50.0 109.133 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 83' ' ' MET . 21.4 mtm180 -132.6 154.76 49.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.138 -1.213 . . . . 50.0 110.555 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.6 mt -94.15 129.67 40.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.383 -0.823 . . . . 50.0 109.866 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.424 ' CG2' ' HG2' ' A' ' 84' ' ' GLU . 24.2 t -80.84 -32.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.184 -0.948 . . . . 50.0 110.38 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' VAL . 15.2 t -79.33 168.35 19.64 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -0.964 . . . . 50.0 110.099 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.414 ' O ' ' O ' ' A' ' 65' ' ' THR . 7.3 m -50.99 179.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.191 -0.943 . . . . 50.0 110.057 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.617 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 14.1 m120 -46.96 143.62 4.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.204 -0.935 . . . . 50.0 110.058 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.456 ' O ' ' CD1' ' A' ' 46' ' ' ILE . 47.0 Cg_endo -73.56 66.42 4.65 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.963 1.507 . . . . 50.0 110.583 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.629 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 18.2 m-30 -118.3 121.84 41.42 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.895 . . . . 50.0 110.12 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.545 ' CG1' ' CB ' ' A' ' 75' ' ' ALA . 42.9 t -77.55 60.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.119 -0.988 . . . . 50.0 109.99 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.551 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -85.37 59.37 5.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.15 -0.969 . . . . 50.0 110.185 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -142.95 165.46 27.29 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 50.0 110.388 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -94.42 -4.4 48.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.308 -0.87 . . . . 50.0 110.005 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.62 7.91 11.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.304 -0.872 . . . . 99.989999999999995 110.204 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.545 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -76.05 8.58 3.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 110.102 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -86.56 19.29 2.91 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.266 -0.896 . . . . 99.989999999999995 109.25 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.556 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.1 p -128.68 -172.36 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.463 -0.773 . . . . 99.989999999999995 109.41 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.531 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 4.6 mttp -62.91 88.72 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.467 -0.893 . . . . 99.989999999999995 109.283 179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.553 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 28.9 m -76.43 173.85 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.318 -0.864 . . . . 99.989999999999995 109.418 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 33' ' ' ILE . 5.7 tt -126.18 125.56 42.66 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.933 -1.104 . . . . 50.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.436 HG23 ' CD1' ' A' ' 35' ' ' LEU . 1.2 t -122.29 166.03 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.387 -0.821 . . . . 50.0 109.868 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.431 ' OE1' ' C ' ' A' ' 81' ' ' VAL . 3.1 pm0 -147.4 160.29 42.73 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.181 -0.949 . . . . 50.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.473 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 2.5 ptt? -157.07 158.98 37.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 50.0 110.202 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.424 ' HG2' ' CG2' ' A' ' 64' ' ' VAL . 0.4 OUTLIER -115.86 57.05 1.31 Allowed Pre-proline 0 C--N 1.307 -1.247 0 O-C-N 121.111 -0.993 . . . . 50.0 110.746 -179.781 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.473 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.9 Cg_endo -71.44 170.48 18.35 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.936 1.493 . . . . 50.0 110.5 179.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -70.36 161.67 45.16 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.998 1.525 . . . . 50.0 110.439 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -74.88 144.67 43.25 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.272 -0.893 . . . . 50.0 110.155 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.38 178.87 16.62 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.285 -1.526 . . . . 50.0 109.285 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -67.85 131.21 45.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 50.0 110.102 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.619 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -120.28 140.71 50.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.25 -0.906 . . . . 50.0 110.351 -179.912 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.573 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.8 m-30 -94.02 104.72 16.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 50.0 109.788 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.504 ' O ' ' HA ' ' A' ' 102' ' ' ASN . 3.2 mm -97.88 125.54 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 50.0 109.918 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 101' ' ' ILE . 21.2 t -125.2 125.05 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.069 -1.02 . . . . 50.0 110.825 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.566 ' CG2' HG12 ' A' ' 48' ' ' ILE . 95.4 t -106.87 105.01 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.858 . . . . 50.0 109.785 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.498 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.43 155.64 24.19 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.963 -1.255 . . . . 50.0 109.963 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.53 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 3.7 ttm -111.17 -69.21 0.88 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.39 -1.065 . . . . 50.0 110.297 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.71 28.55 0.23 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.62 -1.392 . . . . 50.0 109.62 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -160.56 -50.91 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.173 -1.192 . . . . 50.0 110.241 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -126.16 149.34 49.05 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.301 -0.875 . . . . 50.0 110.164 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.599 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.99 148.92 42.59 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 49.57 110.481 -179.876 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.573 HD13 ' CE1' ' A' ' 103' ' ' HIS . 0.0 OUTLIER -126.2 124.23 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.331 -0.856 . . . . 49.57 109.552 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.0 p-10 -111.26 134.83 52.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.073 -1.017 . . . . 49.57 110.843 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.688 ' CD2' ' CD2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -127.59 124.09 37.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 49.57 110.105 179.608 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -78.9 98.44 6.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.375 -0.828 . . . . 49.57 110.337 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.528 ' CE3' ' HD2' ' A' ' 23' ' ' PRO . 8.1 m95 . . . . . 0 C--N 1.305 -1.354 0 O-C-N 121.266 -0.896 . . . . 49.57 110.477 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.604 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 10.4 mtp . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 121.066 0.46 . . . . 50.0 110.045 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.712 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.7 p -148.95 107.35 3.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.994 -1.066 . . . . 99.989999999999995 111.196 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.594 HG22 ' CE1' ' A' ' 37' ' ' TYR . 2.6 m -161.58 53.95 0.26 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.731 -1.231 . . . . 99.989999999999995 110.549 179.286 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.532 ' HB3' ' CB ' ' A' ' 96' ' ' MET . 18.7 pt-20 -75.29 4.72 6.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.089 -1.007 . . . . 99.989999999999995 110.181 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.517 ' HD2' ' CA ' ' A' ' 39' ' ' GLY . 6.3 mttp -92.36 61.31 3.8 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.216 -0.927 . . . . 50.0 110.397 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.6 ' CE1' ' HB2' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -96.65 145.87 25.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.05 -1.031 . . . . 50.0 109.926 179.647 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -127.17 104.42 7.95 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.209 -0.932 . . . . 50.0 110.392 -179.743 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -60.97 96.87 0.05 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.248 -0.908 . . . . 50.0 110.39 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.444 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -84.67 -29.21 25.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -0.924 . . . . 50.0 110.01 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.522 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 14.4 mttm -144.68 147.03 32.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 50.0 110.091 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -73.79 162.12 75.57 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 50.0 110.163 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.595 ' HG2' ' CD2' ' A' ' 105' ' ' TRP . 44.8 Cg_endo -72.44 131.8 18.13 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.023 1.538 . . . . 50.0 110.222 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -126.25 147.86 49.6 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.183 -0.948 . . . . 50.0 110.358 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -77.81 113.76 16.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.314 -0.866 . . . . 50.0 110.186 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -79.19 -14.22 59.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 50.0 110.343 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.74 -106.58 0.22 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . 0.465 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 9.4 p80 -121.98 102.67 8.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -1.144 . . . . 50.0 110.264 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 81.92 23.93 56.47 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.654 -1.378 . . . . 50.0 109.654 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 30.5 p -129.88 107.89 9.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.168 -1.195 . . . . 50.0 110.338 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.538 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -111.22 135.32 50.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.291 -0.881 . . . . 50.0 109.793 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.535 ' CG2' ' OG1' ' A' ' 26' ' ' THR . 1.4 t -114.65 136.75 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 50.0 110.542 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.546 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -141.89 133.2 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.459 -0.775 . . . . 50.0 109.499 179.784 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.526 ' N ' HD13 ' A' ' 33' ' ' ILE . 34.0 tt0 -112.21 117.52 32.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.141 -0.974 . . . . 50.0 111.274 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.6 ' HB2' ' CE1' ' A' ' 17' ' ' PHE . 0.1 OUTLIER -128.76 143.77 51.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.363 -0.836 . . . . 50.0 108.969 178.945 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.535 ' CA ' ' HA ' ' A' ' 78' ' ' LYS . 0.0 OUTLIER -95.61 132.42 40.78 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.98 -1.075 . . . . 50.0 110.209 -179.525 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.594 ' CE1' HG22 ' A' ' 14' ' ' THR . 6.9 t80 -95.02 99.6 11.58 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.253 -0.979 . . . . 50.0 109.731 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.1 t -95.93 69.82 2.86 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.202 -0.936 . . . . 50.0 110.144 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.517 ' CA ' ' HD2' ' A' ' 16' ' ' LYS . . . -120.72 118.08 3.71 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.51 -1.436 . . . . 99.989999999999995 109.51 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.8 p -85.39 21.81 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -1.154 . . . . 99.989999999999995 110.419 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.87 -0.52 50.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.024 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.69 -172.54 26.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.435 -1.466 . . . . 99.989999999999995 109.435 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.509 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 42.8 Cg_endo -70.82 152.69 64.04 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.195 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.712 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.04 161.59 8.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.223 -0.923 . . . . 50.0 109.902 -179.385 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.604 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.7 OUTLIER -77.29 129.18 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.159 -0.963 . . . . 50.0 109.583 179.373 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.583 HG23 ' CD1' ' A' ' 48' ' ' ILE . 10.0 mt -84.01 112.36 40.14 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.188 -0.945 . . . . 50.0 110.39 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.5 ' C ' ' CD1' ' A' ' 48' ' ' ILE . 50.0 Cg_endo -77.41 74.9 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 124.001 1.527 . . . . 50.0 110.306 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.609 HG13 ' CG2' ' A' ' 94' ' ' VAL . 1.4 mp -115.41 151.04 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.146 -0.971 . . . . 50.0 110.294 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 23.8 m -128.32 147.15 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.439 -0.788 . . . . 50.0 110.09 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -122.25 100.76 7.13 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.362 -0.836 . . . . 50.0 109.654 179.673 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 91' ' ' TYR . 25.4 m -114.99 160.86 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.234 -0.916 . . . . 50.0 110.421 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.456 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -60.25 164.63 4.06 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.42 -0.8 . . . . 50.0 109.927 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.7 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 3.4 t -66.64 120.49 13.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.181 -0.949 . . . . 50.0 109.805 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.7 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.1 tp 87.18 29.27 0.03 OUTLIER 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.658 -0.652 . . . . 50.0 110.725 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.486 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 66.9 m-80 -144.18 84.81 1.78 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.114 -0.991 . . . . 50.0 110.182 179.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.22 6.24 42.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.197 -0.939 . . . . 50.0 110.111 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.2 mmt -107.83 -14.59 14.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.26 -0.9 . . . . 50.0 110.081 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.3 p -133.14 119.83 15.82 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 50.0 110.04 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.84 125.85 10.83 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.942 1.496 . . . . 50.0 110.245 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.473 HG13 ' HA ' ' A' ' 51' ' ' VAL . 3.4 p -131.45 -33.72 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 50.0 110.025 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.91 143.45 34.95 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.697 -1.761 . . . . 50.0 108.697 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.466 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -126.62 156.27 41.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.055 -1.262 . . . . 50.0 110.794 -179.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -93.84 129.8 40.11 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.808 . . . . 50.0 109.927 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.489 HG13 ' HB2' ' A' ' 82' ' ' GLU . 4.0 p -54.07 -26.11 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.158 -0.964 . . . . 50.0 110.209 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -114.56 176.05 5.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.285 -0.885 . . . . 50.0 110.117 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.5 m -59.15 -170.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.162 -0.961 . . . . 50.0 110.225 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.623 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 15.2 t30 -46.79 140.3 6.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 50.0 109.987 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.552 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 47.7 Cg_endo -74.84 78.07 2.93 Favored 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 123.989 1.521 . . . . 50.0 110.557 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.623 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.3 p90 -105.4 136.06 45.64 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.137 -0.977 . . . . 50.0 110.402 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.554 ' CG2' ' CD1' ' A' ' 46' ' ' ILE . 85.7 t -91.66 60.65 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 50.0 109.976 179.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.509 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -82.13 57.79 3.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.324 -0.86 . . . . 50.0 110.017 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 169.11 18.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.315 -0.865 . . . . 50.0 110.177 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -100.2 -5.59 27.43 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 50.0 109.977 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.8 t -121.25 10.12 10.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 110.507 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.535 ' CB ' HG11 ' A' ' 70' ' ' VAL . . . -80.77 10.43 4.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.018 -1.051 . . . . 99.989999999999995 110.004 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.464 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 96.6 m-20 -84.51 16.81 2.94 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.314 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.514 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.3 OUTLIER -120.44 -172.42 2.36 Favored 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.441 -0.787 . . . . 99.989999999999995 109.347 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.535 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.2 OUTLIER -62.79 87.94 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.354 -0.938 . . . . 99.989999999999995 109.006 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.566 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 13.4 m -77.18 175.97 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.356 -0.84 . . . . 99.989999999999995 109.685 -179.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -127.93 142.01 51.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.918 -1.114 . . . . 50.0 110.705 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.587 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 0.0 OUTLIER -134.54 166.66 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.423 -0.798 . . . . 50.0 109.867 179.745 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.489 ' HB2' HG13 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -145.11 152.45 40.07 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.289 -0.882 . . . . 50.0 110.266 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.487 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 9.7 ptt? -155.3 144.96 21.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 50.0 110.302 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.43 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -106.93 74.87 0.39 Allowed Pre-proline 0 C--N 1.305 -1.369 0 O-C-N 121.286 -0.884 . . . . 50.0 110.397 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.538 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.4 Cg_endo -72.88 167.71 26.57 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.914 1.481 . . . . 50.0 110.5 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.45 ' HG3' HG23 ' A' ' 60' ' ' VAL . 45.6 Cg_endo -71.43 154.32 60.68 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.947 1.498 . . . . 50.0 110.584 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.94 134.26 48.6 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.237 -0.914 . . . . 50.0 110.04 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.87 -168.54 13.68 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.379 -1.489 . . . . 50.0 109.379 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.527 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 7.2 m-20 -82.91 153.16 25.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -1.16 . . . . 50.0 110.116 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.542 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -136.96 138.61 40.77 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.284 -0.885 . . . . 50.0 110.296 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.582 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.7 m-30 -99.23 124.3 44.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.097 -1.002 . . . . 50.0 109.797 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.438 ' N ' ' CD1' ' A' ' 92' ' ' ILE . 4.9 mp -111.0 132.35 59.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.249 -0.907 . . . . 50.0 110.159 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 101' ' ' ILE . 20.9 t -125.16 120.81 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.822 -1.174 . . . . 50.0 111.365 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.609 ' CG2' HG13 ' A' ' 48' ' ' ILE . 94.9 t -98.19 106.56 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -0.849 . . . . 50.0 109.436 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.485 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.42 142.99 13.34 Favored Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.568 -1.301 . . . . 50.0 110.093 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.532 ' CB ' ' HB3' ' A' ' 15' ' ' GLU . 25.8 ttp -115.74 70.07 0.74 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -1.042 . . . . 50.0 109.957 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 56.03 18.9 20.89 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.559 -1.416 . . . . 50.0 109.559 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -149.36 -88.1 0.08 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -1.104 . . . . 50.0 110.098 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.444 ' O ' ' CA ' ' A' ' 95' ' ' GLY . 0.9 OUTLIER -79.76 155.18 28.04 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.244 -0.91 . . . . 50.0 110.322 -179.876 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.684 ' HG2' ' O ' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -140.75 87.74 2.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.182 -0.949 . . . . 49.57 110.695 179.768 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.55 ' CG2' ' HB ' ' A' ' 94' ' ' VAL . 1.1 tp -85.32 116.45 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.015 -1.053 . . . . 49.57 109.781 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 22.5 p30 -106.77 151.94 24.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.853 . . . . 49.57 110.963 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.447 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.2 OUTLIER -129.67 156.94 43.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.5 -0.75 . . . . 49.57 109.573 179.787 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.57 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 5.7 m170 -114.27 80.83 1.45 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.314 -0.867 . . . . 49.57 110.581 -179.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.595 ' CD2' ' HG2' ' A' ' 23' ' ' PRO . 10.4 t-105 . . . . . 0 N--CA 1.489 1.493 0 O-C-N 121.298 -0.877 . . . . 49.57 110.027 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.524 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.131 0.491 . . . . 50.0 109.952 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.652 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -141.15 106.64 5.06 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.216 -0.927 . . . . 99.989999999999995 110.848 -179.883 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.559 ' CB ' ' HA ' ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.98 35.63 0.12 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 99.989999999999995 110.288 179.029 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.415 ' HB2' ' HB3' ' A' ' 96' ' ' MET . 6.9 tm-20 -68.25 3.51 1.66 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.214 -0.929 . . . . 99.989999999999995 110.422 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.18 60.55 0.68 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 50.0 110.836 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.542 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -92.81 142.39 27.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.114 -0.991 . . . . 50.0 109.499 179.074 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.563 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.0 t -127.4 98.38 5.23 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.117 -0.989 . . . . 50.0 110.608 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD1' HD22 ' A' ' 35' ' ' LEU . 17.8 m-85 -56.02 97.1 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.23 -0.919 . . . . 50.0 109.857 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.06 -29.85 26.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 50.0 110.491 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.473 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 26.9 mttm -143.11 145.43 32.84 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.098 -1.001 . . . . 50.0 110.397 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.441 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 10.8 p30 -66.74 163.79 39.42 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 50.0 109.922 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.508 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.4 Cg_endo -71.78 134.59 24.15 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.903 1.475 . . . . 50.0 110.288 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -128.17 160.86 30.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.209 -0.932 . . . . 50.0 110.194 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -94.46 143.16 26.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.226 -0.921 . . . . 50.0 110.253 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.83 -39.66 5.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.223 -0.923 . . . . 50.0 110.157 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -142.72 -105.12 0.53 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.405 -1.478 . . . . 50.0 109.405 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -129.61 97.91 4.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.135 -1.215 . . . . 50.0 110.25 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.38 30.31 10.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 45.4 p -134.62 114.91 13.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.252 -1.146 . . . . 50.0 110.366 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.508 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 43.7 t -111.29 124.93 68.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.307 -0.871 . . . . 50.0 109.907 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.414 HG12 HD21 ' A' ' 80' ' ' LEU . 2.1 t -108.18 151.76 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.231 -0.918 . . . . 50.0 110.489 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.549 ' CG2' ' HB ' ' A' ' 81' ' ' VAL . 7.4 tt -150.45 166.96 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.448 -0.782 . . . . 50.0 109.515 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.553 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 6.4 tp10 -136.66 104.15 5.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.116 -0.99 . . . . 50.0 110.711 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.595 ' CD1' ' CG2' ' A' ' 81' ' ' VAL . 0.4 OUTLIER -114.28 137.02 52.32 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.256 -0.903 . . . . 50.0 109.536 179.338 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.518 ' HA ' ' HA ' ' A' ' 78' ' ' LYS . 4.7 m -86.46 126.4 34.38 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.079 -1.013 . . . . 50.0 109.769 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.523 ' CD2' HG13 ' A' ' 70' ' ' VAL . 10.9 t80 -93.32 102.42 14.68 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.028 -1.069 . . . . 50.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -96.34 70.07 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.309 -0.869 . . . . 50.0 110.149 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -115.91 123.26 5.83 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.533 -1.427 . . . . 99.989999999999995 109.533 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.99 12.4 4.17 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.245 -1.15 . . . . 99.989999999999995 110.355 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' N ' ' OD1' ' A' ' 41' ' ' ASP . 0.8 OUTLIER -97.6 -1.73 43.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 99.989999999999995 110.016 179.837 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 91.15 -156.61 24.4 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.527 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.5 Cg_endo -71.47 150.89 58.62 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 124.035 1.545 . . . . 99.989999999999995 110.358 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.652 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.8 OUTLIER -170.73 162.69 7.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.269 -0.895 . . . . 50.0 110.036 -179.522 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.591 ' HD2' ' CG ' ' A' ' 69' ' ' PHE . 44.9 mmtt -72.89 131.74 42.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.103 -0.998 . . . . 50.0 110.045 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.567 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 2.4 mt -89.62 109.32 31.15 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.204 -0.935 . . . . 50.0 110.624 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.9 Cg_endo -79.13 68.44 8.28 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.087 1.572 . . . . 50.0 110.14 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.567 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 1.7 mp -111.59 145.62 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.161 -0.962 . . . . 50.0 110.25 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 49' ' ' VAL . 34.1 m -118.14 139.13 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.334 -0.854 . . . . 50.0 110.108 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -119.9 100.66 7.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.326 -0.859 . . . . 50.0 109.806 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.504 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.7 m -124.0 159.82 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.306 -0.871 . . . . 50.0 110.284 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.432 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.51 163.88 1.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.392 -0.818 . . . . 50.0 109.766 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.829 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 2.2 m -73.57 104.27 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -0.993 . . . . 50.0 110.034 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.829 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 117.69 19.61 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.318 0 CA-C-O 121.113 0.482 . . . . 50.0 110.509 179.791 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.409 ' ND2' ' HB ' ' A' ' 58' ' ' THR . 0.2 OUTLIER -138.01 84.67 2.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.969 -1.082 . . . . 50.0 110.324 179.42 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.57 14.74 23.71 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.242 -0.911 . . . . 50.0 109.727 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 ttt -126.22 -12.99 6.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.327 -0.858 . . . . 50.0 110.383 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.409 ' HB ' ' ND2' ' A' ' 55' ' ' ASN . 3.6 m -128.58 129.78 23.53 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.913 . . . . 50.0 110.23 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.457 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.57 132.48 18.98 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 O-C-N 124.044 1.55 . . . . 50.0 110.182 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.86 -42.32 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.125 -0.984 . . . . 50.0 110.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.09 135.4 17.62 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.055 -1.618 . . . . 50.0 109.055 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.492 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.9 mtm180 -119.43 152.27 37.15 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.099 -1.236 . . . . 50.0 110.626 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mt -94.08 124.36 38.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.268 -0.895 . . . . 50.0 110.074 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.493 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 94.1 t -81.16 -38.8 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.218 -0.926 . . . . 50.0 110.364 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -65.84 172.73 3.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.186 -0.946 . . . . 50.0 110.095 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.3 m -53.4 179.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.219 -0.926 . . . . 50.0 110.007 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.638 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.84 144.22 3.85 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 50.0 110.154 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.5 Cg_endo -73.59 66.52 4.67 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.999 1.526 . . . . 50.0 110.961 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.638 ' CD2' ' HB3' ' A' ' 67' ' ' ASN . 19.9 m-30 -126.31 122.37 35.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.317 -0.864 . . . . 50.0 110.07 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.543 ' CG1' ' HB3' ' A' ' 75' ' ' ALA . 41.1 t -70.31 61.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.047 -1.033 . . . . 50.0 109.879 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.527 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -96.07 66.35 2.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.166 -0.959 . . . . 50.0 110.212 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.67 169.44 17.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.297 -0.877 . . . . 50.0 110.292 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.08 -14.56 31.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 50.0 110.184 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 75.1 m -121.16 23.2 10.65 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.332 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.543 ' HB3' ' CG1' ' A' ' 70' ' ' VAL . . . -80.56 9.94 5.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.126 -0.984 . . . . 99.989999999999995 110.31 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -88.05 18.01 4.58 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 109.188 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 36' ' ' SER . 18.1 t -133.01 -171.91 2.8 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.554 -0.716 . . . . 99.989999999999995 109.551 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.54 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 0.4 OUTLIER -62.86 90.48 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 109.187 179.539 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.553 ' O ' ' HA ' ' A' ' 34' ' ' GLU . 31.4 m -76.19 172.01 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.286 -0.884 . . . . 99.989999999999995 109.555 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.439 HD13 ' OE1' ' A' ' 34' ' ' GLU . 7.8 tt -117.14 119.75 36.18 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.055 -1.028 . . . . 50.0 111.005 -179.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.595 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 2.9 t -108.58 169.91 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.33 -0.857 . . . . 50.0 109.571 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.493 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 2.6 mt-10 -151.17 151.29 31.71 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.034 . . . . 50.0 110.58 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.488 ' HB2' ' O ' ' A' ' 62' ' ' ARG . 8.3 ptt? -160.36 153.3 21.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.865 . . . . 50.0 110.18 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.492 ' HG3' ' HB2' ' A' ' 62' ' ' ARG . 2.2 pt-20 -114.46 59.3 1.0 Allowed Pre-proline 0 C--N 1.306 -1.292 0 O-C-N 121.152 -0.967 . . . . 50.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.487 ' HD3' ' HG3' ' A' ' 83' ' ' MET . 44.1 Cg_endo -71.34 170.24 18.83 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.859 1.452 . . . . 50.0 110.331 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.14 163.19 39.47 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.035 1.545 . . . . 50.0 110.363 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -72.33 144.15 48.4 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.172 -0.955 . . . . 50.0 110.168 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 118.32 -160.42 13.9 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.306 -1.517 . . . . 50.0 109.306 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.514 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 3.2 m-20 -90.45 146.98 23.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.255 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.517 ' HA ' ' N ' ' A' ' 53' ' ' SER . 78.8 p -130.33 143.75 50.96 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 50.0 110.078 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' A' ' 104' ' ' HIS . 0.1 OUTLIER -91.48 108.34 19.83 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.161 -0.962 . . . . 50.0 110.173 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 3.0 mp -101.22 125.75 55.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.281 -0.887 . . . . 50.0 109.355 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.532 ' CG2' ' HB3' ' A' ' 102' ' ' ASN . 26.3 t -124.7 117.41 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.893 -1.13 . . . . 50.0 111.268 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.526 HG13 ' CG1' ' A' ' 48' ' ' ILE . 15.0 t -95.25 105.98 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.321 -0.862 . . . . 50.0 109.34 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.476 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -133.91 140.11 11.49 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.683 -1.246 . . . . 50.0 110.064 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.512 ' HG3' ' HA ' ' A' ' 13' ' ' CYS . 10.0 tmm? -131.32 -26.28 2.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.368 -1.078 . . . . 50.0 110.239 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 166.73 -24.39 0.13 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.778 -1.329 . . . . 50.0 109.778 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -81.39 -70.16 0.56 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -1.163 . . . . 50.0 110.343 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -150.53 136.54 18.45 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.285 -0.885 . . . . 50.0 110.022 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.568 ' NE2' ' N ' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -78.47 108.06 11.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.283 -0.886 . . . . 49.57 110.547 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.437 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 4.1 mt -94.88 110.75 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 49.57 110.131 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.532 ' HB3' ' CG2' ' A' ' 93' ' ' VAL . 15.3 p30 -106.4 130.03 54.28 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.245 -0.909 . . . . 49.57 110.422 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.93 134.72 44.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 49.57 110.187 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.62 ' NE2' ' CZ ' ' A' ' 91' ' ' TYR . 1.7 m-70 -72.32 140.91 48.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 49.57 110.073 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.48 ' HA ' ' CE3' ' A' ' 105' ' ' TRP . 2.4 m95 . . . . . 0 C--N 1.305 -1.335 0 O-C-N 121.158 -0.963 . . . . 49.57 110.4 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.57 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.047 0.451 . . . . 50.0 110.192 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.765 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.83 105.58 3.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.021 -1.05 . . . . 99.989999999999995 111.507 -179.779 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.688 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.93 19.54 0.08 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.922 -1.112 . . . . 99.989999999999995 110.427 178.392 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.445 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 1.1 pp20? -57.77 -11.87 2.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.09 -1.007 . . . . 99.989999999999995 110.42 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.407 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 4.3 mptt -80.15 60.71 3.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 50.0 110.382 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.459 ' CD2' HG13 ' A' ' 94' ' ' VAL . 0.1 OUTLIER -93.75 149.36 21.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.249 -0.907 . . . . 50.0 109.917 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.666 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 t -127.43 136.34 51.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.178 -0.951 . . . . 50.0 109.799 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 0.4 OUTLIER -83.48 115.14 21.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.068 -1.02 . . . . 50.0 110.185 -179.769 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 34' ' ' GLU . . . -104.71 -35.8 7.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.35 -0.844 . . . . 50.0 109.953 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.52 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 16.5 mttm -147.53 153.57 39.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.212 -0.93 . . . . 50.0 110.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 29.6 p-10 -68.26 165.16 36.37 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 50.0 109.875 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.8 141.58 37.6 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.854 1.449 . . . . 50.0 110.199 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.455 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -137.68 165.64 25.89 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.191 -0.943 . . . . 50.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -90.49 159.08 16.7 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 50.0 110.136 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -134.24 -45.55 0.77 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.326 -0.859 . . . . 50.0 110.217 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -133.38 -111.51 1.26 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.496 -1.442 . . . . 50.0 109.496 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -128.68 91.39 3.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -1.124 . . . . 50.0 110.211 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 95.4 31.0 7.77 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.506 -1.438 . . . . 50.0 109.506 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.444 HG23 HG11 ' A' ' 64' ' ' VAL . 0.2 OUTLIER -137.04 110.24 7.81 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.238 -1.154 . . . . 50.0 110.42 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 41.3 t -95.94 149.19 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.273 -0.892 . . . . 50.0 110.059 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.455 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -124.06 148.5 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 50.0 110.577 -179.761 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.47 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -147.36 142.3 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.42 -0.8 . . . . 50.0 109.776 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -109.53 101.98 10.87 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 50.0 110.309 -179.736 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.666 ' HA ' ' O ' ' A' ' 18' ' ' SER . 0.3 OUTLIER -120.86 137.71 54.43 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.327 -0.858 . . . . 50.0 109.45 179.525 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -91.44 132.73 36.03 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.081 -1.012 . . . . 50.0 110.064 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.557 ' CE1' HG21 ' A' ' 14' ' ' THR . 33.4 t80 -96.1 95.51 8.22 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.843 -1.143 . . . . 50.0 109.761 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.66 69.64 2.52 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.336 -0.852 . . . . 50.0 109.725 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.07 135.13 12.65 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.691 -1.364 . . . . 99.989999999999995 109.691 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 95.2 p -86.12 13.52 7.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 99.989999999999995 110.27 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -98.48 -20.0 17.34 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.264 -0.898 . . . . 99.989999999999995 110.134 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.64 -165.63 14.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.364 -1.494 . . . . 99.989999999999995 109.364 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.409 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.3 Cg_endo -73.28 140.42 30.59 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 123.868 1.457 . . . . 99.989999999999995 110.563 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.765 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -167.53 162.13 14.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.585 -0.697 . . . . 50.0 109.131 -179.887 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.57 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 9.9 mmtm -59.84 138.28 57.84 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.947 -1.095 . . . . 50.0 110.49 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.688 ' HA ' ' HB ' ' A' ' 14' ' ' THR . 1.5 mt -93.11 109.11 37.64 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 50.0 110.545 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.0 Cg_endo -75.55 96.06 1.03 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.154 1.607 . . . . 50.0 110.219 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.545 HG12 ' CG2' ' A' ' 94' ' ' VAL . 10.2 mt -132.38 145.57 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.881 . . . . 50.0 110.356 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.6 m -115.96 130.93 69.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.324 -0.86 . . . . 50.0 109.912 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.566 ' O ' ' N ' ' A' ' 61' ' ' GLY . 13.3 m -114.71 101.27 8.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 50.0 109.81 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.9 m -131.12 159.7 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.285 -0.885 . . . . 50.0 110.236 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.522 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.13 163.92 1.43 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 50.0 109.898 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.627 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 29.3 t -63.47 122.54 16.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.156 -0.965 . . . . 50.0 110.484 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.627 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 78.72 30.24 0.37 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.513 -0.742 . . . . 50.0 110.579 179.785 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.473 ' O ' HG23 ' A' ' 51' ' ' VAL . 49.8 m-80 -136.23 84.64 2.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 50.0 110.086 179.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -105.43 8.6 33.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.245 -0.909 . . . . 50.0 110.187 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.9 ttt -103.75 -18.29 14.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 50.0 109.921 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -136.08 128.51 17.59 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.508 -0.745 . . . . 50.0 109.911 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.465 ' HA ' HG12 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.46 132.31 20.41 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 123.931 1.49 . . . . 50.0 110.396 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.475 HG11 ' HG3' ' A' ' 86' ' ' PRO . 12.1 t -135.12 -43.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.342 -0.849 . . . . 50.0 109.771 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.78 149.4 44.75 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.685 -1.766 . . . . 50.0 108.685 179.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.493 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 9.5 mtp85 -141.07 157.03 45.87 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.85 -1.382 . . . . 50.0 110.908 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 6.6 mp -94.32 129.54 40.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 50.0 109.845 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.549 ' CG2' ' HG2' ' A' ' 84' ' ' GLU . 43.9 t -79.87 7.3 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.234 -0.916 . . . . 50.0 110.329 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.464 ' CG2' ' HB2' ' A' ' 82' ' ' GLU . 68.9 p -115.5 167.05 11.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.136 -0.978 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 65' ' ' THR . 16.7 m -52.87 -170.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 O-C-N 121.225 -0.922 . . . . 50.0 110.089 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -46.41 149.95 1.26 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.128 -0.982 . . . . 50.0 110.044 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.16 91.03 0.75 Allowed 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.006 1.529 . . . . 50.0 110.691 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.676 ' CZ ' ' CB ' ' A' ' 71' ' ' ALA . 1.2 t80 -155.12 121.51 5.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.345 -0.847 . . . . 50.0 109.932 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.563 ' CG1' ' O ' ' A' ' 70' ' ' VAL . 6.5 p -95.43 60.84 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.252 -0.905 . . . . 50.0 110.166 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.676 ' CB ' ' CZ ' ' A' ' 69' ' ' PHE . . . -73.9 82.44 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 50.0 110.235 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.74 148.88 37.97 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.229 -0.92 . . . . 50.0 110.359 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.2 t -68.45 -15.57 63.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 50.0 109.874 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -121.09 23.31 10.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.301 -0.874 . . . . 99.989999999999995 110.373 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.546 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . . . -72.32 1.34 7.94 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.099 -1.0 . . . . 99.989999999999995 110.397 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.477 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 57.8 m-80 -87.2 24.12 1.66 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.174 -0.954 . . . . 99.989999999999995 109.397 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.581 ' O ' ' HA ' ' A' ' 36' ' ' SER . 2.3 p -128.7 -173.08 2.87 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.476 -0.765 . . . . 99.989999999999995 109.268 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.449 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -63.44 88.83 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.334 -0.854 . . . . 99.989999999999995 109.186 179.478 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.57 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 15.9 m -76.52 176.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.449 -0.782 . . . . 99.989999999999995 109.695 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 2.5 tt -127.57 128.36 45.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.888 -1.132 . . . . 50.0 111.054 -179.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 35' ' ' LEU . 3.2 t -115.45 172.19 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.354 -0.841 . . . . 50.0 110.024 179.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.464 ' HB2' ' CG2' ' A' ' 65' ' ' THR . 2.6 mt-10 -148.1 140.79 24.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.169 -0.957 . . . . 50.0 110.195 179.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.455 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 6.7 ptt? -151.52 146.75 26.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.122 -0.987 . . . . 50.0 110.62 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.549 ' HG2' ' CG2' ' A' ' 64' ' ' VAL . 0.9 OUTLIER -109.34 75.55 0.74 Allowed Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.408 -0.808 . . . . 50.0 110.132 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.26 159.43 47.08 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 124.044 1.549 . . . . 50.0 110.536 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.475 ' HG3' HG11 ' A' ' 60' ' ' VAL . 44.0 Cg_endo -71.02 148.44 56.93 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.079 1.568 . . . . 50.0 110.685 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -58.82 137.23 57.84 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.295 -0.878 . . . . 50.0 110.203 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.78 -125.96 6.43 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.537 ' HB3' ' CB ' ' A' ' 53' ' ' SER . 19.9 t0 -120.51 146.03 46.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -1.147 . . . . 50.0 110.213 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.532 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -141.7 137.57 31.81 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -0.894 . . . . 50.0 110.247 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.592 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 1.9 m-30 -98.98 117.28 33.14 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 50.0 109.952 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.477 ' CD1' ' HB2' ' A' ' 105' ' ' TRP . 3.2 mp -109.5 133.2 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 50.0 110.139 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.412 ' HB ' HG22 ' A' ' 49' ' ' VAL . 11.5 t -124.8 121.39 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.03 . . . . 50.0 110.734 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.545 ' CG2' HG12 ' A' ' 48' ' ' ILE . 24.5 t -106.9 101.67 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.279 -0.888 . . . . 50.0 109.747 179.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.487 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.32 168.31 33.09 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.793 -1.323 . . . . 50.0 109.793 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.445 ' HB2' ' HB3' ' A' ' 15' ' ' GLU . 6.4 ttm -107.13 -55.15 2.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.395 -1.062 . . . . 50.0 110.175 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -166.37 -40.72 0.02 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.6 -85.26 0.22 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -1.172 . . . . 50.0 110.031 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.6 mmtm -79.72 128.87 33.95 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.262 -0.898 . . . . 50.0 110.061 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.654 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -132.53 149.75 52.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 49.57 109.894 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.427 HD13 HG21 ' A' ' 101' ' ' ILE . 49.4 mm -122.81 122.5 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.117 -0.989 . . . . 49.57 110.258 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.403 ' OD1' ' N ' ' A' ' 102' ' ' ASN . 20.1 p-10 -109.99 136.57 49.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 49.57 110.349 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -124.43 164.54 19.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.886 . . . . 49.57 109.917 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -113.78 88.55 2.87 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.285 -0.884 . . . . 49.57 110.563 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.477 ' HB2' ' CD1' ' A' ' 92' ' ' ILE . 1.7 t90 . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.321 -0.862 . . . . 49.57 110.227 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.495 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 23.0 mtm . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 121.151 0.501 . . . . 50.0 110.442 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.661 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 7.2 p -148.74 108.84 4.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.173 -0.954 . . . . 99.989999999999995 110.538 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.611 HG21 ' CE1' ' A' ' 37' ' ' TYR . 1.2 m -160.27 50.37 0.29 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.93 -1.106 . . . . 99.989999999999995 110.264 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.606 ' CB ' ' CB ' ' A' ' 96' ' ' MET . 3.8 pt-20 -77.88 28.18 0.17 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 99.989999999999995 110.743 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.445 ' HG2' ' C ' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -129.24 60.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.89 -1.131 . . . . 50.0 110.878 -179.87 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.543 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -91.98 143.69 26.22 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.136 -0.978 . . . . 50.0 109.743 179.328 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.596 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 m -127.33 103.85 7.61 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 50.0 110.466 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -61.24 98.38 0.08 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.153 -0.967 . . . . 50.0 110.0 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.469 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -84.88 -32.96 22.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 50.0 109.879 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.469 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 0.1 OUTLIER -142.54 145.23 33.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.352 -0.842 . . . . 50.0 110.187 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' CZ3' ' A' ' 105' ' ' TRP . 24.6 p30 -67.37 161.14 67.18 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 50.0 110.013 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.588 ' HG2' ' CD1' ' A' ' 105' ' ' TRP . 44.5 Cg_endo -71.55 126.07 11.79 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.909 1.479 . . . . 50.0 110.347 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -123.06 152.72 40.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 50.0 110.282 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.5 p30 -90.87 130.03 36.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 50.0 110.078 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.21 -0.69 22.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.18 -0.95 . . . . 50.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -174.59 -129.46 1.19 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.77 98.43 7.4 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -1.162 . . . . 50.0 110.225 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.29 28.23 23.18 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 3.8 p -130.15 107.55 9.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -1.206 . . . . 50.0 110.182 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.525 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 57.8 t -111.22 114.89 48.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 50.0 110.086 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.2 m -94.56 139.45 18.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.208 -0.932 . . . . 50.0 110.522 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.563 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -143.57 137.38 25.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.4 -0.812 . . . . 50.0 109.678 179.68 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.468 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 18.5 tt0 -113.08 117.24 31.44 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.078 -1.014 . . . . 50.0 110.883 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.596 ' HA ' ' O ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -128.15 141.54 51.45 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.306 -0.871 . . . . 50.0 109.407 179.233 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.551 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -86.84 123.66 32.21 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.072 -1.017 . . . . 50.0 109.753 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.611 ' CE1' HG21 ' A' ' 14' ' ' THR . 4.9 t80 -91.52 101.66 14.32 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.932 -1.107 . . . . 50.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.407 ' O ' ' HB3' ' A' ' 16' ' ' LYS . 0.2 OUTLIER -96.24 69.64 2.71 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.239 -0.913 . . . . 50.0 109.877 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.448 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -111.31 127.69 8.32 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 8.1 p -77.29 6.09 7.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.296 -1.12 . . . . 99.989999999999995 110.488 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.53 -3.7 42.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.215 -0.928 . . . . 99.989999999999995 109.925 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' OH ' ' A' ' 37' ' ' TYR . . . 81.42 -137.65 17.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.437 -1.465 . . . . 99.989999999999995 109.437 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.572 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 43.3 Cg_endo -70.91 142.42 42.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.968 1.509 . . . . 99.989999999999995 110.327 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.659 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.13 162.42 8.87 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.349 -0.844 . . . . 50.0 110.078 -179.403 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.646 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 25.7 mmtt -74.67 113.34 11.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 50.0 109.906 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.599 ' HA ' ' HB ' ' A' ' 14' ' ' THR . 3.2 mt -74.51 117.08 59.29 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.112 -0.993 . . . . 50.0 110.072 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.7 Cg_endo -81.79 70.13 7.35 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 124.087 1.572 . . . . 50.0 110.158 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.508 ' CD1' HG23 ' A' ' 46' ' ' ILE . 1.7 mp -118.13 146.96 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 50.0 110.226 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.504 ' CG2' ' HB3' ' A' ' 59' ' ' PRO . 6.2 p -127.13 140.36 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.394 -0.816 . . . . 50.0 110.143 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.453 ' OG ' ' HG2' ' A' ' 83' ' ' MET . 75.2 m -107.32 100.5 9.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 50.0 109.8 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.548 ' O ' ' N ' ' A' ' 91' ' ' TYR . 59.4 t -107.72 157.0 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.313 -0.867 . . . . 50.0 110.127 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -71.94 164.23 26.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 50.0 109.215 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.627 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 29.6 t -70.79 100.86 1.98 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.74 -1.225 . . . . 50.0 109.321 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 173.19 -71.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 C-N-CA 118.52 -1.272 . . . . 50.0 111.382 -179.725 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.465 ' HB3' ' OG1' ' A' ' 58' ' ' THR . 80.8 m-20 -84.15 155.12 22.74 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.135 -0.978 . . . . 50.0 110.287 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -106.24 -23.5 12.55 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 50.0 110.118 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.38 37.09 4.38 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.268 -0.895 . . . . 50.0 110.267 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.465 ' OG1' ' HB3' ' A' ' 55' ' ' ASN . 0.6 OUTLIER -134.9 103.23 10.9 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.176 -0.952 . . . . 50.0 110.322 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.536 ' HA ' ' CG2' ' A' ' 51' ' ' VAL . 48.9 Cg_endo -73.72 125.84 10.31 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.063 1.559 . . . . 50.0 110.601 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.47 HG23 ' HA ' ' A' ' 51' ' ' VAL . 12.0 m -135.22 -28.07 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.338 -0.851 . . . . 50.0 110.271 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.82 170.78 48.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.895 -1.682 . . . . 50.0 108.895 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.475 ' O ' ' HG3' ' A' ' 83' ' ' MET . 14.8 mtt180 -140.36 155.91 46.6 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.045 -1.268 . . . . 50.0 110.602 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.456 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 2.2 mp -92.21 115.95 28.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 50.0 109.651 179.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.562 ' CG1' ' HG2' ' A' ' 82' ' ' GLU . 7.5 p -77.69 -34.54 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.087 -1.008 . . . . 50.0 110.352 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 7.3 t -82.58 173.28 12.1 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.087 -1.008 . . . . 50.0 109.821 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 67' ' ' ASN . 47.2 t -41.23 159.78 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.212 -0.93 . . . . 50.0 109.789 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.605 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 8.7 m120 -46.58 158.59 0.39 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 50.0 109.709 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.2 Cg_endo -73.61 65.83 4.72 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.882 1.464 . . . . 50.0 110.511 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 16.4 m-30 -126.23 121.68 33.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 50.0 110.034 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.461 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.3 OUTLIER -86.97 60.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 50.0 109.589 179.487 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.572 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -71.75 59.35 0.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.415 -0.803 . . . . 50.0 110.158 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.84 158.25 43.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.245 -0.91 . . . . 50.0 110.361 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.3 m -85.98 -10.64 54.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.372 -0.83 . . . . 50.0 109.698 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.99 14.59 16.13 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 99.989999999999995 110.124 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.461 ' HB2' ' HB ' ' A' ' 70' ' ' VAL . . . -80.26 10.99 3.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -0.885 . . . . 99.989999999999995 109.964 179.702 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 1.1 m-80 -85.84 16.16 4.3 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.286 -0.883 . . . . 99.989999999999995 109.435 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.551 ' O ' ' HA ' ' A' ' 36' ' ' SER . 60.3 p -121.91 -172.75 2.5 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.496 -0.752 . . . . 99.989999999999995 109.299 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 0.6 OUTLIER -63.14 88.65 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.177 -0.952 . . . . 99.989999999999995 109.077 179.506 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 28.0 m -76.35 176.08 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.33 -0.856 . . . . 99.989999999999995 109.603 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.76 127.15 44.62 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.945 -1.097 . . . . 50.0 110.759 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.521 HG22 ' CD1' ' A' ' 35' ' ' LEU . 1.8 t -118.43 169.72 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -0.918 . . . . 50.0 110.251 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.562 ' HG2' ' CG1' ' A' ' 64' ' ' VAL . 2.3 tt0 -138.23 135.7 35.83 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.288 -0.882 . . . . 50.0 110.065 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.475 ' HG3' ' O ' ' A' ' 62' ' ' ARG . 1.6 mpp? -138.02 149.26 45.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.123 -0.986 . . . . 50.0 110.53 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.477 ' HG2' ' HB ' ' A' ' 64' ' ' VAL . 2.0 pt-20 -115.33 66.24 2.2 Favored Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.118 -0.989 . . . . 50.0 110.357 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.458 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 47.9 Cg_endo -73.09 164.62 34.96 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.026 1.54 . . . . 50.0 110.411 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.58 152.27 64.98 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.048 1.552 . . . . 50.0 110.405 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.9 OUTLIER -52.76 142.67 18.19 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 50.0 110.263 -179.855 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.39 161.75 14.67 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.345 -1.502 . . . . 50.0 109.345 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.529 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 74.9 m-20 -52.78 163.1 0.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -1.188 . . . . 50.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.544 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -142.37 135.85 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.1 -1.0 . . . . 50.0 110.828 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 5.4 m-30 -96.11 108.21 20.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.245 -0.91 . . . . 50.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 3.6 mp -90.29 137.86 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.224 -0.922 . . . . 50.0 109.789 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 101' ' ' ILE . 22.0 t -125.59 108.33 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 120.882 -1.136 . . . . 50.0 111.421 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.463 ' HA ' HG13 ' A' ' 48' ' ' ILE . 59.5 t -85.36 107.44 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.173 -0.955 . . . . 50.0 108.896 178.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.487 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -90.3 170.23 35.49 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.783 -1.198 . . . . 50.0 110.254 -178.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.606 ' CB ' ' CB ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -153.54 13.89 0.49 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -1.041 . . . . 50.0 110.166 -179.811 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 136.36 -86.6 0.24 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.235 -1.546 . . . . 50.0 109.235 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -99.44 -68.71 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 50.0 109.971 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.89 151.66 30.04 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.201 -0.937 . . . . 50.0 110.04 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.615 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.07 148.6 42.0 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.088 -1.008 . . . . 49.57 110.349 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.0 mt -90.94 146.72 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.152 -0.968 . . . . 49.57 109.638 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -132.83 132.02 41.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.108 -0.995 . . . . 49.57 110.845 -179.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.465 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.0 OUTLIER -118.71 152.92 35.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.391 -0.818 . . . . 49.57 109.518 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.606 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 16.8 p-80 -116.23 83.1 1.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 49.57 110.554 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.588 ' CD1' ' HG2' ' A' ' 23' ' ' PRO . 10.1 t-105 . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.934 . . . . 49.57 109.943 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.621 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 121.167 0.508 . . . . 50.0 110.343 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 4.0 p -149.07 107.17 3.72 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.13 -0.981 . . . . 99.989999999999995 111.006 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.582 ' CG2' HG12 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -162.25 28.9 0.11 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.643 -1.286 . . . . 99.989999999999995 110.505 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 -11.31 3.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.12 -0.988 . . . . 99.989999999999995 110.236 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -71.0 61.05 0.26 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 50.0 110.429 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.489 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -105.62 141.4 37.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.155 -0.966 . . . . 50.0 109.859 179.564 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.572 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.8 OUTLIER -125.09 119.86 29.8 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.189 -0.944 . . . . 50.0 110.198 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.61 ' CE2' ' NE2' ' A' ' 103' ' ' HIS . 7.3 m-85 -63.13 115.25 4.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -0.931 . . . . 50.0 110.027 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.472 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -104.3 -28.34 11.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.241 -0.912 . . . . 50.0 110.103 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.482 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 19.0 mttm -146.14 151.94 38.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 50.0 110.171 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.88 164.04 61.78 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 50.0 110.218 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.9 Cg_endo -72.87 128.09 12.89 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.997 1.525 . . . . 50.0 110.206 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.23 152.84 44.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.913 . . . . 50.0 110.369 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.408 ' HA ' ' O ' ' A' ' 30' ' ' THR . 11.3 t70 -85.72 145.43 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.337 -0.852 . . . . 50.0 110.108 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -135.8 33.97 2.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.252 -0.905 . . . . 50.0 110.186 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.59 -109.87 0.41 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -128.02 88.99 2.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -1.155 . . . . 50.0 110.132 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 84' ' ' GLU . . . 87.11 -7.59 79.96 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.719 -1.352 . . . . 50.0 109.719 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.566 ' HA ' ' HG2' ' A' ' 84' ' ' GLU . 41.4 p -80.37 114.14 19.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -1.176 . . . . 50.0 110.194 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.556 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -106.47 141.46 21.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.224 -0.923 . . . . 50.0 110.326 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.4 OUTLIER -112.41 142.4 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.269 -0.894 . . . . 50.0 110.334 -179.803 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -141.37 140.26 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.348 -0.845 . . . . 50.0 109.706 179.695 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.482 ' CG ' ' O ' ' A' ' 79' ' ' VAL . 18.3 tt0 -121.79 117.03 25.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -0.975 . . . . 50.0 110.535 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.58 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -126.38 139.53 53.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.307 -0.871 . . . . 50.0 109.529 179.413 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.2 OUTLIER -87.77 126.94 35.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.059 -1.026 . . . . 50.0 109.704 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.526 ' CD2' ' O ' ' A' ' 37' ' ' TYR . 32.2 t80 -90.47 95.72 10.3 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.77 -1.172 . . . . 50.0 109.71 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.4 t -94.58 70.02 3.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.246 -0.909 . . . . 50.0 110.032 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -121.75 126.76 6.61 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.515 -1.434 . . . . 99.989999999999995 109.515 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.44 25.31 1.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -1.161 . . . . 99.989999999999995 110.36 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -99.76 -0.96 38.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 99.989999999999995 110.051 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.4 -163.28 31.23 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.391 -1.484 . . . . 99.989999999999995 109.391 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.57 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.8 Cg_endo -72.71 151.6 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 124.019 1.536 . . . . 99.989999999999995 110.515 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.73 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 3.7 t -170.22 161.71 8.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.391 -0.818 . . . . 50.0 109.666 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.621 ' HB2' ' HA ' ' A' ' 12' ' ' MET . 25.1 mmtt -77.23 121.5 23.76 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.009 -1.057 . . . . 50.0 110.047 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.582 HG12 ' CG2' ' A' ' 14' ' ' THR . 2.8 mt -83.92 110.3 24.67 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.367 -0.833 . . . . 50.0 110.585 -179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.547 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.2 Cg_endo -80.47 106.29 1.84 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.009 1.531 . . . . 50.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.539 HD12 ' CG2' ' A' ' 46' ' ' ILE . 3.0 mp -123.2 142.94 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.163 -0.961 . . . . 50.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.531 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 5.9 m -120.71 96.62 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.84 . . . . 50.0 109.724 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.489 ' HA ' HG23 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -87.95 104.08 16.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.309 -179.625 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.522 ' CG1' ' HA ' ' A' ' 59' ' ' PRO . 16.8 m -130.42 162.07 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.231 -0.918 . . . . 50.0 110.073 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.505 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -68.18 164.02 21.39 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.882 . . . . 50.0 109.304 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.599 ' O ' ' HB2' ' A' ' 54' ' ' LEU . 2.2 t -67.61 99.9 0.83 Allowed 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 118.529 -1.268 . . . . 50.0 108.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.599 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 172.06 -67.15 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.264 -1.374 . . . . 50.0 111.458 -179.688 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -99.64 122.03 42.08 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.087 -1.008 . . . . 50.0 110.299 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -106.18 19.45 20.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.952 . . . . 50.0 110.074 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.19 -7.15 6.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.29 -0.881 . . . . 50.0 110.37 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.457 ' O ' HG13 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -134.44 140.88 37.05 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.19 -0.944 . . . . 50.0 110.288 -179.869 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.522 ' HA ' ' CG1' ' A' ' 51' ' ' VAL . 46.5 Cg_endo -73.07 136.13 24.21 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 124.072 1.564 . . . . 50.0 110.443 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 60' ' ' VAL . 52.8 t -147.18 10.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.216 -0.927 . . . . 50.0 110.381 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -110.08 170.78 14.39 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.271 -1.532 . . . . 50.0 109.271 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.498 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 5.1 mmt180 -107.07 145.13 32.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.101 -1.235 . . . . 50.0 110.218 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.477 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 0.1 OUTLIER -116.99 110.34 18.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 50.0 110.065 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.536 ' CG2' ' HG3' ' A' ' 84' ' ' GLU . 73.5 t -100.07 42.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.168 -0.958 . . . . 50.0 110.124 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.504 ' OG1' ' N ' ' A' ' 82' ' ' GLU . 1.6 m -130.71 144.89 51.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.868 . . . . 50.0 110.096 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 65' ' ' THR . 26.0 m -52.72 -171.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.217 -0.927 . . . . 50.0 110.052 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.492 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 2.3 m-20 -46.83 115.46 3.34 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.128 -0.982 . . . . 50.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.625 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 45.0 Cg_endo -71.89 66.27 3.23 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.964 1.507 . . . . 50.0 110.136 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 68' ' ' PRO . 13.5 m-85 -135.76 123.62 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.474 -0.766 . . . . 50.0 110.054 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.537 ' N ' HD12 ' A' ' 46' ' ' ILE . 53.4 t -71.97 60.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.038 -1.039 . . . . 50.0 109.84 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.57 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -86.63 57.47 4.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 50.0 109.828 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.3 169.13 18.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.328 -0.857 . . . . 50.0 110.337 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.25 -7.34 35.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 50.0 109.999 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 14.6 p -121.06 13.18 11.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.312 -0.868 . . . . 99.989999999999995 110.313 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.531 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.99 5.45 8.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 99.989999999999995 109.958 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.505 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 40.2 m-20 -83.42 20.41 1.35 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.391 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.598 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.6 OUTLIER -122.51 -172.91 2.57 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.363 -0.835 . . . . 99.989999999999995 109.444 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.16 89.03 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.118 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.58 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 10.4 m -76.23 175.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.406 -0.809 . . . . 99.989999999999995 109.663 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -131.47 139.97 49.46 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.879 -1.138 . . . . 50.0 111.028 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.21 172.26 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.452 -0.78 . . . . 50.0 109.991 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.504 ' N ' ' OG1' ' A' ' 65' ' ' THR . 37.9 mt-10 -135.41 142.41 45.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.155 -0.966 . . . . 50.0 110.084 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.517 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -153.02 142.37 21.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.108 -0.995 . . . . 50.0 110.234 -179.71 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.566 ' HG2' ' HA ' ' A' ' 30' ' ' THR . 1.5 mm-40 -110.79 67.89 0.56 Allowed Pre-proline 0 C--N 1.304 -1.37 0 O-C-N 121.022 -1.049 . . . . 50.0 110.619 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.556 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.26 155.78 55.79 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.978 1.515 . . . . 50.0 110.528 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.22 163.28 39.17 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.105 1.582 . . . . 50.0 110.463 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -73.54 138.46 45.01 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.201 -0.937 . . . . 50.0 110.172 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.43 -150.14 17.17 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.362 -1.495 . . . . 50.0 109.362 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -92.3 137.11 32.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 50.0 110.0 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.577 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -130.23 133.4 46.51 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.23 -0.919 . . . . 50.0 110.247 179.984 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.522 ' O ' ' CG2' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -91.65 97.08 10.81 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.159 -0.963 . . . . 50.0 109.996 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.489 HG23 ' HA ' ' A' ' 50' ' ' SER . 1.7 pt -102.56 116.95 47.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.271 -0.893 . . . . 50.0 109.839 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.531 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 42.5 t -118.57 131.07 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 50.0 110.556 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.469 HG13 ' CG1' ' A' ' 48' ' ' ILE . 14.7 t -107.28 96.66 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.278 -0.888 . . . . 50.0 109.86 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.519 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.42 165.42 32.39 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.623 -1.391 . . . . 50.0 109.623 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 10.8 ptp -107.48 -33.41 7.36 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.282 -1.129 . . . . 50.0 110.316 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . 0.516 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 176.36 -63.21 0.1 OUTLIER Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.478 -1.449 . . . . 50.0 109.478 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -63.75 -107.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.204 -1.174 . . . . 50.0 110.132 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -79.29 123.35 27.37 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.111 -0.993 . . . . 50.0 110.161 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.781 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -131.41 150.17 52.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 49.57 110.064 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 46.0 mt -102.88 106.7 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.996 -1.065 . . . . 49.57 110.136 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.424 ' HB2' HG23 ' A' ' 93' ' ' VAL . 7.6 p-10 -97.4 130.8 44.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 49.57 110.196 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.61 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -126.99 160.45 31.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.34 -0.85 . . . . 49.57 110.238 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.3 p80 -123.26 86.53 2.59 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 49.57 110.131 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.431 ' CE3' ' C ' ' A' ' 105' ' ' TRP . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 49.57 110.042 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.655 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.106 0.479 . . . . 50.0 110.299 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.679 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.13 105.88 3.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.111 -0.993 . . . . 99.989999999999995 111.151 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.568 ' CG2' HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.22 25.09 0.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.115 -0.991 . . . . 99.989999999999995 109.938 178.458 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 96' ' ' MET . 17.9 tt0 -49.78 -18.67 0.51 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.316 -0.865 . . . . 99.989999999999995 110.375 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.432 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 1.2 mmtt -76.2 61.43 1.61 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 50.0 110.411 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.584 ' CZ ' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -99.0 138.68 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.926 . . . . 50.0 109.94 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 12.7 t -128.29 97.47 4.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.205 -0.934 . . . . 50.0 110.621 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 6.7 p90 -56.5 117.95 4.34 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.993 -1.067 . . . . 50.0 109.836 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -107.34 -19.64 13.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 50.0 110.651 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.512 ' CE ' ' OE1' ' A' ' 34' ' ' GLU . 25.9 mttm -140.79 150.79 43.8 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.14 -0.975 . . . . 50.0 110.684 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -67.64 165.44 30.4 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.447 -0.783 . . . . 50.0 110.145 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.5 Cg_endo -72.75 142.89 36.39 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 124.012 1.533 . . . . 50.0 110.305 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.422 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -133.5 152.52 51.92 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.218 -0.926 . . . . 50.0 110.249 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.6 p30 -92.55 130.94 38.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -0.881 . . . . 50.0 110.338 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.66 -80.84 0.48 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 50.0 110.035 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.41 -109.14 0.61 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.431 -1.467 . . . . 50.0 109.431 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -129.73 97.32 4.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.276 -1.132 . . . . 50.0 110.145 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 96.84 8.8 56.8 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 82.5 p -103.2 128.22 50.25 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -1.084 . . . . 50.0 110.263 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.466 HG21 ' HD2' ' A' ' 85' ' ' PRO . 39.2 t -109.74 137.71 40.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.366 -0.834 . . . . 50.0 109.906 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.54 HG13 ' CD2' ' A' ' 80' ' ' LEU . 1.5 t -117.57 143.43 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 50.0 110.436 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.547 HG12 ' CD1' ' A' ' 35' ' ' LEU . 3.6 tt -142.93 145.11 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 50.0 109.759 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.521 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 17.7 tt0 -116.46 102.55 9.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.16 -0.962 . . . . 50.0 110.721 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.588 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -113.56 136.77 52.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.259 -0.9 . . . . 50.0 109.536 179.45 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.4 OUTLIER -86.36 129.85 34.71 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.155 -0.966 . . . . 50.0 109.92 -179.57 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.522 ' CD1' HG22 ' A' ' 14' ' ' THR . 10.7 t80 -95.59 99.6 11.45 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 118.983 -1.087 . . . . 50.0 109.869 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -96.27 72.29 2.83 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.116 -0.99 . . . . 50.0 110.135 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -124.67 124.03 5.27 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.532 -1.427 . . . . 99.989999999999995 109.532 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 29.45 2.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.212 -1.17 . . . . 99.989999999999995 110.265 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' OD1' ' C ' ' A' ' 41' ' ' ASP . 2.1 p30 -102.99 0.39 32.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.291 -0.881 . . . . 99.989999999999995 110.155 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.67 174.67 25.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.273 -1.531 . . . . 99.989999999999995 109.273 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.548 ' CB ' ' O ' ' A' ' 70' ' ' VAL . 45.0 Cg_endo -72.81 149.74 48.52 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.001 1.527 . . . . 99.989999999999995 110.599 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.679 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -167.47 162.66 14.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.439 -0.788 . . . . 50.0 109.56 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.655 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 23.2 mmtt -67.5 141.44 56.91 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.968 -1.082 . . . . 50.0 109.745 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.634 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 7.1 mt -90.78 108.81 30.21 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.299 -0.875 . . . . 50.0 110.649 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.551 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 49.9 Cg_endo -75.48 96.48 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 124.152 1.606 . . . . 50.0 110.955 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.634 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 0.5 OUTLIER -131.64 115.79 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 50.0 109.992 179.462 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.548 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 18.0 m -93.07 107.44 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.852 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -86.18 100.88 12.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 50.0 109.765 179.869 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.567 ' O ' ' N ' ' A' ' 91' ' ' TYR . 95.7 t -118.71 150.56 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.313 -0.867 . . . . 50.0 110.468 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.438 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -67.51 164.73 18.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.373 -0.83 . . . . 50.0 109.62 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.606 ' N ' ' HA ' ' A' ' 90' ' ' SER . 5.4 t -70.05 101.84 1.9 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.834 -1.166 . . . . 50.0 109.424 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.498 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 171.0 -64.12 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.057 -1.457 . . . . 50.0 111.703 -179.906 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.53 ' CB ' ' HB ' ' A' ' 58' ' ' THR . 41.4 m-80 -88.05 164.99 15.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.094 . . . . 50.0 110.315 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 56' ' ' ASP . 49.9 t0 -105.9 -37.87 6.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 50.0 110.238 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.0 ttm -123.85 30.39 6.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 50.0 110.217 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.53 ' HB ' ' CB ' ' A' ' 55' ' ' ASN . 17.3 m -111.85 120.62 41.74 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.256 -0.902 . . . . 50.0 110.049 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -72.58 130.05 15.47 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.989 1.52 . . . . 50.0 110.414 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.441 HG23 HG13 ' A' ' 51' ' ' VAL . 10.5 t -142.3 -36.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.259 -0.901 . . . . 50.0 110.26 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -77.54 164.74 52.37 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.138 -1.585 . . . . 50.0 109.138 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.42 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 10.5 mtt180 -138.49 156.45 47.52 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.095 -1.238 . . . . 50.0 110.445 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.49 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 2.5 mt -97.97 122.4 41.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 50.0 109.776 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.497 HG23 ' HG2' ' A' ' 84' ' ' GLU . 30.6 t -63.33 -13.5 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.217 -0.927 . . . . 50.0 110.12 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 66' ' ' VAL . 34.6 m -124.77 163.21 22.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.295 -0.878 . . . . 50.0 109.955 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 65' ' ' THR . 74.1 t -44.09 168.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 50.0 109.959 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.628 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 18.2 t-20 -46.68 142.73 4.56 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.196 -0.94 . . . . 50.0 110.11 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.555 ' O ' HG13 ' A' ' 46' ' ' ILE . 49.8 Cg_endo -76.22 98.56 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.927 1.488 . . . . 50.0 110.452 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.628 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 9.2 p90 -120.51 138.49 53.81 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.225 -0.922 . . . . 50.0 110.346 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.56 HG21 ' CG2' ' A' ' 14' ' ' THR . 73.6 t -91.01 60.94 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.198 -0.939 . . . . 50.0 110.181 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.507 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -89.76 57.44 3.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 50.0 110.346 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.7 m -143.43 169.12 18.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 50.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.7 p -94.23 -6.83 43.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 50.0 109.92 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.14 17.74 11.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 99.989999999999995 110.41 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -79.79 7.29 8.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.15 -0.969 . . . . 99.989999999999995 110.066 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.492 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 53.6 m-20 -85.17 18.78 2.44 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.234 -0.917 . . . . 99.989999999999995 109.341 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.59 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.1 OUTLIER -122.68 -172.73 2.54 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.404 -0.81 . . . . 99.989999999999995 109.277 179.97 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 40.0 mttt -62.98 88.47 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.327 -0.858 . . . . 99.989999999999995 109.168 179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.57 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 11.4 m -76.68 176.48 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.376 -0.827 . . . . 99.989999999999995 109.392 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.54 ' CD2' HG13 ' A' ' 32' ' ' VAL . 8.0 tt -135.23 133.92 39.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.781 -1.2 . . . . 50.0 111.212 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.438 ' O ' HD21 ' A' ' 80' ' ' LEU . 1.9 t -119.98 178.31 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.483 -0.76 . . . . 50.0 109.829 179.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 61.7 mt-10 -148.52 139.24 22.86 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.996 -1.065 . . . . 50.0 110.546 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.49 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 14.2 ptt? -155.81 139.03 15.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.268 -0.895 . . . . 50.0 110.245 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.497 ' HG2' HG23 ' A' ' 64' ' ' VAL . 1.3 pt-20 -109.24 76.62 0.81 Allowed Pre-proline 0 C--N 1.305 -1.327 0 O-C-N 121.183 -0.948 . . . . 50.0 110.619 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HD2' HG21 ' A' ' 31' ' ' VAL . 47.5 Cg_endo -73.86 170.34 20.3 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.02 1.537 . . . . 50.0 110.344 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.33 161.94 42.95 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.061 1.559 . . . . 50.0 110.42 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -67.13 145.35 55.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.171 -0.956 . . . . 50.0 110.154 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.28 158.62 16.74 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.189 -1.564 . . . . 50.0 109.189 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 89' ' ' ASP . 1.0 OUTLIER -52.41 148.55 6.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -1.22 . . . . 50.0 109.928 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.606 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.4 p -130.49 138.77 50.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.118 -0.989 . . . . 50.0 110.705 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.567 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -90.65 104.35 16.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.16 -0.963 . . . . 50.0 109.415 179.334 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 3.3 tt -103.43 135.02 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 50.0 110.341 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.548 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 10.7 t -125.15 114.52 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.089 -1.007 . . . . 50.0 110.863 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.52 ' CG1' HD13 ' A' ' 48' ' ' ILE . 17.6 t -103.97 104.14 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.195 -0.941 . . . . 50.0 109.444 179.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.551 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.27 169.92 33.29 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.614 -1.279 . . . . 50.0 110.195 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.404 ' HB2' ' HB2' ' A' ' 15' ' ' GLU . 19.7 ttm -111.72 -51.35 2.86 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.355 -1.085 . . . . 50.0 110.597 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.85 -145.14 12.18 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.845 -1.302 . . . . 50.0 109.845 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -63.52 -36.11 82.68 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.219 -1.165 . . . . 50.0 110.384 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.37 116.56 19.68 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.207 -0.933 . . . . 50.0 110.184 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.606 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.45 148.69 43.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.323 -0.861 . . . . 49.57 110.114 -179.808 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.544 ' CG2' ' O ' ' A' ' 101' ' ' ILE . 3.5 tp -94.87 110.32 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.258 -0.901 . . . . 49.57 110.012 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.445 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 32.8 p-10 -101.93 131.82 48.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 49.57 110.475 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -121.12 171.36 8.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.38 -0.825 . . . . 49.57 110.146 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -119.34 79.92 1.49 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 49.57 110.471 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.452 ' HA ' ' CE3' ' A' ' 105' ' ' TRP . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 49.57 109.983 179.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.536 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.212 0.529 . . . . 50.0 110.248 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.658 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 11.6 p -148.69 107.35 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.204 -0.935 . . . . 99.989999999999995 110.415 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.589 ' CB ' HD12 ' A' ' 46' ' ' ILE . 1.3 m -161.5 62.8 0.26 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.674 -1.266 . . . . 99.989999999999995 110.549 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.471 ' HG3' ' HE3' ' A' ' 16' ' ' LYS . 1.5 pp20? -84.63 25.18 0.93 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.156 -0.965 . . . . 99.989999999999995 110.117 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.486 ' HD3' ' HA3' ' A' ' 39' ' ' GLY . 1.8 mptt -123.47 61.02 1.06 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.177 -0.952 . . . . 50.0 110.782 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' CD2' HD13 ' A' ' 48' ' ' ILE . 0.0 OUTLIER -99.11 146.88 25.64 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.054 -1.029 . . . . 50.0 109.8 179.429 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.662 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.11 145.41 51.02 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.124 -0.985 . . . . 50.0 110.294 -179.898 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.489 ' CZ ' ' CD1' ' A' ' 101' ' ' ILE . 1.2 m-85 -85.32 104.28 15.01 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.962 -1.086 . . . . 50.0 109.617 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.516 ' CB ' ' O ' ' A' ' 34' ' ' GLU . . . -93.2 -34.53 13.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.128 -0.983 . . . . 50.0 110.648 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.499 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 13.6 mttm -145.09 166.71 24.6 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.06 -1.025 . . . . 50.0 110.614 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.59 165.16 39.36 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 50.0 110.09 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.486 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.71 136.75 26.15 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.969 1.51 . . . . 50.0 110.46 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.44 167.53 14.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.251 -0.906 . . . . 50.0 110.346 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -105.81 132.31 52.08 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 50.0 110.37 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 p -108.78 -23.17 11.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 50.0 110.136 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.46 -114.64 0.59 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.468 -1.453 . . . . 50.0 109.468 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' HIS . . . . . 0.513 ' O ' ' CD2' ' A' ' 28' ' ' HIS . 11.5 p-80 -130.17 88.87 2.71 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -1.163 . . . . 50.0 110.296 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 105.1 14.94 21.37 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.8 p -121.73 111.53 17.28 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.311 -1.111 . . . . 50.0 110.186 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.486 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -104.61 150.56 7.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.218 -0.926 . . . . 50.0 110.313 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.444 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -128.19 135.09 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.244 -0.91 . . . . 50.0 110.271 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.509 HG22 ' CD1' ' A' ' 35' ' ' LEU . 8.0 tt -134.28 150.3 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.864 . . . . 50.0 109.518 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.609 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 2.4 tt0 -119.84 103.78 9.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 50.0 110.767 -179.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.662 ' HA ' ' O ' ' A' ' 18' ' ' SER . 1.2 mp -110.89 137.36 48.63 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.226 -0.921 . . . . 50.0 109.691 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -84.68 124.78 31.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.058 -1.026 . . . . 50.0 109.696 179.954 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.581 ' CE1' HG21 ' A' ' 14' ' ' THR . 6.3 t80 -92.34 97.84 11.12 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.904 -1.118 . . . . 50.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.9 t -95.14 72.09 3.34 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.391 -0.818 . . . . 50.0 110.163 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.486 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -125.57 126.68 5.96 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.574 -1.41 . . . . 99.989999999999995 109.574 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -83.55 16.85 2.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -1.151 . . . . 99.989999999999995 110.201 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -92.4 -22.47 19.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 99.989999999999995 110.149 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.46 ' O ' ' OH ' ' A' ' 37' ' ' TYR . . . 110.76 -163.31 12.31 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.641 -1.384 . . . . 99.989999999999995 109.641 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.7 Cg_endo -73.5 150.31 45.78 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 O-C-N 123.966 1.509 . . . . 99.989999999999995 110.418 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.628 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.55 161.87 7.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.309 -0.87 . . . . 50.0 109.851 -179.531 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.536 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 13.7 mmtt -69.0 117.53 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.067 -1.021 . . . . 50.0 109.382 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.61 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 4.4 mm -71.4 112.83 15.19 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.058 -1.026 . . . . 50.0 110.372 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.543 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 51.8 Cg_endo -80.26 91.87 1.13 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.061 1.558 . . . . 50.0 110.171 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.61 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 63.3 mt -133.11 149.98 32.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.128 -0.982 . . . . 50.0 110.541 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.554 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 26.1 m -124.14 159.66 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.382 -0.824 . . . . 50.0 109.661 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.477 ' O ' ' HA3' ' A' ' 61' ' ' GLY . 0.3 OUTLIER -134.76 107.66 7.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 50.0 110.066 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.5 m -125.2 156.76 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.284 -0.885 . . . . 50.0 110.203 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.433 ' H ' ' CG2' ' A' ' 60' ' ' VAL . . . -55.93 163.64 1.42 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.355 -0.841 . . . . 50.0 110.012 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.609 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.4 OUTLIER -59.5 121.21 10.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.211 -0.931 . . . . 50.0 110.649 -179.556 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.609 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 78.58 30.55 0.38 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.565 -0.709 . . . . 50.0 110.976 179.549 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 52' ' ' ALA . 30.1 m120 -128.0 84.28 2.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.21 -0.931 . . . . 50.0 110.068 179.066 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.49 9.6 31.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.234 -0.917 . . . . 50.0 110.211 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.4 mtt -113.85 -15.65 12.35 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -0.863 . . . . 50.0 110.111 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -136.37 121.01 12.85 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.334 -0.854 . . . . 50.0 110.246 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.424 ' O ' HG13 ' A' ' 60' ' ' VAL . 46.3 Cg_endo -72.98 133.66 20.2 Favored 'Trans proline' 0 C--N 1.305 -1.755 0 O-C-N 123.989 1.52 . . . . 50.0 110.16 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.467 HG21 ' HA ' ' A' ' 51' ' ' VAL . 31.3 m -142.31 -31.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.223 -0.923 . . . . 50.0 110.429 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.41 144.79 37.94 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.397 -1.881 . . . . 50.0 108.397 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.467 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 11.7 mtp180 -123.6 157.0 34.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.851 -1.382 . . . . 50.0 110.892 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.82 124.91 40.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.876 . . . . 50.0 109.86 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.48 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 17.9 t -50.76 -21.45 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.177 -0.952 . . . . 50.0 110.248 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 66' ' ' VAL . 5.8 t -136.33 170.68 15.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 50.0 110.153 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 27.7 m -52.23 -172.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.237 -0.915 . . . . 50.0 110.157 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.552 ' O ' ' CE2' ' A' ' 69' ' ' PHE . 6.7 p30 -46.88 131.04 8.74 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.142 -0.973 . . . . 50.0 110.003 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.514 ' O ' HG12 ' A' ' 46' ' ' ILE . 46.8 Cg_endo -72.58 123.24 8.91 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.941 1.495 . . . . 50.0 110.559 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 67' ' ' ASN . 0.2 OUTLIER -135.14 157.07 47.86 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.286 -0.884 . . . . 50.0 110.069 -179.942 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.559 ' CG2' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -116.29 60.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.179 -0.951 . . . . 50.0 109.6 179.292 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.515 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -73.55 58.91 0.6 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 50.0 110.347 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.0 m -142.59 155.2 44.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.32 -0.863 . . . . 50.0 110.233 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.61 -4.9 53.65 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.334 -0.854 . . . . 50.0 109.857 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.5 p -115.45 17.31 16.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 99.989999999999995 110.255 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ALA . . . . . 0.524 ' CB ' HG12 ' A' ' 70' ' ' VAL . . . -79.91 8.61 6.58 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.182 -0.949 . . . . 99.989999999999995 109.966 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -87.63 19.55 3.35 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 109.243 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' SER . . . . . 0.519 ' O ' ' HA ' ' A' ' 36' ' ' SER . 96.5 p -128.96 -172.56 2.75 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.536 -0.728 . . . . 99.989999999999995 109.346 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 0.3 OUTLIER -63.35 88.82 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.263 -0.898 . . . . 99.989999999999995 109.291 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 34' ' ' GLU . 35.3 m -76.16 176.28 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.352 -0.843 . . . . 99.989999999999995 109.21 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 2.8 tt -134.02 132.93 40.66 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.884 -1.135 . . . . 50.0 111.239 -179.487 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.4 t -122.64 178.08 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.435 -0.791 . . . . 50.0 109.681 179.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . 0.48 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 22.8 mt-10 -132.85 142.65 49.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.021 -1.049 . . . . 50.0 110.479 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.453 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -147.78 142.22 26.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.281 -0.887 . . . . 50.0 110.234 179.995 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.468 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -114.69 66.38 1.75 Allowed Pre-proline 0 C--N 1.306 -1.296 0 O-C-N 121.151 -0.968 . . . . 50.0 110.563 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.453 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.21 164.94 33.99 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.969 1.51 . . . . 50.0 110.28 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.51 140.83 33.74 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.92 1.484 . . . . 50.0 110.354 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -52.54 137.08 31.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.231 -0.918 . . . . 50.0 110.194 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.76 167.37 13.32 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.384 -1.486 . . . . 50.0 109.384 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ASP . . . . . 0.484 ' HB2' ' HB2' ' A' ' 53' ' ' SER . 23.1 m-20 -53.25 146.5 11.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.3 -1.118 . . . . 50.0 110.051 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.553 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -141.43 141.37 33.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 50.0 110.604 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' TYR . . . . . 0.565 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 1.0 OUTLIER -97.49 112.02 24.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 50.0 109.672 179.462 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.463 HG21 ' CZ3' ' A' ' 105' ' ' TRP . 5.0 tt -103.44 136.91 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.101 -0.999 . . . . 50.0 110.406 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.554 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 27.1 t -125.15 113.12 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.088 -1.007 . . . . 50.0 110.316 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.521 ' CG2' HG12 ' A' ' 48' ' ' ILE . 42.1 t -105.13 100.54 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.901 . . . . 50.0 110.065 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.457 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -150.82 164.8 30.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.71 -1.356 . . . . 50.0 109.71 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' MET . . . . . 0.543 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ttm -103.44 -29.71 11.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.32 -1.106 . . . . 50.0 110.319 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 179.71 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.07 -67.9 0.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.27 -1.135 . . . . 50.0 110.422 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.1 tptt -79.47 109.38 13.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.208 -0.933 . . . . 50.0 110.109 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . 0.652 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -134.82 149.73 50.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 49.57 110.111 -179.739 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.489 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 5.6 pt -118.92 154.7 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 49.57 109.905 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.459 ' O ' ' OD1' ' A' ' 102' ' ' ASN . 14.4 p30 -143.1 136.35 28.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.164 -0.96 . . . . 49.57 110.429 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.485 ' CE1' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -120.78 168.25 11.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.24 -0.912 . . . . 49.57 110.28 179.887 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.565 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 8.8 p-80 -131.08 106.08 8.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.363 -0.836 . . . . 49.57 109.981 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' TRP . . . . . 0.469 ' CZ3' ' HB3' ' A' ' 103' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 49.57 110.629 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.334 0.588 . . . . 50.0 110.206 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.9 mmtp -107.93 132.74 53.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.277 -0.889 . . . . 50.0 110.094 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.2 mp -129.71 101.55 5.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.255 -0.903 . . . . 50.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.87 122.54 42.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.211 -0.931 . . . . 50.0 110.153 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -108.37 106.55 16.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.252 -0.905 . . . . 50.0 110.162 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 16.9 tttm -105.01 163.33 12.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.886 . . . . 50.0 110.307 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.58 19.07 29.18 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.48 -1.448 . . . . 50.0 109.48 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.4 t -57.48 167.03 1.09 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.275 -1.133 . . . . 50.0 110.221 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -47.56 109.43 0.22 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 50.0 110.281 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -127.95 167.76 16.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.179 -0.95 . . . . 50.0 110.124 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.15 101.42 0.86 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.53 -1.428 . . . . 50.0 109.53 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.539 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 74.1 mtp -77.05 114.88 16.33 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.286 -1.126 . . . . 50.0 110.263 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.76 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 8.6 p -149.01 108.06 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.608 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.583 ' HB ' HG22 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -161.57 41.96 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.611 -1.305 . . . . 99.989999999999995 110.678 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.7 tm-20 -70.03 -3.78 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.122 -0.986 . . . . 99.989999999999995 110.075 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.535 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -79.71 62.45 3.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.315 -0.866 . . . . 50.0 110.206 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.585 ' CD2' HG11 ' A' ' 94' ' ' VAL . 0.3 OUTLIER -102.64 140.87 36.34 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.188 -0.945 . . . . 50.0 110.431 -179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.647 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.4 t -125.53 119.69 28.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 50.0 109.81 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -73.62 108.41 6.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.125 -0.985 . . . . 50.0 110.298 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -94.87 -33.49 12.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 50.0 109.916 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.474 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 17.3 mtmt -144.78 150.29 36.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.288 -0.882 . . . . 50.0 110.202 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.467 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 11.2 m-20 -69.23 165.15 42.0 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.291 -0.881 . . . . 50.0 110.107 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD2' ' HB3' ' A' ' 22' ' ' ASN . 45.1 Cg_endo -72.84 122.53 8.24 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.946 1.498 . . . . 50.0 110.31 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.37 141.71 51.28 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.905 . . . . 50.0 110.287 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 30' ' ' THR . 2.7 p30 -81.89 131.65 35.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 50.0 110.312 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.501 HG22 ' CG2' ' A' ' 32' ' ' VAL . 1.2 p -123.54 52.46 1.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.312 -0.868 . . . . 50.0 110.137 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.57 -129.2 2.85 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.435 -1.466 . . . . 50.0 109.435 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -116.54 95.79 5.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.206 -1.173 . . . . 50.0 110.243 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.58 23.04 63.27 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -117.87 107.71 14.43 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -1.16 . . . . 50.0 110.219 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.448 HG21 ' HD2' ' A' ' 85' ' ' PRO . 11.8 t -103.58 137.3 32.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.307 -0.87 . . . . 50.0 110.208 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.501 ' CG2' HG22 ' A' ' 26' ' ' THR . 0.7 OUTLIER -110.82 136.46 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.224 -0.923 . . . . 50.0 110.294 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.536 HG22 ' CD1' ' A' ' 35' ' ' LEU . 12.7 tt -130.62 144.49 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.413 -0.805 . . . . 50.0 109.68 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.441 ' O ' ' HB2' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -122.62 105.26 9.94 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.982 . . . . 50.0 110.639 -179.495 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.647 ' HA ' ' O ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -123.12 141.63 51.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.238 -0.914 . . . . 50.0 109.511 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 78' ' ' LYS . 0.7 OUTLIER -90.74 128.93 36.84 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.102 -0.999 . . . . 50.0 109.855 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.535 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 11.4 t80 -91.44 98.58 11.77 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 118.935 -1.106 . . . . 50.0 109.679 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.77 69.6 8.69 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.291 -0.881 . . . . 50.0 109.711 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.499 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -124.24 119.85 3.87 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.634 -1.386 . . . . 99.989999999999995 109.634 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.1 m -86.22 20.04 2.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.327 -1.101 . . . . 99.989999999999995 110.278 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -97.47 -0.85 45.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 99.989999999999995 110.105 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.71 -158.3 26.05 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.411 -1.475 . . . . 99.989999999999995 109.411 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.529 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -73.06 151.32 49.75 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.959 1.505 . . . . 99.989999999999995 110.222 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.76 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -170.23 161.48 8.34 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -0.907 . . . . 50.0 109.784 -179.402 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.583 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 5.0 mmtt -79.48 114.39 18.37 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.979 -1.076 . . . . 50.0 110.125 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.583 HG22 ' HB ' ' A' ' 14' ' ' THR . 2.6 mt -75.06 113.58 26.42 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 50.0 110.194 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.497 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 46.5 Cg_endo -74.13 88.79 1.08 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 124.043 1.549 . . . . 50.0 110.013 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.573 ' CD1' HG21 ' A' ' 46' ' ' ILE . 79.4 mt -125.54 151.79 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 50.0 110.741 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.508 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 32.4 m -133.12 137.29 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.499 -0.751 . . . . 50.0 109.337 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -116.48 108.81 16.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.003 -1.061 . . . . 50.0 110.313 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 91' ' ' TYR . 14.8 m -131.58 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 50.0 110.113 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.48 163.6 1.7 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.31 -0.869 . . . . 50.0 110.184 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.665 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -62.85 120.46 11.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -0.887 . . . . 50.0 110.545 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.665 ' CB ' ' O ' ' A' ' 53' ' ' SER . 3.8 tp 81.47 29.96 0.15 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.582 -0.699 . . . . 50.0 110.725 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.518 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 64.6 m-80 -137.38 84.75 2.08 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 50.0 110.101 179.247 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -105.36 11.13 33.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 50.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.4 tpt -109.04 -14.15 14.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 50.0 110.211 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.3 p -136.04 142.84 41.71 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.289 -0.882 . . . . 50.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.457 ' O ' HG22 ' A' ' 60' ' ' VAL . 46.1 Cg_endo -72.68 137.2 27.01 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.006 1.53 . . . . 50.0 110.321 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.492 ' CG1' ' HG3' ' A' ' 86' ' ' PRO . 4.0 t -143.89 -49.08 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.305 -0.872 . . . . 50.0 110.079 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -86.29 147.22 21.43 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.085 -1.606 . . . . 50.0 109.085 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.448 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 10.1 mtp180 -138.66 156.38 47.48 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.057 -1.261 . . . . 50.0 110.686 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.505 ' HA ' ' HG2' ' A' ' 83' ' ' MET . 5.0 mp -91.91 109.62 20.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.32 -0.863 . . . . 50.0 110.051 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.545 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 77.9 t -55.93 -42.89 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.218 -0.926 . . . . 50.0 110.51 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.48 ' OG1' ' HB2' ' A' ' 82' ' ' GLU . 1.4 m -73.76 169.49 17.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.162 -0.961 . . . . 50.0 110.173 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 23.3 t -44.65 170.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.236 -0.915 . . . . 50.0 110.114 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.646 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . 60.7 m-80 -47.08 157.7 0.48 Allowed Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.243 -0.91 . . . . 50.0 109.979 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.525 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 45.4 Cg_endo -73.32 66.36 4.42 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 123.955 1.503 . . . . 50.0 110.58 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE2' ' CB ' ' A' ' 67' ' ' ASN . 16.7 m-30 -120.8 121.7 38.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 50.0 109.878 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.532 HG22 ' CG1' ' A' ' 46' ' ' ILE . 80.8 t -79.91 60.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 50.0 110.096 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.529 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -83.31 61.6 6.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.082 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.453 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -142.65 164.41 30.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.253 -0.905 . . . . 50.0 110.335 -179.758 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 p -94.08 -10.79 32.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 50.0 109.874 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 67.4 m -120.95 18.24 11.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -0.872 . . . . 99.989999999999995 110.253 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.523 ' CB ' HG11 ' A' ' 70' ' ' VAL . . . -81.98 11.44 5.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.136 -0.977 . . . . 99.989999999999995 110.073 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.1 m-20 -85.22 15.06 4.51 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.253 -0.904 . . . . 99.989999999999995 109.337 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 36' ' ' SER . 9.3 p -124.27 -171.98 2.45 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.464 -0.773 . . . . 99.989999999999995 109.574 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 11.8 pttt -62.87 88.86 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.559 -0.856 . . . . 99.989999999999995 109.115 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.534 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 22.2 m -76.52 174.42 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.41 -0.806 . . . . 99.989999999999995 109.651 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.461 HD21 ' O ' ' A' ' 33' ' ' ILE . 1.6 tt -138.8 120.39 15.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.977 -1.077 . . . . 50.0 110.942 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.402 ' N ' HD21 ' A' ' 80' ' ' LEU . 2.0 t -116.91 172.69 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 50.0 109.9 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.545 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 83.7 mt-10 -120.69 154.75 35.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.142 -0.974 . . . . 50.0 110.339 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.505 ' HG2' ' HA ' ' A' ' 63' ' ' LEU . 0.0 OUTLIER -146.14 140.39 26.64 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.332 -0.855 . . . . 50.0 110.027 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.434 ' HG2' HG21 ' A' ' 64' ' ' VAL . 0.4 OUTLIER -113.43 62.87 0.92 Allowed Pre-proline 0 C--N 1.306 -1.315 0 O-C-N 121.258 -0.901 . . . . 50.0 110.712 -179.864 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.494 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.4 Cg_endo -72.7 148.44 46.89 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 123.848 1.447 . . . . 50.0 110.357 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.492 ' HG3' ' CG1' ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.66 152.51 59.19 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 123.963 1.507 . . . . 50.0 110.413 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -52.8 133.63 37.13 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.19 -0.944 . . . . 50.0 110.136 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.53 161.68 11.41 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.532 -1.427 . . . . 50.0 109.532 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.522 ' CB ' ' HB2' ' A' ' 53' ' ' SER . 5.4 p30 -53.01 155.24 2.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 50.0 110.108 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.479 ' HA ' ' N ' ' A' ' 53' ' ' SER . 17.6 p -143.03 137.98 29.65 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.229 -0.919 . . . . 50.0 110.387 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 1.2 m-30 -101.56 103.34 14.18 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.88 . . . . 50.0 110.275 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.475 HD12 ' O ' ' A' ' 90' ' ' SER . 3.2 mp -101.5 138.95 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.201 -0.937 . . . . 50.0 109.871 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.508 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 75.5 t -125.37 113.73 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 50.0 110.785 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.585 HG11 ' CD2' ' A' ' 17' ' ' PHE . 41.3 t -101.97 91.54 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.958 . . . . 50.0 109.785 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.55 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.59 167.83 33.14 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.774 -1.33 . . . . 50.0 109.774 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.472 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ptp -108.38 -150.77 0.46 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -1.113 . . . . 50.0 110.08 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -73.7 -44.12 33.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.729 -1.348 . . . . 50.0 109.729 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 99' ' ' LYS . 39.5 t0 -74.98 -105.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.205 -1.174 . . . . 50.0 110.293 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.489 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 8.5 tttp -79.61 136.1 36.75 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.048 -1.032 . . . . 50.0 110.352 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.778 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -140.1 150.13 43.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.197 -0.939 . . . . 49.57 110.07 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 7.5 mt -115.72 146.98 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.856 -1.153 . . . . 49.57 110.182 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 24.0 p-10 -130.67 129.76 43.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -0.904 . . . . 49.57 110.469 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -135.48 163.79 29.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.442 -0.786 . . . . 49.57 110.018 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.627 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 10.3 p80 -134.39 164.15 28.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.931 . . . . 49.57 110.221 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -144.16 133.29 22.91 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.257 -0.902 . . . . 49.57 110.236 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.578 ' CE1' ' O ' ' A' ' 108' ' ' ALA . 66.6 t60 -120.08 133.56 55.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 49.57 110.123 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.86 -16.88 13.45 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.238 -0.914 . . . . 49.57 110.381 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.578 ' O ' ' CE1' ' A' ' 106' ' ' HIS . . . 179.76 152.36 0.43 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.339 -0.85 . . . . 49.57 110.241 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -159.92 45.58 0.42 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.497 -1.441 . . . . 49.57 109.497 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.3 p -90.55 172.39 8.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -1.173 . . . . 49.57 110.148 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 118.059 -0.972 . . . . 49.57 110.316 179.979 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.404 ' C ' ' OD1' ' A' ' 1' ' ' ASP . 21.1 t0 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.26 0.552 . . . . 50.0 110.252 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -74.61 134.07 42.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.151 -0.968 . . . . 50.0 110.28 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.4 pp -82.91 136.84 34.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 50.0 110.245 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.11 113.44 22.17 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.254 -0.904 . . . . 50.0 110.014 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 tp -107.55 99.8 9.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 50.0 110.327 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.403 ' HD2' ' OG1' ' A' ' 8' ' ' THR . 1.2 ptpp? -106.66 -164.03 0.96 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.901 . . . . 50.0 110.217 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.01 66.24 0.36 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.477 HG23 ' N ' ' A' ' 9' ' ' THR . 73.3 m -120.13 148.72 43.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -1.123 . . . . 50.0 110.255 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.477 ' N ' HG23 ' A' ' 8' ' ' THR . 1.4 p -108.92 140.0 43.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 50.0 110.072 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.7 p90 -131.75 177.28 7.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.238 -0.914 . . . . 50.0 110.282 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.468 ' O ' ' HG2' ' A' ' 45' ' ' LYS . . . -80.54 101.31 2.0 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.677 -1.369 . . . . 50.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.547 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -113.06 105.09 13.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -1.095 . . . . 50.0 110.208 179.869 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.661 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.7 p -148.6 107.53 3.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.112 -0.992 . . . . 99.989999999999995 110.567 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.482 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 6.7 m -160.84 42.12 0.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.679 -1.263 . . . . 99.989999999999995 110.602 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -65.14 -5.95 7.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.14 -0.975 . . . . 99.989999999999995 109.906 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 mmtm -83.44 61.21 6.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 50.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.584 ' CZ ' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -101.44 142.44 32.82 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.204 -0.935 . . . . 50.0 109.668 179.45 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 t -127.13 97.58 4.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.154 -0.966 . . . . 50.0 110.197 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 11.4 p90 -63.0 118.06 7.3 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.36 -0.837 . . . . 50.0 110.04 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -102.22 -22.41 14.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.093 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.491 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -138.06 145.99 42.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 50.0 110.137 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.425 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 22.9 p30 -66.83 162.62 50.74 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 50.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.425 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 45.0 Cg_endo -72.14 114.48 3.99 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.966 1.509 . . . . 50.0 110.37 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -105.02 140.13 38.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.284 -0.885 . . . . 50.0 110.368 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -90.53 111.24 22.45 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.36 -0.837 . . . . 50.0 110.184 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.5 59.02 5.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.228 -0.92 . . . . 50.0 110.158 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 128.31 -128.16 5.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -132.59 89.21 2.61 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -1.205 . . . . 50.0 110.138 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.68 31.05 2.43 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.521 -1.431 . . . . 50.0 109.521 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -154.95 111.19 3.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.214 -1.168 . . . . 50.0 110.343 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.499 ' HB ' ' O ' ' A' ' 83' ' ' MET . 57.7 t -109.27 147.88 13.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.295 -0.878 . . . . 50.0 110.253 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.92 118.26 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 50.0 110.318 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.446 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.6 OUTLIER -116.04 149.54 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.311 -0.868 . . . . 50.0 109.785 179.64 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.491 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.7 OUTLIER -126.69 104.87 8.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.207 -0.933 . . . . 50.0 110.534 -179.653 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.594 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -123.78 144.52 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.319 -0.863 . . . . 50.0 109.302 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.23 133.51 39.02 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.031 -1.043 . . . . 50.0 110.028 -179.688 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.507 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 6.8 t80 -94.0 97.56 10.42 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.065 -1.054 . . . . 50.0 109.863 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 59.1 p -95.41 70.06 3.11 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.27 -0.894 . . . . 50.0 110.14 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -122.39 129.38 7.53 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.575 -1.41 . . . . 99.989999999999995 109.575 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.0 p -92.86 24.78 3.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.274 -1.133 . . . . 99.989999999999995 110.244 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.452 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.2 p30 -98.43 -1.32 41.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.084 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -168.63 24.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.461 -1.456 . . . . 99.989999999999995 109.461 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.566 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.7 Cg_endo -73.56 153.4 49.39 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.976 1.513 . . . . 99.989999999999995 110.324 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.661 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.29 161.33 8.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.34 -0.85 . . . . 50.0 110.002 -179.378 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.547 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.0 OUTLIER -76.04 133.86 40.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.095 -1.003 . . . . 50.0 109.305 178.951 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.584 ' CD1' ' CZ ' ' A' ' 17' ' ' PHE . 9.5 mt -89.25 108.41 24.26 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 120.996 -1.065 . . . . 50.0 110.157 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.52 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 47.6 Cg_endo -74.49 99.99 1.27 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 124.043 1.549 . . . . 50.0 110.7 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.562 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 2.6 mt -126.55 150.34 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 50.0 110.172 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 93' ' ' VAL . 2.7 p -128.21 130.43 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.416 -0.802 . . . . 50.0 109.983 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.498 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.1 OUTLIER -115.35 106.47 14.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 50.0 109.931 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.548 HG12 ' CB ' ' A' ' 55' ' ' ASN . 2.9 t -132.78 163.09 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.187 -0.946 . . . . 50.0 110.698 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.459 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.24 164.43 1.31 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.485 -0.759 . . . . 50.0 110.393 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.647 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -58.69 122.28 13.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.441 -0.787 . . . . 50.0 110.598 -179.602 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.647 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 81.17 29.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.594 -0.691 . . . . 50.0 110.906 179.627 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.548 ' CB ' HG12 ' A' ' 51' ' ' VAL . 14.7 m120 -132.99 84.35 2.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 50.0 109.995 178.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 56' ' ' ASP . 10.4 m-20 -106.7 18.09 22.34 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.164 -0.96 . . . . 50.0 110.349 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 18.4 mtt -125.0 -8.93 7.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 50.0 110.474 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.542 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -136.2 144.29 47.33 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.151 -0.968 . . . . 50.0 110.391 -179.854 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.48 125.8 9.85 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.036 1.545 . . . . 50.0 110.239 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.0 t -139.2 -36.22 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 50.0 110.093 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -79.49 161.65 46.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.023 -1.631 . . . . 50.0 109.023 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.459 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -123.63 156.92 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 50.0 110.532 -179.527 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.446 ' HA ' ' HG3' ' A' ' 83' ' ' MET . 1.2 mt -107.16 132.75 52.69 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.314 -0.866 . . . . 50.0 109.944 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.495 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 27.2 t -63.71 -17.27 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -0.946 . . . . 50.0 110.451 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 66' ' ' VAL . 6.2 t -147.11 167.42 24.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 50.0 110.193 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.474 HG12 ' OD1' ' A' ' 67' ' ' ASN . 21.2 t -47.16 173.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 50.0 110.02 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.566 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 5.4 p30 -46.73 138.26 7.05 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.202 -0.936 . . . . 50.0 110.239 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.473 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 46.7 Cg_endo -74.01 103.05 1.6 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.934 1.492 . . . . 50.0 110.38 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.566 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -113.8 134.01 55.04 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.18 -0.95 . . . . 50.0 110.495 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.526 HG22 ' CD1' ' A' ' 46' ' ' ILE . 61.9 t -87.63 60.46 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 50.0 109.684 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.566 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.9 57.42 4.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.295 -0.878 . . . . 50.0 110.021 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.43 169.01 18.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 50.0 110.424 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.87 -7.15 34.19 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.872 . . . . 50.0 109.909 179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.11 12.59 11.12 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.31 -0.869 . . . . 99.989999999999995 110.242 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.509 ' CB ' HG12 ' A' ' 70' ' ' VAL . . . -77.15 6.82 5.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.079 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.507 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 8.2 m-80 -84.62 19.56 1.97 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.333 -0.855 . . . . 99.989999999999995 109.384 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 36' ' ' SER . 31.0 m -121.09 -172.54 2.42 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.414 -0.804 . . . . 99.989999999999995 109.177 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.459 ' HB3' ' OE2' ' A' ' 34' ' ' GLU . 6.8 mttp -63.21 88.06 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.235 -0.915 . . . . 99.989999999999995 109.064 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.573 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 11.2 m -76.95 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.331 -0.856 . . . . 99.989999999999995 109.318 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.44 ' CD2' ' O ' ' A' ' 33' ' ' ILE . 0.4 OUTLIER -133.87 130.36 37.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.785 -1.197 . . . . 50.0 111.1 -179.66 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.5 t -120.45 168.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.476 -0.765 . . . . 50.0 109.947 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.495 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 4.0 mt-10 -132.96 147.99 52.28 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.179 -0.951 . . . . 50.0 110.176 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.499 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -146.83 143.17 28.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.214 -0.929 . . . . 50.0 110.393 -179.853 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 62' ' ' ARG . 0.2 OUTLIER -117.95 68.56 6.65 Favored Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.115 -0.991 . . . . 50.0 110.477 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.86 161.44 41.48 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 O-C-N 123.975 1.513 . . . . 50.0 110.358 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.43 146.7 40.12 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 124.003 1.528 . . . . 50.0 110.446 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 87' ' ' PHE . 0.8 OUTLIER -52.74 135.18 35.82 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.281 -0.887 . . . . 50.0 110.07 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 124.81 165.63 12.19 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 53' ' ' SER . 92.8 m-20 -62.2 135.42 57.48 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -1.193 . . . . 50.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.551 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.7 OUTLIER -132.27 145.27 51.18 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.308 -0.87 . . . . 50.0 110.138 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.599 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.9 m-30 -100.74 113.16 25.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.081 -1.012 . . . . 50.0 110.026 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.426 HD13 ' HB2' ' A' ' 90' ' ' SER . 3.5 mp -109.06 131.1 60.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 50.0 110.108 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.506 ' HB ' ' CG1' ' A' ' 49' ' ' VAL . 71.3 t -124.89 118.86 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.17 -0.956 . . . . 50.0 110.437 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.513 ' HB ' ' CG1' ' A' ' 101' ' ' ILE . 21.7 t -101.41 93.78 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 50.0 109.88 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.481 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -156.15 170.73 33.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.784 -1.326 . . . . 50.0 109.784 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.535 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 15.9 ptp -112.2 -28.33 7.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.262 -1.14 . . . . 50.0 109.919 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . 0.535 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 171.3 -61.56 0.17 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -64.0 -108.41 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.232 -1.158 . . . . 50.0 110.268 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -79.62 127.98 32.83 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.093 -1.004 . . . . 50.0 110.182 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.77 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.8 pp0? -136.16 150.2 48.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.231 -0.918 . . . . 49.57 110.226 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.513 ' CG1' ' HB ' ' A' ' 94' ' ' VAL . 32.4 pt -102.95 148.94 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.974 -1.079 . . . . 49.57 110.186 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -132.27 142.39 49.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 49.57 110.397 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -128.46 166.74 18.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 49.57 110.193 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.586 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 8.8 p80 -118.61 85.36 2.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.327 -0.858 . . . . 49.57 110.346 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.494 ' C ' ' CD1' ' A' ' 105' ' ' TRP . 1.7 t-105 -45.9 122.51 3.84 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.156 -0.965 . . . . 49.57 110.051 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.99 114.86 10.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 49.57 110.159 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -89.37 -8.64 52.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 49.57 110.163 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -172.69 131.06 0.54 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 49.57 110.114 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.38 38.52 3.19 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.578 -1.409 . . . . 49.57 109.578 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -140.81 123.09 15.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.141 -1.211 . . . . 49.57 110.251 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 117.99 -1.005 . . . . 49.57 110.175 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.437 ' O ' ' OD1' ' A' ' 1' ' ' ASP . 36.9 t0 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.267 0.556 . . . . 50.0 110.232 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -162.87 160.18 24.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.315 -0.866 . . . . 50.0 110.128 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.4 pp -78.7 121.02 24.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 50.0 110.176 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.55 94.15 6.24 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.279 -0.888 . . . . 50.0 110.149 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 tp -111.28 137.25 49.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.878 . . . . 50.0 110.004 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.24 165.25 24.58 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 50.0 110.254 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.88 17.64 48.57 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.612 -1.395 . . . . 50.0 109.612 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.9 p -102.22 101.45 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -1.189 . . . . 50.0 110.214 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.449 ' O ' ' O ' ' A' ' 10' ' ' TYR . 1.1 t -155.06 -177.83 6.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.241 -0.912 . . . . 50.0 110.17 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.449 ' O ' ' O ' ' A' ' 9' ' ' THR . 1.0 OUTLIER -46.79 174.47 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 50.0 110.335 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.98 124.17 7.69 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.672 -1.371 . . . . 50.0 109.672 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.551 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? -78.13 114.24 16.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.251 -1.146 . . . . 50.0 110.016 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.646 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.83 108.01 3.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 110.655 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.476 ' OG1' ' O ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -161.43 44.04 0.16 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.876 -1.14 . . . . 99.989999999999995 110.489 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.419 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.4 OUTLIER -76.83 10.43 2.25 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.147 -0.97 . . . . 99.989999999999995 110.615 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.463 ' HE2' ' HA2' ' A' ' 39' ' ' GLY . 0.0 OUTLIER -111.48 61.85 0.61 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.028 -1.045 . . . . 50.0 110.59 -179.964 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.547 ' CZ ' HD11 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -94.68 148.74 21.96 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.093 -1.004 . . . . 50.0 109.994 179.603 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.576 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 28.6 t -125.15 114.31 18.85 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 50.0 110.153 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.601 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 9.7 m-85 -64.94 112.92 3.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.26 -0.9 . . . . 50.0 110.188 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.48 ' C ' ' HG2' ' A' ' 21' ' ' LYS . . . -96.51 -32.94 12.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.19 -0.944 . . . . 50.0 110.152 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.48 ' HG2' ' C ' ' A' ' 20' ' ' ALA . 0.5 OUTLIER -138.96 163.03 33.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 50.0 110.229 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.446 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 36.7 p-10 -76.89 164.3 60.06 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 50.0 110.134 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.446 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.19 126.78 12.7 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.431 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -121.53 148.83 43.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.22 -0.925 . . . . 50.0 110.344 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 10.3 t70 -94.62 122.07 36.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 50.0 110.203 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.1 p -79.35 -51.33 9.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.166 -0.959 . . . . 50.0 110.278 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.425 ' O ' ' OD1' ' A' ' 25' ' ' ASP . . . -128.59 -108.1 1.38 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.641 -1.384 . . . . 50.0 109.641 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -127.11 108.37 10.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.127 . . . . 50.0 110.296 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.48 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 85.19 31.28 23.14 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.632 -1.387 . . . . 50.0 109.632 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.434 ' HA ' HG22 ' A' ' 64' ' ' VAL . 1.1 p -145.36 107.92 4.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.149 -1.207 . . . . 50.0 110.361 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.469 HG22 ' HD2' ' A' ' 85' ' ' PRO . 21.4 t -104.24 148.59 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 O-C-N 121.342 -0.849 . . . . 50.0 110.175 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -122.65 132.81 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 50.0 110.406 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.516 HG22 ' CD1' ' A' ' 35' ' ' LEU . 8.4 tp -128.49 133.6 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.335 -0.853 . . . . 50.0 109.781 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.479 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 8.9 tt0 -108.54 111.34 23.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.187 -0.946 . . . . 50.0 110.572 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.582 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 0.4 OUTLIER -125.2 143.12 51.1 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.32 -0.862 . . . . 50.0 109.183 179.299 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.465 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -89.45 126.01 35.4 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.98 -1.075 . . . . 50.0 109.925 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.59 ' CE1' ' HA3' ' A' ' 39' ' ' GLY . 1.3 t80 -93.56 101.77 13.96 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.987 -1.085 . . . . 50.0 109.357 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 79.5 p -96.36 69.73 2.66 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.281 -0.887 . . . . 50.0 110.261 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.59 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -117.47 130.77 9.01 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.334 -1.506 . . . . 99.989999999999995 109.334 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 36.9 m -84.42 25.55 0.86 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -1.176 . . . . 99.989999999999995 110.539 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.08 -0.91 26.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.077 -1.014 . . . . 99.989999999999995 110.219 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.33 -157.99 28.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.409 -1.477 . . . . 99.989999999999995 109.409 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.22 137.24 28.29 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.923 1.486 . . . . 99.989999999999995 110.265 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.642 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -153.02 161.18 42.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.855 . . . . 50.0 110.107 -179.432 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.551 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 26.8 mmtt -75.68 130.93 39.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 50.0 109.157 178.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.595 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 20.1 mt -89.71 107.31 18.0 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.088 -1.007 . . . . 50.0 110.672 -179.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.551 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.2 Cg_endo -74.84 100.7 1.37 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.031 1.543 . . . . 50.0 110.078 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.595 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 66.1 mt -135.87 146.83 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.165 -0.96 . . . . 50.0 110.563 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.438 HG21 ' HB ' ' A' ' 93' ' ' VAL . 15.7 m -121.41 161.7 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.353 -0.842 . . . . 50.0 109.664 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -132.72 104.33 6.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.127 -0.983 . . . . 50.0 110.119 -179.846 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.558 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.4 m -127.22 158.96 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.295 -0.878 . . . . 50.0 110.017 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.41 ' HB2' ' CG ' ' A' ' 55' ' ' ASN . . . -55.83 163.35 1.46 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.361 -0.837 . . . . 50.0 110.054 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.632 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.0 OUTLIER -59.53 118.53 6.16 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.255 -0.903 . . . . 50.0 110.454 -179.534 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.632 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.2 tp 79.53 30.51 0.29 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.568 -0.707 . . . . 50.0 110.673 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.41 ' CG ' ' HB2' ' A' ' 52' ' ' ALA . 6.5 m120 -124.51 84.87 2.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.284 -0.885 . . . . 50.0 110.341 179.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.442 ' OD1' ' HE1' ' A' ' 57' ' ' MET . 2.8 p30 -101.77 9.82 40.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 50.0 109.88 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.442 ' HE1' ' OD1' ' A' ' 56' ' ' ASP . 3.8 mtt -123.44 -12.88 7.7 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 50.0 110.106 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.6 m -130.26 119.02 18.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.378 -0.826 . . . . 50.0 110.035 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.55 136.94 29.42 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.922 1.485 . . . . 50.0 110.162 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.473 HG12 ' HG3' ' A' ' 86' ' ' PRO . 44.7 t -148.24 -37.37 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.176 -0.953 . . . . 50.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.81 145.18 37.95 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.817 -1.713 . . . . 50.0 108.817 179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.45 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.1 mmp_? -124.06 157.26 34.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.991 -1.3 . . . . 50.0 110.53 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.4 mt -101.67 127.43 48.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.298 -0.876 . . . . 50.0 109.731 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.51 ' CB ' ' HG2' ' A' ' 82' ' ' GLU . 22.8 t -64.5 -13.19 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 50.0 110.262 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' VAL . 14.0 t -140.8 165.97 26.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.215 -0.928 . . . . 50.0 110.215 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.442 ' CG1' ' H ' ' A' ' 67' ' ' ASN . 3.8 t -55.07 -170.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 50.0 109.881 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.612 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 3.0 t30 -46.31 132.66 7.62 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.023 -1.048 . . . . 50.0 110.08 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.524 ' O ' ' CD1' ' A' ' 46' ' ' ILE . 46.9 Cg_endo -73.51 75.36 3.01 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.042 1.549 . . . . 50.0 110.554 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.612 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.8 p90 -95.15 136.94 34.87 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.239 -0.913 . . . . 50.0 110.141 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.591 ' CG1' ' CB ' ' A' ' 75' ' ' ALA . 2.3 t -97.12 60.58 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 50.0 109.649 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -71.33 59.48 0.28 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.341 -0.849 . . . . 50.0 110.238 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 2.4 t -142.62 164.66 29.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 50.0 110.257 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.7 t -84.26 11.25 8.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.137 -0.977 . . . . 50.0 110.081 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -121.63 13.64 10.87 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 99.989999999999995 110.358 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.591 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -61.9 -10.98 10.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.18 -0.95 . . . . 99.989999999999995 110.172 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 63.5 m-20 -86.49 20.91 2.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.143 -0.973 . . . . 99.989999999999995 109.351 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.5 OUTLIER -132.69 -173.24 3.12 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.725 -179.872 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.463 ' HG3' ' OG ' ' A' ' 36' ' ' SER . 0.8 OUTLIER -64.34 89.56 0.06 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.196 179.256 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.582 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 27.0 m -75.74 174.83 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.221 -0.924 . . . . 99.989999999999995 109.165 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.69 134.29 44.61 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.764 -1.21 . . . . 50.0 111.432 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 t -121.03 178.25 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.736 . . . . 50.0 109.696 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.51 ' HG2' ' CB ' ' A' ' 64' ' ' VAL . 10.5 tt0 -143.69 138.78 29.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.172 -0.955 . . . . 50.0 110.342 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.4 mtm -147.25 145.44 29.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.151 -0.968 . . . . 50.0 110.383 -179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.48 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -118.07 70.05 7.66 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 121.341 -0.849 . . . . 50.0 110.563 -179.999 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.469 ' HD2' HG22 ' A' ' 31' ' ' VAL . 46.0 Cg_endo -74.11 162.28 39.16 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.012 1.533 . . . . 50.0 110.126 179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.473 ' HG3' HG12 ' A' ' 60' ' ' VAL . 47.1 Cg_endo -72.7 150.28 50.15 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 123.896 1.472 . . . . 50.0 110.335 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.54 120.56 5.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.197 -0.94 . . . . 50.0 110.029 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 134.64 178.31 15.56 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.562 -1.415 . . . . 50.0 109.562 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 106' ' ' HIS . 25.3 p-10 -77.17 141.05 40.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -1.14 . . . . 50.0 110.208 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.536 ' HA ' ' N ' ' A' ' 53' ' ' SER . 53.6 p -135.11 150.62 50.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 50.0 110.164 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.588 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 0.5 OUTLIER -96.94 105.02 17.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 50.0 110.275 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.567 HG23 ' CE3' ' A' ' 105' ' ' TRP . 0.0 OUTLIER -96.06 136.4 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.226 -0.921 . . . . 50.0 109.505 179.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.506 ' N ' HD11 ' A' ' 92' ' ' ILE . 33.5 t -123.84 117.54 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.131 -0.98 . . . . 50.0 110.88 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.542 ' HA ' HG12 ' A' ' 48' ' ' ILE . 97.0 t -106.14 95.03 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.328 -0.857 . . . . 50.0 109.893 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.59 170.3 33.51 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.665 -1.374 . . . . 50.0 109.665 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 9.2 mtm -80.4 -63.52 1.39 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -1.157 . . . . 50.0 110.178 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -156.06 -68.48 0.01 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.561 -1.416 . . . . 50.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -71.14 -75.58 0.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -1.11 . . . . 50.0 110.279 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -79.67 119.62 22.86 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.289 -0.882 . . . . 50.0 110.305 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.607 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.54 148.72 41.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 49.57 110.091 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.7 mm -98.69 111.46 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.12 -0.988 . . . . 49.57 110.039 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.416 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 36.7 p-10 -101.57 130.37 47.86 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.154 -0.966 . . . . 49.57 110.275 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.601 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -128.93 170.62 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.355 -0.841 . . . . 49.57 110.324 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.454 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 50.0 p-80 -123.7 125.33 44.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.33 -0.857 . . . . 49.57 110.127 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.567 ' CE3' HG23 ' A' ' 92' ' ' ILE . 9.1 m0 -123.33 132.58 54.04 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.182 -0.949 . . . . 49.57 110.328 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 89' ' ' ASP . 13.6 p80 -118.27 126.66 52.61 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.287 -0.883 . . . . 49.57 110.118 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . 0.447 ' O ' ' HB1' ' A' ' 108' ' ' ALA . 0.6 OUTLIER -89.61 -16.73 29.9 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 49.57 110.073 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.447 ' HB1' ' O ' ' A' ' 107' ' ' LYS . . . 179.73 141.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.418 -0.801 . . . . 49.57 110.21 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -86.32 110.6 3.51 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.414 -1.474 . . . . 49.57 109.414 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 29.7 p -114.99 44.06 1.86 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -1.144 . . . . 49.57 110.309 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.962 -1.018 . . . . 49.57 110.18 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.273 0.559 . . . . 50.0 110.204 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.82 155.2 50.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 50.0 110.141 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.28 148.86 22.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.223 -0.923 . . . . 50.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.03 92.64 6.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.321 -0.862 . . . . 50.0 110.183 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.21 151.8 27.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.895 . . . . 50.0 110.106 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.02 -176.32 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.245 -0.91 . . . . 50.0 110.046 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.72 43.11 2.62 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.517 -1.433 . . . . 50.0 109.517 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.48 164.67 0.67 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.331 -1.1 . . . . 50.0 110.227 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 p -46.67 155.42 0.25 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 50.0 110.064 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.23 104.75 13.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.222 -0.924 . . . . 50.0 110.282 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.492 ' HA3' ' HA ' ' A' ' 44' ' ' CYS . . . -97.89 151.8 19.75 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 3.4 mtm -107.4 95.25 5.57 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.292 -1.122 . . . . 50.0 110.37 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.548 ' HB3' ' O ' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -112.24 -175.5 2.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 99.989999999999995 109.929 179.674 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.619 ' HA ' ' HG3' ' A' ' 47' ' ' PRO . 21.8 p -158.24 -76.55 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.342 -0.849 . . . . 99.989999999999995 110.307 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.538 ' O ' ' CG ' ' A' ' 15' ' ' GLU . 20.6 tt0 -118.76 8.46 11.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 110.351 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.529 ' HB3' ' CD1' ' A' ' 37' ' ' TYR . 0.9 OUTLIER -56.04 81.97 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.349 -0.845 . . . . 50.0 111.021 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.26 142.06 12.7 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.174 -0.954 . . . . 50.0 110.205 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.477 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 m -127.75 97.46 4.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -0.892 . . . . 50.0 110.267 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p90 -57.12 119.55 6.53 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.25 -0.906 . . . . 50.0 110.249 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -107.15 -21.94 12.8 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.33 -0.856 . . . . 50.0 110.101 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.475 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 14.8 mttm -145.02 149.69 35.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.968 . . . . 50.0 110.278 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -67.66 159.45 78.48 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.849 . . . . 50.0 110.279 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.475 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.7 Cg_endo -72.93 134.16 21.13 Favored 'Trans proline' 0 C--N 1.303 -1.818 0 O-C-N 124.013 1.533 . . . . 50.0 110.401 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -130.51 155.32 46.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.231 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -83.69 148.46 27.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.232 -0.917 . . . . 50.0 110.122 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.488 HG22 HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -136.62 22.22 3.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.193 -0.942 . . . . 50.0 110.207 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.28 -133.71 3.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.577 -1.409 . . . . 50.0 109.577 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -104.77 92.78 4.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -1.129 . . . . 50.0 110.343 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 84' ' ' GLU . . . 80.41 30.83 39.46 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.627 -1.389 . . . . 50.0 109.627 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 p -122.59 107.62 12.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.2 -1.176 . . . . 50.0 110.275 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.475 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -100.11 145.19 11.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.276 -0.89 . . . . 50.0 110.099 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.488 HG22 HG22 ' A' ' 26' ' ' THR . 0.0 OUTLIER -122.42 148.9 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.147 -0.971 . . . . 50.0 110.388 -179.73 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.496 ' O ' ' CD2' ' A' ' 80' ' ' LEU . 6.1 tt -148.17 156.37 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 50.0 109.65 179.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.475 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 17.3 tt0 -126.09 103.81 7.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.117 -0.989 . . . . 50.0 110.696 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.568 ' HB2' ' CE1' ' A' ' 17' ' ' PHE . 0.2 OUTLIER -121.84 140.17 52.72 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.349 -0.845 . . . . 50.0 109.263 179.4 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.518 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -92.7 132.84 36.58 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.044 -1.035 . . . . 50.0 110.107 -179.563 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.529 ' CD1' ' HB3' ' A' ' 16' ' ' LYS . 9.4 t80 -94.88 103.05 14.92 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.088 -1.045 . . . . 50.0 109.742 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 t -96.48 69.7 2.6 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.313 -0.867 . . . . 50.0 109.929 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.488 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -112.89 130.57 9.58 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.661 -1.376 . . . . 99.989999999999995 109.661 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.52 5.72 10.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 99.989999999999995 110.344 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.27 -1.35 42.1 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.213 -0.93 . . . . 99.989999999999995 110.116 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' CE2' ' A' ' 37' ' ' TYR . . . 80.93 -131.91 10.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.457 -1.457 . . . . 99.989999999999995 109.457 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.541 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 45.6 Cg_endo -73.0 131.01 16.21 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.888 1.467 . . . . 99.989999999999995 110.441 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.492 ' HA ' ' HA3' ' A' ' 11' ' ' GLY . 30.5 p -147.81 161.84 40.45 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.323 -0.861 . . . . 50.0 110.126 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.548 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 17.2 mmtt -87.23 108.67 19.04 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 50.0 109.929 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.619 ' CD1' ' CE2' ' A' ' 17' ' ' PHE . 4.2 mt -84.51 116.48 65.33 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 50.0 110.353 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.619 ' HG3' ' HA ' ' A' ' 14' ' ' THR . 47.2 Cg_endo -71.94 104.7 1.68 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 124.117 1.588 . . . . 50.0 110.344 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.539 HG12 ' CG2' ' A' ' 94' ' ' VAL . 1.2 mt -125.86 151.15 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 50.0 110.233 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 49' ' ' VAL . 5.8 p -132.99 141.29 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.913 . . . . 50.0 110.051 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 61' ' ' GLY . 3.5 m -115.64 104.79 12.05 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.311 -0.868 . . . . 50.0 109.887 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.474 ' HB ' ' O ' ' A' ' 55' ' ' ASN . 30.4 m -131.78 162.94 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.265 -0.897 . . . . 50.0 110.322 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -55.58 163.97 1.17 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.422 -0.799 . . . . 50.0 110.18 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.636 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 10.2 t -63.15 118.26 7.68 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 50.0 110.711 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.599 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 77.21 30.76 0.52 Allowed 'General case' 0 N--CA 1.496 1.829 0 C-N-CA 119.876 -0.73 . . . . 50.0 110.765 179.485 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.474 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 10.5 m120 -134.9 84.95 2.14 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 50.0 110.032 179.124 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -104.53 18.54 22.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.273 -0.892 . . . . 50.0 110.373 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 ttt -102.87 -24.98 13.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -0.961 . . . . 50.0 110.136 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.41 138.59 27.28 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.462 -0.774 . . . . 50.0 110.196 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.431 ' C ' HG23 ' A' ' 60' ' ' VAL . 47.0 Cg_endo -72.37 133.23 20.51 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.997 1.525 . . . . 50.0 110.361 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.431 HG23 ' C ' ' A' ' 59' ' ' PRO . 21.7 t -143.86 -36.41 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.158 -0.964 . . . . 50.0 110.277 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.11 159.21 50.3 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.052 -1.619 . . . . 50.0 109.052 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 14.8 mtt-85 -129.36 156.22 44.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.049 -1.265 . . . . 50.0 110.372 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 56.6 mt -94.89 124.67 39.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.276 -0.89 . . . . 50.0 110.132 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.518 HG22 ' N ' ' A' ' 84' ' ' GLU . 54.5 t -70.54 -38.93 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.198 -0.939 . . . . 50.0 110.122 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.73 175.72 6.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.317 -0.864 . . . . 50.0 110.086 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.6 m -57.92 -175.02 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.217 -0.927 . . . . 50.0 110.315 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.478 ' HB2' ' CD1' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.93 156.91 0.51 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.264 -0.897 . . . . 50.0 110.045 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.533 ' HB2' ' CD1' ' A' ' 48' ' ' ILE . 48.1 Cg_endo -74.61 65.61 5.68 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.931 1.49 . . . . 50.0 110.9 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.604 ' CD2' ' O ' ' A' ' 69' ' ' PHE . 49.0 p90 -132.45 121.79 23.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.114 -0.991 . . . . 50.0 110.187 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.544 ' HB ' ' CB ' ' A' ' 75' ' ' ALA . 6.8 m -88.19 60.85 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.061 -1.024 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.541 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -66.09 65.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.3 -0.875 . . . . 50.0 110.307 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.455 ' N ' ' O ' ' A' ' 70' ' ' VAL . 1.5 m -142.49 159.26 42.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.2 -0.937 . . . . 50.0 110.244 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -86.16 -13.23 47.67 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.296 -0.878 . . . . 50.0 109.908 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.1 p -114.79 15.81 17.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.381 -0.824 . . . . 99.989999999999995 110.057 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.544 ' CB ' ' HB ' ' A' ' 70' ' ' VAL . . . -81.13 9.79 6.27 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 109.959 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 84.5 m-20 -85.2 16.86 3.31 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.335 -0.853 . . . . 99.989999999999995 109.441 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.518 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.0 t -121.66 -172.44 2.43 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.412 -0.805 . . . . 99.989999999999995 109.352 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 2.4 mttp -62.96 88.33 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.442 -0.903 . . . . 99.989999999999995 109.068 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.566 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 24.3 m -76.68 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.391 -0.818 . . . . 99.989999999999995 109.832 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.496 ' CD2' ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -123.51 129.65 51.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.971 -1.08 . . . . 50.0 110.953 -179.642 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.512 HG22 ' CD1' ' A' ' 35' ' ' LEU . 2.0 t -116.35 178.03 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.388 -0.82 . . . . 50.0 109.872 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.48 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 66.2 mt-10 -153.3 151.0 29.5 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.069 -1.02 . . . . 50.0 110.354 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' CD ' ' A' ' 85' ' ' PRO . 0.4 OUTLIER -149.54 130.86 14.65 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.236 -0.915 . . . . 50.0 110.267 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.518 ' N ' HG22 ' A' ' 64' ' ' VAL . 0.1 OUTLIER -106.57 72.72 0.3 Allowed Pre-proline 0 C--N 1.306 -1.285 0 O-C-N 121.255 -0.903 . . . . 50.0 110.802 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.49 ' CD ' ' O ' ' A' ' 83' ' ' MET . 47.1 Cg_endo -73.0 170.36 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.842 1.443 . . . . 50.0 110.089 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.35 157.0 57.83 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 123.974 1.513 . . . . 50.0 110.479 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -52.84 125.45 17.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.275 -0.891 . . . . 50.0 110.136 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 129.25 -161.15 22.68 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.51 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 15.3 p-10 -99.4 129.47 45.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.202 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.535 ' HA ' ' N ' ' A' ' 53' ' ' SER . 65.3 p -122.12 152.06 40.28 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.391 -0.818 . . . . 50.0 110.092 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.676 ' CZ ' ' CD2' ' A' ' 104' ' ' HIS . 1.8 m-30 -106.2 118.83 37.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 50.0 110.27 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.512 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.7 mp -109.08 133.32 54.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.259 -0.901 . . . . 50.0 109.83 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.525 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 18.7 t -123.61 128.21 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.038 -1.039 . . . . 50.0 110.769 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.539 ' CG2' HG12 ' A' ' 48' ' ' ILE . 35.5 t -107.82 88.77 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 50.0 109.98 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.492 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.84 -179.8 31.19 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.841 -1.304 . . . . 50.0 109.841 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.556 ' CE ' ' HB ' ' A' ' 14' ' ' THR . 3.8 ptp -99.05 -32.64 11.17 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -1.131 . . . . 50.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 175.86 -72.03 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.534 -1.427 . . . . 50.0 109.534 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -65.97 -82.82 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.239 -1.154 . . . . 50.0 110.102 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 118.24 21.32 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.209 -0.932 . . . . 50.0 110.182 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.61 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.32 148.77 41.86 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 49.57 110.308 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 66.2 mt -93.06 105.84 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.116 -0.99 . . . . 49.57 109.926 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -93.83 136.37 34.18 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.14 -0.975 . . . . 49.57 110.536 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.53 159.7 35.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.251 -0.905 . . . . 49.57 110.165 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.676 ' CD2' ' CZ ' ' A' ' 91' ' ' TYR . 7.1 m170 -118.98 106.84 12.84 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.351 -0.843 . . . . 49.57 110.589 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.415 ' CE3' ' HG2' ' A' ' 23' ' ' PRO . 1.3 t-105 -88.35 91.58 8.85 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.221 -0.924 . . . . 49.57 110.146 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.435 ' O ' ' CG ' ' A' ' 106' ' ' HIS . 2.8 p80 -99.84 134.55 42.58 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.267 -0.896 . . . . 49.57 110.287 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.83 -8.42 43.56 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 49.57 110.301 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -168.51 123.03 0.9 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.2 -0.937 . . . . 49.57 110.225 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -132.16 153.66 20.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.492 -1.443 . . . . 49.57 109.492 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.8 m -65.15 -150.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -1.167 . . . . 49.57 110.213 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.931 -1.033 . . . . 49.57 110.199 179.976 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 24.5 p-10 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.333 0.587 . . . . 50.0 110.211 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -88.72 138.89 31.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 50.0 110.247 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.5 HD23 ' N ' ' A' ' 3' ' ' LEU . 1.0 OUTLIER -80.96 164.25 22.7 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.292 -0.88 . . . . 50.0 110.308 -179.874 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.05 99.55 6.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.266 -0.896 . . . . 50.0 110.201 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.71 73.98 1.21 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.189 -0.945 . . . . 50.0 110.239 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 3.6 tttm -111.86 160.68 17.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.89 . . . . 50.0 110.189 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.84 -54.12 0.46 Allowed Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.47 -1.452 . . . . 50.0 109.47 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.8 t -107.66 163.43 13.09 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.288 -1.124 . . . . 50.0 110.123 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.26 76.3 0.98 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.285 -0.884 . . . . 50.0 110.175 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -114.86 177.91 4.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -0.895 . . . . 50.0 110.24 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.448 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -107.55 137.34 13.95 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.535 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.7 mtt -84.67 106.34 16.15 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.285 -1.127 . . . . 50.0 110.334 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.652 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 10.7 p -148.71 108.2 3.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.312 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.598 HG23 ' CD1' ' A' ' 37' ' ' TYR . 0.3 OUTLIER -160.54 61.7 0.32 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.888 -1.133 . . . . 99.989999999999995 110.55 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.427 ' HG3' ' HD2' ' A' ' 16' ' ' LYS . 0.5 OUTLIER -89.68 28.27 1.35 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.161 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.545 ' CD ' ' N ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -133.36 67.06 1.54 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 50.0 110.829 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.646 ' CZ ' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -102.78 142.12 34.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.15 -0.969 . . . . 50.0 110.024 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -127.93 97.88 4.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.27 -0.894 . . . . 50.0 110.542 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.625 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 24.5 p90 -57.33 116.92 3.61 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.058 -1.026 . . . . 50.0 110.241 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.54 -18.05 14.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 50.0 109.994 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.47 ' HE2' ' HB2' ' A' ' 34' ' ' GLU . 21.1 mtmt -137.97 141.78 40.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.194 -0.941 . . . . 50.0 110.286 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.505 ' N ' ' OD1' ' A' ' 22' ' ' ASN . 16.0 p-10 -66.57 164.86 28.59 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.305 -0.872 . . . . 50.0 110.034 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.53 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 43.5 Cg_endo -71.09 136.46 29.56 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.983 1.517 . . . . 50.0 110.505 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' CG2' ' A' ' 32' ' ' VAL . . . -132.53 126.27 32.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.318 -0.864 . . . . 50.0 110.181 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 30' ' ' THR . 26.6 t0 -70.37 111.26 5.81 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.264 -0.898 . . . . 50.0 110.171 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.433 HG21 HG22 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -88.3 22.94 2.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -0.959 . . . . 50.0 110.243 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.04 -117.41 0.67 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.567 -1.413 . . . . 50.0 109.567 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 1.1 p80 -129.72 89.42 2.82 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.256 -1.144 . . . . 50.0 110.322 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.452 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 101.25 -2.67 54.5 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.609 -1.396 . . . . 50.0 109.609 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.463 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 16.5 p -102.17 107.83 19.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.17 -1.194 . . . . 50.0 110.242 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.53 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 16.0 t -102.59 135.88 37.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.233 -0.917 . . . . 50.0 110.081 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -120.98 132.83 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.184 -0.947 . . . . 50.0 110.208 -179.885 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.593 HG23 ' CG1' ' A' ' 81' ' ' VAL . 0.0 OUTLIER -134.73 144.16 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 50.0 109.682 179.734 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.538 ' N ' ' CD1' ' A' ' 33' ' ' ILE . 6.4 tt0 -109.68 130.8 55.48 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.201 -0.937 . . . . 50.0 110.872 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.564 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 1.1 mp -135.39 134.49 39.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.357 -0.84 . . . . 50.0 109.237 179.233 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.531 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -79.89 121.84 25.92 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.991 -1.068 . . . . 50.0 109.236 -179.822 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.598 ' CD1' HG23 ' A' ' 14' ' ' THR . 10.1 t80 -91.61 106.16 18.27 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.584 -1.247 . . . . 50.0 109.458 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.79 69.84 3.41 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.367 -0.833 . . . . 50.0 110.09 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.589 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -121.62 127.86 7.06 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.541 -1.424 . . . . 99.989999999999995 109.541 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.3 p -87.96 28.28 1.06 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -1.117 . . . . 99.989999999999995 110.272 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.463 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.9 p-10 -110.28 -0.92 17.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -0.917 . . . . 99.989999999999995 110.247 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.37 -157.41 23.94 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.408 -1.477 . . . . 99.989999999999995 109.408 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.72 153.82 54.04 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.034 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.652 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.18 157.48 6.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.144 -0.973 . . . . 50.0 110.126 -179.489 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.535 ' CG ' ' HG2' ' A' ' 12' ' ' MET . 0.4 OUTLIER -70.56 125.76 27.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 50.0 109.256 179.171 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.646 ' CD1' ' CZ ' ' A' ' 17' ' ' PHE . 2.0 mt -80.98 110.48 17.81 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.164 -0.96 . . . . 50.0 110.481 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.535 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.6 Cg_endo -75.33 84.43 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.034 1.544 . . . . 50.0 110.204 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.575 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 71.2 mt -124.29 149.26 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.917 . . . . 50.0 110.457 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.473 HG21 ' HB ' ' A' ' 93' ' ' VAL . 4.1 m -116.81 142.88 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 50.0 109.844 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 61' ' ' GLY . 22.8 m -122.56 100.88 7.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 50.0 110.016 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.536 ' O ' ' N ' ' A' ' 91' ' ' TYR . 36.0 m -129.02 157.49 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.334 -0.854 . . . . 50.0 110.238 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.21 163.95 1.45 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.389 -0.82 . . . . 50.0 109.998 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 12.7 t -62.12 121.3 12.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.167 -0.958 . . . . 50.0 110.491 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.644 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 80.07 30.39 0.24 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.61 -0.681 . . . . 50.0 110.738 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.497 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 11.4 m120 -135.41 84.29 2.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.144 -0.972 . . . . 50.0 110.182 179.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -106.75 8.57 30.99 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 50.0 110.471 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.07 -18.01 14.72 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.134 -0.979 . . . . 50.0 110.424 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 p -136.18 146.42 56.28 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.372 -0.83 . . . . 50.0 110.15 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.57 132.67 17.76 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.108 1.583 . . . . 50.0 110.496 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 2.9 t -133.83 -59.42 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -0.866 . . . . 50.0 109.817 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.3 154.12 51.45 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.69 -1.764 . . . . 50.0 108.69 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.418 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 6.2 mtt180 -142.83 156.71 45.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.963 -1.316 . . . . 50.0 110.681 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 1.1 mt -86.23 138.41 31.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.193 -0.942 . . . . 50.0 109.998 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.529 HG21 ' N ' ' A' ' 84' ' ' GLU . 76.2 t -91.64 -29.79 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 50.0 110.458 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.472 ' O ' ' O ' ' A' ' 66' ' ' VAL . 10.1 t -95.1 176.11 6.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 50.0 110.219 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' A' ' 65' ' ' THR . 53.8 t -44.34 171.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.294 -0.879 . . . . 50.0 110.225 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.448 ' OD1' HG11 ' A' ' 66' ' ' VAL . 7.4 p-10 -46.86 162.2 0.27 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 50.0 109.973 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.507 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.66 90.89 0.8 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.97 1.51 . . . . 50.0 110.319 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.648 ' CE2' ' CB ' ' A' ' 71' ' ' ALA . 2.2 t80 -149.6 121.79 8.34 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 50.0 110.366 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.537 HG12 ' CB ' ' A' ' 75' ' ' ALA . 2.2 t -88.27 63.42 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.232 -0.918 . . . . 50.0 110.064 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.648 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . . . -70.56 64.78 0.29 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.233 -0.917 . . . . 50.0 110.251 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.473 HG23 ' HB2' ' A' ' 75' ' ' ALA . 6.5 t -142.62 154.82 44.73 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.233 -0.917 . . . . 50.0 110.256 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 t -77.82 -2.83 38.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 50.0 110.082 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -117.93 23.14 11.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.247 -0.908 . . . . 99.989999999999995 110.187 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.569 ' O ' ' HB3' ' A' ' 37' ' ' TYR . . . -65.3 -5.61 7.67 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.267 -0.896 . . . . 99.989999999999995 110.418 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -85.23 22.86 1.38 Allowed 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.032 -1.043 . . . . 99.989999999999995 109.339 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.531 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.6 OUTLIER -131.59 -173.24 3.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.291 -0.88 . . . . 99.989999999999995 109.635 -179.802 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.466 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 17.3 pttt -63.92 89.11 0.05 Allowed 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.705 -0.798 . . . . 99.989999999999995 109.103 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.564 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 15.4 m -76.07 176.31 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.317 -0.864 . . . . 99.989999999999995 109.358 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.21 145.02 47.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.84 -1.162 . . . . 50.0 111.019 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.593 ' CG1' HG23 ' A' ' 33' ' ' ILE . 14.5 p -132.52 175.7 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.359 -0.838 . . . . 50.0 109.861 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 81' ' ' VAL . 3.9 mt-10 -140.29 144.87 36.63 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.085 -1.009 . . . . 50.0 110.605 -179.705 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.485 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -160.24 136.64 8.81 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.265 -0.897 . . . . 50.0 110.165 179.758 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.529 ' N ' HG21 ' A' ' 64' ' ' VAL . 2.9 pt-20 -106.13 73.96 0.31 Allowed Pre-proline 0 C--N 1.305 -1.343 0 O-C-N 121.263 -0.898 . . . . 50.0 110.579 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.7 Cg_endo -72.41 169.9 20.59 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.166 179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.18 136.93 27.79 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 123.983 1.517 . . . . 50.0 110.097 179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -53.71 103.49 0.08 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.236 -0.915 . . . . 50.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.17 -173.04 33.46 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.421 -1.471 . . . . 50.0 109.421 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.539 ' CB ' ' CD2' ' A' ' 106' ' ' HIS . 35.0 p-10 -69.34 145.52 52.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.275 -1.132 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.556 ' HA ' ' N ' ' A' ' 53' ' ' SER . 1.4 p -143.0 140.85 31.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.276 -0.89 . . . . 50.0 110.368 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.536 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -97.13 119.94 36.56 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.217 -0.927 . . . . 50.0 109.532 179.567 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 2.4 tt -114.96 132.08 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.141 -0.975 . . . . 50.0 110.38 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.473 ' HB ' HG21 ' A' ' 49' ' ' VAL . 45.3 t -120.74 120.81 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.054 -1.029 . . . . 50.0 110.405 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.518 ' CG1' HG12 ' A' ' 48' ' ' ILE . 62.0 t -109.0 99.64 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 50.0 110.107 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -153.64 160.44 29.28 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.616 -1.394 . . . . 50.0 109.616 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.459 ' SD ' ' HA ' ' A' ' 13' ' ' CYS . 4.4 ttm -115.5 -44.36 2.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -1.16 . . . . 50.0 110.271 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -115.32 -115.17 2.99 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.805 -1.318 . . . . 50.0 109.805 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.34 -35.07 17.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -1.133 . . . . 50.0 110.504 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -79.51 116.12 19.54 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.139 -0.976 . . . . 50.0 110.248 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.798 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.76 150.21 44.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.281 -0.887 . . . . 49.57 110.287 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.517 HD11 ' N ' ' A' ' 101' ' ' ILE . 4.4 mp -111.36 106.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.005 -1.059 . . . . 49.57 109.905 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.461 ' O ' ' OD1' ' A' ' 102' ' ' ASN . 16.3 p30 -95.32 130.17 42.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 49.57 110.523 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.605 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -115.38 160.79 19.41 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.373 -0.83 . . . . 49.57 109.834 179.812 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.528 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 7.4 p80 -121.6 86.64 2.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.198 -0.939 . . . . 49.57 110.386 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.485 ' O ' ' HA ' ' A' ' 89' ' ' ASP . 15.5 t-105 -58.06 93.59 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 49.57 110.051 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.539 ' CD2' ' CB ' ' A' ' 89' ' ' ASP . 1.6 t-80 -136.57 136.06 38.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.215 -0.928 . . . . 49.57 110.315 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -105.1 -8.05 18.72 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.874 . . . . 49.57 110.178 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -151.87 117.55 5.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.214 -0.929 . . . . 49.57 110.239 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -146.5 144.75 13.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.465 -1.454 . . . . 49.57 109.465 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -164.3 -179.9 6.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -1.171 . . . . 49.57 110.173 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.924 -1.036 . . . . 49.57 110.224 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.0 p30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.179 0.514 . . . . 50.0 110.234 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.8 ttmm -117.03 167.6 11.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.265 -0.897 . . . . 50.0 110.311 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -72.66 121.4 19.72 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.327 -0.858 . . . . 50.0 110.132 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -85.86 161.7 18.96 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.26 -0.9 . . . . 50.0 110.243 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mt -98.85 71.38 1.9 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 50.0 110.197 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -105.17 160.03 15.39 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.232 -0.918 . . . . 50.0 110.293 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.32 -35.05 1.85 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.373 -1.491 . . . . 50.0 109.373 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.433 ' O ' HG22 ' A' ' 8' ' ' THR . 2.6 t -127.8 113.76 16.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.303 -1.116 . . . . 50.0 110.056 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.8 p -94.45 98.96 11.23 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.114 -0.991 . . . . 50.0 110.226 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -105.68 173.86 6.13 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 50.0 110.082 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.17 137.68 14.86 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.619 -1.392 . . . . 50.0 109.619 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.538 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.8 ptm -81.52 117.72 22.15 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.265 -1.138 . . . . 50.0 110.236 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.715 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.4 p -149.06 107.89 3.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.229 -0.919 . . . . 99.989999999999995 110.485 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.554 ' CG2' HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.32 51.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.629 -1.294 . . . . 99.989999999999995 110.759 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 2.0 pt-20 -78.9 12.19 2.29 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.084 -1.01 . . . . 99.989999999999995 110.005 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mptt -101.48 61.29 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.243 -0.911 . . . . 50.0 110.388 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.425 ' CE1' HD12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -100.41 144.17 29.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.11 -0.994 . . . . 50.0 109.66 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 30.6 t -127.28 100.13 5.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.065 -1.022 . . . . 50.0 110.658 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.588 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 10.2 p90 -59.02 107.94 0.6 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.202 -0.936 . . . . 50.0 110.258 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -94.58 -23.51 17.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.907 . . . . 50.0 109.824 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.463 ' HE3' ' OE1' ' A' ' 34' ' ' GLU . 13.0 mttt -142.11 143.81 33.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 50.0 110.084 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 43.9 p-10 -66.77 162.82 48.49 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 50.0 110.209 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 46.5 Cg_endo -73.0 135.07 22.52 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.947 1.498 . . . . 50.0 110.285 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.486 ' O ' HG21 ' A' ' 32' ' ' VAL . . . -136.55 156.83 48.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.191 -0.943 . . . . 50.0 110.317 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -85.53 148.53 25.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 50.0 110.043 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.492 HG21 HG13 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -116.91 -5.89 11.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.251 -0.905 . . . . 50.0 110.194 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -172.67 -105.77 0.19 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.318 -1.513 . . . . 50.0 109.318 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.59 88.8 2.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 50.0 110.024 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.407 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 97.93 31.23 6.72 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.557 -1.417 . . . . 50.0 109.557 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -136.62 107.85 6.82 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.22 -1.164 . . . . 50.0 110.431 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.445 HG21 ' CD ' ' A' ' 85' ' ' PRO . 21.7 t -97.01 145.48 8.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.253 -0.905 . . . . 50.0 110.118 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.492 HG13 HG21 ' A' ' 26' ' ' THR . 0.0 OUTLIER -126.27 137.74 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.236 -0.915 . . . . 50.0 110.486 -179.834 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 3.3 tt -140.33 152.86 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 50.0 109.893 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.463 ' OE1' ' HE3' ' A' ' 21' ' ' LYS . 2.0 tt0 -127.02 108.04 10.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.154 -0.966 . . . . 50.0 110.304 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.584 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 0.2 OUTLIER -122.7 138.97 54.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.252 -0.905 . . . . 50.0 109.544 179.588 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.635 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.9 OUTLIER -91.77 132.07 36.67 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.086 -1.009 . . . . 50.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.464 ' CE1' HG22 ' A' ' 14' ' ' THR . 8.3 t80 -93.87 95.7 9.26 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.911 -1.115 . . . . 50.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 81.8 p -96.11 69.52 2.76 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.305 -0.872 . . . . 50.0 109.977 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -119.3 131.0 8.8 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.318 -1.513 . . . . 99.989999999999995 109.318 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.1 m -84.71 21.93 1.44 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -1.135 . . . . 99.989999999999995 110.227 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.01 -2.09 44.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.918 . . . . 99.989999999999995 109.984 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.69 -159.39 31.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.597 -1.401 . . . . 99.989999999999995 109.597 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.559 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.6 Cg_endo -72.85 148.64 46.35 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.137 1.598 . . . . 99.989999999999995 110.497 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.715 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -170.42 161.43 7.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.924 . . . . 50.0 110.129 -179.582 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.562 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -74.81 128.3 35.24 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.091 -1.006 . . . . 50.0 109.563 179.35 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.577 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 9.6 mt -87.73 114.31 58.44 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.118 -0.989 . . . . 50.0 110.52 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.51 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 48.1 Cg_endo -76.88 101.72 1.54 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.063 1.56 . . . . 50.0 110.398 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.577 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 2.4 mp -129.04 155.11 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -0.927 . . . . 50.0 110.302 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 92' ' ' ILE . 14.8 p -130.65 145.32 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.294 -0.879 . . . . 50.0 109.814 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.445 ' O ' ' N ' ' A' ' 61' ' ' GLY . 61.5 m -122.76 111.25 16.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.134 -0.979 . . . . 50.0 109.895 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.529 ' HA ' HG22 ' A' ' 60' ' ' VAL . 35.9 m -135.91 161.49 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 50.0 110.561 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -56.2 164.44 1.29 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.471 -0.768 . . . . 50.0 110.097 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.655 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 1.3 m -60.31 114.64 3.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 50.0 110.292 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 79.72 30.49 0.27 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.548 -0.72 . . . . 50.0 110.498 179.776 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.446 ' O ' HG23 ' A' ' 51' ' ' VAL . 7.6 m-20 -122.5 85.02 2.35 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 50.0 110.302 179.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.66 16.81 24.62 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.945 . . . . 50.0 110.059 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 ttt -126.12 -10.23 6.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.314 -0.866 . . . . 50.0 110.348 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.14 115.65 14.12 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.226 -0.921 . . . . 50.0 110.212 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.64 127.77 12.75 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.96 1.505 . . . . 50.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.529 HG22 ' HA ' ' A' ' 51' ' ' VAL . 2.2 m -148.07 -33.67 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.253 -0.904 . . . . 50.0 110.294 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.64 146.35 40.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.479 ' O ' ' HB2' ' A' ' 83' ' ' MET . 4.6 mtt180 -139.12 156.95 46.77 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.071 -1.252 . . . . 50.0 110.736 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.405 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 5.9 mt -88.34 141.5 28.5 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 50.0 109.975 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.528 ' CG1' ' OE1' ' A' ' 82' ' ' GLU . 92.5 t -85.42 -12.76 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 50.0 110.213 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.526 ' OG1' ' CG ' ' A' ' 82' ' ' GLU . 0.0 OUTLIER -111.54 175.74 5.3 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.23 -0.919 . . . . 50.0 110.152 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.2 m -58.14 176.16 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.296 -0.877 . . . . 50.0 110.067 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.62 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 75.3 m-20 -46.83 141.92 5.24 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.208 -0.932 . . . . 50.0 109.992 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.472 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 50.2 Cg_endo -76.81 70.04 6.65 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.93 1.489 . . . . 50.0 110.896 -179.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 11.2 p90 -110.11 129.67 55.66 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.057 -1.027 . . . . 50.0 110.269 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.576 ' CG2' ' CD1' ' A' ' 46' ' ' ILE . 94.0 t -85.65 60.84 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 50.0 110.097 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.559 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.77 57.4 4.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.172 -0.955 . . . . 50.0 110.006 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.71 169.63 17.39 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.269 -0.894 . . . . 50.0 110.288 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 p -97.43 -4.34 38.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 50.0 109.833 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 93.2 p -121.19 9.47 10.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.324 -0.86 . . . . 99.989999999999995 110.538 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.551 ' HB2' ' CG1' ' A' ' 70' ' ' VAL . . . -78.51 8.11 5.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.047 -1.033 . . . . 99.989999999999995 109.941 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.436 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 20.1 m-80 -86.11 20.03 2.44 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 109.281 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.635 ' O ' ' HA ' ' A' ' 36' ' ' SER . 3.7 m -124.41 -173.08 2.69 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.386 -0.821 . . . . 99.989999999999995 109.359 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.545 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.0 OUTLIER -63.19 88.62 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.42 -0.8 . . . . 99.989999999999995 109.267 179.564 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.556 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 10.3 m -76.68 174.62 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.359 -0.838 . . . . 99.989999999999995 109.658 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.74 131.74 52.47 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.933 -1.104 . . . . 50.0 110.786 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.452 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -125.46 176.62 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 109.917 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.528 ' OE1' ' CG1' ' A' ' 64' ' ' VAL . 8.4 pt-20 -160.22 156.26 26.25 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -0.998 . . . . 50.0 110.354 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.531 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.8 OUTLIER -160.05 140.12 11.56 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -0.875 . . . . 50.0 110.291 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.407 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -104.11 86.36 1.28 Allowed Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.386 -0.821 . . . . 50.0 110.466 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 83' ' ' MET . 45.4 Cg_endo -71.44 170.16 19.11 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.818 1.431 . . . . 50.0 110.409 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.13 163.2 39.44 Favored 'Trans proline' 0 C--N 1.304 -1.814 0 O-C-N 124.036 1.545 . . . . 50.0 110.414 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.56 127.68 23.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.301 -0.874 . . . . 50.0 110.036 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.94 152.95 12.83 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.588 ' HB3' ' CD2' ' A' ' 106' ' ' HIS . 13.8 p30 -53.05 155.12 2.64 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 50.0 110.195 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.602 ' HA ' ' N ' ' A' ' 53' ' ' SER . 11.9 p -141.47 153.32 44.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.254 -0.904 . . . . 50.0 110.386 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.592 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.5 m-30 -104.72 119.72 39.67 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.253 -0.905 . . . . 50.0 110.119 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.535 HG21 HD12 ' A' ' 92' ' ' ILE . 0.0 OUTLIER -110.91 129.7 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.166 -0.959 . . . . 50.0 110.027 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 21.2 t -115.56 139.19 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.157 -0.965 . . . . 50.0 110.536 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.55 ' CG2' HG12 ' A' ' 48' ' ' ILE . 53.8 t -120.91 104.03 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.409 -0.807 . . . . 50.0 110.081 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.515 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.95 168.55 33.46 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.708 -1.357 . . . . 50.0 109.708 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.51 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 26.5 ttm -98.36 -71.41 0.69 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.244 -1.151 . . . . 50.0 110.296 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.95 36.38 0.3 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.508 -1.437 . . . . 50.0 109.508 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.44 ' OD1' ' OE1' ' A' ' 15' ' ' GLU . 0.9 OUTLIER -162.18 -46.96 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.328 -1.101 . . . . 50.0 109.823 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.53 129.93 39.72 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.364 -0.835 . . . . 50.0 109.709 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.783 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.96 150.42 44.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.12 -0.987 . . . . 49.57 110.707 -179.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 1.4 mp -112.08 123.91 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.131 -0.98 . . . . 49.57 109.761 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -101.0 139.44 36.68 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.17 -0.956 . . . . 49.57 110.686 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.486 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 5.6 m-70 -120.41 160.93 22.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.416 -0.802 . . . . 49.57 109.856 179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' A' ' 104' ' ' HIS . 51.7 p-80 -118.38 92.28 3.78 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.204 -0.935 . . . . 49.57 110.509 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 2.3 t-105 -67.93 111.27 4.27 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.158 -0.964 . . . . 49.57 110.035 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.588 ' CD2' ' HB3' ' A' ' 89' ' ' ASP . 0.1 OUTLIER -131.22 138.89 49.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 49.57 110.248 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 6.3 tttm -72.36 -9.74 58.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.244 -0.91 . . . . 49.57 110.246 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -176.47 151.85 1.0 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 49.57 110.141 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -130.02 -173.61 13.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.64 -1.384 . . . . 49.57 109.64 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -141.65 43.3 1.73 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.332 -1.099 . . . . 49.57 110.217 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.011 -0.995 . . . . 49.57 110.222 179.99 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 47.0 p30 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.189 0.518 . . . . 50.0 110.181 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.1 tptt -123.43 133.71 54.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 50.0 110.271 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.44 ' N ' HD22 ' A' ' 3' ' ' LEU . 0.3 OUTLIER -126.86 95.39 4.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 50.0 110.156 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -84.3 172.86 11.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 50.0 110.306 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.19 132.69 54.12 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.947 . . . . 50.0 110.132 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.28 -165.12 1.15 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 50.0 110.193 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.41 82.73 0.37 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.538 -1.425 . . . . 50.0 109.538 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -83.75 153.54 24.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -1.175 . . . . 50.0 110.388 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 99.2 m -74.66 100.84 4.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.292 -0.88 . . . . 50.0 110.174 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -133.23 152.73 51.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 50.0 110.213 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.34 111.03 3.42 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.48 -1.448 . . . . 50.0 109.48 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.506 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.4 mtt -73.81 117.58 15.75 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.19 -1.182 . . . . 50.0 110.241 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.644 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.75 107.55 3.84 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.054 -1.029 . . . . 99.989999999999995 110.558 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.482 HG23 HG12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -161.75 35.84 0.13 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.006 -1.059 . . . . 99.989999999999995 110.213 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.466 ' HG2' ' CE ' ' A' ' 96' ' ' MET . 1.1 pp20? -66.52 -5.44 11.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.451 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.567 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 8.8 mmtm -89.28 61.51 5.73 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 50.0 110.542 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.593 ' CZ ' HD11 ' A' ' 46' ' ' ILE . 0.0 OUTLIER -95.02 141.78 28.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.102 -0.999 . . . . 50.0 110.128 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.12 97.9 4.93 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 50.0 110.035 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.67 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 10.5 p90 -59.53 123.92 18.41 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.021 -1.049 . . . . 50.0 110.457 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.4 -23.96 12.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.335 -0.853 . . . . 50.0 109.969 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.477 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 11.8 mtmt -142.33 151.5 42.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 50.0 110.105 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -67.53 162.31 57.75 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 50.0 110.153 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.559 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.1 Cg_endo -71.86 127.79 13.39 Favored 'Trans proline' 0 C--N 1.303 -1.816 0 O-C-N 124.052 1.554 . . . . 50.0 110.3 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.98 147.83 46.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.257 -0.902 . . . . 50.0 110.37 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.474 ' HA ' ' O ' ' A' ' 30' ' ' THR . 18.5 t0 -87.75 148.11 24.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.885 . . . . 50.0 110.143 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.16 -69.55 0.86 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.125 -0.984 . . . . 50.0 110.237 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.41 -101.81 1.58 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.533 -1.427 . . . . 50.0 109.533 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 34.0 t60 -131.96 89.01 2.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -1.152 . . . . 50.0 110.342 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.496 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 100.15 5.92 54.18 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.661 -1.375 . . . . 50.0 109.661 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 14.4 p -101.9 107.67 18.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -1.169 . . . . 50.0 110.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.559 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 39.0 t -102.53 139.85 22.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.177 -0.952 . . . . 50.0 110.19 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.13 150.69 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -0.95 . . . . 50.0 110.319 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.57 HG12 ' CD1' ' A' ' 35' ' ' LEU . 0.6 OUTLIER -136.96 154.03 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.399 -0.813 . . . . 50.0 109.75 179.689 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.477 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 2.1 tp10 -119.55 91.44 3.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.129 -0.982 . . . . 50.0 110.9 -179.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.583 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 0.1 OUTLIER -119.03 138.79 52.6 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.289 -0.882 . . . . 50.0 109.081 179.274 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.568 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -93.78 135.16 35.37 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.06 -1.025 . . . . 50.0 110.175 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.567 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 5.8 t80 -94.38 103.34 15.33 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.964 -1.094 . . . . 50.0 109.558 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.82 69.6 3.38 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.22 -0.925 . . . . 50.0 110.038 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.491 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -118.46 139.33 14.47 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.439 -1.464 . . . . 99.989999999999995 109.439 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 40' ' ' SER . 2.6 t -82.95 31.08 0.43 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -1.124 . . . . 99.989999999999995 110.298 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.463 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -108.33 -11.96 15.12 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 99.989999999999995 110.243 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 -139.84 19.31 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.488 -1.445 . . . . 99.989999999999995 109.488 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.421 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -71.16 139.67 35.92 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.987 1.52 . . . . 99.989999999999995 110.248 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.601 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -169.38 157.57 7.51 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -0.867 . . . . 50.0 110.014 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.556 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.3 mmtt -76.34 129.15 36.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 50.0 109.178 178.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.615 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 10.3 mt -86.34 109.36 22.75 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 50.0 110.714 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 52.3 Cg_endo -78.98 99.42 1.26 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 O-C-N 124.056 1.556 . . . . 50.0 110.129 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.615 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 6.9 mt -136.11 144.01 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.072 -1.018 . . . . 50.0 110.471 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 23.0 m -116.19 148.54 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.399 -0.813 . . . . 50.0 109.835 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.5 OUTLIER -124.19 105.8 9.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.146 -0.971 . . . . 50.0 109.86 -179.932 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.489 ' O ' ' N ' ' A' ' 91' ' ' TYR . 4.3 m -129.7 159.49 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.281 -0.887 . . . . 50.0 110.34 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.435 ' HB1' ' CG ' ' A' ' 55' ' ' ASN . . . -55.94 163.72 1.41 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.856 . . . . 50.0 110.027 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.602 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 37.6 t -58.44 122.25 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.26 -0.9 . . . . 50.0 110.739 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.602 ' CB ' ' O ' ' A' ' 53' ' ' SER . 1.2 tp 78.32 30.56 0.41 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.919 -0.712 . . . . 50.0 110.827 179.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.435 ' CG ' ' HB1' ' A' ' 52' ' ' ALA . 10.3 m120 -126.66 84.11 2.23 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -0.957 . . . . 50.0 110.198 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -106.42 8.61 31.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.279 -0.888 . . . . 50.0 109.917 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.7 ttm -116.11 -13.26 11.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.418 -0.801 . . . . 50.0 110.131 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.16 134.06 19.96 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.368 -0.832 . . . . 50.0 110.104 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.79 134.75 22.41 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.941 1.495 . . . . 50.0 110.258 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 55.3 t -139.31 -46.87 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.237 -0.914 . . . . 50.0 109.848 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -75.43 156.35 48.27 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.67 -1.772 . . . . 50.0 108.67 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.434 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 15.3 mtp180 -138.04 157.15 46.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.881 -1.364 . . . . 50.0 110.722 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mp -91.3 134.65 34.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 50.0 109.737 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.499 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 4.0 t -72.83 -40.91 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.167 -0.958 . . . . 50.0 110.147 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.432 ' CG2' ' OE1' ' A' ' 82' ' ' GLU . 14.9 t -103.43 175.79 5.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.17 -0.956 . . . . 50.0 110.165 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 6.5 m -54.76 -172.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.394 -0.816 . . . . 50.0 110.098 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.603 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 1.8 m-20 -47.45 137.78 8.96 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.952 . . . . 50.0 110.073 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.553 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 48.0 Cg_endo -75.14 74.32 4.11 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.974 1.513 . . . . 50.0 110.707 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.603 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -107.27 141.32 38.78 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.141 -0.974 . . . . 50.0 110.282 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -103.69 60.26 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 50.0 109.358 179.398 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.421 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -69.67 57.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.359 -0.838 . . . . 50.0 110.364 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.38 165.09 28.37 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 50.0 110.104 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.68 7.32 17.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.151 -0.968 . . . . 50.0 110.117 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 8.0 t -121.47 17.62 11.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.26 -0.9 . . . . 99.989999999999995 110.488 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -69.03 -4.11 15.68 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.153 -0.967 . . . . 99.989999999999995 109.93 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.436 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 64.1 m-80 -88.58 24.01 2.09 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.364 -0.835 . . . . 99.989999999999995 109.416 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.568 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.3 OUTLIER -129.31 -173.19 2.93 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.368 -0.832 . . . . 99.989999999999995 109.442 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.52 ' N ' ' OG ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -63.7 88.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.114 179.507 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.583 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 15.8 m -76.45 174.35 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.292 -0.88 . . . . 99.989999999999995 109.199 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.3 tt -134.71 136.6 42.84 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.736 -1.227 . . . . 50.0 111.084 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.485 ' C ' ' HG3' ' A' ' 82' ' ' GLU . 2.1 t -117.33 166.73 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.456 -0.777 . . . . 50.0 109.751 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.499 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 5.6 mt-10 -134.75 146.34 49.29 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.071 -1.018 . . . . 50.0 110.271 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.468 ' HE1' ' HB ' ' A' ' 33' ' ' ILE . 0.0 OUTLIER -159.95 151.64 20.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.18 -0.95 . . . . 50.0 110.347 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.496 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -120.93 60.94 9.11 Favored Pre-proline 0 C--N 1.306 -1.286 0 O-C-N 121.239 -0.913 . . . . 50.0 110.509 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -73.34 158.78 47.94 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.073 1.565 . . . . 50.0 110.201 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.88 146.76 48.42 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.044 1.549 . . . . 50.0 110.453 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -52.97 146.89 10.14 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.269 -0.894 . . . . 50.0 110.062 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 122.71 172.75 14.03 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.394 -1.482 . . . . 50.0 109.394 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 11.4 m-20 -71.73 128.55 36.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.208 -1.171 . . . . 50.0 110.161 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.533 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.6 p -124.82 141.86 51.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 50.0 110.157 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.605 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -99.69 116.66 32.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.221 -0.924 . . . . 50.0 110.035 179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.494 ' C ' ' CD1' ' A' ' 92' ' ' ILE . 0.0 OUTLIER -103.83 133.88 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 50.0 109.947 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.467 ' N ' HD13 ' A' ' 92' ' ' ILE . 11.1 t -118.33 119.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.572 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.427 ' CG2' HG12 ' A' ' 48' ' ' ILE . 33.6 t -100.6 103.34 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 50.0 109.958 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.445 ' O ' ' HB2' ' A' ' 47' ' ' PRO . . . -155.25 147.78 17.2 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.484 -1.446 . . . . 50.0 109.484 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.535 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 12.3 ptp -102.28 1.71 36.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.257 -1.143 . . . . 50.0 110.224 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.89 -60.05 0.55 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.38 -77.61 0.23 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.23 -1.159 . . . . 50.0 110.205 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.5 mmtt -79.57 124.0 28.11 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.221 -0.925 . . . . 50.0 110.313 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.603 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.19 148.56 41.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.267 -0.895 . . . . 49.57 110.249 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.466 HG21 HD12 ' A' ' 101' ' ' ILE . 11.1 pt -137.29 130.13 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.243 -0.91 . . . . 49.57 110.232 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.455 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 34.0 p-10 -109.46 132.31 54.25 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.21 -0.932 . . . . 49.57 110.394 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.67 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -122.12 169.9 10.4 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.24 -0.912 . . . . 49.57 110.061 179.866 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.605 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 45.5 p-80 -118.68 123.89 46.03 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.213 -0.929 . . . . 49.57 110.4 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.538 ' CH2' HD11 ' A' ' 33' ' ' ILE . 26.1 m0 -106.55 145.1 32.29 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.294 -0.879 . . . . 49.57 110.23 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -125.13 123.41 39.63 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 49.57 110.255 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -112.94 -6.6 13.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 49.57 110.245 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -174.57 111.94 0.15 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 49.57 110.038 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -133.66 165.51 24.16 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.691 -1.363 . . . . 49.57 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.7 t -82.57 132.0 35.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.319 -1.107 . . . . 49.57 110.17 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.002 -0.999 . . . . 49.57 110.294 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.158 0.504 . . . . 50.0 110.218 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.45 136.8 51.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.32 -0.862 . . . . 50.0 110.245 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 15.7 tp -82.07 142.21 32.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.274 -0.891 . . . . 50.0 110.043 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.43 149.54 36.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.194 -0.941 . . . . 50.0 110.434 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.2 mt -111.24 120.11 41.16 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.324 -0.86 . . . . 50.0 110.307 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -101.06 -170.21 1.81 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.275 -0.891 . . . . 50.0 110.03 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.74 20.47 44.82 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.588 -1.405 . . . . 50.0 109.588 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.1 p -83.88 161.43 20.87 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -1.112 . . . . 50.0 110.188 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -72.74 169.66 16.23 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.208 -0.933 . . . . 50.0 110.165 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -154.37 177.39 11.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.195 -0.941 . . . . 50.0 110.267 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.88 104.73 2.8 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.518 -1.433 . . . . 50.0 109.518 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.509 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 1.1 mtm -98.08 96.66 8.28 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -1.109 . . . . 50.0 110.025 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.707 ' O ' ' CB ' ' A' ' 44' ' ' CYS . 12.0 p -148.89 107.23 3.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.067 -1.021 . . . . 99.989999999999995 110.785 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.494 ' HB ' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.76 31.8 0.15 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.672 -1.267 . . . . 99.989999999999995 110.489 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.458 ' HG3' ' HA2' ' A' ' 95' ' ' GLY . 10.3 tm-20 -71.01 -0.38 9.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -0.976 . . . . 99.989999999999995 110.106 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -87.94 61.68 6.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 50.0 110.403 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -94.72 146.28 24.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.894 . . . . 50.0 109.887 179.632 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 57.8 m -127.4 100.17 5.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.043 . . . . 50.0 110.659 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 103' ' ' HIS . 16.1 m-85 -57.2 115.24 2.55 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.193 -0.942 . . . . 50.0 109.802 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.455 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -102.81 -27.0 12.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.24 -0.912 . . . . 50.0 110.476 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 4.9 mttt -145.53 151.43 38.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.183 -0.948 . . . . 50.0 110.23 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.406 ' HA ' ' CH2' ' A' ' 105' ' ' TRP . 13.1 p30 -67.09 154.97 91.53 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 50.0 110.232 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.528 ' HD2' ' CE3' ' A' ' 105' ' ' TRP . 46.6 Cg_endo -73.24 141.2 31.91 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 O-C-N 124.097 1.577 . . . . 50.0 110.419 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.456 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -146.63 168.07 22.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.274 -0.891 . . . . 50.0 110.29 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -89.07 154.62 20.04 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 50.0 110.341 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.63 -48.06 1.4 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.307 -0.87 . . . . 50.0 110.074 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.52 -101.48 2.32 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.453 -1.459 . . . . 50.0 109.453 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -133.15 93.69 3.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -1.155 . . . . 50.0 110.23 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.6 19.75 57.68 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 50.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 70.7 p -115.35 107.83 15.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.28 -1.129 . . . . 50.0 110.283 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.457 HG22 ' HD2' ' A' ' 85' ' ' PRO . 98.7 t -85.32 143.82 10.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.251 -0.906 . . . . 50.0 110.174 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.456 HG23 ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -125.14 149.32 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.213 -0.929 . . . . 50.0 110.409 -179.884 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.499 HG23 ' CD1' ' A' ' 35' ' ' LEU . 2.0 tt -152.51 163.4 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -0.851 . . . . 50.0 109.906 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.472 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.6 OUTLIER -132.46 102.07 5.59 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.12 -0.988 . . . . 50.0 110.502 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.567 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 0.2 OUTLIER -119.12 139.91 51.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.314 -0.867 . . . . 50.0 109.165 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.556 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -92.46 131.44 37.61 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.041 -1.037 . . . . 50.0 110.068 -179.457 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.476 ' HB3' ' O ' ' A' ' 75' ' ' ALA . 6.6 t80 -92.12 98.79 11.76 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.984 -1.086 . . . . 50.0 109.497 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 t -96.11 69.76 2.77 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.318 -0.864 . . . . 50.0 110.028 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -118.46 132.22 9.63 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.631 -1.388 . . . . 99.989999999999995 109.631 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 45.3 m -83.95 18.5 2.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.231 -1.158 . . . . 99.989999999999995 110.317 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -99.92 -1.08 38.17 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.241 -0.912 . . . . 99.989999999999995 110.225 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.6 -149.93 29.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.105 -1.598 . . . . 99.989999999999995 109.105 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.551 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.9 Cg_endo -73.35 150.67 47.19 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.916 1.482 . . . . 99.989999999999995 110.406 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.707 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -169.87 161.48 9.0 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.377 -0.827 . . . . 50.0 109.96 -179.487 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.629 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 24.0 mmtt -75.61 111.03 10.51 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.018 -1.051 . . . . 50.0 109.229 178.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.622 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 2.2 mt -72.29 110.66 8.5 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.966 . . . . 50.0 110.423 -179.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 50.3 Cg_endo -84.54 97.67 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.026 1.54 . . . . 50.0 110.652 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.622 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 24.2 mt -133.33 153.76 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 50.0 110.243 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 49' ' ' VAL . 11.2 p -125.78 110.97 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 50.0 110.23 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.478 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -91.52 100.74 13.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 50.0 109.751 179.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.536 ' CG1' ' O ' ' A' ' 58' ' ' THR . 24.8 t -122.2 155.2 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 50.0 110.223 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.517 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -60.92 164.36 4.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.204 -0.935 . . . . 50.0 109.208 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.619 ' N ' ' HA ' ' A' ' 90' ' ' SER . 16.8 t -71.53 101.27 2.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.721 -1.237 . . . . 50.0 108.936 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.542 ' HB2' ' O ' ' A' ' 53' ' ' SER . 5.0 tp 170.68 -61.67 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 C-N-CA 118.071 -1.451 . . . . 50.0 111.661 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.465 ' HB3' ' HB ' ' A' ' 58' ' ' THR . 60.4 m-20 -92.92 149.92 20.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.904 -1.123 . . . . 50.0 110.273 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -106.12 -20.61 13.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.226 -0.921 . . . . 50.0 110.187 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.9 ttp -126.55 31.31 5.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.282 -0.886 . . . . 50.0 110.27 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.536 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 59.6 m -126.87 120.62 22.81 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 50.0 110.171 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.5 126.0 11.16 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.968 1.509 . . . . 50.0 110.212 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.41 HG23 HG12 ' A' ' 51' ' ' VAL . 24.4 t -135.02 -47.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.91 . . . . 50.0 110.05 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.43 158.8 49.45 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.133 -1.587 . . . . 50.0 109.133 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 83' ' ' MET . 21.4 mtm180 -132.6 154.76 49.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.138 -1.213 . . . . 50.0 110.555 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.6 mt -94.15 129.67 40.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.383 -0.823 . . . . 50.0 109.866 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.424 ' CG2' ' HG2' ' A' ' 84' ' ' GLU . 24.2 t -80.84 -32.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.184 -0.948 . . . . 50.0 110.38 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' VAL . 15.2 t -79.33 168.35 19.64 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -0.964 . . . . 50.0 110.099 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.414 ' O ' ' O ' ' A' ' 65' ' ' THR . 7.3 m -50.99 179.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.191 -0.943 . . . . 50.0 110.057 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.617 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 14.1 m120 -46.96 143.62 4.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.204 -0.935 . . . . 50.0 110.058 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.456 ' O ' ' CD1' ' A' ' 46' ' ' ILE . 47.0 Cg_endo -73.56 66.42 4.65 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.963 1.507 . . . . 50.0 110.583 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.629 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 18.2 m-30 -118.3 121.84 41.42 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.895 . . . . 50.0 110.12 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.545 ' CG1' ' CB ' ' A' ' 75' ' ' ALA . 42.9 t -77.55 60.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.119 -0.988 . . . . 50.0 109.99 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.551 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -85.37 59.37 5.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.15 -0.969 . . . . 50.0 110.185 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -142.95 165.46 27.29 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 50.0 110.388 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -94.42 -4.4 48.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.308 -0.87 . . . . 50.0 110.005 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.62 7.91 11.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.304 -0.872 . . . . 99.989999999999995 110.204 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.545 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -76.05 8.58 3.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 110.102 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -86.56 19.29 2.91 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.266 -0.896 . . . . 99.989999999999995 109.25 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.556 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.1 p -128.68 -172.36 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.463 -0.773 . . . . 99.989999999999995 109.41 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.531 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 4.6 mttp -62.91 88.72 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.467 -0.893 . . . . 99.989999999999995 109.283 179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.553 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 28.9 m -76.43 173.85 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.318 -0.864 . . . . 99.989999999999995 109.418 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 33' ' ' ILE . 5.7 tt -126.18 125.56 42.66 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.933 -1.104 . . . . 50.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.436 HG23 ' CD1' ' A' ' 35' ' ' LEU . 1.2 t -122.29 166.03 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.387 -0.821 . . . . 50.0 109.868 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.431 ' OE1' ' C ' ' A' ' 81' ' ' VAL . 3.1 pm0 -147.4 160.29 42.73 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.181 -0.949 . . . . 50.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.473 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 2.5 ptt? -157.07 158.98 37.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 50.0 110.202 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.424 ' HG2' ' CG2' ' A' ' 64' ' ' VAL . 0.4 OUTLIER -115.86 57.05 1.31 Allowed Pre-proline 0 C--N 1.307 -1.247 0 O-C-N 121.111 -0.993 . . . . 50.0 110.746 -179.781 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.473 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.9 Cg_endo -71.44 170.48 18.35 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.936 1.493 . . . . 50.0 110.5 179.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -70.36 161.67 45.16 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.998 1.525 . . . . 50.0 110.439 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -74.88 144.67 43.25 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.272 -0.893 . . . . 50.0 110.155 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.38 178.87 16.62 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.285 -1.526 . . . . 50.0 109.285 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -67.85 131.21 45.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 50.0 110.102 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.619 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -120.28 140.71 50.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.25 -0.906 . . . . 50.0 110.351 -179.912 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.573 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.8 m-30 -94.02 104.72 16.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 50.0 109.788 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.504 ' O ' ' HA ' ' A' ' 102' ' ' ASN . 3.2 mm -97.88 125.54 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 50.0 109.918 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 101' ' ' ILE . 21.2 t -125.2 125.05 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.069 -1.02 . . . . 50.0 110.825 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.566 ' CG2' HG12 ' A' ' 48' ' ' ILE . 95.4 t -106.87 105.01 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.858 . . . . 50.0 109.785 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.498 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.43 155.64 24.19 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.963 -1.255 . . . . 50.0 109.963 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.53 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 3.7 ttm -111.17 -69.21 0.88 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.39 -1.065 . . . . 50.0 110.297 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.71 28.55 0.23 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.62 -1.392 . . . . 50.0 109.62 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -160.56 -50.91 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.173 -1.192 . . . . 50.0 110.241 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -126.16 149.34 49.05 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.301 -0.875 . . . . 50.0 110.164 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.599 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.99 148.92 42.59 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 49.57 110.481 -179.876 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.573 HD13 ' CE1' ' A' ' 103' ' ' HIS . 0.0 OUTLIER -126.2 124.23 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.331 -0.856 . . . . 49.57 109.552 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.0 p-10 -111.26 134.83 52.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.073 -1.017 . . . . 49.57 110.843 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.688 ' CD2' ' CD2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -127.59 124.09 37.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 49.57 110.105 179.608 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -78.9 98.44 6.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.375 -0.828 . . . . 49.57 110.337 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.528 ' CE3' ' HD2' ' A' ' 23' ' ' PRO . 8.1 m95 -94.51 160.99 14.4 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.266 -0.896 . . . . 49.57 110.477 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 32.5 p-80 -150.82 136.72 18.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.293 -0.88 . . . . 49.57 109.986 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -98.84 -9.02 24.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.275 -0.891 . . . . 49.57 110.488 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -100.44 126.66 46.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.942 . . . . 49.57 110.301 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -90.74 96.28 2.18 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.439 -1.465 . . . . 49.57 109.439 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 11.3 m -111.1 -68.9 0.9 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 49.57 110.306 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 117.97 -1.014 . . . . 49.57 110.329 -179.91 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.401 ' OD2' ' O ' ' A' ' 1' ' ' ASP . 4.7 p-10 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.214 0.531 . . . . 50.0 110.248 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.0 tptm -129.24 152.74 48.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.211 -0.931 . . . . 50.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 5.0 mt -103.97 137.31 42.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 110.149 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.89 143.22 49.04 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.224 -0.922 . . . . 50.0 110.258 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.1 77.99 4.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 50.0 110.233 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 158.71 15.3 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.282 -0.886 . . . . 50.0 110.135 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -116.33 87.13 0.43 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.592 -1.403 . . . . 50.0 109.592 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.81 148.81 38.14 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.214 -1.168 . . . . 50.0 110.15 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 70.7 p -80.46 99.2 7.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 50.0 110.401 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -153.47 157.66 40.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.231 -0.918 . . . . 50.0 109.993 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -91.41 139.63 14.85 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.759 -1.337 . . . . 50.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.604 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 10.4 mtp -73.31 109.33 6.75 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.305 -1.115 . . . . 50.0 110.045 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.712 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.7 p -148.95 107.35 3.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.994 -1.066 . . . . 99.989999999999995 111.196 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.594 HG22 ' CE1' ' A' ' 37' ' ' TYR . 2.6 m -161.58 53.95 0.26 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.731 -1.231 . . . . 99.989999999999995 110.549 179.286 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.532 ' HB3' ' CB ' ' A' ' 96' ' ' MET . 18.7 pt-20 -75.29 4.72 6.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.089 -1.007 . . . . 99.989999999999995 110.181 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.517 ' HD2' ' CA ' ' A' ' 39' ' ' GLY . 6.3 mttp -92.36 61.31 3.8 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.216 -0.927 . . . . 50.0 110.397 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.6 ' CE1' ' HB2' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -96.65 145.87 25.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.05 -1.031 . . . . 50.0 109.926 179.647 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -127.17 104.42 7.95 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.209 -0.932 . . . . 50.0 110.392 -179.743 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -60.97 96.87 0.05 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.248 -0.908 . . . . 50.0 110.39 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.444 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -84.67 -29.21 25.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -0.924 . . . . 50.0 110.01 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.522 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 14.4 mttm -144.68 147.03 32.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 50.0 110.091 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -73.79 162.12 75.57 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 50.0 110.163 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.595 ' HG2' ' CD2' ' A' ' 105' ' ' TRP . 44.8 Cg_endo -72.44 131.8 18.13 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.023 1.538 . . . . 50.0 110.222 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -126.25 147.86 49.6 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.183 -0.948 . . . . 50.0 110.358 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -77.81 113.76 16.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.314 -0.866 . . . . 50.0 110.186 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -79.19 -14.22 59.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 50.0 110.343 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.74 -106.58 0.22 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . 0.465 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 9.4 p80 -121.98 102.67 8.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -1.144 . . . . 50.0 110.264 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 81.92 23.93 56.47 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.654 -1.378 . . . . 50.0 109.654 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 30.5 p -129.88 107.89 9.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.168 -1.195 . . . . 50.0 110.338 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.538 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -111.22 135.32 50.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.291 -0.881 . . . . 50.0 109.793 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.535 ' CG2' ' OG1' ' A' ' 26' ' ' THR . 1.4 t -114.65 136.75 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 50.0 110.542 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.546 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -141.89 133.2 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.459 -0.775 . . . . 50.0 109.499 179.784 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.526 ' N ' HD13 ' A' ' 33' ' ' ILE . 34.0 tt0 -112.21 117.52 32.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.141 -0.974 . . . . 50.0 111.274 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.6 ' HB2' ' CE1' ' A' ' 17' ' ' PHE . 0.1 OUTLIER -128.76 143.77 51.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.363 -0.836 . . . . 50.0 108.969 178.945 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.535 ' CA ' ' HA ' ' A' ' 78' ' ' LYS . 0.0 OUTLIER -95.61 132.42 40.78 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.98 -1.075 . . . . 50.0 110.209 -179.525 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.594 ' CE1' HG22 ' A' ' 14' ' ' THR . 6.9 t80 -95.02 99.6 11.58 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.253 -0.979 . . . . 50.0 109.731 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.1 t -95.93 69.82 2.86 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.202 -0.936 . . . . 50.0 110.144 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.517 ' CA ' ' HD2' ' A' ' 16' ' ' LYS . . . -120.72 118.08 3.71 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.51 -1.436 . . . . 99.989999999999995 109.51 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.8 p -85.39 21.81 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -1.154 . . . . 99.989999999999995 110.419 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.87 -0.52 50.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.024 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.69 -172.54 26.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.435 -1.466 . . . . 99.989999999999995 109.435 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.509 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 42.8 Cg_endo -70.82 152.69 64.04 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.195 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.712 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.04 161.59 8.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.223 -0.923 . . . . 50.0 109.902 -179.385 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.604 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.7 OUTLIER -77.29 129.18 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.159 -0.963 . . . . 50.0 109.583 179.373 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.583 HG23 ' CD1' ' A' ' 48' ' ' ILE . 10.0 mt -84.01 112.36 40.14 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.188 -0.945 . . . . 50.0 110.39 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.5 ' C ' ' CD1' ' A' ' 48' ' ' ILE . 50.0 Cg_endo -77.41 74.9 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 124.001 1.527 . . . . 50.0 110.306 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.609 HG13 ' CG2' ' A' ' 94' ' ' VAL . 1.4 mp -115.41 151.04 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.146 -0.971 . . . . 50.0 110.294 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 23.8 m -128.32 147.15 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.439 -0.788 . . . . 50.0 110.09 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -122.25 100.76 7.13 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.362 -0.836 . . . . 50.0 109.654 179.673 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 91' ' ' TYR . 25.4 m -114.99 160.86 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.234 -0.916 . . . . 50.0 110.421 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.456 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -60.25 164.63 4.06 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.42 -0.8 . . . . 50.0 109.927 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.7 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 3.4 t -66.64 120.49 13.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.181 -0.949 . . . . 50.0 109.805 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.7 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.1 tp 87.18 29.27 0.03 OUTLIER 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.658 -0.652 . . . . 50.0 110.725 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.486 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 66.9 m-80 -144.18 84.81 1.78 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.114 -0.991 . . . . 50.0 110.182 179.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.22 6.24 42.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.197 -0.939 . . . . 50.0 110.111 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.2 mmt -107.83 -14.59 14.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.26 -0.9 . . . . 50.0 110.081 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.3 p -133.14 119.83 15.82 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 50.0 110.04 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.84 125.85 10.83 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.942 1.496 . . . . 50.0 110.245 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.473 HG13 ' HA ' ' A' ' 51' ' ' VAL . 3.4 p -131.45 -33.72 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 50.0 110.025 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.91 143.45 34.95 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.697 -1.761 . . . . 50.0 108.697 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.466 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -126.62 156.27 41.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.055 -1.262 . . . . 50.0 110.794 -179.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -93.84 129.8 40.11 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.808 . . . . 50.0 109.927 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.489 HG13 ' HB2' ' A' ' 82' ' ' GLU . 4.0 p -54.07 -26.11 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.158 -0.964 . . . . 50.0 110.209 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -114.56 176.05 5.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.285 -0.885 . . . . 50.0 110.117 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.5 m -59.15 -170.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.162 -0.961 . . . . 50.0 110.225 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.623 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 15.2 t30 -46.79 140.3 6.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 50.0 109.987 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.552 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 47.7 Cg_endo -74.84 78.07 2.93 Favored 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 123.989 1.521 . . . . 50.0 110.557 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.623 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.3 p90 -105.4 136.06 45.64 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.137 -0.977 . . . . 50.0 110.402 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.554 ' CG2' ' CD1' ' A' ' 46' ' ' ILE . 85.7 t -91.66 60.65 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 50.0 109.976 179.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.509 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -82.13 57.79 3.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.324 -0.86 . . . . 50.0 110.017 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 169.11 18.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.315 -0.865 . . . . 50.0 110.177 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -100.2 -5.59 27.43 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 50.0 109.977 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.8 t -121.25 10.12 10.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 110.507 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.535 ' CB ' HG11 ' A' ' 70' ' ' VAL . . . -80.77 10.43 4.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.018 -1.051 . . . . 99.989999999999995 110.004 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.464 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 96.6 m-20 -84.51 16.81 2.94 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.314 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.514 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.3 OUTLIER -120.44 -172.42 2.36 Favored 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.441 -0.787 . . . . 99.989999999999995 109.347 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.535 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.2 OUTLIER -62.79 87.94 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.354 -0.938 . . . . 99.989999999999995 109.006 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.566 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 13.4 m -77.18 175.97 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.356 -0.84 . . . . 99.989999999999995 109.685 -179.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -127.93 142.01 51.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.918 -1.114 . . . . 50.0 110.705 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.587 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 0.0 OUTLIER -134.54 166.66 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.423 -0.798 . . . . 50.0 109.867 179.745 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.489 ' HB2' HG13 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -145.11 152.45 40.07 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.289 -0.882 . . . . 50.0 110.266 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.487 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 9.7 ptt? -155.3 144.96 21.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 50.0 110.302 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.43 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -106.93 74.87 0.39 Allowed Pre-proline 0 C--N 1.305 -1.369 0 O-C-N 121.286 -0.884 . . . . 50.0 110.397 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.538 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.4 Cg_endo -72.88 167.71 26.57 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.914 1.481 . . . . 50.0 110.5 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.45 ' HG3' HG23 ' A' ' 60' ' ' VAL . 45.6 Cg_endo -71.43 154.32 60.68 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.947 1.498 . . . . 50.0 110.584 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.94 134.26 48.6 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.237 -0.914 . . . . 50.0 110.04 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.87 -168.54 13.68 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.379 -1.489 . . . . 50.0 109.379 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.578 ' OD2' ' CG ' ' A' ' 106' ' ' HIS . 7.2 m-20 -82.91 153.16 25.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -1.16 . . . . 50.0 110.116 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.542 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -136.96 138.61 40.77 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.284 -0.885 . . . . 50.0 110.296 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.582 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.7 m-30 -99.23 124.3 44.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.097 -1.002 . . . . 50.0 109.797 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.438 ' N ' ' CD1' ' A' ' 92' ' ' ILE . 4.9 mp -111.0 132.35 59.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.249 -0.907 . . . . 50.0 110.159 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 101' ' ' ILE . 20.9 t -125.16 120.81 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.822 -1.174 . . . . 50.0 111.365 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.609 ' CG2' HG13 ' A' ' 48' ' ' ILE . 94.9 t -98.19 106.56 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -0.849 . . . . 50.0 109.436 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.485 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.42 142.99 13.34 Favored Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.568 -1.301 . . . . 50.0 110.093 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.532 ' CB ' ' HB3' ' A' ' 15' ' ' GLU . 25.8 ttp -115.74 70.07 0.74 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -1.042 . . . . 50.0 109.957 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 56.03 18.9 20.89 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.559 -1.416 . . . . 50.0 109.559 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -149.36 -88.1 0.08 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -1.104 . . . . 50.0 110.098 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.444 ' O ' ' CA ' ' A' ' 95' ' ' GLY . 0.9 OUTLIER -79.76 155.18 28.04 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.244 -0.91 . . . . 50.0 110.322 -179.876 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.684 ' HG2' ' O ' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -140.75 87.74 2.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.182 -0.949 . . . . 49.57 110.695 179.768 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.55 ' CG2' ' HB ' ' A' ' 94' ' ' VAL . 1.1 tp -85.32 116.45 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.015 -1.053 . . . . 49.57 109.781 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 22.5 p30 -106.77 151.94 24.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.853 . . . . 49.57 110.963 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.447 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.2 OUTLIER -129.67 156.94 43.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.5 -0.75 . . . . 49.57 109.573 179.787 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.57 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 5.7 m170 -114.27 80.83 1.45 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.314 -0.867 . . . . 49.57 110.581 -179.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.595 ' CD2' ' HG2' ' A' ' 23' ' ' PRO . 10.4 t-105 -61.98 106.97 0.78 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.298 -0.877 . . . . 49.57 110.027 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.578 ' CG ' ' OD2' ' A' ' 89' ' ' ASP . 0.5 OUTLIER -104.86 139.27 39.86 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.266 -0.896 . . . . 49.57 110.367 -179.887 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.82 -11.59 13.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.231 -0.918 . . . . 49.57 110.244 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -178.02 156.24 1.03 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 49.57 110.134 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -155.75 147.06 15.3 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.434 . . . . 49.57 109.514 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -174.7 -33.79 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -1.185 . . . . 49.57 110.19 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 16.8 m . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 118.031 -0.985 . . . . 49.57 110.183 -179.976 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.263 0.554 . . . . 50.0 110.259 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.57 174.84 5.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.251 -0.906 . . . . 50.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.8 mt -88.94 141.94 28.06 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 50.0 110.121 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.07 159.12 23.04 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 50.0 110.279 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.3 tp -110.95 62.58 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 50.0 110.193 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 4.5 tptp -132.14 124.39 29.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.936 . . . . 50.0 110.324 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.01 131.36 2.58 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.541 -1.423 . . . . 50.0 109.541 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -53.81 166.61 0.32 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -1.112 . . . . 50.0 110.288 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.7 t -52.6 163.52 0.44 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.285 -0.884 . . . . 50.0 110.203 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -166.16 178.03 6.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.192 -0.942 . . . . 50.0 110.275 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.407 ' O ' ' HG2' ' A' ' 45' ' ' LYS . . . -106.16 160.13 14.79 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.638 -1.385 . . . . 50.0 109.638 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.524 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -111.0 120.47 42.49 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.279 -1.13 . . . . 50.0 109.952 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.652 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -141.15 106.64 5.06 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.216 -0.927 . . . . 99.989999999999995 110.848 -179.883 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.559 ' CB ' ' HA ' ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.98 35.63 0.12 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 99.989999999999995 110.288 179.029 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.415 ' HB2' ' HB3' ' A' ' 96' ' ' MET . 6.9 tm-20 -68.25 3.51 1.66 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.214 -0.929 . . . . 99.989999999999995 110.422 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.18 60.55 0.68 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 50.0 110.836 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.542 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -92.81 142.39 27.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.114 -0.991 . . . . 50.0 109.499 179.074 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.563 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.0 t -127.4 98.38 5.23 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.117 -0.989 . . . . 50.0 110.608 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.482 ' CD1' HD22 ' A' ' 35' ' ' LEU . 17.8 m-85 -56.02 97.1 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.23 -0.919 . . . . 50.0 109.857 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.06 -29.85 26.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 50.0 110.491 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.473 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 26.9 mttm -143.11 145.43 32.84 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.098 -1.001 . . . . 50.0 110.397 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.441 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 10.8 p30 -66.74 163.79 39.42 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 50.0 109.922 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.508 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.4 Cg_endo -71.78 134.59 24.15 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.903 1.475 . . . . 50.0 110.288 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -128.17 160.86 30.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.209 -0.932 . . . . 50.0 110.194 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -94.46 143.16 26.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.226 -0.921 . . . . 50.0 110.253 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.83 -39.66 5.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.223 -0.923 . . . . 50.0 110.157 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -142.72 -105.12 0.53 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.405 -1.478 . . . . 50.0 109.405 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -129.61 97.91 4.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.135 -1.215 . . . . 50.0 110.25 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.38 30.31 10.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 45.4 p -134.62 114.91 13.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.252 -1.146 . . . . 50.0 110.366 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.508 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 43.7 t -111.29 124.93 68.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.307 -0.871 . . . . 50.0 109.907 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.414 HG12 HD21 ' A' ' 80' ' ' LEU . 2.1 t -108.18 151.76 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.231 -0.918 . . . . 50.0 110.489 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.549 ' CG2' ' HB ' ' A' ' 81' ' ' VAL . 7.4 tt -150.45 166.96 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.448 -0.782 . . . . 50.0 109.515 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.553 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 6.4 tp10 -136.66 104.15 5.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.116 -0.99 . . . . 50.0 110.711 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.595 ' CD1' ' CG2' ' A' ' 81' ' ' VAL . 0.4 OUTLIER -114.28 137.02 52.32 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.256 -0.903 . . . . 50.0 109.536 179.338 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.518 ' HA ' ' HA ' ' A' ' 78' ' ' LYS . 4.7 m -86.46 126.4 34.38 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.079 -1.013 . . . . 50.0 109.769 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.523 ' CD2' HG13 ' A' ' 70' ' ' VAL . 10.9 t80 -93.32 102.42 14.68 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.028 -1.069 . . . . 50.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -96.34 70.07 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.309 -0.869 . . . . 50.0 110.149 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -115.91 123.26 5.83 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.533 -1.427 . . . . 99.989999999999995 109.533 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.99 12.4 4.17 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.245 -1.15 . . . . 99.989999999999995 110.355 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' N ' ' OD1' ' A' ' 41' ' ' ASP . 0.8 OUTLIER -97.6 -1.73 43.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 99.989999999999995 110.016 179.837 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 91.15 -156.61 24.4 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.527 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.5 Cg_endo -71.47 150.89 58.62 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 124.035 1.545 . . . . 99.989999999999995 110.358 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.652 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.8 OUTLIER -170.73 162.69 7.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.269 -0.895 . . . . 50.0 110.036 -179.522 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.591 ' HD2' ' CG ' ' A' ' 69' ' ' PHE . 44.9 mmtt -72.89 131.74 42.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.103 -0.998 . . . . 50.0 110.045 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.567 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 2.4 mt -89.62 109.32 31.15 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.204 -0.935 . . . . 50.0 110.624 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.9 Cg_endo -79.13 68.44 8.28 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.087 1.572 . . . . 50.0 110.14 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.567 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 1.7 mp -111.59 145.62 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.161 -0.962 . . . . 50.0 110.25 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 49' ' ' VAL . 34.1 m -118.14 139.13 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.334 -0.854 . . . . 50.0 110.108 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -119.9 100.66 7.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.326 -0.859 . . . . 50.0 109.806 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.504 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.7 m -124.0 159.82 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.306 -0.871 . . . . 50.0 110.284 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.432 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.51 163.88 1.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.392 -0.818 . . . . 50.0 109.766 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.829 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 2.2 m -73.57 104.27 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -0.993 . . . . 50.0 110.034 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.829 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 117.69 19.61 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.318 0 CA-C-O 121.113 0.482 . . . . 50.0 110.509 179.791 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.409 ' ND2' ' HB ' ' A' ' 58' ' ' THR . 0.2 OUTLIER -138.01 84.67 2.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.969 -1.082 . . . . 50.0 110.324 179.42 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.57 14.74 23.71 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.242 -0.911 . . . . 50.0 109.727 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 ttt -126.22 -12.99 6.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.327 -0.858 . . . . 50.0 110.383 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.409 ' HB ' ' ND2' ' A' ' 55' ' ' ASN . 3.6 m -128.58 129.78 23.53 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.913 . . . . 50.0 110.23 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.457 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.57 132.48 18.98 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 O-C-N 124.044 1.55 . . . . 50.0 110.182 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.86 -42.32 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.125 -0.984 . . . . 50.0 110.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.09 135.4 17.62 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.055 -1.618 . . . . 50.0 109.055 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.492 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.9 mtm180 -119.43 152.27 37.15 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.099 -1.236 . . . . 50.0 110.626 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mt -94.08 124.36 38.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.268 -0.895 . . . . 50.0 110.074 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.493 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 94.1 t -81.16 -38.8 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.218 -0.926 . . . . 50.0 110.364 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -65.84 172.73 3.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.186 -0.946 . . . . 50.0 110.095 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 4.3 m -53.4 179.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.219 -0.926 . . . . 50.0 110.007 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.638 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.84 144.22 3.85 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 50.0 110.154 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.5 Cg_endo -73.59 66.52 4.67 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.999 1.526 . . . . 50.0 110.961 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.638 ' CD2' ' HB3' ' A' ' 67' ' ' ASN . 19.9 m-30 -126.31 122.37 35.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.317 -0.864 . . . . 50.0 110.07 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.543 ' CG1' ' HB3' ' A' ' 75' ' ' ALA . 41.1 t -70.31 61.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.047 -1.033 . . . . 50.0 109.879 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.527 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -96.07 66.35 2.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.166 -0.959 . . . . 50.0 110.212 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.67 169.44 17.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.297 -0.877 . . . . 50.0 110.292 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.08 -14.56 31.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 50.0 110.184 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 75.1 m -121.16 23.2 10.65 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.332 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.543 ' HB3' ' CG1' ' A' ' 70' ' ' VAL . . . -80.56 9.94 5.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.126 -0.984 . . . . 99.989999999999995 110.31 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -88.05 18.01 4.58 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 109.188 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 36' ' ' SER . 18.1 t -133.01 -171.91 2.8 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.554 -0.716 . . . . 99.989999999999995 109.551 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.54 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 0.4 OUTLIER -62.86 90.48 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 109.187 179.539 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.553 ' O ' ' HA ' ' A' ' 34' ' ' GLU . 31.4 m -76.19 172.01 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.286 -0.884 . . . . 99.989999999999995 109.555 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.439 HD13 ' OE1' ' A' ' 34' ' ' GLU . 7.8 tt -117.14 119.75 36.18 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.055 -1.028 . . . . 50.0 111.005 -179.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.595 ' CG2' ' CD1' ' A' ' 35' ' ' LEU . 2.9 t -108.58 169.91 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.33 -0.857 . . . . 50.0 109.571 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.493 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 2.6 mt-10 -151.17 151.29 31.71 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.034 . . . . 50.0 110.58 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.488 ' HB2' ' O ' ' A' ' 62' ' ' ARG . 8.3 ptt? -160.36 153.3 21.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.865 . . . . 50.0 110.18 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.492 ' HG3' ' HB2' ' A' ' 62' ' ' ARG . 2.2 pt-20 -114.46 59.3 1.0 Allowed Pre-proline 0 C--N 1.306 -1.292 0 O-C-N 121.152 -0.967 . . . . 50.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.487 ' HD3' ' HG3' ' A' ' 83' ' ' MET . 44.1 Cg_endo -71.34 170.24 18.83 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.859 1.452 . . . . 50.0 110.331 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.14 163.19 39.47 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.035 1.545 . . . . 50.0 110.363 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -72.33 144.15 48.4 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.172 -0.955 . . . . 50.0 110.168 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 118.32 -160.42 13.9 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.306 -1.517 . . . . 50.0 109.306 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.514 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 3.2 m-20 -90.45 146.98 23.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.255 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.517 ' HA ' ' N ' ' A' ' 53' ' ' SER . 78.8 p -130.33 143.75 50.96 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 50.0 110.078 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' A' ' 104' ' ' HIS . 0.1 OUTLIER -91.48 108.34 19.83 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.161 -0.962 . . . . 50.0 110.173 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 3.0 mp -101.22 125.75 55.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.281 -0.887 . . . . 50.0 109.355 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.532 ' CG2' ' HB3' ' A' ' 102' ' ' ASN . 26.3 t -124.7 117.41 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.893 -1.13 . . . . 50.0 111.268 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.526 HG13 ' CG1' ' A' ' 48' ' ' ILE . 15.0 t -95.25 105.98 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.321 -0.862 . . . . 50.0 109.34 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.476 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -133.91 140.11 11.49 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.683 -1.246 . . . . 50.0 110.064 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.512 ' HG3' ' HA ' ' A' ' 13' ' ' CYS . 10.0 tmm? -131.32 -26.28 2.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.368 -1.078 . . . . 50.0 110.239 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 166.73 -24.39 0.13 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.778 -1.329 . . . . 50.0 109.778 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -81.39 -70.16 0.56 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -1.163 . . . . 50.0 110.343 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -150.53 136.54 18.45 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.285 -0.885 . . . . 50.0 110.022 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.568 ' NE2' ' N ' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -78.47 108.06 11.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.283 -0.886 . . . . 49.57 110.547 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.437 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 4.1 mt -94.88 110.75 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 49.57 110.131 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.532 ' HB3' ' CG2' ' A' ' 93' ' ' VAL . 15.3 p30 -106.4 130.03 54.28 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.245 -0.909 . . . . 49.57 110.422 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.93 134.72 44.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 49.57 110.187 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.62 ' NE2' ' CZ ' ' A' ' 91' ' ' TYR . 1.7 m-70 -72.32 140.91 48.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 49.57 110.073 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.48 ' HA ' ' CE3' ' A' ' 105' ' ' TRP . 2.4 m95 -134.22 137.66 44.53 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.158 -0.963 . . . . 49.57 110.4 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.466 ' CD2' ' N ' ' A' ' 106' ' ' HIS . 6.7 p80 -159.9 131.98 6.31 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 49.57 110.144 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.28 -10.19 59.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.232 -0.917 . . . . 49.57 110.205 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -98.33 111.22 23.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.21 -0.931 . . . . 49.57 110.279 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -98.13 -168.81 31.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.517 -1.433 . . . . 49.57 109.517 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.428 ' C ' ' OG1' ' A' ' 111' ' ' THR . 3.3 m -111.68 -57.68 2.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.202 -1.175 . . . . 49.57 110.126 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 110' ' ' SER . 4.1 p . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 117.999 -1.001 . . . . 49.57 110.138 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.284 0.564 . . . . 50.0 110.22 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.43 162.82 28.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 50.0 110.208 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.6 tp -113.34 146.68 39.05 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.247 -0.908 . . . . 50.0 110.13 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.59 155.55 17.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.893 . . . . 50.0 110.265 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.451 ' HG ' ' O ' ' A' ' 5' ' ' LEU . 0.5 OUTLIER -106.16 86.89 2.44 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.282 -0.886 . . . . 50.0 110.245 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -104.41 137.35 42.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.217 -0.927 . . . . 50.0 110.121 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.3 127.28 6.56 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.53 -1.428 . . . . 50.0 109.53 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.467 ' O ' ' N ' ' A' ' 10' ' ' TYR . 44.5 p -59.6 168.0 1.81 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -1.124 . . . . 50.0 110.274 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -45.44 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.272 -0.893 . . . . 50.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 8' ' ' THR . 1.2 m-85 -110.29 167.98 9.79 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.171 -0.955 . . . . 50.0 110.214 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -106.94 123.35 7.28 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.622 -1.391 . . . . 50.0 109.622 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.57 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -83.16 121.54 27.2 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.215 -1.168 . . . . 50.0 110.192 -179.913 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.765 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.83 105.58 3.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.021 -1.05 . . . . 99.989999999999995 111.507 -179.779 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.688 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.93 19.54 0.08 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.922 -1.112 . . . . 99.989999999999995 110.427 178.392 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.445 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 1.1 pp20? -57.77 -11.87 2.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.09 -1.007 . . . . 99.989999999999995 110.42 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.407 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 4.3 mptt -80.15 60.71 3.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 50.0 110.382 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.459 ' CD2' HG13 ' A' ' 94' ' ' VAL . 0.1 OUTLIER -93.75 149.36 21.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.249 -0.907 . . . . 50.0 109.917 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.666 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 t -127.43 136.34 51.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.178 -0.951 . . . . 50.0 109.799 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 0.4 OUTLIER -83.48 115.14 21.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.068 -1.02 . . . . 50.0 110.185 -179.769 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 34' ' ' GLU . . . -104.71 -35.8 7.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.35 -0.844 . . . . 50.0 109.953 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.52 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 16.5 mttm -147.53 153.57 39.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.212 -0.93 . . . . 50.0 110.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 29.6 p-10 -68.26 165.16 36.37 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 50.0 109.875 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.8 141.58 37.6 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.854 1.449 . . . . 50.0 110.199 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.455 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -137.68 165.64 25.89 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.191 -0.943 . . . . 50.0 110.321 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -90.49 159.08 16.7 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 50.0 110.136 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -134.24 -45.55 0.77 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.326 -0.859 . . . . 50.0 110.217 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -133.38 -111.51 1.26 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.496 -1.442 . . . . 50.0 109.496 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -128.68 91.39 3.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -1.124 . . . . 50.0 110.211 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 95.4 31.0 7.77 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.506 -1.438 . . . . 50.0 109.506 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.444 HG23 HG11 ' A' ' 64' ' ' VAL . 0.2 OUTLIER -137.04 110.24 7.81 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.238 -1.154 . . . . 50.0 110.42 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 41.3 t -95.94 149.19 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.273 -0.892 . . . . 50.0 110.059 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.455 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -124.06 148.5 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 50.0 110.577 -179.761 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.47 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -147.36 142.3 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.42 -0.8 . . . . 50.0 109.776 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -109.53 101.98 10.87 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 50.0 110.309 -179.736 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.666 ' HA ' ' O ' ' A' ' 18' ' ' SER . 0.3 OUTLIER -120.86 137.71 54.43 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.327 -0.858 . . . . 50.0 109.45 179.525 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -91.44 132.73 36.03 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.081 -1.012 . . . . 50.0 110.064 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.557 ' CE1' HG21 ' A' ' 14' ' ' THR . 33.4 t80 -96.1 95.51 8.22 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.843 -1.143 . . . . 50.0 109.761 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.66 69.64 2.52 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.336 -0.852 . . . . 50.0 109.725 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.07 135.13 12.65 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.691 -1.364 . . . . 99.989999999999995 109.691 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 95.2 p -86.12 13.52 7.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 99.989999999999995 110.27 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -98.48 -20.0 17.34 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.264 -0.898 . . . . 99.989999999999995 110.134 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.64 -165.63 14.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.364 -1.494 . . . . 99.989999999999995 109.364 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.409 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.3 Cg_endo -73.28 140.42 30.59 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 123.868 1.457 . . . . 99.989999999999995 110.563 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.765 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -167.53 162.13 14.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.585 -0.697 . . . . 50.0 109.131 -179.887 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.57 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 9.9 mmtm -59.84 138.28 57.84 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.947 -1.095 . . . . 50.0 110.49 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.688 ' HA ' ' HB ' ' A' ' 14' ' ' THR . 1.5 mt -93.11 109.11 37.64 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 50.0 110.545 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.0 Cg_endo -75.55 96.06 1.03 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.154 1.607 . . . . 50.0 110.219 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.545 HG12 ' CG2' ' A' ' 94' ' ' VAL . 10.2 mt -132.38 145.57 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.881 . . . . 50.0 110.356 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.6 m -115.96 130.93 69.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.324 -0.86 . . . . 50.0 109.912 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.566 ' O ' ' N ' ' A' ' 61' ' ' GLY . 13.3 m -114.71 101.27 8.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 50.0 109.81 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.9 m -131.12 159.7 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.285 -0.885 . . . . 50.0 110.236 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.522 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.13 163.92 1.43 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 50.0 109.898 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.627 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 29.3 t -63.47 122.54 16.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.156 -0.965 . . . . 50.0 110.484 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.627 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 78.72 30.24 0.37 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.513 -0.742 . . . . 50.0 110.579 179.785 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.473 ' O ' HG23 ' A' ' 51' ' ' VAL . 49.8 m-80 -136.23 84.64 2.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 50.0 110.086 179.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -105.43 8.6 33.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.245 -0.909 . . . . 50.0 110.187 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.9 ttt -103.75 -18.29 14.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 50.0 109.921 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -136.08 128.51 17.59 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.508 -0.745 . . . . 50.0 109.911 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.465 ' HA ' HG12 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.46 132.31 20.41 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 123.931 1.49 . . . . 50.0 110.396 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.475 HG11 ' HG3' ' A' ' 86' ' ' PRO . 12.1 t -135.12 -43.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.342 -0.849 . . . . 50.0 109.771 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.78 149.4 44.75 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.685 -1.766 . . . . 50.0 108.685 179.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.493 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 9.5 mtp85 -141.07 157.03 45.87 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.85 -1.382 . . . . 50.0 110.908 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 6.6 mp -94.32 129.54 40.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 50.0 109.845 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.549 ' CG2' ' HG2' ' A' ' 84' ' ' GLU . 43.9 t -79.87 7.3 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.234 -0.916 . . . . 50.0 110.329 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.464 ' CG2' ' HB2' ' A' ' 82' ' ' GLU . 68.9 p -115.5 167.05 11.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.136 -0.978 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 65' ' ' THR . 16.7 m -52.87 -170.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 O-C-N 121.225 -0.922 . . . . 50.0 110.089 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -46.41 149.95 1.26 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.128 -0.982 . . . . 50.0 110.044 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.16 91.03 0.75 Allowed 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.006 1.529 . . . . 50.0 110.691 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.676 ' CZ ' ' CB ' ' A' ' 71' ' ' ALA . 1.2 t80 -155.12 121.51 5.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.345 -0.847 . . . . 50.0 109.932 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.563 ' CG1' ' O ' ' A' ' 70' ' ' VAL . 6.5 p -95.43 60.84 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.252 -0.905 . . . . 50.0 110.166 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.676 ' CB ' ' CZ ' ' A' ' 69' ' ' PHE . . . -73.9 82.44 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 50.0 110.235 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.74 148.88 37.97 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.229 -0.92 . . . . 50.0 110.359 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.2 t -68.45 -15.57 63.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 50.0 109.874 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -121.09 23.31 10.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.301 -0.874 . . . . 99.989999999999995 110.373 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.546 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . . . -72.32 1.34 7.94 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.099 -1.0 . . . . 99.989999999999995 110.397 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.477 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 57.8 m-80 -87.2 24.12 1.66 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.174 -0.954 . . . . 99.989999999999995 109.397 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.581 ' O ' ' HA ' ' A' ' 36' ' ' SER . 2.3 p -128.7 -173.08 2.87 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.476 -0.765 . . . . 99.989999999999995 109.268 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.449 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -63.44 88.83 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.334 -0.854 . . . . 99.989999999999995 109.186 179.478 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.57 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 15.9 m -76.52 176.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.449 -0.782 . . . . 99.989999999999995 109.695 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 2.5 tt -127.57 128.36 45.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.888 -1.132 . . . . 50.0 111.054 -179.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 35' ' ' LEU . 3.2 t -115.45 172.19 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.354 -0.841 . . . . 50.0 110.024 179.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.464 ' HB2' ' CG2' ' A' ' 65' ' ' THR . 2.6 mt-10 -148.1 140.79 24.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.169 -0.957 . . . . 50.0 110.195 179.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.455 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 6.7 ptt? -151.52 146.75 26.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.122 -0.987 . . . . 50.0 110.62 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.549 ' HG2' ' CG2' ' A' ' 64' ' ' VAL . 0.9 OUTLIER -109.34 75.55 0.74 Allowed Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.408 -0.808 . . . . 50.0 110.132 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.26 159.43 47.08 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 124.044 1.549 . . . . 50.0 110.536 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.475 ' HG3' HG11 ' A' ' 60' ' ' VAL . 44.0 Cg_endo -71.02 148.44 56.93 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.079 1.568 . . . . 50.0 110.685 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -58.82 137.23 57.84 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.295 -0.878 . . . . 50.0 110.203 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.78 -125.96 6.43 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.537 ' HB3' ' CB ' ' A' ' 53' ' ' SER . 19.9 t0 -120.51 146.03 46.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -1.147 . . . . 50.0 110.213 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.532 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -141.7 137.57 31.81 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -0.894 . . . . 50.0 110.247 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.592 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 1.9 m-30 -98.98 117.28 33.14 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 50.0 109.952 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.477 ' CD1' ' HB2' ' A' ' 105' ' ' TRP . 3.2 mp -109.5 133.2 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 50.0 110.139 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.412 ' HB ' HG22 ' A' ' 49' ' ' VAL . 11.5 t -124.8 121.39 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.03 . . . . 50.0 110.734 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.545 ' CG2' HG12 ' A' ' 48' ' ' ILE . 24.5 t -106.9 101.67 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.279 -0.888 . . . . 50.0 109.747 179.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.487 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.32 168.31 33.09 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.793 -1.323 . . . . 50.0 109.793 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.445 ' HB2' ' HB3' ' A' ' 15' ' ' GLU . 6.4 ttm -107.13 -55.15 2.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.395 -1.062 . . . . 50.0 110.175 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -166.37 -40.72 0.02 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.6 -85.26 0.22 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -1.172 . . . . 50.0 110.031 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.6 mmtm -79.72 128.87 33.95 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.262 -0.898 . . . . 50.0 110.061 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.654 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -132.53 149.75 52.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 49.57 109.894 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.427 HD13 HG21 ' A' ' 101' ' ' ILE . 49.4 mm -122.81 122.5 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.117 -0.989 . . . . 49.57 110.258 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.403 ' OD1' ' N ' ' A' ' 102' ' ' ASN . 20.1 p-10 -109.99 136.57 49.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 49.57 110.349 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -124.43 164.54 19.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.886 . . . . 49.57 109.917 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -113.78 88.55 2.87 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.285 -0.884 . . . . 49.57 110.563 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.477 ' HB2' ' CD1' ' A' ' 92' ' ' ILE . 1.7 t90 -59.78 109.52 0.95 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.321 -0.862 . . . . 49.57 110.227 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 1.7 t-160 -147.41 120.66 8.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 49.57 110.318 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.91 -7.46 14.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.269 -0.894 . . . . 49.57 110.373 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -135.13 131.85 37.36 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.161 -0.962 . . . . 49.57 110.451 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -136.19 -141.86 4.39 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.437 -1.465 . . . . 49.57 109.437 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.409 ' C ' HG21 ' A' ' 111' ' ' THR . 0.9 OUTLIER 57.17 101.48 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 49.57 110.157 179.964 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.409 HG21 ' C ' ' A' ' 110' ' ' SER . 70.7 p . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.042 -0.98 . . . . 49.57 110.229 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.305 0.574 . . . . 50.0 110.164 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 4.3 mtpp -106.79 172.38 6.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.212 -0.93 . . . . 50.0 110.238 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.5 116.88 29.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.316 -0.865 . . . . 50.0 110.096 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.513 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . . . -81.93 159.54 23.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.895 . . . . 50.0 110.276 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.466 ' CG ' ' O ' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -105.71 81.67 1.7 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.331 -0.856 . . . . 50.0 110.268 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.513 ' HE2' ' CB ' ' A' ' 4' ' ' ALA . 33.3 mttm -104.7 -179.37 3.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.311 -0.868 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.21 35.84 3.8 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.639 -1.384 . . . . 50.0 109.639 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -52.68 144.0 14.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.238 -1.154 . . . . 50.0 110.162 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.579 ' O ' ' CG ' ' A' ' 10' ' ' TYR . 0.8 OUTLIER -44.64 156.37 0.08 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.286 -0.884 . . . . 50.0 110.199 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.579 ' CG ' ' O ' ' A' ' 9' ' ' THR . 0.8 OUTLIER -177.77 167.88 2.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.202 -0.936 . . . . 50.0 110.216 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.61 101.16 2.34 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.452 -1.459 . . . . 50.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.495 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 23.0 mtm -82.8 111.47 18.74 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.378 -1.072 . . . . 50.0 110.442 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.661 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 7.2 p -148.74 108.84 4.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.173 -0.954 . . . . 99.989999999999995 110.538 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.611 HG21 ' CE1' ' A' ' 37' ' ' TYR . 1.2 m -160.27 50.37 0.29 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.93 -1.106 . . . . 99.989999999999995 110.264 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.606 ' CB ' ' CB ' ' A' ' 96' ' ' MET . 3.8 pt-20 -77.88 28.18 0.17 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 99.989999999999995 110.743 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.445 ' HG2' ' C ' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -129.24 60.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.89 -1.131 . . . . 50.0 110.878 -179.87 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.543 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -91.98 143.69 26.22 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.136 -0.978 . . . . 50.0 109.743 179.328 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.596 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 m -127.33 103.85 7.61 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 50.0 110.466 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -61.24 98.38 0.08 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.153 -0.967 . . . . 50.0 110.0 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.469 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -84.88 -32.96 22.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 50.0 109.879 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.469 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 0.1 OUTLIER -142.54 145.23 33.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.352 -0.842 . . . . 50.0 110.187 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' CZ3' ' A' ' 105' ' ' TRP . 24.6 p30 -67.37 161.14 67.18 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 50.0 110.013 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.588 ' HG2' ' CD1' ' A' ' 105' ' ' TRP . 44.5 Cg_endo -71.55 126.07 11.79 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.909 1.479 . . . . 50.0 110.347 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -123.06 152.72 40.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 50.0 110.282 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.5 p30 -90.87 130.03 36.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 50.0 110.078 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.21 -0.69 22.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.18 -0.95 . . . . 50.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -174.59 -129.46 1.19 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.77 98.43 7.4 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -1.162 . . . . 50.0 110.225 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.29 28.23 23.18 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 3.8 p -130.15 107.55 9.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -1.206 . . . . 50.0 110.182 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.525 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 57.8 t -111.22 114.89 48.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 50.0 110.086 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.2 m -94.56 139.45 18.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.208 -0.932 . . . . 50.0 110.522 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.563 ' CD1' ' HG ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -143.57 137.38 25.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.4 -0.812 . . . . 50.0 109.678 179.68 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.468 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 18.5 tt0 -113.08 117.24 31.44 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.078 -1.014 . . . . 50.0 110.883 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.596 ' HA ' ' O ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -128.15 141.54 51.45 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.306 -0.871 . . . . 50.0 109.407 179.233 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.551 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -86.84 123.66 32.21 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.072 -1.017 . . . . 50.0 109.753 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.611 ' CE1' HG21 ' A' ' 14' ' ' THR . 4.9 t80 -91.52 101.66 14.32 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.932 -1.107 . . . . 50.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.407 ' O ' ' HB3' ' A' ' 16' ' ' LYS . 0.2 OUTLIER -96.24 69.64 2.71 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.239 -0.913 . . . . 50.0 109.877 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.448 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -111.31 127.69 8.32 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 8.1 p -77.29 6.09 7.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.296 -1.12 . . . . 99.989999999999995 110.488 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.53 -3.7 42.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.215 -0.928 . . . . 99.989999999999995 109.925 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.461 ' O ' ' OH ' ' A' ' 37' ' ' TYR . . . 81.42 -137.65 17.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.437 -1.465 . . . . 99.989999999999995 109.437 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.572 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 43.3 Cg_endo -70.91 142.42 42.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.968 1.509 . . . . 99.989999999999995 110.327 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.659 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.13 162.42 8.87 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.349 -0.844 . . . . 50.0 110.078 -179.403 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.646 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 25.7 mmtt -74.67 113.34 11.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 50.0 109.906 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.599 ' HA ' ' HB ' ' A' ' 14' ' ' THR . 3.2 mt -74.51 117.08 59.29 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.112 -0.993 . . . . 50.0 110.072 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.7 Cg_endo -81.79 70.13 7.35 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 124.087 1.572 . . . . 50.0 110.158 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.508 ' CD1' HG23 ' A' ' 46' ' ' ILE . 1.7 mp -118.13 146.96 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 50.0 110.226 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.504 ' CG2' ' HB3' ' A' ' 59' ' ' PRO . 6.2 p -127.13 140.36 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.394 -0.816 . . . . 50.0 110.143 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.453 ' OG ' ' HG2' ' A' ' 83' ' ' MET . 75.2 m -107.32 100.5 9.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 50.0 109.8 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.548 ' O ' ' N ' ' A' ' 91' ' ' TYR . 59.4 t -107.72 157.0 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.313 -0.867 . . . . 50.0 110.127 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -71.94 164.23 26.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 50.0 109.215 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.627 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 29.6 t -70.79 100.86 1.98 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.74 -1.225 . . . . 50.0 109.321 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 173.19 -71.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 C-N-CA 118.52 -1.272 . . . . 50.0 111.382 -179.725 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.465 ' HB3' ' OG1' ' A' ' 58' ' ' THR . 80.8 m-20 -84.15 155.12 22.74 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.135 -0.978 . . . . 50.0 110.287 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -106.24 -23.5 12.55 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 50.0 110.118 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.38 37.09 4.38 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.268 -0.895 . . . . 50.0 110.267 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.465 ' OG1' ' HB3' ' A' ' 55' ' ' ASN . 0.6 OUTLIER -134.9 103.23 10.9 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.176 -0.952 . . . . 50.0 110.322 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.536 ' HA ' ' CG2' ' A' ' 51' ' ' VAL . 48.9 Cg_endo -73.72 125.84 10.31 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.063 1.559 . . . . 50.0 110.601 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.47 HG23 ' HA ' ' A' ' 51' ' ' VAL . 12.0 m -135.22 -28.07 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.338 -0.851 . . . . 50.0 110.271 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.82 170.78 48.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.895 -1.682 . . . . 50.0 108.895 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.475 ' O ' ' HG3' ' A' ' 83' ' ' MET . 14.8 mtt180 -140.36 155.91 46.6 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.045 -1.268 . . . . 50.0 110.602 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.456 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 2.2 mp -92.21 115.95 28.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 50.0 109.651 179.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.562 ' CG1' ' HG2' ' A' ' 82' ' ' GLU . 7.5 p -77.69 -34.54 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.087 -1.008 . . . . 50.0 110.352 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 7.3 t -82.58 173.28 12.1 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.087 -1.008 . . . . 50.0 109.821 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 67' ' ' ASN . 47.2 t -41.23 159.78 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.212 -0.93 . . . . 50.0 109.789 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.605 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 8.7 m120 -46.58 158.59 0.39 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 50.0 109.709 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.454 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.2 Cg_endo -73.61 65.83 4.72 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.882 1.464 . . . . 50.0 110.511 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 16.4 m-30 -126.23 121.68 33.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 50.0 110.034 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.461 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.3 OUTLIER -86.97 60.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 50.0 109.589 179.487 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.572 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -71.75 59.35 0.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.415 -0.803 . . . . 50.0 110.158 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.84 158.25 43.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.245 -0.91 . . . . 50.0 110.361 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.3 m -85.98 -10.64 54.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.372 -0.83 . . . . 50.0 109.698 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.99 14.59 16.13 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 99.989999999999995 110.124 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.461 ' HB2' ' HB ' ' A' ' 70' ' ' VAL . . . -80.26 10.99 3.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -0.885 . . . . 99.989999999999995 109.964 179.702 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 1.1 m-80 -85.84 16.16 4.3 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.286 -0.883 . . . . 99.989999999999995 109.435 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.551 ' O ' ' HA ' ' A' ' 36' ' ' SER . 60.3 p -121.91 -172.75 2.5 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.496 -0.752 . . . . 99.989999999999995 109.299 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 0.6 OUTLIER -63.14 88.65 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.177 -0.952 . . . . 99.989999999999995 109.077 179.506 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 28.0 m -76.35 176.08 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.33 -0.856 . . . . 99.989999999999995 109.603 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.76 127.15 44.62 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.945 -1.097 . . . . 50.0 110.759 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.521 HG22 ' CD1' ' A' ' 35' ' ' LEU . 1.8 t -118.43 169.72 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -0.918 . . . . 50.0 110.251 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.562 ' HG2' ' CG1' ' A' ' 64' ' ' VAL . 2.3 tt0 -138.23 135.7 35.83 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.288 -0.882 . . . . 50.0 110.065 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.475 ' HG3' ' O ' ' A' ' 62' ' ' ARG . 1.6 mpp? -138.02 149.26 45.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.123 -0.986 . . . . 50.0 110.53 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.477 ' HG2' ' HB ' ' A' ' 64' ' ' VAL . 2.0 pt-20 -115.33 66.24 2.2 Favored Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.118 -0.989 . . . . 50.0 110.357 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.458 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 47.9 Cg_endo -73.09 164.62 34.96 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.026 1.54 . . . . 50.0 110.411 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.58 152.27 64.98 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.048 1.552 . . . . 50.0 110.405 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.9 OUTLIER -52.76 142.67 18.19 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 50.0 110.263 -179.855 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.39 161.75 14.67 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.345 -1.502 . . . . 50.0 109.345 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.529 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 74.9 m-20 -52.78 163.1 0.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -1.188 . . . . 50.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.544 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -142.37 135.85 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.1 -1.0 . . . . 50.0 110.828 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 5.4 m-30 -96.11 108.21 20.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.245 -0.91 . . . . 50.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 3.6 mp -90.29 137.86 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.224 -0.922 . . . . 50.0 109.789 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 101' ' ' ILE . 22.0 t -125.59 108.33 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 120.882 -1.136 . . . . 50.0 111.421 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.463 ' HA ' HG13 ' A' ' 48' ' ' ILE . 59.5 t -85.36 107.44 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.173 -0.955 . . . . 50.0 108.896 178.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.487 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -90.3 170.23 35.49 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.783 -1.198 . . . . 50.0 110.254 -178.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.606 ' CB ' ' CB ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -153.54 13.89 0.49 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -1.041 . . . . 50.0 110.166 -179.811 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 136.36 -86.6 0.24 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.235 -1.546 . . . . 50.0 109.235 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -99.44 -68.71 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 50.0 109.971 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.89 151.66 30.04 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.201 -0.937 . . . . 50.0 110.04 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.615 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.07 148.6 42.0 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.088 -1.008 . . . . 49.57 110.349 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.0 mt -90.94 146.72 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.152 -0.968 . . . . 49.57 109.638 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -132.83 132.02 41.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.108 -0.995 . . . . 49.57 110.845 -179.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.465 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.0 OUTLIER -118.71 152.92 35.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.391 -0.818 . . . . 49.57 109.518 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.606 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 16.8 p-80 -116.23 83.1 1.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 49.57 110.554 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.588 ' CD1' ' HG2' ' A' ' 23' ' ' PRO . 10.1 t-105 -58.51 93.89 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.934 . . . . 49.57 109.943 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.44 ' HA ' ' OD1' ' A' ' 89' ' ' ASP . 6.8 t60 -124.79 112.0 16.19 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.318 -0.863 . . . . 49.57 110.172 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -6.9 23.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.296 -0.877 . . . . 49.57 110.396 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.416 ' HB2' ' CE1' ' A' ' 106' ' ' HIS . . . -56.7 138.84 52.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -0.975 . . . . 49.57 110.225 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 110' ' ' SER . . . -116.38 23.85 10.19 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.583 -1.407 . . . . 49.57 109.583 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 109' ' ' GLY . 25.8 m -43.44 -58.09 2.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.231 -1.158 . . . . 49.57 110.312 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 118.002 -0.999 . . . . 49.57 110.193 -179.89 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.22 0.533 . . . . 50.0 110.217 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -140.19 172.16 13.15 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.317 -0.865 . . . . 50.0 110.163 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -117.28 154.17 31.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.291 -0.881 . . . . 50.0 110.268 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.74 102.17 10.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.937 . . . . 50.0 110.214 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.9 mp -111.16 166.74 10.83 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 50.0 110.01 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.68 -171.14 2.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 50.0 110.148 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -138.55 59.07 0.61 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.584 -1.406 . . . . 50.0 109.584 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.416 ' O ' ' C ' ' A' ' 9' ' ' THR . 10.4 p -72.11 161.09 31.38 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.216 -1.167 . . . . 50.0 110.14 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' THR . 0.8 OUTLIER -43.35 115.29 0.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.271 -0.893 . . . . 50.0 110.112 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 12.1 p90 -129.23 155.42 45.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.215 -0.928 . . . . 50.0 110.39 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.457 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -107.57 122.21 6.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.387 -1.485 . . . . 50.0 109.387 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.621 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -83.55 85.36 7.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.243 -1.151 . . . . 50.0 110.343 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 4.0 p -149.07 107.17 3.72 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.13 -0.981 . . . . 99.989999999999995 111.006 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.582 ' CG2' HG12 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -162.25 28.9 0.11 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.643 -1.286 . . . . 99.989999999999995 110.505 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 -11.31 3.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.12 -0.988 . . . . 99.989999999999995 110.236 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -71.0 61.05 0.26 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 50.0 110.429 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.489 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -105.62 141.4 37.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.155 -0.966 . . . . 50.0 109.859 179.564 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.572 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.8 OUTLIER -125.09 119.86 29.8 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.189 -0.944 . . . . 50.0 110.198 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.61 ' CE2' ' NE2' ' A' ' 103' ' ' HIS . 7.3 m-85 -63.13 115.25 4.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -0.931 . . . . 50.0 110.027 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.472 ' O ' ' HG2' ' A' ' 21' ' ' LYS . . . -104.3 -28.34 11.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.241 -0.912 . . . . 50.0 110.103 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.482 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 19.0 mttm -146.14 151.94 38.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 50.0 110.171 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.88 164.04 61.78 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 50.0 110.218 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.9 Cg_endo -72.87 128.09 12.89 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.997 1.525 . . . . 50.0 110.206 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.23 152.84 44.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.913 . . . . 50.0 110.369 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.408 ' HA ' ' O ' ' A' ' 30' ' ' THR . 11.3 t70 -85.72 145.43 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.337 -0.852 . . . . 50.0 110.108 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -135.8 33.97 2.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.252 -0.905 . . . . 50.0 110.186 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.59 -109.87 0.41 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -128.02 88.99 2.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -1.155 . . . . 50.0 110.132 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 84' ' ' GLU . . . 87.11 -7.59 79.96 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.719 -1.352 . . . . 50.0 109.719 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.566 ' HA ' ' HG2' ' A' ' 84' ' ' GLU . 41.4 p -80.37 114.14 19.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -1.176 . . . . 50.0 110.194 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.556 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -106.47 141.46 21.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.224 -0.923 . . . . 50.0 110.326 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.4 OUTLIER -112.41 142.4 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.269 -0.894 . . . . 50.0 110.334 -179.803 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -141.37 140.26 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.348 -0.845 . . . . 50.0 109.706 179.695 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.482 ' CG ' ' O ' ' A' ' 79' ' ' VAL . 18.3 tt0 -121.79 117.03 25.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -0.975 . . . . 50.0 110.535 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.58 ' O ' ' CG2' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -126.38 139.53 53.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.307 -0.871 . . . . 50.0 109.529 179.413 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.2 OUTLIER -87.77 126.94 35.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.059 -1.026 . . . . 50.0 109.704 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.526 ' CD2' ' O ' ' A' ' 37' ' ' TYR . 32.2 t80 -90.47 95.72 10.3 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.77 -1.172 . . . . 50.0 109.71 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.4 t -94.58 70.02 3.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.246 -0.909 . . . . 50.0 110.032 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -121.75 126.76 6.61 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.515 -1.434 . . . . 99.989999999999995 109.515 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.44 25.31 1.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -1.161 . . . . 99.989999999999995 110.36 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -99.76 -0.96 38.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 99.989999999999995 110.051 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.4 -163.28 31.23 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.391 -1.484 . . . . 99.989999999999995 109.391 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.57 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.8 Cg_endo -72.71 151.6 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 124.019 1.536 . . . . 99.989999999999995 110.515 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.73 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 3.7 t -170.22 161.71 8.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.391 -0.818 . . . . 50.0 109.666 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.621 ' HB2' ' HA ' ' A' ' 12' ' ' MET . 25.1 mmtt -77.23 121.5 23.76 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.009 -1.057 . . . . 50.0 110.047 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.582 HG12 ' CG2' ' A' ' 14' ' ' THR . 2.8 mt -83.92 110.3 24.67 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.367 -0.833 . . . . 50.0 110.585 -179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.547 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.2 Cg_endo -80.47 106.29 1.84 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.009 1.531 . . . . 50.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.539 HD12 ' CG2' ' A' ' 46' ' ' ILE . 3.0 mp -123.2 142.94 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.163 -0.961 . . . . 50.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.531 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 5.9 m -120.71 96.62 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.84 . . . . 50.0 109.724 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.489 ' HA ' HG23 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -87.95 104.08 16.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.309 -179.625 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.522 ' CG1' ' HA ' ' A' ' 59' ' ' PRO . 16.8 m -130.42 162.07 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.231 -0.918 . . . . 50.0 110.073 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.505 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -68.18 164.02 21.39 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.882 . . . . 50.0 109.304 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.599 ' O ' ' HB2' ' A' ' 54' ' ' LEU . 2.2 t -67.61 99.9 0.83 Allowed 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 118.529 -1.268 . . . . 50.0 108.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.599 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 172.06 -67.15 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.264 -1.374 . . . . 50.0 111.458 -179.688 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -99.64 122.03 42.08 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.087 -1.008 . . . . 50.0 110.299 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -106.18 19.45 20.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.952 . . . . 50.0 110.074 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.19 -7.15 6.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.29 -0.881 . . . . 50.0 110.37 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.457 ' O ' HG13 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -134.44 140.88 37.05 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.19 -0.944 . . . . 50.0 110.288 -179.869 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.522 ' HA ' ' CG1' ' A' ' 51' ' ' VAL . 46.5 Cg_endo -73.07 136.13 24.21 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 124.072 1.564 . . . . 50.0 110.443 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 60' ' ' VAL . 52.8 t -147.18 10.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.216 -0.927 . . . . 50.0 110.381 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -110.08 170.78 14.39 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.271 -1.532 . . . . 50.0 109.271 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.498 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 5.1 mmt180 -107.07 145.13 32.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.101 -1.235 . . . . 50.0 110.218 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.477 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 0.1 OUTLIER -116.99 110.34 18.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 50.0 110.065 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.536 ' CG2' ' HG3' ' A' ' 84' ' ' GLU . 73.5 t -100.07 42.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.168 -0.958 . . . . 50.0 110.124 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.504 ' OG1' ' N ' ' A' ' 82' ' ' GLU . 1.6 m -130.71 144.89 51.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.868 . . . . 50.0 110.096 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 65' ' ' THR . 26.0 m -52.72 -171.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.217 -0.927 . . . . 50.0 110.052 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.492 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 2.3 m-20 -46.83 115.46 3.34 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.128 -0.982 . . . . 50.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.625 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 45.0 Cg_endo -71.89 66.27 3.23 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.964 1.507 . . . . 50.0 110.136 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 68' ' ' PRO . 13.5 m-85 -135.76 123.62 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.474 -0.766 . . . . 50.0 110.054 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.537 ' N ' HD12 ' A' ' 46' ' ' ILE . 53.4 t -71.97 60.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.038 -1.039 . . . . 50.0 109.84 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.57 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -86.63 57.47 4.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 50.0 109.828 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.3 169.13 18.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.328 -0.857 . . . . 50.0 110.337 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.25 -7.34 35.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 50.0 109.999 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 14.6 p -121.06 13.18 11.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.312 -0.868 . . . . 99.989999999999995 110.313 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.531 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.99 5.45 8.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 99.989999999999995 109.958 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.505 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 40.2 m-20 -83.42 20.41 1.35 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.391 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.598 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.6 OUTLIER -122.51 -172.91 2.57 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.363 -0.835 . . . . 99.989999999999995 109.444 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.16 89.03 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.118 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.58 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 10.4 m -76.23 175.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.406 -0.809 . . . . 99.989999999999995 109.663 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -131.47 139.97 49.46 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.879 -1.138 . . . . 50.0 111.028 -179.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.21 172.26 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.452 -0.78 . . . . 50.0 109.991 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.504 ' N ' ' OG1' ' A' ' 65' ' ' THR . 37.9 mt-10 -135.41 142.41 45.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.155 -0.966 . . . . 50.0 110.084 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.517 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -153.02 142.37 21.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.108 -0.995 . . . . 50.0 110.234 -179.71 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.566 ' HG2' ' HA ' ' A' ' 30' ' ' THR . 1.5 mm-40 -110.79 67.89 0.56 Allowed Pre-proline 0 C--N 1.304 -1.37 0 O-C-N 121.022 -1.049 . . . . 50.0 110.619 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.556 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.26 155.78 55.79 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.978 1.515 . . . . 50.0 110.528 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.22 163.28 39.17 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.105 1.582 . . . . 50.0 110.463 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -73.54 138.46 45.01 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.201 -0.937 . . . . 50.0 110.172 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.43 -150.14 17.17 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.362 -1.495 . . . . 50.0 109.362 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -92.3 137.11 32.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 50.0 110.0 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.577 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -130.23 133.4 46.51 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.23 -0.919 . . . . 50.0 110.247 179.984 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.522 ' O ' ' CG2' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -91.65 97.08 10.81 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.159 -0.963 . . . . 50.0 109.996 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.489 HG23 ' HA ' ' A' ' 50' ' ' SER . 1.7 pt -102.56 116.95 47.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.271 -0.893 . . . . 50.0 109.839 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.531 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 42.5 t -118.57 131.07 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 50.0 110.556 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.469 HG13 ' CG1' ' A' ' 48' ' ' ILE . 14.7 t -107.28 96.66 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.278 -0.888 . . . . 50.0 109.86 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.519 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.42 165.42 32.39 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.623 -1.391 . . . . 50.0 109.623 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.516 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 10.8 ptp -107.48 -33.41 7.36 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.282 -1.129 . . . . 50.0 110.316 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . 0.516 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 176.36 -63.21 0.1 OUTLIER Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.478 -1.449 . . . . 50.0 109.478 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -63.75 -107.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.204 -1.174 . . . . 50.0 110.132 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -79.29 123.35 27.37 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.111 -0.993 . . . . 50.0 110.161 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.781 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -131.41 150.17 52.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 49.57 110.064 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 46.0 mt -102.88 106.7 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.996 -1.065 . . . . 49.57 110.136 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.424 ' HB2' HG23 ' A' ' 93' ' ' VAL . 7.6 p-10 -97.4 130.8 44.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 49.57 110.196 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.61 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -126.99 160.45 31.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.34 -0.85 . . . . 49.57 110.238 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.3 p80 -123.26 86.53 2.59 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 49.57 110.131 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.55 ' CH2' ' HA ' ' A' ' 107' ' ' LYS . 0.1 OUTLIER -51.76 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 49.57 110.042 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.472 ' N ' ' CE3' ' A' ' 105' ' ' TRP . 0.9 OUTLIER -104.55 106.47 16.98 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.326 -0.859 . . . . 49.57 110.194 -179.879 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . 0.55 ' HA ' ' CH2' ' A' ' 105' ' ' TRP . 0.0 OUTLIER -81.34 -10.36 59.57 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.309 -0.869 . . . . 49.57 110.274 179.956 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -118.09 -174.49 2.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 49.57 110.24 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -158.08 -73.84 0.02 OUTLIER Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.516 -1.434 . . . . 49.57 109.516 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -91.22 143.07 27.04 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.282 -1.128 . . . . 49.57 110.186 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 118.051 -0.976 . . . . 49.57 110.214 -179.972 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.31 0.576 . . . . 50.0 110.107 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.3 pttm -136.94 151.93 49.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 50.0 110.057 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.413 ' O ' ' HG ' ' A' ' 3' ' ' LEU . 0.5 OUTLIER -107.18 98.95 8.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.197 -0.94 . . . . 50.0 110.224 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.21 133.85 54.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.246 -0.909 . . . . 50.0 110.342 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.413 ' N ' HD22 ' A' ' 5' ' ' LEU . 1.4 mm? -111.23 170.23 8.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 50.0 109.749 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 3.3 ttpt -100.97 142.99 31.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.129 -0.982 . . . . 50.0 110.334 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 122.84 -36.84 2.98 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.38 -1.488 . . . . 50.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -132.92 99.29 4.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -1.091 . . . . 50.0 110.102 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 10' ' ' TYR . 5.1 t -173.76 170.13 4.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.258 -0.901 . . . . 50.0 110.27 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.468 ' O ' ' O ' ' A' ' 9' ' ' THR . 0.6 OUTLIER -48.07 179.06 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.413 -0.804 . . . . 50.0 110.171 179.823 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.97 168.95 49.59 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.655 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? -112.3 127.96 56.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.269 -1.136 . . . . 50.0 110.299 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.679 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.13 105.88 3.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.111 -0.993 . . . . 99.989999999999995 111.151 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.568 ' CG2' HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.22 25.09 0.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.115 -0.991 . . . . 99.989999999999995 109.938 178.458 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 96' ' ' MET . 17.9 tt0 -49.78 -18.67 0.51 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.316 -0.865 . . . . 99.989999999999995 110.375 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.432 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 1.2 mmtt -76.2 61.43 1.61 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 50.0 110.411 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.584 ' CZ ' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -99.0 138.68 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.926 . . . . 50.0 109.94 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 12.7 t -128.29 97.47 4.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.205 -0.934 . . . . 50.0 110.621 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 6.7 p90 -56.5 117.95 4.34 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.993 -1.067 . . . . 50.0 109.836 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -107.34 -19.64 13.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 50.0 110.651 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.512 ' CE ' ' OE1' ' A' ' 34' ' ' GLU . 25.9 mttm -140.79 150.79 43.8 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.14 -0.975 . . . . 50.0 110.684 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -67.64 165.44 30.4 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.447 -0.783 . . . . 50.0 110.145 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.5 Cg_endo -72.75 142.89 36.39 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 124.012 1.533 . . . . 50.0 110.305 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.422 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -133.5 152.52 51.92 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.218 -0.926 . . . . 50.0 110.249 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.6 p30 -92.55 130.94 38.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -0.881 . . . . 50.0 110.338 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.66 -80.84 0.48 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 50.0 110.035 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.41 -109.14 0.61 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.431 -1.467 . . . . 50.0 109.431 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -129.73 97.32 4.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.276 -1.132 . . . . 50.0 110.145 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 96.84 8.8 56.8 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 82.5 p -103.2 128.22 50.25 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -1.084 . . . . 50.0 110.263 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.466 HG21 ' HD2' ' A' ' 85' ' ' PRO . 39.2 t -109.74 137.71 40.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.366 -0.834 . . . . 50.0 109.906 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.54 HG13 ' CD2' ' A' ' 80' ' ' LEU . 1.5 t -117.57 143.43 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 50.0 110.436 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.547 HG12 ' CD1' ' A' ' 35' ' ' LEU . 3.6 tt -142.93 145.11 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 50.0 109.759 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.521 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 17.7 tt0 -116.46 102.55 9.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.16 -0.962 . . . . 50.0 110.721 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.588 ' CD1' ' N ' ' A' ' 35' ' ' LEU . 1.0 OUTLIER -113.56 136.77 52.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.259 -0.9 . . . . 50.0 109.536 179.45 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.4 OUTLIER -86.36 129.85 34.71 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.155 -0.966 . . . . 50.0 109.92 -179.57 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.522 ' CD1' HG22 ' A' ' 14' ' ' THR . 10.7 t80 -95.59 99.6 11.45 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 118.983 -1.087 . . . . 50.0 109.869 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -96.27 72.29 2.83 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.116 -0.99 . . . . 50.0 110.135 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -124.67 124.03 5.27 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.532 -1.427 . . . . 99.989999999999995 109.532 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 29.45 2.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.212 -1.17 . . . . 99.989999999999995 110.265 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' OD1' ' C ' ' A' ' 41' ' ' ASP . 2.1 p30 -102.99 0.39 32.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.291 -0.881 . . . . 99.989999999999995 110.155 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.67 174.67 25.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.273 -1.531 . . . . 99.989999999999995 109.273 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.548 ' CB ' ' O ' ' A' ' 70' ' ' VAL . 45.0 Cg_endo -72.81 149.74 48.52 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.001 1.527 . . . . 99.989999999999995 110.599 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.679 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -167.47 162.66 14.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.439 -0.788 . . . . 50.0 109.56 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.655 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 23.2 mmtt -67.5 141.44 56.91 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.968 -1.082 . . . . 50.0 109.745 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.634 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 7.1 mt -90.78 108.81 30.21 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.299 -0.875 . . . . 50.0 110.649 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.551 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 49.9 Cg_endo -75.48 96.48 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 124.152 1.606 . . . . 50.0 110.955 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.634 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 0.5 OUTLIER -131.64 115.79 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 50.0 109.992 179.462 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.548 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 18.0 m -93.07 107.44 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.852 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -86.18 100.88 12.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 50.0 109.765 179.869 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.567 ' O ' ' N ' ' A' ' 91' ' ' TYR . 95.7 t -118.71 150.56 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.313 -0.867 . . . . 50.0 110.468 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.438 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -67.51 164.73 18.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.373 -0.83 . . . . 50.0 109.62 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.606 ' N ' ' HA ' ' A' ' 90' ' ' SER . 5.4 t -70.05 101.84 1.9 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.834 -1.166 . . . . 50.0 109.424 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.498 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 171.0 -64.12 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.057 -1.457 . . . . 50.0 111.703 -179.906 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.53 ' CB ' ' HB ' ' A' ' 58' ' ' THR . 41.4 m-80 -88.05 164.99 15.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.094 . . . . 50.0 110.315 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 56' ' ' ASP . 49.9 t0 -105.9 -37.87 6.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 50.0 110.238 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.0 ttm -123.85 30.39 6.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 50.0 110.217 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.53 ' HB ' ' CB ' ' A' ' 55' ' ' ASN . 17.3 m -111.85 120.62 41.74 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.256 -0.902 . . . . 50.0 110.049 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -72.58 130.05 15.47 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.989 1.52 . . . . 50.0 110.414 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.441 HG23 HG13 ' A' ' 51' ' ' VAL . 10.5 t -142.3 -36.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.259 -0.901 . . . . 50.0 110.26 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -77.54 164.74 52.37 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.138 -1.585 . . . . 50.0 109.138 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.42 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 10.5 mtt180 -138.49 156.45 47.52 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.095 -1.238 . . . . 50.0 110.445 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.49 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 2.5 mt -97.97 122.4 41.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 50.0 109.776 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.497 HG23 ' HG2' ' A' ' 84' ' ' GLU . 30.6 t -63.33 -13.5 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.217 -0.927 . . . . 50.0 110.12 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 66' ' ' VAL . 34.6 m -124.77 163.21 22.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.295 -0.878 . . . . 50.0 109.955 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 65' ' ' THR . 74.1 t -44.09 168.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 50.0 109.959 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.628 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 18.2 t-20 -46.68 142.73 4.56 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.196 -0.94 . . . . 50.0 110.11 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.555 ' O ' HG13 ' A' ' 46' ' ' ILE . 49.8 Cg_endo -76.22 98.56 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.927 1.488 . . . . 50.0 110.452 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.628 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 9.2 p90 -120.51 138.49 53.81 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.225 -0.922 . . . . 50.0 110.346 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.56 HG21 ' CG2' ' A' ' 14' ' ' THR . 73.6 t -91.01 60.94 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.198 -0.939 . . . . 50.0 110.181 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.507 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -89.76 57.44 3.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 50.0 110.346 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.7 m -143.43 169.12 18.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 50.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.7 p -94.23 -6.83 43.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 50.0 109.92 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.14 17.74 11.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 99.989999999999995 110.41 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.55 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -79.79 7.29 8.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.15 -0.969 . . . . 99.989999999999995 110.066 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.492 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 53.6 m-20 -85.17 18.78 2.44 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.234 -0.917 . . . . 99.989999999999995 109.341 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.59 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.1 OUTLIER -122.68 -172.73 2.54 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.404 -0.81 . . . . 99.989999999999995 109.277 179.97 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 40.0 mttt -62.98 88.47 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.327 -0.858 . . . . 99.989999999999995 109.168 179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.57 ' CG2' ' O ' ' A' ' 35' ' ' LEU . 11.4 m -76.68 176.48 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.376 -0.827 . . . . 99.989999999999995 109.392 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.54 ' CD2' HG13 ' A' ' 32' ' ' VAL . 8.0 tt -135.23 133.92 39.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.781 -1.2 . . . . 50.0 111.212 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.438 ' O ' HD21 ' A' ' 80' ' ' LEU . 1.9 t -119.98 178.31 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.483 -0.76 . . . . 50.0 109.829 179.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 61.7 mt-10 -148.52 139.24 22.86 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.996 -1.065 . . . . 50.0 110.546 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.49 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 14.2 ptt? -155.81 139.03 15.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.268 -0.895 . . . . 50.0 110.245 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.497 ' HG2' HG23 ' A' ' 64' ' ' VAL . 1.3 pt-20 -109.24 76.62 0.81 Allowed Pre-proline 0 C--N 1.305 -1.327 0 O-C-N 121.183 -0.948 . . . . 50.0 110.619 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HD2' HG21 ' A' ' 31' ' ' VAL . 47.5 Cg_endo -73.86 170.34 20.3 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.02 1.537 . . . . 50.0 110.344 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.33 161.94 42.95 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.061 1.559 . . . . 50.0 110.42 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -67.13 145.35 55.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.171 -0.956 . . . . 50.0 110.154 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.28 158.62 16.74 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.189 -1.564 . . . . 50.0 109.189 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.496 ' OD2' ' CD2' ' A' ' 106' ' ' HIS . 1.0 OUTLIER -52.41 148.55 6.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -1.22 . . . . 50.0 109.928 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.606 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.4 p -130.49 138.77 50.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.118 -0.989 . . . . 50.0 110.705 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.567 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -90.65 104.35 16.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.16 -0.963 . . . . 50.0 109.415 179.334 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 3.3 tt -103.43 135.02 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 50.0 110.341 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.548 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 10.7 t -125.15 114.52 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.089 -1.007 . . . . 50.0 110.863 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.52 ' CG1' HD13 ' A' ' 48' ' ' ILE . 17.6 t -103.97 104.14 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.195 -0.941 . . . . 50.0 109.444 179.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.551 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.27 169.92 33.29 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.614 -1.279 . . . . 50.0 110.195 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.404 ' HB2' ' HB2' ' A' ' 15' ' ' GLU . 19.7 ttm -111.72 -51.35 2.86 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.355 -1.085 . . . . 50.0 110.597 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.85 -145.14 12.18 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.845 -1.302 . . . . 50.0 109.845 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -63.52 -36.11 82.68 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.219 -1.165 . . . . 50.0 110.384 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.37 116.56 19.68 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.207 -0.933 . . . . 50.0 110.184 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.606 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.45 148.69 43.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.323 -0.861 . . . . 49.57 110.114 -179.808 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.544 ' CG2' ' O ' ' A' ' 101' ' ' ILE . 3.5 tp -94.87 110.32 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.258 -0.901 . . . . 49.57 110.012 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.445 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 32.8 p-10 -101.93 131.82 48.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 49.57 110.475 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -121.12 171.36 8.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.38 -0.825 . . . . 49.57 110.146 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -119.34 79.92 1.49 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 49.57 110.471 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.452 ' HA ' ' CE3' ' A' ' 105' ' ' TRP . 0.1 OUTLIER -52.43 134.74 34.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 49.57 109.983 179.781 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.496 ' CD2' ' OD2' ' A' ' 89' ' ' ASP . 0.2 OUTLIER -110.52 98.75 7.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.179 -0.951 . . . . 49.57 110.412 -179.803 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -9.75 13.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.855 . . . . 49.57 110.036 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -47.49 154.72 0.42 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -0.874 . . . . 49.57 110.082 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -154.54 142.36 8.98 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.603 -1.399 . . . . 49.57 109.603 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.3 p -66.46 -177.22 0.53 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -1.145 . . . . 49.57 110.141 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' THR . . . . . 0.453 HG23 ' O ' ' A' ' 111' ' ' THR . 22.0 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.042 -0.98 . . . . 49.57 110.263 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 45.8 m-20 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.263 0.554 . . . . 50.0 110.313 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -150.41 155.77 40.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 50.0 110.228 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.422 ' O ' ' HG ' ' A' ' 3' ' ' LEU . 0.7 OUTLIER -83.82 155.95 22.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 50.0 110.206 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.98 168.97 9.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.273 -0.892 . . . . 50.0 110.201 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.5 mp -89.91 61.69 5.4 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.24 -0.913 . . . . 50.0 110.142 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 4.1 tttt -97.27 149.32 22.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.338 -0.851 . . . . 50.0 110.171 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.461 ' O ' HG22 ' A' ' 8' ' ' THR . . . 130.92 -53.26 0.81 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.658 -1.377 . . . . 50.0 109.658 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.461 HG22 ' O ' ' A' ' 7' ' ' GLY . 38.7 p -141.8 127.59 19.26 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 50.0 110.345 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.17 173.87 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.906 . . . . 50.0 110.196 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -138.41 161.02 38.04 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 50.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -72.28 117.38 6.27 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.47 -1.452 . . . . 50.0 109.47 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.536 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -111.87 102.79 11.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -1.177 . . . . 50.0 110.248 -179.948 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.658 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 11.6 p -148.69 107.35 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.204 -0.935 . . . . 99.989999999999995 110.415 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.589 ' CB ' HD12 ' A' ' 46' ' ' ILE . 1.3 m -161.5 62.8 0.26 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.674 -1.266 . . . . 99.989999999999995 110.549 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.471 ' HG3' ' HE3' ' A' ' 16' ' ' LYS . 1.5 pp20? -84.63 25.18 0.93 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.156 -0.965 . . . . 99.989999999999995 110.117 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.486 ' HD3' ' HA3' ' A' ' 39' ' ' GLY . 1.8 mptt -123.47 61.02 1.06 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.177 -0.952 . . . . 50.0 110.782 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' CD2' HD13 ' A' ' 48' ' ' ILE . 0.0 OUTLIER -99.11 146.88 25.64 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.054 -1.029 . . . . 50.0 109.8 179.429 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.662 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.11 145.41 51.02 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.124 -0.985 . . . . 50.0 110.294 -179.898 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.489 ' CZ ' ' CD1' ' A' ' 101' ' ' ILE . 1.2 m-85 -85.32 104.28 15.01 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.962 -1.086 . . . . 50.0 109.617 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.516 ' CB ' ' O ' ' A' ' 34' ' ' GLU . . . -93.2 -34.53 13.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.128 -0.983 . . . . 50.0 110.648 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.499 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 13.6 mttm -145.09 166.71 24.6 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.06 -1.025 . . . . 50.0 110.614 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.59 165.16 39.36 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 50.0 110.09 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.486 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.71 136.75 26.15 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.969 1.51 . . . . 50.0 110.46 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.44 167.53 14.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.251 -0.906 . . . . 50.0 110.346 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -105.81 132.31 52.08 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 50.0 110.37 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 p -108.78 -23.17 11.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 50.0 110.136 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.46 -114.64 0.59 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.468 -1.453 . . . . 50.0 109.468 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' HIS . . . . . 0.513 ' O ' ' CD2' ' A' ' 28' ' ' HIS . 11.5 p-80 -130.17 88.87 2.71 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -1.163 . . . . 50.0 110.296 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.468 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 105.1 14.94 21.37 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.8 p -121.73 111.53 17.28 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.311 -1.111 . . . . 50.0 110.186 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.486 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -104.61 150.56 7.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.218 -0.926 . . . . 50.0 110.313 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.444 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -128.19 135.09 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.244 -0.91 . . . . 50.0 110.271 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.509 HG22 ' CD1' ' A' ' 35' ' ' LEU . 8.0 tt -134.28 150.3 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.864 . . . . 50.0 109.518 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.609 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 2.4 tt0 -119.84 103.78 9.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 50.0 110.767 -179.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.662 ' HA ' ' O ' ' A' ' 18' ' ' SER . 1.2 mp -110.89 137.36 48.63 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.226 -0.921 . . . . 50.0 109.691 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -84.68 124.78 31.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.058 -1.026 . . . . 50.0 109.696 179.954 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.581 ' CE1' HG21 ' A' ' 14' ' ' THR . 6.3 t80 -92.34 97.84 11.12 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.904 -1.118 . . . . 50.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.9 t -95.14 72.09 3.34 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.391 -0.818 . . . . 50.0 110.163 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.486 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -125.57 126.68 5.96 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.574 -1.41 . . . . 99.989999999999995 109.574 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -83.55 16.85 2.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -1.151 . . . . 99.989999999999995 110.201 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -92.4 -22.47 19.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 99.989999999999995 110.149 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.46 ' O ' ' OH ' ' A' ' 37' ' ' TYR . . . 110.76 -163.31 12.31 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.641 -1.384 . . . . 99.989999999999995 109.641 179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.7 Cg_endo -73.5 150.31 45.78 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 O-C-N 123.966 1.509 . . . . 99.989999999999995 110.418 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.628 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.55 161.87 7.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.309 -0.87 . . . . 50.0 109.851 -179.531 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.536 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 13.7 mmtt -69.0 117.53 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.067 -1.021 . . . . 50.0 109.382 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.61 ' CG2' ' CD1' ' A' ' 48' ' ' ILE . 4.4 mm -71.4 112.83 15.19 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.058 -1.026 . . . . 50.0 110.372 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.543 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 51.8 Cg_endo -80.26 91.87 1.13 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.061 1.558 . . . . 50.0 110.171 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.61 ' CD1' ' CG2' ' A' ' 46' ' ' ILE . 63.3 mt -133.11 149.98 32.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.128 -0.982 . . . . 50.0 110.541 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.554 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 26.1 m -124.14 159.66 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.382 -0.824 . . . . 50.0 109.661 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.477 ' O ' ' HA3' ' A' ' 61' ' ' GLY . 0.3 OUTLIER -134.76 107.66 7.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 50.0 110.066 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.5 m -125.2 156.76 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.284 -0.885 . . . . 50.0 110.203 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.433 ' H ' ' CG2' ' A' ' 60' ' ' VAL . . . -55.93 163.64 1.42 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.355 -0.841 . . . . 50.0 110.012 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.609 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.4 OUTLIER -59.5 121.21 10.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.211 -0.931 . . . . 50.0 110.649 -179.556 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.609 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 78.58 30.55 0.38 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.565 -0.709 . . . . 50.0 110.976 179.549 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.428 ' OD1' ' HB2' ' A' ' 52' ' ' ALA . 30.1 m120 -128.0 84.28 2.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.21 -0.931 . . . . 50.0 110.068 179.066 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.49 9.6 31.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.234 -0.917 . . . . 50.0 110.211 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.4 mtt -113.85 -15.65 12.35 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -0.863 . . . . 50.0 110.111 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -136.37 121.01 12.85 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.334 -0.854 . . . . 50.0 110.246 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.424 ' O ' HG13 ' A' ' 60' ' ' VAL . 46.3 Cg_endo -72.98 133.66 20.2 Favored 'Trans proline' 0 C--N 1.305 -1.755 0 O-C-N 123.989 1.52 . . . . 50.0 110.16 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.467 HG21 ' HA ' ' A' ' 51' ' ' VAL . 31.3 m -142.31 -31.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.223 -0.923 . . . . 50.0 110.429 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.41 144.79 37.94 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.397 -1.881 . . . . 50.0 108.397 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.467 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 11.7 mtp180 -123.6 157.0 34.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.851 -1.382 . . . . 50.0 110.892 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.82 124.91 40.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.876 . . . . 50.0 109.86 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.48 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 17.9 t -50.76 -21.45 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.177 -0.952 . . . . 50.0 110.248 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 66' ' ' VAL . 5.8 t -136.33 170.68 15.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 50.0 110.153 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 27.7 m -52.23 -172.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.237 -0.915 . . . . 50.0 110.157 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.552 ' O ' ' CE2' ' A' ' 69' ' ' PHE . 6.7 p30 -46.88 131.04 8.74 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.142 -0.973 . . . . 50.0 110.003 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.514 ' O ' HG12 ' A' ' 46' ' ' ILE . 46.8 Cg_endo -72.58 123.24 8.91 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.941 1.495 . . . . 50.0 110.559 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 67' ' ' ASN . 0.2 OUTLIER -135.14 157.07 47.86 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.286 -0.884 . . . . 50.0 110.069 -179.942 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.559 ' CG2' ' CD1' ' A' ' 46' ' ' ILE . 0.1 OUTLIER -116.29 60.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.179 -0.951 . . . . 50.0 109.6 179.292 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.515 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -73.55 58.91 0.6 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 50.0 110.347 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.0 m -142.59 155.2 44.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.32 -0.863 . . . . 50.0 110.233 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.61 -4.9 53.65 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.334 -0.854 . . . . 50.0 109.857 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.5 p -115.45 17.31 16.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 99.989999999999995 110.255 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.524 ' CB ' HG12 ' A' ' 70' ' ' VAL . . . -79.91 8.61 6.58 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.182 -0.949 . . . . 99.989999999999995 109.966 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -87.63 19.55 3.35 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 109.243 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.519 ' O ' ' HA ' ' A' ' 36' ' ' SER . 96.5 p -128.96 -172.56 2.75 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.536 -0.728 . . . . 99.989999999999995 109.346 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 36' ' ' SER . 0.3 OUTLIER -63.35 88.82 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.263 -0.898 . . . . 99.989999999999995 109.291 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 34' ' ' GLU . 35.3 m -76.16 176.28 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.352 -0.843 . . . . 99.989999999999995 109.21 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ILE . 2.8 tt -134.02 132.93 40.66 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.884 -1.135 . . . . 50.0 111.239 -179.487 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.4 t -122.64 178.08 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.435 -0.791 . . . . 50.0 109.681 179.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.48 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 22.8 mt-10 -132.85 142.65 49.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.021 -1.049 . . . . 50.0 110.479 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.453 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -147.78 142.22 26.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.281 -0.887 . . . . 50.0 110.234 179.995 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.468 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -114.69 66.38 1.75 Allowed Pre-proline 0 C--N 1.306 -1.296 0 O-C-N 121.151 -0.968 . . . . 50.0 110.563 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.453 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.21 164.94 33.99 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.969 1.51 . . . . 50.0 110.28 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.51 140.83 33.74 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.92 1.484 . . . . 50.0 110.354 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -52.54 137.08 31.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.231 -0.918 . . . . 50.0 110.194 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.76 167.37 13.32 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.384 -1.486 . . . . 50.0 109.384 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ASP . . . . . 0.484 ' HB2' ' HB2' ' A' ' 53' ' ' SER . 23.1 m-20 -53.25 146.5 11.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.3 -1.118 . . . . 50.0 110.051 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.553 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -141.43 141.37 33.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 50.0 110.604 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' TYR . . . . . 0.565 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 1.0 OUTLIER -97.49 112.02 24.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 50.0 109.672 179.462 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.463 HG21 ' CZ3' ' A' ' 105' ' ' TRP . 5.0 tt -103.44 136.91 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.101 -0.999 . . . . 50.0 110.406 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.554 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 27.1 t -125.15 113.12 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.088 -1.007 . . . . 50.0 110.316 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.521 ' CG2' HG12 ' A' ' 48' ' ' ILE . 42.1 t -105.13 100.54 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.901 . . . . 50.0 110.065 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.457 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -150.82 164.8 30.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.71 -1.356 . . . . 50.0 109.71 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' MET . . . . . 0.543 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ttm -103.44 -29.71 11.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.32 -1.106 . . . . 50.0 110.319 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 179.71 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.07 -67.9 0.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.27 -1.135 . . . . 50.0 110.422 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.1 tptt -79.47 109.38 13.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.208 -0.933 . . . . 50.0 110.109 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . 0.652 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -134.82 149.73 50.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 49.57 110.111 -179.739 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.489 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 5.6 pt -118.92 154.7 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 49.57 109.905 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.459 ' O ' ' OD1' ' A' ' 102' ' ' ASN . 14.4 p30 -143.1 136.35 28.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.164 -0.96 . . . . 49.57 110.429 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.485 ' CE1' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -120.78 168.25 11.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.24 -0.912 . . . . 49.57 110.28 179.887 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.565 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 8.8 p-80 -131.08 106.08 8.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.363 -0.836 . . . . 49.57 109.981 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' TRP . . . . . 0.469 ' CZ3' ' HB3' ' A' ' 103' ' ' HIS . 0.8 OUTLIER -87.69 112.84 22.79 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 49.57 110.629 -179.611 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' HIS . . . . . 0.593 ' O ' ' CG ' ' A' ' 106' ' ' HIS . 21.0 p80 -159.49 102.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.338 -0.851 . . . . 49.57 110.075 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -103.73 -10.89 17.97 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.204 -0.935 . . . . 49.57 110.381 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -79.63 123.97 28.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.28 -0.887 . . . . 49.57 110.259 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -146.69 70.46 0.35 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.535 -1.426 . . . . 49.57 109.535 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 13.6 m -148.3 98.17 2.87 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 49.57 110.154 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 35.2 p . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 118.048 -0.977 . . . . 49.57 110.174 -179.908 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.547 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 74.1 mtp . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.204 0.526 . . . . 50.0 110.263 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.778 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 8.6 p -149.01 108.06 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.608 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.657 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -161.57 41.96 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.611 -1.305 . . . . 99.989999999999995 110.678 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.7 tm-20 -70.03 -3.78 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.122 -0.986 . . . . 99.989999999999995 110.075 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.543 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -79.71 62.45 3.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.315 -0.866 . . . . 50.0 110.206 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.646 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.3 OUTLIER -102.64 140.87 36.34 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.188 -0.945 . . . . 50.0 110.431 -179.883 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.678 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.4 t -125.53 119.69 28.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 50.0 109.81 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -73.62 108.41 6.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.125 -0.985 . . . . 50.0 110.298 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.798 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -94.87 -33.49 12.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 50.0 109.916 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.49 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 17.3 mtmt -144.78 150.29 36.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.288 -0.882 . . . . 50.0 110.202 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.473 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 11.2 m-20 -69.23 165.15 42.0 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.291 -0.881 . . . . 50.0 110.107 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.543 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.1 Cg_endo -72.84 122.53 8.24 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.946 1.498 . . . . 50.0 110.31 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -122.37 141.71 51.28 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.905 . . . . 50.0 110.287 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.537 ' HA ' ' O ' ' A' ' 30' ' ' THR . 2.7 p30 -81.89 131.65 35.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 50.0 110.312 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.2 p -123.54 52.46 1.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.312 -0.868 . . . . 50.0 110.137 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.57 -129.2 2.85 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.435 -1.466 . . . . 50.0 109.435 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -116.54 95.79 5.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.206 -1.173 . . . . 50.0 110.243 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.58 23.04 63.27 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -117.87 107.71 14.43 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -1.16 . . . . 50.0 110.219 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.543 HG11 ' HB2' ' A' ' 23' ' ' PRO . 11.8 t -103.58 137.3 32.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.307 -0.87 . . . . 50.0 110.208 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -110.82 136.46 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.224 -0.923 . . . . 50.0 110.294 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HD11 ' A' ' 35' ' ' LEU . 12.7 tt -130.62 144.49 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.413 -0.805 . . . . 50.0 109.68 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.798 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -122.62 105.26 9.94 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.982 . . . . 50.0 110.639 -179.495 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.989 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.12 141.63 51.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.238 -0.914 . . . . 50.0 109.511 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -90.74 128.93 36.84 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.102 -0.999 . . . . 50.0 109.855 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.543 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 11.4 t80 -91.44 98.58 11.77 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 118.935 -1.106 . . . . 50.0 109.679 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.77 69.6 8.69 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.291 -0.881 . . . . 50.0 109.711 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.536 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -124.24 119.85 3.87 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.634 -1.386 . . . . 99.989999999999995 109.634 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.1 m -86.22 20.04 2.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.327 -1.101 . . . . 99.989999999999995 110.278 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -97.47 -0.85 45.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 99.989999999999995 110.105 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.71 -158.3 26.05 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.411 -1.475 . . . . 99.989999999999995 109.411 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -73.06 151.32 49.75 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.959 1.505 . . . . 99.989999999999995 110.222 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.778 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -170.23 161.48 8.34 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -0.907 . . . . 50.0 109.784 -179.402 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.602 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 5.0 mmtt -79.48 114.39 18.37 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.979 -1.076 . . . . 50.0 110.125 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.064 HD11 HG23 ' A' ' 70' ' ' VAL . 2.6 mt -75.06 113.58 26.42 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 50.0 110.194 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.497 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 46.5 Cg_endo -74.13 88.79 1.08 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 124.043 1.549 . . . . 50.0 110.013 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.673 HD11 HG21 ' A' ' 46' ' ' ILE . 79.4 mt -125.54 151.79 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 50.0 110.741 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.517 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 32.4 m -133.12 137.29 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.499 -0.751 . . . . 50.0 109.337 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -116.48 108.81 16.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.003 -1.061 . . . . 50.0 110.313 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 91' ' ' TYR . 14.8 m -131.58 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 50.0 110.113 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.48 163.6 1.7 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.31 -0.869 . . . . 50.0 110.184 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.665 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -62.85 120.46 11.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -0.887 . . . . 50.0 110.545 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.665 ' CB ' ' O ' ' A' ' 53' ' ' SER . 3.8 tp 81.47 29.96 0.15 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.582 -0.699 . . . . 50.0 110.725 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.524 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 24.8 m120 -137.38 84.75 2.08 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 50.0 110.101 179.247 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -105.36 11.13 33.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 50.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.4 tpt -109.04 -14.15 14.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 50.0 110.211 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.3 p -136.04 142.84 41.71 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.289 -0.882 . . . . 50.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.68 137.2 27.01 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.006 1.53 . . . . 50.0 110.321 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.817 HG12 ' HG3' ' A' ' 86' ' ' PRO . 4.0 t -143.89 -49.08 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.305 -0.872 . . . . 50.0 110.079 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -86.29 147.22 21.43 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.085 -1.606 . . . . 50.0 109.085 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 10.1 mtp180 -138.66 156.38 47.48 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.057 -1.261 . . . . 50.0 110.686 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.487 ' HA ' ' HG2' ' A' ' 83' ' ' MET . 5.0 mp -91.91 109.62 20.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.32 -0.863 . . . . 50.0 110.051 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.553 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 77.9 t -55.93 -42.89 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.218 -0.926 . . . . 50.0 110.51 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.466 ' OG1' ' HB2' ' A' ' 82' ' ' GLU . 1.4 m -73.76 169.49 17.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.162 -0.961 . . . . 50.0 110.173 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 67' ' ' ASN . 23.3 t -44.65 170.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.236 -0.915 . . . . 50.0 110.114 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.646 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . 60.7 m-80 -47.08 157.7 0.48 Allowed Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.243 -0.91 . . . . 50.0 109.979 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.863 ' C ' HD12 ' A' ' 46' ' ' ILE . 45.4 Cg_endo -73.32 66.36 4.42 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 123.955 1.503 . . . . 50.0 110.58 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE2' ' CB ' ' A' ' 67' ' ' ASN . 16.7 m-30 -120.8 121.7 38.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 50.0 109.878 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.064 HG23 HD11 ' A' ' 46' ' ' ILE . 80.8 t -79.91 60.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 50.0 110.096 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -83.31 61.6 6.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.082 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -142.65 164.41 30.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.253 -0.905 . . . . 50.0 110.335 -179.758 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 p -94.08 -10.79 32.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 50.0 109.874 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 67.4 m -120.95 18.24 11.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -0.872 . . . . 99.989999999999995 110.253 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.842 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -81.98 11.44 5.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.136 -0.977 . . . . 99.989999999999995 110.073 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.1 m-20 -85.22 15.06 4.51 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.253 -0.904 . . . . 99.989999999999995 109.337 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 9.3 p -124.27 -171.98 2.45 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.464 -0.773 . . . . 99.989999999999995 109.574 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.484 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 11.8 pttt -62.87 88.86 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.559 -0.856 . . . . 99.989999999999995 109.115 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.989 HG22 ' O ' ' A' ' 35' ' ' LEU . 22.2 m -76.52 174.42 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.41 -0.806 . . . . 99.989999999999995 109.651 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.445 HD23 ' O ' ' A' ' 33' ' ' ILE . 1.6 tt -138.8 120.39 15.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.977 -1.077 . . . . 50.0 110.942 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.426 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.0 t -116.91 172.69 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 50.0 109.9 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.553 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 83.7 mt-10 -120.69 154.75 35.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.142 -0.974 . . . . 50.0 110.339 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.527 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -146.14 140.39 26.64 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.332 -0.855 . . . . 50.0 110.027 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.43 62.87 0.92 Allowed Pre-proline 0 C--N 1.306 -1.315 0 O-C-N 121.258 -0.901 . . . . 50.0 110.712 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.527 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.4 Cg_endo -72.7 148.44 46.89 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 123.848 1.447 . . . . 50.0 110.357 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.817 ' HG3' HG12 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.66 152.51 59.19 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 123.963 1.507 . . . . 50.0 110.413 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -52.8 133.63 37.13 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.19 -0.944 . . . . 50.0 110.136 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.53 161.68 11.41 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.532 -1.427 . . . . 50.0 109.532 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.537 ' CB ' ' HB2' ' A' ' 53' ' ' SER . 5.4 p30 -53.01 155.24 2.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 50.0 110.108 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.513 ' HA ' ' N ' ' A' ' 53' ' ' SER . 17.6 p -143.03 137.98 29.65 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.229 -0.919 . . . . 50.0 110.387 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 1.2 m-30 -101.56 103.34 14.18 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.88 . . . . 50.0 110.275 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.739 ' H ' HD12 ' A' ' 92' ' ' ILE . 3.2 mp -101.5 138.95 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.201 -0.937 . . . . 50.0 109.871 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.517 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 75.5 t -125.37 113.73 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 50.0 110.785 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.646 HG11 ' CB ' ' A' ' 17' ' ' PHE . 41.3 t -101.97 91.54 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.958 . . . . 50.0 109.785 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.56 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.59 167.83 33.14 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.774 -1.33 . . . . 50.0 109.774 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.424 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ptp -108.38 -150.77 0.46 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -1.113 . . . . 50.0 110.08 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -73.7 -44.12 33.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.729 -1.348 . . . . 50.0 109.729 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 99' ' ' LYS . 39.5 t0 -74.98 -105.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.205 -1.174 . . . . 50.0 110.293 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.489 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 8.5 tttp -79.61 136.1 36.75 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.048 -1.032 . . . . 50.0 110.352 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.632 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.1 150.13 43.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.197 -0.939 . . . . 0.0 110.07 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 7.5 mt -115.72 146.98 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 24.0 p-10 -130.67 129.76 43.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -0.904 . . . . 0.0 110.469 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -135.48 163.79 29.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.442 -0.786 . . . . 0.0 110.018 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.627 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 10.3 p80 -134.39 164.15 28.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.931 . . . . 0.0 110.221 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 58.8 m95 . . . . . 0 C--N 1.305 -1.327 0 O-C-N 121.257 -0.902 . . . . 0.0 110.236 179.925 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 121.123 0.487 . . . . 50.0 110.208 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.689 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.7 p -148.6 107.53 3.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.112 -0.992 . . . . 99.989999999999995 110.567 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.642 HG21 HG12 ' A' ' 46' ' ' ILE . 6.7 m -160.84 42.12 0.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.679 -1.263 . . . . 99.989999999999995 110.602 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -65.14 -5.95 7.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.14 -0.975 . . . . 99.989999999999995 109.906 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 mmtm -83.44 61.21 6.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 50.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 1.061 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -101.44 142.44 32.82 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.204 -0.935 . . . . 50.0 109.668 179.45 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 t -127.13 97.58 4.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.154 -0.966 . . . . 50.0 110.197 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 11.4 p90 -63.0 118.06 7.3 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.36 -0.837 . . . . 50.0 110.04 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -102.22 -22.41 14.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.093 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -138.06 145.99 42.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 50.0 110.137 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.432 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 22.9 p30 -66.83 162.62 50.74 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 50.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.478 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.0 Cg_endo -72.14 114.48 3.99 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.966 1.509 . . . . 50.0 110.37 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -105.02 140.13 38.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.284 -0.885 . . . . 50.0 110.368 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -90.53 111.24 22.45 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.36 -0.837 . . . . 50.0 110.184 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.5 59.02 5.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.228 -0.92 . . . . 50.0 110.158 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 128.31 -128.16 5.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -132.59 89.21 2.61 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -1.205 . . . . 50.0 110.138 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 30' ' ' THR . . . 113.68 31.05 2.43 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.521 -1.431 . . . . 50.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.464 HG23 ' O ' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -154.95 111.19 3.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.214 -1.168 . . . . 50.0 110.343 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 57.7 t -109.27 147.88 13.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.295 -0.878 . . . . 50.0 110.253 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.67 HG12 ' CD2' ' A' ' 80' ' ' LEU . 0.4 OUTLIER -124.92 118.26 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 50.0 110.318 -179.913 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.719 ' O ' HD23 ' A' ' 80' ' ' LEU . 0.6 OUTLIER -116.04 149.54 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.311 -0.868 . . . . 50.0 109.785 179.64 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.502 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.7 OUTLIER -126.69 104.87 8.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.207 -0.933 . . . . 50.0 110.534 -179.653 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.997 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.78 144.52 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.319 -0.863 . . . . 50.0 109.302 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.569 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.23 133.51 39.02 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.031 -1.043 . . . . 50.0 110.028 -179.688 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.796 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.8 t80 -94.0 97.56 10.42 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.065 -1.054 . . . . 50.0 109.863 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 59.1 p -95.41 70.06 3.11 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.27 -0.894 . . . . 50.0 110.14 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -122.39 129.38 7.53 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.575 -1.41 . . . . 99.989999999999995 109.575 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.0 p -92.86 24.78 3.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.274 -1.133 . . . . 99.989999999999995 110.244 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.2 p30 -98.43 -1.32 41.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.084 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -168.63 24.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.461 -1.456 . . . . 99.989999999999995 109.461 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.619 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.7 Cg_endo -73.56 153.4 49.39 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.976 1.513 . . . . 99.989999999999995 110.324 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.689 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.29 161.33 8.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.34 -0.85 . . . . 50.0 110.002 -179.378 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.565 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -76.04 133.86 40.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.095 -1.003 . . . . 50.0 109.305 178.951 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.061 HD13 ' CZ ' ' A' ' 17' ' ' PHE . 9.5 mt -89.25 108.41 24.26 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 120.996 -1.065 . . . . 50.0 110.157 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 47.6 Cg_endo -74.49 99.99 1.27 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 124.043 1.549 . . . . 50.0 110.7 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.82 ' CG1' HG13 ' A' ' 94' ' ' VAL . 2.6 mt -126.55 150.34 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 50.0 110.172 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.621 HG22 HG23 ' A' ' 51' ' ' VAL . 2.7 p -128.21 130.43 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.416 -0.802 . . . . 50.0 109.983 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.498 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.1 OUTLIER -115.35 106.47 14.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 50.0 109.931 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.621 HG23 HG22 ' A' ' 49' ' ' VAL . 2.9 t -132.78 163.09 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.187 -0.946 . . . . 50.0 110.698 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.511 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -56.24 164.43 1.31 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.485 -0.759 . . . . 50.0 110.393 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.647 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -58.69 122.28 13.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.441 -0.787 . . . . 50.0 110.598 -179.602 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.647 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 81.17 29.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.594 -0.691 . . . . 50.0 110.906 179.627 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.538 ' CB ' HG12 ' A' ' 51' ' ' VAL . 14.7 m120 -132.99 84.35 2.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 50.0 109.995 178.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 56' ' ' ASP . 10.4 m-20 -106.7 18.09 22.34 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.164 -0.96 . . . . 50.0 110.349 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 18.4 mtt -125.0 -8.93 7.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 50.0 110.474 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.635 HG22 ' HD2' ' A' ' 59' ' ' PRO . 0.2 OUTLIER -136.2 144.29 47.33 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.151 -0.968 . . . . 50.0 110.391 -179.854 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.635 ' HD2' HG22 ' A' ' 58' ' ' THR . 47.1 Cg_endo -74.48 125.8 9.85 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.036 1.545 . . . . 50.0 110.239 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.511 HG11 ' HB2' ' A' ' 52' ' ' ALA . 75.0 t -139.2 -36.22 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 50.0 110.093 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -79.49 161.65 46.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.023 -1.631 . . . . 50.0 109.023 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -123.63 156.92 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 50.0 110.532 -179.527 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.467 ' HA ' ' HG3' ' A' ' 83' ' ' MET . 1.2 mt -107.16 132.75 52.69 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.314 -0.866 . . . . 50.0 109.944 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 27.2 t -63.71 -17.27 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -0.946 . . . . 50.0 110.451 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 66' ' ' VAL . 6.2 t -147.11 167.42 24.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 50.0 110.193 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 67' ' ' ASN . 21.2 t -47.16 173.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 50.0 110.02 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.566 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 5.4 p30 -46.73 138.26 7.05 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.202 -0.936 . . . . 50.0 110.239 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.479 ' HB2' HD12 ' A' ' 46' ' ' ILE . 46.7 Cg_endo -74.01 103.05 1.6 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.934 1.492 . . . . 50.0 110.38 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.566 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -113.8 134.01 55.04 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.18 -0.95 . . . . 50.0 110.495 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.818 HG13 ' CB ' ' A' ' 75' ' ' ALA . 61.9 t -87.63 60.46 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 50.0 109.684 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.619 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.9 57.42 4.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.295 -0.878 . . . . 50.0 110.021 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.43 169.01 18.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 50.0 110.424 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.87 -7.15 34.19 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.872 . . . . 50.0 109.909 179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.11 12.59 11.12 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.31 -0.869 . . . . 99.989999999999995 110.242 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.818 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -77.15 6.82 5.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.079 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.555 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 2.4 m120 -84.62 19.56 1.97 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.333 -0.855 . . . . 99.989999999999995 109.384 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.672 ' O ' HG13 ' A' ' 79' ' ' VAL . 31.0 m -121.09 -172.54 2.42 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.414 -0.804 . . . . 99.989999999999995 109.177 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.444 ' HB3' ' OE2' ' A' ' 34' ' ' GLU . 6.8 mttp -63.21 88.06 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.235 -0.915 . . . . 99.989999999999995 109.064 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.997 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.2 m -76.95 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.331 -0.856 . . . . 99.989999999999995 109.318 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.719 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.4 OUTLIER -133.87 130.36 37.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.785 -1.197 . . . . 50.0 111.1 -179.66 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.5 t -120.45 168.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.476 -0.765 . . . . 50.0 109.947 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.5 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 4.0 mt-10 -132.96 147.99 52.28 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.179 -0.951 . . . . 50.0 110.176 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -146.83 143.17 28.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.214 -0.929 . . . . 50.0 110.393 -179.853 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.46 ' O ' ' HB2' ' A' ' 62' ' ' ARG . 0.2 OUTLIER -117.95 68.56 6.65 Favored Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.115 -0.991 . . . . 50.0 110.477 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.404 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.86 161.44 41.48 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 O-C-N 123.975 1.513 . . . . 50.0 110.358 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.425 ' HD3' ' HA2' ' A' ' 61' ' ' GLY . 45.8 Cg_endo -73.43 146.7 40.12 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 124.003 1.528 . . . . 50.0 110.446 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 87' ' ' PHE . 0.8 OUTLIER -52.74 135.18 35.82 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.281 -0.887 . . . . 50.0 110.07 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 124.81 165.63 12.19 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.52 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 92.8 m-20 -62.2 135.42 57.48 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -1.193 . . . . 50.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.572 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.7 OUTLIER -132.27 145.27 51.18 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.308 -0.87 . . . . 50.0 110.138 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.616 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.9 m-30 -100.74 113.16 25.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.081 -1.012 . . . . 50.0 110.026 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.5 mp -109.06 131.1 60.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 50.0 110.108 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 49' ' ' VAL . 71.3 t -124.89 118.86 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.17 -0.956 . . . . 50.0 110.437 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.82 HG13 ' CG1' ' A' ' 48' ' ' ILE . 21.7 t -101.41 93.78 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 50.0 109.88 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.524 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -156.15 170.73 33.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.784 -1.326 . . . . 50.0 109.784 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.544 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 15.9 ptp -112.2 -28.33 7.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.262 -1.14 . . . . 50.0 109.919 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' GLY . . . . . 0.544 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 171.3 -61.56 0.17 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -64.0 -108.41 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.232 -1.158 . . . . 50.0 110.268 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -79.62 127.98 32.83 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.093 -1.004 . . . . 50.0 110.182 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.77 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.8 pp0? -136.16 150.2 48.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.231 -0.918 . . . . 0.0 110.226 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.522 ' CG1' ' HB ' ' A' ' 94' ' ' VAL . 32.4 pt -102.95 148.94 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.974 -1.079 . . . . 0.0 110.186 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -132.27 142.39 49.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 110.397 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -128.46 166.74 18.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 110.193 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.586 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 43.2 p-80 -118.61 85.36 2.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.327 -0.858 . . . . 0.0 110.346 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.494 ' C ' ' CD1' ' A' ' 105' ' ' TRP . 1.7 t-105 . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.156 -0.965 . . . . 0.0 110.051 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.56 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.107 0.479 . . . . 50.0 110.016 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.664 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 12.2 p -148.83 108.01 3.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 110.655 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.733 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.43 44.04 0.16 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.876 -1.14 . . . . 99.989999999999995 110.489 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.419 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.4 OUTLIER -76.83 10.43 2.25 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.147 -0.97 . . . . 99.989999999999995 110.615 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.492 ' HE2' ' HA2' ' A' ' 39' ' ' GLY . 0.0 OUTLIER -111.48 61.85 0.61 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.028 -1.045 . . . . 50.0 110.59 -179.964 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.883 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -94.68 148.74 21.96 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.093 -1.004 . . . . 50.0 109.994 179.603 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.607 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 28.6 t -125.15 114.31 18.85 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 50.0 110.153 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.691 ' CD1' HD23 ' A' ' 35' ' ' LEU . 9.7 m-85 -64.94 112.92 3.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.26 -0.9 . . . . 50.0 110.188 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.538 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -96.51 -32.94 12.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.19 -0.944 . . . . 50.0 110.152 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.504 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.5 OUTLIER -138.96 163.03 33.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 50.0 110.229 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.449 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 36.7 p-10 -76.89 164.3 60.06 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 50.0 110.134 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HB2' HG11 ' A' ' 31' ' ' VAL . 44.6 Cg_endo -71.19 126.78 12.7 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.431 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -121.53 148.83 43.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.22 -0.925 . . . . 50.0 110.344 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 10.3 t70 -94.62 122.07 36.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 50.0 110.203 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.44 HG23 ' CG2' ' A' ' 32' ' ' VAL . 7.1 p -79.35 -51.33 9.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.166 -0.959 . . . . 50.0 110.278 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.425 ' O ' ' OD1' ' A' ' 25' ' ' ASP . . . -128.59 -108.1 1.38 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.641 -1.384 . . . . 50.0 109.641 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -127.11 108.37 10.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.127 . . . . 50.0 110.296 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 85.19 31.28 23.14 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.632 -1.387 . . . . 50.0 109.632 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.425 ' HA ' HG21 ' A' ' 64' ' ' VAL . 1.1 p -145.36 107.92 4.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.149 -1.207 . . . . 50.0 110.361 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 21.4 t -104.24 148.59 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 O-C-N 121.342 -0.849 . . . . 50.0 110.175 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.44 ' CG2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -122.65 132.81 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 50.0 110.406 -179.882 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.832 HG23 HD11 ' A' ' 35' ' ' LEU . 8.4 tp -128.49 133.6 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.335 -0.853 . . . . 50.0 109.781 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.538 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 8.9 tt0 -108.54 111.34 23.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.187 -0.946 . . . . 50.0 110.572 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.938 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -125.2 143.12 51.1 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.32 -0.862 . . . . 50.0 109.183 179.299 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -89.45 126.01 35.4 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.98 -1.075 . . . . 50.0 109.925 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.583 ' CE1' ' HA3' ' A' ' 39' ' ' GLY . 1.3 t80 -93.56 101.77 13.96 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.987 -1.085 . . . . 50.0 109.357 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 79.5 p -96.36 69.73 2.66 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.281 -0.887 . . . . 50.0 110.261 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.583 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -117.47 130.77 9.01 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.334 -1.506 . . . . 99.989999999999995 109.334 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 36.9 m -84.42 25.55 0.86 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -1.176 . . . . 99.989999999999995 110.539 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.08 -0.91 26.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.077 -1.014 . . . . 99.989999999999995 110.219 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.33 -157.99 28.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.409 -1.477 . . . . 99.989999999999995 109.409 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.22 137.24 28.29 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.923 1.486 . . . . 99.989999999999995 110.265 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.664 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -153.02 161.18 42.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.855 . . . . 50.0 110.107 -179.432 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.568 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 26.8 mmtt -75.68 130.93 39.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 50.0 109.157 178.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.101 HD11 ' CG2' ' A' ' 70' ' ' VAL . 20.1 mt -89.71 107.31 18.0 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.088 -1.007 . . . . 50.0 110.672 -179.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.2 Cg_endo -74.84 100.7 1.37 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.031 1.543 . . . . 50.0 110.078 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.958 ' CG2' HD11 ' A' ' 92' ' ' ILE . 66.1 mt -135.87 146.83 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.165 -0.96 . . . . 50.0 110.563 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.535 HG22 ' HB ' ' A' ' 93' ' ' VAL . 15.7 m -121.41 161.7 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.353 -0.842 . . . . 50.0 109.664 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -132.72 104.33 6.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.127 -0.983 . . . . 50.0 110.119 -179.846 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.558 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.4 m -127.22 158.96 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.295 -0.878 . . . . 50.0 110.017 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB3' ' CG ' ' A' ' 55' ' ' ASN . . . -55.83 163.35 1.46 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.361 -0.837 . . . . 50.0 110.054 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.632 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.0 OUTLIER -59.53 118.53 6.16 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.255 -0.903 . . . . 50.0 110.454 -179.534 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.632 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.2 tp 79.53 30.51 0.29 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.568 -0.707 . . . . 50.0 110.673 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.4 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 6.5 m120 -124.51 84.87 2.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.284 -0.885 . . . . 50.0 110.341 179.266 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.77 9.82 40.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 50.0 109.88 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.8 mtt -123.44 -12.88 7.7 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 50.0 110.106 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.6 m -130.26 119.02 18.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.378 -0.826 . . . . 50.0 110.035 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.473 ' C ' HG23 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.55 136.94 29.42 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.922 1.485 . . . . 50.0 110.162 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.6 HG12 ' HG3' ' A' ' 86' ' ' PRO . 44.7 t -148.24 -37.37 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.176 -0.953 . . . . 50.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.81 145.18 37.95 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.817 -1.713 . . . . 50.0 108.817 179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.451 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.1 mmp_? -124.06 157.26 34.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.991 -1.3 . . . . 50.0 110.53 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.4 mt -101.67 127.43 48.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.298 -0.876 . . . . 50.0 109.731 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.528 HG11 ' CD ' ' A' ' 82' ' ' GLU . 22.8 t -64.5 -13.19 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 50.0 110.262 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' VAL . 14.0 t -140.8 165.97 26.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.215 -0.928 . . . . 50.0 110.215 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.797 HG12 ' H ' ' A' ' 67' ' ' ASN . 3.8 t -55.07 -170.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 50.0 109.881 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.797 ' H ' HG12 ' A' ' 66' ' ' VAL . 1.3 t-20 -46.31 132.66 7.62 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.023 -1.048 . . . . 50.0 110.08 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.719 ' O ' HD12 ' A' ' 46' ' ' ILE . 46.9 Cg_endo -73.51 75.36 3.01 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.042 1.549 . . . . 50.0 110.554 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.612 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.8 p90 -95.15 136.94 34.87 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.239 -0.913 . . . . 50.0 110.141 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.101 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.3 t -97.12 60.58 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 50.0 109.649 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -71.33 59.48 0.28 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.341 -0.849 . . . . 50.0 110.238 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.428 ' CG2' HG12 ' A' ' 70' ' ' VAL . 2.4 t -142.62 164.66 29.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 50.0 110.257 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.7 t -84.26 11.25 8.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.137 -0.977 . . . . 50.0 110.081 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -121.63 13.64 10.87 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 99.989999999999995 110.358 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.621 ' HB2' HG12 ' A' ' 70' ' ' VAL . . . -61.9 -10.98 10.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.18 -0.95 . . . . 99.989999999999995 110.172 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.496 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 63.5 m-20 -86.49 20.91 2.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.143 -0.973 . . . . 99.989999999999995 109.351 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.496 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.5 OUTLIER -132.69 -173.24 3.12 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.725 -179.872 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.477 ' HG3' ' OG ' ' A' ' 36' ' ' SER . 0.8 OUTLIER -64.34 89.56 0.06 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.196 179.256 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.938 HG22 ' O ' ' A' ' 35' ' ' LEU . 27.0 m -75.74 174.83 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.221 -0.924 . . . . 99.989999999999995 109.165 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.69 134.29 44.61 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.764 -1.21 . . . . 50.0 111.432 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.8 t -121.03 178.25 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.736 . . . . 50.0 109.696 179.458 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.528 ' CD ' HG11 ' A' ' 64' ' ' VAL . 10.5 tt0 -143.69 138.78 29.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.172 -0.955 . . . . 50.0 110.342 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.409 ' HG2' ' O ' ' A' ' 62' ' ' ARG . 2.4 mtm -147.25 145.44 29.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.151 -0.968 . . . . 50.0 110.383 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.498 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -118.07 70.05 7.66 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 121.341 -0.849 . . . . 50.0 110.563 -179.999 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.11 162.28 39.16 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.012 1.533 . . . . 50.0 110.126 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.6 ' HG3' HG12 ' A' ' 60' ' ' VAL . 47.1 Cg_endo -72.7 150.28 50.15 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 123.896 1.472 . . . . 50.0 110.335 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.54 120.56 5.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.197 -0.94 . . . . 50.0 110.029 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 134.64 178.31 15.56 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.562 -1.415 . . . . 50.0 109.562 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.42 ' HA ' ' O ' ' A' ' 105' ' ' TRP . 25.3 p-10 -77.17 141.05 40.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -1.14 . . . . 50.0 110.208 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.568 ' HA ' ' N ' ' A' ' 53' ' ' SER . 53.6 p -135.11 150.62 50.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 50.0 110.164 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.612 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 0.5 OUTLIER -96.94 105.02 17.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 50.0 110.275 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.958 HD11 ' CG2' ' A' ' 48' ' ' ILE . 0.0 OUTLIER -96.06 136.4 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.226 -0.921 . . . . 50.0 109.505 179.664 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.953 ' N ' HD13 ' A' ' 92' ' ' ILE . 33.5 t -123.84 117.54 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.131 -0.98 . . . . 50.0 110.88 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.756 HG13 HG12 ' A' ' 48' ' ' ILE . 97.0 t -106.14 95.03 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.328 -0.857 . . . . 50.0 109.893 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.59 170.3 33.51 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.665 -1.374 . . . . 50.0 109.665 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 9.2 mtm -80.4 -63.52 1.39 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -1.157 . . . . 50.0 110.178 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -156.06 -68.48 0.01 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.561 -1.416 . . . . 50.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -71.14 -75.58 0.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -1.11 . . . . 50.0 110.279 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -79.67 119.62 22.86 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.289 -0.882 . . . . 50.0 110.305 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.472 ' HB3' ' HA3' ' A' ' 95' ' ' GLY . 0.0 OUTLIER -140.54 148.72 41.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 110.091 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.7 mm -98.69 111.46 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.12 -0.988 . . . . 0.0 110.039 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 36.7 p-10 -101.57 130.37 47.86 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.154 -0.966 . . . . 0.0 110.275 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.601 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -128.93 170.62 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.355 -0.841 . . . . 0.0 110.324 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.477 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 50.0 p-80 -123.7 125.33 44.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.33 -0.857 . . . . 0.0 110.127 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.744 ' CZ3' HG21 ' A' ' 92' ' ' ILE . 9.1 m0 . . . . . 0 C--N 1.304 -1.397 0 O-C-N 121.182 -0.949 . . . . 0.0 110.328 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 3.4 mtm . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.157 0.503 . . . . 50.0 110.37 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.641 ' O ' HG23 ' A' ' 14' ' ' THR . 0.1 OUTLIER -112.24 -175.5 2.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 99.989999999999995 109.929 179.674 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.674 ' HA ' ' HG3' ' A' ' 47' ' ' PRO . 21.8 p -158.24 -76.55 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.342 -0.849 . . . . 99.989999999999995 110.307 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.538 ' O ' ' CG ' ' A' ' 15' ' ' GLU . 20.6 tt0 -118.76 8.46 11.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 110.351 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.534 ' HB3' ' CD1' ' A' ' 37' ' ' TYR . 0.9 OUTLIER -56.04 81.97 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.349 -0.845 . . . . 50.0 111.021 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.967 ' CD2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.26 142.06 12.7 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.174 -0.954 . . . . 50.0 110.205 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 m -127.75 97.46 4.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -0.892 . . . . 50.0 110.267 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p90 -57.12 119.55 6.53 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.25 -0.906 . . . . 50.0 110.249 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.15 -21.94 12.8 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.33 -0.856 . . . . 50.0 110.101 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.484 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 14.8 mttm -145.02 149.69 35.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.968 . . . . 50.0 110.278 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -67.66 159.45 78.48 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.849 . . . . 50.0 110.279 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.7 Cg_endo -72.93 134.16 21.13 Favored 'Trans proline' 0 C--N 1.303 -1.818 0 O-C-N 124.013 1.533 . . . . 50.0 110.401 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -130.51 155.32 46.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.231 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -83.69 148.46 27.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.232 -0.917 . . . . 50.0 110.122 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.62 22.22 3.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.193 -0.942 . . . . 50.0 110.207 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.28 -133.71 3.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.577 -1.409 . . . . 50.0 109.577 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -104.77 92.78 4.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -1.129 . . . . 50.0 110.343 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 84' ' ' GLU . . . 80.41 30.83 39.46 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.627 -1.389 . . . . 50.0 109.627 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 p -122.59 107.62 12.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.2 -1.176 . . . . 50.0 110.275 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 18.3 t -100.11 145.19 11.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.276 -0.89 . . . . 50.0 110.099 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -122.42 148.9 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.147 -0.971 . . . . 50.0 110.388 -179.73 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.824 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.1 tt -148.17 156.37 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 50.0 109.65 179.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.548 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 17.3 tt0 -126.09 103.81 7.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.117 -0.989 . . . . 50.0 110.696 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.951 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -121.84 140.17 52.72 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.349 -0.845 . . . . 50.0 109.263 179.4 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.547 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -92.7 132.84 36.58 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.044 -1.035 . . . . 50.0 110.107 -179.563 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.534 ' CD1' ' HB3' ' A' ' 16' ' ' LYS . 9.4 t80 -94.88 103.05 14.92 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.088 -1.045 . . . . 50.0 109.742 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 t -96.48 69.7 2.6 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.313 -0.867 . . . . 50.0 109.929 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.48 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -112.89 130.57 9.58 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.661 -1.376 . . . . 99.989999999999995 109.661 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.52 5.72 10.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 99.989999999999995 110.344 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.27 -1.35 42.1 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.213 -0.93 . . . . 99.989999999999995 110.116 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' CE2' ' A' ' 37' ' ' TYR . . . 80.93 -131.91 10.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.457 -1.457 . . . . 99.989999999999995 109.457 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.58 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 45.6 Cg_endo -73.0 131.01 16.21 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.888 1.467 . . . . 99.989999999999995 110.441 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.484 ' SG ' ' CE1' ' A' ' 37' ' ' TYR . 30.5 p -147.81 161.84 40.45 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.323 -0.861 . . . . 50.0 110.126 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.572 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 17.2 mmtt -87.23 108.67 19.04 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 50.0 109.929 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.967 HG21 ' CD2' ' A' ' 17' ' ' PHE . 4.2 mt -84.51 116.48 65.33 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 50.0 110.353 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.674 ' HG3' ' HA ' ' A' ' 14' ' ' THR . 47.2 Cg_endo -71.94 104.7 1.68 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 124.117 1.588 . . . . 50.0 110.344 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.013 HG12 HG22 ' A' ' 94' ' ' VAL . 1.2 mt -125.86 151.15 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 50.0 110.233 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.578 HG22 HG13 ' A' ' 51' ' ' VAL . 5.8 p -132.99 141.29 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.913 . . . . 50.0 110.051 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.528 ' O ' ' N ' ' A' ' 61' ' ' GLY . 3.5 m -115.64 104.79 12.05 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.311 -0.868 . . . . 50.0 109.887 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.578 HG13 HG22 ' A' ' 49' ' ' VAL . 30.4 m -131.78 162.94 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.265 -0.897 . . . . 50.0 110.322 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -55.58 163.97 1.17 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.422 -0.799 . . . . 50.0 110.18 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.636 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 10.2 t -63.15 118.26 7.68 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 50.0 110.711 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.599 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 77.21 30.76 0.52 Allowed 'General case' 0 N--CA 1.496 1.829 0 C-N-CA 119.876 -0.73 . . . . 50.0 110.765 179.485 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.48 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 10.5 m120 -134.9 84.95 2.14 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 50.0 110.032 179.124 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -104.53 18.54 22.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.273 -0.892 . . . . 50.0 110.373 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 ttt -102.87 -24.98 13.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -0.961 . . . . 50.0 110.136 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.41 138.59 27.28 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.462 -0.774 . . . . 50.0 110.196 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.468 ' HA ' HG12 ' A' ' 51' ' ' VAL . 47.0 Cg_endo -72.37 133.23 20.51 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.997 1.525 . . . . 50.0 110.361 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.7 t -143.86 -36.41 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.158 -0.964 . . . . 50.0 110.277 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.11 159.21 50.3 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.052 -1.619 . . . . 50.0 109.052 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.485 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 14.8 mtt-85 -129.36 156.22 44.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.049 -1.265 . . . . 50.0 110.372 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.757 HD23 ' HG3' ' A' ' 83' ' ' MET . 56.6 mt -94.89 124.67 39.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.276 -0.89 . . . . 50.0 110.132 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.673 HG23 ' N ' ' A' ' 84' ' ' GLU . 54.5 t -70.54 -38.93 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.198 -0.939 . . . . 50.0 110.122 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.73 175.72 6.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.317 -0.864 . . . . 50.0 110.086 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.6 m -57.92 -175.02 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.217 -0.927 . . . . 50.0 110.315 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.493 ' HB2' ' CD1' ' A' ' 69' ' ' PHE . 9.5 m-20 -46.93 156.91 0.51 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.264 -0.897 . . . . 50.0 110.045 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.643 ' HB2' HD12 ' A' ' 48' ' ' ILE . 48.1 Cg_endo -74.61 65.61 5.68 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.931 1.49 . . . . 50.0 110.9 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.604 ' CD2' ' O ' ' A' ' 69' ' ' PHE . 49.0 p90 -132.45 121.79 23.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.114 -0.991 . . . . 50.0 110.187 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.713 ' HB ' ' HB1' ' A' ' 75' ' ' ALA . 6.8 m -88.19 60.85 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.061 -1.024 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.58 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -66.09 65.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.3 -0.875 . . . . 50.0 110.307 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.564 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 1.5 m -142.49 159.26 42.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.2 -0.937 . . . . 50.0 110.244 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -86.16 -13.23 47.67 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.296 -0.878 . . . . 50.0 109.908 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.1 p -114.79 15.81 17.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.381 -0.824 . . . . 99.989999999999995 110.057 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.713 ' HB1' ' HB ' ' A' ' 70' ' ' VAL . . . -81.13 9.79 6.27 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 109.959 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.512 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 84.5 m-20 -85.2 16.86 3.31 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.335 -0.853 . . . . 99.989999999999995 109.441 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.628 ' O ' HG13 ' A' ' 79' ' ' VAL . 19.0 t -121.66 -172.44 2.43 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.412 -0.805 . . . . 99.989999999999995 109.352 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.483 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 2.4 mttp -62.96 88.33 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.442 -0.903 . . . . 99.989999999999995 109.068 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 35' ' ' LEU . 24.3 m -76.68 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.391 -0.818 . . . . 99.989999999999995 109.832 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -123.51 129.65 51.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.971 -1.08 . . . . 50.0 110.953 -179.642 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.476 HG23 ' CD1' ' A' ' 35' ' ' LEU . 2.0 t -116.35 178.03 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.388 -0.82 . . . . 50.0 109.872 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.488 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 66.2 mt-10 -153.3 151.0 29.5 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.069 -1.02 . . . . 50.0 110.354 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.757 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -149.54 130.86 14.65 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.236 -0.915 . . . . 50.0 110.267 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.673 ' N ' HG23 ' A' ' 64' ' ' VAL . 0.1 OUTLIER -106.57 72.72 0.3 Allowed Pre-proline 0 C--N 1.306 -1.285 0 O-C-N 121.255 -0.903 . . . . 50.0 110.802 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.505 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.1 Cg_endo -73.0 170.36 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.842 1.443 . . . . 50.0 110.089 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.35 157.0 57.83 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 123.974 1.513 . . . . 50.0 110.479 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -52.84 125.45 17.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.275 -0.891 . . . . 50.0 110.136 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 129.25 -161.15 22.68 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.51 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 15.3 p-10 -99.4 129.47 45.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.202 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 65.3 p -122.12 152.06 40.28 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.391 -0.818 . . . . 50.0 110.092 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.676 ' CZ ' ' CD2' ' A' ' 104' ' ' HIS . 1.8 m-30 -106.2 118.83 37.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 50.0 110.27 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.7 mp -109.08 133.32 54.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.259 -0.901 . . . . 50.0 109.83 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 18.7 t -123.61 128.21 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.038 -1.039 . . . . 50.0 110.769 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 1.013 HG22 HG12 ' A' ' 48' ' ' ILE . 35.5 t -107.82 88.77 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 50.0 109.98 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.499 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.84 -179.8 31.19 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.841 -1.304 . . . . 50.0 109.841 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.565 ' CE ' ' HB ' ' A' ' 14' ' ' THR . 3.8 ptp -99.05 -32.64 11.17 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -1.131 . . . . 50.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 175.86 -72.03 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.534 -1.427 . . . . 50.0 109.534 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -65.97 -82.82 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.239 -1.154 . . . . 50.0 110.102 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 118.24 21.32 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.209 -0.932 . . . . 50.0 110.182 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.538 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -140.32 148.77 41.86 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 110.308 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 66.2 mt -93.06 105.84 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.116 -0.99 . . . . 0.0 109.926 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -93.83 136.37 34.18 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.14 -0.975 . . . . 0.0 110.536 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.53 159.7 35.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.251 -0.905 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.676 ' CD2' ' CZ ' ' A' ' 91' ' ' TYR . 7.1 m170 -118.98 106.84 12.84 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.351 -0.843 . . . . 0.0 110.589 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.421 ' CE3' ' HG2' ' A' ' 23' ' ' PRO . 1.3 t-105 . . . . . 0 N--CA 1.486 1.34 0 O-C-N 121.221 -0.924 . . . . 0.0 110.146 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.539 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.7 mtt . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 121.217 0.532 . . . . 50.0 110.334 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.675 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 10.7 p -148.71 108.2 3.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.312 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.502 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 0.3 OUTLIER -160.54 61.7 0.32 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.888 -1.133 . . . . 99.989999999999995 110.55 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.458 ' HG3' ' HD2' ' A' ' 16' ' ' LYS . 0.5 OUTLIER -89.68 28.27 1.35 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.161 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.545 ' CD ' ' N ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -133.36 67.06 1.54 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 50.0 110.829 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.832 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -102.78 142.12 34.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.15 -0.969 . . . . 50.0 110.024 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -127.93 97.88 4.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.27 -0.894 . . . . 50.0 110.542 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.625 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 24.5 p90 -57.33 116.92 3.61 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.058 -1.026 . . . . 50.0 110.241 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.54 -18.05 14.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 50.0 109.994 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.516 ' HE2' ' HB2' ' A' ' 34' ' ' GLU . 21.1 mtmt -137.97 141.78 40.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.194 -0.941 . . . . 50.0 110.286 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 22' ' ' ASN . 16.0 p-10 -66.57 164.86 28.59 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.305 -0.872 . . . . 50.0 110.034 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.555 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 43.5 Cg_endo -71.09 136.46 29.56 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.983 1.517 . . . . 50.0 110.505 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' CG2' ' A' ' 32' ' ' VAL . . . -132.53 126.27 32.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.318 -0.864 . . . . 50.0 110.181 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.506 ' HA ' ' O ' ' A' ' 30' ' ' THR . 26.6 t0 -70.37 111.26 5.81 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.264 -0.898 . . . . 50.0 110.171 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.3 22.94 2.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -0.959 . . . . 50.0 110.243 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.04 -117.41 0.67 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.567 -1.413 . . . . 50.0 109.567 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 1.1 p80 -129.72 89.42 2.82 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.256 -1.144 . . . . 50.0 110.322 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 101.25 -2.67 54.5 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.609 -1.396 . . . . 50.0 109.609 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 16.5 p -102.17 107.83 19.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.17 -1.194 . . . . 50.0 110.242 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.555 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 16.0 t -102.59 135.88 37.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.233 -0.917 . . . . 50.0 110.081 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -120.98 132.83 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.184 -0.947 . . . . 50.0 110.208 -179.885 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.052 HD13 ' N ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -134.73 144.16 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 50.0 109.682 179.734 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 1.052 ' N ' HD13 ' A' ' 33' ' ' ILE . 6.4 tt0 -109.68 130.8 55.48 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.201 -0.937 . . . . 50.0 110.872 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.089 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.1 mp -135.39 134.49 39.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.357 -0.84 . . . . 50.0 109.237 179.233 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -79.89 121.84 25.92 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.991 -1.068 . . . . 50.0 109.236 -179.822 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.58 ' CZ ' ' HA3' ' A' ' 39' ' ' GLY . 10.1 t80 -91.61 106.16 18.27 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.584 -1.247 . . . . 50.0 109.458 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.79 69.84 3.41 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.367 -0.833 . . . . 50.0 110.09 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -121.62 127.86 7.06 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.541 -1.424 . . . . 99.989999999999995 109.541 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.3 p -87.96 28.28 1.06 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -1.117 . . . . 99.989999999999995 110.272 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.463 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.9 p-10 -110.28 -0.92 17.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -0.917 . . . . 99.989999999999995 110.247 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.37 -157.41 23.94 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.408 -1.477 . . . . 99.989999999999995 109.408 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.72 153.82 54.04 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.034 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.675 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.18 157.48 6.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.144 -0.973 . . . . 50.0 110.126 -179.489 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 0.4 OUTLIER -70.56 125.76 27.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 50.0 109.256 179.171 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.892 HD11 ' CG2' ' A' ' 70' ' ' VAL . 2.0 mt -80.98 110.48 17.81 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.164 -0.96 . . . . 50.0 110.481 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.541 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.6 Cg_endo -75.33 84.43 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.034 1.544 . . . . 50.0 110.204 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.768 HG12 HG13 ' A' ' 94' ' ' VAL . 71.2 mt -124.29 149.26 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.917 . . . . 50.0 110.457 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.623 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.1 m -116.81 142.88 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 50.0 109.844 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 61' ' ' GLY . 22.8 m -122.56 100.88 7.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 50.0 110.016 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.536 ' O ' ' N ' ' A' ' 91' ' ' TYR . 36.0 m -129.02 157.49 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.334 -0.854 . . . . 50.0 110.238 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -56.21 163.95 1.45 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.389 -0.82 . . . . 50.0 109.998 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 12.7 t -62.12 121.3 12.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.167 -0.958 . . . . 50.0 110.491 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.644 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 80.07 30.39 0.24 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.61 -0.681 . . . . 50.0 110.738 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.587 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 11.4 m120 -135.41 84.29 2.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.144 -0.972 . . . . 50.0 110.182 179.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -106.75 8.57 30.99 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 50.0 110.471 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.07 -18.01 14.72 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.134 -0.979 . . . . 50.0 110.424 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 p -136.18 146.42 56.28 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.372 -0.83 . . . . 50.0 110.15 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.57 132.67 17.76 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.108 1.583 . . . . 50.0 110.496 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.583 HG12 ' HG3' ' A' ' 86' ' ' PRO . 2.9 t -133.83 -59.42 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -0.866 . . . . 50.0 109.817 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.3 154.12 51.45 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.69 -1.764 . . . . 50.0 108.69 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.432 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 6.2 mtt180 -142.83 156.71 45.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.963 -1.316 . . . . 50.0 110.681 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 1.1 mt -86.23 138.41 31.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.193 -0.942 . . . . 50.0 109.998 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.586 HG22 ' HG2' ' A' ' 84' ' ' GLU . 76.2 t -91.64 -29.79 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 50.0 110.458 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.472 ' O ' ' O ' ' A' ' 66' ' ' VAL . 10.1 t -95.1 176.11 6.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 50.0 110.219 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.543 HG12 ' N ' ' A' ' 67' ' ' ASN . 53.8 t -44.34 171.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.294 -0.879 . . . . 50.0 110.225 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.543 ' N ' HG12 ' A' ' 66' ' ' VAL . 7.4 p-10 -46.86 162.2 0.27 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 50.0 109.973 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.507 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.66 90.89 0.8 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.97 1.51 . . . . 50.0 110.319 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 1.166 ' CE2' ' HB2' ' A' ' 71' ' ' ALA . 2.2 t80 -149.6 121.79 8.34 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 50.0 110.366 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.892 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.2 t -88.27 63.42 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.232 -0.918 . . . . 50.0 110.064 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.166 ' HB2' ' CE2' ' A' ' 69' ' ' PHE . . . -70.56 64.78 0.29 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.233 -0.917 . . . . 50.0 110.251 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 70' ' ' VAL . 6.5 t -142.62 154.82 44.73 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.233 -0.917 . . . . 50.0 110.256 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 t -77.82 -2.83 38.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 50.0 110.082 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -117.93 23.14 11.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.247 -0.908 . . . . 99.989999999999995 110.187 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.569 ' O ' ' HB3' ' A' ' 37' ' ' TYR . . . -65.3 -5.61 7.67 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.267 -0.896 . . . . 99.989999999999995 110.418 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.425 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 76.5 m-20 -85.23 22.86 1.38 Allowed 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.032 -1.043 . . . . 99.989999999999995 109.339 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.624 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -131.59 -173.24 3.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.291 -0.88 . . . . 99.989999999999995 109.635 -179.802 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 17.3 pttt -63.92 89.11 0.05 Allowed 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.705 -0.798 . . . . 99.989999999999995 109.103 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 1.089 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.4 m -76.07 176.31 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.317 -0.864 . . . . 99.989999999999995 109.358 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.21 145.02 47.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.84 -1.162 . . . . 50.0 111.019 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.761 ' CG1' HG22 ' A' ' 33' ' ' ILE . 14.5 p -132.52 175.7 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.359 -0.838 . . . . 50.0 109.861 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 81' ' ' VAL . 3.9 mt-10 -140.29 144.87 36.63 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.085 -1.009 . . . . 50.0 110.605 -179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -160.24 136.64 8.81 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.265 -0.897 . . . . 50.0 110.165 179.758 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.586 ' HG2' HG22 ' A' ' 64' ' ' VAL . 2.9 pt-20 -106.13 73.96 0.31 Allowed Pre-proline 0 C--N 1.305 -1.343 0 O-C-N 121.263 -0.898 . . . . 50.0 110.579 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.7 Cg_endo -72.41 169.9 20.59 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.166 179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.583 ' HG3' HG12 ' A' ' 60' ' ' VAL . 45.5 Cg_endo -72.18 136.93 27.79 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 123.983 1.517 . . . . 50.0 110.097 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -53.71 103.49 0.08 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.236 -0.915 . . . . 50.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.17 -173.04 33.46 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.421 -1.471 . . . . 50.0 109.421 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 105' ' ' TRP . 35.0 p-10 -69.34 145.52 52.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.275 -1.132 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.588 ' HA ' ' N ' ' A' ' 53' ' ' SER . 1.4 p -143.0 140.85 31.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.276 -0.89 . . . . 50.0 110.368 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.549 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 0.5 OUTLIER -97.13 119.94 36.56 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.217 -0.927 . . . . 50.0 109.532 179.567 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.46 HG23 ' O ' ' A' ' 92' ' ' ILE . 2.4 tt -114.96 132.08 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.141 -0.975 . . . . 50.0 110.38 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.623 ' HB ' HG22 ' A' ' 49' ' ' VAL . 45.3 t -120.74 120.81 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.054 -1.029 . . . . 50.0 110.405 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.768 HG13 HG12 ' A' ' 48' ' ' ILE . 62.0 t -109.0 99.64 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 50.0 110.107 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -153.64 160.44 29.28 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.616 -1.394 . . . . 50.0 109.616 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.463 ' SD ' ' HA ' ' A' ' 13' ' ' CYS . 4.4 ttm -115.5 -44.36 2.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -1.16 . . . . 50.0 110.271 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -115.32 -115.17 2.99 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.805 -1.318 . . . . 50.0 109.805 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.34 -35.07 17.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -1.133 . . . . 50.0 110.504 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -79.51 116.12 19.54 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.139 -0.976 . . . . 50.0 110.248 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.642 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.76 150.21 44.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -179.776 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.565 ' N ' HD12 ' A' ' 101' ' ' ILE . 4.4 mp -111.36 106.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.005 -1.059 . . . . 0.0 109.905 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.611 ' ND2' ' O ' ' A' ' 102' ' ' ASN . 0.6 OUTLIER -95.32 130.17 42.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 110.523 -179.703 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.605 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -115.38 160.79 19.41 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.373 -0.83 . . . . 0.0 109.834 179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.549 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 18.3 p-80 -121.6 86.64 2.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.198 -0.939 . . . . 0.0 110.386 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.496 ' O ' ' HA ' ' A' ' 89' ' ' ASP . 15.5 t-105 . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 110.051 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.8 ptm . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.281 0.562 . . . . 50.0 110.236 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.4 p -149.06 107.89 3.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.229 -0.919 . . . . 99.989999999999995 110.485 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.32 51.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.629 -1.294 . . . . 99.989999999999995 110.759 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.593 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 2.0 pt-20 -78.9 12.19 2.29 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.084 -1.01 . . . . 99.989999999999995 110.005 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mptt -101.48 61.29 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.243 -0.911 . . . . 50.0 110.388 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.689 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -100.41 144.17 29.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.11 -0.994 . . . . 50.0 109.66 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.53 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 30.6 t -127.28 100.13 5.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.065 -1.022 . . . . 50.0 110.658 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.657 ' HB3' ' HE2' ' A' ' 103' ' ' HIS . 10.2 p90 -59.02 107.94 0.6 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.202 -0.936 . . . . 50.0 110.258 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -94.58 -23.51 17.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.907 . . . . 50.0 109.824 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.475 ' HE3' ' OE1' ' A' ' 34' ' ' GLU . 13.0 mttt -142.11 143.81 33.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 50.0 110.084 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 43.9 p-10 -66.77 162.82 48.49 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 50.0 110.209 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 46.5 Cg_endo -73.0 135.07 22.52 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.947 1.498 . . . . 50.0 110.285 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -136.55 156.83 48.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.191 -0.943 . . . . 50.0 110.317 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.427 ' HA ' ' O ' ' A' ' 30' ' ' THR . 13.8 t70 -85.53 148.53 25.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 50.0 110.043 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.626 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -116.91 -5.89 11.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.251 -0.905 . . . . 50.0 110.194 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -172.67 -105.77 0.19 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.318 -1.513 . . . . 50.0 109.318 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.59 88.8 2.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 50.0 110.024 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.429 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 97.93 31.23 6.72 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.557 -1.417 . . . . 50.0 109.557 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.62 HG23 ' H ' ' A' ' 26' ' ' THR . 0.8 OUTLIER -136.62 107.85 6.82 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.22 -1.164 . . . . 50.0 110.431 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.447 HG23 ' HD2' ' A' ' 85' ' ' PRO . 21.7 t -97.01 145.48 8.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.253 -0.905 . . . . 50.0 110.118 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.626 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -126.27 137.74 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.236 -0.915 . . . . 50.0 110.486 -179.834 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.816 HG23 HD11 ' A' ' 35' ' ' LEU . 3.3 tt -140.33 152.86 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 50.0 109.893 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 21' ' ' LYS . 2.0 tt0 -127.02 108.04 10.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.154 -0.966 . . . . 50.0 110.304 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.055 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -122.7 138.97 54.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.252 -0.905 . . . . 50.0 109.544 179.588 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.9 OUTLIER -91.77 132.07 36.67 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.086 -1.009 . . . . 50.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.642 ' CD2' HG11 ' A' ' 70' ' ' VAL . 8.3 t80 -93.87 95.7 9.26 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.911 -1.115 . . . . 50.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 81.8 p -96.11 69.52 2.76 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.305 -0.872 . . . . 50.0 109.977 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -119.3 131.0 8.8 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.318 -1.513 . . . . 99.989999999999995 109.318 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.1 m -84.71 21.93 1.44 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -1.135 . . . . 99.989999999999995 110.227 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.01 -2.09 44.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.918 . . . . 99.989999999999995 109.984 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.69 -159.39 31.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.597 -1.401 . . . . 99.989999999999995 109.597 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.595 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.6 Cg_endo -72.85 148.64 46.35 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.137 1.598 . . . . 99.989999999999995 110.497 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.736 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -170.42 161.43 7.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.924 . . . . 50.0 110.129 -179.582 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.58 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -74.81 128.3 35.24 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.091 -1.006 . . . . 50.0 109.563 179.35 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.993 HD11 ' CG2' ' A' ' 70' ' ' VAL . 9.6 mt -87.73 114.31 58.44 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.118 -0.989 . . . . 50.0 110.52 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.509 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.1 Cg_endo -76.88 101.72 1.54 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.063 1.56 . . . . 50.0 110.398 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.993 HD11 ' CG2' ' A' ' 46' ' ' ILE . 2.4 mp -129.04 155.11 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -0.927 . . . . 50.0 110.302 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 92' ' ' ILE . 14.8 p -130.65 145.32 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.294 -0.879 . . . . 50.0 109.814 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.452 ' HB2' ' C ' ' A' ' 61' ' ' GLY . 61.5 m -122.76 111.25 16.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.134 -0.979 . . . . 50.0 109.895 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 55' ' ' ASN . 35.9 m -135.91 161.49 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 50.0 110.561 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.688 ' HB3' ' ND2' ' A' ' 55' ' ' ASN . . . -56.2 164.44 1.29 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.471 -0.768 . . . . 50.0 110.097 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.655 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 1.3 m -60.31 114.64 3.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 50.0 110.292 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 79.72 30.49 0.27 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.548 -0.72 . . . . 50.0 110.498 179.776 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.688 ' ND2' ' HB3' ' A' ' 52' ' ' ALA . 7.6 m-20 -122.5 85.02 2.35 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 50.0 110.302 179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.66 16.81 24.62 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.945 . . . . 50.0 110.059 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 ttt -126.12 -10.23 6.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.314 -0.866 . . . . 50.0 110.348 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.14 115.65 14.12 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.226 -0.921 . . . . 50.0 110.212 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.64 127.77 12.75 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.96 1.505 . . . . 50.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 2.2 m -148.07 -33.67 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.253 -0.904 . . . . 50.0 110.294 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.452 ' C ' ' HB2' ' A' ' 50' ' ' SER . . . -71.64 146.35 40.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HB2' ' A' ' 83' ' ' MET . 4.6 mtt180 -139.12 156.95 46.77 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.071 -1.252 . . . . 50.0 110.736 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.468 HD13 ' HD3' ' A' ' 68' ' ' PRO . 5.9 mt -88.34 141.5 28.5 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 50.0 109.975 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.528 ' CG1' ' OE1' ' A' ' 82' ' ' GLU . 92.5 t -85.42 -12.76 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 50.0 110.213 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.956 HG23 ' OE2' ' A' ' 82' ' ' GLU . 0.0 OUTLIER -111.54 175.74 5.3 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.23 -0.919 . . . . 50.0 110.152 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.2 m -58.14 176.16 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.296 -0.877 . . . . 50.0 110.067 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.62 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 75.3 m-20 -46.83 141.92 5.24 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.208 -0.932 . . . . 50.0 109.992 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.482 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 50.2 Cg_endo -76.81 70.04 6.65 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.93 1.489 . . . . 50.0 110.896 -179.585 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 11.2 p90 -110.11 129.67 55.66 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.057 -1.027 . . . . 50.0 110.269 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.993 ' CG2' HD11 ' A' ' 46' ' ' ILE . 94.0 t -85.65 60.84 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 50.0 110.097 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.595 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.77 57.4 4.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.172 -0.955 . . . . 50.0 110.006 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.71 169.63 17.39 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.269 -0.894 . . . . 50.0 110.288 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 p -97.43 -4.34 38.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 50.0 109.833 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 93.2 p -121.19 9.47 10.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.324 -0.86 . . . . 99.989999999999995 110.538 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.929 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -78.51 8.11 5.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.047 -1.033 . . . . 99.989999999999995 109.941 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 20.1 m-80 -86.11 20.03 2.44 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 109.281 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.664 ' O ' ' HA ' ' A' ' 36' ' ' SER . 3.7 m -124.41 -173.08 2.69 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.386 -0.821 . . . . 99.989999999999995 109.359 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.54 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.0 OUTLIER -63.19 88.62 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.42 -0.8 . . . . 99.989999999999995 109.267 179.564 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 1.055 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.3 m -76.68 174.62 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.359 -0.838 . . . . 99.989999999999995 109.658 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.406 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -125.74 131.74 52.47 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.933 -1.104 . . . . 50.0 110.786 -179.76 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -125.46 176.62 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 109.917 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.956 ' OE2' HG23 ' A' ' 65' ' ' THR . 8.4 pt-20 -160.22 156.26 26.25 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -0.998 . . . . 50.0 110.354 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.568 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.8 OUTLIER -160.05 140.12 11.56 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -0.875 . . . . 50.0 110.291 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.429 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -104.11 86.36 1.28 Allowed Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.386 -0.821 . . . . 50.0 110.466 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 83' ' ' MET . 45.4 Cg_endo -71.44 170.16 19.11 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.818 1.431 . . . . 50.0 110.409 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.13 163.2 39.44 Favored 'Trans proline' 0 C--N 1.304 -1.814 0 O-C-N 124.036 1.545 . . . . 50.0 110.414 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.56 127.68 23.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.301 -0.874 . . . . 50.0 110.036 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.94 152.95 12.83 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 89' ' ' ASP . 13.8 p30 -53.05 155.12 2.64 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 50.0 110.195 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.642 ' HA ' ' N ' ' A' ' 53' ' ' SER . 11.9 p -141.47 153.32 44.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.254 -0.904 . . . . 50.0 110.386 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.594 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.5 m-30 -104.72 119.72 39.67 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.253 -0.905 . . . . 50.0 110.119 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.789 HD13 ' N ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.91 129.7 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.166 -0.959 . . . . 50.0 110.027 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.789 ' N ' HD13 ' A' ' 92' ' ' ILE . 21.2 t -115.56 139.19 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.157 -0.965 . . . . 50.0 110.536 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.982 HG22 HG12 ' A' ' 48' ' ' ILE . 53.8 t -120.91 104.03 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.409 -0.807 . . . . 50.0 110.081 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.532 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.95 168.55 33.46 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.708 -1.357 . . . . 50.0 109.708 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.593 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 26.5 ttm -98.36 -71.41 0.69 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.244 -1.151 . . . . 50.0 110.296 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.95 36.38 0.3 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.508 -1.437 . . . . 50.0 109.508 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.44 ' OD1' ' OE1' ' A' ' 15' ' ' GLU . 0.9 OUTLIER -162.18 -46.96 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.328 -1.101 . . . . 50.0 109.823 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.53 129.93 39.72 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.364 -0.835 . . . . 50.0 109.709 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.783 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.96 150.42 44.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.707 -179.432 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 1.4 mp -112.08 123.91 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.131 -0.98 . . . . 0.0 109.761 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.514 ' CB ' HG22 ' A' ' 93' ' ' VAL . 9.4 p30 -101.0 139.44 36.68 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.17 -0.956 . . . . 0.0 110.686 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.657 ' HE2' ' HB3' ' A' ' 19' ' ' PHE . 5.6 m-70 -120.41 160.93 22.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.416 -0.802 . . . . 0.0 109.856 179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' A' ' 104' ' ' HIS . 51.7 p-80 -118.38 92.28 3.78 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.204 -0.935 . . . . 0.0 110.509 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 2.3 t-105 . . . . . 0 N--CA 1.488 1.457 0 O-C-N 121.158 -0.964 . . . . 0.0 110.035 179.668 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.511 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.4 mtt . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 121.149 0.499 . . . . 50.0 110.241 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.644 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.75 107.55 3.84 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.054 -1.029 . . . . 99.989999999999995 110.558 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.694 HG21 HG12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -161.75 35.84 0.13 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.006 -1.059 . . . . 99.989999999999995 110.213 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.611 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 1.1 pp20? -66.52 -5.44 11.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.451 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.563 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 8.8 mmtm -89.28 61.51 5.73 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 50.0 110.542 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.912 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.0 OUTLIER -95.02 141.78 28.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.102 -0.999 . . . . 50.0 110.128 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.521 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.12 97.9 4.93 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 50.0 110.035 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.67 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 10.5 p90 -59.53 123.92 18.41 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.021 -1.049 . . . . 50.0 110.457 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.614 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.4 -23.96 12.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.335 -0.853 . . . . 50.0 109.969 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 11.8 mtmt -142.33 151.5 42.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 50.0 110.105 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -67.53 162.31 57.75 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 50.0 110.153 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.574 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.1 Cg_endo -71.86 127.79 13.39 Favored 'Trans proline' 0 C--N 1.303 -1.816 0 O-C-N 124.052 1.554 . . . . 50.0 110.3 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.98 147.83 46.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.257 -0.902 . . . . 50.0 110.37 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 30' ' ' THR . 18.5 t0 -87.75 148.11 24.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.885 . . . . 50.0 110.143 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.16 -69.55 0.86 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.125 -0.984 . . . . 50.0 110.237 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.41 -101.81 1.58 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.533 -1.427 . . . . 50.0 109.533 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 34.0 t60 -131.96 89.01 2.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -1.152 . . . . 50.0 110.342 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 100.15 5.92 54.18 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.661 -1.375 . . . . 50.0 109.661 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 14.4 p -101.9 107.67 18.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -1.169 . . . . 50.0 110.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.574 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 39.0 t -102.53 139.85 22.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.177 -0.952 . . . . 50.0 110.19 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.431 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -123.13 150.69 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -0.95 . . . . 50.0 110.319 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.929 HG23 HD11 ' A' ' 35' ' ' LEU . 0.6 OUTLIER -136.96 154.03 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.399 -0.813 . . . . 50.0 109.75 179.689 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.614 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.1 tp10 -119.55 91.44 3.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.129 -0.982 . . . . 50.0 110.9 -179.468 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.95 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -119.03 138.79 52.6 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.289 -0.882 . . . . 50.0 109.081 179.274 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -93.78 135.16 35.37 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.06 -1.025 . . . . 50.0 110.175 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.563 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 5.8 t80 -94.38 103.34 15.33 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.964 -1.094 . . . . 50.0 109.558 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.82 69.6 3.38 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.22 -0.925 . . . . 50.0 110.038 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.483 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -118.46 139.33 14.47 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.439 -1.464 . . . . 99.989999999999995 109.439 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 40' ' ' SER . 2.6 t -82.95 31.08 0.43 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -1.124 . . . . 99.989999999999995 110.298 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.477 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -108.33 -11.96 15.12 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 99.989999999999995 110.243 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 -139.84 19.31 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.488 -1.445 . . . . 99.989999999999995 109.488 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.478 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -71.16 139.67 35.92 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.987 1.52 . . . . 99.989999999999995 110.248 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.625 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -169.38 157.57 7.51 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -0.867 . . . . 50.0 110.014 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.563 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.3 mmtt -76.34 129.15 36.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 50.0 109.178 178.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.931 HD11 HG22 ' A' ' 70' ' ' VAL . 10.3 mt -86.34 109.36 22.75 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 50.0 110.714 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.563 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 52.3 Cg_endo -78.98 99.42 1.26 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 O-C-N 124.056 1.556 . . . . 50.0 110.129 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.066 HG23 HD11 ' A' ' 92' ' ' ILE . 6.9 mt -136.11 144.01 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.072 -1.018 . . . . 50.0 110.471 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.459 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 23.0 m -116.19 148.54 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.399 -0.813 . . . . 50.0 109.835 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.5 OUTLIER -124.19 105.8 9.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.146 -0.971 . . . . 50.0 109.86 -179.932 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.489 ' O ' ' N ' ' A' ' 91' ' ' TYR . 4.3 m -129.7 159.49 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.281 -0.887 . . . . 50.0 110.34 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -55.94 163.72 1.41 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.856 . . . . 50.0 110.027 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.602 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 37.6 t -58.44 122.25 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.26 -0.9 . . . . 50.0 110.739 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.602 ' CB ' ' O ' ' A' ' 53' ' ' SER . 1.2 tp 78.32 30.56 0.41 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.919 -0.712 . . . . 50.0 110.827 179.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.419 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 10.3 m120 -126.66 84.11 2.23 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -0.957 . . . . 50.0 110.198 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -106.42 8.61 31.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.279 -0.888 . . . . 50.0 109.917 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.7 ttm -116.11 -13.26 11.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.418 -0.801 . . . . 50.0 110.131 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.16 134.06 19.96 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.368 -0.832 . . . . 50.0 110.104 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.79 134.75 22.41 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.941 1.495 . . . . 50.0 110.258 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.412 HG11 ' HB2' ' A' ' 52' ' ' ALA . 55.3 t -139.31 -46.87 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.237 -0.914 . . . . 50.0 109.848 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -75.43 156.35 48.27 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.67 -1.772 . . . . 50.0 108.67 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.45 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 15.3 mtp180 -138.04 157.15 46.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.881 -1.364 . . . . 50.0 110.722 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.754 HD22 ' HD3' ' A' ' 68' ' ' PRO . 1.1 mp -91.3 134.65 34.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 50.0 109.737 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.544 HG23 ' C ' ' A' ' 83' ' ' MET . 4.0 t -72.83 -40.91 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.167 -0.958 . . . . 50.0 110.147 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 ' OE1' ' A' ' 82' ' ' GLU . 14.9 t -103.43 175.79 5.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.17 -0.956 . . . . 50.0 110.165 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 66' ' ' VAL . 6.5 m -54.76 -172.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.394 -0.816 . . . . 50.0 110.098 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.603 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 1.8 m-20 -47.45 137.78 8.96 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.952 . . . . 50.0 110.073 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.754 ' HD3' HD22 ' A' ' 63' ' ' LEU . 48.0 Cg_endo -75.14 74.32 4.11 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.974 1.513 . . . . 50.0 110.707 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.603 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -107.27 141.32 38.78 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.141 -0.974 . . . . 50.0 110.282 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.931 HG22 HD11 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -103.69 60.26 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 50.0 109.358 179.398 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -69.67 57.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.359 -0.838 . . . . 50.0 110.364 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.427 ' N ' ' O ' ' A' ' 70' ' ' VAL . 0.0 OUTLIER -142.38 165.09 28.37 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 50.0 110.104 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.68 7.32 17.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.151 -0.968 . . . . 50.0 110.117 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 8.0 t -121.47 17.62 11.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.26 -0.9 . . . . 99.989999999999995 110.488 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -69.03 -4.11 15.68 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.153 -0.967 . . . . 99.989999999999995 109.93 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.471 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 64.1 m-80 -88.58 24.01 2.09 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.364 -0.835 . . . . 99.989999999999995 109.416 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -129.31 -173.19 2.93 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.368 -0.832 . . . . 99.989999999999995 109.442 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.52 ' N ' ' OG ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -63.7 88.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.114 179.507 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.95 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.8 m -76.45 174.35 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.292 -0.88 . . . . 99.989999999999995 109.199 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.431 HD21 HG12 ' A' ' 32' ' ' VAL . 1.3 tt -134.71 136.6 42.84 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.736 -1.227 . . . . 50.0 111.084 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.571 HG21 ' HE2' ' A' ' 17' ' ' PHE . 2.1 t -117.33 166.73 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.456 -0.777 . . . . 50.0 109.751 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.545 ' OE1' HG21 ' A' ' 65' ' ' THR . 5.6 mt-10 -134.75 146.34 49.29 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.071 -1.018 . . . . 50.0 110.271 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.544 ' C ' HG23 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -159.95 151.64 20.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.18 -0.95 . . . . 50.0 110.347 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.507 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -120.93 60.94 9.11 Favored Pre-proline 0 C--N 1.306 -1.286 0 O-C-N 121.239 -0.913 . . . . 50.0 110.509 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.429 ' HD3' ' C ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.34 158.78 47.94 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.073 1.565 . . . . 50.0 110.201 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.88 146.76 48.42 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.044 1.549 . . . . 50.0 110.453 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -52.97 146.89 10.14 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.269 -0.894 . . . . 50.0 110.062 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 122.71 172.75 14.03 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.394 -1.482 . . . . 50.0 109.394 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.469 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 11.4 m-20 -71.73 128.55 36.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.208 -1.171 . . . . 50.0 110.161 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.567 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.6 p -124.82 141.86 51.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 50.0 110.157 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.605 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -99.69 116.66 32.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.221 -0.924 . . . . 50.0 110.035 179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 1.066 HD11 HG23 ' A' ' 48' ' ' ILE . 0.0 OUTLIER -103.83 133.88 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 50.0 109.947 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.899 ' N ' HD13 ' A' ' 92' ' ' ILE . 11.1 t -118.33 119.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.572 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.841 HG11 ' HB2' ' A' ' 17' ' ' PHE . 33.6 t -100.6 103.34 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 50.0 109.958 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.434 ' O ' ' HB2' ' A' ' 47' ' ' PRO . . . -155.25 147.78 17.2 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.484 -1.446 . . . . 50.0 109.484 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.611 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 12.3 ptp -102.28 1.71 36.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.257 -1.143 . . . . 50.0 110.224 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.89 -60.05 0.55 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.38 -77.61 0.23 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.23 -1.159 . . . . 50.0 110.205 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.5 mmtt -79.57 124.0 28.11 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.221 -0.925 . . . . 50.0 110.313 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.453 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.19 148.56 41.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.267 -0.895 . . . . 0.0 110.249 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.1 pt -137.29 130.13 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.243 -0.91 . . . . 0.0 110.232 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.451 ' CB ' HG22 ' A' ' 93' ' ' VAL . 34.0 p-10 -109.46 132.31 54.25 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.21 -0.932 . . . . 0.0 110.394 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.67 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -122.12 169.9 10.4 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.24 -0.912 . . . . 0.0 110.061 179.866 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.605 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 45.5 p-80 -118.68 123.89 46.03 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.213 -0.929 . . . . 0.0 110.4 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.693 ' CH2' HD13 ' A' ' 33' ' ' ILE . 26.1 m0 . . . . . 0 C--N 1.304 -1.375 0 O-C-N 121.294 -0.879 . . . . 0.0 110.23 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.52 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 1.1 mtm . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.041 0.448 . . . . 50.0 110.025 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.707 ' O ' ' CB ' ' A' ' 44' ' ' CYS . 12.0 p -148.89 107.23 3.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.067 -1.021 . . . . 99.989999999999995 110.785 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.634 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.76 31.8 0.15 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.672 -1.267 . . . . 99.989999999999995 110.489 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HA2' ' A' ' 95' ' ' GLY . 10.3 tm-20 -71.01 -0.38 9.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -0.976 . . . . 99.989999999999995 110.106 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -87.94 61.68 6.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 50.0 110.403 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.605 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -94.72 146.28 24.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.894 . . . . 50.0 109.887 179.632 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.585 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 57.8 m -127.4 100.17 5.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.043 . . . . 50.0 110.659 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.719 ' CD1' HD23 ' A' ' 35' ' ' LEU . 16.1 m-85 -57.2 115.24 2.55 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.193 -0.942 . . . . 50.0 109.802 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -102.81 -27.0 12.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.24 -0.912 . . . . 50.0 110.476 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 4.9 mttt -145.53 151.43 38.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.183 -0.948 . . . . 50.0 110.23 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.1 p30 -67.09 154.97 91.53 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 50.0 110.232 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.556 ' HD2' ' CE3' ' A' ' 105' ' ' TRP . 46.6 Cg_endo -73.24 141.2 31.91 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 O-C-N 124.097 1.577 . . . . 50.0 110.419 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.477 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -146.63 168.07 22.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.274 -0.891 . . . . 50.0 110.29 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -89.07 154.62 20.04 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 50.0 110.341 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.63 -48.06 1.4 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.307 -0.87 . . . . 50.0 110.074 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.52 -101.48 2.32 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.453 -1.459 . . . . 50.0 109.453 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -133.15 93.69 3.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -1.155 . . . . 50.0 110.23 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.6 19.75 57.68 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 50.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 70.7 p -115.35 107.83 15.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.28 -1.129 . . . . 50.0 110.283 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 98.7 t -85.32 143.82 10.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.251 -0.906 . . . . 50.0 110.174 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -125.14 149.32 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.213 -0.929 . . . . 50.0 110.409 -179.884 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.799 HG23 HD11 ' A' ' 35' ' ' LEU . 2.0 tt -152.51 163.4 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -0.851 . . . . 50.0 109.906 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.803 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.6 OUTLIER -132.46 102.07 5.59 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.12 -0.988 . . . . 50.0 110.502 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -119.12 139.91 51.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.314 -0.867 . . . . 50.0 109.165 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -92.46 131.44 37.61 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.041 -1.037 . . . . 50.0 110.068 -179.457 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.613 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.6 t80 -92.12 98.79 11.76 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.984 -1.086 . . . . 50.0 109.497 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 t -96.11 69.76 2.77 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.318 -0.864 . . . . 50.0 110.028 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -118.46 132.22 9.63 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.631 -1.388 . . . . 99.989999999999995 109.631 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 45.3 m -83.95 18.5 2.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.231 -1.158 . . . . 99.989999999999995 110.317 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -99.92 -1.08 38.17 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.241 -0.912 . . . . 99.989999999999995 110.225 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.6 -149.93 29.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.105 -1.598 . . . . 99.989999999999995 109.105 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.59 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.9 Cg_endo -73.35 150.67 47.19 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.916 1.482 . . . . 99.989999999999995 110.406 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.707 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -169.87 161.48 9.0 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.377 -0.827 . . . . 50.0 109.96 -179.487 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.653 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 24.0 mmtt -75.61 111.03 10.51 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.018 -1.051 . . . . 50.0 109.229 178.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.014 HD11 HG23 ' A' ' 70' ' ' VAL . 2.2 mt -72.29 110.66 8.5 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.966 . . . . 50.0 110.423 -179.232 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 50.3 Cg_endo -84.54 97.67 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.026 1.54 . . . . 50.0 110.652 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.824 ' CD1' HG22 ' A' ' 46' ' ' ILE . 24.2 mt -133.33 153.76 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 50.0 110.243 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.738 ' O ' HG13 ' A' ' 49' ' ' VAL . 11.2 p -125.78 110.97 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 50.0 110.23 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.456 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -91.52 100.74 13.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 50.0 109.751 179.871 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.656 HG23 HG22 ' A' ' 49' ' ' VAL . 24.8 t -122.2 155.2 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 50.0 110.223 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.544 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -60.92 164.36 4.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.204 -0.935 . . . . 50.0 109.208 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.65 ' N ' ' HA ' ' A' ' 90' ' ' SER . 16.8 t -71.53 101.27 2.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.721 -1.237 . . . . 50.0 108.936 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.553 ' HB2' ' O ' ' A' ' 53' ' ' SER . 5.0 tp 170.68 -61.67 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 C-N-CA 118.071 -1.451 . . . . 50.0 111.661 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 58' ' ' THR . 60.4 m-20 -92.92 149.92 20.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.904 -1.123 . . . . 50.0 110.273 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -106.12 -20.61 13.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.226 -0.921 . . . . 50.0 110.187 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.9 ttp -126.55 31.31 5.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.282 -0.886 . . . . 50.0 110.27 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.536 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 59.6 m -126.87 120.62 22.81 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 50.0 110.171 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.5 126.0 11.16 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.968 1.509 . . . . 50.0 110.212 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 24.4 t -135.02 -47.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.91 . . . . 50.0 110.05 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.43 158.8 49.45 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.133 -1.587 . . . . 50.0 109.133 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.444 ' O ' ' HB2' ' A' ' 83' ' ' MET . 21.4 mtm180 -132.6 154.76 49.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.138 -1.213 . . . . 50.0 110.555 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.6 mt -94.15 129.67 40.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.383 -0.823 . . . . 50.0 109.866 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.527 HG23 ' HG2' ' A' ' 84' ' ' GLU . 24.2 t -80.84 -32.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.184 -0.948 . . . . 50.0 110.38 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' VAL . 15.2 t -79.33 168.35 19.64 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -0.964 . . . . 50.0 110.099 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.45 ' H ' HG13 ' A' ' 66' ' ' VAL . 7.3 m -50.99 179.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.191 -0.943 . . . . 50.0 110.057 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.64 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 14.1 m120 -46.96 143.62 4.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.204 -0.935 . . . . 50.0 110.058 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.873 ' C ' HD12 ' A' ' 46' ' ' ILE . 47.0 Cg_endo -73.56 66.42 4.65 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.963 1.507 . . . . 50.0 110.583 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.653 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 18.2 m-30 -118.3 121.84 41.42 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.895 . . . . 50.0 110.12 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.014 HG23 HD11 ' A' ' 46' ' ' ILE . 42.9 t -77.55 60.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.119 -0.988 . . . . 50.0 109.99 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -85.37 59.37 5.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.15 -0.969 . . . . 50.0 110.185 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -142.95 165.46 27.29 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 50.0 110.388 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -94.42 -4.4 48.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.308 -0.87 . . . . 50.0 110.005 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.62 7.91 11.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.304 -0.872 . . . . 99.989999999999995 110.204 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.985 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.05 8.58 3.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 110.102 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -86.56 19.29 2.91 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.266 -0.896 . . . . 99.989999999999995 109.25 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.589 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.1 p -128.68 -172.36 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.463 -0.773 . . . . 99.989999999999995 109.41 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.529 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 4.6 mttp -62.91 88.72 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.467 -0.893 . . . . 99.989999999999995 109.283 179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.9 m -76.43 173.85 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.318 -0.864 . . . . 99.989999999999995 109.418 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 33' ' ' ILE . 5.7 tt -126.18 125.56 42.66 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.933 -1.104 . . . . 50.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.541 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.2 t -122.29 166.03 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.387 -0.821 . . . . 50.0 109.868 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.431 ' OE1' ' C ' ' A' ' 81' ' ' VAL . 3.1 pm0 -147.4 160.29 42.73 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.181 -0.949 . . . . 50.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.509 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 2.5 ptt? -157.07 158.98 37.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 50.0 110.202 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 64' ' ' VAL . 0.4 OUTLIER -115.86 57.05 1.31 Allowed Pre-proline 0 C--N 1.307 -1.247 0 O-C-N 121.111 -0.993 . . . . 50.0 110.746 -179.781 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.509 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.9 Cg_endo -71.44 170.48 18.35 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.936 1.493 . . . . 50.0 110.5 179.598 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -70.36 161.67 45.16 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.998 1.525 . . . . 50.0 110.439 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -74.88 144.67 43.25 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.272 -0.893 . . . . 50.0 110.155 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.38 178.87 16.62 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.285 -1.526 . . . . 50.0 109.285 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -67.85 131.21 45.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 50.0 110.102 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.65 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -120.28 140.71 50.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.25 -0.906 . . . . 50.0 110.351 -179.912 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.637 ' C ' HD13 ' A' ' 92' ' ' ILE . 3.8 m-30 -94.02 104.72 16.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 50.0 109.788 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD13 ' A' ' 92' ' ' ILE . 3.2 mm -97.88 125.54 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 50.0 109.918 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.506 HG22 ' CB ' ' A' ' 102' ' ' ASN . 21.2 t -125.2 125.05 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.069 -1.02 . . . . 50.0 110.825 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 48' ' ' ILE . 95.4 t -106.87 105.01 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.858 . . . . 50.0 109.785 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.43 155.64 24.19 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.963 -1.255 . . . . 50.0 109.963 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.503 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 3.7 ttm -111.17 -69.21 0.88 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.39 -1.065 . . . . 50.0 110.297 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.71 28.55 0.23 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.62 -1.392 . . . . 50.0 109.62 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -160.56 -50.91 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.173 -1.192 . . . . 50.0 110.241 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -126.16 149.34 49.05 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.301 -0.875 . . . . 50.0 110.164 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.449 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.99 148.92 42.59 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 110.481 -179.876 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.712 HD13 ' N ' ' A' ' 102' ' ' ASN . 0.0 OUTLIER -126.2 124.23 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.331 -0.856 . . . . 0.0 109.552 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.712 ' N ' HD13 ' A' ' 101' ' ' ILE . 23.0 p-10 -111.26 134.83 52.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.073 -1.017 . . . . 0.0 110.843 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.707 ' CE1' HD11 ' A' ' 101' ' ' ILE . 0.1 OUTLIER -127.59 124.09 37.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.105 179.608 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -78.9 98.44 6.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.375 -0.828 . . . . 0.0 110.337 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.556 ' CE3' ' HD2' ' A' ' 23' ' ' PRO . 8.1 m95 . . . . . 0 C--N 1.305 -1.354 0 O-C-N 121.266 -0.896 . . . . 0.0 110.477 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.615 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 10.4 mtp . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 121.066 0.46 . . . . 50.0 110.045 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.7 p -148.95 107.35 3.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.994 -1.066 . . . . 99.989999999999995 111.196 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.67 HG23 ' CE1' ' A' ' 37' ' ' TYR . 2.6 m -161.58 53.95 0.26 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.731 -1.231 . . . . 99.989999999999995 110.549 179.286 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HB3' ' CB ' ' A' ' 96' ' ' MET . 18.7 pt-20 -75.29 4.72 6.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.089 -1.007 . . . . 99.989999999999995 110.181 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HD2' ' CA ' ' A' ' 39' ' ' GLY . 6.3 mttp -92.36 61.31 3.8 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.216 -0.927 . . . . 50.0 110.397 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 1.018 ' CE2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -96.65 145.87 25.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.05 -1.031 . . . . 50.0 109.926 179.647 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.584 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -127.17 104.42 7.95 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.209 -0.932 . . . . 50.0 110.392 -179.743 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.591 ' CD1' HD23 ' A' ' 35' ' ' LEU . 22.6 m-85 -60.97 96.87 0.05 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.248 -0.908 . . . . 50.0 110.39 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.67 -29.21 25.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -0.924 . . . . 50.0 110.01 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.522 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 14.4 mttm -144.68 147.03 32.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 50.0 110.091 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -73.79 162.12 75.57 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 50.0 110.163 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.616 ' HG2' ' CD2' ' A' ' 105' ' ' TRP . 44.8 Cg_endo -72.44 131.8 18.13 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.023 1.538 . . . . 50.0 110.222 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -126.25 147.86 49.6 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.183 -0.948 . . . . 50.0 110.358 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -77.81 113.76 16.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.314 -0.866 . . . . 50.0 110.186 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -79.19 -14.22 59.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 50.0 110.343 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.74 -106.58 0.22 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' HIS . . . . . 0.465 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 9.4 p80 -121.98 102.67 8.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -1.144 . . . . 50.0 110.264 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 81.92 23.93 56.47 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.654 -1.378 . . . . 50.0 109.654 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 30.5 p -129.88 107.89 9.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.168 -1.195 . . . . 50.0 110.338 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.552 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -111.22 135.32 50.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.291 -0.881 . . . . 50.0 109.793 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 80' ' ' LEU . 1.4 t -114.65 136.75 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 50.0 110.542 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.03 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -141.89 133.2 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.459 -0.775 . . . . 50.0 109.499 179.784 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.574 ' N ' HD13 ' A' ' 33' ' ' ILE . 34.0 tt0 -112.21 117.52 32.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.141 -0.974 . . . . 50.0 111.274 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.03 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.76 143.77 51.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.363 -0.836 . . . . 50.0 108.969 178.945 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.61 132.42 40.78 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.98 -1.075 . . . . 50.0 110.209 -179.525 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.688 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.9 t80 -95.02 99.6 11.58 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.253 -0.979 . . . . 50.0 109.731 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.1 t -95.93 69.82 2.86 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.202 -0.936 . . . . 50.0 110.144 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.541 ' CA ' ' HD2' ' A' ' 16' ' ' LYS . . . -120.72 118.08 3.71 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.51 -1.436 . . . . 99.989999999999995 109.51 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.8 p -85.39 21.81 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -1.154 . . . . 99.989999999999995 110.419 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.87 -0.52 50.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.024 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.69 -172.54 26.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.435 -1.466 . . . . 99.989999999999995 109.435 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.561 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 42.8 Cg_endo -70.82 152.69 64.04 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.195 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.73 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.04 161.59 8.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.223 -0.923 . . . . 50.0 109.902 -179.385 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.615 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.7 OUTLIER -77.29 129.18 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.159 -0.963 . . . . 50.0 109.583 179.373 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.049 HG22 ' CD1' ' A' ' 48' ' ' ILE . 10.0 mt -84.01 112.36 40.14 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.188 -0.945 . . . . 50.0 110.39 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.822 ' C ' HD12 ' A' ' 48' ' ' ILE . 50.0 Cg_endo -77.41 74.9 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 124.001 1.527 . . . . 50.0 110.306 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.049 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.4 mp -115.41 151.04 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.146 -0.971 . . . . 50.0 110.294 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 23.8 m -128.32 147.15 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.439 -0.788 . . . . 50.0 110.09 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -122.25 100.76 7.13 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.362 -0.836 . . . . 50.0 109.654 179.673 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.838 HG12 ' HA ' ' A' ' 59' ' ' PRO . 25.4 m -114.99 160.86 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.234 -0.916 . . . . 50.0 110.421 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.63 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -60.25 164.63 4.06 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.42 -0.8 . . . . 50.0 109.927 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.7 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 3.4 t -66.64 120.49 13.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.181 -0.949 . . . . 50.0 109.805 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.7 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.1 tp 87.18 29.27 0.03 OUTLIER 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.658 -0.652 . . . . 50.0 110.725 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.493 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 25.5 m120 -144.18 84.81 1.78 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.114 -0.991 . . . . 50.0 110.182 179.259 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.22 6.24 42.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.197 -0.939 . . . . 50.0 110.111 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.2 mmt -107.83 -14.59 14.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.26 -0.9 . . . . 50.0 110.081 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.3 p -133.14 119.83 15.82 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 50.0 110.04 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.838 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.84 125.85 10.83 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.942 1.496 . . . . 50.0 110.245 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.63 HG11 ' HB2' ' A' ' 52' ' ' ALA . 3.4 p -131.45 -33.72 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 50.0 110.025 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.91 143.45 34.95 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.697 -1.761 . . . . 50.0 108.697 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.469 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -126.62 156.27 41.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.055 -1.262 . . . . 50.0 110.794 -179.285 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -93.84 129.8 40.11 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.808 . . . . 50.0 109.927 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.636 HG11 ' HB2' ' A' ' 82' ' ' GLU . 4.0 p -54.07 -26.11 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.158 -0.964 . . . . 50.0 110.209 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -114.56 176.05 5.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.285 -0.885 . . . . 50.0 110.117 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 69' ' ' PHE . 15.5 m -59.15 -170.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.162 -0.961 . . . . 50.0 110.225 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.623 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 15.2 t30 -46.79 140.3 6.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 50.0 109.987 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.559 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 47.7 Cg_endo -74.84 78.07 2.93 Favored 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 123.989 1.521 . . . . 50.0 110.557 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.623 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.3 p90 -105.4 136.06 45.64 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.137 -0.977 . . . . 50.0 110.402 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.006 ' CG2' HD11 ' A' ' 46' ' ' ILE . 85.7 t -91.66 60.65 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 50.0 109.976 179.751 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -82.13 57.79 3.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.324 -0.86 . . . . 50.0 110.017 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 169.11 18.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.315 -0.865 . . . . 50.0 110.177 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -100.2 -5.59 27.43 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 50.0 109.977 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.8 t -121.25 10.12 10.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 110.507 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.827 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -80.77 10.43 4.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.018 -1.051 . . . . 99.989999999999995 110.004 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.519 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 96.6 m-20 -84.51 16.81 2.94 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.314 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.683 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.44 -172.42 2.36 Favored 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.441 -0.787 . . . . 99.989999999999995 109.347 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.541 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.2 OUTLIER -62.79 87.94 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.354 -0.938 . . . . 99.989999999999995 109.006 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.999 HG22 ' O ' ' A' ' 35' ' ' LEU . 13.4 m -77.18 175.97 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.356 -0.84 . . . . 99.989999999999995 109.685 -179.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -127.93 142.01 51.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.918 -1.114 . . . . 50.0 110.705 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.605 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.0 OUTLIER -134.54 166.66 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.423 -0.798 . . . . 50.0 109.867 179.745 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.636 ' HB2' HG11 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -145.11 152.45 40.07 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.289 -0.882 . . . . 50.0 110.266 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 9.7 ptt? -155.3 144.96 21.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 50.0 110.302 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -106.93 74.87 0.39 Allowed Pre-proline 0 C--N 1.305 -1.369 0 O-C-N 121.286 -0.884 . . . . 50.0 110.397 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.4 Cg_endo -72.88 167.71 26.57 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.914 1.481 . . . . 50.0 110.5 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.43 154.32 60.68 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.947 1.498 . . . . 50.0 110.584 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.94 134.26 48.6 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.237 -0.914 . . . . 50.0 110.04 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.87 -168.54 13.68 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.379 -1.489 . . . . 50.0 109.379 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.55 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 7.2 m-20 -82.91 153.16 25.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -1.16 . . . . 50.0 110.116 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -136.96 138.61 40.77 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.284 -0.885 . . . . 50.0 110.296 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.593 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.7 m-30 -99.23 124.3 44.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.097 -1.002 . . . . 50.0 109.797 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 92' ' ' ILE . 4.9 mp -111.0 132.35 59.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.249 -0.907 . . . . 50.0 110.159 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.658 HG22 ' CB ' ' A' ' 102' ' ' ASN . 20.9 t -125.16 120.81 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.822 -1.174 . . . . 50.0 111.365 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 1.015 HG22 HG13 ' A' ' 48' ' ' ILE . 94.9 t -98.19 106.56 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -0.849 . . . . 50.0 109.436 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.492 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.42 142.99 13.34 Favored Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.568 -1.301 . . . . 50.0 110.093 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.545 ' CB ' ' HB3' ' A' ' 15' ' ' GLU . 25.8 ttp -115.74 70.07 0.74 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -1.042 . . . . 50.0 109.957 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 56.03 18.9 20.89 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.559 -1.416 . . . . 50.0 109.559 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -149.36 -88.1 0.08 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -1.104 . . . . 50.0 110.098 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.446 ' O ' ' HA2' ' A' ' 95' ' ' GLY . 0.9 OUTLIER -79.76 155.18 28.04 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.244 -0.91 . . . . 50.0 110.322 -179.876 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.675 ' HG2' ' O ' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -140.75 87.74 2.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.182 -0.949 . . . . 0.0 110.695 179.768 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.705 ' O ' HG23 ' A' ' 101' ' ' ILE . 1.1 tp -85.32 116.45 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.015 -1.053 . . . . 0.0 109.781 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.658 ' CB ' HG22 ' A' ' 93' ' ' VAL . 22.5 p30 -106.77 151.94 24.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.853 . . . . 0.0 110.963 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.484 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.2 OUTLIER -129.67 156.94 43.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.5 -0.75 . . . . 0.0 109.573 179.787 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.567 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 3.3 m-70 -114.27 80.83 1.45 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.314 -0.867 . . . . 0.0 110.581 -179.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.616 ' CD2' ' HG2' ' A' ' 23' ' ' PRO . 10.4 t-105 . . . . . 0 N--CA 1.489 1.493 0 O-C-N 121.298 -0.877 . . . . 0.0 110.027 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.535 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.131 0.491 . . . . 50.0 109.952 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.678 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -141.15 106.64 5.06 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.216 -0.927 . . . . 99.989999999999995 110.848 -179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.891 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.98 35.63 0.12 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 99.989999999999995 110.288 179.029 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.446 ' HB2' ' HB3' ' A' ' 96' ' ' MET . 6.9 tm-20 -68.25 3.51 1.66 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.214 -0.929 . . . . 99.989999999999995 110.422 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.18 60.55 0.68 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 50.0 110.836 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.762 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -92.81 142.39 27.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.114 -0.991 . . . . 50.0 109.499 179.074 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.597 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.0 t -127.4 98.38 5.23 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.117 -0.989 . . . . 50.0 110.608 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.693 ' CD1' HD23 ' A' ' 35' ' ' LEU . 17.8 m-85 -56.02 97.1 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.23 -0.919 . . . . 50.0 109.857 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.06 -29.85 26.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 50.0 110.491 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.485 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 26.9 mttm -143.11 145.43 32.84 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.098 -1.001 . . . . 50.0 110.397 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.442 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 10.8 p30 -66.74 163.79 39.42 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 50.0 109.922 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.531 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.4 Cg_endo -71.78 134.59 24.15 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.903 1.475 . . . . 50.0 110.288 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -128.17 160.86 30.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.209 -0.932 . . . . 50.0 110.194 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -94.46 143.16 26.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.226 -0.921 . . . . 50.0 110.253 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.83 -39.66 5.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.223 -0.923 . . . . 50.0 110.157 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -142.72 -105.12 0.53 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.405 -1.478 . . . . 50.0 109.405 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -129.61 97.91 4.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.135 -1.215 . . . . 50.0 110.25 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.38 30.31 10.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 45.4 p -134.62 114.91 13.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.252 -1.146 . . . . 50.0 110.366 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 43.7 t -111.29 124.93 68.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.307 -0.871 . . . . 50.0 109.907 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.92 ' CG1' HD21 ' A' ' 80' ' ' LEU . 2.1 t -108.18 151.76 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.231 -0.918 . . . . 50.0 110.489 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.558 ' CG2' ' HB ' ' A' ' 81' ' ' VAL . 7.4 tt -150.45 166.96 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.448 -0.782 . . . . 50.0 109.515 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.74 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 6.4 tp10 -136.66 104.15 5.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.116 -0.99 . . . . 50.0 110.711 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.949 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -114.28 137.02 52.32 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.256 -0.903 . . . . 50.0 109.536 179.338 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 77' ' ' SER . 4.7 m -86.46 126.4 34.38 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.079 -1.013 . . . . 50.0 109.769 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.686 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.9 t80 -93.32 102.42 14.68 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.028 -1.069 . . . . 50.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -96.34 70.07 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.309 -0.869 . . . . 50.0 110.149 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -115.91 123.26 5.83 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.533 -1.427 . . . . 99.989999999999995 109.533 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.99 12.4 4.17 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.245 -1.15 . . . . 99.989999999999995 110.355 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' N ' ' OD1' ' A' ' 41' ' ' ASP . 0.8 OUTLIER -97.6 -1.73 43.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 99.989999999999995 110.016 179.837 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 91.15 -156.61 24.4 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.5 Cg_endo -71.47 150.89 58.62 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 124.035 1.545 . . . . 99.989999999999995 110.358 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.678 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.8 OUTLIER -170.73 162.69 7.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.269 -0.895 . . . . 50.0 110.036 -179.522 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.614 ' HD2' ' CG ' ' A' ' 69' ' ' PHE . 44.9 mmtt -72.89 131.74 42.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.103 -0.998 . . . . 50.0 110.045 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.086 HG22 ' CD1' ' A' ' 48' ' ' ILE . 2.4 mt -89.62 109.32 31.15 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.204 -0.935 . . . . 50.0 110.624 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.69 ' C ' HD12 ' A' ' 48' ' ' ILE . 51.9 Cg_endo -79.13 68.44 8.28 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.087 1.572 . . . . 50.0 110.14 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.086 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -111.59 145.62 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.161 -0.962 . . . . 50.0 110.25 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 34.1 m -118.14 139.13 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.334 -0.854 . . . . 50.0 110.108 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -119.9 100.66 7.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.326 -0.859 . . . . 50.0 109.806 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.7 m -124.0 159.82 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.306 -0.871 . . . . 50.0 110.284 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.51 163.88 1.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.392 -0.818 . . . . 50.0 109.766 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.829 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 2.2 m -73.57 104.27 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -0.993 . . . . 50.0 110.034 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.829 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 117.69 19.61 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.318 0 CA-C-O 121.113 0.482 . . . . 50.0 110.509 179.791 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -138.01 84.67 2.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.969 -1.082 . . . . 50.0 110.324 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.57 14.74 23.71 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.242 -0.911 . . . . 50.0 109.727 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 ttt -126.22 -12.99 6.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.327 -0.858 . . . . 50.0 110.383 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 m -128.58 129.78 23.53 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.913 . . . . 50.0 110.23 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.471 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.57 132.48 18.98 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 O-C-N 124.044 1.55 . . . . 50.0 110.182 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.86 -42.32 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.125 -0.984 . . . . 50.0 110.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.09 135.4 17.62 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.055 -1.618 . . . . 50.0 109.055 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.519 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.9 mtm180 -119.43 152.27 37.15 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.099 -1.236 . . . . 50.0 110.626 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mt -94.08 124.36 38.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.268 -0.895 . . . . 50.0 110.074 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.519 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 94.1 t -81.16 -38.8 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.218 -0.926 . . . . 50.0 110.364 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -65.84 172.73 3.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.186 -0.946 . . . . 50.0 110.095 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.436 ' H ' HG22 ' A' ' 66' ' ' VAL . 4.3 m -53.4 179.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.219 -0.926 . . . . 50.0 110.007 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.65 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.84 144.22 3.85 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 50.0 110.154 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.5 Cg_endo -73.59 66.52 4.67 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.999 1.526 . . . . 50.0 110.961 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.65 ' CD2' ' HB3' ' A' ' 67' ' ' ASN . 19.9 m-30 -126.31 122.37 35.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.317 -0.864 . . . . 50.0 110.07 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.914 HG23 HD11 ' A' ' 46' ' ' ILE . 41.1 t -70.31 61.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.047 -1.033 . . . . 50.0 109.879 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -96.07 66.35 2.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.166 -0.959 . . . . 50.0 110.212 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.67 169.44 17.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.297 -0.877 . . . . 50.0 110.292 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.08 -14.56 31.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 50.0 110.184 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 75.1 m -121.16 23.2 10.65 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.332 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.765 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -80.56 9.94 5.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.126 -0.984 . . . . 99.989999999999995 110.31 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -88.05 18.01 4.58 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 109.188 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.524 ' O ' ' HA ' ' A' ' 36' ' ' SER . 18.1 t -133.01 -171.91 2.8 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.554 -0.716 . . . . 99.989999999999995 109.551 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.54 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 0.4 OUTLIER -62.86 90.48 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 109.187 179.539 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.949 HG22 ' O ' ' A' ' 35' ' ' LEU . 31.4 m -76.19 172.01 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.286 -0.884 . . . . 99.989999999999995 109.555 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.92 HD21 ' CG1' ' A' ' 32' ' ' VAL . 7.8 tt -117.14 119.75 36.18 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.055 -1.028 . . . . 50.0 111.005 -179.388 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.731 HG21 HD13 ' A' ' 35' ' ' LEU . 2.9 t -108.58 169.91 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.33 -0.857 . . . . 50.0 109.571 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 2.6 mt-10 -151.17 151.29 31.71 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.034 . . . . 50.0 110.58 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.518 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 8.3 ptt? -160.36 153.3 21.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.865 . . . . 50.0 110.18 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.519 ' HG3' ' HB2' ' A' ' 62' ' ' ARG . 2.2 pt-20 -114.46 59.3 1.0 Allowed Pre-proline 0 C--N 1.306 -1.292 0 O-C-N 121.152 -0.967 . . . . 50.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.1 Cg_endo -71.34 170.24 18.83 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.859 1.452 . . . . 50.0 110.331 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.14 163.19 39.47 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.035 1.545 . . . . 50.0 110.363 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -72.33 144.15 48.4 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.172 -0.955 . . . . 50.0 110.168 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 118.32 -160.42 13.9 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.306 -1.517 . . . . 50.0 109.306 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.531 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 3.2 m-20 -90.45 146.98 23.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.255 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.54 ' HA ' ' N ' ' A' ' 53' ' ' SER . 78.8 p -130.33 143.75 50.96 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 50.0 110.078 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' A' ' 104' ' ' HIS . 0.1 OUTLIER -91.48 108.34 19.83 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.161 -0.962 . . . . 50.0 110.173 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.707 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.0 mp -101.22 125.75 55.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.281 -0.887 . . . . 50.0 109.355 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.866 HG22 ' CB ' ' A' ' 102' ' ' ASN . 26.3 t -124.7 117.41 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.893 -1.13 . . . . 50.0 111.268 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.923 HG13 HD11 ' A' ' 48' ' ' ILE . 15.0 t -95.25 105.98 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.321 -0.862 . . . . 50.0 109.34 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -133.91 140.11 11.49 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.683 -1.246 . . . . 50.0 110.064 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.566 ' HG3' ' HA ' ' A' ' 13' ' ' CYS . 10.0 tmm? -131.32 -26.28 2.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.368 -1.078 . . . . 50.0 110.239 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 166.73 -24.39 0.13 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.778 -1.329 . . . . 50.0 109.778 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -81.39 -70.16 0.56 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -1.163 . . . . 50.0 110.343 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -150.53 136.54 18.45 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.285 -0.885 . . . . 50.0 110.022 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.516 ' N ' ' CD ' ' A' ' 100' ' ' GLN . 1.9 mp0 -78.47 108.06 11.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.283 -0.886 . . . . 0.0 110.547 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.48 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 4.1 mt -94.88 110.75 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 110.131 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.866 ' CB ' HG22 ' A' ' 93' ' ' VAL . 0.5 OUTLIER -106.4 130.03 54.28 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.245 -0.909 . . . . 0.0 110.422 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.93 134.72 44.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 110.187 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.62 ' NE2' ' CZ ' ' A' ' 91' ' ' TYR . 1.7 m-70 -72.32 140.91 48.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 110.073 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.707 ' HB2' HD13 ' A' ' 92' ' ' ILE . 2.4 m95 . . . . . 0 C--N 1.305 -1.335 0 O-C-N 121.158 -0.963 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.583 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.047 0.451 . . . . 50.0 110.192 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.793 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.83 105.58 3.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.021 -1.05 . . . . 99.989999999999995 111.507 -179.779 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.874 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.93 19.54 0.08 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.922 -1.112 . . . . 99.989999999999995 110.427 178.392 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 1.1 pp20? -57.77 -11.87 2.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.09 -1.007 . . . . 99.989999999999995 110.42 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 4.3 mptt -80.15 60.71 3.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 50.0 110.382 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.496 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -93.75 149.36 21.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.249 -0.907 . . . . 50.0 109.917 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.685 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 t -127.43 136.34 51.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.178 -0.951 . . . . 50.0 109.799 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.855 ' HZ ' HG21 ' A' ' 101' ' ' ILE . 0.4 OUTLIER -83.48 115.14 21.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.068 -1.02 . . . . 50.0 110.185 -179.769 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.71 -35.8 7.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.35 -0.844 . . . . 50.0 109.953 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.532 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 16.5 mttm -147.53 153.57 39.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.212 -0.93 . . . . 50.0 110.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 29.6 p-10 -68.26 165.16 36.37 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 50.0 109.875 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.8 141.58 37.6 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.854 1.449 . . . . 50.0 110.199 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -137.68 165.64 25.89 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.191 -0.943 . . . . 50.0 110.321 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -90.49 159.08 16.7 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 50.0 110.136 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HG21 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -134.24 -45.55 0.77 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.326 -0.859 . . . . 50.0 110.217 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -133.38 -111.51 1.26 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.496 -1.442 . . . . 50.0 109.496 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -128.68 91.39 3.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -1.124 . . . . 50.0 110.211 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.492 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 95.4 31.0 7.77 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.506 -1.438 . . . . 50.0 109.506 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.736 HG22 HG11 ' A' ' 64' ' ' VAL . 0.2 OUTLIER -137.04 110.24 7.81 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.238 -1.154 . . . . 50.0 110.42 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 41.3 t -95.94 149.19 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.273 -0.892 . . . . 50.0 110.059 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -124.06 148.5 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 50.0 110.577 -179.761 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.907 HG23 HD11 ' A' ' 35' ' ' LEU . 0.5 OUTLIER -147.36 142.3 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.42 -0.8 . . . . 50.0 109.776 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.908 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -109.53 101.98 10.87 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 50.0 110.309 -179.736 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.016 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.86 137.71 54.43 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.327 -0.858 . . . . 50.0 109.45 179.525 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -91.44 132.73 36.03 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.081 -1.012 . . . . 50.0 110.064 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.509 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 33.4 t80 -96.1 95.51 8.22 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.843 -1.143 . . . . 50.0 109.761 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.66 69.64 2.52 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.336 -0.852 . . . . 50.0 109.725 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.07 135.13 12.65 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.691 -1.364 . . . . 99.989999999999995 109.691 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 95.2 p -86.12 13.52 7.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 99.989999999999995 110.27 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -98.48 -20.0 17.34 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.264 -0.898 . . . . 99.989999999999995 110.134 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.64 -165.63 14.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.364 -1.494 . . . . 99.989999999999995 109.364 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.442 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.3 Cg_endo -73.28 140.42 30.59 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 123.868 1.457 . . . . 99.989999999999995 110.563 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.793 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -167.53 162.13 14.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.585 -0.697 . . . . 50.0 109.131 -179.887 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.583 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 9.9 mmtm -59.84 138.28 57.84 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.947 -1.095 . . . . 50.0 110.49 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.874 HG23 ' HB ' ' A' ' 14' ' ' THR . 1.5 mt -93.11 109.11 37.64 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 50.0 110.545 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.0 Cg_endo -75.55 96.06 1.03 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.154 1.607 . . . . 50.0 110.219 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.913 HG12 HG22 ' A' ' 94' ' ' VAL . 10.2 mt -132.38 145.57 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.881 . . . . 50.0 110.356 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.6 m -115.96 130.93 69.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.324 -0.86 . . . . 50.0 109.912 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.566 ' O ' ' N ' ' A' ' 61' ' ' GLY . 13.3 m -114.71 101.27 8.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 50.0 109.81 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.612 HG12 ' HA ' ' A' ' 59' ' ' PRO . 33.9 m -131.12 159.7 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.285 -0.885 . . . . 50.0 110.236 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.13 163.92 1.43 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 50.0 109.898 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.627 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 29.3 t -63.47 122.54 16.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.156 -0.965 . . . . 50.0 110.484 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.627 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 78.72 30.24 0.37 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.513 -0.742 . . . . 50.0 110.579 179.785 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.451 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 20.8 m120 -136.23 84.64 2.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 50.0 110.086 179.179 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -105.43 8.6 33.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.245 -0.909 . . . . 50.0 110.187 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.9 ttt -103.75 -18.29 14.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 50.0 109.921 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -136.08 128.51 17.59 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.508 -0.745 . . . . 50.0 109.911 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.612 ' HA ' HG12 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.46 132.31 20.41 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 123.931 1.49 . . . . 50.0 110.396 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.1 t -135.12 -43.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.342 -0.849 . . . . 50.0 109.771 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.78 149.4 44.75 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.685 -1.766 . . . . 50.0 108.685 179.236 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 9.5 mtp85 -141.07 157.03 45.87 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.85 -1.382 . . . . 50.0 110.908 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.557 HD12 ' N ' ' A' ' 63' ' ' LEU . 6.6 mp -94.32 129.54 40.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 50.0 109.845 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.736 HG11 HG22 ' A' ' 30' ' ' THR . 43.9 t -79.87 7.3 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.234 -0.916 . . . . 50.0 110.329 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.483 ' CG2' ' HB2' ' A' ' 82' ' ' GLU . 68.9 p -115.5 167.05 11.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.136 -0.978 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 65' ' ' THR . 16.7 m -52.87 -170.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 O-C-N 121.225 -0.922 . . . . 50.0 110.089 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -46.41 149.95 1.26 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.128 -0.982 . . . . 50.0 110.044 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.16 91.03 0.75 Allowed 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.006 1.529 . . . . 50.0 110.691 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 1.117 ' CZ ' ' HB2' ' A' ' 71' ' ' ALA . 1.2 t80 -155.12 121.51 5.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.345 -0.847 . . . . 50.0 109.932 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.82 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.5 p -95.43 60.84 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.252 -0.905 . . . . 50.0 110.166 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 1.117 ' HB2' ' CZ ' ' A' ' 69' ' ' PHE . . . -73.9 82.44 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 50.0 110.235 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.74 148.88 37.97 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.229 -0.92 . . . . 50.0 110.359 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.2 t -68.45 -15.57 63.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 50.0 109.874 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -121.09 23.31 10.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.301 -0.874 . . . . 99.989999999999995 110.373 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.673 ' CB ' HG22 ' A' ' 70' ' ' VAL . . . -72.32 1.34 7.94 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.099 -1.0 . . . . 99.989999999999995 110.397 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.509 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 57.8 m-80 -87.2 24.12 1.66 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.174 -0.954 . . . . 99.989999999999995 109.397 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.647 ' O ' HG13 ' A' ' 79' ' ' VAL . 2.3 p -128.7 -173.08 2.87 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.476 -0.765 . . . . 99.989999999999995 109.268 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.433 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -63.44 88.83 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.334 -0.854 . . . . 99.989999999999995 109.186 179.478 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 1.016 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.9 m -76.52 176.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.449 -0.782 . . . . 99.989999999999995 109.695 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 81' ' ' VAL . 2.5 tt -127.57 128.36 45.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.888 -1.132 . . . . 50.0 111.054 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.47 ' HB ' ' CG2' ' A' ' 33' ' ' ILE . 3.2 t -115.45 172.19 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.354 -0.841 . . . . 50.0 110.024 179.716 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.483 ' HB2' ' CG2' ' A' ' 65' ' ' THR . 2.6 mt-10 -148.1 140.79 24.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.169 -0.957 . . . . 50.0 110.195 179.867 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.468 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 6.7 ptt? -151.52 146.75 26.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.122 -0.987 . . . . 50.0 110.62 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.705 ' HG2' HG22 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -109.34 75.55 0.74 Allowed Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.408 -0.808 . . . . 50.0 110.132 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.26 159.43 47.08 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 124.044 1.549 . . . . 50.0 110.536 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -71.02 148.44 56.93 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.079 1.568 . . . . 50.0 110.685 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -58.82 137.23 57.84 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.295 -0.878 . . . . 50.0 110.203 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.78 -125.96 6.43 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.526 ' HB3' ' CB ' ' A' ' 53' ' ' SER . 19.9 t0 -120.51 146.03 46.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -1.147 . . . . 50.0 110.213 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -141.7 137.57 31.81 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -0.894 . . . . 50.0 110.247 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.59 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 1.9 m-30 -98.98 117.28 33.14 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 50.0 109.952 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.689 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.2 mp -109.5 133.2 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 50.0 110.139 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.57 ' HB ' HG22 ' A' ' 49' ' ' VAL . 11.5 t -124.8 121.39 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.03 . . . . 50.0 110.734 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.913 HG22 HG12 ' A' ' 48' ' ' ILE . 24.5 t -106.9 101.67 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.279 -0.888 . . . . 50.0 109.747 179.388 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.32 168.31 33.09 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.793 -1.323 . . . . 50.0 109.793 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.48 ' HG3' ' HG3' ' A' ' 47' ' ' PRO . 6.4 ttm -107.13 -55.15 2.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.395 -1.062 . . . . 50.0 110.175 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -166.37 -40.72 0.02 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.6 -85.26 0.22 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -1.172 . . . . 50.0 110.031 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.6 mmtm -79.72 128.87 33.95 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.262 -0.898 . . . . 50.0 110.061 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.498 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -132.53 149.75 52.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.855 HG21 ' HZ ' ' A' ' 19' ' ' PHE . 49.4 mm -122.81 122.5 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.117 -0.989 . . . . 0.0 110.258 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -109.99 136.57 49.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.349 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -124.43 164.54 19.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.886 . . . . 0.0 109.917 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -113.78 88.55 2.87 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.285 -0.884 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 92' ' ' ILE . 1.7 t90 . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.321 -0.862 . . . . 0.0 110.227 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 23.0 mtm . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 121.151 0.501 . . . . 50.0 110.442 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.676 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 7.2 p -148.74 108.84 4.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.173 -0.954 . . . . 99.989999999999995 110.538 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.85 HG21 HG12 ' A' ' 46' ' ' ILE . 1.2 m -160.27 50.37 0.29 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.93 -1.106 . . . . 99.989999999999995 110.264 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.606 ' CB ' ' CB ' ' A' ' 96' ' ' MET . 3.8 pt-20 -77.88 28.18 0.17 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 99.989999999999995 110.743 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.446 ' HG2' ' C ' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -129.24 60.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.89 -1.131 . . . . 50.0 110.878 -179.87 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.829 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -91.98 143.69 26.22 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.136 -0.978 . . . . 50.0 109.743 179.328 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.632 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 m -127.33 103.85 7.61 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 50.0 110.466 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -61.24 98.38 0.08 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.153 -0.967 . . . . 50.0 110.0 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.589 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.88 -32.96 22.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 50.0 109.879 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 0.1 OUTLIER -142.54 145.23 33.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.352 -0.842 . . . . 50.0 110.187 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.482 ' HB2' ' CZ3' ' A' ' 105' ' ' TRP . 24.6 p30 -67.37 161.14 67.18 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 50.0 110.013 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.609 ' HG2' ' CD1' ' A' ' 105' ' ' TRP . 44.5 Cg_endo -71.55 126.07 11.79 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.909 1.479 . . . . 50.0 110.347 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -123.06 152.72 40.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 50.0 110.282 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.452 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.5 p30 -90.87 130.03 36.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 50.0 110.078 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.21 -0.69 22.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.18 -0.95 . . . . 50.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -174.59 -129.46 1.19 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.77 98.43 7.4 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -1.162 . . . . 50.0 110.225 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.29 28.23 23.18 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 3.8 p -130.15 107.55 9.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -1.206 . . . . 50.0 110.182 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.544 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 57.8 t -111.22 114.89 48.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 50.0 110.086 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.427 ' H ' HG22 ' A' ' 32' ' ' VAL . 5.2 m -94.56 139.45 18.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.208 -0.932 . . . . 50.0 110.522 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.087 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -143.57 137.38 25.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.4 -0.812 . . . . 50.0 109.678 179.68 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.898 ' N ' HD13 ' A' ' 33' ' ' ILE . 18.5 tt0 -113.08 117.24 31.44 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.078 -1.014 . . . . 50.0 110.883 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.087 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.15 141.54 51.45 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.306 -0.871 . . . . 50.0 109.407 179.233 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -86.84 123.66 32.21 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.072 -1.017 . . . . 50.0 109.753 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.707 ' CE1' HG23 ' A' ' 14' ' ' THR . 4.9 t80 -91.52 101.66 14.32 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.932 -1.107 . . . . 50.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.421 ' O ' ' HB3' ' A' ' 16' ' ' LYS . 0.2 OUTLIER -96.24 69.64 2.71 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.239 -0.913 . . . . 50.0 109.877 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.448 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -111.31 127.69 8.32 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 8.1 p -77.29 6.09 7.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.296 -1.12 . . . . 99.989999999999995 110.488 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.53 -3.7 42.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.215 -0.928 . . . . 99.989999999999995 109.925 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.42 -137.65 17.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.437 -1.465 . . . . 99.989999999999995 109.437 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.609 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 43.3 Cg_endo -70.91 142.42 42.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.968 1.509 . . . . 99.989999999999995 110.327 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.676 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.13 162.42 8.87 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.349 -0.844 . . . . 50.0 110.078 -179.403 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 25.7 mmtt -74.67 113.34 11.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 50.0 109.906 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.999 HG22 ' CD1' ' A' ' 48' ' ' ILE . 3.2 mt -74.51 117.08 59.29 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.112 -0.993 . . . . 50.0 110.072 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.835 ' C ' HD12 ' A' ' 48' ' ' ILE . 48.7 Cg_endo -81.79 70.13 7.35 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 124.087 1.572 . . . . 50.0 110.158 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.999 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -118.13 146.96 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 50.0 110.226 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.602 HG21 ' HB3' ' A' ' 59' ' ' PRO . 6.2 p -127.13 140.36 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.394 -0.816 . . . . 50.0 110.143 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.464 ' OG ' ' HG2' ' A' ' 83' ' ' MET . 75.2 m -107.32 100.5 9.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 50.0 109.8 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.94 HG22 ' HA ' ' A' ' 59' ' ' PRO . 59.4 t -107.72 157.0 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.313 -0.867 . . . . 50.0 110.127 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -71.94 164.23 26.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 50.0 109.215 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.621 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 29.6 t -70.79 100.86 1.98 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.74 -1.225 . . . . 50.0 109.321 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 173.19 -71.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 C-N-CA 118.52 -1.272 . . . . 50.0 111.382 -179.725 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.474 ' HB3' ' OG1' ' A' ' 58' ' ' THR . 80.8 m-20 -84.15 155.12 22.74 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.135 -0.978 . . . . 50.0 110.287 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -106.24 -23.5 12.55 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 50.0 110.118 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.38 37.09 4.38 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.268 -0.895 . . . . 50.0 110.267 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.502 ' O ' HG13 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -134.9 103.23 10.9 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.176 -0.952 . . . . 50.0 110.322 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.94 ' HA ' HG22 ' A' ' 51' ' ' VAL . 48.9 Cg_endo -73.72 125.84 10.31 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.063 1.559 . . . . 50.0 110.601 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.537 HG22 HG13 ' A' ' 51' ' ' VAL . 12.0 m -135.22 -28.07 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.338 -0.851 . . . . 50.0 110.271 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.82 170.78 48.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.895 -1.682 . . . . 50.0 108.895 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HG3' ' A' ' 83' ' ' MET . 14.8 mtt180 -140.36 155.91 46.6 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.045 -1.268 . . . . 50.0 110.602 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.593 HD22 ' HD3' ' A' ' 68' ' ' PRO . 2.2 mp -92.21 115.95 28.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 50.0 109.651 179.474 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.727 HG11 ' HG2' ' A' ' 82' ' ' GLU . 7.5 p -77.69 -34.54 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.087 -1.008 . . . . 50.0 110.352 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.544 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 7.3 t -82.58 173.28 12.1 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.087 -1.008 . . . . 50.0 109.821 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.458 ' C ' ' O ' ' A' ' 65' ' ' THR . 47.2 t -41.23 159.78 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.212 -0.93 . . . . 50.0 109.789 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.63 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 8.7 m120 -46.58 158.59 0.39 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 50.0 109.709 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.593 ' HD3' HD22 ' A' ' 63' ' ' LEU . 46.2 Cg_endo -73.61 65.83 4.72 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.882 1.464 . . . . 50.0 110.511 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.663 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 16.4 m-30 -126.23 121.68 33.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 50.0 110.034 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.857 HG13 HD11 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -86.97 60.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 50.0 109.589 179.487 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -71.75 59.35 0.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.415 -0.803 . . . . 50.0 110.158 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.443 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.3 OUTLIER -142.84 158.25 43.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.245 -0.91 . . . . 50.0 110.361 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.3 m -85.98 -10.64 54.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.372 -0.83 . . . . 50.0 109.698 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.99 14.59 16.13 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 99.989999999999995 110.124 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.443 ' HB2' ' HB ' ' A' ' 72' ' ' THR . . . -80.26 10.99 3.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -0.885 . . . . 99.989999999999995 109.964 179.702 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 3.2 m-20 -85.84 16.16 4.3 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.286 -0.883 . . . . 99.989999999999995 109.435 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.583 ' O ' ' HA ' ' A' ' 36' ' ' SER . 60.3 p -121.91 -172.75 2.5 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.496 -0.752 . . . . 99.989999999999995 109.299 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.467 ' HG3' ' HB3' ' A' ' 36' ' ' SER . 0.6 OUTLIER -63.14 88.65 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.177 -0.952 . . . . 99.989999999999995 109.077 179.506 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.908 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.0 m -76.35 176.08 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.33 -0.856 . . . . 99.989999999999995 109.603 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.76 127.15 44.62 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.945 -1.097 . . . . 50.0 110.759 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 t -118.43 169.72 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -0.918 . . . . 50.0 110.251 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.727 ' HG2' HG11 ' A' ' 64' ' ' VAL . 2.3 tt0 -138.23 135.7 35.83 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.288 -0.882 . . . . 50.0 110.065 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.486 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 1.6 mpp? -138.02 149.26 45.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.123 -0.986 . . . . 50.0 110.53 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.476 ' HG2' ' HB ' ' A' ' 64' ' ' VAL . 2.0 pt-20 -115.33 66.24 2.2 Favored Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.118 -0.989 . . . . 50.0 110.357 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.486 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.9 Cg_endo -73.09 164.62 34.96 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.026 1.54 . . . . 50.0 110.411 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.58 152.27 64.98 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.048 1.552 . . . . 50.0 110.405 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.9 OUTLIER -52.76 142.67 18.19 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 50.0 110.263 -179.855 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.39 161.75 14.67 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.345 -1.502 . . . . 50.0 109.345 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.552 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 74.9 m-20 -52.78 163.1 0.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -1.188 . . . . 50.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -142.37 135.85 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.1 -1.0 . . . . 50.0 110.828 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.621 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 5.4 m-30 -96.11 108.21 20.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.245 -0.91 . . . . 50.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.6 mp -90.29 137.86 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.224 -0.922 . . . . 50.0 109.789 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.542 ' HB ' HG12 ' A' ' 49' ' ' VAL . 22.0 t -125.59 108.33 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 120.882 -1.136 . . . . 50.0 111.421 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.682 HG13 HD11 ' A' ' 48' ' ' ILE . 59.5 t -85.36 107.44 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.173 -0.955 . . . . 50.0 108.896 178.41 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.517 ' HA2' ' HB3' ' A' ' 100' ' ' GLN . . . -90.3 170.23 35.49 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.783 -1.198 . . . . 50.0 110.254 -178.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.606 ' CB ' ' CB ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -153.54 13.89 0.49 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -1.041 . . . . 50.0 110.166 -179.811 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 136.36 -86.6 0.24 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.235 -1.546 . . . . 50.0 109.235 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -99.44 -68.71 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 50.0 109.971 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.89 151.66 30.04 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.201 -0.937 . . . . 50.0 110.04 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.517 ' HB3' ' HA2' ' A' ' 95' ' ' GLY . 0.0 OUTLIER -140.07 148.6 42.0 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.088 -1.008 . . . . 0.0 110.349 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.0 mt -90.94 146.72 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.152 -0.968 . . . . 0.0 109.638 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -132.83 132.02 41.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.108 -0.995 . . . . 0.0 110.845 -179.541 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.498 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.0 OUTLIER -118.71 152.92 35.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.391 -0.818 . . . . 0.0 109.518 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.597 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 16.8 p-80 -116.23 83.1 1.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.554 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.609 ' CD1' ' HG2' ' A' ' 23' ' ' PRO . 10.1 t-105 . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.934 . . . . 0.0 109.943 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.613 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 121.167 0.508 . . . . 50.0 110.343 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.741 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 4.0 p -149.07 107.17 3.72 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.13 -0.981 . . . . 99.989999999999995 111.006 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.671 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -162.25 28.9 0.11 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.643 -1.286 . . . . 99.989999999999995 110.505 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 -11.31 3.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.12 -0.988 . . . . 99.989999999999995 110.236 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.45 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -71.0 61.05 0.26 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 50.0 110.429 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.748 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -105.62 141.4 37.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.155 -0.966 . . . . 50.0 109.859 179.564 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.8 OUTLIER -125.09 119.86 29.8 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.189 -0.944 . . . . 50.0 110.198 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.61 ' CE2' ' NE2' ' A' ' 103' ' ' HIS . 7.3 m-85 -63.13 115.25 4.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -0.931 . . . . 50.0 110.027 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.3 -28.34 11.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.241 -0.912 . . . . 50.0 110.103 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 19.0 mttm -146.14 151.94 38.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 50.0 110.171 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.88 164.04 61.78 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 50.0 110.218 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.504 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.9 Cg_endo -72.87 128.09 12.89 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.997 1.525 . . . . 50.0 110.206 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.654 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -125.23 152.84 44.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.913 . . . . 50.0 110.369 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.454 ' HA ' ' O ' ' A' ' 30' ' ' THR . 11.3 t70 -85.72 145.43 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.337 -0.852 . . . . 50.0 110.108 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -135.8 33.97 2.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.252 -0.905 . . . . 50.0 110.186 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.59 -109.87 0.41 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -128.02 88.99 2.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -1.155 . . . . 50.0 110.132 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 84' ' ' GLU . . . 87.11 -7.59 79.96 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.719 -1.352 . . . . 50.0 109.719 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.584 ' HA ' ' HG2' ' A' ' 84' ' ' GLU . 41.4 p -80.37 114.14 19.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -1.176 . . . . 50.0 110.194 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.566 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -106.47 141.46 21.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.224 -0.923 . . . . 50.0 110.326 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.654 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -112.41 142.4 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.269 -0.894 . . . . 50.0 110.334 -179.803 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.615 HG12 HD11 ' A' ' 35' ' ' LEU . 0.4 OUTLIER -141.37 140.26 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.348 -0.845 . . . . 50.0 109.706 179.695 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 18.3 tt0 -121.79 117.03 25.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -0.975 . . . . 50.0 110.535 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.102 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.5 OUTLIER -126.38 139.53 53.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.307 -0.871 . . . . 50.0 109.529 179.413 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.638 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.2 OUTLIER -87.77 126.94 35.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.059 -1.026 . . . . 50.0 109.704 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.553 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 32.2 t80 -90.47 95.72 10.3 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.77 -1.172 . . . . 50.0 109.71 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.4 t -94.58 70.02 3.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.246 -0.909 . . . . 50.0 110.032 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -121.75 126.76 6.61 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.515 -1.434 . . . . 99.989999999999995 109.515 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.44 25.31 1.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -1.161 . . . . 99.989999999999995 110.36 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -99.76 -0.96 38.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 99.989999999999995 110.051 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.4 -163.28 31.23 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.391 -1.484 . . . . 99.989999999999995 109.391 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.62 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.8 Cg_endo -72.71 151.6 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 124.019 1.536 . . . . 99.989999999999995 110.515 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.741 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 3.7 t -170.22 161.71 8.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.391 -0.818 . . . . 50.0 109.666 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 12' ' ' MET . 25.1 mmtt -77.23 121.5 23.76 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.009 -1.057 . . . . 50.0 110.047 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.005 HG22 HD11 ' A' ' 48' ' ' ILE . 2.8 mt -83.92 110.3 24.67 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.367 -0.833 . . . . 50.0 110.585 -179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.2 Cg_endo -80.47 106.29 1.84 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.009 1.531 . . . . 50.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.005 HD11 HG22 ' A' ' 46' ' ' ILE . 3.0 mp -123.2 142.94 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.163 -0.961 . . . . 50.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 93' ' ' VAL . 5.9 m -120.71 96.62 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.84 . . . . 50.0 109.724 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.451 ' HA ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -87.95 104.08 16.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.309 -179.625 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.718 HG12 ' H ' ' A' ' 60' ' ' VAL . 16.8 m -130.42 162.07 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.231 -0.918 . . . . 50.0 110.073 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -68.18 164.02 21.39 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.882 . . . . 50.0 109.304 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.607 ' N ' ' HA ' ' A' ' 90' ' ' SER . 2.2 t -67.61 99.9 0.83 Allowed 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 118.529 -1.268 . . . . 50.0 108.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.592 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 172.06 -67.15 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.264 -1.374 . . . . 50.0 111.458 -179.688 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -99.64 122.03 42.08 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.087 -1.008 . . . . 50.0 110.299 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -106.18 19.45 20.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.952 . . . . 50.0 110.074 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.19 -7.15 6.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.29 -0.881 . . . . 50.0 110.37 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.67 ' O ' HG11 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -134.44 140.88 37.05 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.19 -0.944 . . . . 50.0 110.288 -179.869 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.577 ' HA ' ' CG1' ' A' ' 51' ' ' VAL . 46.5 Cg_endo -73.07 136.13 24.21 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 124.072 1.564 . . . . 50.0 110.443 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.718 ' H ' HG12 ' A' ' 51' ' ' VAL . 52.8 t -147.18 10.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.216 -0.927 . . . . 50.0 110.381 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -110.08 170.78 14.39 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.271 -1.532 . . . . 50.0 109.271 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.544 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 5.1 mmt180 -107.07 145.13 32.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.101 -1.235 . . . . 50.0 110.218 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.486 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 0.1 OUTLIER -116.99 110.34 18.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 50.0 110.065 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.804 HG12 ' O ' ' A' ' 64' ' ' VAL . 73.5 t -100.07 42.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.168 -0.958 . . . . 50.0 110.124 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.494 ' OG1' ' N ' ' A' ' 82' ' ' GLU . 1.6 m -130.71 144.89 51.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.868 . . . . 50.0 110.096 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 65' ' ' THR . 26.0 m -52.72 -171.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.217 -0.927 . . . . 50.0 110.052 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 2.3 m-20 -46.83 115.46 3.34 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.128 -0.982 . . . . 50.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.625 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 45.0 Cg_endo -71.89 66.27 3.23 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.964 1.507 . . . . 50.0 110.136 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 68' ' ' PRO . 13.5 m-85 -135.76 123.62 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.474 -0.766 . . . . 50.0 110.054 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.99 HG23 HD11 ' A' ' 46' ' ' ILE . 53.4 t -71.97 60.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.038 -1.039 . . . . 50.0 109.84 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.62 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -86.63 57.47 4.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 50.0 109.828 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.3 169.13 18.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.328 -0.857 . . . . 50.0 110.337 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.25 -7.34 35.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 50.0 109.999 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 14.6 p -121.06 13.18 11.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.312 -0.868 . . . . 99.989999999999995 110.313 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.962 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.99 5.45 8.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 99.989999999999995 109.958 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 40.2 m-20 -83.42 20.41 1.35 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.391 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.661 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -122.51 -172.91 2.57 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.363 -0.835 . . . . 99.989999999999995 109.444 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.16 89.03 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.118 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 1.102 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.4 m -76.23 175.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.406 -0.809 . . . . 99.989999999999995 109.663 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 81' ' ' VAL . 0.8 OUTLIER -131.47 139.97 49.46 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.879 -1.138 . . . . 50.0 111.028 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.438 ' N ' HD23 ' A' ' 80' ' ' LEU . 0.2 OUTLIER -131.21 172.26 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.452 -0.78 . . . . 50.0 109.991 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.494 ' N ' ' OG1' ' A' ' 65' ' ' THR . 37.9 mt-10 -135.41 142.41 45.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.155 -0.966 . . . . 50.0 110.084 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.522 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -153.02 142.37 21.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.108 -0.995 . . . . 50.0 110.234 -179.71 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.642 ' HG3' HG21 ' A' ' 64' ' ' VAL . 1.5 mm-40 -110.79 67.89 0.56 Allowed Pre-proline 0 C--N 1.304 -1.37 0 O-C-N 121.022 -1.049 . . . . 50.0 110.619 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.566 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.26 155.78 55.79 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.978 1.515 . . . . 50.0 110.528 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.22 163.28 39.17 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.105 1.582 . . . . 50.0 110.463 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -73.54 138.46 45.01 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.201 -0.937 . . . . 50.0 110.172 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.43 -150.14 17.17 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.362 -1.495 . . . . 50.0 109.362 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.409 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 8.6 m-20 -92.3 137.11 32.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 50.0 110.0 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.607 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -130.23 133.4 46.51 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.23 -0.919 . . . . 50.0 110.247 179.984 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.522 ' O ' ' CG2' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -91.65 97.08 10.81 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.159 -0.963 . . . . 50.0 109.996 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 50' ' ' SER . 1.7 pt -102.56 116.95 47.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.271 -0.893 . . . . 50.0 109.839 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 102' ' ' ASN . 42.5 t -118.57 131.07 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 50.0 110.556 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.821 HG13 HG13 ' A' ' 48' ' ' ILE . 14.7 t -107.28 96.66 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.278 -0.888 . . . . 50.0 109.86 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.536 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.42 165.42 32.39 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.623 -1.391 . . . . 50.0 109.623 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.529 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 10.8 ptp -107.48 -33.41 7.36 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.282 -1.129 . . . . 50.0 110.316 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' GLY . . . . . 0.529 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 176.36 -63.21 0.1 OUTLIER Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.478 -1.449 . . . . 50.0 109.478 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -63.75 -107.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.204 -1.174 . . . . 50.0 110.132 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -79.29 123.35 27.37 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.111 -0.993 . . . . 50.0 110.161 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.781 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -131.41 150.17 52.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 110.064 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 46.0 mt -102.88 106.7 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.996 -1.065 . . . . 0.0 110.136 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.643 ' HA ' HG22 ' A' ' 93' ' ' VAL . 7.6 p-10 -97.4 130.8 44.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 110.196 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.61 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -126.99 160.45 31.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.34 -0.85 . . . . 0.0 110.238 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.403 ' CD2' ' H ' ' A' ' 104' ' ' HIS . 7.3 p80 -123.26 86.53 2.59 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 110.131 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.431 ' CE3' ' C ' ' A' ' 105' ' ' TRP . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 110.042 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.671 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.106 0.479 . . . . 50.0 110.299 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.705 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.13 105.88 3.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.111 -0.993 . . . . 99.989999999999995 111.151 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.908 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.22 25.09 0.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.115 -0.991 . . . . 99.989999999999995 109.938 178.458 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 96' ' ' MET . 17.9 tt0 -49.78 -18.67 0.51 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.316 -0.865 . . . . 99.989999999999995 110.375 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 1.2 mmtt -76.2 61.43 1.61 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 50.0 110.411 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.919 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -99.0 138.68 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.926 . . . . 50.0 109.94 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 12.7 t -128.29 97.47 4.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.205 -0.934 . . . . 50.0 110.621 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 6.7 p90 -56.5 117.95 4.34 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.993 -1.067 . . . . 50.0 109.836 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB1' ' HE2' ' A' ' 78' ' ' LYS . . . -107.34 -19.64 13.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 50.0 110.651 -179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.512 ' CE ' ' OE1' ' A' ' 34' ' ' GLU . 25.9 mttm -140.79 150.79 43.8 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.14 -0.975 . . . . 50.0 110.684 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -67.64 165.44 30.4 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.447 -0.783 . . . . 50.0 110.145 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.5 Cg_endo -72.75 142.89 36.39 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 124.012 1.533 . . . . 50.0 110.305 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -133.5 152.52 51.92 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.218 -0.926 . . . . 50.0 110.249 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.6 p30 -92.55 130.94 38.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -0.881 . . . . 50.0 110.338 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.401 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -100.66 -80.84 0.48 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 50.0 110.035 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.41 -109.14 0.61 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.431 -1.467 . . . . 50.0 109.431 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -129.73 97.32 4.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.276 -1.132 . . . . 50.0 110.145 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 96.84 8.8 56.8 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 82.5 p -103.2 128.22 50.25 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -1.084 . . . . 50.0 110.263 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 39.2 t -109.74 137.71 40.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.366 -0.834 . . . . 50.0 109.906 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.083 ' CG1' HD21 ' A' ' 80' ' ' LEU . 1.5 t -117.57 143.43 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 50.0 110.436 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.791 HG12 HD11 ' A' ' 35' ' ' LEU . 3.6 tt -142.93 145.11 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 50.0 109.759 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.564 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 17.7 tt0 -116.46 102.55 9.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.16 -0.962 . . . . 50.0 110.721 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 1.081 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.0 OUTLIER -113.56 136.77 52.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.259 -0.9 . . . . 50.0 109.536 179.45 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.624 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.4 OUTLIER -86.36 129.85 34.71 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.155 -0.966 . . . . 50.0 109.92 -179.57 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.617 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.7 t80 -95.59 99.6 11.45 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 118.983 -1.087 . . . . 50.0 109.869 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -96.27 72.29 2.83 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.116 -0.99 . . . . 50.0 110.135 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -124.67 124.03 5.27 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.532 -1.427 . . . . 99.989999999999995 109.532 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 29.45 2.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.212 -1.17 . . . . 99.989999999999995 110.265 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' OD1' ' C ' ' A' ' 41' ' ' ASP . 2.1 p30 -102.99 0.39 32.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.291 -0.881 . . . . 99.989999999999995 110.155 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.67 174.67 25.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.273 -1.531 . . . . 99.989999999999995 109.273 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.548 ' CB ' ' O ' ' A' ' 70' ' ' VAL . 45.0 Cg_endo -72.81 149.74 48.52 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.001 1.527 . . . . 99.989999999999995 110.599 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.705 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -167.47 162.66 14.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.439 -0.788 . . . . 50.0 109.56 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.671 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 23.2 mmtt -67.5 141.44 56.91 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.968 -1.082 . . . . 50.0 109.745 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.054 HG22 ' CD1' ' A' ' 48' ' ' ILE . 7.1 mt -90.78 108.81 30.21 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.299 -0.875 . . . . 50.0 110.649 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 49.9 Cg_endo -75.48 96.48 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 124.152 1.606 . . . . 50.0 110.955 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 1.054 ' CD1' HG22 ' A' ' 46' ' ' ILE . 0.5 OUTLIER -131.64 115.79 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 50.0 109.992 179.462 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.749 HG23 ' O ' ' A' ' 49' ' ' VAL . 18.0 m -93.07 107.44 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.852 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -86.18 100.88 12.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 50.0 109.765 179.869 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.567 ' O ' ' N ' ' A' ' 91' ' ' TYR . 95.7 t -118.71 150.56 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.313 -0.867 . . . . 50.0 110.468 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -67.51 164.73 18.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.373 -0.83 . . . . 50.0 109.62 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.639 ' N ' ' HA ' ' A' ' 90' ' ' SER . 5.4 t -70.05 101.84 1.9 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.834 -1.166 . . . . 50.0 109.424 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.498 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 171.0 -64.12 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.057 -1.457 . . . . 50.0 111.703 -179.906 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.537 ' CB ' ' HB ' ' A' ' 58' ' ' THR . 41.4 m-80 -88.05 164.99 15.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.094 . . . . 50.0 110.315 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 56' ' ' ASP . 49.9 t0 -105.9 -37.87 6.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 50.0 110.238 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.0 ttm -123.85 30.39 6.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 50.0 110.217 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.537 ' HB ' ' CB ' ' A' ' 55' ' ' ASN . 17.3 m -111.85 120.62 41.74 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.256 -0.902 . . . . 50.0 110.049 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.416 ' HA ' HG22 ' A' ' 51' ' ' VAL . 44.4 Cg_endo -72.58 130.05 15.47 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.989 1.52 . . . . 50.0 110.414 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.413 HG23 HG13 ' A' ' 51' ' ' VAL . 10.5 t -142.3 -36.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.259 -0.901 . . . . 50.0 110.26 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -77.54 164.74 52.37 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.138 -1.585 . . . . 50.0 109.138 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.434 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 10.5 mtt180 -138.49 156.45 47.52 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.095 -1.238 . . . . 50.0 110.445 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.665 HD13 ' HD3' ' A' ' 68' ' ' PRO . 2.5 mt -97.97 122.4 41.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 50.0 109.776 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.711 HG22 ' HG2' ' A' ' 84' ' ' GLU . 30.6 t -63.33 -13.5 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.217 -0.927 . . . . 50.0 110.12 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 66' ' ' VAL . 34.6 m -124.77 163.21 22.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.295 -0.878 . . . . 50.0 109.955 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.528 HG12 ' N ' ' A' ' 67' ' ' ASN . 74.1 t -44.09 168.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 50.0 109.959 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.628 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 18.2 t-20 -46.68 142.73 4.56 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.196 -0.94 . . . . 50.0 110.11 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.665 ' HD3' HD13 ' A' ' 63' ' ' LEU . 49.8 Cg_endo -76.22 98.56 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.927 1.488 . . . . 50.0 110.452 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.628 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 9.2 p90 -120.51 138.49 53.81 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.225 -0.922 . . . . 50.0 110.346 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.982 HG13 ' CB ' ' A' ' 75' ' ' ALA . 73.6 t -91.01 60.94 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.198 -0.939 . . . . 50.0 110.181 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.532 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -89.76 57.44 3.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 50.0 110.346 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.7 m -143.43 169.12 18.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 50.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.7 p -94.23 -6.83 43.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 50.0 109.92 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.14 17.74 11.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 99.989999999999995 110.41 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.982 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -79.79 7.29 8.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.15 -0.969 . . . . 99.989999999999995 110.066 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 53.6 m-20 -85.17 18.78 2.44 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.234 -0.917 . . . . 99.989999999999995 109.341 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.684 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -122.68 -172.73 2.54 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.404 -0.81 . . . . 99.989999999999995 109.277 179.97 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.487 ' HE2' ' HB1' ' A' ' 20' ' ' ALA . 40.0 mttt -62.98 88.47 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.327 -0.858 . . . . 99.989999999999995 109.168 179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 1.081 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.4 m -76.68 176.48 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.376 -0.827 . . . . 99.989999999999995 109.392 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 1.083 HD21 ' CG1' ' A' ' 32' ' ' VAL . 8.0 tt -135.23 133.92 39.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.781 -1.2 . . . . 50.0 111.212 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.9 t -119.98 178.31 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.483 -0.76 . . . . 50.0 109.829 179.574 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 61.7 mt-10 -148.52 139.24 22.86 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.996 -1.065 . . . . 50.0 110.546 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.492 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 14.2 ptt? -155.81 139.03 15.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.268 -0.895 . . . . 50.0 110.245 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.711 ' HG2' HG22 ' A' ' 64' ' ' VAL . 1.3 pt-20 -109.24 76.62 0.81 Allowed Pre-proline 0 C--N 1.305 -1.327 0 O-C-N 121.183 -0.948 . . . . 50.0 110.619 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 83' ' ' MET . 47.5 Cg_endo -73.86 170.34 20.3 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.02 1.537 . . . . 50.0 110.344 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.33 161.94 42.95 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.061 1.559 . . . . 50.0 110.42 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -67.13 145.35 55.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.171 -0.956 . . . . 50.0 110.154 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.28 158.62 16.74 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.189 -1.564 . . . . 50.0 109.189 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 89' ' ' ASP . 1.0 OUTLIER -52.41 148.55 6.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -1.22 . . . . 50.0 109.928 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.639 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.4 p -130.49 138.77 50.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.118 -0.989 . . . . 50.0 110.705 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.567 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -90.65 104.35 16.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.16 -0.963 . . . . 50.0 109.415 179.334 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 92' ' ' ILE . 3.3 tt -103.43 135.02 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 50.0 110.341 -179.374 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 100' ' ' GLN . 10.7 t -125.15 114.52 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.089 -1.007 . . . . 50.0 110.863 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.853 HG13 ' CD1' ' A' ' 48' ' ' ILE . 17.6 t -103.97 104.14 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.195 -0.941 . . . . 50.0 109.444 179.236 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.27 169.92 33.29 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.614 -1.279 . . . . 50.0 110.195 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.434 ' HB2' ' HB2' ' A' ' 15' ' ' GLU . 19.7 ttm -111.72 -51.35 2.86 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.355 -1.085 . . . . 50.0 110.597 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.85 -145.14 12.18 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.845 -1.302 . . . . 50.0 109.845 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.403 ' O ' ' HG3' ' A' ' 100' ' ' GLN . 2.3 p30 -63.52 -36.11 82.68 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.219 -1.165 . . . . 50.0 110.384 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.37 116.56 19.68 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.207 -0.933 . . . . 50.0 110.184 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.574 ' HB2' HG12 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -139.45 148.69 43.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.323 -0.861 . . . . 0.0 110.114 -179.808 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.734 ' O ' HG23 ' A' ' 101' ' ' ILE . 3.5 tp -94.87 110.32 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.258 -0.901 . . . . 0.0 110.012 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.418 ' OD1' ' N ' ' A' ' 102' ' ' ASN . 32.8 p-10 -101.93 131.82 48.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 0.0 110.475 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -121.12 171.36 8.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.38 -0.825 . . . . 0.0 110.146 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -119.34 79.92 1.49 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 110.471 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.433 ' HZ2' HD11 ' A' ' 33' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.983 179.781 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.546 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.212 0.529 . . . . 50.0 110.248 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.658 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 11.6 p -148.69 107.35 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.204 -0.935 . . . . 99.989999999999995 110.415 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . 1.019 HG21 ' CD1' ' A' ' 46' ' ' ILE . 1.3 m -161.5 62.8 0.26 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.674 -1.266 . . . . 99.989999999999995 110.549 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HE3' ' A' ' 16' ' ' LYS . 1.5 pp20? -84.63 25.18 0.93 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.156 -0.965 . . . . 99.989999999999995 110.117 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.514 ' HD3' ' HA3' ' A' ' 39' ' ' GLY . 1.8 mptt -123.47 61.02 1.06 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.177 -0.952 . . . . 50.0 110.782 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.816 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.0 OUTLIER -99.11 146.88 25.64 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.054 -1.029 . . . . 50.0 109.8 179.429 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.675 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.11 145.41 51.02 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.124 -0.985 . . . . 50.0 110.294 -179.898 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.738 ' CZ ' HD12 ' A' ' 101' ' ' ILE . 1.2 m-85 -85.32 104.28 15.01 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.962 -1.086 . . . . 50.0 109.617 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.929 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -93.2 -34.53 13.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.128 -0.983 . . . . 50.0 110.648 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.512 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 13.6 mttm -145.09 166.71 24.6 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.06 -1.025 . . . . 50.0 110.614 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.59 165.16 39.36 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 50.0 110.09 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.512 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.71 136.75 26.15 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.969 1.51 . . . . 50.0 110.46 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.44 167.53 14.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.251 -0.906 . . . . 50.0 110.346 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -105.81 132.31 52.08 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 50.0 110.37 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 p -108.78 -23.17 11.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 50.0 110.136 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.46 -114.64 0.59 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.468 -1.453 . . . . 50.0 109.468 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 14.5 p80 -130.17 88.87 2.71 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -1.163 . . . . 50.0 110.296 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.484 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 105.1 14.94 21.37 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.8 p -121.73 111.53 17.28 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.311 -1.111 . . . . 50.0 110.186 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -104.61 150.56 7.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.218 -0.926 . . . . 50.0 110.313 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.758 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -128.19 135.09 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.244 -0.91 . . . . 50.0 110.271 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.944 HG23 HD11 ' A' ' 35' ' ' LEU . 8.0 tt -134.28 150.3 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.864 . . . . 50.0 109.518 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.929 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.4 tt0 -119.84 103.78 9.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 50.0 110.767 -179.494 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.961 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.2 mp -110.89 137.36 48.63 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.226 -0.921 . . . . 50.0 109.691 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -84.68 124.78 31.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.058 -1.026 . . . . 50.0 109.696 179.954 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.518 ' HB3' ' O ' ' A' ' 75' ' ' ALA . 6.3 t80 -92.34 97.84 11.12 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.904 -1.118 . . . . 50.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.9 t -95.14 72.09 3.34 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.391 -0.818 . . . . 50.0 110.163 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.514 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -125.57 126.68 5.96 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.574 -1.41 . . . . 99.989999999999995 109.574 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -83.55 16.85 2.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -1.151 . . . . 99.989999999999995 110.201 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -92.4 -22.47 19.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 99.989999999999995 110.149 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.76 -163.31 12.31 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.641 -1.384 . . . . 99.989999999999995 109.641 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.536 ' HB3' ' O ' ' A' ' 70' ' ' VAL . 44.7 Cg_endo -73.5 150.31 45.78 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 O-C-N 123.966 1.509 . . . . 99.989999999999995 110.418 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.628 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.55 161.87 7.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.309 -0.87 . . . . 50.0 109.851 -179.531 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 13.7 mmtt -69.0 117.53 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.067 -1.021 . . . . 50.0 109.382 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 1.092 HD11 ' CG2' ' A' ' 70' ' ' VAL . 4.4 mm -71.4 112.83 15.19 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.058 -1.026 . . . . 50.0 110.372 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.508 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 51.8 Cg_endo -80.26 91.87 1.13 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.061 1.558 . . . . 50.0 110.171 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.791 HG12 HG22 ' A' ' 94' ' ' VAL . 63.3 mt -133.11 149.98 32.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.128 -0.982 . . . . 50.0 110.541 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.564 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 26.1 m -124.14 159.66 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.382 -0.824 . . . . 50.0 109.661 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.455 ' O ' ' HA3' ' A' ' 61' ' ' GLY . 0.3 OUTLIER -134.76 107.66 7.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 50.0 110.066 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.5 m -125.2 156.76 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.284 -0.885 . . . . 50.0 110.203 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.675 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -55.93 163.64 1.42 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.355 -0.841 . . . . 50.0 110.012 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.609 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.4 OUTLIER -59.5 121.21 10.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.211 -0.931 . . . . 50.0 110.649 -179.556 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.609 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 78.58 30.55 0.38 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.565 -0.709 . . . . 50.0 110.976 179.549 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.675 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 30.1 m120 -128.0 84.28 2.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.21 -0.931 . . . . 50.0 110.068 179.066 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.49 9.6 31.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.234 -0.917 . . . . 50.0 110.211 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.4 mtt -113.85 -15.65 12.35 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -0.863 . . . . 50.0 110.111 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -136.37 121.01 12.85 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.334 -0.854 . . . . 50.0 110.246 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.461 ' HA ' HG12 ' A' ' 51' ' ' VAL . 46.3 Cg_endo -72.98 133.66 20.2 Favored 'Trans proline' 0 C--N 1.305 -1.755 0 O-C-N 123.989 1.52 . . . . 50.0 110.16 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.435 ' CG2' ' H ' ' A' ' 52' ' ' ALA . 31.3 m -142.31 -31.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.223 -0.923 . . . . 50.0 110.429 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.41 144.79 37.94 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.397 -1.881 . . . . 50.0 108.397 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.471 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 11.7 mtp180 -123.6 157.0 34.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.851 -1.382 . . . . 50.0 110.892 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.42 ' HG ' ' HG3' ' A' ' 83' ' ' MET . 0.2 OUTLIER -96.82 124.91 40.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.876 . . . . 50.0 109.86 179.627 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.486 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 17.9 t -50.76 -21.45 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.177 -0.952 . . . . 50.0 110.248 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 66' ' ' VAL . 5.8 t -136.33 170.68 15.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 50.0 110.153 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 27.7 m -52.23 -172.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.237 -0.915 . . . . 50.0 110.157 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.552 ' O ' ' CE2' ' A' ' 69' ' ' PHE . 6.7 p30 -46.88 131.04 8.74 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.142 -0.973 . . . . 50.0 110.003 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.52 ' O ' HG12 ' A' ' 46' ' ' ILE . 46.8 Cg_endo -72.58 123.24 8.91 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.941 1.495 . . . . 50.0 110.559 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 67' ' ' ASN . 0.2 OUTLIER -135.14 157.07 47.86 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.286 -0.884 . . . . 50.0 110.069 -179.942 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 1.092 ' CG2' HD11 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -116.29 60.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.179 -0.951 . . . . 50.0 109.6 179.292 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -73.55 58.91 0.6 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 50.0 110.347 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.0 m -142.59 155.2 44.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.32 -0.863 . . . . 50.0 110.233 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.61 -4.9 53.65 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.334 -0.854 . . . . 50.0 109.857 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.5 p -115.45 17.31 16.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 99.989999999999995 110.255 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ALA . . . . . 0.83 ' HB1' ' CG1' ' A' ' 70' ' ' VAL . . . -79.91 8.61 6.58 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.182 -0.949 . . . . 99.989999999999995 109.966 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -87.63 19.55 3.35 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 109.243 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' SER . . . . . 0.549 ' O ' ' HA ' ' A' ' 36' ' ' SER . 96.5 p -128.96 -172.56 2.75 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.536 -0.728 . . . . 99.989999999999995 109.346 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.428 ' HD2' ' OE2' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -63.35 88.82 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.263 -0.898 . . . . 99.989999999999995 109.291 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.961 HG22 ' O ' ' A' ' 35' ' ' LEU . 35.3 m -76.16 176.28 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.352 -0.843 . . . . 99.989999999999995 109.21 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.758 HD21 HG12 ' A' ' 32' ' ' VAL . 2.8 tt -134.02 132.93 40.66 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.884 -1.135 . . . . 50.0 111.239 -179.487 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.4 t -122.64 178.08 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.435 -0.791 . . . . 50.0 109.681 179.455 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.486 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 22.8 mt-10 -132.85 142.65 49.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.021 -1.049 . . . . 50.0 110.479 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.481 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -147.78 142.22 26.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.281 -0.887 . . . . 50.0 110.234 179.995 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.484 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -114.69 66.38 1.75 Allowed Pre-proline 0 C--N 1.306 -1.296 0 O-C-N 121.151 -0.968 . . . . 50.0 110.563 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.481 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.21 164.94 33.99 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.969 1.51 . . . . 50.0 110.28 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.51 140.83 33.74 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.92 1.484 . . . . 50.0 110.354 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -52.54 137.08 31.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.231 -0.918 . . . . 50.0 110.194 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.76 167.37 13.32 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.384 -1.486 . . . . 50.0 109.384 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ASP . . . . . 0.514 ' HB2' ' HB2' ' A' ' 53' ' ' SER . 23.1 m-20 -53.25 146.5 11.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.3 -1.118 . . . . 50.0 110.051 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.581 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -141.43 141.37 33.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 50.0 110.604 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 1.0 OUTLIER -97.49 112.02 24.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 50.0 109.672 179.462 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' ILE . 5.0 tt -103.44 136.91 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.101 -0.999 . . . . 50.0 110.406 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.564 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 27.1 t -125.15 113.12 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.088 -1.007 . . . . 50.0 110.316 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.816 HG11 ' CB ' ' A' ' 17' ' ' PHE . 42.1 t -105.13 100.54 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.901 . . . . 50.0 110.065 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -150.82 164.8 30.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.71 -1.356 . . . . 50.0 109.71 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' MET . . . . . 0.508 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ttm -103.44 -29.71 11.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.32 -1.106 . . . . 50.0 110.319 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 179.71 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.07 -67.9 0.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.27 -1.135 . . . . 50.0 110.422 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.1 tptt -79.47 109.38 13.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.208 -0.933 . . . . 50.0 110.109 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLN . . . . . 0.503 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -134.82 149.73 50.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 110.111 -179.739 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.738 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 5.6 pt -118.92 154.7 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 0.0 109.905 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.459 ' O ' ' OD1' ' A' ' 102' ' ' ASN . 14.4 p30 -143.1 136.35 28.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.164 -0.96 . . . . 0.0 110.429 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.491 ' HB3' ' CZ3' ' A' ' 105' ' ' TRP . 0.1 OUTLIER -120.78 168.25 11.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.24 -0.912 . . . . 0.0 110.28 179.887 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.588 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 12.9 p80 -131.08 106.08 8.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.363 -0.836 . . . . 0.0 109.981 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' TRP . . . . . 0.491 ' CZ3' ' HB3' ' A' ' 103' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 110.629 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.334 0.588 . . . . 50.0 110.206 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.9 mmtp -107.93 132.74 53.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.277 -0.889 . . . . 50.0 110.094 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.549 HD12 ' N ' ' A' ' 3' ' ' LEU . 2.2 mp -129.71 101.55 5.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.255 -0.903 . . . . 50.0 110.254 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.87 122.54 42.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.211 -0.931 . . . . 50.0 110.153 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -108.37 106.55 16.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.252 -0.905 . . . . 50.0 110.162 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 16.9 tttm -105.01 163.33 12.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.886 . . . . 50.0 110.307 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.58 19.07 29.18 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.48 -1.448 . . . . 50.0 109.48 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.4 t -57.48 167.03 1.09 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.275 -1.133 . . . . 50.0 110.221 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -47.56 109.43 0.22 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 50.0 110.281 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -127.95 167.76 16.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.179 -0.95 . . . . 50.0 110.124 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.15 101.42 0.86 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.53 -1.428 . . . . 50.0 109.53 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.547 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 74.1 mtp -77.05 114.88 16.33 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.286 -1.126 . . . . 50.0 110.263 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.778 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 8.6 p -149.01 108.06 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.608 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.657 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -161.57 41.96 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.611 -1.305 . . . . 99.989999999999995 110.678 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.7 tm-20 -70.03 -3.78 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.122 -0.986 . . . . 99.989999999999995 110.075 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.543 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -79.71 62.45 3.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.315 -0.866 . . . . 50.0 110.206 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.646 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.3 OUTLIER -102.64 140.87 36.34 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.188 -0.945 . . . . 50.0 110.431 -179.883 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.678 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.4 t -125.53 119.69 28.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 50.0 109.81 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -73.62 108.41 6.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.125 -0.985 . . . . 50.0 110.298 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.798 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -94.87 -33.49 12.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 50.0 109.916 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.49 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 17.3 mtmt -144.78 150.29 36.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.288 -0.882 . . . . 50.0 110.202 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.473 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 11.2 m-20 -69.23 165.15 42.0 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.291 -0.881 . . . . 50.0 110.107 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.543 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.1 Cg_endo -72.84 122.53 8.24 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.946 1.498 . . . . 50.0 110.31 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -122.37 141.71 51.28 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.905 . . . . 50.0 110.287 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.537 ' HA ' ' O ' ' A' ' 30' ' ' THR . 2.7 p30 -81.89 131.65 35.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 50.0 110.312 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.2 p -123.54 52.46 1.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.312 -0.868 . . . . 50.0 110.137 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.57 -129.2 2.85 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.435 -1.466 . . . . 50.0 109.435 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -116.54 95.79 5.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.206 -1.173 . . . . 50.0 110.243 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.58 23.04 63.27 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -117.87 107.71 14.43 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -1.16 . . . . 50.0 110.219 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.543 HG11 ' HB2' ' A' ' 23' ' ' PRO . 11.8 t -103.58 137.3 32.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.307 -0.87 . . . . 50.0 110.208 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -110.82 136.46 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.224 -0.923 . . . . 50.0 110.294 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HD11 ' A' ' 35' ' ' LEU . 12.7 tt -130.62 144.49 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.413 -0.805 . . . . 50.0 109.68 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.798 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -122.62 105.26 9.94 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.982 . . . . 50.0 110.639 -179.495 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.989 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.12 141.63 51.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.238 -0.914 . . . . 50.0 109.511 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -90.74 128.93 36.84 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.102 -0.999 . . . . 50.0 109.855 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.543 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 11.4 t80 -91.44 98.58 11.77 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 118.935 -1.106 . . . . 50.0 109.679 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.77 69.6 8.69 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.291 -0.881 . . . . 50.0 109.711 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.536 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -124.24 119.85 3.87 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.634 -1.386 . . . . 99.989999999999995 109.634 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.1 m -86.22 20.04 2.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.327 -1.101 . . . . 99.989999999999995 110.278 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -97.47 -0.85 45.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 99.989999999999995 110.105 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.71 -158.3 26.05 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.411 -1.475 . . . . 99.989999999999995 109.411 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -73.06 151.32 49.75 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.959 1.505 . . . . 99.989999999999995 110.222 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.778 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -170.23 161.48 8.34 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -0.907 . . . . 50.0 109.784 -179.402 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.602 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 5.0 mmtt -79.48 114.39 18.37 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.979 -1.076 . . . . 50.0 110.125 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.064 HD11 HG23 ' A' ' 70' ' ' VAL . 2.6 mt -75.06 113.58 26.42 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 50.0 110.194 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.497 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 46.5 Cg_endo -74.13 88.79 1.08 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 124.043 1.549 . . . . 50.0 110.013 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.673 HD11 HG21 ' A' ' 46' ' ' ILE . 79.4 mt -125.54 151.79 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 50.0 110.741 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.517 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 32.4 m -133.12 137.29 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.499 -0.751 . . . . 50.0 109.337 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -116.48 108.81 16.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.003 -1.061 . . . . 50.0 110.313 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 91' ' ' TYR . 14.8 m -131.58 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 50.0 110.113 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.48 163.6 1.7 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.31 -0.869 . . . . 50.0 110.184 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.665 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -62.85 120.46 11.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -0.887 . . . . 50.0 110.545 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.665 ' CB ' ' O ' ' A' ' 53' ' ' SER . 3.8 tp 81.47 29.96 0.15 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.582 -0.699 . . . . 50.0 110.725 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.524 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 24.8 m120 -137.38 84.75 2.08 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 50.0 110.101 179.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -105.36 11.13 33.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 50.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.4 tpt -109.04 -14.15 14.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 50.0 110.211 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.3 p -136.04 142.84 41.71 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.289 -0.882 . . . . 50.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.68 137.2 27.01 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.006 1.53 . . . . 50.0 110.321 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.817 HG12 ' HG3' ' A' ' 86' ' ' PRO . 4.0 t -143.89 -49.08 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.305 -0.872 . . . . 50.0 110.079 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -86.29 147.22 21.43 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.085 -1.606 . . . . 50.0 109.085 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 10.1 mtp180 -138.66 156.38 47.48 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.057 -1.261 . . . . 50.0 110.686 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.487 ' HA ' ' HG2' ' A' ' 83' ' ' MET . 5.0 mp -91.91 109.62 20.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.32 -0.863 . . . . 50.0 110.051 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.553 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 77.9 t -55.93 -42.89 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.218 -0.926 . . . . 50.0 110.51 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.466 ' OG1' ' HB2' ' A' ' 82' ' ' GLU . 1.4 m -73.76 169.49 17.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.162 -0.961 . . . . 50.0 110.173 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 67' ' ' ASN . 23.3 t -44.65 170.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.236 -0.915 . . . . 50.0 110.114 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.646 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . 60.7 m-80 -47.08 157.7 0.48 Allowed Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.243 -0.91 . . . . 50.0 109.979 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.863 ' C ' HD12 ' A' ' 46' ' ' ILE . 45.4 Cg_endo -73.32 66.36 4.42 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 123.955 1.503 . . . . 50.0 110.58 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE2' ' CB ' ' A' ' 67' ' ' ASN . 16.7 m-30 -120.8 121.7 38.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 50.0 109.878 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.064 HG23 HD11 ' A' ' 46' ' ' ILE . 80.8 t -79.91 60.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 50.0 110.096 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -83.31 61.6 6.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.082 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -142.65 164.41 30.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.253 -0.905 . . . . 50.0 110.335 -179.758 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 p -94.08 -10.79 32.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 50.0 109.874 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 67.4 m -120.95 18.24 11.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -0.872 . . . . 99.989999999999995 110.253 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.842 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -81.98 11.44 5.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.136 -0.977 . . . . 99.989999999999995 110.073 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.1 m-20 -85.22 15.06 4.51 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.253 -0.904 . . . . 99.989999999999995 109.337 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 9.3 p -124.27 -171.98 2.45 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.464 -0.773 . . . . 99.989999999999995 109.574 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.484 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 11.8 pttt -62.87 88.86 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.559 -0.856 . . . . 99.989999999999995 109.115 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.989 HG22 ' O ' ' A' ' 35' ' ' LEU . 22.2 m -76.52 174.42 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.41 -0.806 . . . . 99.989999999999995 109.651 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.445 HD23 ' O ' ' A' ' 33' ' ' ILE . 1.6 tt -138.8 120.39 15.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.977 -1.077 . . . . 50.0 110.942 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.426 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.0 t -116.91 172.69 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 50.0 109.9 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.553 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 83.7 mt-10 -120.69 154.75 35.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.142 -0.974 . . . . 50.0 110.339 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.527 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -146.14 140.39 26.64 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.332 -0.855 . . . . 50.0 110.027 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.43 62.87 0.92 Allowed Pre-proline 0 C--N 1.306 -1.315 0 O-C-N 121.258 -0.901 . . . . 50.0 110.712 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.527 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.4 Cg_endo -72.7 148.44 46.89 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 123.848 1.447 . . . . 50.0 110.357 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.817 ' HG3' HG12 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.66 152.51 59.19 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 123.963 1.507 . . . . 50.0 110.413 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -52.8 133.63 37.13 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.19 -0.944 . . . . 50.0 110.136 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.53 161.68 11.41 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.532 -1.427 . . . . 50.0 109.532 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.537 ' CB ' ' HB2' ' A' ' 53' ' ' SER . 5.4 p30 -53.01 155.24 2.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 50.0 110.108 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.513 ' HA ' ' N ' ' A' ' 53' ' ' SER . 17.6 p -143.03 137.98 29.65 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.229 -0.919 . . . . 50.0 110.387 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 1.2 m-30 -101.56 103.34 14.18 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.88 . . . . 50.0 110.275 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.739 ' H ' HD12 ' A' ' 92' ' ' ILE . 3.2 mp -101.5 138.95 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.201 -0.937 . . . . 50.0 109.871 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.517 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 75.5 t -125.37 113.73 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 50.0 110.785 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.646 HG11 ' CB ' ' A' ' 17' ' ' PHE . 41.3 t -101.97 91.54 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.958 . . . . 50.0 109.785 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.56 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.59 167.83 33.14 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.774 -1.33 . . . . 50.0 109.774 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.424 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ptp -108.38 -150.77 0.46 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -1.113 . . . . 50.0 110.08 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -73.7 -44.12 33.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.729 -1.348 . . . . 50.0 109.729 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 99' ' ' LYS . 39.5 t0 -74.98 -105.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.205 -1.174 . . . . 50.0 110.293 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.489 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 8.5 tttp -79.61 136.1 36.75 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.048 -1.032 . . . . 50.0 110.352 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.632 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.1 150.13 43.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.197 -0.939 . . . . 0.0 110.07 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 7.5 mt -115.72 146.98 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 24.0 p-10 -130.67 129.76 43.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -0.904 . . . . 0.0 110.469 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -135.48 163.79 29.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.442 -0.786 . . . . 0.0 110.018 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.627 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 10.3 p80 -134.39 164.15 28.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.931 . . . . 0.0 110.221 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -144.16 133.29 22.91 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.257 -0.902 . . . . 0.0 110.236 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.578 ' CE1' ' O ' ' A' ' 108' ' ' ALA . 66.6 t60 -120.08 133.56 55.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 110.123 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LYS . . . . . 0.5 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 0.0 OUTLIER -110.86 -16.88 13.45 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.238 -0.914 . . . . 0.0 110.381 -179.862 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.578 ' O ' ' CE1' ' A' ' 106' ' ' HIS . . . 179.76 152.36 0.43 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.339 -0.85 . . . . 0.0 110.241 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -159.92 45.58 0.42 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.3 p -90.55 172.39 8.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -1.173 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 118.059 -0.972 . . . . 49.57 110.316 179.979 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.404 ' C ' ' OD1' ' A' ' 1' ' ' ASP . 21.1 t0 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.26 0.552 . . . . 50.0 110.252 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -74.61 134.07 42.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.151 -0.968 . . . . 50.0 110.28 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.453 ' O ' HD12 ' A' ' 3' ' ' LEU . 3.4 pp -82.91 136.84 34.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 50.0 110.245 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.11 113.44 22.17 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.254 -0.904 . . . . 50.0 110.014 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 tp -107.55 99.8 9.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 50.0 110.327 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -106.66 -164.03 0.96 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.901 . . . . 50.0 110.217 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.01 66.24 0.36 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.3 m -120.13 148.72 43.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -1.123 . . . . 50.0 110.255 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 p -108.92 140.0 43.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 50.0 110.072 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.7 p90 -131.75 177.28 7.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.238 -0.914 . . . . 50.0 110.282 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.483 ' O ' ' HG2' ' A' ' 45' ' ' LYS . . . -80.54 101.31 2.0 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.677 -1.369 . . . . 50.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -113.06 105.09 13.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -1.095 . . . . 50.0 110.208 179.869 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.689 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.7 p -148.6 107.53 3.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.112 -0.992 . . . . 99.989999999999995 110.567 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.642 HG21 HG12 ' A' ' 46' ' ' ILE . 6.7 m -160.84 42.12 0.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.679 -1.263 . . . . 99.989999999999995 110.602 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -65.14 -5.95 7.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.14 -0.975 . . . . 99.989999999999995 109.906 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 mmtm -83.44 61.21 6.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 50.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 1.061 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -101.44 142.44 32.82 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.204 -0.935 . . . . 50.0 109.668 179.45 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 t -127.13 97.58 4.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.154 -0.966 . . . . 50.0 110.197 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 11.4 p90 -63.0 118.06 7.3 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.36 -0.837 . . . . 50.0 110.04 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -102.22 -22.41 14.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.093 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -138.06 145.99 42.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 50.0 110.137 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.432 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 22.9 p30 -66.83 162.62 50.74 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 50.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.478 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.0 Cg_endo -72.14 114.48 3.99 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.966 1.509 . . . . 50.0 110.37 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -105.02 140.13 38.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.284 -0.885 . . . . 50.0 110.368 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -90.53 111.24 22.45 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.36 -0.837 . . . . 50.0 110.184 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.5 59.02 5.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.228 -0.92 . . . . 50.0 110.158 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 128.31 -128.16 5.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -132.59 89.21 2.61 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -1.205 . . . . 50.0 110.138 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 30' ' ' THR . . . 113.68 31.05 2.43 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.521 -1.431 . . . . 50.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.464 HG23 ' O ' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -154.95 111.19 3.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.214 -1.168 . . . . 50.0 110.343 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 57.7 t -109.27 147.88 13.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.295 -0.878 . . . . 50.0 110.253 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.67 HG12 ' CD2' ' A' ' 80' ' ' LEU . 0.4 OUTLIER -124.92 118.26 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 50.0 110.318 -179.913 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.719 ' O ' HD23 ' A' ' 80' ' ' LEU . 0.6 OUTLIER -116.04 149.54 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.311 -0.868 . . . . 50.0 109.785 179.64 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.502 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.7 OUTLIER -126.69 104.87 8.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.207 -0.933 . . . . 50.0 110.534 -179.653 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.997 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.78 144.52 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.319 -0.863 . . . . 50.0 109.302 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.569 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.23 133.51 39.02 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.031 -1.043 . . . . 50.0 110.028 -179.688 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.796 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.8 t80 -94.0 97.56 10.42 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.065 -1.054 . . . . 50.0 109.863 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 59.1 p -95.41 70.06 3.11 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.27 -0.894 . . . . 50.0 110.14 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -122.39 129.38 7.53 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.575 -1.41 . . . . 99.989999999999995 109.575 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.0 p -92.86 24.78 3.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.274 -1.133 . . . . 99.989999999999995 110.244 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.2 p30 -98.43 -1.32 41.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.188 -0.945 . . . . 99.989999999999995 110.084 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -168.63 24.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.461 -1.456 . . . . 99.989999999999995 109.461 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.619 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.7 Cg_endo -73.56 153.4 49.39 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.976 1.513 . . . . 99.989999999999995 110.324 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.689 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.29 161.33 8.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.34 -0.85 . . . . 50.0 110.002 -179.378 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.565 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -76.04 133.86 40.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.095 -1.003 . . . . 50.0 109.305 178.951 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.061 HD13 ' CZ ' ' A' ' 17' ' ' PHE . 9.5 mt -89.25 108.41 24.26 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 120.996 -1.065 . . . . 50.0 110.157 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 47.6 Cg_endo -74.49 99.99 1.27 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 124.043 1.549 . . . . 50.0 110.7 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.82 ' CG1' HG13 ' A' ' 94' ' ' VAL . 2.6 mt -126.55 150.34 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 50.0 110.172 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.621 HG22 HG23 ' A' ' 51' ' ' VAL . 2.7 p -128.21 130.43 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.416 -0.802 . . . . 50.0 109.983 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.498 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.1 OUTLIER -115.35 106.47 14.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 50.0 109.931 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.621 HG23 HG22 ' A' ' 49' ' ' VAL . 2.9 t -132.78 163.09 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.187 -0.946 . . . . 50.0 110.698 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.511 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -56.24 164.43 1.31 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.485 -0.759 . . . . 50.0 110.393 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.647 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -58.69 122.28 13.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.441 -0.787 . . . . 50.0 110.598 -179.602 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.647 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 81.17 29.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.594 -0.691 . . . . 50.0 110.906 179.627 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.538 ' CB ' HG12 ' A' ' 51' ' ' VAL . 14.7 m120 -132.99 84.35 2.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 50.0 109.995 178.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 56' ' ' ASP . 10.4 m-20 -106.7 18.09 22.34 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.164 -0.96 . . . . 50.0 110.349 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 18.4 mtt -125.0 -8.93 7.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 50.0 110.474 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.635 HG22 ' HD2' ' A' ' 59' ' ' PRO . 0.2 OUTLIER -136.2 144.29 47.33 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.151 -0.968 . . . . 50.0 110.391 -179.854 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.635 ' HD2' HG22 ' A' ' 58' ' ' THR . 47.1 Cg_endo -74.48 125.8 9.85 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.036 1.545 . . . . 50.0 110.239 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.511 HG11 ' HB2' ' A' ' 52' ' ' ALA . 75.0 t -139.2 -36.22 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 50.0 110.093 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -79.49 161.65 46.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.023 -1.631 . . . . 50.0 109.023 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -123.63 156.92 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 50.0 110.532 -179.527 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.467 ' HA ' ' HG3' ' A' ' 83' ' ' MET . 1.2 mt -107.16 132.75 52.69 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.314 -0.866 . . . . 50.0 109.944 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 27.2 t -63.71 -17.27 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -0.946 . . . . 50.0 110.451 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 66' ' ' VAL . 6.2 t -147.11 167.42 24.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 50.0 110.193 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 67' ' ' ASN . 21.2 t -47.16 173.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 50.0 110.02 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.566 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 5.4 p30 -46.73 138.26 7.05 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.202 -0.936 . . . . 50.0 110.239 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.479 ' HB2' HD12 ' A' ' 46' ' ' ILE . 46.7 Cg_endo -74.01 103.05 1.6 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.934 1.492 . . . . 50.0 110.38 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.566 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -113.8 134.01 55.04 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.18 -0.95 . . . . 50.0 110.495 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.818 HG13 ' CB ' ' A' ' 75' ' ' ALA . 61.9 t -87.63 60.46 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 50.0 109.684 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.619 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.9 57.42 4.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.295 -0.878 . . . . 50.0 110.021 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.43 169.01 18.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 50.0 110.424 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.87 -7.15 34.19 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.872 . . . . 50.0 109.909 179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.11 12.59 11.12 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.31 -0.869 . . . . 99.989999999999995 110.242 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.818 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -77.15 6.82 5.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.079 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.555 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 2.4 m120 -84.62 19.56 1.97 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.333 -0.855 . . . . 99.989999999999995 109.384 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.672 ' O ' HG13 ' A' ' 79' ' ' VAL . 31.0 m -121.09 -172.54 2.42 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.414 -0.804 . . . . 99.989999999999995 109.177 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.444 ' HB3' ' OE2' ' A' ' 34' ' ' GLU . 6.8 mttp -63.21 88.06 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.235 -0.915 . . . . 99.989999999999995 109.064 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.997 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.2 m -76.95 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.331 -0.856 . . . . 99.989999999999995 109.318 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.719 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.4 OUTLIER -133.87 130.36 37.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.785 -1.197 . . . . 50.0 111.1 -179.66 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.5 t -120.45 168.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.476 -0.765 . . . . 50.0 109.947 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.5 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 4.0 mt-10 -132.96 147.99 52.28 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.179 -0.951 . . . . 50.0 110.176 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -146.83 143.17 28.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.214 -0.929 . . . . 50.0 110.393 -179.853 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.46 ' O ' ' HB2' ' A' ' 62' ' ' ARG . 0.2 OUTLIER -117.95 68.56 6.65 Favored Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.115 -0.991 . . . . 50.0 110.477 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.404 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.86 161.44 41.48 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 O-C-N 123.975 1.513 . . . . 50.0 110.358 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.425 ' HD3' ' HA2' ' A' ' 61' ' ' GLY . 45.8 Cg_endo -73.43 146.7 40.12 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 124.003 1.528 . . . . 50.0 110.446 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 87' ' ' PHE . 0.8 OUTLIER -52.74 135.18 35.82 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.281 -0.887 . . . . 50.0 110.07 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 124.81 165.63 12.19 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.52 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 92.8 m-20 -62.2 135.42 57.48 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -1.193 . . . . 50.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.572 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.7 OUTLIER -132.27 145.27 51.18 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.308 -0.87 . . . . 50.0 110.138 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.616 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.9 m-30 -100.74 113.16 25.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.081 -1.012 . . . . 50.0 110.026 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.5 mp -109.06 131.1 60.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 50.0 110.108 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 49' ' ' VAL . 71.3 t -124.89 118.86 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.17 -0.956 . . . . 50.0 110.437 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.82 HG13 ' CG1' ' A' ' 48' ' ' ILE . 21.7 t -101.41 93.78 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 50.0 109.88 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.524 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -156.15 170.73 33.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.784 -1.326 . . . . 50.0 109.784 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.544 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 15.9 ptp -112.2 -28.33 7.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.262 -1.14 . . . . 50.0 109.919 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLY . . . . . 0.544 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 171.3 -61.56 0.17 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -64.0 -108.41 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.232 -1.158 . . . . 50.0 110.268 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -79.62 127.98 32.83 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.093 -1.004 . . . . 50.0 110.182 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.77 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.8 pp0? -136.16 150.2 48.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.231 -0.918 . . . . 0.0 110.226 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.522 ' CG1' ' HB ' ' A' ' 94' ' ' VAL . 32.4 pt -102.95 148.94 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.974 -1.079 . . . . 0.0 110.186 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -132.27 142.39 49.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 110.397 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -128.46 166.74 18.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 110.193 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.586 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 43.2 p-80 -118.61 85.36 2.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.327 -0.858 . . . . 0.0 110.346 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.494 ' C ' ' CD1' ' A' ' 105' ' ' TRP . 1.7 t-105 -45.9 122.51 3.84 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.156 -0.965 . . . . 0.0 110.051 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.99 114.86 10.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 110.159 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -89.37 -8.64 52.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 110.163 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -172.69 131.06 0.54 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 110.114 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.38 38.52 3.19 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -140.81 123.09 15.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.141 -1.211 . . . . 0.0 110.251 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 117.99 -1.005 . . . . 49.57 110.175 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.437 ' O ' ' OD1' ' A' ' 1' ' ' ASP . 36.9 t0 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.267 0.556 . . . . 50.0 110.232 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -162.87 160.18 24.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.315 -0.866 . . . . 50.0 110.128 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.4 pp -78.7 121.02 24.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 50.0 110.176 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.55 94.15 6.24 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.279 -0.888 . . . . 50.0 110.149 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 tp -111.28 137.25 49.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.878 . . . . 50.0 110.004 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.24 165.25 24.58 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 50.0 110.254 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.88 17.64 48.57 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.612 -1.395 . . . . 50.0 109.612 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.9 p -102.22 101.45 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -1.189 . . . . 50.0 110.214 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.449 ' O ' ' O ' ' A' ' 10' ' ' TYR . 1.1 t -155.06 -177.83 6.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.241 -0.912 . . . . 50.0 110.17 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.449 ' O ' ' O ' ' A' ' 9' ' ' THR . 1.0 OUTLIER -46.79 174.47 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 50.0 110.335 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.98 124.17 7.69 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.672 -1.371 . . . . 50.0 109.672 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.56 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? -78.13 114.24 16.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.251 -1.146 . . . . 50.0 110.016 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.664 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 12.2 p -148.83 108.01 3.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 110.655 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.733 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.43 44.04 0.16 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.876 -1.14 . . . . 99.989999999999995 110.489 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.419 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.4 OUTLIER -76.83 10.43 2.25 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.147 -0.97 . . . . 99.989999999999995 110.615 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.492 ' HE2' ' HA2' ' A' ' 39' ' ' GLY . 0.0 OUTLIER -111.48 61.85 0.61 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.028 -1.045 . . . . 50.0 110.59 -179.964 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.883 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -94.68 148.74 21.96 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.093 -1.004 . . . . 50.0 109.994 179.603 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.607 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 28.6 t -125.15 114.31 18.85 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 50.0 110.153 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.691 ' CD1' HD23 ' A' ' 35' ' ' LEU . 9.7 m-85 -64.94 112.92 3.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.26 -0.9 . . . . 50.0 110.188 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.538 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -96.51 -32.94 12.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.19 -0.944 . . . . 50.0 110.152 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.504 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.5 OUTLIER -138.96 163.03 33.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 50.0 110.229 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.449 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 36.7 p-10 -76.89 164.3 60.06 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 50.0 110.134 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HB2' HG11 ' A' ' 31' ' ' VAL . 44.6 Cg_endo -71.19 126.78 12.7 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.431 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -121.53 148.83 43.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.22 -0.925 . . . . 50.0 110.344 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 10.3 t70 -94.62 122.07 36.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 50.0 110.203 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.44 HG23 ' CG2' ' A' ' 32' ' ' VAL . 7.1 p -79.35 -51.33 9.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.166 -0.959 . . . . 50.0 110.278 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.425 ' O ' ' OD1' ' A' ' 25' ' ' ASP . . . -128.59 -108.1 1.38 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.641 -1.384 . . . . 50.0 109.641 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -127.11 108.37 10.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.127 . . . . 50.0 110.296 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 85.19 31.28 23.14 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.632 -1.387 . . . . 50.0 109.632 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.425 ' HA ' HG21 ' A' ' 64' ' ' VAL . 1.1 p -145.36 107.92 4.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.149 -1.207 . . . . 50.0 110.361 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 21.4 t -104.24 148.59 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 O-C-N 121.342 -0.849 . . . . 50.0 110.175 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.44 ' CG2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -122.65 132.81 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 50.0 110.406 -179.882 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.832 HG23 HD11 ' A' ' 35' ' ' LEU . 8.4 tp -128.49 133.6 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.335 -0.853 . . . . 50.0 109.781 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.538 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 8.9 tt0 -108.54 111.34 23.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.187 -0.946 . . . . 50.0 110.572 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.938 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -125.2 143.12 51.1 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.32 -0.862 . . . . 50.0 109.183 179.299 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -89.45 126.01 35.4 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.98 -1.075 . . . . 50.0 109.925 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.583 ' CE1' ' HA3' ' A' ' 39' ' ' GLY . 1.3 t80 -93.56 101.77 13.96 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.987 -1.085 . . . . 50.0 109.357 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 79.5 p -96.36 69.73 2.66 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.281 -0.887 . . . . 50.0 110.261 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.583 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -117.47 130.77 9.01 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.334 -1.506 . . . . 99.989999999999995 109.334 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 36.9 m -84.42 25.55 0.86 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -1.176 . . . . 99.989999999999995 110.539 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.08 -0.91 26.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.077 -1.014 . . . . 99.989999999999995 110.219 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.33 -157.99 28.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.409 -1.477 . . . . 99.989999999999995 109.409 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.22 137.24 28.29 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.923 1.486 . . . . 99.989999999999995 110.265 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.664 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -153.02 161.18 42.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.855 . . . . 50.0 110.107 -179.432 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.568 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 26.8 mmtt -75.68 130.93 39.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 50.0 109.157 178.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.101 HD11 ' CG2' ' A' ' 70' ' ' VAL . 20.1 mt -89.71 107.31 18.0 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.088 -1.007 . . . . 50.0 110.672 -179.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.2 Cg_endo -74.84 100.7 1.37 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.031 1.543 . . . . 50.0 110.078 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.958 ' CG2' HD11 ' A' ' 92' ' ' ILE . 66.1 mt -135.87 146.83 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.165 -0.96 . . . . 50.0 110.563 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.535 HG22 ' HB ' ' A' ' 93' ' ' VAL . 15.7 m -121.41 161.7 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.353 -0.842 . . . . 50.0 109.664 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -132.72 104.33 6.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.127 -0.983 . . . . 50.0 110.119 -179.846 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.558 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.4 m -127.22 158.96 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.295 -0.878 . . . . 50.0 110.017 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB3' ' CG ' ' A' ' 55' ' ' ASN . . . -55.83 163.35 1.46 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.361 -0.837 . . . . 50.0 110.054 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.632 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.0 OUTLIER -59.53 118.53 6.16 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.255 -0.903 . . . . 50.0 110.454 -179.534 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.632 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.2 tp 79.53 30.51 0.29 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.568 -0.707 . . . . 50.0 110.673 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.4 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 6.5 m120 -124.51 84.87 2.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.284 -0.885 . . . . 50.0 110.341 179.266 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.77 9.82 40.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 50.0 109.88 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.8 mtt -123.44 -12.88 7.7 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 50.0 110.106 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.6 m -130.26 119.02 18.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.378 -0.826 . . . . 50.0 110.035 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.473 ' C ' HG23 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.55 136.94 29.42 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.922 1.485 . . . . 50.0 110.162 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.6 HG12 ' HG3' ' A' ' 86' ' ' PRO . 44.7 t -148.24 -37.37 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.176 -0.953 . . . . 50.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.81 145.18 37.95 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.817 -1.713 . . . . 50.0 108.817 179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.451 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.1 mmp_? -124.06 157.26 34.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.991 -1.3 . . . . 50.0 110.53 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.4 mt -101.67 127.43 48.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.298 -0.876 . . . . 50.0 109.731 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.528 HG11 ' CD ' ' A' ' 82' ' ' GLU . 22.8 t -64.5 -13.19 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 50.0 110.262 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' VAL . 14.0 t -140.8 165.97 26.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.215 -0.928 . . . . 50.0 110.215 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.797 HG12 ' H ' ' A' ' 67' ' ' ASN . 3.8 t -55.07 -170.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 50.0 109.881 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.797 ' H ' HG12 ' A' ' 66' ' ' VAL . 1.3 t-20 -46.31 132.66 7.62 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.023 -1.048 . . . . 50.0 110.08 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.719 ' O ' HD12 ' A' ' 46' ' ' ILE . 46.9 Cg_endo -73.51 75.36 3.01 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.042 1.549 . . . . 50.0 110.554 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.612 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.8 p90 -95.15 136.94 34.87 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.239 -0.913 . . . . 50.0 110.141 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.101 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.3 t -97.12 60.58 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 50.0 109.649 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -71.33 59.48 0.28 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.341 -0.849 . . . . 50.0 110.238 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.428 ' CG2' HG12 ' A' ' 70' ' ' VAL . 2.4 t -142.62 164.66 29.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 50.0 110.257 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.7 t -84.26 11.25 8.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.137 -0.977 . . . . 50.0 110.081 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -121.63 13.64 10.87 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 99.989999999999995 110.358 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.621 ' HB2' HG12 ' A' ' 70' ' ' VAL . . . -61.9 -10.98 10.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.18 -0.95 . . . . 99.989999999999995 110.172 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.496 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 63.5 m-20 -86.49 20.91 2.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.143 -0.973 . . . . 99.989999999999995 109.351 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.496 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.5 OUTLIER -132.69 -173.24 3.12 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.725 -179.872 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.477 ' HG3' ' OG ' ' A' ' 36' ' ' SER . 0.8 OUTLIER -64.34 89.56 0.06 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.196 179.256 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.938 HG22 ' O ' ' A' ' 35' ' ' LEU . 27.0 m -75.74 174.83 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.221 -0.924 . . . . 99.989999999999995 109.165 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.69 134.29 44.61 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.764 -1.21 . . . . 50.0 111.432 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.8 t -121.03 178.25 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.736 . . . . 50.0 109.696 179.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.528 ' CD ' HG11 ' A' ' 64' ' ' VAL . 10.5 tt0 -143.69 138.78 29.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.172 -0.955 . . . . 50.0 110.342 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.409 ' HG2' ' O ' ' A' ' 62' ' ' ARG . 2.4 mtm -147.25 145.44 29.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.151 -0.968 . . . . 50.0 110.383 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.498 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -118.07 70.05 7.66 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 121.341 -0.849 . . . . 50.0 110.563 -179.999 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.11 162.28 39.16 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.012 1.533 . . . . 50.0 110.126 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.6 ' HG3' HG12 ' A' ' 60' ' ' VAL . 47.1 Cg_endo -72.7 150.28 50.15 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 123.896 1.472 . . . . 50.0 110.335 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.54 120.56 5.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.197 -0.94 . . . . 50.0 110.029 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 134.64 178.31 15.56 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.562 -1.415 . . . . 50.0 109.562 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.42 ' HA ' ' O ' ' A' ' 105' ' ' TRP . 25.3 p-10 -77.17 141.05 40.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -1.14 . . . . 50.0 110.208 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.568 ' HA ' ' N ' ' A' ' 53' ' ' SER . 53.6 p -135.11 150.62 50.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 50.0 110.164 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.612 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 0.5 OUTLIER -96.94 105.02 17.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 50.0 110.275 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.958 HD11 ' CG2' ' A' ' 48' ' ' ILE . 0.0 OUTLIER -96.06 136.4 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.226 -0.921 . . . . 50.0 109.505 179.664 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.953 ' N ' HD13 ' A' ' 92' ' ' ILE . 33.5 t -123.84 117.54 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.131 -0.98 . . . . 50.0 110.88 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.756 HG13 HG12 ' A' ' 48' ' ' ILE . 97.0 t -106.14 95.03 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.328 -0.857 . . . . 50.0 109.893 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.59 170.3 33.51 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.665 -1.374 . . . . 50.0 109.665 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 9.2 mtm -80.4 -63.52 1.39 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -1.157 . . . . 50.0 110.178 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -156.06 -68.48 0.01 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.561 -1.416 . . . . 50.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -71.14 -75.58 0.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -1.11 . . . . 50.0 110.279 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -79.67 119.62 22.86 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.289 -0.882 . . . . 50.0 110.305 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.472 ' HB3' ' HA3' ' A' ' 95' ' ' GLY . 0.0 OUTLIER -140.54 148.72 41.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 110.091 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.7 mm -98.69 111.46 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.12 -0.988 . . . . 0.0 110.039 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 36.7 p-10 -101.57 130.37 47.86 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.154 -0.966 . . . . 0.0 110.275 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.601 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -128.93 170.62 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.355 -0.841 . . . . 0.0 110.324 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.477 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 50.0 p-80 -123.7 125.33 44.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.33 -0.857 . . . . 0.0 110.127 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.744 ' CZ3' HG21 ' A' ' 92' ' ' ILE . 9.1 m0 -123.33 132.58 54.04 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.182 -0.949 . . . . 0.0 110.328 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 52.5 p-80 -118.27 126.66 52.61 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.287 -0.883 . . . . 0.0 110.118 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LYS . . . . . 0.493 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 0.6 OUTLIER -89.61 -16.73 29.9 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 110.073 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.493 ' HB2' ' O ' ' A' ' 107' ' ' LYS . . . 179.73 141.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.418 -0.801 . . . . 0.0 110.21 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -86.32 110.6 3.51 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 29.7 p -114.99 44.06 1.86 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -1.144 . . . . 0.0 110.309 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.962 -1.018 . . . . 49.57 110.18 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.273 0.559 . . . . 50.0 110.204 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.82 155.2 50.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 50.0 110.141 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.441 ' HA ' HD22 ' A' ' 3' ' ' LEU . 0.2 OUTLIER -90.28 148.86 22.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.223 -0.923 . . . . 50.0 110.284 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.424 ' H ' HD13 ' A' ' 3' ' ' LEU . . . -82.03 92.64 6.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.321 -0.862 . . . . 50.0 110.183 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.21 151.8 27.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.895 . . . . 50.0 110.106 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.02 -176.32 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.245 -0.91 . . . . 50.0 110.046 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.72 43.11 2.62 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.517 -1.433 . . . . 50.0 109.517 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.48 164.67 0.67 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.331 -1.1 . . . . 50.0 110.227 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 p -46.67 155.42 0.25 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 50.0 110.064 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.23 104.75 13.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.222 -0.924 . . . . 50.0 110.282 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 44' ' ' CYS . . . -97.89 151.8 19.75 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 3.4 mtm -107.4 95.25 5.57 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.292 -1.122 . . . . 50.0 110.37 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.641 ' O ' HG23 ' A' ' 14' ' ' THR . 0.1 OUTLIER -112.24 -175.5 2.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 99.989999999999995 109.929 179.674 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.674 ' HA ' ' HG3' ' A' ' 47' ' ' PRO . 21.8 p -158.24 -76.55 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.342 -0.849 . . . . 99.989999999999995 110.307 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.538 ' O ' ' CG ' ' A' ' 15' ' ' GLU . 20.6 tt0 -118.76 8.46 11.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 110.351 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.534 ' HB3' ' CD1' ' A' ' 37' ' ' TYR . 0.9 OUTLIER -56.04 81.97 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.349 -0.845 . . . . 50.0 111.021 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.967 ' CD2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.26 142.06 12.7 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.174 -0.954 . . . . 50.0 110.205 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 m -127.75 97.46 4.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -0.892 . . . . 50.0 110.267 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p90 -57.12 119.55 6.53 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.25 -0.906 . . . . 50.0 110.249 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.15 -21.94 12.8 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.33 -0.856 . . . . 50.0 110.101 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.484 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 14.8 mttm -145.02 149.69 35.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.968 . . . . 50.0 110.278 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -67.66 159.45 78.48 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.849 . . . . 50.0 110.279 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.7 Cg_endo -72.93 134.16 21.13 Favored 'Trans proline' 0 C--N 1.303 -1.818 0 O-C-N 124.013 1.533 . . . . 50.0 110.401 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -130.51 155.32 46.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.231 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -83.69 148.46 27.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.232 -0.917 . . . . 50.0 110.122 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.62 22.22 3.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.193 -0.942 . . . . 50.0 110.207 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.28 -133.71 3.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.577 -1.409 . . . . 50.0 109.577 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -104.77 92.78 4.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -1.129 . . . . 50.0 110.343 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 84' ' ' GLU . . . 80.41 30.83 39.46 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.627 -1.389 . . . . 50.0 109.627 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 p -122.59 107.62 12.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.2 -1.176 . . . . 50.0 110.275 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 18.3 t -100.11 145.19 11.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.276 -0.89 . . . . 50.0 110.099 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -122.42 148.9 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.147 -0.971 . . . . 50.0 110.388 -179.73 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.824 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.1 tt -148.17 156.37 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 50.0 109.65 179.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.548 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 17.3 tt0 -126.09 103.81 7.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.117 -0.989 . . . . 50.0 110.696 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.951 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -121.84 140.17 52.72 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.349 -0.845 . . . . 50.0 109.263 179.4 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.547 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -92.7 132.84 36.58 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.044 -1.035 . . . . 50.0 110.107 -179.563 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.534 ' CD1' ' HB3' ' A' ' 16' ' ' LYS . 9.4 t80 -94.88 103.05 14.92 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.088 -1.045 . . . . 50.0 109.742 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 t -96.48 69.7 2.6 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.313 -0.867 . . . . 50.0 109.929 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.48 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -112.89 130.57 9.58 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.661 -1.376 . . . . 99.989999999999995 109.661 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.52 5.72 10.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 99.989999999999995 110.344 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.27 -1.35 42.1 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.213 -0.93 . . . . 99.989999999999995 110.116 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' CE2' ' A' ' 37' ' ' TYR . . . 80.93 -131.91 10.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.457 -1.457 . . . . 99.989999999999995 109.457 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.58 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 45.6 Cg_endo -73.0 131.01 16.21 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.888 1.467 . . . . 99.989999999999995 110.441 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.507 ' HA ' ' HA3' ' A' ' 11' ' ' GLY . 30.5 p -147.81 161.84 40.45 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.323 -0.861 . . . . 50.0 110.126 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.572 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 17.2 mmtt -87.23 108.67 19.04 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 50.0 109.929 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.967 HG21 ' CD2' ' A' ' 17' ' ' PHE . 4.2 mt -84.51 116.48 65.33 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 50.0 110.353 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.674 ' HG3' ' HA ' ' A' ' 14' ' ' THR . 47.2 Cg_endo -71.94 104.7 1.68 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 124.117 1.588 . . . . 50.0 110.344 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.013 HG12 HG22 ' A' ' 94' ' ' VAL . 1.2 mt -125.86 151.15 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 50.0 110.233 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.578 HG22 HG13 ' A' ' 51' ' ' VAL . 5.8 p -132.99 141.29 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.913 . . . . 50.0 110.051 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.528 ' O ' ' N ' ' A' ' 61' ' ' GLY . 3.5 m -115.64 104.79 12.05 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.311 -0.868 . . . . 50.0 109.887 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.578 HG13 HG22 ' A' ' 49' ' ' VAL . 30.4 m -131.78 162.94 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.265 -0.897 . . . . 50.0 110.322 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -55.58 163.97 1.17 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.422 -0.799 . . . . 50.0 110.18 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.636 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 10.2 t -63.15 118.26 7.68 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 50.0 110.711 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.599 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 77.21 30.76 0.52 Allowed 'General case' 0 N--CA 1.496 1.829 0 C-N-CA 119.876 -0.73 . . . . 50.0 110.765 179.485 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.48 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 10.5 m120 -134.9 84.95 2.14 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 50.0 110.032 179.124 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -104.53 18.54 22.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.273 -0.892 . . . . 50.0 110.373 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 ttt -102.87 -24.98 13.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -0.961 . . . . 50.0 110.136 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.41 138.59 27.28 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.462 -0.774 . . . . 50.0 110.196 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.468 ' HA ' HG12 ' A' ' 51' ' ' VAL . 47.0 Cg_endo -72.37 133.23 20.51 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.997 1.525 . . . . 50.0 110.361 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.7 t -143.86 -36.41 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.158 -0.964 . . . . 50.0 110.277 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.11 159.21 50.3 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.052 -1.619 . . . . 50.0 109.052 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.485 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 14.8 mtt-85 -129.36 156.22 44.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.049 -1.265 . . . . 50.0 110.372 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.757 HD23 ' HG3' ' A' ' 83' ' ' MET . 56.6 mt -94.89 124.67 39.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.276 -0.89 . . . . 50.0 110.132 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.673 HG23 ' N ' ' A' ' 84' ' ' GLU . 54.5 t -70.54 -38.93 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.198 -0.939 . . . . 50.0 110.122 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.73 175.72 6.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.317 -0.864 . . . . 50.0 110.086 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.6 m -57.92 -175.02 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.217 -0.927 . . . . 50.0 110.315 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.493 ' HB2' ' CD1' ' A' ' 69' ' ' PHE . 9.5 m-20 -46.93 156.91 0.51 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.264 -0.897 . . . . 50.0 110.045 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.643 ' HB2' HD12 ' A' ' 48' ' ' ILE . 48.1 Cg_endo -74.61 65.61 5.68 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.931 1.49 . . . . 50.0 110.9 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.604 ' CD2' ' O ' ' A' ' 69' ' ' PHE . 49.0 p90 -132.45 121.79 23.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.114 -0.991 . . . . 50.0 110.187 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.713 ' HB ' ' HB1' ' A' ' 75' ' ' ALA . 6.8 m -88.19 60.85 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.061 -1.024 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.58 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -66.09 65.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.3 -0.875 . . . . 50.0 110.307 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.564 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 1.5 m -142.49 159.26 42.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.2 -0.937 . . . . 50.0 110.244 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -86.16 -13.23 47.67 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.296 -0.878 . . . . 50.0 109.908 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.1 p -114.79 15.81 17.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.381 -0.824 . . . . 99.989999999999995 110.057 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.713 ' HB1' ' HB ' ' A' ' 70' ' ' VAL . . . -81.13 9.79 6.27 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.321 -0.862 . . . . 99.989999999999995 109.959 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.512 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 84.5 m-20 -85.2 16.86 3.31 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.335 -0.853 . . . . 99.989999999999995 109.441 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.628 ' O ' HG13 ' A' ' 79' ' ' VAL . 19.0 t -121.66 -172.44 2.43 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.412 -0.805 . . . . 99.989999999999995 109.352 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.483 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 2.4 mttp -62.96 88.33 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.442 -0.903 . . . . 99.989999999999995 109.068 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 35' ' ' LEU . 24.3 m -76.68 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.391 -0.818 . . . . 99.989999999999995 109.832 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -123.51 129.65 51.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.971 -1.08 . . . . 50.0 110.953 -179.642 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.476 HG23 ' CD1' ' A' ' 35' ' ' LEU . 2.0 t -116.35 178.03 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.388 -0.82 . . . . 50.0 109.872 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.488 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 66.2 mt-10 -153.3 151.0 29.5 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.069 -1.02 . . . . 50.0 110.354 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.757 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -149.54 130.86 14.65 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.236 -0.915 . . . . 50.0 110.267 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.673 ' N ' HG23 ' A' ' 64' ' ' VAL . 0.1 OUTLIER -106.57 72.72 0.3 Allowed Pre-proline 0 C--N 1.306 -1.285 0 O-C-N 121.255 -0.903 . . . . 50.0 110.802 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.505 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.1 Cg_endo -73.0 170.36 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.842 1.443 . . . . 50.0 110.089 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.35 157.0 57.83 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 123.974 1.513 . . . . 50.0 110.479 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -52.84 125.45 17.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.275 -0.891 . . . . 50.0 110.136 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 129.25 -161.15 22.68 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.51 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 15.3 p-10 -99.4 129.47 45.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.202 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 65.3 p -122.12 152.06 40.28 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.391 -0.818 . . . . 50.0 110.092 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.676 ' CZ ' ' CD2' ' A' ' 104' ' ' HIS . 1.8 m-30 -106.2 118.83 37.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 50.0 110.27 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.7 mp -109.08 133.32 54.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.259 -0.901 . . . . 50.0 109.83 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 18.7 t -123.61 128.21 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.038 -1.039 . . . . 50.0 110.769 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 1.013 HG22 HG12 ' A' ' 48' ' ' ILE . 35.5 t -107.82 88.77 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 50.0 109.98 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.499 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.84 -179.8 31.19 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.841 -1.304 . . . . 50.0 109.841 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.565 ' CE ' ' HB ' ' A' ' 14' ' ' THR . 3.8 ptp -99.05 -32.64 11.17 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -1.131 . . . . 50.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 175.86 -72.03 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.534 -1.427 . . . . 50.0 109.534 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -65.97 -82.82 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.239 -1.154 . . . . 50.0 110.102 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 118.24 21.32 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.209 -0.932 . . . . 50.0 110.182 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.538 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -140.32 148.77 41.86 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 110.308 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 66.2 mt -93.06 105.84 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.116 -0.99 . . . . 0.0 109.926 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -93.83 136.37 34.18 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.14 -0.975 . . . . 0.0 110.536 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.53 159.7 35.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.251 -0.905 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.676 ' CD2' ' CZ ' ' A' ' 91' ' ' TYR . 7.1 m170 -118.98 106.84 12.84 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.351 -0.843 . . . . 0.0 110.589 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.421 ' CE3' ' HG2' ' A' ' 23' ' ' PRO . 1.3 t-105 -88.35 91.58 8.85 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.221 -0.924 . . . . 0.0 110.146 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.435 ' O ' ' CG ' ' A' ' 106' ' ' HIS . 13.5 p-80 -99.84 134.55 42.58 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.267 -0.896 . . . . 0.0 110.287 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.83 -8.42 43.56 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 110.301 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -168.51 123.03 0.9 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.2 -0.937 . . . . 0.0 110.225 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -132.16 153.66 20.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.8 m -65.15 -150.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -1.167 . . . . 0.0 110.213 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.931 -1.033 . . . . 49.57 110.199 179.976 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 24.5 p-10 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.333 0.587 . . . . 50.0 110.211 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -88.72 138.89 31.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 50.0 110.247 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.555 ' O ' HD23 ' A' ' 3' ' ' LEU . 1.0 OUTLIER -80.96 164.25 22.7 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.292 -0.88 . . . . 50.0 110.308 -179.874 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.05 99.55 6.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.266 -0.896 . . . . 50.0 110.201 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.467 HD23 ' H ' ' A' ' 5' ' ' LEU . 0.5 OUTLIER -103.71 73.98 1.21 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.189 -0.945 . . . . 50.0 110.239 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 3.6 tttm -111.86 160.68 17.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.89 . . . . 50.0 110.189 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.84 -54.12 0.46 Allowed Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.47 -1.452 . . . . 50.0 109.47 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.8 t -107.66 163.43 13.09 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.288 -1.124 . . . . 50.0 110.123 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.26 76.3 0.98 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.285 -0.884 . . . . 50.0 110.175 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.435 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -114.86 177.91 4.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -0.895 . . . . 50.0 110.24 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.448 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -107.55 137.34 13.95 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.539 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.7 mtt -84.67 106.34 16.15 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.285 -1.127 . . . . 50.0 110.334 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.675 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 10.7 p -148.71 108.2 3.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.312 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.502 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 0.3 OUTLIER -160.54 61.7 0.32 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.888 -1.133 . . . . 99.989999999999995 110.55 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.458 ' HG3' ' HD2' ' A' ' 16' ' ' LYS . 0.5 OUTLIER -89.68 28.27 1.35 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.161 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.545 ' CD ' ' N ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -133.36 67.06 1.54 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 50.0 110.829 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.832 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -102.78 142.12 34.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.15 -0.969 . . . . 50.0 110.024 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -127.93 97.88 4.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.27 -0.894 . . . . 50.0 110.542 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.625 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 24.5 p90 -57.33 116.92 3.61 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.058 -1.026 . . . . 50.0 110.241 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.54 -18.05 14.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 50.0 109.994 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.516 ' HE2' ' HB2' ' A' ' 34' ' ' GLU . 21.1 mtmt -137.97 141.78 40.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.194 -0.941 . . . . 50.0 110.286 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 22' ' ' ASN . 16.0 p-10 -66.57 164.86 28.59 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.305 -0.872 . . . . 50.0 110.034 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.555 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 43.5 Cg_endo -71.09 136.46 29.56 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.983 1.517 . . . . 50.0 110.505 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' CG2' ' A' ' 32' ' ' VAL . . . -132.53 126.27 32.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.318 -0.864 . . . . 50.0 110.181 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.506 ' HA ' ' O ' ' A' ' 30' ' ' THR . 26.6 t0 -70.37 111.26 5.81 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.264 -0.898 . . . . 50.0 110.171 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.3 22.94 2.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -0.959 . . . . 50.0 110.243 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.04 -117.41 0.67 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.567 -1.413 . . . . 50.0 109.567 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' HIS . . . . . 0.504 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 1.1 p80 -129.72 89.42 2.82 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.256 -1.144 . . . . 50.0 110.322 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 101.25 -2.67 54.5 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.609 -1.396 . . . . 50.0 109.609 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 16.5 p -102.17 107.83 19.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.17 -1.194 . . . . 50.0 110.242 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.555 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 16.0 t -102.59 135.88 37.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.233 -0.917 . . . . 50.0 110.081 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -120.98 132.83 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.184 -0.947 . . . . 50.0 110.208 -179.885 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.052 HD13 ' N ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -134.73 144.16 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 50.0 109.682 179.734 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 1.052 ' N ' HD13 ' A' ' 33' ' ' ILE . 6.4 tt0 -109.68 130.8 55.48 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.201 -0.937 . . . . 50.0 110.872 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.089 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.1 mp -135.39 134.49 39.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.357 -0.84 . . . . 50.0 109.237 179.233 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -79.89 121.84 25.92 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.991 -1.068 . . . . 50.0 109.236 -179.822 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.58 ' CZ ' ' HA3' ' A' ' 39' ' ' GLY . 10.1 t80 -91.61 106.16 18.27 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.584 -1.247 . . . . 50.0 109.458 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.79 69.84 3.41 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.367 -0.833 . . . . 50.0 110.09 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -121.62 127.86 7.06 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.541 -1.424 . . . . 99.989999999999995 109.541 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.3 p -87.96 28.28 1.06 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -1.117 . . . . 99.989999999999995 110.272 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.463 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.9 p-10 -110.28 -0.92 17.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -0.917 . . . . 99.989999999999995 110.247 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.37 -157.41 23.94 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.408 -1.477 . . . . 99.989999999999995 109.408 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.72 153.82 54.04 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.034 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.675 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.18 157.48 6.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.144 -0.973 . . . . 50.0 110.126 -179.489 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 0.4 OUTLIER -70.56 125.76 27.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 50.0 109.256 179.171 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.892 HD11 ' CG2' ' A' ' 70' ' ' VAL . 2.0 mt -80.98 110.48 17.81 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.164 -0.96 . . . . 50.0 110.481 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.541 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.6 Cg_endo -75.33 84.43 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.034 1.544 . . . . 50.0 110.204 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.768 HG12 HG13 ' A' ' 94' ' ' VAL . 71.2 mt -124.29 149.26 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.917 . . . . 50.0 110.457 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.623 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.1 m -116.81 142.88 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 50.0 109.844 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 61' ' ' GLY . 22.8 m -122.56 100.88 7.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 50.0 110.016 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.536 ' O ' ' N ' ' A' ' 91' ' ' TYR . 36.0 m -129.02 157.49 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.334 -0.854 . . . . 50.0 110.238 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -56.21 163.95 1.45 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.389 -0.82 . . . . 50.0 109.998 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 12.7 t -62.12 121.3 12.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.167 -0.958 . . . . 50.0 110.491 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.644 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 80.07 30.39 0.24 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.61 -0.681 . . . . 50.0 110.738 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.587 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 11.4 m120 -135.41 84.29 2.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.144 -0.972 . . . . 50.0 110.182 179.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -106.75 8.57 30.99 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 50.0 110.471 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.07 -18.01 14.72 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.134 -0.979 . . . . 50.0 110.424 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 p -136.18 146.42 56.28 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.372 -0.83 . . . . 50.0 110.15 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.57 132.67 17.76 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.108 1.583 . . . . 50.0 110.496 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.583 HG12 ' HG3' ' A' ' 86' ' ' PRO . 2.9 t -133.83 -59.42 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -0.866 . . . . 50.0 109.817 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.3 154.12 51.45 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.69 -1.764 . . . . 50.0 108.69 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.432 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 6.2 mtt180 -142.83 156.71 45.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.963 -1.316 . . . . 50.0 110.681 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 1.1 mt -86.23 138.41 31.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.193 -0.942 . . . . 50.0 109.998 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.586 HG22 ' HG2' ' A' ' 84' ' ' GLU . 76.2 t -91.64 -29.79 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 50.0 110.458 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.472 ' O ' ' O ' ' A' ' 66' ' ' VAL . 10.1 t -95.1 176.11 6.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 50.0 110.219 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.543 HG12 ' N ' ' A' ' 67' ' ' ASN . 53.8 t -44.34 171.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.294 -0.879 . . . . 50.0 110.225 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.543 ' N ' HG12 ' A' ' 66' ' ' VAL . 7.4 p-10 -46.86 162.2 0.27 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 50.0 109.973 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.507 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.66 90.89 0.8 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.97 1.51 . . . . 50.0 110.319 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 1.166 ' CE2' ' HB2' ' A' ' 71' ' ' ALA . 2.2 t80 -149.6 121.79 8.34 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 50.0 110.366 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.892 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.2 t -88.27 63.42 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.232 -0.918 . . . . 50.0 110.064 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.166 ' HB2' ' CE2' ' A' ' 69' ' ' PHE . . . -70.56 64.78 0.29 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.233 -0.917 . . . . 50.0 110.251 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 70' ' ' VAL . 6.5 t -142.62 154.82 44.73 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.233 -0.917 . . . . 50.0 110.256 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 t -77.82 -2.83 38.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 50.0 110.082 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -117.93 23.14 11.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.247 -0.908 . . . . 99.989999999999995 110.187 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.569 ' O ' ' HB3' ' A' ' 37' ' ' TYR . . . -65.3 -5.61 7.67 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.267 -0.896 . . . . 99.989999999999995 110.418 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.425 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 76.5 m-20 -85.23 22.86 1.38 Allowed 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.032 -1.043 . . . . 99.989999999999995 109.339 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.624 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -131.59 -173.24 3.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.291 -0.88 . . . . 99.989999999999995 109.635 -179.802 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 17.3 pttt -63.92 89.11 0.05 Allowed 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.705 -0.798 . . . . 99.989999999999995 109.103 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 1.089 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.4 m -76.07 176.31 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.317 -0.864 . . . . 99.989999999999995 109.358 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.21 145.02 47.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.84 -1.162 . . . . 50.0 111.019 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.761 ' CG1' HG22 ' A' ' 33' ' ' ILE . 14.5 p -132.52 175.7 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.359 -0.838 . . . . 50.0 109.861 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 81' ' ' VAL . 3.9 mt-10 -140.29 144.87 36.63 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.085 -1.009 . . . . 50.0 110.605 -179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -160.24 136.64 8.81 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.265 -0.897 . . . . 50.0 110.165 179.758 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.586 ' HG2' HG22 ' A' ' 64' ' ' VAL . 2.9 pt-20 -106.13 73.96 0.31 Allowed Pre-proline 0 C--N 1.305 -1.343 0 O-C-N 121.263 -0.898 . . . . 50.0 110.579 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.7 Cg_endo -72.41 169.9 20.59 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.166 179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.583 ' HG3' HG12 ' A' ' 60' ' ' VAL . 45.5 Cg_endo -72.18 136.93 27.79 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 123.983 1.517 . . . . 50.0 110.097 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -53.71 103.49 0.08 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.236 -0.915 . . . . 50.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.17 -173.04 33.46 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.421 -1.471 . . . . 50.0 109.421 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.539 ' CB ' ' CD2' ' A' ' 106' ' ' HIS . 35.0 p-10 -69.34 145.52 52.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.275 -1.132 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.588 ' HA ' ' N ' ' A' ' 53' ' ' SER . 1.4 p -143.0 140.85 31.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.276 -0.89 . . . . 50.0 110.368 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.549 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 0.5 OUTLIER -97.13 119.94 36.56 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.217 -0.927 . . . . 50.0 109.532 179.567 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.46 HG23 ' O ' ' A' ' 92' ' ' ILE . 2.4 tt -114.96 132.08 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.141 -0.975 . . . . 50.0 110.38 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.623 ' HB ' HG22 ' A' ' 49' ' ' VAL . 45.3 t -120.74 120.81 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.054 -1.029 . . . . 50.0 110.405 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.768 HG13 HG12 ' A' ' 48' ' ' ILE . 62.0 t -109.0 99.64 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 50.0 110.107 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -153.64 160.44 29.28 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.616 -1.394 . . . . 50.0 109.616 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.463 ' SD ' ' HA ' ' A' ' 13' ' ' CYS . 4.4 ttm -115.5 -44.36 2.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -1.16 . . . . 50.0 110.271 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -115.32 -115.17 2.99 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.805 -1.318 . . . . 50.0 109.805 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.34 -35.07 17.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -1.133 . . . . 50.0 110.504 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -79.51 116.12 19.54 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.139 -0.976 . . . . 50.0 110.248 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.642 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.76 150.21 44.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -179.776 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.565 ' N ' HD12 ' A' ' 101' ' ' ILE . 4.4 mp -111.36 106.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.005 -1.059 . . . . 0.0 109.905 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.611 ' ND2' ' O ' ' A' ' 102' ' ' ASN . 0.6 OUTLIER -95.32 130.17 42.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 110.523 -179.703 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.605 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -115.38 160.79 19.41 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.373 -0.83 . . . . 0.0 109.834 179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.549 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 18.3 p-80 -121.6 86.64 2.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.198 -0.939 . . . . 0.0 110.386 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.496 ' O ' ' HA ' ' A' ' 89' ' ' ASP . 15.5 t-105 -58.06 93.59 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 110.051 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.539 ' CD2' ' CB ' ' A' ' 89' ' ' ASP . 1.6 t-80 -136.57 136.06 38.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.215 -0.928 . . . . 0.0 110.315 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -105.1 -8.05 18.72 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.874 . . . . 0.0 110.178 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -151.87 117.55 5.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.214 -0.929 . . . . 0.0 110.239 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -146.5 144.75 13.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -164.3 -179.9 6.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -1.171 . . . . 0.0 110.173 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.924 -1.036 . . . . 49.57 110.224 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.0 p30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.179 0.514 . . . . 50.0 110.234 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.8 ttmm -117.03 167.6 11.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.265 -0.897 . . . . 50.0 110.311 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -72.66 121.4 19.72 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.327 -0.858 . . . . 50.0 110.132 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -85.86 161.7 18.96 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.26 -0.9 . . . . 50.0 110.243 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mt -98.85 71.38 1.9 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 50.0 110.197 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -105.17 160.03 15.39 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.232 -0.918 . . . . 50.0 110.293 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.32 -35.05 1.85 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.373 -1.491 . . . . 50.0 109.373 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.521 ' O ' HG23 ' A' ' 8' ' ' THR . 2.6 t -127.8 113.76 16.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.303 -1.116 . . . . 50.0 110.056 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.8 p -94.45 98.96 11.23 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.114 -0.991 . . . . 50.0 110.226 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -105.68 173.86 6.13 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 50.0 110.082 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.17 137.68 14.86 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.619 -1.392 . . . . 50.0 109.619 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.8 ptm -81.52 117.72 22.15 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.265 -1.138 . . . . 50.0 110.236 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.4 p -149.06 107.89 3.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.229 -0.919 . . . . 99.989999999999995 110.485 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.32 51.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.629 -1.294 . . . . 99.989999999999995 110.759 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.593 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 2.0 pt-20 -78.9 12.19 2.29 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.084 -1.01 . . . . 99.989999999999995 110.005 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mptt -101.48 61.29 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.243 -0.911 . . . . 50.0 110.388 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.689 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -100.41 144.17 29.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.11 -0.994 . . . . 50.0 109.66 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.53 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 30.6 t -127.28 100.13 5.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.065 -1.022 . . . . 50.0 110.658 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.657 ' HB3' ' HE2' ' A' ' 103' ' ' HIS . 10.2 p90 -59.02 107.94 0.6 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.202 -0.936 . . . . 50.0 110.258 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -94.58 -23.51 17.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.907 . . . . 50.0 109.824 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.475 ' HE3' ' OE1' ' A' ' 34' ' ' GLU . 13.0 mttt -142.11 143.81 33.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 50.0 110.084 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 43.9 p-10 -66.77 162.82 48.49 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 50.0 110.209 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 46.5 Cg_endo -73.0 135.07 22.52 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.947 1.498 . . . . 50.0 110.285 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -136.55 156.83 48.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.191 -0.943 . . . . 50.0 110.317 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.427 ' HA ' ' O ' ' A' ' 30' ' ' THR . 13.8 t70 -85.53 148.53 25.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 50.0 110.043 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.626 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -116.91 -5.89 11.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.251 -0.905 . . . . 50.0 110.194 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -172.67 -105.77 0.19 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.318 -1.513 . . . . 50.0 109.318 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.59 88.8 2.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 50.0 110.024 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.429 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 97.93 31.23 6.72 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.557 -1.417 . . . . 50.0 109.557 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.62 HG23 ' H ' ' A' ' 26' ' ' THR . 0.8 OUTLIER -136.62 107.85 6.82 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.22 -1.164 . . . . 50.0 110.431 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.447 HG23 ' HD2' ' A' ' 85' ' ' PRO . 21.7 t -97.01 145.48 8.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.253 -0.905 . . . . 50.0 110.118 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.626 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -126.27 137.74 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.236 -0.915 . . . . 50.0 110.486 -179.834 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.816 HG23 HD11 ' A' ' 35' ' ' LEU . 3.3 tt -140.33 152.86 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 50.0 109.893 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 21' ' ' LYS . 2.0 tt0 -127.02 108.04 10.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.154 -0.966 . . . . 50.0 110.304 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.055 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -122.7 138.97 54.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.252 -0.905 . . . . 50.0 109.544 179.588 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.9 OUTLIER -91.77 132.07 36.67 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.086 -1.009 . . . . 50.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.642 ' CD2' HG11 ' A' ' 70' ' ' VAL . 8.3 t80 -93.87 95.7 9.26 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.911 -1.115 . . . . 50.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 81.8 p -96.11 69.52 2.76 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.305 -0.872 . . . . 50.0 109.977 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -119.3 131.0 8.8 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.318 -1.513 . . . . 99.989999999999995 109.318 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.1 m -84.71 21.93 1.44 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -1.135 . . . . 99.989999999999995 110.227 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.01 -2.09 44.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.918 . . . . 99.989999999999995 109.984 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.69 -159.39 31.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.597 -1.401 . . . . 99.989999999999995 109.597 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.595 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.6 Cg_endo -72.85 148.64 46.35 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.137 1.598 . . . . 99.989999999999995 110.497 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.736 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -170.42 161.43 7.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.924 . . . . 50.0 110.129 -179.582 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.58 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -74.81 128.3 35.24 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.091 -1.006 . . . . 50.0 109.563 179.35 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.993 HD11 ' CG2' ' A' ' 70' ' ' VAL . 9.6 mt -87.73 114.31 58.44 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.118 -0.989 . . . . 50.0 110.52 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.509 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.1 Cg_endo -76.88 101.72 1.54 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.063 1.56 . . . . 50.0 110.398 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.993 HD11 ' CG2' ' A' ' 46' ' ' ILE . 2.4 mp -129.04 155.11 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -0.927 . . . . 50.0 110.302 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 92' ' ' ILE . 14.8 p -130.65 145.32 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.294 -0.879 . . . . 50.0 109.814 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.452 ' HB2' ' C ' ' A' ' 61' ' ' GLY . 61.5 m -122.76 111.25 16.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.134 -0.979 . . . . 50.0 109.895 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 55' ' ' ASN . 35.9 m -135.91 161.49 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 50.0 110.561 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.688 ' HB3' ' ND2' ' A' ' 55' ' ' ASN . . . -56.2 164.44 1.29 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.471 -0.768 . . . . 50.0 110.097 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.655 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 1.3 m -60.31 114.64 3.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 50.0 110.292 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 79.72 30.49 0.27 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.548 -0.72 . . . . 50.0 110.498 179.776 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.688 ' ND2' ' HB3' ' A' ' 52' ' ' ALA . 7.6 m-20 -122.5 85.02 2.35 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 50.0 110.302 179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.66 16.81 24.62 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.945 . . . . 50.0 110.059 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 ttt -126.12 -10.23 6.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.314 -0.866 . . . . 50.0 110.348 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.14 115.65 14.12 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.226 -0.921 . . . . 50.0 110.212 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.64 127.77 12.75 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.96 1.505 . . . . 50.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 2.2 m -148.07 -33.67 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.253 -0.904 . . . . 50.0 110.294 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.452 ' C ' ' HB2' ' A' ' 50' ' ' SER . . . -71.64 146.35 40.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HB2' ' A' ' 83' ' ' MET . 4.6 mtt180 -139.12 156.95 46.77 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.071 -1.252 . . . . 50.0 110.736 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.468 HD13 ' HD3' ' A' ' 68' ' ' PRO . 5.9 mt -88.34 141.5 28.5 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 50.0 109.975 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.528 ' CG1' ' OE1' ' A' ' 82' ' ' GLU . 92.5 t -85.42 -12.76 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 50.0 110.213 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.956 HG23 ' OE2' ' A' ' 82' ' ' GLU . 0.0 OUTLIER -111.54 175.74 5.3 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.23 -0.919 . . . . 50.0 110.152 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.2 m -58.14 176.16 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.296 -0.877 . . . . 50.0 110.067 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.62 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 75.3 m-20 -46.83 141.92 5.24 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.208 -0.932 . . . . 50.0 109.992 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.482 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 50.2 Cg_endo -76.81 70.04 6.65 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.93 1.489 . . . . 50.0 110.896 -179.585 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 11.2 p90 -110.11 129.67 55.66 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.057 -1.027 . . . . 50.0 110.269 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.993 ' CG2' HD11 ' A' ' 46' ' ' ILE . 94.0 t -85.65 60.84 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 50.0 110.097 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.595 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.77 57.4 4.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.172 -0.955 . . . . 50.0 110.006 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.71 169.63 17.39 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.269 -0.894 . . . . 50.0 110.288 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 p -97.43 -4.34 38.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 50.0 109.833 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 93.2 p -121.19 9.47 10.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.324 -0.86 . . . . 99.989999999999995 110.538 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.929 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -78.51 8.11 5.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.047 -1.033 . . . . 99.989999999999995 109.941 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 20.1 m-80 -86.11 20.03 2.44 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.227 -0.92 . . . . 99.989999999999995 109.281 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.664 ' O ' ' HA ' ' A' ' 36' ' ' SER . 3.7 m -124.41 -173.08 2.69 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.386 -0.821 . . . . 99.989999999999995 109.359 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.54 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.0 OUTLIER -63.19 88.62 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.42 -0.8 . . . . 99.989999999999995 109.267 179.564 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 1.055 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.3 m -76.68 174.62 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.359 -0.838 . . . . 99.989999999999995 109.658 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.406 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -125.74 131.74 52.47 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.933 -1.104 . . . . 50.0 110.786 -179.76 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -125.46 176.62 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 109.917 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.956 ' OE2' HG23 ' A' ' 65' ' ' THR . 8.4 pt-20 -160.22 156.26 26.25 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -0.998 . . . . 50.0 110.354 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.568 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.8 OUTLIER -160.05 140.12 11.56 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -0.875 . . . . 50.0 110.291 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.429 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -104.11 86.36 1.28 Allowed Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.386 -0.821 . . . . 50.0 110.466 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 83' ' ' MET . 45.4 Cg_endo -71.44 170.16 19.11 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.818 1.431 . . . . 50.0 110.409 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.13 163.2 39.44 Favored 'Trans proline' 0 C--N 1.304 -1.814 0 O-C-N 124.036 1.545 . . . . 50.0 110.414 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.56 127.68 23.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.301 -0.874 . . . . 50.0 110.036 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.94 152.95 12.83 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.562 ' OD2' ' CE1' ' A' ' 106' ' ' HIS . 13.8 p30 -53.05 155.12 2.64 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 50.0 110.195 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.642 ' HA ' ' N ' ' A' ' 53' ' ' SER . 11.9 p -141.47 153.32 44.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.254 -0.904 . . . . 50.0 110.386 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.594 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.5 m-30 -104.72 119.72 39.67 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.253 -0.905 . . . . 50.0 110.119 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.789 HD13 ' N ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.91 129.7 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.166 -0.959 . . . . 50.0 110.027 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.789 ' N ' HD13 ' A' ' 92' ' ' ILE . 21.2 t -115.56 139.19 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.157 -0.965 . . . . 50.0 110.536 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.982 HG22 HG12 ' A' ' 48' ' ' ILE . 53.8 t -120.91 104.03 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.409 -0.807 . . . . 50.0 110.081 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.532 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.95 168.55 33.46 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.708 -1.357 . . . . 50.0 109.708 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.593 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 26.5 ttm -98.36 -71.41 0.69 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.244 -1.151 . . . . 50.0 110.296 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.95 36.38 0.3 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.508 -1.437 . . . . 50.0 109.508 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.44 ' OD1' ' OE1' ' A' ' 15' ' ' GLU . 0.9 OUTLIER -162.18 -46.96 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.328 -1.101 . . . . 50.0 109.823 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.53 129.93 39.72 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.364 -0.835 . . . . 50.0 109.709 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.783 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.96 150.42 44.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.707 -179.432 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 1.4 mp -112.08 123.91 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.131 -0.98 . . . . 0.0 109.761 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.514 ' CB ' HG22 ' A' ' 93' ' ' VAL . 9.4 p30 -101.0 139.44 36.68 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.17 -0.956 . . . . 0.0 110.686 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.657 ' HE2' ' HB3' ' A' ' 19' ' ' PHE . 5.6 m-70 -120.41 160.93 22.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.416 -0.802 . . . . 0.0 109.856 179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.567 ' CD2' ' O ' ' A' ' 104' ' ' HIS . 51.7 p-80 -118.38 92.28 3.78 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.204 -0.935 . . . . 0.0 110.509 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 2.3 t-105 -67.93 111.27 4.27 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.158 -0.964 . . . . 0.0 110.035 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.562 ' CE1' ' OD2' ' A' ' 89' ' ' ASP . 0.3 OUTLIER -131.22 138.89 49.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.248 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 6.3 tttm -72.36 -9.74 58.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.244 -0.91 . . . . 0.0 110.246 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.404 ' HB2' ' O ' ' A' ' 107' ' ' LYS . . . -176.47 151.85 1.0 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 110.141 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -130.02 -173.61 13.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -141.65 43.3 1.73 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.332 -1.099 . . . . 0.0 110.217 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.011 -0.995 . . . . 49.57 110.222 179.99 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 47.0 p30 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.189 0.518 . . . . 50.0 110.181 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.1 tptt -123.43 133.71 54.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 50.0 110.271 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.503 HD23 ' N ' ' A' ' 3' ' ' LEU . 0.3 OUTLIER -126.86 95.39 4.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 50.0 110.156 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -84.3 172.86 11.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 50.0 110.306 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.19 132.69 54.12 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.947 . . . . 50.0 110.132 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.28 -165.12 1.15 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 50.0 110.193 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.41 82.73 0.37 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.538 -1.425 . . . . 50.0 109.538 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -83.75 153.54 24.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -1.175 . . . . 50.0 110.388 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 99.2 m -74.66 100.84 4.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.292 -0.88 . . . . 50.0 110.174 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -133.23 152.73 51.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 50.0 110.213 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.34 111.03 3.42 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.48 -1.448 . . . . 50.0 109.48 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.511 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.4 mtt -73.81 117.58 15.75 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.19 -1.182 . . . . 50.0 110.241 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.644 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.75 107.55 3.84 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.054 -1.029 . . . . 99.989999999999995 110.558 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.694 HG21 HG12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -161.75 35.84 0.13 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.006 -1.059 . . . . 99.989999999999995 110.213 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.611 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 1.1 pp20? -66.52 -5.44 11.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 99.989999999999995 110.451 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.563 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 8.8 mmtm -89.28 61.51 5.73 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 50.0 110.542 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.912 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.0 OUTLIER -95.02 141.78 28.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.102 -0.999 . . . . 50.0 110.128 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.521 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.12 97.9 4.93 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 50.0 110.035 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.67 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 10.5 p90 -59.53 123.92 18.41 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.021 -1.049 . . . . 50.0 110.457 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.614 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.4 -23.96 12.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.335 -0.853 . . . . 50.0 109.969 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 11.8 mtmt -142.33 151.5 42.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 50.0 110.105 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -67.53 162.31 57.75 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 50.0 110.153 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.574 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.1 Cg_endo -71.86 127.79 13.39 Favored 'Trans proline' 0 C--N 1.303 -1.816 0 O-C-N 124.052 1.554 . . . . 50.0 110.3 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.98 147.83 46.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.257 -0.902 . . . . 50.0 110.37 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 30' ' ' THR . 18.5 t0 -87.75 148.11 24.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.885 . . . . 50.0 110.143 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.16 -69.55 0.86 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.125 -0.984 . . . . 50.0 110.237 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.41 -101.81 1.58 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.533 -1.427 . . . . 50.0 109.533 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 34.0 t60 -131.96 89.01 2.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -1.152 . . . . 50.0 110.342 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 100.15 5.92 54.18 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.661 -1.375 . . . . 50.0 109.661 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 14.4 p -101.9 107.67 18.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -1.169 . . . . 50.0 110.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.574 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 39.0 t -102.53 139.85 22.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.177 -0.952 . . . . 50.0 110.19 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.431 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -123.13 150.69 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -0.95 . . . . 50.0 110.319 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.929 HG23 HD11 ' A' ' 35' ' ' LEU . 0.6 OUTLIER -136.96 154.03 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.399 -0.813 . . . . 50.0 109.75 179.689 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.614 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.1 tp10 -119.55 91.44 3.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.129 -0.982 . . . . 50.0 110.9 -179.468 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.95 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -119.03 138.79 52.6 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.289 -0.882 . . . . 50.0 109.081 179.274 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -93.78 135.16 35.37 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.06 -1.025 . . . . 50.0 110.175 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.563 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 5.8 t80 -94.38 103.34 15.33 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.964 -1.094 . . . . 50.0 109.558 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.82 69.6 3.38 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.22 -0.925 . . . . 50.0 110.038 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.483 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -118.46 139.33 14.47 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.439 -1.464 . . . . 99.989999999999995 109.439 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 40' ' ' SER . 2.6 t -82.95 31.08 0.43 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -1.124 . . . . 99.989999999999995 110.298 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.477 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -108.33 -11.96 15.12 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 99.989999999999995 110.243 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 -139.84 19.31 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.488 -1.445 . . . . 99.989999999999995 109.488 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.478 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -71.16 139.67 35.92 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.987 1.52 . . . . 99.989999999999995 110.248 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.625 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -169.38 157.57 7.51 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -0.867 . . . . 50.0 110.014 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.563 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.3 mmtt -76.34 129.15 36.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 50.0 109.178 178.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.931 HD11 HG22 ' A' ' 70' ' ' VAL . 10.3 mt -86.34 109.36 22.75 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 50.0 110.714 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.563 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 52.3 Cg_endo -78.98 99.42 1.26 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 O-C-N 124.056 1.556 . . . . 50.0 110.129 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.066 HG23 HD11 ' A' ' 92' ' ' ILE . 6.9 mt -136.11 144.01 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.072 -1.018 . . . . 50.0 110.471 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.459 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 23.0 m -116.19 148.54 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.399 -0.813 . . . . 50.0 109.835 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.5 OUTLIER -124.19 105.8 9.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.146 -0.971 . . . . 50.0 109.86 -179.932 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.489 ' O ' ' N ' ' A' ' 91' ' ' TYR . 4.3 m -129.7 159.49 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.281 -0.887 . . . . 50.0 110.34 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -55.94 163.72 1.41 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.856 . . . . 50.0 110.027 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.602 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 37.6 t -58.44 122.25 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.26 -0.9 . . . . 50.0 110.739 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.602 ' CB ' ' O ' ' A' ' 53' ' ' SER . 1.2 tp 78.32 30.56 0.41 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.919 -0.712 . . . . 50.0 110.827 179.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.419 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 10.3 m120 -126.66 84.11 2.23 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -0.957 . . . . 50.0 110.198 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -106.42 8.61 31.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.279 -0.888 . . . . 50.0 109.917 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.7 ttm -116.11 -13.26 11.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.418 -0.801 . . . . 50.0 110.131 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.16 134.06 19.96 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.368 -0.832 . . . . 50.0 110.104 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.79 134.75 22.41 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.941 1.495 . . . . 50.0 110.258 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.412 HG11 ' HB2' ' A' ' 52' ' ' ALA . 55.3 t -139.31 -46.87 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.237 -0.914 . . . . 50.0 109.848 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -75.43 156.35 48.27 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.67 -1.772 . . . . 50.0 108.67 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.45 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 15.3 mtp180 -138.04 157.15 46.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.881 -1.364 . . . . 50.0 110.722 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.754 HD22 ' HD3' ' A' ' 68' ' ' PRO . 1.1 mp -91.3 134.65 34.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 50.0 109.737 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.544 HG23 ' C ' ' A' ' 83' ' ' MET . 4.0 t -72.83 -40.91 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.167 -0.958 . . . . 50.0 110.147 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 ' OE1' ' A' ' 82' ' ' GLU . 14.9 t -103.43 175.79 5.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.17 -0.956 . . . . 50.0 110.165 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 66' ' ' VAL . 6.5 m -54.76 -172.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.394 -0.816 . . . . 50.0 110.098 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.603 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 1.8 m-20 -47.45 137.78 8.96 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.952 . . . . 50.0 110.073 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.754 ' HD3' HD22 ' A' ' 63' ' ' LEU . 48.0 Cg_endo -75.14 74.32 4.11 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.974 1.513 . . . . 50.0 110.707 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.603 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -107.27 141.32 38.78 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.141 -0.974 . . . . 50.0 110.282 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.931 HG22 HD11 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -103.69 60.26 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 50.0 109.358 179.398 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -69.67 57.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.359 -0.838 . . . . 50.0 110.364 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.427 ' N ' ' O ' ' A' ' 70' ' ' VAL . 0.0 OUTLIER -142.38 165.09 28.37 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 50.0 110.104 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.68 7.32 17.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.151 -0.968 . . . . 50.0 110.117 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 8.0 t -121.47 17.62 11.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.26 -0.9 . . . . 99.989999999999995 110.488 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -69.03 -4.11 15.68 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.153 -0.967 . . . . 99.989999999999995 109.93 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.471 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 64.1 m-80 -88.58 24.01 2.09 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.364 -0.835 . . . . 99.989999999999995 109.416 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -129.31 -173.19 2.93 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.368 -0.832 . . . . 99.989999999999995 109.442 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.52 ' N ' ' OG ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -63.7 88.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.114 179.507 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.95 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.8 m -76.45 174.35 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.292 -0.88 . . . . 99.989999999999995 109.199 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.431 HD21 HG12 ' A' ' 32' ' ' VAL . 1.3 tt -134.71 136.6 42.84 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.736 -1.227 . . . . 50.0 111.084 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.571 HG21 ' HE2' ' A' ' 17' ' ' PHE . 2.1 t -117.33 166.73 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.456 -0.777 . . . . 50.0 109.751 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.545 ' OE1' HG21 ' A' ' 65' ' ' THR . 5.6 mt-10 -134.75 146.34 49.29 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.071 -1.018 . . . . 50.0 110.271 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.544 ' C ' HG23 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -159.95 151.64 20.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.18 -0.95 . . . . 50.0 110.347 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.507 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -120.93 60.94 9.11 Favored Pre-proline 0 C--N 1.306 -1.286 0 O-C-N 121.239 -0.913 . . . . 50.0 110.509 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.429 ' HD3' ' C ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.34 158.78 47.94 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.073 1.565 . . . . 50.0 110.201 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.88 146.76 48.42 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.044 1.549 . . . . 50.0 110.453 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -52.97 146.89 10.14 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.269 -0.894 . . . . 50.0 110.062 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 122.71 172.75 14.03 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.394 -1.482 . . . . 50.0 109.394 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.469 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 11.4 m-20 -71.73 128.55 36.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.208 -1.171 . . . . 50.0 110.161 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.567 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.6 p -124.82 141.86 51.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 50.0 110.157 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.605 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -99.69 116.66 32.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.221 -0.924 . . . . 50.0 110.035 179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 1.066 HD11 HG23 ' A' ' 48' ' ' ILE . 0.0 OUTLIER -103.83 133.88 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 50.0 109.947 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.899 ' N ' HD13 ' A' ' 92' ' ' ILE . 11.1 t -118.33 119.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.572 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.841 HG11 ' HB2' ' A' ' 17' ' ' PHE . 33.6 t -100.6 103.34 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 50.0 109.958 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.434 ' O ' ' HB2' ' A' ' 47' ' ' PRO . . . -155.25 147.78 17.2 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.484 -1.446 . . . . 50.0 109.484 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.611 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 12.3 ptp -102.28 1.71 36.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.257 -1.143 . . . . 50.0 110.224 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.89 -60.05 0.55 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.38 -77.61 0.23 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.23 -1.159 . . . . 50.0 110.205 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.5 mmtt -79.57 124.0 28.11 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.221 -0.925 . . . . 50.0 110.313 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.453 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.19 148.56 41.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.267 -0.895 . . . . 0.0 110.249 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.1 pt -137.29 130.13 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.243 -0.91 . . . . 0.0 110.232 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.451 ' CB ' HG22 ' A' ' 93' ' ' VAL . 34.0 p-10 -109.46 132.31 54.25 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.21 -0.932 . . . . 0.0 110.394 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.67 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -122.12 169.9 10.4 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.24 -0.912 . . . . 0.0 110.061 179.866 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.605 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 45.5 p-80 -118.68 123.89 46.03 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.213 -0.929 . . . . 0.0 110.4 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.693 ' CH2' HD13 ' A' ' 33' ' ' ILE . 26.1 m0 -106.55 145.1 32.29 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.294 -0.879 . . . . 0.0 110.23 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 30.9 p-80 -125.13 123.41 39.63 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 110.255 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -112.94 -6.6 13.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 110.245 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -174.57 111.94 0.15 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 110.038 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -133.66 165.51 24.16 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.7 t -82.57 132.0 35.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.319 -1.107 . . . . 0.0 110.17 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.002 -0.999 . . . . 49.57 110.294 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.158 0.504 . . . . 50.0 110.218 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.45 136.8 51.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.32 -0.862 . . . . 50.0 110.245 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.519 HD12 ' HA ' ' A' ' 3' ' ' LEU . 15.7 tp -82.07 142.21 32.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.274 -0.891 . . . . 50.0 110.043 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.43 149.54 36.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.194 -0.941 . . . . 50.0 110.434 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.2 mt -111.24 120.11 41.16 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.324 -0.86 . . . . 50.0 110.307 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -101.06 -170.21 1.81 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.275 -0.891 . . . . 50.0 110.03 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.74 20.47 44.82 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.588 -1.405 . . . . 50.0 109.588 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.1 p -83.88 161.43 20.87 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -1.112 . . . . 50.0 110.188 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -72.74 169.66 16.23 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.208 -0.933 . . . . 50.0 110.165 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -154.37 177.39 11.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.195 -0.941 . . . . 50.0 110.267 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.88 104.73 2.8 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.518 -1.433 . . . . 50.0 109.518 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.52 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 1.1 mtm -98.08 96.66 8.28 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -1.109 . . . . 50.0 110.025 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.707 ' O ' ' CB ' ' A' ' 44' ' ' CYS . 12.0 p -148.89 107.23 3.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.067 -1.021 . . . . 99.989999999999995 110.785 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.634 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.76 31.8 0.15 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.672 -1.267 . . . . 99.989999999999995 110.489 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HA2' ' A' ' 95' ' ' GLY . 10.3 tm-20 -71.01 -0.38 9.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -0.976 . . . . 99.989999999999995 110.106 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -87.94 61.68 6.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 50.0 110.403 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.605 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -94.72 146.28 24.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.894 . . . . 50.0 109.887 179.632 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.585 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 57.8 m -127.4 100.17 5.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.043 . . . . 50.0 110.659 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.719 ' CD1' HD23 ' A' ' 35' ' ' LEU . 16.1 m-85 -57.2 115.24 2.55 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.193 -0.942 . . . . 50.0 109.802 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -102.81 -27.0 12.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.24 -0.912 . . . . 50.0 110.476 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 4.9 mttt -145.53 151.43 38.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.183 -0.948 . . . . 50.0 110.23 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.1 p30 -67.09 154.97 91.53 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 50.0 110.232 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.556 ' HD2' ' CE3' ' A' ' 105' ' ' TRP . 46.6 Cg_endo -73.24 141.2 31.91 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 O-C-N 124.097 1.577 . . . . 50.0 110.419 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.477 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -146.63 168.07 22.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.274 -0.891 . . . . 50.0 110.29 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -89.07 154.62 20.04 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 50.0 110.341 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.63 -48.06 1.4 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.307 -0.87 . . . . 50.0 110.074 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.52 -101.48 2.32 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.453 -1.459 . . . . 50.0 109.453 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -133.15 93.69 3.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -1.155 . . . . 50.0 110.23 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.6 19.75 57.68 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 50.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 70.7 p -115.35 107.83 15.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.28 -1.129 . . . . 50.0 110.283 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 98.7 t -85.32 143.82 10.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.251 -0.906 . . . . 50.0 110.174 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -125.14 149.32 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.213 -0.929 . . . . 50.0 110.409 -179.884 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.799 HG23 HD11 ' A' ' 35' ' ' LEU . 2.0 tt -152.51 163.4 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -0.851 . . . . 50.0 109.906 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.803 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.6 OUTLIER -132.46 102.07 5.59 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.12 -0.988 . . . . 50.0 110.502 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -119.12 139.91 51.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.314 -0.867 . . . . 50.0 109.165 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -92.46 131.44 37.61 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.041 -1.037 . . . . 50.0 110.068 -179.457 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.613 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.6 t80 -92.12 98.79 11.76 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.984 -1.086 . . . . 50.0 109.497 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 t -96.11 69.76 2.77 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.318 -0.864 . . . . 50.0 110.028 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -118.46 132.22 9.63 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.631 -1.388 . . . . 99.989999999999995 109.631 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 45.3 m -83.95 18.5 2.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.231 -1.158 . . . . 99.989999999999995 110.317 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -99.92 -1.08 38.17 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.241 -0.912 . . . . 99.989999999999995 110.225 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.6 -149.93 29.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.105 -1.598 . . . . 99.989999999999995 109.105 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.59 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.9 Cg_endo -73.35 150.67 47.19 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.916 1.482 . . . . 99.989999999999995 110.406 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.707 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -169.87 161.48 9.0 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.377 -0.827 . . . . 50.0 109.96 -179.487 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.653 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 24.0 mmtt -75.61 111.03 10.51 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.018 -1.051 . . . . 50.0 109.229 178.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.014 HD11 HG23 ' A' ' 70' ' ' VAL . 2.2 mt -72.29 110.66 8.5 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.966 . . . . 50.0 110.423 -179.232 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 50.3 Cg_endo -84.54 97.67 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.026 1.54 . . . . 50.0 110.652 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.824 ' CD1' HG22 ' A' ' 46' ' ' ILE . 24.2 mt -133.33 153.76 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 50.0 110.243 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.738 ' O ' HG13 ' A' ' 49' ' ' VAL . 11.2 p -125.78 110.97 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 50.0 110.23 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.456 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -91.52 100.74 13.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 50.0 109.751 179.871 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.656 HG23 HG22 ' A' ' 49' ' ' VAL . 24.8 t -122.2 155.2 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 50.0 110.223 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.544 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -60.92 164.36 4.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.204 -0.935 . . . . 50.0 109.208 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.65 ' N ' ' HA ' ' A' ' 90' ' ' SER . 16.8 t -71.53 101.27 2.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.721 -1.237 . . . . 50.0 108.936 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.553 ' HB2' ' O ' ' A' ' 53' ' ' SER . 5.0 tp 170.68 -61.67 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 C-N-CA 118.071 -1.451 . . . . 50.0 111.661 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 58' ' ' THR . 60.4 m-20 -92.92 149.92 20.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.904 -1.123 . . . . 50.0 110.273 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -106.12 -20.61 13.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.226 -0.921 . . . . 50.0 110.187 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.9 ttp -126.55 31.31 5.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.282 -0.886 . . . . 50.0 110.27 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.536 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 59.6 m -126.87 120.62 22.81 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 50.0 110.171 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.5 126.0 11.16 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.968 1.509 . . . . 50.0 110.212 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 24.4 t -135.02 -47.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.91 . . . . 50.0 110.05 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.43 158.8 49.45 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.133 -1.587 . . . . 50.0 109.133 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.444 ' O ' ' HB2' ' A' ' 83' ' ' MET . 21.4 mtm180 -132.6 154.76 49.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.138 -1.213 . . . . 50.0 110.555 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.6 mt -94.15 129.67 40.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.383 -0.823 . . . . 50.0 109.866 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.527 HG23 ' HG2' ' A' ' 84' ' ' GLU . 24.2 t -80.84 -32.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.184 -0.948 . . . . 50.0 110.38 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' VAL . 15.2 t -79.33 168.35 19.64 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -0.964 . . . . 50.0 110.099 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.45 ' H ' HG13 ' A' ' 66' ' ' VAL . 7.3 m -50.99 179.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.191 -0.943 . . . . 50.0 110.057 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.64 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 14.1 m120 -46.96 143.62 4.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.204 -0.935 . . . . 50.0 110.058 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.873 ' C ' HD12 ' A' ' 46' ' ' ILE . 47.0 Cg_endo -73.56 66.42 4.65 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.963 1.507 . . . . 50.0 110.583 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.653 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 18.2 m-30 -118.3 121.84 41.42 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.895 . . . . 50.0 110.12 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.014 HG23 HD11 ' A' ' 46' ' ' ILE . 42.9 t -77.55 60.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.119 -0.988 . . . . 50.0 109.99 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -85.37 59.37 5.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.15 -0.969 . . . . 50.0 110.185 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -142.95 165.46 27.29 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 50.0 110.388 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -94.42 -4.4 48.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.308 -0.87 . . . . 50.0 110.005 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.62 7.91 11.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.304 -0.872 . . . . 99.989999999999995 110.204 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.985 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.05 8.58 3.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 110.102 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -86.56 19.29 2.91 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.266 -0.896 . . . . 99.989999999999995 109.25 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.589 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.1 p -128.68 -172.36 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.463 -0.773 . . . . 99.989999999999995 109.41 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.529 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 4.6 mttp -62.91 88.72 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.467 -0.893 . . . . 99.989999999999995 109.283 179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.9 m -76.43 173.85 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.318 -0.864 . . . . 99.989999999999995 109.418 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 33' ' ' ILE . 5.7 tt -126.18 125.56 42.66 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.933 -1.104 . . . . 50.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.541 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.2 t -122.29 166.03 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.387 -0.821 . . . . 50.0 109.868 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.431 ' OE1' ' C ' ' A' ' 81' ' ' VAL . 3.1 pm0 -147.4 160.29 42.73 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.181 -0.949 . . . . 50.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.509 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 2.5 ptt? -157.07 158.98 37.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 50.0 110.202 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 64' ' ' VAL . 0.4 OUTLIER -115.86 57.05 1.31 Allowed Pre-proline 0 C--N 1.307 -1.247 0 O-C-N 121.111 -0.993 . . . . 50.0 110.746 -179.781 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.509 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.9 Cg_endo -71.44 170.48 18.35 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.936 1.493 . . . . 50.0 110.5 179.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -70.36 161.67 45.16 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.998 1.525 . . . . 50.0 110.439 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -74.88 144.67 43.25 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.272 -0.893 . . . . 50.0 110.155 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.38 178.87 16.62 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.285 -1.526 . . . . 50.0 109.285 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -67.85 131.21 45.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 50.0 110.102 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.65 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -120.28 140.71 50.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.25 -0.906 . . . . 50.0 110.351 -179.912 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.637 ' C ' HD13 ' A' ' 92' ' ' ILE . 3.8 m-30 -94.02 104.72 16.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 50.0 109.788 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD13 ' A' ' 92' ' ' ILE . 3.2 mm -97.88 125.54 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 50.0 109.918 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.506 HG22 ' CB ' ' A' ' 102' ' ' ASN . 21.2 t -125.2 125.05 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.069 -1.02 . . . . 50.0 110.825 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 48' ' ' ILE . 95.4 t -106.87 105.01 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.858 . . . . 50.0 109.785 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.43 155.64 24.19 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.963 -1.255 . . . . 50.0 109.963 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.503 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 3.7 ttm -111.17 -69.21 0.88 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.39 -1.065 . . . . 50.0 110.297 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.71 28.55 0.23 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.62 -1.392 . . . . 50.0 109.62 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -160.56 -50.91 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.173 -1.192 . . . . 50.0 110.241 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -126.16 149.34 49.05 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.301 -0.875 . . . . 50.0 110.164 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.449 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.99 148.92 42.59 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 110.481 -179.876 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.712 HD13 ' N ' ' A' ' 102' ' ' ASN . 0.0 OUTLIER -126.2 124.23 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.331 -0.856 . . . . 0.0 109.552 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.712 ' N ' HD13 ' A' ' 101' ' ' ILE . 23.0 p-10 -111.26 134.83 52.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.073 -1.017 . . . . 0.0 110.843 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.707 ' CE1' HD11 ' A' ' 101' ' ' ILE . 0.1 OUTLIER -127.59 124.09 37.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.105 179.608 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -78.9 98.44 6.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.375 -0.828 . . . . 0.0 110.337 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.556 ' CE3' ' HD2' ' A' ' 23' ' ' PRO . 8.1 m95 -94.51 160.99 14.4 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.266 -0.896 . . . . 0.0 110.477 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 32.5 p-80 -150.82 136.72 18.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.293 -0.88 . . . . 0.0 109.986 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LYS . . . . . 0.401 ' O ' ' HG2' ' A' ' 107' ' ' LYS . 1.4 ttpm? -98.84 -9.02 24.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -100.44 126.66 46.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.942 . . . . 0.0 110.301 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -90.74 96.28 2.18 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 11.3 m -111.1 -68.9 0.9 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 117.97 -1.014 . . . . 49.57 110.329 -179.91 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.401 ' OD2' ' O ' ' A' ' 1' ' ' ASP . 4.7 p-10 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.214 0.531 . . . . 50.0 110.248 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.0 tptm -129.24 152.74 48.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.211 -0.931 . . . . 50.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 5.0 mt -103.97 137.31 42.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 110.149 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.89 143.22 49.04 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.224 -0.922 . . . . 50.0 110.258 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.1 77.99 4.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 50.0 110.233 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 158.71 15.3 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.282 -0.886 . . . . 50.0 110.135 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -116.33 87.13 0.43 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.592 -1.403 . . . . 50.0 109.592 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.81 148.81 38.14 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.214 -1.168 . . . . 50.0 110.15 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 70.7 p -80.46 99.2 7.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 50.0 110.401 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -153.47 157.66 40.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.231 -0.918 . . . . 50.0 109.993 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -91.41 139.63 14.85 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.759 -1.337 . . . . 50.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.615 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 10.4 mtp -73.31 109.33 6.75 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.305 -1.115 . . . . 50.0 110.045 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.7 p -148.95 107.35 3.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.994 -1.066 . . . . 99.989999999999995 111.196 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.67 HG23 ' CE1' ' A' ' 37' ' ' TYR . 2.6 m -161.58 53.95 0.26 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.731 -1.231 . . . . 99.989999999999995 110.549 179.286 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HB3' ' CB ' ' A' ' 96' ' ' MET . 18.7 pt-20 -75.29 4.72 6.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.089 -1.007 . . . . 99.989999999999995 110.181 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HD2' ' CA ' ' A' ' 39' ' ' GLY . 6.3 mttp -92.36 61.31 3.8 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.216 -0.927 . . . . 50.0 110.397 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 1.018 ' CE2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -96.65 145.87 25.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.05 -1.031 . . . . 50.0 109.926 179.647 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.584 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -127.17 104.42 7.95 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.209 -0.932 . . . . 50.0 110.392 -179.743 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.591 ' CD1' HD23 ' A' ' 35' ' ' LEU . 22.6 m-85 -60.97 96.87 0.05 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.248 -0.908 . . . . 50.0 110.39 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.67 -29.21 25.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -0.924 . . . . 50.0 110.01 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.522 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 14.4 mttm -144.68 147.03 32.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 50.0 110.091 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -73.79 162.12 75.57 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 50.0 110.163 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.616 ' HG2' ' CD2' ' A' ' 105' ' ' TRP . 44.8 Cg_endo -72.44 131.8 18.13 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.023 1.538 . . . . 50.0 110.222 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -126.25 147.86 49.6 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.183 -0.948 . . . . 50.0 110.358 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -77.81 113.76 16.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.314 -0.866 . . . . 50.0 110.186 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -79.19 -14.22 59.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 50.0 110.343 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.74 -106.58 0.22 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' HIS . . . . . 0.465 ' ND1' ' O ' ' A' ' 28' ' ' HIS . 9.4 p80 -121.98 102.67 8.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -1.144 . . . . 50.0 110.264 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 81.92 23.93 56.47 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.654 -1.378 . . . . 50.0 109.654 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 30.5 p -129.88 107.89 9.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.168 -1.195 . . . . 50.0 110.338 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.552 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -111.22 135.32 50.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.291 -0.881 . . . . 50.0 109.793 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 80' ' ' LEU . 1.4 t -114.65 136.75 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 50.0 110.542 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.03 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -141.89 133.2 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.459 -0.775 . . . . 50.0 109.499 179.784 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.574 ' N ' HD13 ' A' ' 33' ' ' ILE . 34.0 tt0 -112.21 117.52 32.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.141 -0.974 . . . . 50.0 111.274 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.03 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.76 143.77 51.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.363 -0.836 . . . . 50.0 108.969 178.945 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.61 132.42 40.78 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.98 -1.075 . . . . 50.0 110.209 -179.525 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.688 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.9 t80 -95.02 99.6 11.58 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.253 -0.979 . . . . 50.0 109.731 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.1 t -95.93 69.82 2.86 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.202 -0.936 . . . . 50.0 110.144 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.541 ' CA ' ' HD2' ' A' ' 16' ' ' LYS . . . -120.72 118.08 3.71 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.51 -1.436 . . . . 99.989999999999995 109.51 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.8 p -85.39 21.81 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -1.154 . . . . 99.989999999999995 110.419 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.87 -0.52 50.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 99.989999999999995 110.024 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.69 -172.54 26.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.435 -1.466 . . . . 99.989999999999995 109.435 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.561 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 42.8 Cg_endo -70.82 152.69 64.04 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.893 1.47 . . . . 99.989999999999995 110.195 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.73 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.04 161.59 8.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.223 -0.923 . . . . 50.0 109.902 -179.385 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.615 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.7 OUTLIER -77.29 129.18 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.159 -0.963 . . . . 50.0 109.583 179.373 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.049 HG22 ' CD1' ' A' ' 48' ' ' ILE . 10.0 mt -84.01 112.36 40.14 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.188 -0.945 . . . . 50.0 110.39 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.822 ' C ' HD12 ' A' ' 48' ' ' ILE . 50.0 Cg_endo -77.41 74.9 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 124.001 1.527 . . . . 50.0 110.306 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.049 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.4 mp -115.41 151.04 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.146 -0.971 . . . . 50.0 110.294 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 23.8 m -128.32 147.15 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.439 -0.788 . . . . 50.0 110.09 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -122.25 100.76 7.13 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.362 -0.836 . . . . 50.0 109.654 179.673 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.838 HG12 ' HA ' ' A' ' 59' ' ' PRO . 25.4 m -114.99 160.86 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.234 -0.916 . . . . 50.0 110.421 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.63 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -60.25 164.63 4.06 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.42 -0.8 . . . . 50.0 109.927 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.7 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 3.4 t -66.64 120.49 13.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.181 -0.949 . . . . 50.0 109.805 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.7 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.1 tp 87.18 29.27 0.03 OUTLIER 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.658 -0.652 . . . . 50.0 110.725 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.493 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 25.5 m120 -144.18 84.81 1.78 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.114 -0.991 . . . . 50.0 110.182 179.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.22 6.24 42.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.197 -0.939 . . . . 50.0 110.111 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.2 mmt -107.83 -14.59 14.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.26 -0.9 . . . . 50.0 110.081 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.3 p -133.14 119.83 15.82 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 50.0 110.04 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.838 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.84 125.85 10.83 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.942 1.496 . . . . 50.0 110.245 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.63 HG11 ' HB2' ' A' ' 52' ' ' ALA . 3.4 p -131.45 -33.72 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 50.0 110.025 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.91 143.45 34.95 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.697 -1.761 . . . . 50.0 108.697 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.469 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -126.62 156.27 41.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.055 -1.262 . . . . 50.0 110.794 -179.285 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -93.84 129.8 40.11 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.808 . . . . 50.0 109.927 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.636 HG11 ' HB2' ' A' ' 82' ' ' GLU . 4.0 p -54.07 -26.11 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.158 -0.964 . . . . 50.0 110.209 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -114.56 176.05 5.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.285 -0.885 . . . . 50.0 110.117 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 69' ' ' PHE . 15.5 m -59.15 -170.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.162 -0.961 . . . . 50.0 110.225 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.623 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 15.2 t30 -46.79 140.3 6.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 50.0 109.987 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.559 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 47.7 Cg_endo -74.84 78.07 2.93 Favored 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 123.989 1.521 . . . . 50.0 110.557 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.623 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.3 p90 -105.4 136.06 45.64 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.137 -0.977 . . . . 50.0 110.402 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.006 ' CG2' HD11 ' A' ' 46' ' ' ILE . 85.7 t -91.66 60.65 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 50.0 109.976 179.751 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -82.13 57.79 3.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.324 -0.86 . . . . 50.0 110.017 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 169.11 18.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.315 -0.865 . . . . 50.0 110.177 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -100.2 -5.59 27.43 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 50.0 109.977 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.8 t -121.25 10.12 10.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 110.507 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.827 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -80.77 10.43 4.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.018 -1.051 . . . . 99.989999999999995 110.004 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.519 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 96.6 m-20 -84.51 16.81 2.94 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.325 -0.859 . . . . 99.989999999999995 109.314 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.683 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.44 -172.42 2.36 Favored 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.441 -0.787 . . . . 99.989999999999995 109.347 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.541 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.2 OUTLIER -62.79 87.94 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.354 -0.938 . . . . 99.989999999999995 109.006 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.999 HG22 ' O ' ' A' ' 35' ' ' LEU . 13.4 m -77.18 175.97 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.356 -0.84 . . . . 99.989999999999995 109.685 -179.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -127.93 142.01 51.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.918 -1.114 . . . . 50.0 110.705 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.605 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.0 OUTLIER -134.54 166.66 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.423 -0.798 . . . . 50.0 109.867 179.745 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.636 ' HB2' HG11 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -145.11 152.45 40.07 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.289 -0.882 . . . . 50.0 110.266 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 9.7 ptt? -155.3 144.96 21.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 50.0 110.302 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -106.93 74.87 0.39 Allowed Pre-proline 0 C--N 1.305 -1.369 0 O-C-N 121.286 -0.884 . . . . 50.0 110.397 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.4 Cg_endo -72.88 167.71 26.57 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.914 1.481 . . . . 50.0 110.5 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.43 154.32 60.68 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.947 1.498 . . . . 50.0 110.584 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.94 134.26 48.6 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.237 -0.914 . . . . 50.0 110.04 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.87 -168.54 13.68 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.379 -1.489 . . . . 50.0 109.379 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.578 ' OD2' ' CG ' ' A' ' 106' ' ' HIS . 7.2 m-20 -82.91 153.16 25.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -1.16 . . . . 50.0 110.116 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -136.96 138.61 40.77 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.284 -0.885 . . . . 50.0 110.296 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.593 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.7 m-30 -99.23 124.3 44.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.097 -1.002 . . . . 50.0 109.797 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 92' ' ' ILE . 4.9 mp -111.0 132.35 59.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.249 -0.907 . . . . 50.0 110.159 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.658 HG22 ' CB ' ' A' ' 102' ' ' ASN . 20.9 t -125.16 120.81 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.822 -1.174 . . . . 50.0 111.365 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 1.015 HG22 HG13 ' A' ' 48' ' ' ILE . 94.9 t -98.19 106.56 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -0.849 . . . . 50.0 109.436 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.492 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.42 142.99 13.34 Favored Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.568 -1.301 . . . . 50.0 110.093 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.545 ' CB ' ' HB3' ' A' ' 15' ' ' GLU . 25.8 ttp -115.74 70.07 0.74 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -1.042 . . . . 50.0 109.957 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 56.03 18.9 20.89 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.559 -1.416 . . . . 50.0 109.559 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -149.36 -88.1 0.08 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -1.104 . . . . 50.0 110.098 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.446 ' O ' ' HA2' ' A' ' 95' ' ' GLY . 0.9 OUTLIER -79.76 155.18 28.04 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.244 -0.91 . . . . 50.0 110.322 -179.876 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.675 ' HG2' ' O ' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -140.75 87.74 2.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.182 -0.949 . . . . 0.0 110.695 179.768 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.705 ' O ' HG23 ' A' ' 101' ' ' ILE . 1.1 tp -85.32 116.45 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.015 -1.053 . . . . 0.0 109.781 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.658 ' CB ' HG22 ' A' ' 93' ' ' VAL . 22.5 p30 -106.77 151.94 24.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.853 . . . . 0.0 110.963 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.484 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.2 OUTLIER -129.67 156.94 43.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.5 -0.75 . . . . 0.0 109.573 179.787 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.567 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 3.3 m-70 -114.27 80.83 1.45 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.314 -0.867 . . . . 0.0 110.581 -179.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.616 ' CD2' ' HG2' ' A' ' 23' ' ' PRO . 10.4 t-105 -61.98 106.97 0.78 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.298 -0.877 . . . . 0.0 110.027 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.578 ' CG ' ' OD2' ' A' ' 89' ' ' ASP . 0.5 OUTLIER -104.86 139.27 39.86 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.266 -0.896 . . . . 0.0 110.367 -179.887 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LYS . . . . . 0.44 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 0.1 OUTLIER -61.82 -11.59 13.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.231 -0.918 . . . . 0.0 110.244 179.95 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.44 ' HB2' ' O ' ' A' ' 107' ' ' LYS . . . -178.02 156.24 1.03 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 110.134 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -155.75 147.06 15.3 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -174.7 -33.79 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -1.185 . . . . 0.0 110.19 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.41 ' O ' HG22 ' A' ' 111' ' ' THR . 16.8 m . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 118.031 -0.985 . . . . 49.57 110.183 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.263 0.554 . . . . 50.0 110.259 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.57 174.84 5.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.251 -0.906 . . . . 50.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.8 mt -88.94 141.94 28.06 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 50.0 110.121 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.07 159.12 23.04 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 50.0 110.279 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.3 tp -110.95 62.58 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 50.0 110.193 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 4.5 tptp -132.14 124.39 29.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.936 . . . . 50.0 110.324 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.01 131.36 2.58 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.541 -1.423 . . . . 50.0 109.541 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -53.81 166.61 0.32 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -1.112 . . . . 50.0 110.288 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.7 t -52.6 163.52 0.44 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.285 -0.884 . . . . 50.0 110.203 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -166.16 178.03 6.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.192 -0.942 . . . . 50.0 110.275 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.425 ' O ' ' HG2' ' A' ' 45' ' ' LYS . . . -106.16 160.13 14.79 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.638 -1.385 . . . . 50.0 109.638 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.535 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -111.0 120.47 42.49 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.279 -1.13 . . . . 50.0 109.952 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.678 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -141.15 106.64 5.06 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.216 -0.927 . . . . 99.989999999999995 110.848 -179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.891 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.98 35.63 0.12 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 99.989999999999995 110.288 179.029 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.446 ' HB2' ' HB3' ' A' ' 96' ' ' MET . 6.9 tm-20 -68.25 3.51 1.66 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.214 -0.929 . . . . 99.989999999999995 110.422 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.18 60.55 0.68 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 50.0 110.836 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.762 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -92.81 142.39 27.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.114 -0.991 . . . . 50.0 109.499 179.074 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.597 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.0 t -127.4 98.38 5.23 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.117 -0.989 . . . . 50.0 110.608 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.693 ' CD1' HD23 ' A' ' 35' ' ' LEU . 17.8 m-85 -56.02 97.1 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.23 -0.919 . . . . 50.0 109.857 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.06 -29.85 26.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 50.0 110.491 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.485 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 26.9 mttm -143.11 145.43 32.84 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.098 -1.001 . . . . 50.0 110.397 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.442 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 10.8 p30 -66.74 163.79 39.42 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 50.0 109.922 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.531 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.4 Cg_endo -71.78 134.59 24.15 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.903 1.475 . . . . 50.0 110.288 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -128.17 160.86 30.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.209 -0.932 . . . . 50.0 110.194 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -94.46 143.16 26.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.226 -0.921 . . . . 50.0 110.253 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.83 -39.66 5.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.223 -0.923 . . . . 50.0 110.157 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -142.72 -105.12 0.53 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.405 -1.478 . . . . 50.0 109.405 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -129.61 97.91 4.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.135 -1.215 . . . . 50.0 110.25 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.38 30.31 10.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 45.4 p -134.62 114.91 13.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.252 -1.146 . . . . 50.0 110.366 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 43.7 t -111.29 124.93 68.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.307 -0.871 . . . . 50.0 109.907 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.92 ' CG1' HD21 ' A' ' 80' ' ' LEU . 2.1 t -108.18 151.76 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.231 -0.918 . . . . 50.0 110.489 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.558 ' CG2' ' HB ' ' A' ' 81' ' ' VAL . 7.4 tt -150.45 166.96 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.448 -0.782 . . . . 50.0 109.515 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.74 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 6.4 tp10 -136.66 104.15 5.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.116 -0.99 . . . . 50.0 110.711 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.949 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -114.28 137.02 52.32 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.256 -0.903 . . . . 50.0 109.536 179.338 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 77' ' ' SER . 4.7 m -86.46 126.4 34.38 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.079 -1.013 . . . . 50.0 109.769 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.686 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.9 t80 -93.32 102.42 14.68 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.028 -1.069 . . . . 50.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -96.34 70.07 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.309 -0.869 . . . . 50.0 110.149 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -115.91 123.26 5.83 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.533 -1.427 . . . . 99.989999999999995 109.533 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.99 12.4 4.17 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.245 -1.15 . . . . 99.989999999999995 110.355 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' N ' ' OD1' ' A' ' 41' ' ' ASP . 0.8 OUTLIER -97.6 -1.73 43.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 99.989999999999995 110.016 179.837 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 91.15 -156.61 24.4 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.5 Cg_endo -71.47 150.89 58.62 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 124.035 1.545 . . . . 99.989999999999995 110.358 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.678 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.8 OUTLIER -170.73 162.69 7.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.269 -0.895 . . . . 50.0 110.036 -179.522 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.614 ' HD2' ' CG ' ' A' ' 69' ' ' PHE . 44.9 mmtt -72.89 131.74 42.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.103 -0.998 . . . . 50.0 110.045 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.086 HG22 ' CD1' ' A' ' 48' ' ' ILE . 2.4 mt -89.62 109.32 31.15 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.204 -0.935 . . . . 50.0 110.624 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.69 ' C ' HD12 ' A' ' 48' ' ' ILE . 51.9 Cg_endo -79.13 68.44 8.28 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.087 1.572 . . . . 50.0 110.14 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.086 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -111.59 145.62 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.161 -0.962 . . . . 50.0 110.25 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 34.1 m -118.14 139.13 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.334 -0.854 . . . . 50.0 110.108 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -119.9 100.66 7.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.326 -0.859 . . . . 50.0 109.806 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.7 m -124.0 159.82 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.306 -0.871 . . . . 50.0 110.284 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.51 163.88 1.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.392 -0.818 . . . . 50.0 109.766 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.829 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 2.2 m -73.57 104.27 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -0.993 . . . . 50.0 110.034 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.829 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 117.69 19.61 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.318 0 CA-C-O 121.113 0.482 . . . . 50.0 110.509 179.791 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -138.01 84.67 2.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.969 -1.082 . . . . 50.0 110.324 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.57 14.74 23.71 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.242 -0.911 . . . . 50.0 109.727 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 ttt -126.22 -12.99 6.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.327 -0.858 . . . . 50.0 110.383 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 3.6 m -128.58 129.78 23.53 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.913 . . . . 50.0 110.23 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.471 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.57 132.48 18.98 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 O-C-N 124.044 1.55 . . . . 50.0 110.182 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.86 -42.32 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.125 -0.984 . . . . 50.0 110.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.09 135.4 17.62 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.055 -1.618 . . . . 50.0 109.055 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.519 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.9 mtm180 -119.43 152.27 37.15 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.099 -1.236 . . . . 50.0 110.626 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mt -94.08 124.36 38.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.268 -0.895 . . . . 50.0 110.074 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.519 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 94.1 t -81.16 -38.8 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.218 -0.926 . . . . 50.0 110.364 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -65.84 172.73 3.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.186 -0.946 . . . . 50.0 110.095 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.436 ' H ' HG22 ' A' ' 66' ' ' VAL . 4.3 m -53.4 179.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.219 -0.926 . . . . 50.0 110.007 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.65 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.84 144.22 3.85 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 50.0 110.154 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.5 Cg_endo -73.59 66.52 4.67 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.999 1.526 . . . . 50.0 110.961 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.65 ' CD2' ' HB3' ' A' ' 67' ' ' ASN . 19.9 m-30 -126.31 122.37 35.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.317 -0.864 . . . . 50.0 110.07 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.914 HG23 HD11 ' A' ' 46' ' ' ILE . 41.1 t -70.31 61.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.047 -1.033 . . . . 50.0 109.879 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -96.07 66.35 2.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.166 -0.959 . . . . 50.0 110.212 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.67 169.44 17.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.297 -0.877 . . . . 50.0 110.292 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.08 -14.56 31.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 50.0 110.184 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 75.1 m -121.16 23.2 10.65 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 110.332 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.765 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -80.56 9.94 5.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.126 -0.984 . . . . 99.989999999999995 110.31 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -88.05 18.01 4.58 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.222 -0.924 . . . . 99.989999999999995 109.188 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.524 ' O ' ' HA ' ' A' ' 36' ' ' SER . 18.1 t -133.01 -171.91 2.8 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.554 -0.716 . . . . 99.989999999999995 109.551 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.54 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 0.4 OUTLIER -62.86 90.48 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 99.989999999999995 109.187 179.539 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.949 HG22 ' O ' ' A' ' 35' ' ' LEU . 31.4 m -76.19 172.01 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.286 -0.884 . . . . 99.989999999999995 109.555 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.92 HD21 ' CG1' ' A' ' 32' ' ' VAL . 7.8 tt -117.14 119.75 36.18 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.055 -1.028 . . . . 50.0 111.005 -179.388 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.731 HG21 HD13 ' A' ' 35' ' ' LEU . 2.9 t -108.58 169.91 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.33 -0.857 . . . . 50.0 109.571 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 2.6 mt-10 -151.17 151.29 31.71 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.034 . . . . 50.0 110.58 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.518 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 8.3 ptt? -160.36 153.3 21.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.865 . . . . 50.0 110.18 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.519 ' HG3' ' HB2' ' A' ' 62' ' ' ARG . 2.2 pt-20 -114.46 59.3 1.0 Allowed Pre-proline 0 C--N 1.306 -1.292 0 O-C-N 121.152 -0.967 . . . . 50.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.1 Cg_endo -71.34 170.24 18.83 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.859 1.452 . . . . 50.0 110.331 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.14 163.19 39.47 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.035 1.545 . . . . 50.0 110.363 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -72.33 144.15 48.4 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.172 -0.955 . . . . 50.0 110.168 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 118.32 -160.42 13.9 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.306 -1.517 . . . . 50.0 109.306 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.531 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 3.2 m-20 -90.45 146.98 23.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.255 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.54 ' HA ' ' N ' ' A' ' 53' ' ' SER . 78.8 p -130.33 143.75 50.96 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 50.0 110.078 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' A' ' 104' ' ' HIS . 0.1 OUTLIER -91.48 108.34 19.83 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.161 -0.962 . . . . 50.0 110.173 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.707 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.0 mp -101.22 125.75 55.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.281 -0.887 . . . . 50.0 109.355 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.866 HG22 ' CB ' ' A' ' 102' ' ' ASN . 26.3 t -124.7 117.41 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.893 -1.13 . . . . 50.0 111.268 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.923 HG13 HD11 ' A' ' 48' ' ' ILE . 15.0 t -95.25 105.98 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.321 -0.862 . . . . 50.0 109.34 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -133.91 140.11 11.49 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.683 -1.246 . . . . 50.0 110.064 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.566 ' HG3' ' HA ' ' A' ' 13' ' ' CYS . 10.0 tmm? -131.32 -26.28 2.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.368 -1.078 . . . . 50.0 110.239 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 166.73 -24.39 0.13 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.778 -1.329 . . . . 50.0 109.778 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -81.39 -70.16 0.56 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -1.163 . . . . 50.0 110.343 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -150.53 136.54 18.45 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.285 -0.885 . . . . 50.0 110.022 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.516 ' N ' ' CD ' ' A' ' 100' ' ' GLN . 1.9 mp0 -78.47 108.06 11.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.283 -0.886 . . . . 0.0 110.547 -179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.48 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 4.1 mt -94.88 110.75 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 110.131 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.866 ' CB ' HG22 ' A' ' 93' ' ' VAL . 0.5 OUTLIER -106.4 130.03 54.28 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.245 -0.909 . . . . 0.0 110.422 -179.948 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.93 134.72 44.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 110.187 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.62 ' NE2' ' CZ ' ' A' ' 91' ' ' TYR . 1.7 m-70 -72.32 140.91 48.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 110.073 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.707 ' HB2' HD13 ' A' ' 92' ' ' ILE . 2.4 m95 -134.22 137.66 44.53 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.158 -0.963 . . . . 0.0 110.4 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.466 ' CD2' ' N ' ' A' ' 106' ' ' HIS . 6.7 p80 -159.9 131.98 6.31 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 110.144 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.28 -10.19 59.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.232 -0.917 . . . . 0.0 110.205 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -98.33 111.22 23.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.21 -0.931 . . . . 0.0 110.279 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -98.13 -168.81 31.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.428 ' C ' ' OG1' ' A' ' 111' ' ' THR . 3.3 m -111.68 -57.68 2.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.202 -1.175 . . . . 0.0 110.126 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 110' ' ' SER . 4.1 p . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 117.999 -1.001 . . . . 49.57 110.138 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.284 0.564 . . . . 50.0 110.22 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.43 162.82 28.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 50.0 110.208 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.6 tp -113.34 146.68 39.05 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.247 -0.908 . . . . 50.0 110.13 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.59 155.55 17.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.893 . . . . 50.0 110.265 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 5' ' ' LEU . 0.5 OUTLIER -106.16 86.89 2.44 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.282 -0.886 . . . . 50.0 110.245 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -104.41 137.35 42.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.217 -0.927 . . . . 50.0 110.121 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.3 127.28 6.56 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.53 -1.428 . . . . 50.0 109.53 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.467 ' O ' ' N ' ' A' ' 10' ' ' TYR . 44.5 p -59.6 168.0 1.81 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -1.124 . . . . 50.0 110.274 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -45.44 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.272 -0.893 . . . . 50.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 8' ' ' THR . 1.2 m-85 -110.29 167.98 9.79 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.171 -0.955 . . . . 50.0 110.214 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -106.94 123.35 7.28 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.622 -1.391 . . . . 50.0 109.622 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.583 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -83.16 121.54 27.2 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.215 -1.168 . . . . 50.0 110.192 -179.913 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.793 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.83 105.58 3.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.021 -1.05 . . . . 99.989999999999995 111.507 -179.779 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.874 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.93 19.54 0.08 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.922 -1.112 . . . . 99.989999999999995 110.427 178.392 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 1.1 pp20? -57.77 -11.87 2.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.09 -1.007 . . . . 99.989999999999995 110.42 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 4.3 mptt -80.15 60.71 3.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 50.0 110.382 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.496 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -93.75 149.36 21.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.249 -0.907 . . . . 50.0 109.917 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.685 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 t -127.43 136.34 51.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.178 -0.951 . . . . 50.0 109.799 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.855 ' HZ ' HG21 ' A' ' 101' ' ' ILE . 0.4 OUTLIER -83.48 115.14 21.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.068 -1.02 . . . . 50.0 110.185 -179.769 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.71 -35.8 7.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.35 -0.844 . . . . 50.0 109.953 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.532 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 16.5 mttm -147.53 153.57 39.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.212 -0.93 . . . . 50.0 110.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 29.6 p-10 -68.26 165.16 36.37 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 50.0 109.875 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.8 141.58 37.6 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.854 1.449 . . . . 50.0 110.199 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -137.68 165.64 25.89 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.191 -0.943 . . . . 50.0 110.321 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -90.49 159.08 16.7 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 50.0 110.136 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HG21 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -134.24 -45.55 0.77 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.326 -0.859 . . . . 50.0 110.217 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -133.38 -111.51 1.26 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.496 -1.442 . . . . 50.0 109.496 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -128.68 91.39 3.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -1.124 . . . . 50.0 110.211 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.492 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 95.4 31.0 7.77 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.506 -1.438 . . . . 50.0 109.506 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.736 HG22 HG11 ' A' ' 64' ' ' VAL . 0.2 OUTLIER -137.04 110.24 7.81 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.238 -1.154 . . . . 50.0 110.42 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 41.3 t -95.94 149.19 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.273 -0.892 . . . . 50.0 110.059 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -124.06 148.5 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 50.0 110.577 -179.761 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.907 HG23 HD11 ' A' ' 35' ' ' LEU . 0.5 OUTLIER -147.36 142.3 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.42 -0.8 . . . . 50.0 109.776 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.908 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -109.53 101.98 10.87 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 50.0 110.309 -179.736 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.016 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.86 137.71 54.43 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.327 -0.858 . . . . 50.0 109.45 179.525 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -91.44 132.73 36.03 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.081 -1.012 . . . . 50.0 110.064 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.509 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 33.4 t80 -96.1 95.51 8.22 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.843 -1.143 . . . . 50.0 109.761 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.66 69.64 2.52 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.336 -0.852 . . . . 50.0 109.725 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.07 135.13 12.65 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.691 -1.364 . . . . 99.989999999999995 109.691 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 95.2 p -86.12 13.52 7.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 99.989999999999995 110.27 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -98.48 -20.0 17.34 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.264 -0.898 . . . . 99.989999999999995 110.134 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.64 -165.63 14.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.364 -1.494 . . . . 99.989999999999995 109.364 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.442 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.3 Cg_endo -73.28 140.42 30.59 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 123.868 1.457 . . . . 99.989999999999995 110.563 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.793 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -167.53 162.13 14.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.585 -0.697 . . . . 50.0 109.131 -179.887 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.583 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 9.9 mmtm -59.84 138.28 57.84 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.947 -1.095 . . . . 50.0 110.49 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.874 HG23 ' HB ' ' A' ' 14' ' ' THR . 1.5 mt -93.11 109.11 37.64 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 50.0 110.545 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.0 Cg_endo -75.55 96.06 1.03 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.154 1.607 . . . . 50.0 110.219 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.913 HG12 HG22 ' A' ' 94' ' ' VAL . 10.2 mt -132.38 145.57 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.881 . . . . 50.0 110.356 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.6 m -115.96 130.93 69.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.324 -0.86 . . . . 50.0 109.912 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.566 ' O ' ' N ' ' A' ' 61' ' ' GLY . 13.3 m -114.71 101.27 8.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 50.0 109.81 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.612 HG12 ' HA ' ' A' ' 59' ' ' PRO . 33.9 m -131.12 159.7 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.285 -0.885 . . . . 50.0 110.236 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.13 163.92 1.43 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 50.0 109.898 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 29.3 t -63.47 122.54 16.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.156 -0.965 . . . . 50.0 110.484 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.627 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 78.72 30.24 0.37 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.513 -0.742 . . . . 50.0 110.579 179.785 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.451 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 20.8 m120 -136.23 84.64 2.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 50.0 110.086 179.179 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -105.43 8.6 33.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.245 -0.909 . . . . 50.0 110.187 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.9 ttt -103.75 -18.29 14.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 50.0 109.921 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -136.08 128.51 17.59 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.508 -0.745 . . . . 50.0 109.911 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.612 ' HA ' HG12 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.46 132.31 20.41 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 123.931 1.49 . . . . 50.0 110.396 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.1 t -135.12 -43.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.342 -0.849 . . . . 50.0 109.771 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.78 149.4 44.75 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.685 -1.766 . . . . 50.0 108.685 179.236 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 9.5 mtp85 -141.07 157.03 45.87 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.85 -1.382 . . . . 50.0 110.908 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.557 HD12 ' N ' ' A' ' 63' ' ' LEU . 6.6 mp -94.32 129.54 40.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 50.0 109.845 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.736 HG11 HG22 ' A' ' 30' ' ' THR . 43.9 t -79.87 7.3 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.234 -0.916 . . . . 50.0 110.329 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.483 ' CG2' ' HB2' ' A' ' 82' ' ' GLU . 68.9 p -115.5 167.05 11.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.136 -0.978 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 65' ' ' THR . 16.7 m -52.87 -170.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 O-C-N 121.225 -0.922 . . . . 50.0 110.089 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -46.41 149.95 1.26 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.128 -0.982 . . . . 50.0 110.044 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.16 91.03 0.75 Allowed 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.006 1.529 . . . . 50.0 110.691 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 1.117 ' CZ ' ' HB2' ' A' ' 71' ' ' ALA . 1.2 t80 -155.12 121.51 5.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.345 -0.847 . . . . 50.0 109.932 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.82 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.5 p -95.43 60.84 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.252 -0.905 . . . . 50.0 110.166 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 1.117 ' HB2' ' CZ ' ' A' ' 69' ' ' PHE . . . -73.9 82.44 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 50.0 110.235 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.74 148.88 37.97 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.229 -0.92 . . . . 50.0 110.359 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.2 t -68.45 -15.57 63.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 50.0 109.874 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -121.09 23.31 10.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.301 -0.874 . . . . 99.989999999999995 110.373 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.673 ' CB ' HG22 ' A' ' 70' ' ' VAL . . . -72.32 1.34 7.94 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.099 -1.0 . . . . 99.989999999999995 110.397 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.509 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 57.8 m-80 -87.2 24.12 1.66 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.174 -0.954 . . . . 99.989999999999995 109.397 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.647 ' O ' HG13 ' A' ' 79' ' ' VAL . 2.3 p -128.7 -173.08 2.87 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.476 -0.765 . . . . 99.989999999999995 109.268 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.433 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -63.44 88.83 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.334 -0.854 . . . . 99.989999999999995 109.186 179.478 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 1.016 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.9 m -76.52 176.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.449 -0.782 . . . . 99.989999999999995 109.695 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 81' ' ' VAL . 2.5 tt -127.57 128.36 45.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.888 -1.132 . . . . 50.0 111.054 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.47 ' HB ' ' CG2' ' A' ' 33' ' ' ILE . 3.2 t -115.45 172.19 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.354 -0.841 . . . . 50.0 110.024 179.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.483 ' HB2' ' CG2' ' A' ' 65' ' ' THR . 2.6 mt-10 -148.1 140.79 24.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.169 -0.957 . . . . 50.0 110.195 179.867 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.468 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 6.7 ptt? -151.52 146.75 26.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.122 -0.987 . . . . 50.0 110.62 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.705 ' HG2' HG22 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -109.34 75.55 0.74 Allowed Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.408 -0.808 . . . . 50.0 110.132 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.26 159.43 47.08 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 124.044 1.549 . . . . 50.0 110.536 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -71.02 148.44 56.93 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.079 1.568 . . . . 50.0 110.685 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -58.82 137.23 57.84 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.295 -0.878 . . . . 50.0 110.203 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.78 -125.96 6.43 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.526 ' HB3' ' CB ' ' A' ' 53' ' ' SER . 19.9 t0 -120.51 146.03 46.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -1.147 . . . . 50.0 110.213 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -141.7 137.57 31.81 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -0.894 . . . . 50.0 110.247 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.59 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 1.9 m-30 -98.98 117.28 33.14 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 50.0 109.952 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.689 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.2 mp -109.5 133.2 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 50.0 110.139 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.57 ' HB ' HG22 ' A' ' 49' ' ' VAL . 11.5 t -124.8 121.39 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.03 . . . . 50.0 110.734 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.913 HG22 HG12 ' A' ' 48' ' ' ILE . 24.5 t -106.9 101.67 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.279 -0.888 . . . . 50.0 109.747 179.388 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.32 168.31 33.09 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.793 -1.323 . . . . 50.0 109.793 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.48 ' HG3' ' HG3' ' A' ' 47' ' ' PRO . 6.4 ttm -107.13 -55.15 2.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.395 -1.062 . . . . 50.0 110.175 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -166.37 -40.72 0.02 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.6 -85.26 0.22 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -1.172 . . . . 50.0 110.031 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.6 mmtm -79.72 128.87 33.95 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.262 -0.898 . . . . 50.0 110.061 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.498 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -132.53 149.75 52.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.855 HG21 ' HZ ' ' A' ' 19' ' ' PHE . 49.4 mm -122.81 122.5 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.117 -0.989 . . . . 0.0 110.258 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -109.99 136.57 49.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.349 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -124.43 164.54 19.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.886 . . . . 0.0 109.917 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -113.78 88.55 2.87 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.285 -0.884 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 92' ' ' ILE . 1.7 t90 -59.78 109.52 0.95 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.321 -0.862 . . . . 0.0 110.227 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -147.41 120.66 8.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 0.0 110.318 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.91 -7.46 14.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.269 -0.894 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -135.13 131.85 37.36 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.161 -0.962 . . . . 0.0 110.451 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -136.19 -141.86 4.39 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.17 101.48 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.157 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 70.7 p . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.042 -0.98 . . . . 49.57 110.229 -179.917 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.305 0.574 . . . . 50.0 110.164 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 4.3 mtpp -106.79 172.38 6.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.212 -0.93 . . . . 50.0 110.238 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.5 116.88 29.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.316 -0.865 . . . . 50.0 110.096 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.527 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . . . -81.93 159.54 23.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.895 . . . . 50.0 110.276 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.466 ' CG ' ' O ' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -105.71 81.67 1.7 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.331 -0.856 . . . . 50.0 110.268 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.527 ' HE2' ' CB ' ' A' ' 4' ' ' ALA . 33.3 mttm -104.7 -179.37 3.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.311 -0.868 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.21 35.84 3.8 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.639 -1.384 . . . . 50.0 109.639 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -52.68 144.0 14.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.238 -1.154 . . . . 50.0 110.162 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.579 ' O ' ' CG ' ' A' ' 10' ' ' TYR . 0.8 OUTLIER -44.64 156.37 0.08 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.286 -0.884 . . . . 50.0 110.199 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.579 ' CG ' ' O ' ' A' ' 9' ' ' THR . 0.8 OUTLIER -177.77 167.88 2.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.202 -0.936 . . . . 50.0 110.216 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.61 101.16 2.34 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.452 -1.459 . . . . 50.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 23.0 mtm -82.8 111.47 18.74 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.378 -1.072 . . . . 50.0 110.442 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.676 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 7.2 p -148.74 108.84 4.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.173 -0.954 . . . . 99.989999999999995 110.538 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.85 HG21 HG12 ' A' ' 46' ' ' ILE . 1.2 m -160.27 50.37 0.29 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.93 -1.106 . . . . 99.989999999999995 110.264 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.606 ' CB ' ' CB ' ' A' ' 96' ' ' MET . 3.8 pt-20 -77.88 28.18 0.17 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 99.989999999999995 110.743 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.446 ' HG2' ' C ' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -129.24 60.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.89 -1.131 . . . . 50.0 110.878 -179.87 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.829 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -91.98 143.69 26.22 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.136 -0.978 . . . . 50.0 109.743 179.328 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.632 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 m -127.33 103.85 7.61 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 50.0 110.466 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -61.24 98.38 0.08 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.153 -0.967 . . . . 50.0 110.0 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.589 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.88 -32.96 22.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 50.0 109.879 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 0.1 OUTLIER -142.54 145.23 33.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.352 -0.842 . . . . 50.0 110.187 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.482 ' HB2' ' CZ3' ' A' ' 105' ' ' TRP . 24.6 p30 -67.37 161.14 67.18 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 50.0 110.013 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.609 ' HG2' ' CD1' ' A' ' 105' ' ' TRP . 44.5 Cg_endo -71.55 126.07 11.79 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.909 1.479 . . . . 50.0 110.347 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -123.06 152.72 40.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 50.0 110.282 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.452 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.5 p30 -90.87 130.03 36.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 50.0 110.078 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.21 -0.69 22.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.18 -0.95 . . . . 50.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -174.59 -129.46 1.19 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.77 98.43 7.4 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -1.162 . . . . 50.0 110.225 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.29 28.23 23.18 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 3.8 p -130.15 107.55 9.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -1.206 . . . . 50.0 110.182 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.544 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 57.8 t -111.22 114.89 48.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 50.0 110.086 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.427 ' H ' HG22 ' A' ' 32' ' ' VAL . 5.2 m -94.56 139.45 18.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.208 -0.932 . . . . 50.0 110.522 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.087 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -143.57 137.38 25.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.4 -0.812 . . . . 50.0 109.678 179.68 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.898 ' N ' HD13 ' A' ' 33' ' ' ILE . 18.5 tt0 -113.08 117.24 31.44 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.078 -1.014 . . . . 50.0 110.883 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.087 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.15 141.54 51.45 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.306 -0.871 . . . . 50.0 109.407 179.233 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -86.84 123.66 32.21 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.072 -1.017 . . . . 50.0 109.753 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.707 ' CE1' HG23 ' A' ' 14' ' ' THR . 4.9 t80 -91.52 101.66 14.32 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.932 -1.107 . . . . 50.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.421 ' O ' ' HB3' ' A' ' 16' ' ' LYS . 0.2 OUTLIER -96.24 69.64 2.71 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.239 -0.913 . . . . 50.0 109.877 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.448 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -111.31 127.69 8.32 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.476 -1.45 . . . . 99.989999999999995 109.476 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 8.1 p -77.29 6.09 7.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.296 -1.12 . . . . 99.989999999999995 110.488 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.53 -3.7 42.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.215 -0.928 . . . . 99.989999999999995 109.925 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.42 -137.65 17.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.437 -1.465 . . . . 99.989999999999995 109.437 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.609 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 43.3 Cg_endo -70.91 142.42 42.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.968 1.509 . . . . 99.989999999999995 110.327 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.676 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.13 162.42 8.87 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.349 -0.844 . . . . 50.0 110.078 -179.403 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 25.7 mmtt -74.67 113.34 11.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 50.0 109.906 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.999 HG22 ' CD1' ' A' ' 48' ' ' ILE . 3.2 mt -74.51 117.08 59.29 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.112 -0.993 . . . . 50.0 110.072 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.835 ' C ' HD12 ' A' ' 48' ' ' ILE . 48.7 Cg_endo -81.79 70.13 7.35 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 124.087 1.572 . . . . 50.0 110.158 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.999 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -118.13 146.96 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 50.0 110.226 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.602 HG21 ' HB3' ' A' ' 59' ' ' PRO . 6.2 p -127.13 140.36 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.394 -0.816 . . . . 50.0 110.143 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.464 ' OG ' ' HG2' ' A' ' 83' ' ' MET . 75.2 m -107.32 100.5 9.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 50.0 109.8 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.94 HG22 ' HA ' ' A' ' 59' ' ' PRO . 59.4 t -107.72 157.0 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.313 -0.867 . . . . 50.0 110.127 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -71.94 164.23 26.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 50.0 109.215 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.621 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 29.6 t -70.79 100.86 1.98 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.74 -1.225 . . . . 50.0 109.321 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 173.19 -71.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 C-N-CA 118.52 -1.272 . . . . 50.0 111.382 -179.725 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.474 ' HB3' ' OG1' ' A' ' 58' ' ' THR . 80.8 m-20 -84.15 155.12 22.74 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.135 -0.978 . . . . 50.0 110.287 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -106.24 -23.5 12.55 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 50.0 110.118 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.38 37.09 4.38 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.268 -0.895 . . . . 50.0 110.267 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.502 ' O ' HG13 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -134.9 103.23 10.9 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.176 -0.952 . . . . 50.0 110.322 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.94 ' HA ' HG22 ' A' ' 51' ' ' VAL . 48.9 Cg_endo -73.72 125.84 10.31 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.063 1.559 . . . . 50.0 110.601 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.537 HG22 HG13 ' A' ' 51' ' ' VAL . 12.0 m -135.22 -28.07 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.338 -0.851 . . . . 50.0 110.271 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.82 170.78 48.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.895 -1.682 . . . . 50.0 108.895 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HG3' ' A' ' 83' ' ' MET . 14.8 mtt180 -140.36 155.91 46.6 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.045 -1.268 . . . . 50.0 110.602 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.593 HD22 ' HD3' ' A' ' 68' ' ' PRO . 2.2 mp -92.21 115.95 28.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 50.0 109.651 179.474 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.727 HG11 ' HG2' ' A' ' 82' ' ' GLU . 7.5 p -77.69 -34.54 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.087 -1.008 . . . . 50.0 110.352 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.544 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 7.3 t -82.58 173.28 12.1 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.087 -1.008 . . . . 50.0 109.821 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.458 ' C ' ' O ' ' A' ' 65' ' ' THR . 47.2 t -41.23 159.78 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.212 -0.93 . . . . 50.0 109.789 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.63 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 8.7 m120 -46.58 158.59 0.39 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 50.0 109.709 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.593 ' HD3' HD22 ' A' ' 63' ' ' LEU . 46.2 Cg_endo -73.61 65.83 4.72 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.882 1.464 . . . . 50.0 110.511 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.663 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 16.4 m-30 -126.23 121.68 33.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 50.0 110.034 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.857 HG13 HD11 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -86.97 60.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 50.0 109.589 179.487 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -71.75 59.35 0.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.415 -0.803 . . . . 50.0 110.158 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.443 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.3 OUTLIER -142.84 158.25 43.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.245 -0.91 . . . . 50.0 110.361 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.3 m -85.98 -10.64 54.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.372 -0.83 . . . . 50.0 109.698 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.99 14.59 16.13 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 99.989999999999995 110.124 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.443 ' HB2' ' HB ' ' A' ' 72' ' ' THR . . . -80.26 10.99 3.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -0.885 . . . . 99.989999999999995 109.964 179.702 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 3.2 m-20 -85.84 16.16 4.3 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.286 -0.883 . . . . 99.989999999999995 109.435 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.583 ' O ' ' HA ' ' A' ' 36' ' ' SER . 60.3 p -121.91 -172.75 2.5 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.496 -0.752 . . . . 99.989999999999995 109.299 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.467 ' HG3' ' HB3' ' A' ' 36' ' ' SER . 0.6 OUTLIER -63.14 88.65 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.177 -0.952 . . . . 99.989999999999995 109.077 179.506 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.908 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.0 m -76.35 176.08 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.33 -0.856 . . . . 99.989999999999995 109.603 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.76 127.15 44.62 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.945 -1.097 . . . . 50.0 110.759 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 t -118.43 169.72 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -0.918 . . . . 50.0 110.251 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.727 ' HG2' HG11 ' A' ' 64' ' ' VAL . 2.3 tt0 -138.23 135.7 35.83 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.288 -0.882 . . . . 50.0 110.065 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.486 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 1.6 mpp? -138.02 149.26 45.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.123 -0.986 . . . . 50.0 110.53 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.476 ' HG2' ' HB ' ' A' ' 64' ' ' VAL . 2.0 pt-20 -115.33 66.24 2.2 Favored Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.118 -0.989 . . . . 50.0 110.357 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.486 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.9 Cg_endo -73.09 164.62 34.96 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.026 1.54 . . . . 50.0 110.411 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.58 152.27 64.98 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.048 1.552 . . . . 50.0 110.405 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.9 OUTLIER -52.76 142.67 18.19 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 50.0 110.263 -179.855 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.39 161.75 14.67 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.345 -1.502 . . . . 50.0 109.345 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.552 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 74.9 m-20 -52.78 163.1 0.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -1.188 . . . . 50.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -142.37 135.85 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.1 -1.0 . . . . 50.0 110.828 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.621 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 5.4 m-30 -96.11 108.21 20.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.245 -0.91 . . . . 50.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.6 mp -90.29 137.86 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.224 -0.922 . . . . 50.0 109.789 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.542 ' HB ' HG12 ' A' ' 49' ' ' VAL . 22.0 t -125.59 108.33 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 120.882 -1.136 . . . . 50.0 111.421 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.682 HG13 HD11 ' A' ' 48' ' ' ILE . 59.5 t -85.36 107.44 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.173 -0.955 . . . . 50.0 108.896 178.41 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.517 ' HA2' ' HB3' ' A' ' 100' ' ' GLN . . . -90.3 170.23 35.49 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.783 -1.198 . . . . 50.0 110.254 -178.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.606 ' CB ' ' CB ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -153.54 13.89 0.49 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -1.041 . . . . 50.0 110.166 -179.811 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 136.36 -86.6 0.24 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.235 -1.546 . . . . 50.0 109.235 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -99.44 -68.71 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 50.0 109.971 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.89 151.66 30.04 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.201 -0.937 . . . . 50.0 110.04 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.517 ' HB3' ' HA2' ' A' ' 95' ' ' GLY . 0.0 OUTLIER -140.07 148.6 42.0 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.088 -1.008 . . . . 0.0 110.349 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.0 mt -90.94 146.72 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.152 -0.968 . . . . 0.0 109.638 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -132.83 132.02 41.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.108 -0.995 . . . . 0.0 110.845 -179.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.498 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.0 OUTLIER -118.71 152.92 35.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.391 -0.818 . . . . 0.0 109.518 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.597 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 16.8 p-80 -116.23 83.1 1.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.554 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.609 ' CD1' ' HG2' ' A' ' 23' ' ' PRO . 10.1 t-105 -58.51 93.89 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.934 . . . . 0.0 109.943 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.851 ' CE1' ' HB3' ' A' ' 108' ' ' ALA . 6.8 t60 -124.79 112.0 16.19 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.318 -0.863 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -6.9 23.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.296 -0.877 . . . . 0.0 110.396 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.851 ' HB3' ' CE1' ' A' ' 106' ' ' HIS . . . -56.7 138.84 52.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -0.975 . . . . 0.0 110.225 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 110' ' ' SER . . . -116.38 23.85 10.19 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 109' ' ' GLY . 25.8 m -43.44 -58.09 2.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.231 -1.158 . . . . 0.0 110.312 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.557 HG23 ' OXT' ' A' ' 111' ' ' THR . 8.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 118.002 -0.999 . . . . 49.57 110.193 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.22 0.533 . . . . 50.0 110.217 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.445 ' O ' HD22 ' A' ' 3' ' ' LEU . 5.8 pttt -140.19 172.16 13.15 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.317 -0.865 . . . . 50.0 110.163 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.469 HD13 ' HA ' ' A' ' 3' ' ' LEU . 2.1 mm? -117.28 154.17 31.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.291 -0.881 . . . . 50.0 110.268 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.74 102.17 10.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.937 . . . . 50.0 110.214 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.427 HD23 ' ND2' ' A' ' 67' ' ' ASN . 3.9 mp -111.16 166.74 10.83 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 50.0 110.01 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.68 -171.14 2.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 50.0 110.148 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -138.55 59.07 0.61 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.584 -1.406 . . . . 50.0 109.584 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.416 ' O ' ' C ' ' A' ' 9' ' ' THR . 10.4 p -72.11 161.09 31.38 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.216 -1.167 . . . . 50.0 110.14 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' THR . 0.8 OUTLIER -43.35 115.29 0.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.271 -0.893 . . . . 50.0 110.112 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 12.1 p90 -129.23 155.42 45.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.215 -0.928 . . . . 50.0 110.39 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.457 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -107.57 122.21 6.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.387 -1.485 . . . . 50.0 109.387 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.613 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -83.55 85.36 7.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.243 -1.151 . . . . 50.0 110.343 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.741 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 4.0 p -149.07 107.17 3.72 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.13 -0.981 . . . . 99.989999999999995 111.006 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.671 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -162.25 28.9 0.11 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.643 -1.286 . . . . 99.989999999999995 110.505 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 -11.31 3.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.12 -0.988 . . . . 99.989999999999995 110.236 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.45 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -71.0 61.05 0.26 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 50.0 110.429 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.748 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -105.62 141.4 37.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.155 -0.966 . . . . 50.0 109.859 179.564 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.8 OUTLIER -125.09 119.86 29.8 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.189 -0.944 . . . . 50.0 110.198 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.61 ' CE2' ' NE2' ' A' ' 103' ' ' HIS . 7.3 m-85 -63.13 115.25 4.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -0.931 . . . . 50.0 110.027 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.3 -28.34 11.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.241 -0.912 . . . . 50.0 110.103 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 19.0 mttm -146.14 151.94 38.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 50.0 110.171 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.88 164.04 61.78 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 50.0 110.218 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.504 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.9 Cg_endo -72.87 128.09 12.89 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.997 1.525 . . . . 50.0 110.206 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.654 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -125.23 152.84 44.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.913 . . . . 50.0 110.369 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.454 ' HA ' ' O ' ' A' ' 30' ' ' THR . 11.3 t70 -85.72 145.43 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.337 -0.852 . . . . 50.0 110.108 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -135.8 33.97 2.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.252 -0.905 . . . . 50.0 110.186 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.59 -109.87 0.41 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -128.02 88.99 2.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -1.155 . . . . 50.0 110.132 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 84' ' ' GLU . . . 87.11 -7.59 79.96 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.719 -1.352 . . . . 50.0 109.719 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.584 ' HA ' ' HG2' ' A' ' 84' ' ' GLU . 41.4 p -80.37 114.14 19.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -1.176 . . . . 50.0 110.194 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.566 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -106.47 141.46 21.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.224 -0.923 . . . . 50.0 110.326 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.654 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -112.41 142.4 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.269 -0.894 . . . . 50.0 110.334 -179.803 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.615 HG12 HD11 ' A' ' 35' ' ' LEU . 0.4 OUTLIER -141.37 140.26 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.348 -0.845 . . . . 50.0 109.706 179.695 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 18.3 tt0 -121.79 117.03 25.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -0.975 . . . . 50.0 110.535 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.102 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.5 OUTLIER -126.38 139.53 53.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.307 -0.871 . . . . 50.0 109.529 179.413 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.638 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.2 OUTLIER -87.77 126.94 35.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.059 -1.026 . . . . 50.0 109.704 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.553 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 32.2 t80 -90.47 95.72 10.3 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.77 -1.172 . . . . 50.0 109.71 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.4 t -94.58 70.02 3.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.246 -0.909 . . . . 50.0 110.032 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -121.75 126.76 6.61 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.515 -1.434 . . . . 99.989999999999995 109.515 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.44 25.31 1.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -1.161 . . . . 99.989999999999995 110.36 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -99.76 -0.96 38.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 99.989999999999995 110.051 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.4 -163.28 31.23 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.391 -1.484 . . . . 99.989999999999995 109.391 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.62 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.8 Cg_endo -72.71 151.6 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 124.019 1.536 . . . . 99.989999999999995 110.515 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.741 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 3.7 t -170.22 161.71 8.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.391 -0.818 . . . . 50.0 109.666 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 12' ' ' MET . 25.1 mmtt -77.23 121.5 23.76 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.009 -1.057 . . . . 50.0 110.047 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.005 HG22 HD11 ' A' ' 48' ' ' ILE . 2.8 mt -83.92 110.3 24.67 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.367 -0.833 . . . . 50.0 110.585 -179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.2 Cg_endo -80.47 106.29 1.84 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.009 1.531 . . . . 50.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.005 HD11 HG22 ' A' ' 46' ' ' ILE . 3.0 mp -123.2 142.94 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.163 -0.961 . . . . 50.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 93' ' ' VAL . 5.9 m -120.71 96.62 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.84 . . . . 50.0 109.724 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.451 ' HA ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -87.95 104.08 16.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.309 -179.625 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.718 HG12 ' H ' ' A' ' 60' ' ' VAL . 16.8 m -130.42 162.07 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.231 -0.918 . . . . 50.0 110.073 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -68.18 164.02 21.39 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.882 . . . . 50.0 109.304 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.607 ' N ' ' HA ' ' A' ' 90' ' ' SER . 2.2 t -67.61 99.9 0.83 Allowed 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 118.529 -1.268 . . . . 50.0 108.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.592 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 172.06 -67.15 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.264 -1.374 . . . . 50.0 111.458 -179.688 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -99.64 122.03 42.08 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.087 -1.008 . . . . 50.0 110.299 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -106.18 19.45 20.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.952 . . . . 50.0 110.074 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.19 -7.15 6.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.29 -0.881 . . . . 50.0 110.37 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.67 ' O ' HG11 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -134.44 140.88 37.05 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.19 -0.944 . . . . 50.0 110.288 -179.869 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.577 ' HA ' ' CG1' ' A' ' 51' ' ' VAL . 46.5 Cg_endo -73.07 136.13 24.21 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 124.072 1.564 . . . . 50.0 110.443 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.718 ' H ' HG12 ' A' ' 51' ' ' VAL . 52.8 t -147.18 10.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.216 -0.927 . . . . 50.0 110.381 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -110.08 170.78 14.39 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.271 -1.532 . . . . 50.0 109.271 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.544 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 5.1 mmt180 -107.07 145.13 32.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.101 -1.235 . . . . 50.0 110.218 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.486 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 0.1 OUTLIER -116.99 110.34 18.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 50.0 110.065 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.804 HG12 ' O ' ' A' ' 64' ' ' VAL . 73.5 t -100.07 42.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.168 -0.958 . . . . 50.0 110.124 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.494 ' OG1' ' N ' ' A' ' 82' ' ' GLU . 1.6 m -130.71 144.89 51.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.868 . . . . 50.0 110.096 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 65' ' ' THR . 26.0 m -52.72 -171.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.217 -0.927 . . . . 50.0 110.052 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 2.3 m-20 -46.83 115.46 3.34 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.128 -0.982 . . . . 50.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.625 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 45.0 Cg_endo -71.89 66.27 3.23 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.964 1.507 . . . . 50.0 110.136 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 68' ' ' PRO . 13.5 m-85 -135.76 123.62 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.474 -0.766 . . . . 50.0 110.054 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.99 HG23 HD11 ' A' ' 46' ' ' ILE . 53.4 t -71.97 60.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.038 -1.039 . . . . 50.0 109.84 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.62 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -86.63 57.47 4.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 50.0 109.828 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.3 169.13 18.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.328 -0.857 . . . . 50.0 110.337 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.25 -7.34 35.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 50.0 109.999 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 14.6 p -121.06 13.18 11.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.312 -0.868 . . . . 99.989999999999995 110.313 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.962 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.99 5.45 8.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 99.989999999999995 109.958 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 40.2 m-20 -83.42 20.41 1.35 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.313 -0.867 . . . . 99.989999999999995 109.391 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.661 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -122.51 -172.91 2.57 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.363 -0.835 . . . . 99.989999999999995 109.444 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.16 89.03 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.731 -0.788 . . . . 99.989999999999995 109.118 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 1.102 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.4 m -76.23 175.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.406 -0.809 . . . . 99.989999999999995 109.663 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 81' ' ' VAL . 0.8 OUTLIER -131.47 139.97 49.46 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.879 -1.138 . . . . 50.0 111.028 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.438 ' N ' HD23 ' A' ' 80' ' ' LEU . 0.2 OUTLIER -131.21 172.26 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.452 -0.78 . . . . 50.0 109.991 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.494 ' N ' ' OG1' ' A' ' 65' ' ' THR . 37.9 mt-10 -135.41 142.41 45.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.155 -0.966 . . . . 50.0 110.084 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.522 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -153.02 142.37 21.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.108 -0.995 . . . . 50.0 110.234 -179.71 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.642 ' HG3' HG21 ' A' ' 64' ' ' VAL . 1.5 mm-40 -110.79 67.89 0.56 Allowed Pre-proline 0 C--N 1.304 -1.37 0 O-C-N 121.022 -1.049 . . . . 50.0 110.619 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.566 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.26 155.78 55.79 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.978 1.515 . . . . 50.0 110.528 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.22 163.28 39.17 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.105 1.582 . . . . 50.0 110.463 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -73.54 138.46 45.01 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.201 -0.937 . . . . 50.0 110.172 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.43 -150.14 17.17 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.362 -1.495 . . . . 50.0 109.362 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.409 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 8.6 m-20 -92.3 137.11 32.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 50.0 110.0 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.607 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -130.23 133.4 46.51 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.23 -0.919 . . . . 50.0 110.247 179.984 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.522 ' O ' ' CG2' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -91.65 97.08 10.81 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.159 -0.963 . . . . 50.0 109.996 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 50' ' ' SER . 1.7 pt -102.56 116.95 47.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.271 -0.893 . . . . 50.0 109.839 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 102' ' ' ASN . 42.5 t -118.57 131.07 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 50.0 110.556 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.821 HG13 HG13 ' A' ' 48' ' ' ILE . 14.7 t -107.28 96.66 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.278 -0.888 . . . . 50.0 109.86 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.536 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.42 165.42 32.39 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.623 -1.391 . . . . 50.0 109.623 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.529 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 10.8 ptp -107.48 -33.41 7.36 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.282 -1.129 . . . . 50.0 110.316 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLY . . . . . 0.529 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 176.36 -63.21 0.1 OUTLIER Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.478 -1.449 . . . . 50.0 109.478 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -63.75 -107.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.204 -1.174 . . . . 50.0 110.132 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -79.29 123.35 27.37 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.111 -0.993 . . . . 50.0 110.161 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.781 ' NE2' ' O ' ' A' ' 100' ' ' GLN . 1.7 pp0? -131.41 150.17 52.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 110.064 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 46.0 mt -102.88 106.7 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.996 -1.065 . . . . 0.0 110.136 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.643 ' HA ' HG22 ' A' ' 93' ' ' VAL . 7.6 p-10 -97.4 130.8 44.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 110.196 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.61 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -126.99 160.45 31.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.34 -0.85 . . . . 0.0 110.238 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.403 ' CD2' ' H ' ' A' ' 104' ' ' HIS . 7.3 p80 -123.26 86.53 2.59 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 110.131 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.501 ' CH2' ' HA ' ' A' ' 107' ' ' LYS . 0.1 OUTLIER -51.76 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 110.042 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.472 ' N ' ' CE3' ' A' ' 105' ' ' TRP . 0.9 OUTLIER -104.55 106.47 16.98 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.326 -0.859 . . . . 0.0 110.194 -179.879 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 107' ' ' LYS . . . . . 0.501 ' HA ' ' CH2' ' A' ' 105' ' ' TRP . 0.0 OUTLIER -81.34 -10.36 59.57 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.309 -0.869 . . . . 0.0 110.274 179.956 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -118.09 -174.49 2.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.24 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -158.08 -73.84 0.02 OUTLIER Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -91.22 143.07 27.04 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.282 -1.128 . . . . 0.0 110.186 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 118.051 -0.976 . . . . 49.57 110.214 -179.972 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.31 0.576 . . . . 50.0 110.107 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.3 pttm -136.94 151.93 49.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 50.0 110.057 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.414 ' O ' ' HG ' ' A' ' 3' ' ' LEU . 0.5 OUTLIER -107.18 98.95 8.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.197 -0.94 . . . . 50.0 110.224 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.21 133.85 54.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.246 -0.909 . . . . 50.0 110.342 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.439 HD13 ' HA ' ' A' ' 5' ' ' LEU . 1.4 mm? -111.23 170.23 8.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 50.0 109.749 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 3.3 ttpt -100.97 142.99 31.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.129 -0.982 . . . . 50.0 110.334 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 122.84 -36.84 2.98 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.38 -1.488 . . . . 50.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -132.92 99.29 4.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -1.091 . . . . 50.0 110.102 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 10' ' ' TYR . 5.1 t -173.76 170.13 4.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.258 -0.901 . . . . 50.0 110.27 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.468 ' O ' ' O ' ' A' ' 9' ' ' THR . 0.6 OUTLIER -48.07 179.06 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.413 -0.804 . . . . 50.0 110.171 179.823 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.97 168.95 49.59 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.671 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? -112.3 127.96 56.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.269 -1.136 . . . . 50.0 110.299 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.705 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.13 105.88 3.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.111 -0.993 . . . . 99.989999999999995 111.151 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.908 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.22 25.09 0.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.115 -0.991 . . . . 99.989999999999995 109.938 178.458 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 96' ' ' MET . 17.9 tt0 -49.78 -18.67 0.51 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.316 -0.865 . . . . 99.989999999999995 110.375 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 1.2 mmtt -76.2 61.43 1.61 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 50.0 110.411 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.919 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -99.0 138.68 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.926 . . . . 50.0 109.94 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 12.7 t -128.29 97.47 4.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.205 -0.934 . . . . 50.0 110.621 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 6.7 p90 -56.5 117.95 4.34 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.993 -1.067 . . . . 50.0 109.836 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB1' ' HE2' ' A' ' 78' ' ' LYS . . . -107.34 -19.64 13.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 50.0 110.651 -179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.512 ' CE ' ' OE1' ' A' ' 34' ' ' GLU . 25.9 mttm -140.79 150.79 43.8 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.14 -0.975 . . . . 50.0 110.684 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -67.64 165.44 30.4 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.447 -0.783 . . . . 50.0 110.145 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.5 Cg_endo -72.75 142.89 36.39 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 124.012 1.533 . . . . 50.0 110.305 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -133.5 152.52 51.92 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.218 -0.926 . . . . 50.0 110.249 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.6 p30 -92.55 130.94 38.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -0.881 . . . . 50.0 110.338 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.401 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -100.66 -80.84 0.48 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 50.0 110.035 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.41 -109.14 0.61 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.431 -1.467 . . . . 50.0 109.431 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -129.73 97.32 4.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.276 -1.132 . . . . 50.0 110.145 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 96.84 8.8 56.8 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 82.5 p -103.2 128.22 50.25 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -1.084 . . . . 50.0 110.263 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 39.2 t -109.74 137.71 40.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.366 -0.834 . . . . 50.0 109.906 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.083 ' CG1' HD21 ' A' ' 80' ' ' LEU . 1.5 t -117.57 143.43 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 50.0 110.436 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.791 HG12 HD11 ' A' ' 35' ' ' LEU . 3.6 tt -142.93 145.11 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 50.0 109.759 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.564 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 17.7 tt0 -116.46 102.55 9.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.16 -0.962 . . . . 50.0 110.721 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 1.081 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.0 OUTLIER -113.56 136.77 52.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.259 -0.9 . . . . 50.0 109.536 179.45 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.624 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.4 OUTLIER -86.36 129.85 34.71 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.155 -0.966 . . . . 50.0 109.92 -179.57 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.617 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.7 t80 -95.59 99.6 11.45 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 118.983 -1.087 . . . . 50.0 109.869 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -96.27 72.29 2.83 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.116 -0.99 . . . . 50.0 110.135 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -124.67 124.03 5.27 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.532 -1.427 . . . . 99.989999999999995 109.532 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 29.45 2.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.212 -1.17 . . . . 99.989999999999995 110.265 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' OD1' ' C ' ' A' ' 41' ' ' ASP . 2.1 p30 -102.99 0.39 32.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.291 -0.881 . . . . 99.989999999999995 110.155 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.67 174.67 25.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.273 -1.531 . . . . 99.989999999999995 109.273 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.548 ' CB ' ' O ' ' A' ' 70' ' ' VAL . 45.0 Cg_endo -72.81 149.74 48.52 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.001 1.527 . . . . 99.989999999999995 110.599 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.705 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -167.47 162.66 14.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.439 -0.788 . . . . 50.0 109.56 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.671 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 23.2 mmtt -67.5 141.44 56.91 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.968 -1.082 . . . . 50.0 109.745 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.054 HG22 ' CD1' ' A' ' 48' ' ' ILE . 7.1 mt -90.78 108.81 30.21 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.299 -0.875 . . . . 50.0 110.649 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 49.9 Cg_endo -75.48 96.48 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 124.152 1.606 . . . . 50.0 110.955 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 1.054 ' CD1' HG22 ' A' ' 46' ' ' ILE . 0.5 OUTLIER -131.64 115.79 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 50.0 109.992 179.462 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.749 HG23 ' O ' ' A' ' 49' ' ' VAL . 18.0 m -93.07 107.44 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.852 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -86.18 100.88 12.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 50.0 109.765 179.869 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.567 ' O ' ' N ' ' A' ' 91' ' ' TYR . 95.7 t -118.71 150.56 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.313 -0.867 . . . . 50.0 110.468 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -67.51 164.73 18.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.373 -0.83 . . . . 50.0 109.62 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.639 ' N ' ' HA ' ' A' ' 90' ' ' SER . 5.4 t -70.05 101.84 1.9 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.834 -1.166 . . . . 50.0 109.424 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.498 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 171.0 -64.12 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.057 -1.457 . . . . 50.0 111.703 -179.906 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.537 ' CB ' ' HB ' ' A' ' 58' ' ' THR . 41.4 m-80 -88.05 164.99 15.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.094 . . . . 50.0 110.315 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 56' ' ' ASP . 49.9 t0 -105.9 -37.87 6.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 50.0 110.238 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.0 ttm -123.85 30.39 6.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 50.0 110.217 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.537 ' HB ' ' CB ' ' A' ' 55' ' ' ASN . 17.3 m -111.85 120.62 41.74 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.256 -0.902 . . . . 50.0 110.049 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.416 ' HA ' HG22 ' A' ' 51' ' ' VAL . 44.4 Cg_endo -72.58 130.05 15.47 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.989 1.52 . . . . 50.0 110.414 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.413 HG23 HG13 ' A' ' 51' ' ' VAL . 10.5 t -142.3 -36.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.259 -0.901 . . . . 50.0 110.26 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -77.54 164.74 52.37 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.138 -1.585 . . . . 50.0 109.138 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.434 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 10.5 mtt180 -138.49 156.45 47.52 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.095 -1.238 . . . . 50.0 110.445 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.665 HD13 ' HD3' ' A' ' 68' ' ' PRO . 2.5 mt -97.97 122.4 41.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 50.0 109.776 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.711 HG22 ' HG2' ' A' ' 84' ' ' GLU . 30.6 t -63.33 -13.5 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.217 -0.927 . . . . 50.0 110.12 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 66' ' ' VAL . 34.6 m -124.77 163.21 22.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.295 -0.878 . . . . 50.0 109.955 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.528 HG12 ' N ' ' A' ' 67' ' ' ASN . 74.1 t -44.09 168.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 50.0 109.959 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.628 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 18.2 t-20 -46.68 142.73 4.56 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.196 -0.94 . . . . 50.0 110.11 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.665 ' HD3' HD13 ' A' ' 63' ' ' LEU . 49.8 Cg_endo -76.22 98.56 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.927 1.488 . . . . 50.0 110.452 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.628 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 9.2 p90 -120.51 138.49 53.81 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.225 -0.922 . . . . 50.0 110.346 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.982 HG13 ' CB ' ' A' ' 75' ' ' ALA . 73.6 t -91.01 60.94 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.198 -0.939 . . . . 50.0 110.181 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.532 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -89.76 57.44 3.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 50.0 110.346 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.7 m -143.43 169.12 18.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 50.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.7 p -94.23 -6.83 43.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 50.0 109.92 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.14 17.74 11.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 99.989999999999995 110.41 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.982 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -79.79 7.29 8.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.15 -0.969 . . . . 99.989999999999995 110.066 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 53.6 m-20 -85.17 18.78 2.44 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.234 -0.917 . . . . 99.989999999999995 109.341 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.684 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -122.68 -172.73 2.54 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.404 -0.81 . . . . 99.989999999999995 109.277 179.97 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.487 ' HE2' ' HB1' ' A' ' 20' ' ' ALA . 40.0 mttt -62.98 88.47 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.327 -0.858 . . . . 99.989999999999995 109.168 179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 1.081 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.4 m -76.68 176.48 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.376 -0.827 . . . . 99.989999999999995 109.392 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 1.083 HD21 ' CG1' ' A' ' 32' ' ' VAL . 8.0 tt -135.23 133.92 39.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.781 -1.2 . . . . 50.0 111.212 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.9 t -119.98 178.31 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.483 -0.76 . . . . 50.0 109.829 179.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 61.7 mt-10 -148.52 139.24 22.86 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.996 -1.065 . . . . 50.0 110.546 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.492 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 14.2 ptt? -155.81 139.03 15.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.268 -0.895 . . . . 50.0 110.245 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.711 ' HG2' HG22 ' A' ' 64' ' ' VAL . 1.3 pt-20 -109.24 76.62 0.81 Allowed Pre-proline 0 C--N 1.305 -1.327 0 O-C-N 121.183 -0.948 . . . . 50.0 110.619 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 83' ' ' MET . 47.5 Cg_endo -73.86 170.34 20.3 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.02 1.537 . . . . 50.0 110.344 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.33 161.94 42.95 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.061 1.559 . . . . 50.0 110.42 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -67.13 145.35 55.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.171 -0.956 . . . . 50.0 110.154 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.28 158.62 16.74 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.189 -1.564 . . . . 50.0 109.189 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.496 ' OD2' ' CD2' ' A' ' 106' ' ' HIS . 1.0 OUTLIER -52.41 148.55 6.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -1.22 . . . . 50.0 109.928 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.639 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.4 p -130.49 138.77 50.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.118 -0.989 . . . . 50.0 110.705 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.567 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -90.65 104.35 16.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.16 -0.963 . . . . 50.0 109.415 179.334 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 92' ' ' ILE . 3.3 tt -103.43 135.02 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 50.0 110.341 -179.374 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 100' ' ' GLN . 10.7 t -125.15 114.52 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.089 -1.007 . . . . 50.0 110.863 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.853 HG13 ' CD1' ' A' ' 48' ' ' ILE . 17.6 t -103.97 104.14 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.195 -0.941 . . . . 50.0 109.444 179.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.27 169.92 33.29 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.614 -1.279 . . . . 50.0 110.195 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.434 ' HB2' ' HB2' ' A' ' 15' ' ' GLU . 19.7 ttm -111.72 -51.35 2.86 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.355 -1.085 . . . . 50.0 110.597 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.85 -145.14 12.18 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.845 -1.302 . . . . 50.0 109.845 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.403 ' O ' ' HG3' ' A' ' 100' ' ' GLN . 2.3 p30 -63.52 -36.11 82.68 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.219 -1.165 . . . . 50.0 110.384 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.37 116.56 19.68 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.207 -0.933 . . . . 50.0 110.184 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.574 ' HB2' HG12 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -139.45 148.69 43.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.323 -0.861 . . . . 0.0 110.114 -179.808 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.734 ' O ' HG23 ' A' ' 101' ' ' ILE . 3.5 tp -94.87 110.32 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.258 -0.901 . . . . 0.0 110.012 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.418 ' OD1' ' N ' ' A' ' 102' ' ' ASN . 32.8 p-10 -101.93 131.82 48.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 0.0 110.475 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -121.12 171.36 8.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.38 -0.825 . . . . 0.0 110.146 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -119.34 79.92 1.49 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 110.471 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.433 ' HZ2' HD11 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -52.43 134.74 34.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.983 179.781 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.496 ' CD2' ' OD2' ' A' ' 89' ' ' ASP . 0.2 OUTLIER -110.52 98.75 7.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.179 -0.951 . . . . 0.0 110.412 -179.803 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -9.75 13.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.855 . . . . 0.0 110.036 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -47.49 154.72 0.42 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -0.874 . . . . 0.0 110.082 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -154.54 142.36 8.98 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.3 p -66.46 -177.22 0.53 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -1.145 . . . . 0.0 110.141 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' THR . . . . . 0.556 HG22 ' O ' ' A' ' 111' ' ' THR . 22.0 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.042 -0.98 . . . . 49.57 110.263 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 45.8 m-20 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.263 0.554 . . . . 50.0 110.313 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -150.41 155.77 40.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 50.0 110.228 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.429 ' O ' ' HG ' ' A' ' 3' ' ' LEU . 0.7 OUTLIER -83.82 155.95 22.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 50.0 110.206 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.98 168.97 9.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.273 -0.892 . . . . 50.0 110.201 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.5 mp -89.91 61.69 5.4 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.24 -0.913 . . . . 50.0 110.142 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 4.1 tttt -97.27 149.32 22.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.338 -0.851 . . . . 50.0 110.171 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.92 -53.26 0.81 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.658 -1.377 . . . . 50.0 109.658 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 38.7 p -141.8 127.59 19.26 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 50.0 110.345 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.17 173.87 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.906 . . . . 50.0 110.196 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -138.41 161.02 38.04 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 50.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -72.28 117.38 6.27 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.47 -1.452 . . . . 50.0 109.47 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.546 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -111.87 102.79 11.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -1.177 . . . . 50.0 110.248 -179.948 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.658 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 11.6 p -148.69 107.35 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.204 -0.935 . . . . 99.989999999999995 110.415 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . 1.019 HG21 ' CD1' ' A' ' 46' ' ' ILE . 1.3 m -161.5 62.8 0.26 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.674 -1.266 . . . . 99.989999999999995 110.549 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HE3' ' A' ' 16' ' ' LYS . 1.5 pp20? -84.63 25.18 0.93 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.156 -0.965 . . . . 99.989999999999995 110.117 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.514 ' HD3' ' HA3' ' A' ' 39' ' ' GLY . 1.8 mptt -123.47 61.02 1.06 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.177 -0.952 . . . . 50.0 110.782 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.816 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.0 OUTLIER -99.11 146.88 25.64 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.054 -1.029 . . . . 50.0 109.8 179.429 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.675 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.11 145.41 51.02 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.124 -0.985 . . . . 50.0 110.294 -179.898 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.738 ' CZ ' HD12 ' A' ' 101' ' ' ILE . 1.2 m-85 -85.32 104.28 15.01 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.962 -1.086 . . . . 50.0 109.617 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.929 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -93.2 -34.53 13.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.128 -0.983 . . . . 50.0 110.648 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.512 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 13.6 mttm -145.09 166.71 24.6 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.06 -1.025 . . . . 50.0 110.614 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.59 165.16 39.36 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 50.0 110.09 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.512 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.71 136.75 26.15 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.969 1.51 . . . . 50.0 110.46 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.44 167.53 14.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.251 -0.906 . . . . 50.0 110.346 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -105.81 132.31 52.08 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 50.0 110.37 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 p -108.78 -23.17 11.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 50.0 110.136 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.46 -114.64 0.59 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.468 -1.453 . . . . 50.0 109.468 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 14.5 p80 -130.17 88.87 2.71 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -1.163 . . . . 50.0 110.296 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.484 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 105.1 14.94 21.37 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.8 p -121.73 111.53 17.28 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.311 -1.111 . . . . 50.0 110.186 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -104.61 150.56 7.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.218 -0.926 . . . . 50.0 110.313 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.758 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -128.19 135.09 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.244 -0.91 . . . . 50.0 110.271 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.944 HG23 HD11 ' A' ' 35' ' ' LEU . 8.0 tt -134.28 150.3 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.864 . . . . 50.0 109.518 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.929 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.4 tt0 -119.84 103.78 9.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 50.0 110.767 -179.494 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.961 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.2 mp -110.89 137.36 48.63 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.226 -0.921 . . . . 50.0 109.691 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -84.68 124.78 31.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.058 -1.026 . . . . 50.0 109.696 179.954 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.518 ' HB3' ' O ' ' A' ' 75' ' ' ALA . 6.3 t80 -92.34 97.84 11.12 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.904 -1.118 . . . . 50.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.9 t -95.14 72.09 3.34 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.391 -0.818 . . . . 50.0 110.163 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.514 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -125.57 126.68 5.96 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.574 -1.41 . . . . 99.989999999999995 109.574 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -83.55 16.85 2.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -1.151 . . . . 99.989999999999995 110.201 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -92.4 -22.47 19.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 99.989999999999995 110.149 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.76 -163.31 12.31 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.641 -1.384 . . . . 99.989999999999995 109.641 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.536 ' HB3' ' O ' ' A' ' 70' ' ' VAL . 44.7 Cg_endo -73.5 150.31 45.78 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 O-C-N 123.966 1.509 . . . . 99.989999999999995 110.418 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.628 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.55 161.87 7.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.309 -0.87 . . . . 50.0 109.851 -179.531 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 13.7 mmtt -69.0 117.53 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.067 -1.021 . . . . 50.0 109.382 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 1.092 HD11 ' CG2' ' A' ' 70' ' ' VAL . 4.4 mm -71.4 112.83 15.19 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.058 -1.026 . . . . 50.0 110.372 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.508 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 51.8 Cg_endo -80.26 91.87 1.13 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.061 1.558 . . . . 50.0 110.171 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.791 HG12 HG22 ' A' ' 94' ' ' VAL . 63.3 mt -133.11 149.98 32.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.128 -0.982 . . . . 50.0 110.541 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.564 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 26.1 m -124.14 159.66 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.382 -0.824 . . . . 50.0 109.661 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.455 ' O ' ' HA3' ' A' ' 61' ' ' GLY . 0.3 OUTLIER -134.76 107.66 7.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 50.0 110.066 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.5 m -125.2 156.76 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.284 -0.885 . . . . 50.0 110.203 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.675 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -55.93 163.64 1.42 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.355 -0.841 . . . . 50.0 110.012 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.609 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.4 OUTLIER -59.5 121.21 10.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.211 -0.931 . . . . 50.0 110.649 -179.556 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.609 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 78.58 30.55 0.38 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.565 -0.709 . . . . 50.0 110.976 179.549 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.675 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 30.1 m120 -128.0 84.28 2.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.21 -0.931 . . . . 50.0 110.068 179.066 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.49 9.6 31.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.234 -0.917 . . . . 50.0 110.211 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.4 mtt -113.85 -15.65 12.35 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -0.863 . . . . 50.0 110.111 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -136.37 121.01 12.85 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.334 -0.854 . . . . 50.0 110.246 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.461 ' HA ' HG12 ' A' ' 51' ' ' VAL . 46.3 Cg_endo -72.98 133.66 20.2 Favored 'Trans proline' 0 C--N 1.305 -1.755 0 O-C-N 123.989 1.52 . . . . 50.0 110.16 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.435 ' CG2' ' H ' ' A' ' 52' ' ' ALA . 31.3 m -142.31 -31.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.223 -0.923 . . . . 50.0 110.429 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.41 144.79 37.94 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.397 -1.881 . . . . 50.0 108.397 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.471 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 11.7 mtp180 -123.6 157.0 34.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.851 -1.382 . . . . 50.0 110.892 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.42 ' HG ' ' HG3' ' A' ' 83' ' ' MET . 0.2 OUTLIER -96.82 124.91 40.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.876 . . . . 50.0 109.86 179.627 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.486 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 17.9 t -50.76 -21.45 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.177 -0.952 . . . . 50.0 110.248 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 66' ' ' VAL . 5.8 t -136.33 170.68 15.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 50.0 110.153 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 27.7 m -52.23 -172.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.237 -0.915 . . . . 50.0 110.157 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.552 ' O ' ' CE2' ' A' ' 69' ' ' PHE . 6.7 p30 -46.88 131.04 8.74 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.142 -0.973 . . . . 50.0 110.003 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.52 ' O ' HG12 ' A' ' 46' ' ' ILE . 46.8 Cg_endo -72.58 123.24 8.91 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.941 1.495 . . . . 50.0 110.559 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 67' ' ' ASN . 0.2 OUTLIER -135.14 157.07 47.86 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.286 -0.884 . . . . 50.0 110.069 -179.942 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 1.092 ' CG2' HD11 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -116.29 60.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.179 -0.951 . . . . 50.0 109.6 179.292 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -73.55 58.91 0.6 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 50.0 110.347 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.0 m -142.59 155.2 44.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.32 -0.863 . . . . 50.0 110.233 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.61 -4.9 53.65 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.334 -0.854 . . . . 50.0 109.857 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.5 p -115.45 17.31 16.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 99.989999999999995 110.255 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.83 ' HB1' ' CG1' ' A' ' 70' ' ' VAL . . . -79.91 8.61 6.58 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.182 -0.949 . . . . 99.989999999999995 109.966 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -87.63 19.55 3.35 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.226 -0.921 . . . . 99.989999999999995 109.243 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.549 ' O ' ' HA ' ' A' ' 36' ' ' SER . 96.5 p -128.96 -172.56 2.75 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.536 -0.728 . . . . 99.989999999999995 109.346 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.428 ' HD2' ' OE2' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -63.35 88.82 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.263 -0.898 . . . . 99.989999999999995 109.291 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.961 HG22 ' O ' ' A' ' 35' ' ' LEU . 35.3 m -76.16 176.28 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.352 -0.843 . . . . 99.989999999999995 109.21 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.758 HD21 HG12 ' A' ' 32' ' ' VAL . 2.8 tt -134.02 132.93 40.66 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.884 -1.135 . . . . 50.0 111.239 -179.487 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.4 t -122.64 178.08 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.435 -0.791 . . . . 50.0 109.681 179.455 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.486 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 22.8 mt-10 -132.85 142.65 49.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.021 -1.049 . . . . 50.0 110.479 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.481 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -147.78 142.22 26.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.281 -0.887 . . . . 50.0 110.234 179.995 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.484 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -114.69 66.38 1.75 Allowed Pre-proline 0 C--N 1.306 -1.296 0 O-C-N 121.151 -0.968 . . . . 50.0 110.563 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.481 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.21 164.94 33.99 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.969 1.51 . . . . 50.0 110.28 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.51 140.83 33.74 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.92 1.484 . . . . 50.0 110.354 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -52.54 137.08 31.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.231 -0.918 . . . . 50.0 110.194 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.76 167.37 13.32 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.384 -1.486 . . . . 50.0 109.384 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ASP . . . . . 0.514 ' HB2' ' HB2' ' A' ' 53' ' ' SER . 23.1 m-20 -53.25 146.5 11.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.3 -1.118 . . . . 50.0 110.051 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.581 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -141.43 141.37 33.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 50.0 110.604 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 1.0 OUTLIER -97.49 112.02 24.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 50.0 109.672 179.462 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' ILE . 5.0 tt -103.44 136.91 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.101 -0.999 . . . . 50.0 110.406 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.564 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 27.1 t -125.15 113.12 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.088 -1.007 . . . . 50.0 110.316 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.816 HG11 ' CB ' ' A' ' 17' ' ' PHE . 42.1 t -105.13 100.54 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.901 . . . . 50.0 110.065 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -150.82 164.8 30.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.71 -1.356 . . . . 50.0 109.71 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' MET . . . . . 0.508 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ttm -103.44 -29.71 11.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.32 -1.106 . . . . 50.0 110.319 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 179.71 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.07 -67.9 0.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.27 -1.135 . . . . 50.0 110.422 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.1 tptt -79.47 109.38 13.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.208 -0.933 . . . . 50.0 110.109 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLN . . . . . 0.503 ' O ' ' OE1' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -134.82 149.73 50.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 110.111 -179.739 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.738 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 5.6 pt -118.92 154.7 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 0.0 109.905 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.459 ' O ' ' OD1' ' A' ' 102' ' ' ASN . 14.4 p30 -143.1 136.35 28.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.164 -0.96 . . . . 0.0 110.429 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.491 ' HB3' ' CZ3' ' A' ' 105' ' ' TRP . 0.1 OUTLIER -120.78 168.25 11.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.24 -0.912 . . . . 0.0 110.28 179.887 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.588 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 12.9 p80 -131.08 106.08 8.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.363 -0.836 . . . . 0.0 109.981 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' TRP . . . . . 0.491 ' CZ3' ' HB3' ' A' ' 103' ' ' HIS . 0.8 OUTLIER -87.69 112.84 22.79 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 110.629 -179.611 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 106' ' ' HIS . . . . . 0.593 ' O ' ' CG ' ' A' ' 106' ' ' HIS . 21.0 p80 -159.49 102.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.338 -0.851 . . . . 0.0 110.075 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -103.73 -10.89 17.97 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.204 -0.935 . . . . 0.0 110.381 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -79.63 123.97 28.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.28 -0.887 . . . . 0.0 110.259 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -146.69 70.46 0.35 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 13.6 m -148.3 98.17 2.87 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 0.0 110.154 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 35.2 p . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 118.048 -0.977 . . . . 49.57 110.174 -179.908 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.547 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 74.1 mtp . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.204 0.526 . . . . 50.0 110.263 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.778 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 8.6 p -149.01 108.06 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.188 -0.945 . . . . 99.99 110.608 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.657 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -161.57 41.96 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.611 -1.305 . . . . 99.99 110.678 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.7 tm-20 -70.03 -3.78 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.122 -0.986 . . . . 99.99 110.075 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.543 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -79.71 62.45 3.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.315 -0.866 . . . . 50.0 110.206 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.646 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.3 OUTLIER -102.64 140.87 36.34 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.188 -0.945 . . . . 50.0 110.431 -179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.678 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.4 t -125.53 119.69 28.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 50.0 109.81 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -73.62 108.41 6.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.125 -0.985 . . . . 50.0 110.298 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.798 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -94.87 -33.49 12.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 50.0 109.916 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.49 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 17.3 mtmt -144.78 150.29 36.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.288 -0.882 . . . . 50.0 110.202 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.473 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 11.2 m-20 -69.23 165.15 42.0 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.291 -0.881 . . . . 50.0 110.107 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.543 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.1 Cg_endo -72.84 122.53 8.24 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.946 1.498 . . . . 50.0 110.31 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -122.37 141.71 51.28 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.905 . . . . 50.0 110.287 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.537 ' HA ' ' O ' ' A' ' 30' ' ' THR . 2.7 p30 -81.89 131.65 35.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 50.0 110.312 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.2 p -123.54 52.46 1.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.312 -0.868 . . . . 50.0 110.137 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.57 -129.2 2.85 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.435 -1.466 . . . . 50.0 109.435 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -116.54 95.79 5.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.206 -1.173 . . . . 50.0 110.243 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.58 23.04 63.27 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -117.87 107.71 14.43 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -1.16 . . . . 50.0 110.219 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.543 HG11 ' HB2' ' A' ' 23' ' ' PRO . 11.8 t -103.58 137.3 32.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.307 -0.87 . . . . 50.0 110.208 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -110.82 136.46 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.224 -0.923 . . . . 50.0 110.294 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HD11 ' A' ' 35' ' ' LEU . 12.7 tt -130.62 144.49 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.413 -0.805 . . . . 50.0 109.68 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.798 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -122.62 105.26 9.94 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.982 . . . . 50.0 110.639 -179.495 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.989 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.12 141.63 51.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.238 -0.914 . . . . 50.0 109.511 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -90.74 128.93 36.84 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.102 -0.999 . . . . 50.0 109.855 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.543 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 11.4 t80 -91.44 98.58 11.77 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 118.935 -1.106 . . . . 50.0 109.679 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.77 69.6 8.69 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.291 -0.881 . . . . 50.0 109.711 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.536 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -124.24 119.85 3.87 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.634 -1.386 . . . . 99.99 109.634 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.1 m -86.22 20.04 2.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.327 -1.101 . . . . 99.99 110.278 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -97.47 -0.85 45.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 99.99 110.105 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.71 -158.3 26.05 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.411 -1.475 . . . . 99.99 109.411 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -73.06 151.32 49.75 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.959 1.505 . . . . 99.99 110.222 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.778 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -170.23 161.48 8.34 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -0.907 . . . . 50.0 109.784 -179.402 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.602 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 5.0 mmtt -79.48 114.39 18.37 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.979 -1.076 . . . . 50.0 110.125 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.064 HD11 HG23 ' A' ' 70' ' ' VAL . 2.6 mt -75.06 113.58 26.42 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 50.0 110.194 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.497 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 46.5 Cg_endo -74.13 88.79 1.08 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 124.043 1.549 . . . . 50.0 110.013 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.673 HD11 HG21 ' A' ' 46' ' ' ILE . 79.4 mt -125.54 151.79 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 50.0 110.741 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.517 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 32.4 m -133.12 137.29 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.499 -0.751 . . . . 50.0 109.337 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -116.48 108.81 16.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.003 -1.061 . . . . 50.0 110.313 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 91' ' ' TYR . 14.8 m -131.58 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 50.0 110.113 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.48 163.6 1.7 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.31 -0.869 . . . . 50.0 110.184 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.665 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -62.85 120.46 11.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -0.887 . . . . 50.0 110.545 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.665 ' CB ' ' O ' ' A' ' 53' ' ' SER . 3.8 tp 81.47 29.96 0.15 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.582 -0.699 . . . . 50.0 110.725 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.524 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 64.6 m-80 -137.38 84.75 2.08 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 50.0 110.101 179.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -105.36 11.13 33.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 50.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.4 tpt -109.04 -14.15 14.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 50.0 110.211 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.3 p -136.04 142.84 41.71 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.289 -0.882 . . . . 50.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.68 137.2 27.01 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.006 1.53 . . . . 50.0 110.321 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.817 HG12 ' HG3' ' A' ' 86' ' ' PRO . 4.0 t -143.89 -49.08 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.305 -0.872 . . . . 50.0 110.079 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -86.29 147.22 21.43 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.085 -1.606 . . . . 50.0 109.085 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 10.1 mtp180 -138.66 156.38 47.48 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.057 -1.261 . . . . 50.0 110.686 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.487 ' HA ' ' HG2' ' A' ' 83' ' ' MET . 5.0 mp -91.91 109.62 20.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.32 -0.863 . . . . 50.0 110.051 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.553 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 77.9 t -55.93 -42.89 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.218 -0.926 . . . . 50.0 110.51 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.466 ' OG1' ' HB2' ' A' ' 82' ' ' GLU . 1.4 m -73.76 169.49 17.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.162 -0.961 . . . . 50.0 110.173 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 67' ' ' ASN . 23.3 t -44.65 170.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.236 -0.915 . . . . 50.0 110.114 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.646 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . 60.7 m-80 -47.08 157.7 0.48 Allowed Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.243 -0.91 . . . . 50.0 109.979 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.863 ' C ' HD12 ' A' ' 46' ' ' ILE . 45.4 Cg_endo -73.32 66.36 4.42 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 123.955 1.503 . . . . 50.0 110.58 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE2' ' CB ' ' A' ' 67' ' ' ASN . 16.7 m-30 -120.8 121.7 38.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 50.0 109.878 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.064 HG23 HD11 ' A' ' 46' ' ' ILE . 80.8 t -79.91 60.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 50.0 110.096 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -83.31 61.6 6.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.082 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -142.65 164.41 30.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.253 -0.905 . . . . 50.0 110.335 -179.758 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 p -94.08 -10.79 32.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 50.0 109.874 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 67.4 m -120.95 18.24 11.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -0.872 . . . . 99.99 110.253 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.842 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -81.98 11.44 5.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.136 -0.977 . . . . 99.99 110.073 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.1 m-20 -85.22 15.06 4.51 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.253 -0.904 . . . . 99.99 109.337 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 9.3 p -124.27 -171.98 2.45 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.464 -0.773 . . . . 99.99 109.574 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.484 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 11.8 pttt -62.87 88.86 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.559 -0.856 . . . . 99.99 109.115 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.989 HG22 ' O ' ' A' ' 35' ' ' LEU . 22.2 m -76.52 174.42 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.41 -0.806 . . . . 99.99 109.651 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.445 HD23 ' O ' ' A' ' 33' ' ' ILE . 1.6 tt -138.8 120.39 15.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.977 -1.077 . . . . 50.0 110.942 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.426 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.0 t -116.91 172.69 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 50.0 109.9 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.553 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 83.7 mt-10 -120.69 154.75 35.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.142 -0.974 . . . . 50.0 110.339 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.527 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -146.14 140.39 26.64 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.332 -0.855 . . . . 50.0 110.027 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.43 62.87 0.92 Allowed Pre-proline 0 C--N 1.306 -1.315 0 O-C-N 121.258 -0.901 . . . . 50.0 110.712 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.527 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.4 Cg_endo -72.7 148.44 46.89 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 123.848 1.447 . . . . 50.0 110.357 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.817 ' HG3' HG12 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.66 152.51 59.19 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 123.963 1.507 . . . . 50.0 110.413 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -52.8 133.63 37.13 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.19 -0.944 . . . . 50.0 110.136 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.53 161.68 11.41 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.532 -1.427 . . . . 50.0 109.532 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.537 ' CB ' ' HB2' ' A' ' 53' ' ' SER . 5.4 p30 -53.01 155.24 2.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 50.0 110.108 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.513 ' HA ' ' N ' ' A' ' 53' ' ' SER . 17.6 p -143.03 137.98 29.65 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.229 -0.919 . . . . 50.0 110.387 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 1.2 m-30 -101.56 103.34 14.18 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.88 . . . . 50.0 110.275 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.739 ' H ' HD12 ' A' ' 92' ' ' ILE . 3.2 mp -101.5 138.95 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.201 -0.937 . . . . 50.0 109.871 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.517 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 75.5 t -125.37 113.73 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 50.0 110.785 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.646 HG11 ' CB ' ' A' ' 17' ' ' PHE . 41.3 t -101.97 91.54 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.958 . . . . 50.0 109.785 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.56 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.59 167.83 33.14 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.774 -1.33 . . . . 50.0 109.774 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.424 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ptp -108.38 -150.77 0.46 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -1.113 . . . . 50.0 110.08 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -73.7 -44.12 33.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.729 -1.348 . . . . 50.0 109.729 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 99' ' ' LYS . 39.5 t0 -74.98 -105.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.205 -1.174 . . . . 50.0 110.293 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.489 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 8.5 tttp -79.61 136.1 36.75 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.048 -1.032 . . . . 50.0 110.352 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.778 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -140.1 150.13 43.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.197 -0.939 . . . . 0.0 110.07 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 7.5 mt -115.72 146.98 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 24.0 p-10 -130.67 129.76 43.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -0.904 . . . . 0.0 110.469 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -135.48 163.79 29.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.442 -0.786 . . . . 0.0 110.018 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.627 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 10.3 p80 -134.39 164.15 28.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.931 . . . . 0.0 110.221 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 58.8 m95 . . . . . 0 C--N 1.305 -1.327 0 O-C-N 121.257 -0.902 . . . . 0.0 110.236 179.925 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 121.123 0.487 . . . . 50.0 110.208 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.689 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.7 p -148.6 107.53 3.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.112 -0.992 . . . . 99.99 110.567 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.642 HG21 HG12 ' A' ' 46' ' ' ILE . 6.7 m -160.84 42.12 0.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.679 -1.263 . . . . 99.99 110.602 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -65.14 -5.95 7.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.14 -0.975 . . . . 99.99 109.906 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 mmtm -83.44 61.21 6.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 50.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 1.061 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -101.44 142.44 32.82 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.204 -0.935 . . . . 50.0 109.668 179.45 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 t -127.13 97.58 4.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.154 -0.966 . . . . 50.0 110.197 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 11.4 p90 -63.0 118.06 7.3 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.36 -0.837 . . . . 50.0 110.04 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -102.22 -22.41 14.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.093 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -138.06 145.99 42.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 50.0 110.137 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.432 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 22.9 p30 -66.83 162.62 50.74 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 50.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.478 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.0 Cg_endo -72.14 114.48 3.99 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.966 1.509 . . . . 50.0 110.37 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -105.02 140.13 38.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.284 -0.885 . . . . 50.0 110.368 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -90.53 111.24 22.45 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.36 -0.837 . . . . 50.0 110.184 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.5 59.02 5.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.228 -0.92 . . . . 50.0 110.158 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 128.31 -128.16 5.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -132.59 89.21 2.61 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -1.205 . . . . 50.0 110.138 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 30' ' ' THR . . . 113.68 31.05 2.43 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.521 -1.431 . . . . 50.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.464 HG23 ' O ' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -154.95 111.19 3.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.214 -1.168 . . . . 50.0 110.343 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 57.7 t -109.27 147.88 13.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.295 -0.878 . . . . 50.0 110.253 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.67 HG12 ' CD2' ' A' ' 80' ' ' LEU . 0.4 OUTLIER -124.92 118.26 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 50.0 110.318 -179.913 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.719 ' O ' HD23 ' A' ' 80' ' ' LEU . 0.6 OUTLIER -116.04 149.54 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.311 -0.868 . . . . 50.0 109.785 179.64 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.502 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.7 OUTLIER -126.69 104.87 8.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.207 -0.933 . . . . 50.0 110.534 -179.653 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.997 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.78 144.52 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.319 -0.863 . . . . 50.0 109.302 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.569 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.23 133.51 39.02 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.031 -1.043 . . . . 50.0 110.028 -179.688 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.796 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.8 t80 -94.0 97.56 10.42 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.065 -1.054 . . . . 50.0 109.863 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 59.1 p -95.41 70.06 3.11 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.27 -0.894 . . . . 50.0 110.14 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -122.39 129.38 7.53 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.575 -1.41 . . . . 99.99 109.575 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.0 p -92.86 24.78 3.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.274 -1.133 . . . . 99.99 110.244 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.2 p30 -98.43 -1.32 41.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.188 -0.945 . . . . 99.99 110.084 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -168.63 24.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.461 -1.456 . . . . 99.99 109.461 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.619 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.7 Cg_endo -73.56 153.4 49.39 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.976 1.513 . . . . 99.99 110.324 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.689 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.29 161.33 8.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.34 -0.85 . . . . 50.0 110.002 -179.378 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.565 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -76.04 133.86 40.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.095 -1.003 . . . . 50.0 109.305 178.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.061 HD13 ' CZ ' ' A' ' 17' ' ' PHE . 9.5 mt -89.25 108.41 24.26 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 120.996 -1.065 . . . . 50.0 110.157 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 47.6 Cg_endo -74.49 99.99 1.27 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 124.043 1.549 . . . . 50.0 110.7 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.82 ' CG1' HG13 ' A' ' 94' ' ' VAL . 2.6 mt -126.55 150.34 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 50.0 110.172 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.621 HG22 HG23 ' A' ' 51' ' ' VAL . 2.7 p -128.21 130.43 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.416 -0.802 . . . . 50.0 109.983 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.498 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.1 OUTLIER -115.35 106.47 14.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 50.0 109.931 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.621 HG23 HG22 ' A' ' 49' ' ' VAL . 2.9 t -132.78 163.09 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.187 -0.946 . . . . 50.0 110.698 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.511 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -56.24 164.43 1.31 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.485 -0.759 . . . . 50.0 110.393 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.647 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -58.69 122.28 13.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.441 -0.787 . . . . 50.0 110.598 -179.602 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.647 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 81.17 29.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.594 -0.691 . . . . 50.0 110.906 179.627 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.538 ' CB ' HG12 ' A' ' 51' ' ' VAL . 14.7 m120 -132.99 84.35 2.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 50.0 109.995 178.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 56' ' ' ASP . 10.4 m-20 -106.7 18.09 22.34 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.164 -0.96 . . . . 50.0 110.349 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 18.4 mtt -125.0 -8.93 7.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 50.0 110.474 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.635 HG22 ' HD2' ' A' ' 59' ' ' PRO . 0.2 OUTLIER -136.2 144.29 47.33 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.151 -0.968 . . . . 50.0 110.391 -179.854 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.635 ' HD2' HG22 ' A' ' 58' ' ' THR . 47.1 Cg_endo -74.48 125.8 9.85 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.036 1.545 . . . . 50.0 110.239 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.511 HG11 ' HB2' ' A' ' 52' ' ' ALA . 75.0 t -139.2 -36.22 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 50.0 110.093 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -79.49 161.65 46.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.023 -1.631 . . . . 50.0 109.023 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -123.63 156.92 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 50.0 110.532 -179.527 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.467 ' HA ' ' HG3' ' A' ' 83' ' ' MET . 1.2 mt -107.16 132.75 52.69 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.314 -0.866 . . . . 50.0 109.944 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 27.2 t -63.71 -17.27 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -0.946 . . . . 50.0 110.451 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 66' ' ' VAL . 6.2 t -147.11 167.42 24.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 50.0 110.193 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 67' ' ' ASN . 21.2 t -47.16 173.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 50.0 110.02 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.566 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 5.4 p30 -46.73 138.26 7.05 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.202 -0.936 . . . . 50.0 110.239 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.479 ' HB2' HD12 ' A' ' 46' ' ' ILE . 46.7 Cg_endo -74.01 103.05 1.6 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.934 1.492 . . . . 50.0 110.38 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.566 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -113.8 134.01 55.04 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.18 -0.95 . . . . 50.0 110.495 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.818 HG13 ' CB ' ' A' ' 75' ' ' ALA . 61.9 t -87.63 60.46 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 50.0 109.684 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.619 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.9 57.42 4.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.295 -0.878 . . . . 50.0 110.021 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.43 169.01 18.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 50.0 110.424 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.87 -7.15 34.19 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.872 . . . . 50.0 109.909 179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.11 12.59 11.12 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.31 -0.869 . . . . 99.99 110.242 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.818 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -77.15 6.82 5.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 99.99 110.079 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.555 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 8.2 m-80 -84.62 19.56 1.97 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.333 -0.855 . . . . 99.99 109.384 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.672 ' O ' HG13 ' A' ' 79' ' ' VAL . 31.0 m -121.09 -172.54 2.42 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.414 -0.804 . . . . 99.99 109.177 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.444 ' HB3' ' OE2' ' A' ' 34' ' ' GLU . 6.8 mttp -63.21 88.06 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.235 -0.915 . . . . 99.99 109.064 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.997 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.2 m -76.95 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.331 -0.856 . . . . 99.99 109.318 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.719 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.4 OUTLIER -133.87 130.36 37.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.785 -1.197 . . . . 50.0 111.1 -179.66 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.5 t -120.45 168.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.476 -0.765 . . . . 50.0 109.947 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.5 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 4.0 mt-10 -132.96 147.99 52.28 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.179 -0.951 . . . . 50.0 110.176 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -146.83 143.17 28.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.214 -0.929 . . . . 50.0 110.393 -179.853 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.46 ' O ' ' HB2' ' A' ' 62' ' ' ARG . 0.2 OUTLIER -117.95 68.56 6.65 Favored Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.115 -0.991 . . . . 50.0 110.477 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.404 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.86 161.44 41.48 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 O-C-N 123.975 1.513 . . . . 50.0 110.358 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.425 ' HD3' ' HA2' ' A' ' 61' ' ' GLY . 45.8 Cg_endo -73.43 146.7 40.12 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 124.003 1.528 . . . . 50.0 110.446 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.521 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.8 OUTLIER -52.74 135.18 35.82 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.281 -0.887 . . . . 50.0 110.07 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 124.81 165.63 12.19 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.52 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 92.8 m-20 -62.2 135.42 57.48 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -1.193 . . . . 50.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.572 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.7 OUTLIER -132.27 145.27 51.18 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.308 -0.87 . . . . 50.0 110.138 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.616 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.9 m-30 -100.74 113.16 25.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.081 -1.012 . . . . 50.0 110.026 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.5 mp -109.06 131.1 60.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 50.0 110.108 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 49' ' ' VAL . 71.3 t -124.89 118.86 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.17 -0.956 . . . . 50.0 110.437 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.82 HG13 ' CG1' ' A' ' 48' ' ' ILE . 21.7 t -101.41 93.78 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 50.0 109.88 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.524 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -156.15 170.73 33.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.784 -1.326 . . . . 50.0 109.784 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.544 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 15.9 ptp -112.2 -28.33 7.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.262 -1.14 . . . . 50.0 109.919 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . 0.544 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 171.3 -61.56 0.17 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -64.0 -108.41 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.232 -1.158 . . . . 50.0 110.268 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -79.62 127.98 32.83 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.093 -1.004 . . . . 50.0 110.182 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.77 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.8 pp0? -136.16 150.2 48.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.231 -0.918 . . . . 0.0 110.226 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.522 ' CG1' ' HB ' ' A' ' 94' ' ' VAL . 32.4 pt -102.95 148.94 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.974 -1.079 . . . . 0.0 110.186 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -132.27 142.39 49.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 110.397 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -128.46 166.74 18.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 110.193 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.586 ' CG ' ' O ' ' A' ' 104' ' ' HIS . 8.8 p80 -118.61 85.36 2.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.327 -0.858 . . . . 0.0 110.346 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.494 ' CD1' ' C ' ' A' ' 105' ' ' TRP . 1.7 t-105 . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.156 -0.965 . . . . 0.0 110.051 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.56 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.107 0.479 . . . . 50.0 110.016 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.664 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 12.2 p -148.83 108.01 3.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.92 . . . . 99.99 110.655 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.733 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.43 44.04 0.16 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.876 -1.14 . . . . 99.99 110.489 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.419 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.4 OUTLIER -76.83 10.43 2.25 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.147 -0.97 . . . . 99.99 110.615 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.492 ' HE2' ' HA2' ' A' ' 39' ' ' GLY . 0.0 OUTLIER -111.48 61.85 0.61 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.028 -1.045 . . . . 50.0 110.59 -179.964 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.883 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -94.68 148.74 21.96 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.093 -1.004 . . . . 50.0 109.994 179.603 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.607 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 28.6 t -125.15 114.31 18.85 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 50.0 110.153 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.691 ' CD1' HD23 ' A' ' 35' ' ' LEU . 9.7 m-85 -64.94 112.92 3.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.26 -0.9 . . . . 50.0 110.188 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.538 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -96.51 -32.94 12.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.19 -0.944 . . . . 50.0 110.152 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.504 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.5 OUTLIER -138.96 163.03 33.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 50.0 110.229 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.449 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 36.7 p-10 -76.89 164.3 60.06 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 50.0 110.134 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HB2' HG11 ' A' ' 31' ' ' VAL . 44.6 Cg_endo -71.19 126.78 12.7 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.431 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -121.53 148.83 43.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.22 -0.925 . . . . 50.0 110.344 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 10.3 t70 -94.62 122.07 36.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 50.0 110.203 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.44 HG23 ' CG2' ' A' ' 32' ' ' VAL . 7.1 p -79.35 -51.33 9.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.166 -0.959 . . . . 50.0 110.278 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.425 ' O ' ' OD1' ' A' ' 25' ' ' ASP . . . -128.59 -108.1 1.38 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.641 -1.384 . . . . 50.0 109.641 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -127.11 108.37 10.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.127 . . . . 50.0 110.296 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 85.19 31.28 23.14 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.632 -1.387 . . . . 50.0 109.632 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.425 ' HA ' HG21 ' A' ' 64' ' ' VAL . 1.1 p -145.36 107.92 4.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.149 -1.207 . . . . 50.0 110.361 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 21.4 t -104.24 148.59 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 O-C-N 121.342 -0.849 . . . . 50.0 110.175 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.44 ' CG2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -122.65 132.81 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 50.0 110.406 -179.882 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.832 HG23 HD11 ' A' ' 35' ' ' LEU . 8.4 tp -128.49 133.6 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.335 -0.853 . . . . 50.0 109.781 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.538 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 8.9 tt0 -108.54 111.34 23.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.187 -0.946 . . . . 50.0 110.572 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.938 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -125.2 143.12 51.1 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.32 -0.862 . . . . 50.0 109.183 179.299 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -89.45 126.01 35.4 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.98 -1.075 . . . . 50.0 109.925 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.583 ' CE1' ' HA3' ' A' ' 39' ' ' GLY . 1.3 t80 -93.56 101.77 13.96 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.987 -1.085 . . . . 50.0 109.357 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 79.5 p -96.36 69.73 2.66 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.281 -0.887 . . . . 50.0 110.261 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.583 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -117.47 130.77 9.01 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.334 -1.506 . . . . 99.99 109.334 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 36.9 m -84.42 25.55 0.86 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -1.176 . . . . 99.99 110.539 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.08 -0.91 26.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.077 -1.014 . . . . 99.99 110.219 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.33 -157.99 28.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.409 -1.477 . . . . 99.99 109.409 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.22 137.24 28.29 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.923 1.486 . . . . 99.99 110.265 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.664 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -153.02 161.18 42.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.855 . . . . 50.0 110.107 -179.432 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.568 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 26.8 mmtt -75.68 130.93 39.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 50.0 109.157 178.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.101 HD11 ' CG2' ' A' ' 70' ' ' VAL . 20.1 mt -89.71 107.31 18.0 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.088 -1.007 . . . . 50.0 110.672 -179.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.2 Cg_endo -74.84 100.7 1.37 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.031 1.543 . . . . 50.0 110.078 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.958 ' CG2' HD11 ' A' ' 92' ' ' ILE . 66.1 mt -135.87 146.83 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.165 -0.96 . . . . 50.0 110.563 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.535 HG22 ' HB ' ' A' ' 93' ' ' VAL . 15.7 m -121.41 161.7 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.353 -0.842 . . . . 50.0 109.664 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -132.72 104.33 6.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.127 -0.983 . . . . 50.0 110.119 -179.846 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.558 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.4 m -127.22 158.96 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.295 -0.878 . . . . 50.0 110.017 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB3' ' CG ' ' A' ' 55' ' ' ASN . . . -55.83 163.35 1.46 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.361 -0.837 . . . . 50.0 110.054 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.632 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.0 OUTLIER -59.53 118.53 6.16 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.255 -0.903 . . . . 50.0 110.454 -179.534 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.632 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.2 tp 79.53 30.51 0.29 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.568 -0.707 . . . . 50.0 110.673 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.4 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 6.5 m120 -124.51 84.87 2.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.284 -0.885 . . . . 50.0 110.341 179.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.77 9.82 40.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 50.0 109.88 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.8 mtt -123.44 -12.88 7.7 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 50.0 110.106 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.6 m -130.26 119.02 18.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.378 -0.826 . . . . 50.0 110.035 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.473 ' C ' HG23 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.55 136.94 29.42 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.922 1.485 . . . . 50.0 110.162 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.6 HG12 ' HG3' ' A' ' 86' ' ' PRO . 44.7 t -148.24 -37.37 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.176 -0.953 . . . . 50.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.81 145.18 37.95 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.817 -1.713 . . . . 50.0 108.817 179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.451 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.1 mmp_? -124.06 157.26 34.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.991 -1.3 . . . . 50.0 110.53 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.4 mt -101.67 127.43 48.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.298 -0.876 . . . . 50.0 109.731 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.528 HG11 ' CD ' ' A' ' 82' ' ' GLU . 22.8 t -64.5 -13.19 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 50.0 110.262 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' VAL . 14.0 t -140.8 165.97 26.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.215 -0.928 . . . . 50.0 110.215 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.797 HG12 ' H ' ' A' ' 67' ' ' ASN . 3.8 t -55.07 -170.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 50.0 109.881 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.797 ' H ' HG12 ' A' ' 66' ' ' VAL . 3.0 t30 -46.31 132.66 7.62 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.023 -1.048 . . . . 50.0 110.08 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.719 ' O ' HD12 ' A' ' 46' ' ' ILE . 46.9 Cg_endo -73.51 75.36 3.01 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.042 1.549 . . . . 50.0 110.554 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.612 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.8 p90 -95.15 136.94 34.87 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.239 -0.913 . . . . 50.0 110.141 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.101 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.3 t -97.12 60.58 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 50.0 109.649 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -71.33 59.48 0.28 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.341 -0.849 . . . . 50.0 110.238 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.428 ' CG2' HG12 ' A' ' 70' ' ' VAL . 2.4 t -142.62 164.66 29.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 50.0 110.257 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.7 t -84.26 11.25 8.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.137 -0.977 . . . . 50.0 110.081 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -121.63 13.64 10.87 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 99.99 110.358 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.621 ' HB2' HG12 ' A' ' 70' ' ' VAL . . . -61.9 -10.98 10.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.18 -0.95 . . . . 99.99 110.172 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.496 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 63.5 m-20 -86.49 20.91 2.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.143 -0.973 . . . . 99.99 109.351 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.496 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.5 OUTLIER -132.69 -173.24 3.12 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.325 -0.859 . . . . 99.99 109.725 -179.872 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.477 ' HG3' ' OG ' ' A' ' 36' ' ' SER . 0.8 OUTLIER -64.34 89.56 0.06 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.731 -0.788 . . . . 99.99 109.196 179.256 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.938 HG22 ' O ' ' A' ' 35' ' ' LEU . 27.0 m -75.74 174.83 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.221 -0.924 . . . . 99.99 109.165 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.69 134.29 44.61 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.764 -1.21 . . . . 50.0 111.432 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.8 t -121.03 178.25 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.736 . . . . 50.0 109.696 179.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.528 ' CD ' HG11 ' A' ' 64' ' ' VAL . 10.5 tt0 -143.69 138.78 29.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.172 -0.955 . . . . 50.0 110.342 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.409 ' HG2' ' O ' ' A' ' 62' ' ' ARG . 2.4 mtm -147.25 145.44 29.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.151 -0.968 . . . . 50.0 110.383 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.498 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -118.07 70.05 7.66 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 121.341 -0.849 . . . . 50.0 110.563 -179.999 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.11 162.28 39.16 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.012 1.533 . . . . 50.0 110.126 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.6 ' HG3' HG12 ' A' ' 60' ' ' VAL . 47.1 Cg_endo -72.7 150.28 50.15 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 123.896 1.472 . . . . 50.0 110.335 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.54 120.56 5.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.197 -0.94 . . . . 50.0 110.029 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 134.64 178.31 15.56 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.562 -1.415 . . . . 50.0 109.562 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.42 ' HA ' ' O ' ' A' ' 105' ' ' TRP . 25.3 p-10 -77.17 141.05 40.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -1.14 . . . . 50.0 110.208 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.568 ' HA ' ' N ' ' A' ' 53' ' ' SER . 53.6 p -135.11 150.62 50.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 50.0 110.164 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.612 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 0.5 OUTLIER -96.94 105.02 17.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 50.0 110.275 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.958 HD11 ' CG2' ' A' ' 48' ' ' ILE . 0.0 OUTLIER -96.06 136.4 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.226 -0.921 . . . . 50.0 109.505 179.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.953 ' N ' HD13 ' A' ' 92' ' ' ILE . 33.5 t -123.84 117.54 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.131 -0.98 . . . . 50.0 110.88 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.756 HG13 HG12 ' A' ' 48' ' ' ILE . 97.0 t -106.14 95.03 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.328 -0.857 . . . . 50.0 109.893 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.59 170.3 33.51 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.665 -1.374 . . . . 50.0 109.665 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 9.2 mtm -80.4 -63.52 1.39 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -1.157 . . . . 50.0 110.178 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -156.06 -68.48 0.01 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.561 -1.416 . . . . 50.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -71.14 -75.58 0.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -1.11 . . . . 50.0 110.279 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -79.67 119.62 22.86 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.289 -0.882 . . . . 50.0 110.305 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.607 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.54 148.72 41.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 110.091 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.7 mm -98.69 111.46 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.12 -0.988 . . . . 0.0 110.039 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 36.7 p-10 -101.57 130.37 47.86 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.154 -0.966 . . . . 0.0 110.275 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.601 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -128.93 170.62 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.355 -0.841 . . . . 0.0 110.324 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.477 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 50.0 p-80 -123.7 125.33 44.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.33 -0.857 . . . . 0.0 110.127 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.744 ' CZ3' HG21 ' A' ' 92' ' ' ILE . 9.1 m0 . . . . . 0 C--N 1.304 -1.397 0 O-C-N 121.182 -0.949 . . . . 0.0 110.328 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 3.4 mtm . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.157 0.503 . . . . 50.0 110.37 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.641 ' O ' HG23 ' A' ' 14' ' ' THR . 0.1 OUTLIER -112.24 -175.5 2.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 99.99 109.929 179.674 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.674 ' HA ' ' HG3' ' A' ' 47' ' ' PRO . 21.8 p -158.24 -76.55 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.342 -0.849 . . . . 99.99 110.307 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.538 ' CG ' ' O ' ' A' ' 15' ' ' GLU . 20.6 tt0 -118.76 8.46 11.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 99.99 110.351 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.534 ' HB3' ' CD1' ' A' ' 37' ' ' TYR . 0.9 OUTLIER -56.04 81.97 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.349 -0.845 . . . . 50.0 111.021 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.967 ' CD2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.26 142.06 12.7 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.174 -0.954 . . . . 50.0 110.205 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 m -127.75 97.46 4.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -0.892 . . . . 50.0 110.267 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 10.9 p90 -57.12 119.55 6.53 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.25 -0.906 . . . . 50.0 110.249 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.15 -21.94 12.8 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.33 -0.856 . . . . 50.0 110.101 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.484 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 14.8 mttm -145.02 149.69 35.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.968 . . . . 50.0 110.278 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -67.66 159.45 78.48 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.849 . . . . 50.0 110.279 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.7 Cg_endo -72.93 134.16 21.13 Favored 'Trans proline' 0 C--N 1.303 -1.818 0 O-C-N 124.013 1.533 . . . . 50.0 110.401 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -130.51 155.32 46.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.231 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -83.69 148.46 27.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.232 -0.917 . . . . 50.0 110.122 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.62 22.22 3.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.193 -0.942 . . . . 50.0 110.207 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.28 -133.71 3.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.577 -1.409 . . . . 50.0 109.577 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -104.77 92.78 4.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -1.129 . . . . 50.0 110.343 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 84' ' ' GLU . . . 80.41 30.83 39.46 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.627 -1.389 . . . . 50.0 109.627 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 p -122.59 107.62 12.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.2 -1.176 . . . . 50.0 110.275 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 18.3 t -100.11 145.19 11.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.276 -0.89 . . . . 50.0 110.099 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -122.42 148.9 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.147 -0.971 . . . . 50.0 110.388 -179.73 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.824 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.1 tt -148.17 156.37 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 50.0 109.65 179.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.548 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 17.3 tt0 -126.09 103.81 7.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.117 -0.989 . . . . 50.0 110.696 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.951 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -121.84 140.17 52.72 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.349 -0.845 . . . . 50.0 109.263 179.4 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.547 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -92.7 132.84 36.58 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.044 -1.035 . . . . 50.0 110.107 -179.563 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.534 ' CD1' ' HB3' ' A' ' 16' ' ' LYS . 9.4 t80 -94.88 103.05 14.92 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.088 -1.045 . . . . 50.0 109.742 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 t -96.48 69.7 2.6 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.313 -0.867 . . . . 50.0 109.929 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.48 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -112.89 130.57 9.58 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.661 -1.376 . . . . 99.99 109.661 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.52 5.72 10.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 99.99 110.344 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.27 -1.35 42.1 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.213 -0.93 . . . . 99.99 110.116 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' CE2' ' A' ' 37' ' ' TYR . . . 80.93 -131.91 10.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.457 -1.457 . . . . 99.99 109.457 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.58 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 45.6 Cg_endo -73.0 131.01 16.21 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.888 1.467 . . . . 99.99 110.441 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.484 ' SG ' ' CE1' ' A' ' 37' ' ' TYR . 30.5 p -147.81 161.84 40.45 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.323 -0.861 . . . . 50.0 110.126 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.572 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 17.2 mmtt -87.23 108.67 19.04 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 50.0 109.929 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.967 HG21 ' CD2' ' A' ' 17' ' ' PHE . 4.2 mt -84.51 116.48 65.33 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 50.0 110.353 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.674 ' HG3' ' HA ' ' A' ' 14' ' ' THR . 47.2 Cg_endo -71.94 104.7 1.68 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 124.117 1.588 . . . . 50.0 110.344 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.013 HG12 HG22 ' A' ' 94' ' ' VAL . 1.2 mt -125.86 151.15 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 50.0 110.233 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.578 HG22 HG13 ' A' ' 51' ' ' VAL . 5.8 p -132.99 141.29 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.913 . . . . 50.0 110.051 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.528 ' O ' ' N ' ' A' ' 61' ' ' GLY . 3.5 m -115.64 104.79 12.05 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.311 -0.868 . . . . 50.0 109.887 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.578 HG13 HG22 ' A' ' 49' ' ' VAL . 30.4 m -131.78 162.94 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.265 -0.897 . . . . 50.0 110.322 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -55.58 163.97 1.17 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.422 -0.799 . . . . 50.0 110.18 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.636 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 10.2 t -63.15 118.26 7.68 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 50.0 110.711 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.599 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 77.21 30.76 0.52 Allowed 'General case' 0 N--CA 1.496 1.829 0 C-N-CA 119.876 -0.73 . . . . 50.0 110.765 179.485 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.48 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 10.5 m120 -134.9 84.95 2.14 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 50.0 110.032 179.124 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -104.53 18.54 22.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.273 -0.892 . . . . 50.0 110.373 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 ttt -102.87 -24.98 13.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -0.961 . . . . 50.0 110.136 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.41 138.59 27.28 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.462 -0.774 . . . . 50.0 110.196 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.468 ' HA ' HG12 ' A' ' 51' ' ' VAL . 47.0 Cg_endo -72.37 133.23 20.51 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.997 1.525 . . . . 50.0 110.361 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.7 t -143.86 -36.41 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.158 -0.964 . . . . 50.0 110.277 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.11 159.21 50.3 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.052 -1.619 . . . . 50.0 109.052 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.485 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 14.8 mtt-85 -129.36 156.22 44.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.049 -1.265 . . . . 50.0 110.372 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.757 HD23 ' HG3' ' A' ' 83' ' ' MET . 56.6 mt -94.89 124.67 39.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.276 -0.89 . . . . 50.0 110.132 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.673 HG23 ' N ' ' A' ' 84' ' ' GLU . 54.5 t -70.54 -38.93 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.198 -0.939 . . . . 50.0 110.122 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.73 175.72 6.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.317 -0.864 . . . . 50.0 110.086 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.6 m -57.92 -175.02 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.217 -0.927 . . . . 50.0 110.315 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.493 ' HB2' ' CD1' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.93 156.91 0.51 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.264 -0.897 . . . . 50.0 110.045 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.643 ' HB2' HD12 ' A' ' 48' ' ' ILE . 48.1 Cg_endo -74.61 65.61 5.68 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.931 1.49 . . . . 50.0 110.9 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.604 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 49.0 p90 -132.45 121.79 23.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.114 -0.991 . . . . 50.0 110.187 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.713 ' HB ' ' HB1' ' A' ' 75' ' ' ALA . 6.8 m -88.19 60.85 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.061 -1.024 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.58 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -66.09 65.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.3 -0.875 . . . . 50.0 110.307 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.564 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 1.5 m -142.49 159.26 42.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.2 -0.937 . . . . 50.0 110.244 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -86.16 -13.23 47.67 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.296 -0.878 . . . . 50.0 109.908 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.1 p -114.79 15.81 17.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.381 -0.824 . . . . 99.99 110.057 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.713 ' HB1' ' HB ' ' A' ' 70' ' ' VAL . . . -81.13 9.79 6.27 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.321 -0.862 . . . . 99.99 109.959 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.512 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 84.5 m-20 -85.2 16.86 3.31 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.335 -0.853 . . . . 99.99 109.441 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.628 ' O ' HG13 ' A' ' 79' ' ' VAL . 19.0 t -121.66 -172.44 2.43 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.412 -0.805 . . . . 99.99 109.352 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.483 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 2.4 mttp -62.96 88.33 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.442 -0.903 . . . . 99.99 109.068 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 35' ' ' LEU . 24.3 m -76.68 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.391 -0.818 . . . . 99.99 109.832 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -123.51 129.65 51.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.971 -1.08 . . . . 50.0 110.953 -179.642 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.476 HG23 ' CD1' ' A' ' 35' ' ' LEU . 2.0 t -116.35 178.03 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.388 -0.82 . . . . 50.0 109.872 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.488 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 66.2 mt-10 -153.3 151.0 29.5 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.069 -1.02 . . . . 50.0 110.354 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.757 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -149.54 130.86 14.65 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.236 -0.915 . . . . 50.0 110.267 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.673 ' N ' HG23 ' A' ' 64' ' ' VAL . 0.1 OUTLIER -106.57 72.72 0.3 Allowed Pre-proline 0 C--N 1.306 -1.285 0 O-C-N 121.255 -0.903 . . . . 50.0 110.802 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.505 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.1 Cg_endo -73.0 170.36 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.842 1.443 . . . . 50.0 110.089 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.35 157.0 57.83 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 123.974 1.513 . . . . 50.0 110.479 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -52.84 125.45 17.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.275 -0.891 . . . . 50.0 110.136 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 129.25 -161.15 22.68 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.51 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 15.3 p-10 -99.4 129.47 45.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.202 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 65.3 p -122.12 152.06 40.28 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.391 -0.818 . . . . 50.0 110.092 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.676 ' CZ ' ' CD2' ' A' ' 104' ' ' HIS . 1.8 m-30 -106.2 118.83 37.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 50.0 110.27 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.7 mp -109.08 133.32 54.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.259 -0.901 . . . . 50.0 109.83 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 18.7 t -123.61 128.21 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.038 -1.039 . . . . 50.0 110.769 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 1.013 HG22 HG12 ' A' ' 48' ' ' ILE . 35.5 t -107.82 88.77 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 50.0 109.98 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.499 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.84 -179.8 31.19 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.841 -1.304 . . . . 50.0 109.841 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.565 ' CE ' ' HB ' ' A' ' 14' ' ' THR . 3.8 ptp -99.05 -32.64 11.17 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -1.131 . . . . 50.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 175.86 -72.03 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.534 -1.427 . . . . 50.0 109.534 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -65.97 -82.82 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.239 -1.154 . . . . 50.0 110.102 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 118.24 21.32 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.209 -0.932 . . . . 50.0 110.182 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.61 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.32 148.77 41.86 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 110.308 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 66.2 mt -93.06 105.84 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.116 -0.99 . . . . 0.0 109.926 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -93.83 136.37 34.18 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.14 -0.975 . . . . 0.0 110.536 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.53 159.7 35.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.251 -0.905 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.676 ' CD2' ' CZ ' ' A' ' 91' ' ' TYR . 7.1 m170 -118.98 106.84 12.84 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.351 -0.843 . . . . 0.0 110.589 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.421 ' CE3' ' HG2' ' A' ' 23' ' ' PRO . 1.3 t-105 . . . . . 0 N--CA 1.486 1.34 0 O-C-N 121.221 -0.924 . . . . 0.0 110.146 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.539 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.7 mtt . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 121.217 0.532 . . . . 50.0 110.334 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.675 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 10.7 p -148.71 108.2 3.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 99.99 110.312 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.502 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 0.3 OUTLIER -160.54 61.7 0.32 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.888 -1.133 . . . . 99.99 110.55 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.458 ' HG3' ' HD2' ' A' ' 16' ' ' LYS . 0.5 OUTLIER -89.68 28.27 1.35 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.192 -0.943 . . . . 99.99 110.161 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.545 ' CD ' ' N ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -133.36 67.06 1.54 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 50.0 110.829 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.832 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -102.78 142.12 34.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.15 -0.969 . . . . 50.0 110.024 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -127.93 97.88 4.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.27 -0.894 . . . . 50.0 110.542 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 24.5 p90 -57.33 116.92 3.61 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.058 -1.026 . . . . 50.0 110.241 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.54 -18.05 14.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 50.0 109.994 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.516 ' HE2' ' HB2' ' A' ' 34' ' ' GLU . 21.1 mtmt -137.97 141.78 40.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.194 -0.941 . . . . 50.0 110.286 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 22' ' ' ASN . 16.0 p-10 -66.57 164.86 28.59 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.305 -0.872 . . . . 50.0 110.034 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.555 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 43.5 Cg_endo -71.09 136.46 29.56 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.983 1.517 . . . . 50.0 110.505 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' CG2' ' A' ' 32' ' ' VAL . . . -132.53 126.27 32.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.318 -0.864 . . . . 50.0 110.181 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.506 ' HA ' ' O ' ' A' ' 30' ' ' THR . 26.6 t0 -70.37 111.26 5.81 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.264 -0.898 . . . . 50.0 110.171 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.3 22.94 2.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -0.959 . . . . 50.0 110.243 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.04 -117.41 0.67 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.567 -1.413 . . . . 50.0 109.567 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 28' ' ' HIS . 1.1 p80 -129.72 89.42 2.82 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.256 -1.144 . . . . 50.0 110.322 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 101.25 -2.67 54.5 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.609 -1.396 . . . . 50.0 109.609 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 16.5 p -102.17 107.83 19.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.17 -1.194 . . . . 50.0 110.242 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.555 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 16.0 t -102.59 135.88 37.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.233 -0.917 . . . . 50.0 110.081 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -120.98 132.83 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.184 -0.947 . . . . 50.0 110.208 -179.885 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.052 HD13 ' N ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -134.73 144.16 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 50.0 109.682 179.734 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 1.052 ' N ' HD13 ' A' ' 33' ' ' ILE . 6.4 tt0 -109.68 130.8 55.48 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.201 -0.937 . . . . 50.0 110.872 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.089 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.1 mp -135.39 134.49 39.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.357 -0.84 . . . . 50.0 109.237 179.233 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -79.89 121.84 25.92 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.991 -1.068 . . . . 50.0 109.236 -179.822 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.58 ' CZ ' ' HA3' ' A' ' 39' ' ' GLY . 10.1 t80 -91.61 106.16 18.27 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.584 -1.247 . . . . 50.0 109.458 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.79 69.84 3.41 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.367 -0.833 . . . . 50.0 110.09 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -121.62 127.86 7.06 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.541 -1.424 . . . . 99.99 109.541 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.3 p -87.96 28.28 1.06 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -1.117 . . . . 99.99 110.272 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.463 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.9 p-10 -110.28 -0.92 17.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -0.917 . . . . 99.99 110.247 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.37 -157.41 23.94 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.408 -1.477 . . . . 99.99 109.408 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.72 153.82 54.04 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.893 1.47 . . . . 99.99 110.034 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.675 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.18 157.48 6.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.144 -0.973 . . . . 50.0 110.126 -179.489 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 0.4 OUTLIER -70.56 125.76 27.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 50.0 109.256 179.171 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.892 HD11 ' CG2' ' A' ' 70' ' ' VAL . 2.0 mt -80.98 110.48 17.81 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.164 -0.96 . . . . 50.0 110.481 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.541 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.6 Cg_endo -75.33 84.43 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.034 1.544 . . . . 50.0 110.204 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.768 HG12 HG13 ' A' ' 94' ' ' VAL . 71.2 mt -124.29 149.26 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.917 . . . . 50.0 110.457 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.623 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.1 m -116.81 142.88 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 50.0 109.844 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 61' ' ' GLY . 22.8 m -122.56 100.88 7.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 50.0 110.016 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.536 ' O ' ' N ' ' A' ' 91' ' ' TYR . 36.0 m -129.02 157.49 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.334 -0.854 . . . . 50.0 110.238 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -56.21 163.95 1.45 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.389 -0.82 . . . . 50.0 109.998 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 12.7 t -62.12 121.3 12.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.167 -0.958 . . . . 50.0 110.491 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.644 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 80.07 30.39 0.24 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.61 -0.681 . . . . 50.0 110.738 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.587 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 11.4 m120 -135.41 84.29 2.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.144 -0.972 . . . . 50.0 110.182 179.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -106.75 8.57 30.99 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 50.0 110.471 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.07 -18.01 14.72 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.134 -0.979 . . . . 50.0 110.424 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 p -136.18 146.42 56.28 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.372 -0.83 . . . . 50.0 110.15 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.57 132.67 17.76 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.108 1.583 . . . . 50.0 110.496 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.583 HG12 ' HG3' ' A' ' 86' ' ' PRO . 2.9 t -133.83 -59.42 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -0.866 . . . . 50.0 109.817 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.3 154.12 51.45 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.69 -1.764 . . . . 50.0 108.69 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.432 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 6.2 mtt180 -142.83 156.71 45.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.963 -1.316 . . . . 50.0 110.681 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 1.1 mt -86.23 138.41 31.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.193 -0.942 . . . . 50.0 109.998 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.586 HG22 ' HG2' ' A' ' 84' ' ' GLU . 76.2 t -91.64 -29.79 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 50.0 110.458 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.472 ' O ' ' O ' ' A' ' 66' ' ' VAL . 10.1 t -95.1 176.11 6.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 50.0 110.219 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.543 HG12 ' N ' ' A' ' 67' ' ' ASN . 53.8 t -44.34 171.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.294 -0.879 . . . . 50.0 110.225 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.543 ' N ' HG12 ' A' ' 66' ' ' VAL . 7.4 p-10 -46.86 162.2 0.27 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 50.0 109.973 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.507 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.66 90.89 0.8 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.97 1.51 . . . . 50.0 110.319 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 1.166 ' CE2' ' HB2' ' A' ' 71' ' ' ALA . 2.2 t80 -149.6 121.79 8.34 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 50.0 110.366 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.892 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.2 t -88.27 63.42 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.232 -0.918 . . . . 50.0 110.064 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.166 ' HB2' ' CE2' ' A' ' 69' ' ' PHE . . . -70.56 64.78 0.29 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.233 -0.917 . . . . 50.0 110.251 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 70' ' ' VAL . 6.5 t -142.62 154.82 44.73 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.233 -0.917 . . . . 50.0 110.256 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 t -77.82 -2.83 38.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 50.0 110.082 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -117.93 23.14 11.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.247 -0.908 . . . . 99.99 110.187 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.569 ' O ' ' HB3' ' A' ' 37' ' ' TYR . . . -65.3 -5.61 7.67 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.267 -0.896 . . . . 99.99 110.418 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.425 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 76.5 m-20 -85.23 22.86 1.38 Allowed 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.032 -1.043 . . . . 99.99 109.339 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.624 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -131.59 -173.24 3.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.291 -0.88 . . . . 99.99 109.635 -179.802 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 17.3 pttt -63.92 89.11 0.05 Allowed 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.705 -0.798 . . . . 99.99 109.103 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 1.089 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.4 m -76.07 176.31 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.317 -0.864 . . . . 99.99 109.358 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.21 145.02 47.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.84 -1.162 . . . . 50.0 111.019 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.761 ' CG1' HG22 ' A' ' 33' ' ' ILE . 14.5 p -132.52 175.7 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.359 -0.838 . . . . 50.0 109.861 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 81' ' ' VAL . 3.9 mt-10 -140.29 144.87 36.63 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.085 -1.009 . . . . 50.0 110.605 -179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -160.24 136.64 8.81 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.265 -0.897 . . . . 50.0 110.165 179.758 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.586 ' HG2' HG22 ' A' ' 64' ' ' VAL . 2.9 pt-20 -106.13 73.96 0.31 Allowed Pre-proline 0 C--N 1.305 -1.343 0 O-C-N 121.263 -0.898 . . . . 50.0 110.579 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.7 Cg_endo -72.41 169.9 20.59 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.166 179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.583 ' HG3' HG12 ' A' ' 60' ' ' VAL . 45.5 Cg_endo -72.18 136.93 27.79 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 123.983 1.517 . . . . 50.0 110.097 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -53.71 103.49 0.08 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.236 -0.915 . . . . 50.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.17 -173.04 33.46 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.421 -1.471 . . . . 50.0 109.421 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 105' ' ' TRP . 35.0 p-10 -69.34 145.52 52.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.275 -1.132 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.588 ' HA ' ' N ' ' A' ' 53' ' ' SER . 1.4 p -143.0 140.85 31.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.276 -0.89 . . . . 50.0 110.368 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.549 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 0.5 OUTLIER -97.13 119.94 36.56 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.217 -0.927 . . . . 50.0 109.532 179.567 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.46 HG23 ' O ' ' A' ' 92' ' ' ILE . 2.4 tt -114.96 132.08 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.141 -0.975 . . . . 50.0 110.38 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.623 ' HB ' HG22 ' A' ' 49' ' ' VAL . 45.3 t -120.74 120.81 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.054 -1.029 . . . . 50.0 110.405 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.768 HG13 HG12 ' A' ' 48' ' ' ILE . 62.0 t -109.0 99.64 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 50.0 110.107 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -153.64 160.44 29.28 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.616 -1.394 . . . . 50.0 109.616 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.463 ' SD ' ' HA ' ' A' ' 13' ' ' CYS . 4.4 ttm -115.5 -44.36 2.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -1.16 . . . . 50.0 110.271 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -115.32 -115.17 2.99 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.805 -1.318 . . . . 50.0 109.805 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.34 -35.07 17.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -1.133 . . . . 50.0 110.504 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -79.51 116.12 19.54 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.139 -0.976 . . . . 50.0 110.248 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.798 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.76 150.21 44.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.565 HD12 ' N ' ' A' ' 101' ' ' ILE . 4.4 mp -111.36 106.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.005 -1.059 . . . . 0.0 109.905 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 102' ' ' ASN . 16.3 p30 -95.32 130.17 42.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 110.523 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.605 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -115.38 160.79 19.41 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.373 -0.83 . . . . 0.0 109.834 179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.549 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 7.4 p80 -121.6 86.64 2.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.198 -0.939 . . . . 0.0 110.386 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.496 ' O ' ' HA ' ' A' ' 89' ' ' ASP . 15.5 t-105 . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 110.051 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.8 ptm . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.281 0.562 . . . . 50.0 110.236 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.4 p -149.06 107.89 3.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.229 -0.919 . . . . 99.99 110.485 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.32 51.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.629 -1.294 . . . . 99.99 110.759 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.593 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 2.0 pt-20 -78.9 12.19 2.29 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.084 -1.01 . . . . 99.99 110.005 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mptt -101.48 61.29 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.243 -0.911 . . . . 50.0 110.388 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.689 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -100.41 144.17 29.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.11 -0.994 . . . . 50.0 109.66 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.53 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 30.6 t -127.28 100.13 5.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.065 -1.022 . . . . 50.0 110.658 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.657 ' HB3' ' HE2' ' A' ' 103' ' ' HIS . 10.2 p90 -59.02 107.94 0.6 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.202 -0.936 . . . . 50.0 110.258 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -94.58 -23.51 17.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.907 . . . . 50.0 109.824 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.475 ' HE3' ' OE1' ' A' ' 34' ' ' GLU . 13.0 mttt -142.11 143.81 33.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 50.0 110.084 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 43.9 p-10 -66.77 162.82 48.49 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 50.0 110.209 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 46.5 Cg_endo -73.0 135.07 22.52 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.947 1.498 . . . . 50.0 110.285 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -136.55 156.83 48.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.191 -0.943 . . . . 50.0 110.317 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.427 ' HA ' ' O ' ' A' ' 30' ' ' THR . 13.8 t70 -85.53 148.53 25.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 50.0 110.043 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.626 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -116.91 -5.89 11.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.251 -0.905 . . . . 50.0 110.194 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -172.67 -105.77 0.19 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.318 -1.513 . . . . 50.0 109.318 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.59 88.8 2.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 50.0 110.024 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.429 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 97.93 31.23 6.72 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.557 -1.417 . . . . 50.0 109.557 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.62 HG23 ' H ' ' A' ' 26' ' ' THR . 0.8 OUTLIER -136.62 107.85 6.82 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.22 -1.164 . . . . 50.0 110.431 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.447 HG23 ' HD2' ' A' ' 85' ' ' PRO . 21.7 t -97.01 145.48 8.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.253 -0.905 . . . . 50.0 110.118 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.626 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -126.27 137.74 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.236 -0.915 . . . . 50.0 110.486 -179.834 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.816 HG23 HD11 ' A' ' 35' ' ' LEU . 3.3 tt -140.33 152.86 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 50.0 109.893 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 21' ' ' LYS . 2.0 tt0 -127.02 108.04 10.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.154 -0.966 . . . . 50.0 110.304 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.055 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -122.7 138.97 54.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.252 -0.905 . . . . 50.0 109.544 179.588 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.9 OUTLIER -91.77 132.07 36.67 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.086 -1.009 . . . . 50.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.642 ' CD2' HG11 ' A' ' 70' ' ' VAL . 8.3 t80 -93.87 95.7 9.26 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.911 -1.115 . . . . 50.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 81.8 p -96.11 69.52 2.76 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.305 -0.872 . . . . 50.0 109.977 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -119.3 131.0 8.8 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.318 -1.513 . . . . 99.99 109.318 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.1 m -84.71 21.93 1.44 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -1.135 . . . . 99.99 110.227 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.01 -2.09 44.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.918 . . . . 99.99 109.984 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.69 -159.39 31.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.597 -1.401 . . . . 99.99 109.597 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.595 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.6 Cg_endo -72.85 148.64 46.35 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.137 1.598 . . . . 99.99 110.497 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.736 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -170.42 161.43 7.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.924 . . . . 50.0 110.129 -179.582 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.58 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -74.81 128.3 35.24 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.091 -1.006 . . . . 50.0 109.563 179.35 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.993 ' CG2' HD11 ' A' ' 48' ' ' ILE . 9.6 mt -87.73 114.31 58.44 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.118 -0.989 . . . . 50.0 110.52 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.509 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.1 Cg_endo -76.88 101.72 1.54 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.063 1.56 . . . . 50.0 110.398 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.993 HD11 ' CG2' ' A' ' 46' ' ' ILE . 2.4 mp -129.04 155.11 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -0.927 . . . . 50.0 110.302 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 92' ' ' ILE . 14.8 p -130.65 145.32 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.294 -0.879 . . . . 50.0 109.814 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.452 ' HB2' ' C ' ' A' ' 61' ' ' GLY . 61.5 m -122.76 111.25 16.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.134 -0.979 . . . . 50.0 109.895 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 55' ' ' ASN . 35.9 m -135.91 161.49 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 50.0 110.561 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.688 ' HB3' ' ND2' ' A' ' 55' ' ' ASN . . . -56.2 164.44 1.29 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.471 -0.768 . . . . 50.0 110.097 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.655 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 1.3 m -60.31 114.64 3.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 50.0 110.292 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 79.72 30.49 0.27 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.548 -0.72 . . . . 50.0 110.498 179.776 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.688 ' ND2' ' HB3' ' A' ' 52' ' ' ALA . 7.6 m-20 -122.5 85.02 2.35 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 50.0 110.302 179.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.66 16.81 24.62 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.945 . . . . 50.0 110.059 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 ttt -126.12 -10.23 6.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.314 -0.866 . . . . 50.0 110.348 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.14 115.65 14.12 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.226 -0.921 . . . . 50.0 110.212 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.64 127.77 12.75 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.96 1.505 . . . . 50.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 2.2 m -148.07 -33.67 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.253 -0.904 . . . . 50.0 110.294 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.452 ' C ' ' HB2' ' A' ' 50' ' ' SER . . . -71.64 146.35 40.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HB2' ' A' ' 83' ' ' MET . 4.6 mtt180 -139.12 156.95 46.77 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.071 -1.252 . . . . 50.0 110.736 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.468 HD13 ' HD3' ' A' ' 68' ' ' PRO . 5.9 mt -88.34 141.5 28.5 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 50.0 109.975 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.528 ' CG1' ' OE1' ' A' ' 82' ' ' GLU . 92.5 t -85.42 -12.76 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 50.0 110.213 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.956 HG23 ' OE2' ' A' ' 82' ' ' GLU . 0.0 OUTLIER -111.54 175.74 5.3 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.23 -0.919 . . . . 50.0 110.152 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.2 m -58.14 176.16 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.296 -0.877 . . . . 50.0 110.067 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.62 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 75.3 m-20 -46.83 141.92 5.24 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.208 -0.932 . . . . 50.0 109.992 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.482 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 50.2 Cg_endo -76.81 70.04 6.65 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.93 1.489 . . . . 50.0 110.896 -179.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 11.2 p90 -110.11 129.67 55.66 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.057 -1.027 . . . . 50.0 110.269 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.993 ' CG2' HD11 ' A' ' 46' ' ' ILE . 94.0 t -85.65 60.84 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 50.0 110.097 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.595 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.77 57.4 4.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.172 -0.955 . . . . 50.0 110.006 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.71 169.63 17.39 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.269 -0.894 . . . . 50.0 110.288 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 p -97.43 -4.34 38.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 50.0 109.833 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 93.2 p -121.19 9.47 10.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.324 -0.86 . . . . 99.99 110.538 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.929 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -78.51 8.11 5.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.047 -1.033 . . . . 99.99 109.941 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 20.1 m-80 -86.11 20.03 2.44 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.227 -0.92 . . . . 99.99 109.281 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.664 ' O ' ' HA ' ' A' ' 36' ' ' SER . 3.7 m -124.41 -173.08 2.69 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.386 -0.821 . . . . 99.99 109.359 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.54 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.0 OUTLIER -63.19 88.62 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.42 -0.8 . . . . 99.99 109.267 179.564 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 1.055 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.3 m -76.68 174.62 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.359 -0.838 . . . . 99.99 109.658 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.406 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -125.74 131.74 52.47 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.933 -1.104 . . . . 50.0 110.786 -179.76 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -125.46 176.62 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 109.917 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.956 ' OE2' HG23 ' A' ' 65' ' ' THR . 8.4 pt-20 -160.22 156.26 26.25 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -0.998 . . . . 50.0 110.354 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.568 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.8 OUTLIER -160.05 140.12 11.56 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -0.875 . . . . 50.0 110.291 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.429 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -104.11 86.36 1.28 Allowed Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.386 -0.821 . . . . 50.0 110.466 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 83' ' ' MET . 45.4 Cg_endo -71.44 170.16 19.11 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.818 1.431 . . . . 50.0 110.409 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.13 163.2 39.44 Favored 'Trans proline' 0 C--N 1.304 -1.814 0 O-C-N 124.036 1.545 . . . . 50.0 110.414 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.56 127.68 23.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.301 -0.874 . . . . 50.0 110.036 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.94 152.95 12.83 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 89' ' ' ASP . 13.8 p30 -53.05 155.12 2.64 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 50.0 110.195 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.642 ' HA ' ' N ' ' A' ' 53' ' ' SER . 11.9 p -141.47 153.32 44.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.254 -0.904 . . . . 50.0 110.386 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.594 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.5 m-30 -104.72 119.72 39.67 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.253 -0.905 . . . . 50.0 110.119 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.789 HD13 ' N ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.91 129.7 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.166 -0.959 . . . . 50.0 110.027 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.789 ' N ' HD13 ' A' ' 92' ' ' ILE . 21.2 t -115.56 139.19 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.157 -0.965 . . . . 50.0 110.536 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.982 HG22 HG12 ' A' ' 48' ' ' ILE . 53.8 t -120.91 104.03 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.409 -0.807 . . . . 50.0 110.081 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.532 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.95 168.55 33.46 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.708 -1.357 . . . . 50.0 109.708 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.593 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 26.5 ttm -98.36 -71.41 0.69 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.244 -1.151 . . . . 50.0 110.296 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.95 36.38 0.3 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.508 -1.437 . . . . 50.0 109.508 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.44 ' OD1' ' OE1' ' A' ' 15' ' ' GLU . 0.9 OUTLIER -162.18 -46.96 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.328 -1.101 . . . . 50.0 109.823 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.53 129.93 39.72 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.364 -0.835 . . . . 50.0 109.709 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.783 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.96 150.42 44.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.707 -179.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 1.4 mp -112.08 123.91 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.131 -0.98 . . . . 0.0 109.761 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.514 ' CB ' HG22 ' A' ' 93' ' ' VAL . 9.4 p30 -101.0 139.44 36.68 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.17 -0.956 . . . . 0.0 110.686 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.657 ' HE2' ' HB3' ' A' ' 19' ' ' PHE . 5.6 m-70 -120.41 160.93 22.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.416 -0.802 . . . . 0.0 109.856 179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.567 ' O ' ' CD2' ' A' ' 104' ' ' HIS . 51.7 p-80 -118.38 92.28 3.78 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.204 -0.935 . . . . 0.0 110.509 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 2.3 t-105 . . . . . 0 N--CA 1.488 1.457 0 O-C-N 121.158 -0.964 . . . . 0.0 110.035 179.668 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.511 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.4 mtt . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 121.149 0.499 . . . . 50.0 110.241 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.644 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.75 107.55 3.84 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.054 -1.029 . . . . 99.99 110.558 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.694 HG21 HG12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -161.75 35.84 0.13 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.006 -1.059 . . . . 99.99 110.213 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.611 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 1.1 pp20? -66.52 -5.44 11.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 99.99 110.451 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.563 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 8.8 mmtm -89.28 61.51 5.73 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 50.0 110.542 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.912 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.0 OUTLIER -95.02 141.78 28.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.102 -0.999 . . . . 50.0 110.128 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.521 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.12 97.9 4.93 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 50.0 110.035 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.67 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 10.5 p90 -59.53 123.92 18.41 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.021 -1.049 . . . . 50.0 110.457 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.614 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.4 -23.96 12.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.335 -0.853 . . . . 50.0 109.969 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 11.8 mtmt -142.33 151.5 42.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 50.0 110.105 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -67.53 162.31 57.75 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 50.0 110.153 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.574 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.1 Cg_endo -71.86 127.79 13.39 Favored 'Trans proline' 0 C--N 1.303 -1.816 0 O-C-N 124.052 1.554 . . . . 50.0 110.3 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.98 147.83 46.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.257 -0.902 . . . . 50.0 110.37 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 30' ' ' THR . 18.5 t0 -87.75 148.11 24.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.885 . . . . 50.0 110.143 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.16 -69.55 0.86 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.125 -0.984 . . . . 50.0 110.237 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.41 -101.81 1.58 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.533 -1.427 . . . . 50.0 109.533 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 34.0 t60 -131.96 89.01 2.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -1.152 . . . . 50.0 110.342 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 100.15 5.92 54.18 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.661 -1.375 . . . . 50.0 109.661 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 14.4 p -101.9 107.67 18.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -1.169 . . . . 50.0 110.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.574 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 39.0 t -102.53 139.85 22.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.177 -0.952 . . . . 50.0 110.19 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.431 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -123.13 150.69 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -0.95 . . . . 50.0 110.319 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.929 HG23 HD11 ' A' ' 35' ' ' LEU . 0.6 OUTLIER -136.96 154.03 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.399 -0.813 . . . . 50.0 109.75 179.689 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.614 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.1 tp10 -119.55 91.44 3.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.129 -0.982 . . . . 50.0 110.9 -179.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.95 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -119.03 138.79 52.6 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.289 -0.882 . . . . 50.0 109.081 179.274 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -93.78 135.16 35.37 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.06 -1.025 . . . . 50.0 110.175 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.563 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 5.8 t80 -94.38 103.34 15.33 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.964 -1.094 . . . . 50.0 109.558 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.82 69.6 3.38 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.22 -0.925 . . . . 50.0 110.038 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.483 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -118.46 139.33 14.47 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.439 -1.464 . . . . 99.99 109.439 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 40' ' ' SER . 2.6 t -82.95 31.08 0.43 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -1.124 . . . . 99.99 110.298 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.477 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -108.33 -11.96 15.12 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 99.99 110.243 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 -139.84 19.31 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.488 -1.445 . . . . 99.99 109.488 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.478 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -71.16 139.67 35.92 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.987 1.52 . . . . 99.99 110.248 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.625 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -169.38 157.57 7.51 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -0.867 . . . . 50.0 110.014 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.563 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.3 mmtt -76.34 129.15 36.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 50.0 109.178 178.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.931 HD11 HG22 ' A' ' 70' ' ' VAL . 10.3 mt -86.34 109.36 22.75 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 50.0 110.714 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.563 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 52.3 Cg_endo -78.98 99.42 1.26 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 O-C-N 124.056 1.556 . . . . 50.0 110.129 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.066 HG23 HD11 ' A' ' 92' ' ' ILE . 6.9 mt -136.11 144.01 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.072 -1.018 . . . . 50.0 110.471 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.459 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 23.0 m -116.19 148.54 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.399 -0.813 . . . . 50.0 109.835 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.5 OUTLIER -124.19 105.8 9.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.146 -0.971 . . . . 50.0 109.86 -179.932 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.489 ' O ' ' N ' ' A' ' 91' ' ' TYR . 4.3 m -129.7 159.49 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.281 -0.887 . . . . 50.0 110.34 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -55.94 163.72 1.41 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.856 . . . . 50.0 110.027 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.602 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 37.6 t -58.44 122.25 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.26 -0.9 . . . . 50.0 110.739 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.602 ' CB ' ' O ' ' A' ' 53' ' ' SER . 1.2 tp 78.32 30.56 0.41 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.919 -0.712 . . . . 50.0 110.827 179.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.419 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 10.3 m120 -126.66 84.11 2.23 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -0.957 . . . . 50.0 110.198 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -106.42 8.61 31.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.279 -0.888 . . . . 50.0 109.917 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.7 ttm -116.11 -13.26 11.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.418 -0.801 . . . . 50.0 110.131 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.16 134.06 19.96 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.368 -0.832 . . . . 50.0 110.104 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.79 134.75 22.41 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.941 1.495 . . . . 50.0 110.258 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.412 HG11 ' HB2' ' A' ' 52' ' ' ALA . 55.3 t -139.31 -46.87 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.237 -0.914 . . . . 50.0 109.848 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -75.43 156.35 48.27 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.67 -1.772 . . . . 50.0 108.67 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.45 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 15.3 mtp180 -138.04 157.15 46.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.881 -1.364 . . . . 50.0 110.722 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.754 HD22 ' HD3' ' A' ' 68' ' ' PRO . 1.1 mp -91.3 134.65 34.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 50.0 109.737 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.544 HG23 ' C ' ' A' ' 83' ' ' MET . 4.0 t -72.83 -40.91 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.167 -0.958 . . . . 50.0 110.147 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 ' OE1' ' A' ' 82' ' ' GLU . 14.9 t -103.43 175.79 5.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.17 -0.956 . . . . 50.0 110.165 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 66' ' ' VAL . 6.5 m -54.76 -172.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.394 -0.816 . . . . 50.0 110.098 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.603 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 1.8 m-20 -47.45 137.78 8.96 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.952 . . . . 50.0 110.073 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.754 ' HD3' HD22 ' A' ' 63' ' ' LEU . 48.0 Cg_endo -75.14 74.32 4.11 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.974 1.513 . . . . 50.0 110.707 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.603 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -107.27 141.32 38.78 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.141 -0.974 . . . . 50.0 110.282 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.931 HG22 HD11 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -103.69 60.26 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 50.0 109.358 179.398 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -69.67 57.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.359 -0.838 . . . . 50.0 110.364 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.427 ' N ' ' O ' ' A' ' 70' ' ' VAL . 0.0 OUTLIER -142.38 165.09 28.37 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 50.0 110.104 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.68 7.32 17.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.151 -0.968 . . . . 50.0 110.117 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 8.0 t -121.47 17.62 11.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.26 -0.9 . . . . 99.99 110.488 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -69.03 -4.11 15.68 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.153 -0.967 . . . . 99.99 109.93 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.471 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 64.1 m-80 -88.58 24.01 2.09 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.364 -0.835 . . . . 99.99 109.416 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -129.31 -173.19 2.93 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.368 -0.832 . . . . 99.99 109.442 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.52 ' N ' ' OG ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -63.7 88.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.313 -0.867 . . . . 99.99 109.114 179.507 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.95 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.8 m -76.45 174.35 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.292 -0.88 . . . . 99.99 109.199 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.431 HD21 HG12 ' A' ' 32' ' ' VAL . 1.3 tt -134.71 136.6 42.84 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.736 -1.227 . . . . 50.0 111.084 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.571 HG21 ' HE2' ' A' ' 17' ' ' PHE . 2.1 t -117.33 166.73 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.456 -0.777 . . . . 50.0 109.751 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.545 ' OE1' HG21 ' A' ' 65' ' ' THR . 5.6 mt-10 -134.75 146.34 49.29 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.071 -1.018 . . . . 50.0 110.271 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.544 ' C ' HG23 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -159.95 151.64 20.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.18 -0.95 . . . . 50.0 110.347 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.507 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -120.93 60.94 9.11 Favored Pre-proline 0 C--N 1.306 -1.286 0 O-C-N 121.239 -0.913 . . . . 50.0 110.509 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.429 ' HD3' ' C ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.34 158.78 47.94 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.073 1.565 . . . . 50.0 110.201 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.88 146.76 48.42 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.044 1.549 . . . . 50.0 110.453 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -52.97 146.89 10.14 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.269 -0.894 . . . . 50.0 110.062 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 122.71 172.75 14.03 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.394 -1.482 . . . . 50.0 109.394 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.469 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 11.4 m-20 -71.73 128.55 36.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.208 -1.171 . . . . 50.0 110.161 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.567 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.6 p -124.82 141.86 51.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 50.0 110.157 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.605 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -99.69 116.66 32.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.221 -0.924 . . . . 50.0 110.035 179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 1.066 HD11 HG23 ' A' ' 48' ' ' ILE . 0.0 OUTLIER -103.83 133.88 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 50.0 109.947 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.899 ' N ' HD13 ' A' ' 92' ' ' ILE . 11.1 t -118.33 119.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.572 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.841 HG11 ' HB2' ' A' ' 17' ' ' PHE . 33.6 t -100.6 103.34 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 50.0 109.958 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.434 ' O ' ' HB2' ' A' ' 47' ' ' PRO . . . -155.25 147.78 17.2 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.484 -1.446 . . . . 50.0 109.484 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.611 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 12.3 ptp -102.28 1.71 36.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.257 -1.143 . . . . 50.0 110.224 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.89 -60.05 0.55 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.38 -77.61 0.23 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.23 -1.159 . . . . 50.0 110.205 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.5 mmtt -79.57 124.0 28.11 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.221 -0.925 . . . . 50.0 110.313 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.603 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.19 148.56 41.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.267 -0.895 . . . . 0.0 110.249 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.1 pt -137.29 130.13 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.243 -0.91 . . . . 0.0 110.232 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.451 ' CB ' HG22 ' A' ' 93' ' ' VAL . 34.0 p-10 -109.46 132.31 54.25 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.21 -0.932 . . . . 0.0 110.394 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.67 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -122.12 169.9 10.4 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.24 -0.912 . . . . 0.0 110.061 179.866 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.605 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 45.5 p-80 -118.68 123.89 46.03 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.213 -0.929 . . . . 0.0 110.4 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.693 ' CH2' HD13 ' A' ' 33' ' ' ILE . 26.1 m0 . . . . . 0 C--N 1.304 -1.375 0 O-C-N 121.294 -0.879 . . . . 0.0 110.23 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.52 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 1.1 mtm . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.041 0.448 . . . . 50.0 110.025 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.707 ' O ' ' CB ' ' A' ' 44' ' ' CYS . 12.0 p -148.89 107.23 3.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.067 -1.021 . . . . 99.99 110.785 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.634 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.76 31.8 0.15 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.672 -1.267 . . . . 99.99 110.489 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HA2' ' A' ' 95' ' ' GLY . 10.3 tm-20 -71.01 -0.38 9.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -0.976 . . . . 99.99 110.106 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -87.94 61.68 6.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 50.0 110.403 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.605 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -94.72 146.28 24.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.894 . . . . 50.0 109.887 179.632 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.585 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 57.8 m -127.4 100.17 5.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.043 . . . . 50.0 110.659 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.719 ' CD1' HD23 ' A' ' 35' ' ' LEU . 16.1 m-85 -57.2 115.24 2.55 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.193 -0.942 . . . . 50.0 109.802 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -102.81 -27.0 12.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.24 -0.912 . . . . 50.0 110.476 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 4.9 mttt -145.53 151.43 38.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.183 -0.948 . . . . 50.0 110.23 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.1 p30 -67.09 154.97 91.53 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 50.0 110.232 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.556 ' HD2' ' CE3' ' A' ' 105' ' ' TRP . 46.6 Cg_endo -73.24 141.2 31.91 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 O-C-N 124.097 1.577 . . . . 50.0 110.419 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.477 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -146.63 168.07 22.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.274 -0.891 . . . . 50.0 110.29 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -89.07 154.62 20.04 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 50.0 110.341 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.63 -48.06 1.4 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.307 -0.87 . . . . 50.0 110.074 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.52 -101.48 2.32 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.453 -1.459 . . . . 50.0 109.453 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -133.15 93.69 3.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -1.155 . . . . 50.0 110.23 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.6 19.75 57.68 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 50.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 70.7 p -115.35 107.83 15.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.28 -1.129 . . . . 50.0 110.283 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 98.7 t -85.32 143.82 10.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.251 -0.906 . . . . 50.0 110.174 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -125.14 149.32 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.213 -0.929 . . . . 50.0 110.409 -179.884 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.799 HG23 HD11 ' A' ' 35' ' ' LEU . 2.0 tt -152.51 163.4 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -0.851 . . . . 50.0 109.906 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.803 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.6 OUTLIER -132.46 102.07 5.59 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.12 -0.988 . . . . 50.0 110.502 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -119.12 139.91 51.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.314 -0.867 . . . . 50.0 109.165 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -92.46 131.44 37.61 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.041 -1.037 . . . . 50.0 110.068 -179.457 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.613 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.6 t80 -92.12 98.79 11.76 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.984 -1.086 . . . . 50.0 109.497 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 t -96.11 69.76 2.77 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.318 -0.864 . . . . 50.0 110.028 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -118.46 132.22 9.63 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.631 -1.388 . . . . 99.99 109.631 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 45.3 m -83.95 18.5 2.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.231 -1.158 . . . . 99.99 110.317 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -99.92 -1.08 38.17 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.241 -0.912 . . . . 99.99 110.225 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.6 -149.93 29.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.105 -1.598 . . . . 99.99 109.105 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.59 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.9 Cg_endo -73.35 150.67 47.19 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.916 1.482 . . . . 99.99 110.406 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.707 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -169.87 161.48 9.0 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.377 -0.827 . . . . 50.0 109.96 -179.487 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.653 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 24.0 mmtt -75.61 111.03 10.51 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.018 -1.051 . . . . 50.0 109.229 178.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.014 HD11 HG23 ' A' ' 70' ' ' VAL . 2.2 mt -72.29 110.66 8.5 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.966 . . . . 50.0 110.423 -179.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 50.3 Cg_endo -84.54 97.67 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.026 1.54 . . . . 50.0 110.652 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.824 ' CD1' HG22 ' A' ' 46' ' ' ILE . 24.2 mt -133.33 153.76 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 50.0 110.243 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.738 ' O ' HG13 ' A' ' 49' ' ' VAL . 11.2 p -125.78 110.97 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 50.0 110.23 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.456 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -91.52 100.74 13.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 50.0 109.751 179.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.656 HG23 HG22 ' A' ' 49' ' ' VAL . 24.8 t -122.2 155.2 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 50.0 110.223 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.544 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -60.92 164.36 4.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.204 -0.935 . . . . 50.0 109.208 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.65 ' N ' ' HA ' ' A' ' 90' ' ' SER . 16.8 t -71.53 101.27 2.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.721 -1.237 . . . . 50.0 108.936 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.553 ' HB2' ' O ' ' A' ' 53' ' ' SER . 5.0 tp 170.68 -61.67 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 C-N-CA 118.071 -1.451 . . . . 50.0 111.661 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 58' ' ' THR . 60.4 m-20 -92.92 149.92 20.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.904 -1.123 . . . . 50.0 110.273 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -106.12 -20.61 13.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.226 -0.921 . . . . 50.0 110.187 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.9 ttp -126.55 31.31 5.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.282 -0.886 . . . . 50.0 110.27 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.536 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 59.6 m -126.87 120.62 22.81 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 50.0 110.171 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.5 126.0 11.16 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.968 1.509 . . . . 50.0 110.212 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 24.4 t -135.02 -47.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.91 . . . . 50.0 110.05 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.43 158.8 49.45 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.133 -1.587 . . . . 50.0 109.133 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.444 ' O ' ' HB2' ' A' ' 83' ' ' MET . 21.4 mtm180 -132.6 154.76 49.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.138 -1.213 . . . . 50.0 110.555 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.6 mt -94.15 129.67 40.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.383 -0.823 . . . . 50.0 109.866 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.527 HG23 ' HG2' ' A' ' 84' ' ' GLU . 24.2 t -80.84 -32.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.184 -0.948 . . . . 50.0 110.38 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' VAL . 15.2 t -79.33 168.35 19.64 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -0.964 . . . . 50.0 110.099 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.45 ' H ' HG13 ' A' ' 66' ' ' VAL . 7.3 m -50.99 179.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.191 -0.943 . . . . 50.0 110.057 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.64 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 14.1 m120 -46.96 143.62 4.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.204 -0.935 . . . . 50.0 110.058 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.873 ' C ' HD12 ' A' ' 46' ' ' ILE . 47.0 Cg_endo -73.56 66.42 4.65 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.963 1.507 . . . . 50.0 110.583 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.653 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 18.2 m-30 -118.3 121.84 41.42 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.895 . . . . 50.0 110.12 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.014 HG23 HD11 ' A' ' 46' ' ' ILE . 42.9 t -77.55 60.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.119 -0.988 . . . . 50.0 109.99 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -85.37 59.37 5.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.15 -0.969 . . . . 50.0 110.185 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -142.95 165.46 27.29 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 50.0 110.388 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -94.42 -4.4 48.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.308 -0.87 . . . . 50.0 110.005 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.62 7.91 11.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.304 -0.872 . . . . 99.99 110.204 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.985 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.05 8.58 3.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 99.99 110.102 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -86.56 19.29 2.91 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.266 -0.896 . . . . 99.99 109.25 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.589 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.1 p -128.68 -172.36 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.463 -0.773 . . . . 99.99 109.41 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.529 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 4.6 mttp -62.91 88.72 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.467 -0.893 . . . . 99.99 109.283 179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.9 m -76.43 173.85 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.318 -0.864 . . . . 99.99 109.418 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 33' ' ' ILE . 5.7 tt -126.18 125.56 42.66 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.933 -1.104 . . . . 50.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.541 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.2 t -122.29 166.03 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.387 -0.821 . . . . 50.0 109.868 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.431 ' OE1' ' C ' ' A' ' 81' ' ' VAL . 3.1 pm0 -147.4 160.29 42.73 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.181 -0.949 . . . . 50.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.509 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 2.5 ptt? -157.07 158.98 37.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 50.0 110.202 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 64' ' ' VAL . 0.4 OUTLIER -115.86 57.05 1.31 Allowed Pre-proline 0 C--N 1.307 -1.247 0 O-C-N 121.111 -0.993 . . . . 50.0 110.746 -179.781 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.509 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.9 Cg_endo -71.44 170.48 18.35 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.936 1.493 . . . . 50.0 110.5 179.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -70.36 161.67 45.16 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.998 1.525 . . . . 50.0 110.439 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -74.88 144.67 43.25 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.272 -0.893 . . . . 50.0 110.155 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.38 178.87 16.62 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.285 -1.526 . . . . 50.0 109.285 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -67.85 131.21 45.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 50.0 110.102 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.65 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -120.28 140.71 50.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.25 -0.906 . . . . 50.0 110.351 -179.912 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.637 ' C ' HD13 ' A' ' 92' ' ' ILE . 3.8 m-30 -94.02 104.72 16.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 50.0 109.788 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD13 ' A' ' 92' ' ' ILE . 3.2 mm -97.88 125.54 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 50.0 109.918 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.506 HG22 ' CB ' ' A' ' 102' ' ' ASN . 21.2 t -125.2 125.05 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.069 -1.02 . . . . 50.0 110.825 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 48' ' ' ILE . 95.4 t -106.87 105.01 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.858 . . . . 50.0 109.785 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.43 155.64 24.19 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.963 -1.255 . . . . 50.0 109.963 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.503 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 3.7 ttm -111.17 -69.21 0.88 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.39 -1.065 . . . . 50.0 110.297 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.71 28.55 0.23 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.62 -1.392 . . . . 50.0 109.62 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -160.56 -50.91 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.173 -1.192 . . . . 50.0 110.241 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -126.16 149.34 49.05 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.301 -0.875 . . . . 50.0 110.164 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.599 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.99 148.92 42.59 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 110.481 -179.876 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.712 HD13 ' N ' ' A' ' 102' ' ' ASN . 0.0 OUTLIER -126.2 124.23 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.331 -0.856 . . . . 0.0 109.552 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.712 ' N ' HD13 ' A' ' 101' ' ' ILE . 23.0 p-10 -111.26 134.83 52.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.073 -1.017 . . . . 0.0 110.843 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.707 ' CE1' HD11 ' A' ' 101' ' ' ILE . 0.1 OUTLIER -127.59 124.09 37.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.105 179.608 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -78.9 98.44 6.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.375 -0.828 . . . . 0.0 110.337 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.556 ' CE3' ' HD2' ' A' ' 23' ' ' PRO . 8.1 m95 . . . . . 0 C--N 1.305 -1.354 0 O-C-N 121.266 -0.896 . . . . 0.0 110.477 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.615 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 10.4 mtp . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 121.066 0.46 . . . . 50.0 110.045 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.7 p -148.95 107.35 3.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.994 -1.066 . . . . 99.99 111.196 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.67 HG23 ' CE1' ' A' ' 37' ' ' TYR . 2.6 m -161.58 53.95 0.26 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.731 -1.231 . . . . 99.99 110.549 179.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HB3' ' CB ' ' A' ' 96' ' ' MET . 18.7 pt-20 -75.29 4.72 6.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.089 -1.007 . . . . 99.99 110.181 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HD2' ' CA ' ' A' ' 39' ' ' GLY . 6.3 mttp -92.36 61.31 3.8 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.216 -0.927 . . . . 50.0 110.397 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 1.018 ' CE2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -96.65 145.87 25.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.05 -1.031 . . . . 50.0 109.926 179.647 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.584 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -127.17 104.42 7.95 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.209 -0.932 . . . . 50.0 110.392 -179.743 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.591 ' CD1' HD23 ' A' ' 35' ' ' LEU . 22.6 m-85 -60.97 96.87 0.05 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.248 -0.908 . . . . 50.0 110.39 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.67 -29.21 25.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -0.924 . . . . 50.0 110.01 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.522 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 14.4 mttm -144.68 147.03 32.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 50.0 110.091 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -73.79 162.12 75.57 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 50.0 110.163 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.616 ' HG2' ' CD2' ' A' ' 105' ' ' TRP . 44.8 Cg_endo -72.44 131.8 18.13 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.023 1.538 . . . . 50.0 110.222 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -126.25 147.86 49.6 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.183 -0.948 . . . . 50.0 110.358 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -77.81 113.76 16.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.314 -0.866 . . . . 50.0 110.186 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -79.19 -14.22 59.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 50.0 110.343 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.74 -106.58 0.22 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' A' ' 28' ' ' HIS . 9.4 p80 -121.98 102.67 8.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -1.144 . . . . 50.0 110.264 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 81.92 23.93 56.47 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.654 -1.378 . . . . 50.0 109.654 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 30.5 p -129.88 107.89 9.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.168 -1.195 . . . . 50.0 110.338 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.552 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -111.22 135.32 50.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.291 -0.881 . . . . 50.0 109.793 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 80' ' ' LEU . 1.4 t -114.65 136.75 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 50.0 110.542 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.03 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -141.89 133.2 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.459 -0.775 . . . . 50.0 109.499 179.784 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.574 ' N ' HD13 ' A' ' 33' ' ' ILE . 34.0 tt0 -112.21 117.52 32.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.141 -0.974 . . . . 50.0 111.274 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.03 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.76 143.77 51.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.363 -0.836 . . . . 50.0 108.969 178.945 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.61 132.42 40.78 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.98 -1.075 . . . . 50.0 110.209 -179.525 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.688 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.9 t80 -95.02 99.6 11.58 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.253 -0.979 . . . . 50.0 109.731 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.1 t -95.93 69.82 2.86 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.202 -0.936 . . . . 50.0 110.144 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.541 ' CA ' ' HD2' ' A' ' 16' ' ' LYS . . . -120.72 118.08 3.71 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.51 -1.436 . . . . 99.99 109.51 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.8 p -85.39 21.81 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -1.154 . . . . 99.99 110.419 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.87 -0.52 50.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 99.99 110.024 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.69 -172.54 26.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.435 -1.466 . . . . 99.99 109.435 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.561 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 42.8 Cg_endo -70.82 152.69 64.04 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.893 1.47 . . . . 99.99 110.195 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.73 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.04 161.59 8.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.223 -0.923 . . . . 50.0 109.902 -179.385 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.615 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.7 OUTLIER -77.29 129.18 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.159 -0.963 . . . . 50.0 109.583 179.373 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.049 HG22 ' CD1' ' A' ' 48' ' ' ILE . 10.0 mt -84.01 112.36 40.14 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.188 -0.945 . . . . 50.0 110.39 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.822 ' C ' HD12 ' A' ' 48' ' ' ILE . 50.0 Cg_endo -77.41 74.9 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 124.001 1.527 . . . . 50.0 110.306 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.049 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.4 mp -115.41 151.04 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.146 -0.971 . . . . 50.0 110.294 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 23.8 m -128.32 147.15 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.439 -0.788 . . . . 50.0 110.09 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -122.25 100.76 7.13 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.362 -0.836 . . . . 50.0 109.654 179.673 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.838 HG12 ' HA ' ' A' ' 59' ' ' PRO . 25.4 m -114.99 160.86 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.234 -0.916 . . . . 50.0 110.421 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.63 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -60.25 164.63 4.06 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.42 -0.8 . . . . 50.0 109.927 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.7 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 3.4 t -66.64 120.49 13.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.181 -0.949 . . . . 50.0 109.805 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.7 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.1 tp 87.18 29.27 0.03 OUTLIER 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.658 -0.652 . . . . 50.0 110.725 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.493 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 66.9 m-80 -144.18 84.81 1.78 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.114 -0.991 . . . . 50.0 110.182 179.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.22 6.24 42.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.197 -0.939 . . . . 50.0 110.111 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.2 mmt -107.83 -14.59 14.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.26 -0.9 . . . . 50.0 110.081 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.3 p -133.14 119.83 15.82 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 50.0 110.04 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.838 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.84 125.85 10.83 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.942 1.496 . . . . 50.0 110.245 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.63 HG11 ' HB2' ' A' ' 52' ' ' ALA . 3.4 p -131.45 -33.72 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 50.0 110.025 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.91 143.45 34.95 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.697 -1.761 . . . . 50.0 108.697 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.469 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -126.62 156.27 41.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.055 -1.262 . . . . 50.0 110.794 -179.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -93.84 129.8 40.11 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.808 . . . . 50.0 109.927 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.636 HG11 ' HB2' ' A' ' 82' ' ' GLU . 4.0 p -54.07 -26.11 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.158 -0.964 . . . . 50.0 110.209 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -114.56 176.05 5.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.285 -0.885 . . . . 50.0 110.117 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 69' ' ' PHE . 15.5 m -59.15 -170.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.162 -0.961 . . . . 50.0 110.225 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.623 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 15.2 t30 -46.79 140.3 6.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 50.0 109.987 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.559 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 47.7 Cg_endo -74.84 78.07 2.93 Favored 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 123.989 1.521 . . . . 50.0 110.557 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.623 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.3 p90 -105.4 136.06 45.64 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.137 -0.977 . . . . 50.0 110.402 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.006 ' CG2' HD11 ' A' ' 46' ' ' ILE . 85.7 t -91.66 60.65 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 50.0 109.976 179.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -82.13 57.79 3.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.324 -0.86 . . . . 50.0 110.017 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 169.11 18.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.315 -0.865 . . . . 50.0 110.177 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -100.2 -5.59 27.43 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 50.0 109.977 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.8 t -121.25 10.12 10.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 99.99 110.507 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.827 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -80.77 10.43 4.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.018 -1.051 . . . . 99.99 110.004 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.519 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 96.6 m-20 -84.51 16.81 2.94 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.325 -0.859 . . . . 99.99 109.314 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.683 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.44 -172.42 2.36 Favored 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.441 -0.787 . . . . 99.99 109.347 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.541 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.2 OUTLIER -62.79 87.94 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.354 -0.938 . . . . 99.99 109.006 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.999 HG22 ' O ' ' A' ' 35' ' ' LEU . 13.4 m -77.18 175.97 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.356 -0.84 . . . . 99.99 109.685 -179.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -127.93 142.01 51.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.918 -1.114 . . . . 50.0 110.705 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.605 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.0 OUTLIER -134.54 166.66 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.423 -0.798 . . . . 50.0 109.867 179.745 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.636 ' HB2' HG11 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -145.11 152.45 40.07 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.289 -0.882 . . . . 50.0 110.266 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 9.7 ptt? -155.3 144.96 21.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 50.0 110.302 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -106.93 74.87 0.39 Allowed Pre-proline 0 C--N 1.305 -1.369 0 O-C-N 121.286 -0.884 . . . . 50.0 110.397 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.4 Cg_endo -72.88 167.71 26.57 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.914 1.481 . . . . 50.0 110.5 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.43 154.32 60.68 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.947 1.498 . . . . 50.0 110.584 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.94 134.26 48.6 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.237 -0.914 . . . . 50.0 110.04 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.87 -168.54 13.68 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.379 -1.489 . . . . 50.0 109.379 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.55 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 7.2 m-20 -82.91 153.16 25.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -1.16 . . . . 50.0 110.116 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -136.96 138.61 40.77 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.284 -0.885 . . . . 50.0 110.296 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.593 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.7 m-30 -99.23 124.3 44.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.097 -1.002 . . . . 50.0 109.797 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 92' ' ' ILE . 4.9 mp -111.0 132.35 59.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.249 -0.907 . . . . 50.0 110.159 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.658 HG22 ' CB ' ' A' ' 102' ' ' ASN . 20.9 t -125.16 120.81 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.822 -1.174 . . . . 50.0 111.365 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 1.015 HG22 HG13 ' A' ' 48' ' ' ILE . 94.9 t -98.19 106.56 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -0.849 . . . . 50.0 109.436 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.492 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.42 142.99 13.34 Favored Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.568 -1.301 . . . . 50.0 110.093 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.545 ' CB ' ' HB3' ' A' ' 15' ' ' GLU . 25.8 ttp -115.74 70.07 0.74 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -1.042 . . . . 50.0 109.957 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 56.03 18.9 20.89 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.559 -1.416 . . . . 50.0 109.559 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -149.36 -88.1 0.08 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -1.104 . . . . 50.0 110.098 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.446 ' O ' ' HA2' ' A' ' 95' ' ' GLY . 0.9 OUTLIER -79.76 155.18 28.04 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.244 -0.91 . . . . 50.0 110.322 -179.876 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.675 ' O ' ' HG2' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -140.75 87.74 2.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.182 -0.949 . . . . 0.0 110.695 179.768 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.705 ' O ' HG23 ' A' ' 101' ' ' ILE . 1.1 tp -85.32 116.45 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.015 -1.053 . . . . 0.0 109.781 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.658 ' CB ' HG22 ' A' ' 93' ' ' VAL . 22.5 p30 -106.77 151.94 24.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.853 . . . . 0.0 110.963 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.484 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.2 OUTLIER -129.67 156.94 43.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.5 -0.75 . . . . 0.0 109.573 179.787 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.567 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 5.7 m170 -114.27 80.83 1.45 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.314 -0.867 . . . . 0.0 110.581 -179.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.616 ' CD2' ' HG2' ' A' ' 23' ' ' PRO . 10.4 t-105 . . . . . 0 N--CA 1.489 1.493 0 O-C-N 121.298 -0.877 . . . . 0.0 110.027 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.535 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.131 0.491 . . . . 50.0 109.952 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.678 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -141.15 106.64 5.06 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.216 -0.927 . . . . 99.99 110.848 -179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.891 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.98 35.63 0.12 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 99.99 110.288 179.029 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.446 ' HB2' ' HB3' ' A' ' 96' ' ' MET . 6.9 tm-20 -68.25 3.51 1.66 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.214 -0.929 . . . . 99.99 110.422 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.18 60.55 0.68 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 50.0 110.836 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.762 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -92.81 142.39 27.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.114 -0.991 . . . . 50.0 109.499 179.074 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.597 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.0 t -127.4 98.38 5.23 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.117 -0.989 . . . . 50.0 110.608 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.693 ' CD1' HD23 ' A' ' 35' ' ' LEU . 17.8 m-85 -56.02 97.1 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.23 -0.919 . . . . 50.0 109.857 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.06 -29.85 26.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 50.0 110.491 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.485 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 26.9 mttm -143.11 145.43 32.84 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.098 -1.001 . . . . 50.0 110.397 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.442 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 10.8 p30 -66.74 163.79 39.42 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 50.0 109.922 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.531 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.4 Cg_endo -71.78 134.59 24.15 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.903 1.475 . . . . 50.0 110.288 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -128.17 160.86 30.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.209 -0.932 . . . . 50.0 110.194 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -94.46 143.16 26.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.226 -0.921 . . . . 50.0 110.253 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.83 -39.66 5.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.223 -0.923 . . . . 50.0 110.157 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -142.72 -105.12 0.53 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.405 -1.478 . . . . 50.0 109.405 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -129.61 97.91 4.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.135 -1.215 . . . . 50.0 110.25 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.38 30.31 10.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 45.4 p -134.62 114.91 13.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.252 -1.146 . . . . 50.0 110.366 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 43.7 t -111.29 124.93 68.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.307 -0.871 . . . . 50.0 109.907 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.92 ' CG1' HD21 ' A' ' 80' ' ' LEU . 2.1 t -108.18 151.76 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.231 -0.918 . . . . 50.0 110.489 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.558 ' CG2' ' HB ' ' A' ' 81' ' ' VAL . 7.4 tt -150.45 166.96 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.448 -0.782 . . . . 50.0 109.515 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.74 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 6.4 tp10 -136.66 104.15 5.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.116 -0.99 . . . . 50.0 110.711 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.949 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -114.28 137.02 52.32 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.256 -0.903 . . . . 50.0 109.536 179.338 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 77' ' ' SER . 4.7 m -86.46 126.4 34.38 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.079 -1.013 . . . . 50.0 109.769 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.686 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.9 t80 -93.32 102.42 14.68 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.028 -1.069 . . . . 50.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -96.34 70.07 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.309 -0.869 . . . . 50.0 110.149 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -115.91 123.26 5.83 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.533 -1.427 . . . . 99.99 109.533 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.99 12.4 4.17 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.245 -1.15 . . . . 99.99 110.355 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.423 ' N ' ' OD1' ' A' ' 41' ' ' ASP . 0.8 OUTLIER -97.6 -1.73 43.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 99.99 110.016 179.837 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 91.15 -156.61 24.4 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.476 -1.45 . . . . 99.99 109.476 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.5 Cg_endo -71.47 150.89 58.62 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 124.035 1.545 . . . . 99.99 110.358 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.678 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.8 OUTLIER -170.73 162.69 7.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.269 -0.895 . . . . 50.0 110.036 -179.522 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.614 ' HD2' ' CG ' ' A' ' 69' ' ' PHE . 44.9 mmtt -72.89 131.74 42.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.103 -0.998 . . . . 50.0 110.045 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.086 HG22 ' CD1' ' A' ' 48' ' ' ILE . 2.4 mt -89.62 109.32 31.15 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.204 -0.935 . . . . 50.0 110.624 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.69 ' C ' HD12 ' A' ' 48' ' ' ILE . 51.9 Cg_endo -79.13 68.44 8.28 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.087 1.572 . . . . 50.0 110.14 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.086 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -111.59 145.62 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.161 -0.962 . . . . 50.0 110.25 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 34.1 m -118.14 139.13 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.334 -0.854 . . . . 50.0 110.108 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -119.9 100.66 7.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.326 -0.859 . . . . 50.0 109.806 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.7 m -124.0 159.82 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.306 -0.871 . . . . 50.0 110.284 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.51 163.88 1.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.392 -0.818 . . . . 50.0 109.766 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.829 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 2.2 m -73.57 104.27 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -0.993 . . . . 50.0 110.034 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.829 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 117.69 19.61 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.318 0 CA-C-O 121.113 0.482 . . . . 50.0 110.509 179.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.416 ' ND2' ' HB ' ' A' ' 58' ' ' THR . 0.2 OUTLIER -138.01 84.67 2.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.969 -1.082 . . . . 50.0 110.324 179.42 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.57 14.74 23.71 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.242 -0.911 . . . . 50.0 109.727 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 ttt -126.22 -12.99 6.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.327 -0.858 . . . . 50.0 110.383 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.416 ' HB ' ' ND2' ' A' ' 55' ' ' ASN . 3.6 m -128.58 129.78 23.53 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.913 . . . . 50.0 110.23 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.471 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.57 132.48 18.98 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 O-C-N 124.044 1.55 . . . . 50.0 110.182 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.86 -42.32 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.125 -0.984 . . . . 50.0 110.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.09 135.4 17.62 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.055 -1.618 . . . . 50.0 109.055 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.519 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.9 mtm180 -119.43 152.27 37.15 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.099 -1.236 . . . . 50.0 110.626 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mt -94.08 124.36 38.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.268 -0.895 . . . . 50.0 110.074 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.519 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 94.1 t -81.16 -38.8 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.218 -0.926 . . . . 50.0 110.364 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -65.84 172.73 3.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.186 -0.946 . . . . 50.0 110.095 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.436 ' H ' HG22 ' A' ' 66' ' ' VAL . 4.3 m -53.4 179.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.219 -0.926 . . . . 50.0 110.007 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.65 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.84 144.22 3.85 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 50.0 110.154 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.5 Cg_endo -73.59 66.52 4.67 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.999 1.526 . . . . 50.0 110.961 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.65 ' CD2' ' HB3' ' A' ' 67' ' ' ASN . 19.9 m-30 -126.31 122.37 35.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.317 -0.864 . . . . 50.0 110.07 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.914 HG23 HD11 ' A' ' 46' ' ' ILE . 41.1 t -70.31 61.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.047 -1.033 . . . . 50.0 109.879 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -96.07 66.35 2.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.166 -0.959 . . . . 50.0 110.212 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.67 169.44 17.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.297 -0.877 . . . . 50.0 110.292 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.08 -14.56 31.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 50.0 110.184 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 75.1 m -121.16 23.2 10.65 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.226 -0.921 . . . . 99.99 110.332 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.765 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -80.56 9.94 5.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.126 -0.984 . . . . 99.99 110.31 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -88.05 18.01 4.58 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.222 -0.924 . . . . 99.99 109.188 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.524 ' O ' ' HA ' ' A' ' 36' ' ' SER . 18.1 t -133.01 -171.91 2.8 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.554 -0.716 . . . . 99.99 109.551 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.54 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 0.4 OUTLIER -62.86 90.48 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 99.99 109.187 179.539 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.949 HG22 ' O ' ' A' ' 35' ' ' LEU . 31.4 m -76.19 172.01 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.286 -0.884 . . . . 99.99 109.555 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.92 HD21 ' CG1' ' A' ' 32' ' ' VAL . 7.8 tt -117.14 119.75 36.18 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.055 -1.028 . . . . 50.0 111.005 -179.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.731 HG21 HD13 ' A' ' 35' ' ' LEU . 2.9 t -108.58 169.91 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.33 -0.857 . . . . 50.0 109.571 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 2.6 mt-10 -151.17 151.29 31.71 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.034 . . . . 50.0 110.58 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.518 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 8.3 ptt? -160.36 153.3 21.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.865 . . . . 50.0 110.18 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.519 ' HG3' ' HB2' ' A' ' 62' ' ' ARG . 2.2 pt-20 -114.46 59.3 1.0 Allowed Pre-proline 0 C--N 1.306 -1.292 0 O-C-N 121.152 -0.967 . . . . 50.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.1 Cg_endo -71.34 170.24 18.83 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.859 1.452 . . . . 50.0 110.331 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.14 163.19 39.47 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.035 1.545 . . . . 50.0 110.363 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -72.33 144.15 48.4 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.172 -0.955 . . . . 50.0 110.168 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 118.32 -160.42 13.9 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.306 -1.517 . . . . 50.0 109.306 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.531 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 3.2 m-20 -90.45 146.98 23.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.255 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.54 ' HA ' ' N ' ' A' ' 53' ' ' SER . 78.8 p -130.33 143.75 50.96 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 50.0 110.078 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' A' ' 104' ' ' HIS . 0.1 OUTLIER -91.48 108.34 19.83 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.161 -0.962 . . . . 50.0 110.173 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.707 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.0 mp -101.22 125.75 55.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.281 -0.887 . . . . 50.0 109.355 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.866 HG22 ' CB ' ' A' ' 102' ' ' ASN . 26.3 t -124.7 117.41 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.893 -1.13 . . . . 50.0 111.268 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.923 HG13 HD11 ' A' ' 48' ' ' ILE . 15.0 t -95.25 105.98 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.321 -0.862 . . . . 50.0 109.34 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -133.91 140.11 11.49 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.683 -1.246 . . . . 50.0 110.064 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.566 ' HG3' ' HA ' ' A' ' 13' ' ' CYS . 10.0 tmm? -131.32 -26.28 2.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.368 -1.078 . . . . 50.0 110.239 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 166.73 -24.39 0.13 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.778 -1.329 . . . . 50.0 109.778 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -81.39 -70.16 0.56 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -1.163 . . . . 50.0 110.343 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -150.53 136.54 18.45 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.285 -0.885 . . . . 50.0 110.022 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.568 ' N ' ' NE2' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -78.47 108.06 11.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.283 -0.886 . . . . 0.0 110.547 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.48 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 4.1 mt -94.88 110.75 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 110.131 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.866 ' CB ' HG22 ' A' ' 93' ' ' VAL . 15.3 p30 -106.4 130.03 54.28 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.245 -0.909 . . . . 0.0 110.422 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.93 134.72 44.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 110.187 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.62 ' NE2' ' CZ ' ' A' ' 91' ' ' TYR . 1.7 m-70 -72.32 140.91 48.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 110.073 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.707 ' HB2' HD13 ' A' ' 92' ' ' ILE . 2.4 m95 . . . . . 0 C--N 1.305 -1.335 0 O-C-N 121.158 -0.963 . . . . 0.0 110.4 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.583 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.047 0.451 . . . . 50.0 110.192 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.793 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.83 105.58 3.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.021 -1.05 . . . . 99.99 111.507 -179.779 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.874 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.93 19.54 0.08 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.922 -1.112 . . . . 99.99 110.427 178.392 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 1.1 pp20? -57.77 -11.87 2.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.09 -1.007 . . . . 99.99 110.42 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 4.3 mptt -80.15 60.71 3.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 50.0 110.382 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.496 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -93.75 149.36 21.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.249 -0.907 . . . . 50.0 109.917 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.685 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 t -127.43 136.34 51.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.178 -0.951 . . . . 50.0 109.799 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.855 ' HZ ' HG21 ' A' ' 101' ' ' ILE . 0.4 OUTLIER -83.48 115.14 21.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.068 -1.02 . . . . 50.0 110.185 -179.769 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.71 -35.8 7.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.35 -0.844 . . . . 50.0 109.953 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.532 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 16.5 mttm -147.53 153.57 39.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.212 -0.93 . . . . 50.0 110.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 29.6 p-10 -68.26 165.16 36.37 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 50.0 109.875 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.8 141.58 37.6 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.854 1.449 . . . . 50.0 110.199 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -137.68 165.64 25.89 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.191 -0.943 . . . . 50.0 110.321 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -90.49 159.08 16.7 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 50.0 110.136 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HG21 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -134.24 -45.55 0.77 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.326 -0.859 . . . . 50.0 110.217 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -133.38 -111.51 1.26 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.496 -1.442 . . . . 50.0 109.496 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -128.68 91.39 3.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -1.124 . . . . 50.0 110.211 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.492 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 95.4 31.0 7.77 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.506 -1.438 . . . . 50.0 109.506 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.736 HG22 HG11 ' A' ' 64' ' ' VAL . 0.2 OUTLIER -137.04 110.24 7.81 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.238 -1.154 . . . . 50.0 110.42 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 41.3 t -95.94 149.19 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.273 -0.892 . . . . 50.0 110.059 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -124.06 148.5 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 50.0 110.577 -179.761 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.907 HG23 HD11 ' A' ' 35' ' ' LEU . 0.5 OUTLIER -147.36 142.3 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.42 -0.8 . . . . 50.0 109.776 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.908 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -109.53 101.98 10.87 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 50.0 110.309 -179.736 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.016 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.86 137.71 54.43 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.327 -0.858 . . . . 50.0 109.45 179.525 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -91.44 132.73 36.03 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.081 -1.012 . . . . 50.0 110.064 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.509 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 33.4 t80 -96.1 95.51 8.22 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.843 -1.143 . . . . 50.0 109.761 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.66 69.64 2.52 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.336 -0.852 . . . . 50.0 109.725 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.07 135.13 12.65 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.691 -1.364 . . . . 99.99 109.691 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 95.2 p -86.12 13.52 7.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 99.99 110.27 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -98.48 -20.0 17.34 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.264 -0.898 . . . . 99.99 110.134 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.64 -165.63 14.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.364 -1.494 . . . . 99.99 109.364 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.442 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.3 Cg_endo -73.28 140.42 30.59 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 123.868 1.457 . . . . 99.99 110.563 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.793 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -167.53 162.13 14.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.585 -0.697 . . . . 50.0 109.131 -179.887 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.583 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 9.9 mmtm -59.84 138.28 57.84 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.947 -1.095 . . . . 50.0 110.49 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.874 HG23 ' HB ' ' A' ' 14' ' ' THR . 1.5 mt -93.11 109.11 37.64 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 50.0 110.545 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.0 Cg_endo -75.55 96.06 1.03 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.154 1.607 . . . . 50.0 110.219 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.913 HG12 HG22 ' A' ' 94' ' ' VAL . 10.2 mt -132.38 145.57 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.881 . . . . 50.0 110.356 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.6 m -115.96 130.93 69.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.324 -0.86 . . . . 50.0 109.912 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.566 ' O ' ' N ' ' A' ' 61' ' ' GLY . 13.3 m -114.71 101.27 8.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 50.0 109.81 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.612 HG12 ' HA ' ' A' ' 59' ' ' PRO . 33.9 m -131.12 159.7 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.285 -0.885 . . . . 50.0 110.236 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.13 163.92 1.43 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 50.0 109.898 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.627 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 29.3 t -63.47 122.54 16.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.156 -0.965 . . . . 50.0 110.484 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.627 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 78.72 30.24 0.37 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.513 -0.742 . . . . 50.0 110.579 179.785 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.451 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 49.8 m-80 -136.23 84.64 2.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 50.0 110.086 179.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -105.43 8.6 33.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.245 -0.909 . . . . 50.0 110.187 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.9 ttt -103.75 -18.29 14.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 50.0 109.921 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -136.08 128.51 17.59 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.508 -0.745 . . . . 50.0 109.911 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.612 ' HA ' HG12 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.46 132.31 20.41 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 123.931 1.49 . . . . 50.0 110.396 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.1 t -135.12 -43.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.342 -0.849 . . . . 50.0 109.771 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.78 149.4 44.75 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.685 -1.766 . . . . 50.0 108.685 179.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 9.5 mtp85 -141.07 157.03 45.87 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.85 -1.382 . . . . 50.0 110.908 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.557 ' N ' HD12 ' A' ' 63' ' ' LEU . 6.6 mp -94.32 129.54 40.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 50.0 109.845 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.736 HG11 HG22 ' A' ' 30' ' ' THR . 43.9 t -79.87 7.3 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.234 -0.916 . . . . 50.0 110.329 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.483 ' CG2' ' HB2' ' A' ' 82' ' ' GLU . 68.9 p -115.5 167.05 11.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.136 -0.978 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 65' ' ' THR . 16.7 m -52.87 -170.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 O-C-N 121.225 -0.922 . . . . 50.0 110.089 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -46.41 149.95 1.26 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.128 -0.982 . . . . 50.0 110.044 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.16 91.03 0.75 Allowed 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.006 1.529 . . . . 50.0 110.691 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 1.117 ' CZ ' ' HB2' ' A' ' 71' ' ' ALA . 1.2 t80 -155.12 121.51 5.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.345 -0.847 . . . . 50.0 109.932 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.82 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.5 p -95.43 60.84 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.252 -0.905 . . . . 50.0 110.166 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 1.117 ' HB2' ' CZ ' ' A' ' 69' ' ' PHE . . . -73.9 82.44 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 50.0 110.235 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.74 148.88 37.97 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.229 -0.92 . . . . 50.0 110.359 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.2 t -68.45 -15.57 63.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 50.0 109.874 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -121.09 23.31 10.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.301 -0.874 . . . . 99.99 110.373 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.673 ' CB ' HG22 ' A' ' 70' ' ' VAL . . . -72.32 1.34 7.94 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.099 -1.0 . . . . 99.99 110.397 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.509 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 57.8 m-80 -87.2 24.12 1.66 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.174 -0.954 . . . . 99.99 109.397 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.647 ' O ' HG13 ' A' ' 79' ' ' VAL . 2.3 p -128.7 -173.08 2.87 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.476 -0.765 . . . . 99.99 109.268 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.433 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -63.44 88.83 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.334 -0.854 . . . . 99.99 109.186 179.478 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 1.016 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.9 m -76.52 176.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.449 -0.782 . . . . 99.99 109.695 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 81' ' ' VAL . 2.5 tt -127.57 128.36 45.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.888 -1.132 . . . . 50.0 111.054 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.47 ' HB ' ' CG2' ' A' ' 33' ' ' ILE . 3.2 t -115.45 172.19 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.354 -0.841 . . . . 50.0 110.024 179.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.483 ' HB2' ' CG2' ' A' ' 65' ' ' THR . 2.6 mt-10 -148.1 140.79 24.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.169 -0.957 . . . . 50.0 110.195 179.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.468 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 6.7 ptt? -151.52 146.75 26.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.122 -0.987 . . . . 50.0 110.62 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.705 ' HG2' HG22 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -109.34 75.55 0.74 Allowed Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.408 -0.808 . . . . 50.0 110.132 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.26 159.43 47.08 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 124.044 1.549 . . . . 50.0 110.536 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -71.02 148.44 56.93 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.079 1.568 . . . . 50.0 110.685 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -58.82 137.23 57.84 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.295 -0.878 . . . . 50.0 110.203 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.78 -125.96 6.43 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.526 ' HB3' ' CB ' ' A' ' 53' ' ' SER . 19.9 t0 -120.51 146.03 46.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -1.147 . . . . 50.0 110.213 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -141.7 137.57 31.81 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -0.894 . . . . 50.0 110.247 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.59 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 1.9 m-30 -98.98 117.28 33.14 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 50.0 109.952 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.689 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.2 mp -109.5 133.2 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 50.0 110.139 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.57 ' HB ' HG22 ' A' ' 49' ' ' VAL . 11.5 t -124.8 121.39 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.03 . . . . 50.0 110.734 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.913 HG22 HG12 ' A' ' 48' ' ' ILE . 24.5 t -106.9 101.67 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.279 -0.888 . . . . 50.0 109.747 179.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.32 168.31 33.09 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.793 -1.323 . . . . 50.0 109.793 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.48 ' HG3' ' HG3' ' A' ' 47' ' ' PRO . 6.4 ttm -107.13 -55.15 2.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.395 -1.062 . . . . 50.0 110.175 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -166.37 -40.72 0.02 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.6 -85.26 0.22 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -1.172 . . . . 50.0 110.031 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.6 mmtm -79.72 128.87 33.95 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.262 -0.898 . . . . 50.0 110.061 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.654 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -132.53 149.75 52.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.855 HG21 ' HZ ' ' A' ' 19' ' ' PHE . 49.4 mm -122.81 122.5 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.117 -0.989 . . . . 0.0 110.258 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -109.99 136.57 49.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.349 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -124.43 164.54 19.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.886 . . . . 0.0 109.917 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -113.78 88.55 2.87 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.285 -0.884 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 92' ' ' ILE . 1.7 t90 . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.321 -0.862 . . . . 0.0 110.227 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 23.0 mtm . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 121.151 0.501 . . . . 50.0 110.442 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.676 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 7.2 p -148.74 108.84 4.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.173 -0.954 . . . . 99.99 110.538 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.85 HG21 HG12 ' A' ' 46' ' ' ILE . 1.2 m -160.27 50.37 0.29 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.93 -1.106 . . . . 99.99 110.264 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.606 ' CB ' ' CB ' ' A' ' 96' ' ' MET . 3.8 pt-20 -77.88 28.18 0.17 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 99.99 110.743 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.446 ' HG2' ' C ' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -129.24 60.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.89 -1.131 . . . . 50.0 110.878 -179.87 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.829 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -91.98 143.69 26.22 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.136 -0.978 . . . . 50.0 109.743 179.328 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.632 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 m -127.33 103.85 7.61 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 50.0 110.466 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -61.24 98.38 0.08 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.153 -0.967 . . . . 50.0 110.0 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.589 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.88 -32.96 22.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 50.0 109.879 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 0.1 OUTLIER -142.54 145.23 33.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.352 -0.842 . . . . 50.0 110.187 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.482 ' HB2' ' CZ3' ' A' ' 105' ' ' TRP . 24.6 p30 -67.37 161.14 67.18 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 50.0 110.013 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.609 ' HG2' ' CD1' ' A' ' 105' ' ' TRP . 44.5 Cg_endo -71.55 126.07 11.79 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.909 1.479 . . . . 50.0 110.347 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -123.06 152.72 40.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 50.0 110.282 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.452 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.5 p30 -90.87 130.03 36.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 50.0 110.078 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.21 -0.69 22.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.18 -0.95 . . . . 50.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -174.59 -129.46 1.19 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.77 98.43 7.4 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -1.162 . . . . 50.0 110.225 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.29 28.23 23.18 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 3.8 p -130.15 107.55 9.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -1.206 . . . . 50.0 110.182 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.544 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 57.8 t -111.22 114.89 48.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 50.0 110.086 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.427 ' H ' HG22 ' A' ' 32' ' ' VAL . 5.2 m -94.56 139.45 18.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.208 -0.932 . . . . 50.0 110.522 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.087 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -143.57 137.38 25.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.4 -0.812 . . . . 50.0 109.678 179.68 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.898 ' N ' HD13 ' A' ' 33' ' ' ILE . 18.5 tt0 -113.08 117.24 31.44 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.078 -1.014 . . . . 50.0 110.883 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.087 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.15 141.54 51.45 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.306 -0.871 . . . . 50.0 109.407 179.233 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -86.84 123.66 32.21 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.072 -1.017 . . . . 50.0 109.753 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.707 ' CE1' HG23 ' A' ' 14' ' ' THR . 4.9 t80 -91.52 101.66 14.32 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.932 -1.107 . . . . 50.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.421 ' O ' ' HB3' ' A' ' 16' ' ' LYS . 0.2 OUTLIER -96.24 69.64 2.71 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.239 -0.913 . . . . 50.0 109.877 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.448 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -111.31 127.69 8.32 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.476 -1.45 . . . . 99.99 109.476 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 8.1 p -77.29 6.09 7.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.296 -1.12 . . . . 99.99 110.488 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.53 -3.7 42.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.215 -0.928 . . . . 99.99 109.925 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.42 -137.65 17.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.437 -1.465 . . . . 99.99 109.437 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.609 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 43.3 Cg_endo -70.91 142.42 42.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.968 1.509 . . . . 99.99 110.327 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.676 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.13 162.42 8.87 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.349 -0.844 . . . . 50.0 110.078 -179.403 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 25.7 mmtt -74.67 113.34 11.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 50.0 109.906 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.999 HG22 ' CD1' ' A' ' 48' ' ' ILE . 3.2 mt -74.51 117.08 59.29 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.112 -0.993 . . . . 50.0 110.072 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.835 ' C ' HD12 ' A' ' 48' ' ' ILE . 48.7 Cg_endo -81.79 70.13 7.35 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 124.087 1.572 . . . . 50.0 110.158 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.999 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -118.13 146.96 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 50.0 110.226 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.602 HG21 ' HB3' ' A' ' 59' ' ' PRO . 6.2 p -127.13 140.36 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.394 -0.816 . . . . 50.0 110.143 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.464 ' OG ' ' HG2' ' A' ' 83' ' ' MET . 75.2 m -107.32 100.5 9.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 50.0 109.8 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.94 HG22 ' HA ' ' A' ' 59' ' ' PRO . 59.4 t -107.72 157.0 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.313 -0.867 . . . . 50.0 110.127 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -71.94 164.23 26.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 50.0 109.215 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.621 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 29.6 t -70.79 100.86 1.98 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.74 -1.225 . . . . 50.0 109.321 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 173.19 -71.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 C-N-CA 118.52 -1.272 . . . . 50.0 111.382 -179.725 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.474 ' HB3' ' OG1' ' A' ' 58' ' ' THR . 80.8 m-20 -84.15 155.12 22.74 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.135 -0.978 . . . . 50.0 110.287 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -106.24 -23.5 12.55 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 50.0 110.118 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.38 37.09 4.38 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.268 -0.895 . . . . 50.0 110.267 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.502 ' O ' HG13 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -134.9 103.23 10.9 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.176 -0.952 . . . . 50.0 110.322 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.94 ' HA ' HG22 ' A' ' 51' ' ' VAL . 48.9 Cg_endo -73.72 125.84 10.31 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.063 1.559 . . . . 50.0 110.601 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.537 HG22 HG13 ' A' ' 51' ' ' VAL . 12.0 m -135.22 -28.07 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.338 -0.851 . . . . 50.0 110.271 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.82 170.78 48.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.895 -1.682 . . . . 50.0 108.895 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HG3' ' A' ' 83' ' ' MET . 14.8 mtt180 -140.36 155.91 46.6 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.045 -1.268 . . . . 50.0 110.602 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.593 HD22 ' HD3' ' A' ' 68' ' ' PRO . 2.2 mp -92.21 115.95 28.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 50.0 109.651 179.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.727 HG11 ' HG2' ' A' ' 82' ' ' GLU . 7.5 p -77.69 -34.54 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.087 -1.008 . . . . 50.0 110.352 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.544 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 7.3 t -82.58 173.28 12.1 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.087 -1.008 . . . . 50.0 109.821 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.458 ' C ' ' O ' ' A' ' 65' ' ' THR . 47.2 t -41.23 159.78 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.212 -0.93 . . . . 50.0 109.789 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.63 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 8.7 m120 -46.58 158.59 0.39 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 50.0 109.709 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.593 ' HD3' HD22 ' A' ' 63' ' ' LEU . 46.2 Cg_endo -73.61 65.83 4.72 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.882 1.464 . . . . 50.0 110.511 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.663 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 16.4 m-30 -126.23 121.68 33.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 50.0 110.034 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.857 HG13 HD11 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -86.97 60.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 50.0 109.589 179.487 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -71.75 59.35 0.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.415 -0.803 . . . . 50.0 110.158 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.443 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.3 OUTLIER -142.84 158.25 43.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.245 -0.91 . . . . 50.0 110.361 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.3 m -85.98 -10.64 54.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.372 -0.83 . . . . 50.0 109.698 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.99 14.59 16.13 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 99.99 110.124 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.443 ' HB2' ' HB ' ' A' ' 72' ' ' THR . . . -80.26 10.99 3.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -0.885 . . . . 99.99 109.964 179.702 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 1.1 m-80 -85.84 16.16 4.3 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.286 -0.883 . . . . 99.99 109.435 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.583 ' O ' ' HA ' ' A' ' 36' ' ' SER . 60.3 p -121.91 -172.75 2.5 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.496 -0.752 . . . . 99.99 109.299 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.467 ' HG3' ' HB3' ' A' ' 36' ' ' SER . 0.6 OUTLIER -63.14 88.65 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.177 -0.952 . . . . 99.99 109.077 179.506 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.908 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.0 m -76.35 176.08 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.33 -0.856 . . . . 99.99 109.603 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.76 127.15 44.62 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.945 -1.097 . . . . 50.0 110.759 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 t -118.43 169.72 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -0.918 . . . . 50.0 110.251 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.727 ' HG2' HG11 ' A' ' 64' ' ' VAL . 2.3 tt0 -138.23 135.7 35.83 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.288 -0.882 . . . . 50.0 110.065 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.486 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 1.6 mpp? -138.02 149.26 45.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.123 -0.986 . . . . 50.0 110.53 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.476 ' HG2' ' HB ' ' A' ' 64' ' ' VAL . 2.0 pt-20 -115.33 66.24 2.2 Favored Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.118 -0.989 . . . . 50.0 110.357 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.486 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.9 Cg_endo -73.09 164.62 34.96 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.026 1.54 . . . . 50.0 110.411 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.58 152.27 64.98 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.048 1.552 . . . . 50.0 110.405 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.9 OUTLIER -52.76 142.67 18.19 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 50.0 110.263 -179.855 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.39 161.75 14.67 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.345 -1.502 . . . . 50.0 109.345 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.552 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 74.9 m-20 -52.78 163.1 0.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -1.188 . . . . 50.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -142.37 135.85 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.1 -1.0 . . . . 50.0 110.828 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.621 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 5.4 m-30 -96.11 108.21 20.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.245 -0.91 . . . . 50.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.6 mp -90.29 137.86 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.224 -0.922 . . . . 50.0 109.789 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.542 ' HB ' HG12 ' A' ' 49' ' ' VAL . 22.0 t -125.59 108.33 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 120.882 -1.136 . . . . 50.0 111.421 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.682 HG13 HD11 ' A' ' 48' ' ' ILE . 59.5 t -85.36 107.44 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.173 -0.955 . . . . 50.0 108.896 178.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.517 ' HA2' ' HB3' ' A' ' 100' ' ' GLN . . . -90.3 170.23 35.49 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.783 -1.198 . . . . 50.0 110.254 -178.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.606 ' CB ' ' CB ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -153.54 13.89 0.49 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -1.041 . . . . 50.0 110.166 -179.811 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 136.36 -86.6 0.24 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.235 -1.546 . . . . 50.0 109.235 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -99.44 -68.71 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 50.0 109.971 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.89 151.66 30.04 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.201 -0.937 . . . . 50.0 110.04 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.615 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.07 148.6 42.0 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.088 -1.008 . . . . 0.0 110.349 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.0 mt -90.94 146.72 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.152 -0.968 . . . . 0.0 109.638 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -132.83 132.02 41.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.108 -0.995 . . . . 0.0 110.845 -179.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.498 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.0 OUTLIER -118.71 152.92 35.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.391 -0.818 . . . . 0.0 109.518 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.597 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 16.8 p-80 -116.23 83.1 1.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.554 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.609 ' CD1' ' HG2' ' A' ' 23' ' ' PRO . 10.1 t-105 . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.934 . . . . 0.0 109.943 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.613 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 121.167 0.508 . . . . 50.0 110.343 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.741 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 4.0 p -149.07 107.17 3.72 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.13 -0.981 . . . . 99.99 111.006 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.671 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -162.25 28.9 0.11 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.643 -1.286 . . . . 99.99 110.505 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 -11.31 3.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.12 -0.988 . . . . 99.99 110.236 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.45 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -71.0 61.05 0.26 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 50.0 110.429 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.748 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -105.62 141.4 37.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.155 -0.966 . . . . 50.0 109.859 179.564 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.8 OUTLIER -125.09 119.86 29.8 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.189 -0.944 . . . . 50.0 110.198 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.61 ' CE2' ' NE2' ' A' ' 103' ' ' HIS . 7.3 m-85 -63.13 115.25 4.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -0.931 . . . . 50.0 110.027 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.3 -28.34 11.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.241 -0.912 . . . . 50.0 110.103 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 19.0 mttm -146.14 151.94 38.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 50.0 110.171 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.88 164.04 61.78 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 50.0 110.218 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.504 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.9 Cg_endo -72.87 128.09 12.89 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.997 1.525 . . . . 50.0 110.206 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.654 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -125.23 152.84 44.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.913 . . . . 50.0 110.369 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.454 ' HA ' ' O ' ' A' ' 30' ' ' THR . 11.3 t70 -85.72 145.43 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.337 -0.852 . . . . 50.0 110.108 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -135.8 33.97 2.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.252 -0.905 . . . . 50.0 110.186 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.59 -109.87 0.41 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -128.02 88.99 2.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -1.155 . . . . 50.0 110.132 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 84' ' ' GLU . . . 87.11 -7.59 79.96 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.719 -1.352 . . . . 50.0 109.719 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.584 ' HA ' ' HG2' ' A' ' 84' ' ' GLU . 41.4 p -80.37 114.14 19.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -1.176 . . . . 50.0 110.194 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.566 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -106.47 141.46 21.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.224 -0.923 . . . . 50.0 110.326 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.654 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -112.41 142.4 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.269 -0.894 . . . . 50.0 110.334 -179.803 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.615 HG12 HD11 ' A' ' 35' ' ' LEU . 0.4 OUTLIER -141.37 140.26 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.348 -0.845 . . . . 50.0 109.706 179.695 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 18.3 tt0 -121.79 117.03 25.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -0.975 . . . . 50.0 110.535 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.102 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.5 OUTLIER -126.38 139.53 53.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.307 -0.871 . . . . 50.0 109.529 179.413 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.638 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.2 OUTLIER -87.77 126.94 35.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.059 -1.026 . . . . 50.0 109.704 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.553 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 32.2 t80 -90.47 95.72 10.3 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.77 -1.172 . . . . 50.0 109.71 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.4 t -94.58 70.02 3.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.246 -0.909 . . . . 50.0 110.032 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -121.75 126.76 6.61 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.515 -1.434 . . . . 99.99 109.515 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.44 25.31 1.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -1.161 . . . . 99.99 110.36 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -99.76 -0.96 38.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 99.99 110.051 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.4 -163.28 31.23 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.391 -1.484 . . . . 99.99 109.391 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.62 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.8 Cg_endo -72.71 151.6 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 124.019 1.536 . . . . 99.99 110.515 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.741 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 3.7 t -170.22 161.71 8.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.391 -0.818 . . . . 50.0 109.666 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 12' ' ' MET . 25.1 mmtt -77.23 121.5 23.76 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.009 -1.057 . . . . 50.0 110.047 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.005 HG22 HD11 ' A' ' 48' ' ' ILE . 2.8 mt -83.92 110.3 24.67 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.367 -0.833 . . . . 50.0 110.585 -179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.2 Cg_endo -80.47 106.29 1.84 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.009 1.531 . . . . 50.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.005 HD11 HG22 ' A' ' 46' ' ' ILE . 3.0 mp -123.2 142.94 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.163 -0.961 . . . . 50.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 93' ' ' VAL . 5.9 m -120.71 96.62 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.84 . . . . 50.0 109.724 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.451 ' HA ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -87.95 104.08 16.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.309 -179.625 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.718 HG12 ' H ' ' A' ' 60' ' ' VAL . 16.8 m -130.42 162.07 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.231 -0.918 . . . . 50.0 110.073 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -68.18 164.02 21.39 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.882 . . . . 50.0 109.304 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.607 ' N ' ' HA ' ' A' ' 90' ' ' SER . 2.2 t -67.61 99.9 0.83 Allowed 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 118.529 -1.268 . . . . 50.0 108.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.592 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 172.06 -67.15 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.264 -1.374 . . . . 50.0 111.458 -179.688 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -99.64 122.03 42.08 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.087 -1.008 . . . . 50.0 110.299 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -106.18 19.45 20.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.952 . . . . 50.0 110.074 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.19 -7.15 6.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.29 -0.881 . . . . 50.0 110.37 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.67 ' O ' HG11 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -134.44 140.88 37.05 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.19 -0.944 . . . . 50.0 110.288 -179.869 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.577 ' HA ' ' CG1' ' A' ' 51' ' ' VAL . 46.5 Cg_endo -73.07 136.13 24.21 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 124.072 1.564 . . . . 50.0 110.443 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.718 ' H ' HG12 ' A' ' 51' ' ' VAL . 52.8 t -147.18 10.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.216 -0.927 . . . . 50.0 110.381 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -110.08 170.78 14.39 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.271 -1.532 . . . . 50.0 109.271 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.544 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 5.1 mmt180 -107.07 145.13 32.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.101 -1.235 . . . . 50.0 110.218 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.486 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 0.1 OUTLIER -116.99 110.34 18.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 50.0 110.065 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.804 ' O ' HG12 ' A' ' 64' ' ' VAL . 73.5 t -100.07 42.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.168 -0.958 . . . . 50.0 110.124 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.494 ' OG1' ' N ' ' A' ' 82' ' ' GLU . 1.6 m -130.71 144.89 51.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.868 . . . . 50.0 110.096 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 65' ' ' THR . 26.0 m -52.72 -171.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.217 -0.927 . . . . 50.0 110.052 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 2.3 m-20 -46.83 115.46 3.34 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.128 -0.982 . . . . 50.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.625 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 45.0 Cg_endo -71.89 66.27 3.23 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.964 1.507 . . . . 50.0 110.136 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 68' ' ' PRO . 13.5 m-85 -135.76 123.62 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.474 -0.766 . . . . 50.0 110.054 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.99 HG23 HD11 ' A' ' 46' ' ' ILE . 53.4 t -71.97 60.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.038 -1.039 . . . . 50.0 109.84 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.62 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -86.63 57.47 4.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 50.0 109.828 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.3 169.13 18.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.328 -0.857 . . . . 50.0 110.337 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.25 -7.34 35.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 50.0 109.999 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 14.6 p -121.06 13.18 11.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.312 -0.868 . . . . 99.99 110.313 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.962 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.99 5.45 8.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 99.99 109.958 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 40.2 m-20 -83.42 20.41 1.35 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.313 -0.867 . . . . 99.99 109.391 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.661 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -122.51 -172.91 2.57 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.363 -0.835 . . . . 99.99 109.444 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.16 89.03 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.731 -0.788 . . . . 99.99 109.118 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 1.102 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.4 m -76.23 175.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.406 -0.809 . . . . 99.99 109.663 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 81' ' ' VAL . 0.8 OUTLIER -131.47 139.97 49.46 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.879 -1.138 . . . . 50.0 111.028 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.438 ' N ' HD23 ' A' ' 80' ' ' LEU . 0.2 OUTLIER -131.21 172.26 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.452 -0.78 . . . . 50.0 109.991 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.494 ' N ' ' OG1' ' A' ' 65' ' ' THR . 37.9 mt-10 -135.41 142.41 45.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.155 -0.966 . . . . 50.0 110.084 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.522 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -153.02 142.37 21.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.108 -0.995 . . . . 50.0 110.234 -179.71 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.642 ' HG3' HG21 ' A' ' 64' ' ' VAL . 1.5 mm-40 -110.79 67.89 0.56 Allowed Pre-proline 0 C--N 1.304 -1.37 0 O-C-N 121.022 -1.049 . . . . 50.0 110.619 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.566 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.26 155.78 55.79 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.978 1.515 . . . . 50.0 110.528 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.22 163.28 39.17 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.105 1.582 . . . . 50.0 110.463 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -73.54 138.46 45.01 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.201 -0.937 . . . . 50.0 110.172 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.43 -150.14 17.17 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.362 -1.495 . . . . 50.0 109.362 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.409 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 8.6 m-20 -92.3 137.11 32.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 50.0 110.0 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.607 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -130.23 133.4 46.51 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.23 -0.919 . . . . 50.0 110.247 179.984 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.522 ' O ' ' CG2' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -91.65 97.08 10.81 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.159 -0.963 . . . . 50.0 109.996 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 50' ' ' SER . 1.7 pt -102.56 116.95 47.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.271 -0.893 . . . . 50.0 109.839 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 102' ' ' ASN . 42.5 t -118.57 131.07 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 50.0 110.556 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.821 HG13 HG13 ' A' ' 48' ' ' ILE . 14.7 t -107.28 96.66 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.278 -0.888 . . . . 50.0 109.86 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.536 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.42 165.42 32.39 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.623 -1.391 . . . . 50.0 109.623 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.529 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 10.8 ptp -107.48 -33.41 7.36 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.282 -1.129 . . . . 50.0 110.316 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . 0.529 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 176.36 -63.21 0.1 OUTLIER Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.478 -1.449 . . . . 50.0 109.478 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -63.75 -107.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.204 -1.174 . . . . 50.0 110.132 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -79.29 123.35 27.37 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.111 -0.993 . . . . 50.0 110.161 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.781 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -131.41 150.17 52.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 110.064 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 46.0 mt -102.88 106.7 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.996 -1.065 . . . . 0.0 110.136 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.643 ' HA ' HG22 ' A' ' 93' ' ' VAL . 7.6 p-10 -97.4 130.8 44.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 110.196 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.61 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -126.99 160.45 31.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.34 -0.85 . . . . 0.0 110.238 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.403 ' CD2' ' H ' ' A' ' 104' ' ' HIS . 7.3 p80 -123.26 86.53 2.59 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 110.131 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.431 ' CE3' ' C ' ' A' ' 105' ' ' TRP . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 110.042 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.671 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.106 0.479 . . . . 50.0 110.299 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.705 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.13 105.88 3.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.111 -0.993 . . . . 99.99 111.151 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.908 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.22 25.09 0.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.115 -0.991 . . . . 99.99 109.938 178.458 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 96' ' ' MET . 17.9 tt0 -49.78 -18.67 0.51 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.316 -0.865 . . . . 99.99 110.375 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 1.2 mmtt -76.2 61.43 1.61 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 50.0 110.411 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.919 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -99.0 138.68 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.926 . . . . 50.0 109.94 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 12.7 t -128.29 97.47 4.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.205 -0.934 . . . . 50.0 110.621 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.521 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 6.7 p90 -56.5 117.95 4.34 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.993 -1.067 . . . . 50.0 109.836 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB1' ' HE2' ' A' ' 78' ' ' LYS . . . -107.34 -19.64 13.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 50.0 110.651 -179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.512 ' CE ' ' OE1' ' A' ' 34' ' ' GLU . 25.9 mttm -140.79 150.79 43.8 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.14 -0.975 . . . . 50.0 110.684 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -67.64 165.44 30.4 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.447 -0.783 . . . . 50.0 110.145 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.5 Cg_endo -72.75 142.89 36.39 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 124.012 1.533 . . . . 50.0 110.305 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -133.5 152.52 51.92 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.218 -0.926 . . . . 50.0 110.249 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.6 p30 -92.55 130.94 38.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -0.881 . . . . 50.0 110.338 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.401 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -100.66 -80.84 0.48 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 50.0 110.035 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.41 -109.14 0.61 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.431 -1.467 . . . . 50.0 109.431 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -129.73 97.32 4.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.276 -1.132 . . . . 50.0 110.145 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 96.84 8.8 56.8 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 82.5 p -103.2 128.22 50.25 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -1.084 . . . . 50.0 110.263 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 39.2 t -109.74 137.71 40.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.366 -0.834 . . . . 50.0 109.906 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.083 ' CG1' HD21 ' A' ' 80' ' ' LEU . 1.5 t -117.57 143.43 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 50.0 110.436 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.791 HG12 HD11 ' A' ' 35' ' ' LEU . 3.6 tt -142.93 145.11 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 50.0 109.759 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.564 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 17.7 tt0 -116.46 102.55 9.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.16 -0.962 . . . . 50.0 110.721 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 1.081 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.0 OUTLIER -113.56 136.77 52.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.259 -0.9 . . . . 50.0 109.536 179.45 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.624 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.4 OUTLIER -86.36 129.85 34.71 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.155 -0.966 . . . . 50.0 109.92 -179.57 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.617 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.7 t80 -95.59 99.6 11.45 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 118.983 -1.087 . . . . 50.0 109.869 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -96.27 72.29 2.83 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.116 -0.99 . . . . 50.0 110.135 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -124.67 124.03 5.27 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.532 -1.427 . . . . 99.99 109.532 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 29.45 2.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.212 -1.17 . . . . 99.99 110.265 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.421 ' OD1' ' C ' ' A' ' 41' ' ' ASP . 2.1 p30 -102.99 0.39 32.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.291 -0.881 . . . . 99.99 110.155 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.67 174.67 25.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.273 -1.531 . . . . 99.99 109.273 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.548 ' CB ' ' O ' ' A' ' 70' ' ' VAL . 45.0 Cg_endo -72.81 149.74 48.52 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.001 1.527 . . . . 99.99 110.599 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.705 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -167.47 162.66 14.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.439 -0.788 . . . . 50.0 109.56 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.671 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 23.2 mmtt -67.5 141.44 56.91 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.968 -1.082 . . . . 50.0 109.745 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.054 HG22 ' CD1' ' A' ' 48' ' ' ILE . 7.1 mt -90.78 108.81 30.21 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.299 -0.875 . . . . 50.0 110.649 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 49.9 Cg_endo -75.48 96.48 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 124.152 1.606 . . . . 50.0 110.955 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 1.054 ' CD1' HG22 ' A' ' 46' ' ' ILE . 0.5 OUTLIER -131.64 115.79 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 50.0 109.992 179.462 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.749 ' O ' HG23 ' A' ' 49' ' ' VAL . 18.0 m -93.07 107.44 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.852 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -86.18 100.88 12.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 50.0 109.765 179.869 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.567 ' O ' ' N ' ' A' ' 91' ' ' TYR . 95.7 t -118.71 150.56 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.313 -0.867 . . . . 50.0 110.468 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -67.51 164.73 18.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.373 -0.83 . . . . 50.0 109.62 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.639 ' N ' ' HA ' ' A' ' 90' ' ' SER . 5.4 t -70.05 101.84 1.9 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.834 -1.166 . . . . 50.0 109.424 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.498 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 171.0 -64.12 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.057 -1.457 . . . . 50.0 111.703 -179.906 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.537 ' CB ' ' HB ' ' A' ' 58' ' ' THR . 41.4 m-80 -88.05 164.99 15.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.094 . . . . 50.0 110.315 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 56' ' ' ASP . 49.9 t0 -105.9 -37.87 6.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 50.0 110.238 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.0 ttm -123.85 30.39 6.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 50.0 110.217 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.537 ' HB ' ' CB ' ' A' ' 55' ' ' ASN . 17.3 m -111.85 120.62 41.74 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.256 -0.902 . . . . 50.0 110.049 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.416 ' HA ' HG22 ' A' ' 51' ' ' VAL . 44.4 Cg_endo -72.58 130.05 15.47 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.989 1.52 . . . . 50.0 110.414 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.413 HG23 HG13 ' A' ' 51' ' ' VAL . 10.5 t -142.3 -36.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.259 -0.901 . . . . 50.0 110.26 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -77.54 164.74 52.37 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.138 -1.585 . . . . 50.0 109.138 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.434 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 10.5 mtt180 -138.49 156.45 47.52 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.095 -1.238 . . . . 50.0 110.445 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.665 HD13 ' HD3' ' A' ' 68' ' ' PRO . 2.5 mt -97.97 122.4 41.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 50.0 109.776 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.711 HG22 ' HG2' ' A' ' 84' ' ' GLU . 30.6 t -63.33 -13.5 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.217 -0.927 . . . . 50.0 110.12 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 66' ' ' VAL . 34.6 m -124.77 163.21 22.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.295 -0.878 . . . . 50.0 109.955 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.528 HG12 ' N ' ' A' ' 67' ' ' ASN . 74.1 t -44.09 168.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 50.0 109.959 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.628 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 18.2 t-20 -46.68 142.73 4.56 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.196 -0.94 . . . . 50.0 110.11 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.665 ' HD3' HD13 ' A' ' 63' ' ' LEU . 49.8 Cg_endo -76.22 98.56 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.927 1.488 . . . . 50.0 110.452 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.628 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 9.2 p90 -120.51 138.49 53.81 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.225 -0.922 . . . . 50.0 110.346 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.982 HG13 ' CB ' ' A' ' 75' ' ' ALA . 73.6 t -91.01 60.94 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.198 -0.939 . . . . 50.0 110.181 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.532 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -89.76 57.44 3.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 50.0 110.346 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.7 m -143.43 169.12 18.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 50.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.7 p -94.23 -6.83 43.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 50.0 109.92 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.14 17.74 11.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 99.99 110.41 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.982 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -79.79 7.29 8.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.15 -0.969 . . . . 99.99 110.066 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 53.6 m-20 -85.17 18.78 2.44 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.234 -0.917 . . . . 99.99 109.341 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.684 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -122.68 -172.73 2.54 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.404 -0.81 . . . . 99.99 109.277 179.97 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.487 ' HE2' ' HB1' ' A' ' 20' ' ' ALA . 40.0 mttt -62.98 88.47 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.327 -0.858 . . . . 99.99 109.168 179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 1.081 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.4 m -76.68 176.48 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.376 -0.827 . . . . 99.99 109.392 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 1.083 HD21 ' CG1' ' A' ' 32' ' ' VAL . 8.0 tt -135.23 133.92 39.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.781 -1.2 . . . . 50.0 111.212 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.9 t -119.98 178.31 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.483 -0.76 . . . . 50.0 109.829 179.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 61.7 mt-10 -148.52 139.24 22.86 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.996 -1.065 . . . . 50.0 110.546 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.492 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 14.2 ptt? -155.81 139.03 15.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.268 -0.895 . . . . 50.0 110.245 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.711 ' HG2' HG22 ' A' ' 64' ' ' VAL . 1.3 pt-20 -109.24 76.62 0.81 Allowed Pre-proline 0 C--N 1.305 -1.327 0 O-C-N 121.183 -0.948 . . . . 50.0 110.619 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 83' ' ' MET . 47.5 Cg_endo -73.86 170.34 20.3 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.02 1.537 . . . . 50.0 110.344 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.33 161.94 42.95 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.061 1.559 . . . . 50.0 110.42 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -67.13 145.35 55.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.171 -0.956 . . . . 50.0 110.154 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.28 158.62 16.74 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.189 -1.564 . . . . 50.0 109.189 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 89' ' ' ASP . 1.0 OUTLIER -52.41 148.55 6.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -1.22 . . . . 50.0 109.928 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.639 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.4 p -130.49 138.77 50.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.118 -0.989 . . . . 50.0 110.705 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.567 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -90.65 104.35 16.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.16 -0.963 . . . . 50.0 109.415 179.334 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 92' ' ' ILE . 3.3 tt -103.43 135.02 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 50.0 110.341 -179.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 100' ' ' GLN . 10.7 t -125.15 114.52 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.089 -1.007 . . . . 50.0 110.863 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.853 HG13 ' CD1' ' A' ' 48' ' ' ILE . 17.6 t -103.97 104.14 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.195 -0.941 . . . . 50.0 109.444 179.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.27 169.92 33.29 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.614 -1.279 . . . . 50.0 110.195 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.434 ' HB2' ' HB2' ' A' ' 15' ' ' GLU . 19.7 ttm -111.72 -51.35 2.86 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.355 -1.085 . . . . 50.0 110.597 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.85 -145.14 12.18 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.845 -1.302 . . . . 50.0 109.845 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.403 ' O ' ' HG3' ' A' ' 100' ' ' GLN . 2.3 p30 -63.52 -36.11 82.68 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.219 -1.165 . . . . 50.0 110.384 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.37 116.56 19.68 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.207 -0.933 . . . . 50.0 110.184 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.606 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.45 148.69 43.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.323 -0.861 . . . . 0.0 110.114 -179.808 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.734 ' O ' HG23 ' A' ' 101' ' ' ILE . 3.5 tp -94.87 110.32 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.258 -0.901 . . . . 0.0 110.012 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.418 ' OD1' ' N ' ' A' ' 102' ' ' ASN . 32.8 p-10 -101.93 131.82 48.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 0.0 110.475 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -121.12 171.36 8.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.38 -0.825 . . . . 0.0 110.146 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -119.34 79.92 1.49 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 110.471 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.433 ' HZ2' HD11 ' A' ' 33' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.983 179.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.546 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.212 0.529 . . . . 50.0 110.248 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.658 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 11.6 p -148.69 107.35 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.204 -0.935 . . . . 99.99 110.415 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 1.019 HG21 ' CD1' ' A' ' 46' ' ' ILE . 1.3 m -161.5 62.8 0.26 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.674 -1.266 . . . . 99.99 110.549 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HE3' ' A' ' 16' ' ' LYS . 1.5 pp20? -84.63 25.18 0.93 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.156 -0.965 . . . . 99.99 110.117 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.514 ' HD3' ' HA3' ' A' ' 39' ' ' GLY . 1.8 mptt -123.47 61.02 1.06 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.177 -0.952 . . . . 50.0 110.782 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.816 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.0 OUTLIER -99.11 146.88 25.64 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.054 -1.029 . . . . 50.0 109.8 179.429 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.675 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.11 145.41 51.02 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.124 -0.985 . . . . 50.0 110.294 -179.898 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.738 ' CZ ' HD12 ' A' ' 101' ' ' ILE . 1.2 m-85 -85.32 104.28 15.01 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.962 -1.086 . . . . 50.0 109.617 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.929 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -93.2 -34.53 13.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.128 -0.983 . . . . 50.0 110.648 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.512 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 13.6 mttm -145.09 166.71 24.6 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.06 -1.025 . . . . 50.0 110.614 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.59 165.16 39.36 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 50.0 110.09 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.512 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.71 136.75 26.15 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.969 1.51 . . . . 50.0 110.46 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.44 167.53 14.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.251 -0.906 . . . . 50.0 110.346 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -105.81 132.31 52.08 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 50.0 110.37 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 p -108.78 -23.17 11.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 50.0 110.136 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.46 -114.64 0.59 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.468 -1.453 . . . . 50.0 109.468 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' HIS . . . . . 0.513 ' O ' ' CD2' ' A' ' 28' ' ' HIS . 11.5 p-80 -130.17 88.87 2.71 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -1.163 . . . . 50.0 110.296 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.484 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 105.1 14.94 21.37 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.8 p -121.73 111.53 17.28 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.311 -1.111 . . . . 50.0 110.186 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -104.61 150.56 7.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.218 -0.926 . . . . 50.0 110.313 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.758 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -128.19 135.09 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.244 -0.91 . . . . 50.0 110.271 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.944 HG23 HD11 ' A' ' 35' ' ' LEU . 8.0 tt -134.28 150.3 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.864 . . . . 50.0 109.518 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.929 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.4 tt0 -119.84 103.78 9.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 50.0 110.767 -179.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.961 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.2 mp -110.89 137.36 48.63 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.226 -0.921 . . . . 50.0 109.691 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -84.68 124.78 31.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.058 -1.026 . . . . 50.0 109.696 179.954 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.518 ' HB3' ' O ' ' A' ' 75' ' ' ALA . 6.3 t80 -92.34 97.84 11.12 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.904 -1.118 . . . . 50.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.9 t -95.14 72.09 3.34 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.391 -0.818 . . . . 50.0 110.163 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.514 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -125.57 126.68 5.96 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.574 -1.41 . . . . 99.99 109.574 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -83.55 16.85 2.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -1.151 . . . . 99.99 110.201 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -92.4 -22.47 19.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 99.99 110.149 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.76 -163.31 12.31 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.641 -1.384 . . . . 99.99 109.641 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.536 ' HB3' ' O ' ' A' ' 70' ' ' VAL . 44.7 Cg_endo -73.5 150.31 45.78 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 O-C-N 123.966 1.509 . . . . 99.99 110.418 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.628 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.55 161.87 7.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.309 -0.87 . . . . 50.0 109.851 -179.531 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 13.7 mmtt -69.0 117.53 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.067 -1.021 . . . . 50.0 109.382 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 1.092 HD11 ' CG2' ' A' ' 70' ' ' VAL . 4.4 mm -71.4 112.83 15.19 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.058 -1.026 . . . . 50.0 110.372 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.508 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 51.8 Cg_endo -80.26 91.87 1.13 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.061 1.558 . . . . 50.0 110.171 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.791 HG12 HG22 ' A' ' 94' ' ' VAL . 63.3 mt -133.11 149.98 32.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.128 -0.982 . . . . 50.0 110.541 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.564 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 26.1 m -124.14 159.66 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.382 -0.824 . . . . 50.0 109.661 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.455 ' O ' ' HA3' ' A' ' 61' ' ' GLY . 0.3 OUTLIER -134.76 107.66 7.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 50.0 110.066 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.5 m -125.2 156.76 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.284 -0.885 . . . . 50.0 110.203 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.675 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -55.93 163.64 1.42 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.355 -0.841 . . . . 50.0 110.012 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.609 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.4 OUTLIER -59.5 121.21 10.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.211 -0.931 . . . . 50.0 110.649 -179.556 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.609 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 78.58 30.55 0.38 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.565 -0.709 . . . . 50.0 110.976 179.549 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.675 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 30.1 m120 -128.0 84.28 2.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.21 -0.931 . . . . 50.0 110.068 179.066 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.49 9.6 31.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.234 -0.917 . . . . 50.0 110.211 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.4 mtt -113.85 -15.65 12.35 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -0.863 . . . . 50.0 110.111 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -136.37 121.01 12.85 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.334 -0.854 . . . . 50.0 110.246 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.461 ' HA ' HG12 ' A' ' 51' ' ' VAL . 46.3 Cg_endo -72.98 133.66 20.2 Favored 'Trans proline' 0 C--N 1.305 -1.755 0 O-C-N 123.989 1.52 . . . . 50.0 110.16 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.435 ' CG2' ' H ' ' A' ' 52' ' ' ALA . 31.3 m -142.31 -31.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.223 -0.923 . . . . 50.0 110.429 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.41 144.79 37.94 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.397 -1.881 . . . . 50.0 108.397 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.471 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 11.7 mtp180 -123.6 157.0 34.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.851 -1.382 . . . . 50.0 110.892 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.42 ' HG ' ' HG3' ' A' ' 83' ' ' MET . 0.2 OUTLIER -96.82 124.91 40.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.876 . . . . 50.0 109.86 179.627 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.486 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 17.9 t -50.76 -21.45 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.177 -0.952 . . . . 50.0 110.248 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 66' ' ' VAL . 5.8 t -136.33 170.68 15.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 50.0 110.153 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 27.7 m -52.23 -172.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.237 -0.915 . . . . 50.0 110.157 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.552 ' O ' ' CE2' ' A' ' 69' ' ' PHE . 6.7 p30 -46.88 131.04 8.74 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.142 -0.973 . . . . 50.0 110.003 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.52 ' O ' HG12 ' A' ' 46' ' ' ILE . 46.8 Cg_endo -72.58 123.24 8.91 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.941 1.495 . . . . 50.0 110.559 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 67' ' ' ASN . 0.2 OUTLIER -135.14 157.07 47.86 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.286 -0.884 . . . . 50.0 110.069 -179.942 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 1.092 ' CG2' HD11 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -116.29 60.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.179 -0.951 . . . . 50.0 109.6 179.292 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -73.55 58.91 0.6 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 50.0 110.347 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.0 m -142.59 155.2 44.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.32 -0.863 . . . . 50.0 110.233 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.61 -4.9 53.65 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.334 -0.854 . . . . 50.0 109.857 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.5 p -115.45 17.31 16.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 99.99 110.255 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ALA . . . . . 0.83 ' HB1' ' CG1' ' A' ' 70' ' ' VAL . . . -79.91 8.61 6.58 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.182 -0.949 . . . . 99.99 109.966 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -87.63 19.55 3.35 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.226 -0.921 . . . . 99.99 109.243 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . 0.549 ' O ' ' HA ' ' A' ' 36' ' ' SER . 96.5 p -128.96 -172.56 2.75 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.536 -0.728 . . . . 99.99 109.346 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.428 ' HD2' ' OE2' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -63.35 88.82 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.263 -0.898 . . . . 99.99 109.291 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.961 HG22 ' O ' ' A' ' 35' ' ' LEU . 35.3 m -76.16 176.28 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.352 -0.843 . . . . 99.99 109.21 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.758 HD21 HG12 ' A' ' 32' ' ' VAL . 2.8 tt -134.02 132.93 40.66 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.884 -1.135 . . . . 50.0 111.239 -179.487 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.4 t -122.64 178.08 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.435 -0.791 . . . . 50.0 109.681 179.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.486 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 22.8 mt-10 -132.85 142.65 49.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.021 -1.049 . . . . 50.0 110.479 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.481 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -147.78 142.22 26.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.281 -0.887 . . . . 50.0 110.234 179.995 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.484 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -114.69 66.38 1.75 Allowed Pre-proline 0 C--N 1.306 -1.296 0 O-C-N 121.151 -0.968 . . . . 50.0 110.563 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.481 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.21 164.94 33.99 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.969 1.51 . . . . 50.0 110.28 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.51 140.83 33.74 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.92 1.484 . . . . 50.0 110.354 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -52.54 137.08 31.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.231 -0.918 . . . . 50.0 110.194 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.76 167.37 13.32 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.384 -1.486 . . . . 50.0 109.384 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ASP . . . . . 0.514 ' HB2' ' HB2' ' A' ' 53' ' ' SER . 23.1 m-20 -53.25 146.5 11.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.3 -1.118 . . . . 50.0 110.051 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.581 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -141.43 141.37 33.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 50.0 110.604 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 1.0 OUTLIER -97.49 112.02 24.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 50.0 109.672 179.462 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' ILE . 5.0 tt -103.44 136.91 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.101 -0.999 . . . . 50.0 110.406 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.564 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 27.1 t -125.15 113.12 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.088 -1.007 . . . . 50.0 110.316 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.816 HG11 ' CB ' ' A' ' 17' ' ' PHE . 42.1 t -105.13 100.54 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.901 . . . . 50.0 110.065 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -150.82 164.8 30.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.71 -1.356 . . . . 50.0 109.71 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' MET . . . . . 0.508 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ttm -103.44 -29.71 11.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.32 -1.106 . . . . 50.0 110.319 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 179.71 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.07 -67.9 0.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.27 -1.135 . . . . 50.0 110.422 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.1 tptt -79.47 109.38 13.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.208 -0.933 . . . . 50.0 110.109 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . 0.652 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -134.82 149.73 50.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 110.111 -179.739 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.738 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 5.6 pt -118.92 154.7 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 0.0 109.905 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 102' ' ' ASN . 14.4 p30 -143.1 136.35 28.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.164 -0.96 . . . . 0.0 110.429 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.491 ' HB3' ' CZ3' ' A' ' 105' ' ' TRP . 0.1 OUTLIER -120.78 168.25 11.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.24 -0.912 . . . . 0.0 110.28 179.887 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.588 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 8.8 p-80 -131.08 106.08 8.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.363 -0.836 . . . . 0.0 109.981 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' TRP . . . . . 0.491 ' CZ3' ' HB3' ' A' ' 103' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 110.629 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.334 0.588 . . . . 50.0 110.206 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.9 mmtp -107.93 132.74 53.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.277 -0.889 . . . . 50.0 110.094 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.549 HD12 ' N ' ' A' ' 3' ' ' LEU . 2.2 mp -129.71 101.55 5.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.255 -0.903 . . . . 50.0 110.254 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.87 122.54 42.25 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.211 -0.931 . . . . 50.0 110.153 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -108.37 106.55 16.73 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.252 -0.905 . . . . 50.0 110.162 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 16.9 tttm -105.01 163.33 12.62 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.282 -0.886 . . . . 50.0 110.307 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.58 19.07 29.18 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.48 -1.448 . . . . 50.0 109.48 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 4.4 t -57.48 167.03 1.09 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.275 -1.133 . . . . 50.0 110.221 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.4 m -47.56 109.43 0.22 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.269 -0.894 . . . . 50.0 110.281 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -127.95 167.76 16.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.179 -0.95 . . . . 50.0 110.124 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.15 101.42 0.86 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.53 -1.428 . . . . 50.0 109.53 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.547 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 74.1 mtp -77.05 114.88 16.33 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.286 -1.126 . . . . 50.0 110.263 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.778 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 8.6 p -149.01 108.06 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.188 -0.945 . . . . 99.99 110.608 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.657 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -161.57 41.96 0.15 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.611 -1.305 . . . . 99.99 110.678 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.7 tm-20 -70.03 -3.78 17.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.122 -0.986 . . . . 99.99 110.075 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.543 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -79.71 62.45 3.98 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.315 -0.866 . . . . 50.0 110.206 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.646 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.3 OUTLIER -102.64 140.87 36.34 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.188 -0.945 . . . . 50.0 110.431 -179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.678 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 2.4 t -125.53 119.69 28.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.289 -0.882 . . . . 50.0 109.81 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -73.62 108.41 6.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.125 -0.985 . . . . 50.0 110.298 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.798 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -94.87 -33.49 12.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 50.0 109.916 179.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.49 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 17.3 mtmt -144.78 150.29 36.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.288 -0.882 . . . . 50.0 110.202 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.473 ' HB3' ' HD2' ' A' ' 23' ' ' PRO . 11.2 m-20 -69.23 165.15 42.0 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.291 -0.881 . . . . 50.0 110.107 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.543 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.1 Cg_endo -72.84 122.53 8.24 Favored 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.946 1.498 . . . . 50.0 110.31 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -122.37 141.71 51.28 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.905 . . . . 50.0 110.287 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.537 ' HA ' ' O ' ' A' ' 30' ' ' THR . 2.7 p30 -81.89 131.65 35.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.229 -0.919 . . . . 50.0 110.312 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.2 p -123.54 52.46 1.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.312 -0.868 . . . . 50.0 110.137 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.57 -129.2 2.85 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.435 -1.466 . . . . 50.0 109.435 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -116.54 95.79 5.21 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.206 -1.173 . . . . 50.0 110.243 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.58 23.04 63.27 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.537 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 0.8 OUTLIER -117.87 107.71 14.43 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -1.16 . . . . 50.0 110.219 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.543 HG11 ' HB2' ' A' ' 23' ' ' PRO . 11.8 t -103.58 137.3 32.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.307 -0.87 . . . . 50.0 110.208 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.539 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -110.82 136.46 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.224 -0.923 . . . . 50.0 110.294 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HD11 ' A' ' 35' ' ' LEU . 12.7 tt -130.62 144.49 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.413 -0.805 . . . . 50.0 109.68 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.798 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -122.62 105.26 9.94 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.982 . . . . 50.0 110.639 -179.495 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.989 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.12 141.63 51.76 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.238 -0.914 . . . . 50.0 109.511 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -90.74 128.93 36.84 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.102 -0.999 . . . . 50.0 109.855 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.543 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 11.4 t80 -91.44 98.58 11.77 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 118.935 -1.106 . . . . 50.0 109.679 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.77 69.6 8.69 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.291 -0.881 . . . . 50.0 109.711 -179.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.536 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -124.24 119.85 3.87 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.634 -1.386 . . . . 99.99 109.634 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.1 m -86.22 20.04 2.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.327 -1.101 . . . . 99.99 110.278 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -97.47 -0.85 45.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.246 -0.909 . . . . 99.99 110.105 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.71 -158.3 26.05 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.411 -1.475 . . . . 99.99 109.411 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -73.06 151.32 49.75 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.959 1.505 . . . . 99.99 110.222 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.778 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -170.23 161.48 8.34 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -0.907 . . . . 50.0 109.784 -179.402 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.602 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 5.0 mmtt -79.48 114.39 18.37 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.979 -1.076 . . . . 50.0 110.125 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.064 HD11 HG23 ' A' ' 70' ' ' VAL . 2.6 mt -75.06 113.58 26.42 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 50.0 110.194 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.497 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 46.5 Cg_endo -74.13 88.79 1.08 Allowed 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 124.043 1.549 . . . . 50.0 110.013 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.673 HD11 HG21 ' A' ' 46' ' ' ILE . 79.4 mt -125.54 151.79 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 50.0 110.741 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.517 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 32.4 m -133.12 137.29 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.499 -0.751 . . . . 50.0 109.337 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -116.48 108.81 16.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.003 -1.061 . . . . 50.0 110.313 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.549 ' O ' ' N ' ' A' ' 91' ' ' TYR . 14.8 m -131.58 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.3 -0.875 . . . . 50.0 110.113 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.48 163.6 1.7 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.31 -0.869 . . . . 50.0 110.184 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.665 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.3 OUTLIER -62.85 120.46 11.34 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -0.887 . . . . 50.0 110.545 -179.765 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.665 ' CB ' ' O ' ' A' ' 53' ' ' SER . 3.8 tp 81.47 29.96 0.15 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.582 -0.699 . . . . 50.0 110.725 179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.524 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 64.6 m-80 -137.38 84.75 2.08 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 50.0 110.101 179.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -105.36 11.13 33.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 50.0 110.171 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.4 tpt -109.04 -14.15 14.59 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.294 -0.879 . . . . 50.0 110.211 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.3 p -136.04 142.84 41.71 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.289 -0.882 . . . . 50.0 110.231 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.68 137.2 27.01 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.006 1.53 . . . . 50.0 110.321 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.817 HG12 ' HG3' ' A' ' 86' ' ' PRO . 4.0 t -143.89 -49.08 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.305 -0.872 . . . . 50.0 110.079 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -86.29 147.22 21.43 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.085 -1.606 . . . . 50.0 109.085 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 10.1 mtp180 -138.66 156.38 47.48 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.057 -1.261 . . . . 50.0 110.686 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.487 ' HA ' ' HG2' ' A' ' 83' ' ' MET . 5.0 mp -91.91 109.62 20.96 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.32 -0.863 . . . . 50.0 110.051 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.553 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 77.9 t -55.93 -42.89 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.218 -0.926 . . . . 50.0 110.51 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.466 ' OG1' ' HB2' ' A' ' 82' ' ' GLU . 1.4 m -73.76 169.49 17.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.162 -0.961 . . . . 50.0 110.173 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 67' ' ' ASN . 23.3 t -44.65 170.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.236 -0.915 . . . . 50.0 110.114 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.646 ' CB ' ' CE2' ' A' ' 69' ' ' PHE . 60.7 m-80 -47.08 157.7 0.48 Allowed Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.243 -0.91 . . . . 50.0 109.979 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.863 ' C ' HD12 ' A' ' 46' ' ' ILE . 45.4 Cg_endo -73.32 66.36 4.42 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 123.955 1.503 . . . . 50.0 110.58 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE2' ' CB ' ' A' ' 67' ' ' ASN . 16.7 m-30 -120.8 121.7 38.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 50.0 109.878 179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.064 HG23 HD11 ' A' ' 46' ' ' ILE . 80.8 t -79.91 60.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 50.0 110.096 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -83.31 61.6 6.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.082 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.2 OUTLIER -142.65 164.41 30.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.253 -0.905 . . . . 50.0 110.335 -179.758 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 p -94.08 -10.79 32.22 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 50.0 109.874 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 67.4 m -120.95 18.24 11.74 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -0.872 . . . . 99.99 110.253 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.842 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -81.98 11.44 5.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.136 -0.977 . . . . 99.99 110.073 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.1 m-20 -85.22 15.06 4.51 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.253 -0.904 . . . . 99.99 109.337 179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 9.3 p -124.27 -171.98 2.45 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.464 -0.773 . . . . 99.99 109.574 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.484 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 11.8 pttt -62.87 88.86 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.559 -0.856 . . . . 99.99 109.115 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.989 HG22 ' O ' ' A' ' 35' ' ' LEU . 22.2 m -76.52 174.42 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.41 -0.806 . . . . 99.99 109.651 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.445 HD23 ' O ' ' A' ' 33' ' ' ILE . 1.6 tt -138.8 120.39 15.11 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.977 -1.077 . . . . 50.0 110.942 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.426 ' N ' HD23 ' A' ' 80' ' ' LEU . 2.0 t -116.91 172.69 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.335 -0.853 . . . . 50.0 109.9 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.553 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 83.7 mt-10 -120.69 154.75 35.13 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.142 -0.974 . . . . 50.0 110.339 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.527 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -146.14 140.39 26.64 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.332 -0.855 . . . . 50.0 110.027 -179.935 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.43 62.87 0.92 Allowed Pre-proline 0 C--N 1.306 -1.315 0 O-C-N 121.258 -0.901 . . . . 50.0 110.712 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.527 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.4 Cg_endo -72.7 148.44 46.89 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 123.848 1.447 . . . . 50.0 110.357 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.817 ' HG3' HG12 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.66 152.51 59.19 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 123.963 1.507 . . . . 50.0 110.413 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -52.8 133.63 37.13 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.19 -0.944 . . . . 50.0 110.136 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.53 161.68 11.41 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.532 -1.427 . . . . 50.0 109.532 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.537 ' CB ' ' HB2' ' A' ' 53' ' ' SER . 5.4 p30 -53.01 155.24 2.55 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.177 -1.19 . . . . 50.0 110.108 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.513 ' HA ' ' N ' ' A' ' 53' ' ' SER . 17.6 p -143.03 137.98 29.65 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.229 -0.919 . . . . 50.0 110.387 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.627 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 1.2 m-30 -101.56 103.34 14.18 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.293 -0.88 . . . . 50.0 110.275 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.739 ' H ' HD12 ' A' ' 92' ' ' ILE . 3.2 mp -101.5 138.95 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.201 -0.937 . . . . 50.0 109.871 179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.517 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 75.5 t -125.37 113.73 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 50.0 110.785 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.646 HG11 ' CB ' ' A' ' 17' ' ' PHE . 41.3 t -101.97 91.54 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.958 . . . . 50.0 109.785 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.56 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.59 167.83 33.14 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.774 -1.33 . . . . 50.0 109.774 -179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.424 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ptp -108.38 -150.77 0.46 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.308 -1.113 . . . . 50.0 110.08 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -73.7 -44.12 33.21 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.729 -1.348 . . . . 50.0 109.729 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 99' ' ' LYS . 39.5 t0 -74.98 -105.67 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.205 -1.174 . . . . 50.0 110.293 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.489 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 8.5 tttp -79.61 136.1 36.75 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.048 -1.032 . . . . 50.0 110.352 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.778 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -140.1 150.13 43.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.197 -0.939 . . . . 0.0 110.07 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 7.5 mt -115.72 146.98 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 93' ' ' VAL . 24.0 p-10 -130.67 129.76 43.02 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.253 -0.904 . . . . 0.0 110.469 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -135.48 163.79 29.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.442 -0.786 . . . . 0.0 110.018 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.627 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 10.3 p80 -134.39 164.15 28.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.211 -0.931 . . . . 0.0 110.221 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -144.16 133.29 22.91 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.257 -0.902 . . . . 0.0 110.236 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.578 ' CE1' ' O ' ' A' ' 108' ' ' ALA . 66.6 t60 -120.08 133.56 55.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 110.123 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . 0.5 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 0.0 OUTLIER -110.86 -16.88 13.45 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.238 -0.914 . . . . 0.0 110.381 -179.862 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.578 ' O ' ' CE1' ' A' ' 106' ' ' HIS . . . 179.76 152.36 0.43 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.339 -0.85 . . . . 0.0 110.241 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -159.92 45.58 0.42 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.3 p -90.55 172.39 8.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -1.173 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.2 t . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 118.059 -0.972 . . . . 49.57 110.316 179.979 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.404 ' OD1' ' C ' ' A' ' 1' ' ' ASP . 21.1 t0 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.26 0.552 . . . . 50.0 110.252 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 tttp -74.61 134.07 42.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.151 -0.968 . . . . 50.0 110.28 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.453 HD12 ' O ' ' A' ' 3' ' ' LEU . 3.4 pp -82.91 136.84 34.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 50.0 110.245 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.11 113.44 22.17 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.254 -0.904 . . . . 50.0 110.014 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 tp -107.55 99.8 9.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 50.0 110.327 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -106.66 -164.03 0.96 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.901 . . . . 50.0 110.217 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.01 66.24 0.36 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.3 m -120.13 148.72 43.27 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -1.123 . . . . 50.0 110.255 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 p -108.92 140.0 43.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 50.0 110.072 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 3.7 p90 -131.75 177.28 7.65 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.238 -0.914 . . . . 50.0 110.282 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.483 ' O ' ' HG2' ' A' ' 45' ' ' LYS . . . -80.54 101.31 2.0 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.677 -1.369 . . . . 50.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -113.06 105.09 13.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.339 -1.095 . . . . 50.0 110.208 179.869 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.689 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 11.7 p -148.6 107.53 3.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.112 -0.992 . . . . 99.99 110.567 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.642 HG21 HG12 ' A' ' 46' ' ' ILE . 6.7 m -160.84 42.12 0.17 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.679 -1.263 . . . . 99.99 110.602 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -65.14 -5.95 7.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.14 -0.975 . . . . 99.99 109.906 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 mmtm -83.44 61.21 6.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 50.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 1.061 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -101.44 142.44 32.82 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.204 -0.935 . . . . 50.0 109.668 179.45 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.544 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 t -127.13 97.58 4.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.154 -0.966 . . . . 50.0 110.197 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 11.4 p90 -63.0 118.06 7.3 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.36 -0.837 . . . . 50.0 110.04 179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -102.22 -22.41 14.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.248 -0.907 . . . . 50.0 110.093 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -138.06 145.99 42.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 50.0 110.137 -179.856 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.432 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 22.9 p30 -66.83 162.62 50.74 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 50.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.478 ' HB2' HG11 ' A' ' 31' ' ' VAL . 45.0 Cg_endo -72.14 114.48 3.99 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.966 1.509 . . . . 50.0 110.37 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.539 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -105.02 140.13 38.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.284 -0.885 . . . . 50.0 110.368 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 t0 -90.53 111.24 22.45 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.36 -0.837 . . . . 50.0 110.184 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.5 59.02 5.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.228 -0.92 . . . . 50.0 110.158 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 128.31 -128.16 5.89 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 10.4 p80 -132.59 89.21 2.61 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.152 -1.205 . . . . 50.0 110.138 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.464 ' O ' HG23 ' A' ' 30' ' ' THR . . . 113.68 31.05 2.43 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.521 -1.431 . . . . 50.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.464 HG23 ' O ' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -154.95 111.19 3.2 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.214 -1.168 . . . . 50.0 110.343 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 57.7 t -109.27 147.88 13.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.295 -0.878 . . . . 50.0 110.253 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.67 HG12 ' CD2' ' A' ' 80' ' ' LEU . 0.4 OUTLIER -124.92 118.26 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.183 -0.948 . . . . 50.0 110.318 -179.913 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.719 ' O ' HD23 ' A' ' 80' ' ' LEU . 0.6 OUTLIER -116.04 149.54 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.311 -0.868 . . . . 50.0 109.785 179.64 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.502 ' HB3' ' HG3' ' A' ' 21' ' ' LYS . 0.7 OUTLIER -126.69 104.87 8.32 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.207 -0.933 . . . . 50.0 110.534 -179.653 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.997 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -123.78 144.52 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.319 -0.863 . . . . 50.0 109.302 179.435 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.569 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.23 133.51 39.02 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.031 -1.043 . . . . 50.0 110.028 -179.688 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.796 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.8 t80 -94.0 97.56 10.42 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.065 -1.054 . . . . 50.0 109.863 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 59.1 p -95.41 70.06 3.11 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.27 -0.894 . . . . 50.0 110.14 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -122.39 129.38 7.53 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.575 -1.41 . . . . 99.99 109.575 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 23.0 p -92.86 24.78 3.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.274 -1.133 . . . . 99.99 110.244 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.2 p30 -98.43 -1.32 41.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.188 -0.945 . . . . 99.99 110.084 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -168.63 24.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.461 -1.456 . . . . 99.99 109.461 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.619 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.7 Cg_endo -73.56 153.4 49.39 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.976 1.513 . . . . 99.99 110.324 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.689 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.29 161.33 8.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.34 -0.85 . . . . 50.0 110.002 -179.378 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.565 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -76.04 133.86 40.25 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.095 -1.003 . . . . 50.0 109.305 178.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.061 HD13 ' CZ ' ' A' ' 17' ' ' PHE . 9.5 mt -89.25 108.41 24.26 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 120.996 -1.065 . . . . 50.0 110.157 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.536 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 47.6 Cg_endo -74.49 99.99 1.27 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 124.043 1.549 . . . . 50.0 110.7 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.82 ' CG1' HG13 ' A' ' 94' ' ' VAL . 2.6 mt -126.55 150.34 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 50.0 110.172 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.621 HG22 HG23 ' A' ' 51' ' ' VAL . 2.7 p -128.21 130.43 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.416 -0.802 . . . . 50.0 109.983 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.498 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.1 OUTLIER -115.35 106.47 14.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 50.0 109.931 179.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.621 HG23 HG22 ' A' ' 49' ' ' VAL . 2.9 t -132.78 163.09 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.187 -0.946 . . . . 50.0 110.698 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.511 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -56.24 164.43 1.31 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.485 -0.759 . . . . 50.0 110.393 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.647 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -58.69 122.28 13.12 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.441 -0.787 . . . . 50.0 110.598 -179.602 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.647 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 81.17 29.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.594 -0.691 . . . . 50.0 110.906 179.627 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.538 ' CB ' HG12 ' A' ' 51' ' ' VAL . 14.7 m120 -132.99 84.35 2.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 50.0 109.995 178.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 56' ' ' ASP . 10.4 m-20 -106.7 18.09 22.34 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.164 -0.96 . . . . 50.0 110.349 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 18.4 mtt -125.0 -8.93 7.16 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.193 -0.942 . . . . 50.0 110.474 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.635 HG22 ' HD2' ' A' ' 59' ' ' PRO . 0.2 OUTLIER -136.2 144.29 47.33 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.151 -0.968 . . . . 50.0 110.391 -179.854 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.635 ' HD2' HG22 ' A' ' 58' ' ' THR . 47.1 Cg_endo -74.48 125.8 9.85 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.036 1.545 . . . . 50.0 110.239 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.511 HG11 ' HB2' ' A' ' 52' ' ' ALA . 75.0 t -139.2 -36.22 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -0.94 . . . . 50.0 110.093 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -79.49 161.65 46.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.023 -1.631 . . . . 50.0 109.023 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -123.63 156.92 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 50.0 110.532 -179.527 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.467 ' HA ' ' HG3' ' A' ' 83' ' ' MET . 1.2 mt -107.16 132.75 52.69 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.314 -0.866 . . . . 50.0 109.944 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 27.2 t -63.71 -17.27 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.187 -0.946 . . . . 50.0 110.451 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.443 ' O ' ' O ' ' A' ' 66' ' ' VAL . 6.2 t -147.11 167.42 24.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.211 -0.931 . . . . 50.0 110.193 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.504 HG12 ' N ' ' A' ' 67' ' ' ASN . 21.2 t -47.16 173.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 50.0 110.02 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.566 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 5.4 p30 -46.73 138.26 7.05 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.202 -0.936 . . . . 50.0 110.239 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.479 ' HB2' HD12 ' A' ' 46' ' ' ILE . 46.7 Cg_endo -74.01 103.05 1.6 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.934 1.492 . . . . 50.0 110.38 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.566 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -113.8 134.01 55.04 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.18 -0.95 . . . . 50.0 110.495 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.818 HG13 ' CB ' ' A' ' 75' ' ' ALA . 61.9 t -87.63 60.46 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 50.0 109.684 179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.619 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.9 57.42 4.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.295 -0.878 . . . . 50.0 110.021 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.43 169.01 18.49 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 50.0 110.424 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.87 -7.15 34.19 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.872 . . . . 50.0 109.909 179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -121.11 12.59 11.12 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.31 -0.869 . . . . 99.99 110.242 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.818 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -77.15 6.82 5.87 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.226 -0.921 . . . . 99.99 110.079 179.698 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.555 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 8.2 m-80 -84.62 19.56 1.97 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.333 -0.855 . . . . 99.99 109.384 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.672 ' O ' HG13 ' A' ' 79' ' ' VAL . 31.0 m -121.09 -172.54 2.42 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.414 -0.804 . . . . 99.99 109.177 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.444 ' HB3' ' OE2' ' A' ' 34' ' ' GLU . 6.8 mttp -63.21 88.06 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.235 -0.915 . . . . 99.99 109.064 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.997 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.2 m -76.95 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.331 -0.856 . . . . 99.99 109.318 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.719 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.4 OUTLIER -133.87 130.36 37.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.785 -1.197 . . . . 50.0 111.1 -179.66 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.5 t -120.45 168.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.476 -0.765 . . . . 50.0 109.947 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.5 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 4.0 mt-10 -132.96 147.99 52.28 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.179 -0.951 . . . . 50.0 110.176 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.505 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -146.83 143.17 28.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.214 -0.929 . . . . 50.0 110.393 -179.853 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.46 ' O ' ' HB2' ' A' ' 62' ' ' ARG . 0.2 OUTLIER -117.95 68.56 6.65 Favored Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.115 -0.991 . . . . 50.0 110.477 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.404 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.86 161.44 41.48 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 O-C-N 123.975 1.513 . . . . 50.0 110.358 179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.425 ' HD3' ' HA2' ' A' ' 61' ' ' GLY . 45.8 Cg_endo -73.43 146.7 40.12 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 124.003 1.528 . . . . 50.0 110.446 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.521 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.8 OUTLIER -52.74 135.18 35.82 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.281 -0.887 . . . . 50.0 110.07 -179.958 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 124.81 165.63 12.19 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.52 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 92.8 m-20 -62.2 135.42 57.48 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -1.193 . . . . 50.0 110.214 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.572 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.7 OUTLIER -132.27 145.27 51.18 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.308 -0.87 . . . . 50.0 110.138 179.997 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.616 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.9 m-30 -100.74 113.16 25.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.081 -1.012 . . . . 50.0 110.026 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.5 mp -109.06 131.1 60.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 50.0 110.108 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.516 ' HB ' ' CG1' ' A' ' 49' ' ' VAL . 71.3 t -124.89 118.86 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.17 -0.956 . . . . 50.0 110.437 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.82 HG13 ' CG1' ' A' ' 48' ' ' ILE . 21.7 t -101.41 93.78 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 50.0 109.88 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.524 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -156.15 170.73 33.87 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.784 -1.326 . . . . 50.0 109.784 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.544 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 15.9 ptp -112.2 -28.33 7.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.262 -1.14 . . . . 50.0 109.919 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . 0.544 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 171.3 -61.56 0.17 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.504 -1.438 . . . . 50.0 109.504 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -64.0 -108.41 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.232 -1.158 . . . . 50.0 110.268 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -79.62 127.98 32.83 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.093 -1.004 . . . . 50.0 110.182 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.77 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.8 pp0? -136.16 150.2 48.95 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.231 -0.918 . . . . 0.0 110.226 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.522 ' CG1' ' HB ' ' A' ' 94' ' ' VAL . 32.4 pt -102.95 148.94 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.974 -1.079 . . . . 0.0 110.186 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -132.27 142.39 49.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 110.397 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -128.46 166.74 18.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.351 -0.843 . . . . 0.0 110.193 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.586 ' CG ' ' O ' ' A' ' 104' ' ' HIS . 8.8 p80 -118.61 85.36 2.34 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.327 -0.858 . . . . 0.0 110.346 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.494 ' CD1' ' C ' ' A' ' 105' ' ' TRP . 1.7 t-105 -45.9 122.51 3.84 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.156 -0.965 . . . . 0.0 110.051 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.99 114.86 10.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 110.159 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 22.8 ttpt -89.37 -8.64 52.75 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 110.163 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -172.69 131.06 0.54 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.868 . . . . 0.0 110.114 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.38 38.52 3.19 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -140.81 123.09 15.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.141 -1.211 . . . . 0.0 110.251 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 117.99 -1.005 . . . . 49.57 110.175 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 1' ' ' ASP . 36.9 t0 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.267 0.556 . . . . 50.0 110.232 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 31.5 tptt -162.87 160.18 24.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.315 -0.866 . . . . 50.0 110.128 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.4 pp -78.7 121.02 24.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 50.0 110.176 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.55 94.15 6.24 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.279 -0.888 . . . . 50.0 110.149 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 tp -111.28 137.25 49.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.878 . . . . 50.0 110.004 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.24 165.25 24.58 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 50.0 110.254 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -103.88 17.64 48.57 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.612 -1.395 . . . . 50.0 109.612 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.9 p -102.22 101.45 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.178 -1.189 . . . . 50.0 110.214 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.449 ' O ' ' O ' ' A' ' 10' ' ' TYR . 1.1 t -155.06 -177.83 6.81 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.241 -0.912 . . . . 50.0 110.17 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.449 ' O ' ' O ' ' A' ' 9' ' ' THR . 1.0 OUTLIER -46.79 174.47 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 50.0 110.335 179.971 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -74.98 124.17 7.69 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.672 -1.371 . . . . 50.0 109.672 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.56 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? -78.13 114.24 16.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.251 -1.146 . . . . 50.0 110.016 179.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.664 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 12.2 p -148.83 108.01 3.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.227 -0.92 . . . . 99.99 110.655 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.733 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.43 44.04 0.16 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.876 -1.14 . . . . 99.99 110.489 179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.419 ' O ' ' OE1' ' A' ' 15' ' ' GLU . 0.4 OUTLIER -76.83 10.43 2.25 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.147 -0.97 . . . . 99.99 110.615 -179.829 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.492 ' HE2' ' HA2' ' A' ' 39' ' ' GLY . 0.0 OUTLIER -111.48 61.85 0.61 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.028 -1.045 . . . . 50.0 110.59 -179.964 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.883 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -94.68 148.74 21.96 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.093 -1.004 . . . . 50.0 109.994 179.603 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.607 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 28.6 t -125.15 114.31 18.85 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.145 -0.972 . . . . 50.0 110.153 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.691 ' CD1' HD23 ' A' ' 35' ' ' LEU . 9.7 m-85 -64.94 112.92 3.52 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.26 -0.9 . . . . 50.0 110.188 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.538 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -96.51 -32.94 12.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.19 -0.944 . . . . 50.0 110.152 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.504 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 0.5 OUTLIER -138.96 163.03 33.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.287 -0.883 . . . . 50.0 110.229 -179.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.449 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 36.7 p-10 -76.89 164.3 60.06 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.253 -0.904 . . . . 50.0 110.134 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.464 ' HB2' HG11 ' A' ' 31' ' ' VAL . 44.6 Cg_endo -71.19 126.78 12.7 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.431 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -121.53 148.83 43.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.22 -0.925 . . . . 50.0 110.344 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 27' ' ' GLY . 10.3 t70 -94.62 122.07 36.83 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.322 -0.861 . . . . 50.0 110.203 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.44 HG23 ' CG2' ' A' ' 32' ' ' VAL . 7.1 p -79.35 -51.33 9.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.166 -0.959 . . . . 50.0 110.278 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.425 ' O ' ' OD1' ' A' ' 25' ' ' ASP . . . -128.59 -108.1 1.38 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.641 -1.384 . . . . 50.0 109.641 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.7 t60 -127.11 108.37 10.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.285 -1.127 . . . . 50.0 110.296 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 85.19 31.28 23.14 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.632 -1.387 . . . . 50.0 109.632 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.425 ' HA ' HG21 ' A' ' 64' ' ' VAL . 1.1 p -145.36 107.92 4.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.149 -1.207 . . . . 50.0 110.361 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 21.4 t -104.24 148.59 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 O-C-N 121.342 -0.849 . . . . 50.0 110.175 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.44 ' CG2' HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -122.65 132.81 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.252 -0.905 . . . . 50.0 110.406 -179.882 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.832 HG23 HD11 ' A' ' 35' ' ' LEU . 8.4 tp -128.49 133.6 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.335 -0.853 . . . . 50.0 109.781 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.538 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 8.9 tt0 -108.54 111.34 23.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.187 -0.946 . . . . 50.0 110.572 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.938 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -125.2 143.12 51.1 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.32 -0.862 . . . . 50.0 109.183 179.299 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -89.45 126.01 35.4 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.98 -1.075 . . . . 50.0 109.925 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.583 ' CE1' ' HA3' ' A' ' 39' ' ' GLY . 1.3 t80 -93.56 101.77 13.96 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 118.987 -1.085 . . . . 50.0 109.357 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 79.5 p -96.36 69.73 2.66 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.281 -0.887 . . . . 50.0 110.261 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.583 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -117.47 130.77 9.01 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.334 -1.506 . . . . 99.99 109.334 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 36.9 m -84.42 25.55 0.86 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.201 -1.176 . . . . 99.99 110.539 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.08 -0.91 26.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.077 -1.014 . . . . 99.99 110.219 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.33 -157.99 28.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.409 -1.477 . . . . 99.99 109.409 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.22 137.24 28.29 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.923 1.486 . . . . 99.99 110.265 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.664 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -153.02 161.18 42.84 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.855 . . . . 50.0 110.107 -179.432 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.568 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 26.8 mmtt -75.68 130.93 39.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 50.0 109.157 178.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.101 HD11 ' CG2' ' A' ' 70' ' ' VAL . 20.1 mt -89.71 107.31 18.0 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.088 -1.007 . . . . 50.0 110.672 -179.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.2 Cg_endo -74.84 100.7 1.37 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.031 1.543 . . . . 50.0 110.078 179.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.958 ' CG2' HD11 ' A' ' 92' ' ' ILE . 66.1 mt -135.87 146.83 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.165 -0.96 . . . . 50.0 110.563 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.535 HG22 ' HB ' ' A' ' 93' ' ' VAL . 15.7 m -121.41 161.7 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.353 -0.842 . . . . 50.0 109.664 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.539 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -132.72 104.33 6.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.127 -0.983 . . . . 50.0 110.119 -179.846 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.558 ' O ' ' N ' ' A' ' 91' ' ' TYR . 33.4 m -127.22 158.96 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.295 -0.878 . . . . 50.0 110.017 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB3' ' CG ' ' A' ' 55' ' ' ASN . . . -55.83 163.35 1.46 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.361 -0.837 . . . . 50.0 110.054 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.632 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.0 OUTLIER -59.53 118.53 6.16 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.255 -0.903 . . . . 50.0 110.454 -179.534 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.632 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.2 tp 79.53 30.51 0.29 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.568 -0.707 . . . . 50.0 110.673 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.4 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 6.5 m120 -124.51 84.87 2.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.284 -0.885 . . . . 50.0 110.341 179.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.77 9.82 40.52 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 50.0 109.88 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.8 mtt -123.44 -12.88 7.7 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.29 -0.881 . . . . 50.0 110.106 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.6 m -130.26 119.02 18.44 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.378 -0.826 . . . . 50.0 110.035 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.473 ' C ' HG23 ' A' ' 60' ' ' VAL . 44.2 Cg_endo -71.55 136.94 29.42 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.922 1.485 . . . . 50.0 110.162 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.6 HG12 ' HG3' ' A' ' 86' ' ' PRO . 44.7 t -148.24 -37.37 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.176 -0.953 . . . . 50.0 110.029 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.81 145.18 37.95 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.817 -1.713 . . . . 50.0 108.817 179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.451 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.1 mmp_? -124.06 157.26 34.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.991 -1.3 . . . . 50.0 110.53 -179.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.4 mt -101.67 127.43 48.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.298 -0.876 . . . . 50.0 109.731 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.528 HG11 ' CD ' ' A' ' 82' ' ' GLU . 22.8 t -64.5 -13.19 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.214 -0.929 . . . . 50.0 110.262 -179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' VAL . 14.0 t -140.8 165.97 26.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.215 -0.928 . . . . 50.0 110.215 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.797 HG12 ' H ' ' A' ' 67' ' ' ASN . 3.8 t -55.07 -170.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 50.0 109.881 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.797 ' H ' HG12 ' A' ' 66' ' ' VAL . 3.0 t30 -46.31 132.66 7.62 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.023 -1.048 . . . . 50.0 110.08 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.719 ' O ' HD12 ' A' ' 46' ' ' ILE . 46.9 Cg_endo -73.51 75.36 3.01 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.042 1.549 . . . . 50.0 110.554 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.612 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.8 p90 -95.15 136.94 34.87 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.239 -0.913 . . . . 50.0 110.141 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.101 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.3 t -97.12 60.58 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 50.0 109.649 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -71.33 59.48 0.28 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.341 -0.849 . . . . 50.0 110.238 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.428 ' CG2' HG12 ' A' ' 70' ' ' VAL . 2.4 t -142.62 164.66 29.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.921 . . . . 50.0 110.257 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.7 t -84.26 11.25 8.6 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.137 -0.977 . . . . 50.0 110.081 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.3 m -121.63 13.64 10.87 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 99.99 110.358 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.621 ' HB2' HG12 ' A' ' 70' ' ' VAL . . . -61.9 -10.98 10.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.18 -0.95 . . . . 99.99 110.172 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.496 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 63.5 m-20 -86.49 20.91 2.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.143 -0.973 . . . . 99.99 109.351 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.496 ' O ' ' HA ' ' A' ' 36' ' ' SER . 0.5 OUTLIER -132.69 -173.24 3.12 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.325 -0.859 . . . . 99.99 109.725 -179.872 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.477 ' HG3' ' OG ' ' A' ' 36' ' ' SER . 0.8 OUTLIER -64.34 89.56 0.06 Allowed 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.731 -0.788 . . . . 99.99 109.196 179.256 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.938 HG22 ' O ' ' A' ' 35' ' ' LEU . 27.0 m -75.74 174.83 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.221 -0.924 . . . . 99.99 109.165 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -132.69 134.29 44.61 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.764 -1.21 . . . . 50.0 111.432 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.442 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.8 t -121.03 178.25 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.736 . . . . 50.0 109.696 179.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.528 ' CD ' HG11 ' A' ' 64' ' ' VAL . 10.5 tt0 -143.69 138.78 29.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.172 -0.955 . . . . 50.0 110.342 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.409 ' HG2' ' O ' ' A' ' 62' ' ' ARG . 2.4 mtm -147.25 145.44 29.43 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.151 -0.968 . . . . 50.0 110.383 -179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.498 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -118.07 70.05 7.66 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 121.341 -0.849 . . . . 50.0 110.563 -179.999 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.11 162.28 39.16 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 124.012 1.533 . . . . 50.0 110.126 179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.6 ' HG3' HG12 ' A' ' 60' ' ' VAL . 47.1 Cg_endo -72.7 150.28 50.15 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 123.896 1.472 . . . . 50.0 110.335 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.54 120.56 5.77 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.197 -0.94 . . . . 50.0 110.029 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 134.64 178.31 15.56 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.562 -1.415 . . . . 50.0 109.562 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.42 ' HA ' ' O ' ' A' ' 105' ' ' TRP . 25.3 p-10 -77.17 141.05 40.3 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -1.14 . . . . 50.0 110.208 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.568 ' HA ' ' N ' ' A' ' 53' ' ' SER . 53.6 p -135.11 150.62 50.25 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 50.0 110.164 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.612 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 0.5 OUTLIER -96.94 105.02 17.09 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.298 -0.876 . . . . 50.0 110.275 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.958 HD11 ' CG2' ' A' ' 48' ' ' ILE . 0.0 OUTLIER -96.06 136.4 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.226 -0.921 . . . . 50.0 109.505 179.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.953 ' N ' HD13 ' A' ' 92' ' ' ILE . 33.5 t -123.84 117.54 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.131 -0.98 . . . . 50.0 110.88 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.756 HG13 HG12 ' A' ' 48' ' ' ILE . 97.0 t -106.14 95.03 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.328 -0.857 . . . . 50.0 109.893 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.59 170.3 33.51 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.665 -1.374 . . . . 50.0 109.665 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . . . . . . . . . 9.2 mtm -80.4 -63.52 1.39 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -1.157 . . . . 50.0 110.178 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -156.06 -68.48 0.01 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.561 -1.416 . . . . 50.0 109.561 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -71.14 -75.58 0.12 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -1.11 . . . . 50.0 110.279 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.1 tptt -79.67 119.62 22.86 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.289 -0.882 . . . . 50.0 110.305 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.607 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.54 148.72 41.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 110.091 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.7 mm -98.69 111.46 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.12 -0.988 . . . . 0.0 110.039 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 36.7 p-10 -101.57 130.37 47.86 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.154 -0.966 . . . . 0.0 110.275 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.601 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -128.93 170.62 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.355 -0.841 . . . . 0.0 110.324 -179.899 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.477 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 50.0 p-80 -123.7 125.33 44.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.33 -0.857 . . . . 0.0 110.127 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.744 ' CZ3' HG21 ' A' ' 92' ' ' ILE . 9.1 m0 -123.33 132.58 54.04 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.182 -0.949 . . . . 0.0 110.328 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.451 ' H ' ' CD2' ' A' ' 106' ' ' HIS . 13.6 p80 -118.27 126.66 52.61 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.287 -0.883 . . . . 0.0 110.118 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . 0.493 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 0.6 OUTLIER -89.61 -16.73 29.9 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.219 -0.926 . . . . 0.0 110.073 179.893 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.493 ' HB2' ' O ' ' A' ' 107' ' ' LYS . . . 179.73 141.14 0.13 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.418 -0.801 . . . . 0.0 110.21 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -86.32 110.6 3.51 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 29.7 p -114.99 44.06 1.86 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -1.144 . . . . 0.0 110.309 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.962 -1.018 . . . . 49.57 110.18 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.273 0.559 . . . . 50.0 110.204 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.82 155.2 50.11 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 50.0 110.141 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.441 ' HA ' HD22 ' A' ' 3' ' ' LEU . 0.2 OUTLIER -90.28 148.86 22.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.223 -0.923 . . . . 50.0 110.284 -179.973 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.424 ' H ' HD13 ' A' ' 3' ' ' LEU . . . -82.03 92.64 6.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.321 -0.862 . . . . 50.0 110.183 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.21 151.8 27.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -0.895 . . . . 50.0 110.106 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.02 -176.32 3.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.245 -0.91 . . . . 50.0 110.046 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.72 43.11 2.62 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.517 -1.433 . . . . 50.0 109.517 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -54.48 164.67 0.67 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.331 -1.1 . . . . 50.0 110.227 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.6 p -46.67 155.42 0.25 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 50.0 110.064 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.23 104.75 13.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.222 -0.924 . . . . 50.0 110.282 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 44' ' ' CYS . . . -97.89 151.8 19.75 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 3.4 mtm -107.4 95.25 5.57 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.292 -1.122 . . . . 50.0 110.37 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.641 ' O ' HG23 ' A' ' 14' ' ' THR . 0.1 OUTLIER -112.24 -175.5 2.7 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 99.99 109.929 179.674 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.674 ' HA ' ' HG3' ' A' ' 47' ' ' PRO . 21.8 p -158.24 -76.55 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.342 -0.849 . . . . 99.99 110.307 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.538 ' CG ' ' O ' ' A' ' 15' ' ' GLU . 20.6 tt0 -118.76 8.46 11.84 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 99.99 110.351 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.534 ' HB3' ' CD1' ' A' ' 37' ' ' TYR . 0.9 OUTLIER -56.04 81.97 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.349 -0.845 . . . . 50.0 111.021 -179.451 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.967 ' CD2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.26 142.06 12.7 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.174 -0.954 . . . . 50.0 110.205 179.264 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.51 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 4.6 m -127.75 97.46 4.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.273 -0.892 . . . . 50.0 110.267 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 10.9 p90 -57.12 119.55 6.53 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.25 -0.906 . . . . 50.0 110.249 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.15 -21.94 12.8 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.33 -0.856 . . . . 50.0 110.101 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.484 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 14.8 mttm -145.02 149.69 35.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.152 -0.968 . . . . 50.0 110.278 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -67.66 159.45 78.48 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.849 . . . . 50.0 110.279 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.7 Cg_endo -72.93 134.16 21.13 Favored 'Trans proline' 0 C--N 1.303 -1.818 0 O-C-N 124.013 1.533 . . . . 50.0 110.401 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -130.51 155.32 46.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.231 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -83.69 148.46 27.08 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.232 -0.917 . . . . 50.0 110.122 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.62 22.22 3.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.193 -0.942 . . . . 50.0 110.207 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.28 -133.71 3.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.577 -1.409 . . . . 50.0 109.577 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -104.77 92.78 4.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.281 -1.129 . . . . 50.0 110.343 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 84' ' ' GLU . . . 80.41 30.83 39.46 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.627 -1.389 . . . . 50.0 109.627 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.7 p -122.59 107.62 12.19 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.2 -1.176 . . . . 50.0 110.275 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 18.3 t -100.11 145.19 11.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.276 -0.89 . . . . 50.0 110.099 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -122.42 148.9 25.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.147 -0.971 . . . . 50.0 110.388 -179.73 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.824 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.1 tt -148.17 156.37 9.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.391 -0.818 . . . . 50.0 109.65 179.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.548 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 17.3 tt0 -126.09 103.81 7.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.117 -0.989 . . . . 50.0 110.696 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.951 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -121.84 140.17 52.72 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.349 -0.845 . . . . 50.0 109.263 179.4 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.547 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -92.7 132.84 36.58 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.044 -1.035 . . . . 50.0 110.107 -179.563 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.534 ' CD1' ' HB3' ' A' ' 16' ' ' LYS . 9.4 t80 -94.88 103.05 14.92 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.088 -1.045 . . . . 50.0 109.742 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.2 t -96.48 69.7 2.6 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.313 -0.867 . . . . 50.0 109.929 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.48 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -112.89 130.57 9.58 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.661 -1.376 . . . . 99.99 109.661 -179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -78.52 5.72 10.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 99.99 110.344 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.27 -1.35 42.1 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.213 -0.93 . . . . 99.99 110.116 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' CE2' ' A' ' 37' ' ' TYR . . . 80.93 -131.91 10.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.457 -1.457 . . . . 99.99 109.457 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.58 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 45.6 Cg_endo -73.0 131.01 16.21 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.888 1.467 . . . . 99.99 110.441 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.507 ' HA ' ' HA3' ' A' ' 11' ' ' GLY . 30.5 p -147.81 161.84 40.45 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.323 -0.861 . . . . 50.0 110.126 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.572 ' O ' ' HB3' ' A' ' 13' ' ' CYS . 17.2 mmtt -87.23 108.67 19.04 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.972 . . . . 50.0 109.929 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.967 HG21 ' CD2' ' A' ' 17' ' ' PHE . 4.2 mt -84.51 116.48 65.33 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 50.0 110.353 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.674 ' HG3' ' HA ' ' A' ' 14' ' ' THR . 47.2 Cg_endo -71.94 104.7 1.68 Allowed 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 124.117 1.588 . . . . 50.0 110.344 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.013 HG12 HG22 ' A' ' 94' ' ' VAL . 1.2 mt -125.86 151.15 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 50.0 110.233 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.578 HG22 HG13 ' A' ' 51' ' ' VAL . 5.8 p -132.99 141.29 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.24 -0.913 . . . . 50.0 110.051 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.528 ' O ' ' N ' ' A' ' 61' ' ' GLY . 3.5 m -115.64 104.79 12.05 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.311 -0.868 . . . . 50.0 109.887 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.578 HG13 HG22 ' A' ' 49' ' ' VAL . 30.4 m -131.78 162.94 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.265 -0.897 . . . . 50.0 110.322 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -55.58 163.97 1.17 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.422 -0.799 . . . . 50.0 110.18 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.636 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 10.2 t -63.15 118.26 7.68 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 50.0 110.711 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.599 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 77.21 30.76 0.52 Allowed 'General case' 0 N--CA 1.496 1.829 0 C-N-CA 119.876 -0.73 . . . . 50.0 110.765 179.485 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.48 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 10.5 m120 -134.9 84.95 2.14 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.284 -0.885 . . . . 50.0 110.032 179.124 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -104.53 18.54 22.01 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.273 -0.892 . . . . 50.0 110.373 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.5 ttt -102.87 -24.98 13.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.163 -0.961 . . . . 50.0 110.136 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.41 138.59 27.28 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.462 -0.774 . . . . 50.0 110.196 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.468 ' HA ' HG12 ' A' ' 51' ' ' VAL . 47.0 Cg_endo -72.37 133.23 20.51 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.997 1.525 . . . . 50.0 110.361 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.7 t -143.86 -36.41 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.158 -0.964 . . . . 50.0 110.277 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.11 159.21 50.3 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.052 -1.619 . . . . 50.0 109.052 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.485 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 14.8 mtt-85 -129.36 156.22 44.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.049 -1.265 . . . . 50.0 110.372 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.757 HD23 ' HG3' ' A' ' 83' ' ' MET . 56.6 mt -94.89 124.67 39.06 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.276 -0.89 . . . . 50.0 110.132 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.673 HG23 ' N ' ' A' ' 84' ' ' GLU . 54.5 t -70.54 -38.93 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.198 -0.939 . . . . 50.0 110.122 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.73 175.72 6.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.317 -0.864 . . . . 50.0 110.086 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.6 m -57.92 -175.02 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 121.217 -0.927 . . . . 50.0 110.315 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.493 ' HB2' ' CD1' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.93 156.91 0.51 Allowed Pre-proline 0 N--CA 1.492 1.67 0 O-C-N 121.264 -0.897 . . . . 50.0 110.045 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.643 ' HB2' HD12 ' A' ' 48' ' ' ILE . 48.1 Cg_endo -74.61 65.61 5.68 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.931 1.49 . . . . 50.0 110.9 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.604 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 49.0 p90 -132.45 121.79 23.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.114 -0.991 . . . . 50.0 110.187 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.713 ' HB ' ' HB1' ' A' ' 75' ' ' ALA . 6.8 m -88.19 60.85 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.061 -1.024 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.58 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -66.09 65.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.3 -0.875 . . . . 50.0 110.307 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.564 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 1.5 m -142.49 159.26 42.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.2 -0.937 . . . . 50.0 110.244 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -86.16 -13.23 47.67 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.296 -0.878 . . . . 50.0 109.908 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 5.1 p -114.79 15.81 17.43 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.381 -0.824 . . . . 99.99 110.057 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.713 ' HB1' ' HB ' ' A' ' 70' ' ' VAL . . . -81.13 9.79 6.27 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.321 -0.862 . . . . 99.99 109.959 179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.512 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 84.5 m-20 -85.2 16.86 3.31 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.335 -0.853 . . . . 99.99 109.441 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.628 ' O ' HG13 ' A' ' 79' ' ' VAL . 19.0 t -121.66 -172.44 2.43 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.412 -0.805 . . . . 99.99 109.352 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.483 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 2.4 mttp -62.96 88.33 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.442 -0.903 . . . . 99.99 109.068 179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 35' ' ' LEU . 24.3 m -76.68 173.04 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.391 -0.818 . . . . 99.99 109.832 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.824 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -123.51 129.65 51.52 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.971 -1.08 . . . . 50.0 110.953 -179.642 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.476 HG23 ' CD1' ' A' ' 35' ' ' LEU . 2.0 t -116.35 178.03 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.388 -0.82 . . . . 50.0 109.872 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.488 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 66.2 mt-10 -153.3 151.0 29.5 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.069 -1.02 . . . . 50.0 110.354 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.757 ' HG3' HD23 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -149.54 130.86 14.65 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.236 -0.915 . . . . 50.0 110.267 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.673 ' N ' HG23 ' A' ' 64' ' ' VAL . 0.1 OUTLIER -106.57 72.72 0.3 Allowed Pre-proline 0 C--N 1.306 -1.285 0 O-C-N 121.255 -0.903 . . . . 50.0 110.802 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.505 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.1 Cg_endo -73.0 170.36 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.842 1.443 . . . . 50.0 110.089 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.35 157.0 57.83 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 123.974 1.513 . . . . 50.0 110.479 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -52.84 125.45 17.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.275 -0.891 . . . . 50.0 110.136 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 129.25 -161.15 22.68 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.51 ' OD2' ' CB ' ' A' ' 53' ' ' SER . 15.3 p-10 -99.4 129.47 45.6 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.202 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 65.3 p -122.12 152.06 40.28 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.391 -0.818 . . . . 50.0 110.092 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.676 ' CZ ' ' CD2' ' A' ' 104' ' ' HIS . 1.8 m-30 -106.2 118.83 37.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 50.0 110.27 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.7 mp -109.08 133.32 54.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.259 -0.901 . . . . 50.0 109.83 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.538 ' CG1' ' HB2' ' A' ' 100' ' ' GLN . 18.7 t -123.61 128.21 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.038 -1.039 . . . . 50.0 110.769 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 1.013 HG22 HG12 ' A' ' 48' ' ' ILE . 35.5 t -107.82 88.77 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.343 -0.848 . . . . 50.0 109.98 179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.499 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.84 -179.8 31.19 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.841 -1.304 . . . . 50.0 109.841 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.565 ' CE ' ' HB ' ' A' ' 14' ' ' THR . 3.8 ptp -99.05 -32.64 11.17 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -1.131 . . . . 50.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 175.86 -72.03 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.534 -1.427 . . . . 50.0 109.534 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -65.97 -82.82 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.239 -1.154 . . . . 50.0 110.102 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.67 118.24 21.32 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.209 -0.932 . . . . 50.0 110.182 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.61 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.32 148.77 41.86 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 110.308 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 66.2 mt -93.06 105.84 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.116 -0.99 . . . . 0.0 109.926 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -93.83 136.37 34.18 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.14 -0.975 . . . . 0.0 110.536 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -129.53 159.7 35.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.251 -0.905 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.676 ' CD2' ' CZ ' ' A' ' 91' ' ' TYR . 7.1 m170 -118.98 106.84 12.84 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.351 -0.843 . . . . 0.0 110.589 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.421 ' CE3' ' HG2' ' A' ' 23' ' ' PRO . 1.3 t-105 -88.35 91.58 8.85 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.221 -0.924 . . . . 0.0 110.146 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.435 ' O ' ' CG ' ' A' ' 106' ' ' HIS . 2.8 p80 -99.84 134.55 42.58 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.267 -0.896 . . . . 0.0 110.287 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.83 -8.42 43.56 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 110.301 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -168.51 123.03 0.9 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.2 -0.937 . . . . 0.0 110.225 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -132.16 153.66 20.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.8 m -65.15 -150.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -1.167 . . . . 0.0 110.213 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.931 -1.033 . . . . 49.57 110.199 179.976 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 24.5 p-10 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.333 0.587 . . . . 50.0 110.211 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -88.72 138.89 31.01 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 50.0 110.247 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.555 ' O ' HD23 ' A' ' 3' ' ' LEU . 1.0 OUTLIER -80.96 164.25 22.7 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.292 -0.88 . . . . 50.0 110.308 -179.874 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -122.05 99.55 6.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.266 -0.896 . . . . 50.0 110.201 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.467 ' H ' HD23 ' A' ' 5' ' ' LEU . 0.5 OUTLIER -103.71 73.98 1.21 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.189 -0.945 . . . . 50.0 110.239 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 3.6 tttm -111.86 160.68 17.15 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.89 . . . . 50.0 110.189 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.84 -54.12 0.46 Allowed Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.47 -1.452 . . . . 50.0 109.47 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.8 t -107.66 163.43 13.09 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.288 -1.124 . . . . 50.0 110.123 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.26 76.3 0.98 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.285 -0.884 . . . . 50.0 110.175 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.435 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 0.1 OUTLIER -114.86 177.91 4.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -0.895 . . . . 50.0 110.24 -179.944 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.448 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -107.55 137.34 13.95 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.539 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.7 mtt -84.67 106.34 16.15 Favored 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.285 -1.127 . . . . 50.0 110.334 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.675 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 10.7 p -148.71 108.2 3.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 99.99 110.312 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.502 ' HB ' ' HA ' ' A' ' 46' ' ' ILE . 0.3 OUTLIER -160.54 61.7 0.32 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.888 -1.133 . . . . 99.99 110.55 -179.93 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.458 ' HG3' ' HD2' ' A' ' 16' ' ' LYS . 0.5 OUTLIER -89.68 28.27 1.35 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.192 -0.943 . . . . 99.99 110.161 179.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.545 ' CD ' ' N ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -133.36 67.06 1.54 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 50.0 110.829 -179.788 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.832 ' CZ ' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -102.78 142.12 34.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.15 -0.969 . . . . 50.0 110.024 179.46 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -127.93 97.88 4.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.27 -0.894 . . . . 50.0 110.542 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 24.5 p90 -57.33 116.92 3.61 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.058 -1.026 . . . . 50.0 110.241 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.54 -18.05 14.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.302 -0.874 . . . . 50.0 109.994 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.516 ' HE2' ' HB2' ' A' ' 34' ' ' GLU . 21.1 mtmt -137.97 141.78 40.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.194 -0.941 . . . . 50.0 110.286 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.505 ' OD1' ' N ' ' A' ' 22' ' ' ASN . 16.0 p-10 -66.57 164.86 28.59 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.305 -0.872 . . . . 50.0 110.034 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.555 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 43.5 Cg_endo -71.09 136.46 29.56 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.983 1.517 . . . . 50.0 110.505 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.439 ' O ' ' CG2' ' A' ' 32' ' ' VAL . . . -132.53 126.27 32.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.318 -0.864 . . . . 50.0 110.181 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.506 ' HA ' ' O ' ' A' ' 30' ' ' THR . 26.6 t0 -70.37 111.26 5.81 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.264 -0.898 . . . . 50.0 110.171 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.3 22.94 2.31 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.166 -0.959 . . . . 50.0 110.243 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.04 -117.41 0.67 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.567 -1.413 . . . . 50.0 109.567 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 28' ' ' HIS . 1.1 p80 -129.72 89.42 2.82 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.256 -1.144 . . . . 50.0 110.322 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.466 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 101.25 -2.67 54.5 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.609 -1.396 . . . . 50.0 109.609 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 16.5 p -102.17 107.83 19.04 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.17 -1.194 . . . . 50.0 110.242 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.555 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 16.0 t -102.59 135.88 37.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.233 -0.917 . . . . 50.0 110.081 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' ' O ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -120.98 132.83 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.184 -0.947 . . . . 50.0 110.208 -179.885 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.052 HD13 ' N ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -134.73 144.16 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.268 -0.895 . . . . 50.0 109.682 179.734 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 1.052 ' N ' HD13 ' A' ' 33' ' ' ILE . 6.4 tt0 -109.68 130.8 55.48 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.201 -0.937 . . . . 50.0 110.872 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.089 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.1 mp -135.39 134.49 39.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.357 -0.84 . . . . 50.0 109.237 179.233 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.565 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -79.89 121.84 25.92 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.991 -1.068 . . . . 50.0 109.236 -179.822 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.58 ' CZ ' ' HA3' ' A' ' 39' ' ' GLY . 10.1 t80 -91.61 106.16 18.27 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.584 -1.247 . . . . 50.0 109.458 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.79 69.84 3.41 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.367 -0.833 . . . . 50.0 110.09 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.58 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -121.62 127.86 7.06 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.541 -1.424 . . . . 99.99 109.541 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.3 p -87.96 28.28 1.06 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -1.117 . . . . 99.99 110.272 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.463 ' OD2' ' OH ' ' A' ' 37' ' ' TYR . 2.9 p-10 -110.28 -0.92 17.53 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -0.917 . . . . 99.99 110.247 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.37 -157.41 23.94 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.408 -1.477 . . . . 99.99 109.408 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.72 153.82 54.04 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.893 1.47 . . . . 99.99 110.034 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.675 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.18 157.48 6.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.144 -0.973 . . . . 50.0 110.126 -179.489 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 0.4 OUTLIER -70.56 125.76 27.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 50.0 109.256 179.171 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.892 HD11 ' CG2' ' A' ' 70' ' ' VAL . 2.0 mt -80.98 110.48 17.81 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.164 -0.96 . . . . 50.0 110.481 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.541 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 49.6 Cg_endo -75.33 84.43 1.71 Allowed 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.034 1.544 . . . . 50.0 110.204 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.768 HG12 HG13 ' A' ' 94' ' ' VAL . 71.2 mt -124.29 149.26 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.917 . . . . 50.0 110.457 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.623 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.1 m -116.81 142.88 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 50.0 109.844 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.49 ' O ' ' N ' ' A' ' 61' ' ' GLY . 22.8 m -122.56 100.88 7.16 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.191 -0.943 . . . . 50.0 110.016 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.536 ' O ' ' N ' ' A' ' 91' ' ' TYR . 36.0 m -129.02 157.49 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.334 -0.854 . . . . 50.0 110.238 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.587 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -56.21 163.95 1.45 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.389 -0.82 . . . . 50.0 109.998 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 12.7 t -62.12 121.3 12.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.167 -0.958 . . . . 50.0 110.491 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.644 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 80.07 30.39 0.24 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.61 -0.681 . . . . 50.0 110.738 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.587 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 11.4 m120 -135.41 84.29 2.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.144 -0.972 . . . . 50.0 110.182 179.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -106.75 8.57 30.99 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 50.0 110.471 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.07 -18.01 14.72 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.134 -0.979 . . . . 50.0 110.424 -179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 26.4 p -136.18 146.42 56.28 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.372 -0.83 . . . . 50.0 110.15 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.57 132.67 17.76 Favored 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 124.108 1.583 . . . . 50.0 110.496 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.583 HG12 ' HG3' ' A' ' 86' ' ' PRO . 2.9 t -133.83 -59.42 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -0.866 . . . . 50.0 109.817 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.3 154.12 51.45 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.69 -1.764 . . . . 50.0 108.69 179.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.432 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 6.2 mtt180 -142.83 156.71 45.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.963 -1.316 . . . . 50.0 110.681 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 83' ' ' MET . 1.1 mt -86.23 138.41 31.89 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.193 -0.942 . . . . 50.0 109.998 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.586 HG22 ' HG2' ' A' ' 84' ' ' GLU . 76.2 t -91.64 -29.79 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 50.0 110.458 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.472 ' O ' ' O ' ' A' ' 66' ' ' VAL . 10.1 t -95.1 176.11 6.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.203 -0.936 . . . . 50.0 110.219 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.543 HG12 ' N ' ' A' ' 67' ' ' ASN . 53.8 t -44.34 171.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.294 -0.879 . . . . 50.0 110.225 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.543 ' N ' HG12 ' A' ' 66' ' ' VAL . 7.4 p-10 -46.86 162.2 0.27 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.257 -0.902 . . . . 50.0 109.973 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.507 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.66 90.89 0.8 Allowed 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.97 1.51 . . . . 50.0 110.319 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 1.166 ' CE2' ' HB2' ' A' ' 71' ' ' ALA . 2.2 t80 -149.6 121.79 8.34 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 50.0 110.366 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.892 ' CG2' HD11 ' A' ' 46' ' ' ILE . 2.2 t -88.27 63.42 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.232 -0.918 . . . . 50.0 110.064 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.166 ' HB2' ' CE2' ' A' ' 69' ' ' PHE . . . -70.56 64.78 0.29 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.233 -0.917 . . . . 50.0 110.251 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.602 HG22 HG12 ' A' ' 70' ' ' VAL . 6.5 t -142.62 154.82 44.73 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.233 -0.917 . . . . 50.0 110.256 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 t -77.82 -2.83 38.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 50.0 110.082 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -117.93 23.14 11.85 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.247 -0.908 . . . . 99.99 110.187 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.569 ' O ' ' HB3' ' A' ' 37' ' ' TYR . . . -65.3 -5.61 7.67 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.267 -0.896 . . . . 99.99 110.418 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.425 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 76.5 m-20 -85.23 22.86 1.38 Allowed 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.032 -1.043 . . . . 99.99 109.339 179.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.624 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -131.59 -173.24 3.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.291 -0.88 . . . . 99.99 109.635 -179.802 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 17.3 pttt -63.92 89.11 0.05 Allowed 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.705 -0.798 . . . . 99.99 109.103 179.27 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 1.089 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.4 m -76.07 176.31 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.317 -0.864 . . . . 99.99 109.358 -179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.21 145.02 47.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.84 -1.162 . . . . 50.0 111.019 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.761 ' CG1' HG22 ' A' ' 33' ' ' ILE . 14.5 p -132.52 175.7 10.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.359 -0.838 . . . . 50.0 109.861 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.584 ' N ' HG22 ' A' ' 81' ' ' VAL . 3.9 mt-10 -140.29 144.87 36.63 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.085 -1.009 . . . . 50.0 110.605 -179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -160.24 136.64 8.81 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.265 -0.897 . . . . 50.0 110.165 179.758 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.586 ' HG2' HG22 ' A' ' 64' ' ' VAL . 2.9 pt-20 -106.13 73.96 0.31 Allowed Pre-proline 0 C--N 1.305 -1.343 0 O-C-N 121.263 -0.898 . . . . 50.0 110.579 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.7 Cg_endo -72.41 169.9 20.59 Favored 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 123.948 1.499 . . . . 50.0 110.166 179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.583 ' HG3' HG12 ' A' ' 60' ' ' VAL . 45.5 Cg_endo -72.18 136.93 27.79 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 123.983 1.517 . . . . 50.0 110.097 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -53.71 103.49 0.08 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.236 -0.915 . . . . 50.0 109.975 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.17 -173.04 33.46 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.421 -1.471 . . . . 50.0 109.421 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.539 ' CB ' ' CD2' ' A' ' 106' ' ' HIS . 35.0 p-10 -69.34 145.52 52.91 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.275 -1.132 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.588 ' HA ' ' N ' ' A' ' 53' ' ' SER . 1.4 p -143.0 140.85 31.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.276 -0.89 . . . . 50.0 110.368 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.549 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 0.5 OUTLIER -97.13 119.94 36.56 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.217 -0.927 . . . . 50.0 109.532 179.567 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.46 HG23 ' O ' ' A' ' 92' ' ' ILE . 2.4 tt -114.96 132.08 65.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.141 -0.975 . . . . 50.0 110.38 -179.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.623 ' HB ' HG22 ' A' ' 49' ' ' VAL . 45.3 t -120.74 120.81 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.054 -1.029 . . . . 50.0 110.405 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.768 HG13 HG12 ' A' ' 48' ' ' ILE . 62.0 t -109.0 99.64 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 50.0 110.107 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -153.64 160.44 29.28 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.616 -1.394 . . . . 50.0 109.616 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.463 ' SD ' ' HA ' ' A' ' 13' ' ' CYS . 4.4 ttm -115.5 -44.36 2.98 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.228 -1.16 . . . . 50.0 110.271 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -115.32 -115.17 2.99 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.805 -1.318 . . . . 50.0 109.805 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -88.34 -35.07 17.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.275 -1.133 . . . . 50.0 110.504 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.9 mmmm -79.51 116.12 19.54 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.139 -0.976 . . . . 50.0 110.248 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.798 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.76 150.21 44.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.565 HD12 ' N ' ' A' ' 101' ' ' ILE . 4.4 mp -111.36 106.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.005 -1.059 . . . . 0.0 109.905 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 102' ' ' ASN . 16.3 p30 -95.32 130.17 42.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.248 -0.907 . . . . 0.0 110.523 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.605 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -115.38 160.79 19.41 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.373 -0.83 . . . . 0.0 109.834 179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.549 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 7.4 p80 -121.6 86.64 2.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.198 -0.939 . . . . 0.0 110.386 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.496 ' O ' ' HA ' ' A' ' 89' ' ' ASP . 15.5 t-105 -58.06 93.59 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.308 -0.87 . . . . 0.0 110.051 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.539 ' CD2' ' CB ' ' A' ' 89' ' ' ASP . 1.6 t-80 -136.57 136.06 38.95 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.215 -0.928 . . . . 0.0 110.315 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -105.1 -8.05 18.72 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.874 . . . . 0.0 110.178 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -151.87 117.55 5.41 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.214 -0.929 . . . . 0.0 110.239 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -146.5 144.75 13.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -164.3 -179.9 6.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -1.171 . . . . 0.0 110.173 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 117.924 -1.036 . . . . 49.57 110.224 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.0 p30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.179 0.514 . . . . 50.0 110.234 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.8 ttmm -117.03 167.6 11.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.265 -0.897 . . . . 50.0 110.311 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -72.66 121.4 19.72 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.327 -0.858 . . . . 50.0 110.132 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -85.86 161.7 18.96 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.26 -0.9 . . . . 50.0 110.243 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 mt -98.85 71.38 1.9 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 50.0 110.197 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -105.17 160.03 15.39 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.232 -0.918 . . . . 50.0 110.293 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.32 -35.05 1.85 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.373 -1.491 . . . . 50.0 109.373 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.521 HG23 ' O ' ' A' ' 8' ' ' THR . 2.6 t -127.8 113.76 16.38 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.303 -1.116 . . . . 50.0 110.056 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.8 p -94.45 98.96 11.23 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.114 -0.991 . . . . 50.0 110.226 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -105.68 173.86 6.13 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 50.0 110.082 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.17 137.68 14.86 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.619 -1.392 . . . . 50.0 109.619 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.552 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.8 ptm -81.52 117.72 22.15 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.265 -1.138 . . . . 50.0 110.236 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.4 p -149.06 107.89 3.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.229 -0.919 . . . . 99.99 110.485 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.32 51.16 0.24 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.629 -1.294 . . . . 99.99 110.759 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.593 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 2.0 pt-20 -78.9 12.19 2.29 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.084 -1.01 . . . . 99.99 110.005 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.6 mptt -101.48 61.29 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.243 -0.911 . . . . 50.0 110.388 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.689 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -100.41 144.17 29.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.11 -0.994 . . . . 50.0 109.66 179.593 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.53 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 30.6 t -127.28 100.13 5.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.065 -1.022 . . . . 50.0 110.658 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.657 ' HB3' ' HE2' ' A' ' 103' ' ' HIS . 10.2 p90 -59.02 107.94 0.6 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.202 -0.936 . . . . 50.0 110.258 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -94.58 -23.51 17.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.248 -0.907 . . . . 50.0 109.824 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.475 ' HE3' ' OE1' ' A' ' 34' ' ' GLU . 13.0 mttt -142.11 143.81 33.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 50.0 110.084 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 43.9 p-10 -66.77 162.82 48.49 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 50.0 110.209 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 46.5 Cg_endo -73.0 135.07 22.52 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.947 1.498 . . . . 50.0 110.285 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -136.55 156.83 48.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.191 -0.943 . . . . 50.0 110.317 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.427 ' HA ' ' O ' ' A' ' 30' ' ' THR . 13.8 t70 -85.53 148.53 25.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.298 -0.876 . . . . 50.0 110.043 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.626 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -116.91 -5.89 11.48 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.251 -0.905 . . . . 50.0 110.194 179.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -172.67 -105.77 0.19 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.318 -1.513 . . . . 50.0 109.318 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.59 88.8 2.56 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.155 . . . . 50.0 110.024 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.429 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 97.93 31.23 6.72 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.557 -1.417 . . . . 50.0 109.557 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.62 HG23 ' H ' ' A' ' 26' ' ' THR . 0.8 OUTLIER -136.62 107.85 6.82 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.22 -1.164 . . . . 50.0 110.431 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.447 HG23 ' HD2' ' A' ' 85' ' ' PRO . 21.7 t -97.01 145.48 8.89 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.253 -0.905 . . . . 50.0 110.118 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.626 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -126.27 137.74 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.236 -0.915 . . . . 50.0 110.486 -179.834 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.816 HG23 HD11 ' A' ' 35' ' ' LEU . 3.3 tt -140.33 152.86 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 50.0 109.893 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.475 ' OE1' ' HE3' ' A' ' 21' ' ' LYS . 2.0 tt0 -127.02 108.04 10.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.154 -0.966 . . . . 50.0 110.304 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.055 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -122.7 138.97 54.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.252 -0.905 . . . . 50.0 109.544 179.588 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.9 OUTLIER -91.77 132.07 36.67 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.086 -1.009 . . . . 50.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.642 ' CD2' HG11 ' A' ' 70' ' ' VAL . 8.3 t80 -93.87 95.7 9.26 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.911 -1.115 . . . . 50.0 109.84 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 81.8 p -96.11 69.52 2.76 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.305 -0.872 . . . . 50.0 109.977 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -119.3 131.0 8.8 Favored Glycine 0 N--CA 1.487 2.086 0 N-CA-C 109.318 -1.513 . . . . 99.99 109.318 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.1 m -84.71 21.93 1.44 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.27 -1.135 . . . . 99.99 110.227 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.01 -2.09 44.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.918 . . . . 99.99 109.984 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.69 -159.39 31.74 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.597 -1.401 . . . . 99.99 109.597 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.595 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.6 Cg_endo -72.85 148.64 46.35 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.137 1.598 . . . . 99.99 110.497 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.736 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.5 OUTLIER -170.42 161.43 7.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.924 . . . . 50.0 110.129 -179.582 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.58 ' HD3' ' CB ' ' A' ' 69' ' ' PHE . 0.0 OUTLIER -74.81 128.3 35.24 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.091 -1.006 . . . . 50.0 109.563 179.35 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.993 ' CG2' HD11 ' A' ' 48' ' ' ILE . 9.6 mt -87.73 114.31 58.44 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.118 -0.989 . . . . 50.0 110.52 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.509 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.1 Cg_endo -76.88 101.72 1.54 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.063 1.56 . . . . 50.0 110.398 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.993 HD11 ' CG2' ' A' ' 46' ' ' ILE . 2.4 mp -129.04 155.11 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -0.927 . . . . 50.0 110.302 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 92' ' ' ILE . 14.8 p -130.65 145.32 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.294 -0.879 . . . . 50.0 109.814 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.452 ' HB2' ' C ' ' A' ' 61' ' ' GLY . 61.5 m -122.76 111.25 16.48 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.134 -0.979 . . . . 50.0 109.895 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 55' ' ' ASN . 35.9 m -135.91 161.49 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.257 -0.902 . . . . 50.0 110.561 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.688 ' HB3' ' ND2' ' A' ' 55' ' ' ASN . . . -56.2 164.44 1.29 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.471 -0.768 . . . . 50.0 110.097 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.655 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 1.3 m -60.31 114.64 3.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 50.0 110.292 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 79.72 30.49 0.27 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.548 -0.72 . . . . 50.0 110.498 179.776 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.688 ' ND2' ' HB3' ' A' ' 52' ' ' ALA . 7.6 m-20 -122.5 85.02 2.35 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 50.0 110.302 179.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -101.66 16.81 24.62 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.945 . . . . 50.0 110.059 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 ttt -126.12 -10.23 6.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.314 -0.866 . . . . 50.0 110.348 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.14 115.65 14.12 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.226 -0.921 . . . . 50.0 110.212 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.64 127.77 12.75 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.96 1.505 . . . . 50.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 2.2 m -148.07 -33.67 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.253 -0.904 . . . . 50.0 110.294 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.452 ' C ' ' HB2' ' A' ' 50' ' ' SER . . . -71.64 146.35 40.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HB2' ' A' ' 83' ' ' MET . 4.6 mtt180 -139.12 156.95 46.77 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.071 -1.252 . . . . 50.0 110.736 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.468 HD13 ' HD3' ' A' ' 68' ' ' PRO . 5.9 mt -88.34 141.5 28.5 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.26 -0.9 . . . . 50.0 109.975 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.528 ' CG1' ' OE1' ' A' ' 82' ' ' GLU . 92.5 t -85.42 -12.76 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.144 -0.973 . . . . 50.0 110.213 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.956 HG23 ' OE2' ' A' ' 82' ' ' GLU . 0.0 OUTLIER -111.54 175.74 5.3 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.23 -0.919 . . . . 50.0 110.152 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 24.2 m -58.14 176.16 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.296 -0.877 . . . . 50.0 110.067 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.62 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 75.3 m-20 -46.83 141.92 5.24 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.208 -0.932 . . . . 50.0 109.992 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.482 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 50.2 Cg_endo -76.81 70.04 6.65 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.93 1.489 . . . . 50.0 110.896 -179.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 11.2 p90 -110.11 129.67 55.66 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.057 -1.027 . . . . 50.0 110.269 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.993 ' CG2' HD11 ' A' ' 46' ' ' ILE . 94.0 t -85.65 60.84 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 50.0 110.097 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.595 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -87.77 57.4 4.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.172 -0.955 . . . . 50.0 110.006 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.71 169.63 17.39 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.269 -0.894 . . . . 50.0 110.288 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 12.1 p -97.43 -4.34 38.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 50.0 109.833 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 93.2 p -121.19 9.47 10.46 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.324 -0.86 . . . . 99.99 110.538 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.929 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -78.51 8.11 5.69 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.047 -1.033 . . . . 99.99 109.941 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 20.1 m-80 -86.11 20.03 2.44 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.227 -0.92 . . . . 99.99 109.281 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.664 ' O ' ' HA ' ' A' ' 36' ' ' SER . 3.7 m -124.41 -173.08 2.69 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.386 -0.821 . . . . 99.99 109.359 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.54 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.0 OUTLIER -63.19 88.62 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.42 -0.8 . . . . 99.99 109.267 179.564 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 1.055 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.3 m -76.68 174.62 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.359 -0.838 . . . . 99.99 109.658 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.406 HD23 ' O ' ' A' ' 33' ' ' ILE . 0.6 OUTLIER -125.74 131.74 52.47 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.933 -1.104 . . . . 50.0 110.786 -179.76 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -125.46 176.62 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 109.917 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.956 ' OE2' HG23 ' A' ' 65' ' ' THR . 8.4 pt-20 -160.22 156.26 26.25 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -0.998 . . . . 50.0 110.354 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.568 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 0.8 OUTLIER -160.05 140.12 11.56 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.301 -0.875 . . . . 50.0 110.291 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.429 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -104.11 86.36 1.28 Allowed Pre-proline 0 C--N 1.305 -1.338 0 O-C-N 121.386 -0.821 . . . . 50.0 110.466 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.568 ' HD3' ' O ' ' A' ' 83' ' ' MET . 45.4 Cg_endo -71.44 170.16 19.11 Favored 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.818 1.431 . . . . 50.0 110.409 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.13 163.2 39.44 Favored 'Trans proline' 0 C--N 1.304 -1.814 0 O-C-N 124.036 1.545 . . . . 50.0 110.414 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 1.1 m-85 -52.56 127.68 23.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.301 -0.874 . . . . 50.0 110.036 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.94 152.95 12.83 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.601 ' HB3' ' CD2' ' A' ' 106' ' ' HIS . 13.8 p30 -53.05 155.12 2.64 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.199 -1.177 . . . . 50.0 110.195 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.642 ' HA ' ' N ' ' A' ' 53' ' ' SER . 11.9 p -141.47 153.32 44.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.254 -0.904 . . . . 50.0 110.386 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.594 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 3.5 m-30 -104.72 119.72 39.67 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.253 -0.905 . . . . 50.0 110.119 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.789 HD13 ' N ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.91 129.7 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.166 -0.959 . . . . 50.0 110.027 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.789 ' N ' HD13 ' A' ' 92' ' ' ILE . 21.2 t -115.56 139.19 43.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.157 -0.965 . . . . 50.0 110.536 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.982 HG22 HG12 ' A' ' 48' ' ' ILE . 53.8 t -120.91 104.03 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.409 -0.807 . . . . 50.0 110.081 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.532 ' HA3' ' HB3' ' A' ' 100' ' ' GLN . . . -155.95 168.55 33.46 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.708 -1.357 . . . . 50.0 109.708 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.593 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 26.5 ttm -98.36 -71.41 0.69 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.244 -1.151 . . . . 50.0 110.296 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.95 36.38 0.3 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.508 -1.437 . . . . 50.0 109.508 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.44 ' OD1' ' OE1' ' A' ' 15' ' ' GLU . 0.9 OUTLIER -162.18 -46.96 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.328 -1.101 . . . . 50.0 109.823 179.927 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.53 129.93 39.72 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.364 -0.835 . . . . 50.0 109.709 179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.783 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -139.96 150.42 44.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.707 -179.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 1.4 mp -112.08 123.91 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.131 -0.98 . . . . 0.0 109.761 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.514 ' CB ' HG22 ' A' ' 93' ' ' VAL . 9.4 p30 -101.0 139.44 36.68 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.17 -0.956 . . . . 0.0 110.686 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.657 ' HE2' ' HB3' ' A' ' 19' ' ' PHE . 5.6 m-70 -120.41 160.93 22.1 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.416 -0.802 . . . . 0.0 109.856 179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.567 ' O ' ' CD2' ' A' ' 104' ' ' HIS . 51.7 p-80 -118.38 92.28 3.78 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.204 -0.935 . . . . 0.0 110.509 -179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . . . . . . . . . 2.3 t-105 -67.93 111.27 4.27 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.158 -0.964 . . . . 0.0 110.035 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.601 ' CD2' ' HB3' ' A' ' 89' ' ' ASP . 0.1 OUTLIER -131.22 138.89 49.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.248 -179.895 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 6.3 tttm -72.36 -9.74 58.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.244 -0.91 . . . . 0.0 110.246 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.404 ' HB2' ' O ' ' A' ' 107' ' ' LYS . . . -176.47 151.85 1.0 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.305 -0.872 . . . . 0.0 110.141 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -130.02 -173.61 13.45 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -141.65 43.3 1.73 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.332 -1.099 . . . . 0.0 110.217 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.011 -0.995 . . . . 49.57 110.222 179.99 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 47.0 p30 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.189 0.518 . . . . 50.0 110.181 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.1 tptt -123.43 133.71 54.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.274 -0.891 . . . . 50.0 110.271 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.503 ' N ' HD23 ' A' ' 3' ' ' LEU . 0.3 OUTLIER -126.86 95.39 4.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 50.0 110.156 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -84.3 172.86 11.45 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -0.933 . . . . 50.0 110.306 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.19 132.69 54.12 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.184 -0.947 . . . . 50.0 110.132 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.28 -165.12 1.15 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 50.0 110.193 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -104.41 82.73 0.37 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.538 -1.425 . . . . 50.0 109.538 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 2.5 m -83.75 153.54 24.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.203 -1.175 . . . . 50.0 110.388 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 99.2 m -74.66 100.84 4.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.292 -0.88 . . . . 50.0 110.174 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -133.23 152.73 51.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 50.0 110.213 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.34 111.03 3.42 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.48 -1.448 . . . . 50.0 109.48 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.511 ' HG2' ' CG ' ' A' ' 45' ' ' LYS . 29.4 mtt -73.81 117.58 15.75 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.19 -1.182 . . . . 50.0 110.241 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.644 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 12.2 p -148.75 107.55 3.84 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.054 -1.029 . . . . 99.99 110.558 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.694 HG21 HG12 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -161.75 35.84 0.13 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.006 -1.059 . . . . 99.99 110.213 179.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.611 ' HG2' ' HE3' ' A' ' 96' ' ' MET . 1.1 pp20? -66.52 -5.44 11.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 99.99 110.451 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.563 ' HB2' ' CE1' ' A' ' 37' ' ' TYR . 8.8 mmtm -89.28 61.51 5.73 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 50.0 110.542 -179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.912 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.0 OUTLIER -95.02 141.78 28.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.102 -0.999 . . . . 50.0 110.128 179.683 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.521 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.12 97.9 4.93 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.403 -0.811 . . . . 50.0 110.035 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.67 ' CE2' ' CD2' ' A' ' 103' ' ' HIS . 10.5 p90 -59.53 123.92 18.41 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.021 -1.049 . . . . 50.0 110.457 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.614 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -107.4 -23.96 12.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.335 -0.853 . . . . 50.0 109.969 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 11.8 mtmt -142.33 151.5 42.01 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.304 -0.873 . . . . 50.0 110.105 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 72.6 m-20 -67.53 162.31 57.75 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 50.0 110.153 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.574 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.1 Cg_endo -71.86 127.79 13.39 Favored 'Trans proline' 0 C--N 1.303 -1.816 0 O-C-N 124.052 1.554 . . . . 50.0 110.3 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -122.98 147.83 46.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.257 -0.902 . . . . 50.0 110.37 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 30' ' ' THR . 18.5 t0 -87.75 148.11 24.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.885 . . . . 50.0 110.143 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.16 -69.55 0.86 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.125 -0.984 . . . . 50.0 110.237 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.41 -101.81 1.58 Allowed Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.533 -1.427 . . . . 50.0 109.533 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 34.0 t60 -131.96 89.01 2.62 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -1.152 . . . . 50.0 110.342 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 100.15 5.92 54.18 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.661 -1.375 . . . . 50.0 109.661 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.522 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 14.4 p -101.9 107.67 18.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.212 -1.169 . . . . 50.0 110.166 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.574 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 39.0 t -102.53 139.85 22.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.177 -0.952 . . . . 50.0 110.19 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.431 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -123.13 150.69 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.18 -0.95 . . . . 50.0 110.319 -179.968 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.929 HG23 HD11 ' A' ' 35' ' ' LEU . 0.6 OUTLIER -136.96 154.03 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.399 -0.813 . . . . 50.0 109.75 179.689 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.614 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.1 tp10 -119.55 91.44 3.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.129 -0.982 . . . . 50.0 110.9 -179.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.95 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -119.03 138.79 52.6 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.289 -0.882 . . . . 50.0 109.081 179.274 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -93.78 135.16 35.37 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.06 -1.025 . . . . 50.0 110.175 -179.483 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.563 ' CE1' ' HB2' ' A' ' 16' ' ' LYS . 5.8 t80 -94.38 103.34 15.33 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 118.964 -1.094 . . . . 50.0 109.558 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.82 69.6 3.38 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.22 -0.925 . . . . 50.0 110.038 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.483 ' HA3' ' CZ ' ' A' ' 37' ' ' TYR . . . -118.46 139.33 14.47 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.439 -1.464 . . . . 99.99 109.439 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 40' ' ' SER . 2.6 t -82.95 31.08 0.43 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -1.124 . . . . 99.99 110.298 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.477 ' HB3' ' SG ' ' A' ' 13' ' ' CYS . 0.6 OUTLIER -108.33 -11.96 15.12 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 99.99 110.243 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.31 -139.84 19.31 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.488 -1.445 . . . . 99.99 109.488 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.478 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.0 Cg_endo -71.16 139.67 35.92 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.987 1.52 . . . . 99.99 110.248 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.625 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -169.38 157.57 7.51 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -0.867 . . . . 50.0 110.014 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.563 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 35.3 mmtt -76.34 129.15 36.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.151 -0.968 . . . . 50.0 109.178 178.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.931 HD11 HG22 ' A' ' 70' ' ' VAL . 10.3 mt -86.34 109.36 22.75 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 50.0 110.714 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.563 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 52.3 Cg_endo -78.98 99.42 1.26 Allowed 'Trans proline' 0 C--N 1.308 -1.595 0 O-C-N 124.056 1.556 . . . . 50.0 110.129 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.066 HG23 HD11 ' A' ' 92' ' ' ILE . 6.9 mt -136.11 144.01 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.072 -1.018 . . . . 50.0 110.471 -179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.459 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 23.0 m -116.19 148.54 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.399 -0.813 . . . . 50.0 109.835 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.5 OUTLIER -124.19 105.8 9.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.146 -0.971 . . . . 50.0 109.86 -179.932 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.489 ' O ' ' N ' ' A' ' 91' ' ' TYR . 4.3 m -129.7 159.49 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.281 -0.887 . . . . 50.0 110.34 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.437 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -55.94 163.72 1.41 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.331 -0.856 . . . . 50.0 110.027 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.602 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 37.6 t -58.44 122.25 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.26 -0.9 . . . . 50.0 110.739 -179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.602 ' CB ' ' O ' ' A' ' 53' ' ' SER . 1.2 tp 78.32 30.56 0.41 Allowed 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.919 -0.712 . . . . 50.0 110.827 179.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.419 ' CG ' ' HB3' ' A' ' 52' ' ' ALA . 10.3 m120 -126.66 84.11 2.23 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.168 -0.957 . . . . 50.0 110.198 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -106.42 8.61 31.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.279 -0.888 . . . . 50.0 109.917 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 1.7 ttm -116.11 -13.26 11.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.418 -0.801 . . . . 50.0 110.131 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.16 134.06 19.96 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.368 -0.832 . . . . 50.0 110.104 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.79 134.75 22.41 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.941 1.495 . . . . 50.0 110.258 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.412 HG11 ' HB2' ' A' ' 52' ' ' ALA . 55.3 t -139.31 -46.87 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.237 -0.914 . . . . 50.0 109.848 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -75.43 156.35 48.27 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.67 -1.772 . . . . 50.0 108.67 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.45 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 15.3 mtp180 -138.04 157.15 46.94 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.881 -1.364 . . . . 50.0 110.722 -179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.754 HD22 ' HD3' ' A' ' 68' ' ' PRO . 1.1 mp -91.3 134.65 34.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 50.0 109.737 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.544 HG23 ' C ' ' A' ' 83' ' ' MET . 4.0 t -72.83 -40.91 61.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.167 -0.958 . . . . 50.0 110.147 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 ' OE1' ' A' ' 82' ' ' GLU . 14.9 t -103.43 175.79 5.36 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.17 -0.956 . . . . 50.0 110.165 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 66' ' ' VAL . 6.5 m -54.76 -172.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.394 -0.816 . . . . 50.0 110.098 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.603 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 1.8 m-20 -47.45 137.78 8.96 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.952 . . . . 50.0 110.073 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.754 ' HD3' HD22 ' A' ' 63' ' ' LEU . 48.0 Cg_endo -75.14 74.32 4.11 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.974 1.513 . . . . 50.0 110.707 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.603 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 7.7 p90 -107.27 141.32 38.78 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.141 -0.974 . . . . 50.0 110.282 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.931 HG22 HD11 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -103.69 60.26 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 50.0 109.358 179.398 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -69.67 57.86 0.13 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.359 -0.838 . . . . 50.0 110.364 -179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.427 ' N ' ' O ' ' A' ' 70' ' ' VAL . 0.0 OUTLIER -142.38 165.09 28.37 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 50.0 110.104 -179.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.68 7.32 17.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.151 -0.968 . . . . 50.0 110.117 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 8.0 t -121.47 17.62 11.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.26 -0.9 . . . . 99.99 110.488 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 70' ' ' VAL . . . -69.03 -4.11 15.68 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.153 -0.967 . . . . 99.99 109.93 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.471 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 64.1 m-80 -88.58 24.01 2.09 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.364 -0.835 . . . . 99.99 109.416 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.622 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -129.31 -173.19 2.93 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.368 -0.832 . . . . 99.99 109.442 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.52 ' N ' ' OG ' ' A' ' 77' ' ' SER . 0.1 OUTLIER -63.7 88.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.313 -0.867 . . . . 99.99 109.114 179.507 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.95 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.8 m -76.45 174.35 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.292 -0.88 . . . . 99.99 109.199 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.431 HD21 HG12 ' A' ' 32' ' ' VAL . 1.3 tt -134.71 136.6 42.84 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.736 -1.227 . . . . 50.0 111.084 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.571 HG21 ' HE2' ' A' ' 17' ' ' PHE . 2.1 t -117.33 166.73 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.456 -0.777 . . . . 50.0 109.751 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.545 ' OE1' HG21 ' A' ' 65' ' ' THR . 5.6 mt-10 -134.75 146.34 49.29 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.071 -1.018 . . . . 50.0 110.271 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.544 ' C ' HG23 ' A' ' 64' ' ' VAL . 0.0 OUTLIER -159.95 151.64 20.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.18 -0.95 . . . . 50.0 110.347 179.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.507 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -120.93 60.94 9.11 Favored Pre-proline 0 C--N 1.306 -1.286 0 O-C-N 121.239 -0.913 . . . . 50.0 110.509 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.429 ' HD3' ' C ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.34 158.78 47.94 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.073 1.565 . . . . 50.0 110.201 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -71.88 146.76 48.42 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 124.044 1.549 . . . . 50.0 110.453 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -52.97 146.89 10.14 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.269 -0.894 . . . . 50.0 110.062 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 122.71 172.75 14.03 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.394 -1.482 . . . . 50.0 109.394 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.469 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 11.4 m-20 -71.73 128.55 36.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.208 -1.171 . . . . 50.0 110.161 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.567 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.6 p -124.82 141.86 51.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 50.0 110.157 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.605 ' CE1' ' CB ' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -99.69 116.66 32.3 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.221 -0.924 . . . . 50.0 110.035 179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 1.066 HD11 HG23 ' A' ' 48' ' ' ILE . 0.0 OUTLIER -103.83 133.88 46.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.237 -0.914 . . . . 50.0 109.947 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.899 ' N ' HD13 ' A' ' 92' ' ' ILE . 11.1 t -118.33 119.7 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.572 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.841 HG11 ' HB2' ' A' ' 17' ' ' PHE . 33.6 t -100.6 103.34 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.327 -0.858 . . . . 50.0 109.958 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.434 ' O ' ' HB2' ' A' ' 47' ' ' PRO . . . -155.25 147.78 17.2 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.484 -1.446 . . . . 50.0 109.484 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.611 ' HE3' ' HG2' ' A' ' 15' ' ' GLU . 12.3 ptp -102.28 1.71 36.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.257 -1.143 . . . . 50.0 110.224 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 141.89 -60.05 0.55 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.547 -1.421 . . . . 50.0 109.547 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.38 -77.61 0.23 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.23 -1.159 . . . . 50.0 110.205 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 2.5 mmtt -79.57 124.0 28.11 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.221 -0.925 . . . . 50.0 110.313 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.603 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.19 148.56 41.75 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.267 -0.895 . . . . 0.0 110.249 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.1 pt -137.29 130.13 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.243 -0.91 . . . . 0.0 110.232 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.451 ' CB ' HG22 ' A' ' 93' ' ' VAL . 34.0 p-10 -109.46 132.31 54.25 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.21 -0.932 . . . . 0.0 110.394 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.67 ' CD2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -122.12 169.9 10.4 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.24 -0.912 . . . . 0.0 110.061 179.866 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.605 ' CB ' ' CE1' ' A' ' 91' ' ' TYR . 45.5 p-80 -118.68 123.89 46.03 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.213 -0.929 . . . . 0.0 110.4 -179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.693 ' CH2' HD13 ' A' ' 33' ' ' ILE . 26.1 m0 -106.55 145.1 32.29 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.294 -0.879 . . . . 0.0 110.23 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.413 ' CD2' ' H ' ' A' ' 106' ' ' HIS . 9.6 p80 -125.13 123.41 39.63 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.249 -0.907 . . . . 0.0 110.255 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -112.94 -6.6 13.76 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.246 -0.909 . . . . 0.0 110.245 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -174.57 111.94 0.15 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 110.038 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -133.66 165.51 24.16 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.7 t -82.57 132.0 35.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.319 -1.107 . . . . 0.0 110.17 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.002 -0.999 . . . . 49.57 110.294 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 121.158 0.504 . . . . 50.0 110.218 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -112.45 136.8 51.5 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.32 -0.862 . . . . 50.0 110.245 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.519 ' HA ' HD12 ' A' ' 3' ' ' LEU . 15.7 tp -82.07 142.21 32.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.274 -0.891 . . . . 50.0 110.043 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.43 149.54 36.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.194 -0.941 . . . . 50.0 110.434 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.2 mt -111.24 120.11 41.16 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.324 -0.86 . . . . 50.0 110.307 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 18.0 mttt -101.06 -170.21 1.81 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.275 -0.891 . . . . 50.0 110.03 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.74 20.47 44.82 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.588 -1.405 . . . . 50.0 109.588 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.1 p -83.88 161.43 20.87 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.31 -1.112 . . . . 50.0 110.188 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 11.9 t -72.74 169.66 16.23 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.208 -0.933 . . . . 50.0 110.165 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -154.37 177.39 11.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.195 -0.941 . . . . 50.0 110.267 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.88 104.73 2.8 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.518 -1.433 . . . . 50.0 109.518 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.52 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 1.1 mtm -98.08 96.66 8.28 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.314 -1.109 . . . . 50.0 110.025 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.707 ' O ' ' CB ' ' A' ' 44' ' ' CYS . 12.0 p -148.89 107.23 3.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.067 -1.021 . . . . 99.99 110.785 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.634 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -160.76 31.8 0.15 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.672 -1.267 . . . . 99.99 110.489 179.945 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HA2' ' A' ' 95' ' ' GLY . 10.3 tm-20 -71.01 -0.38 9.26 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.139 -0.976 . . . . 99.99 110.106 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -87.94 61.68 6.49 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.254 -0.904 . . . . 50.0 110.403 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.605 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -94.72 146.28 24.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.894 . . . . 50.0 109.887 179.632 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.585 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 57.8 m -127.4 100.17 5.93 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.043 . . . . 50.0 110.659 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.719 ' CD1' HD23 ' A' ' 35' ' ' LEU . 16.1 m-85 -57.2 115.24 2.55 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.193 -0.942 . . . . 50.0 109.802 179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -102.81 -27.0 12.94 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.24 -0.912 . . . . 50.0 110.476 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.472 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 4.9 mttt -145.53 151.43 38.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.183 -0.948 . . . . 50.0 110.23 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.1 p30 -67.09 154.97 91.53 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.234 -0.916 . . . . 50.0 110.232 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.556 ' HD2' ' CE3' ' A' ' 105' ' ' TRP . 46.6 Cg_endo -73.24 141.2 31.91 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 O-C-N 124.097 1.577 . . . . 50.0 110.419 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.477 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -146.63 168.07 22.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.274 -0.891 . . . . 50.0 110.29 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -89.07 154.62 20.04 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 50.0 110.341 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.63 -48.06 1.4 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.307 -0.87 . . . . 50.0 110.074 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -115.52 -101.48 2.32 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.453 -1.459 . . . . 50.0 109.453 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -133.15 93.69 3.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -1.155 . . . . 50.0 110.23 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.6 19.75 57.68 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 50.0 109.568 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 70.7 p -115.35 107.83 15.73 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.28 -1.129 . . . . 50.0 110.283 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 98.7 t -85.32 143.82 10.85 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.251 -0.906 . . . . 50.0 110.174 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 23' ' ' PRO . 0.0 OUTLIER -125.14 149.32 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.213 -0.929 . . . . 50.0 110.409 -179.884 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.799 HG23 HD11 ' A' ' 35' ' ' LEU . 2.0 tt -152.51 163.4 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -0.851 . . . . 50.0 109.906 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.803 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.6 OUTLIER -132.46 102.07 5.59 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.12 -0.988 . . . . 50.0 110.502 -179.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.862 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.2 OUTLIER -119.12 139.91 51.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.314 -0.867 . . . . 50.0 109.165 179.393 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.7 OUTLIER -92.46 131.44 37.61 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.041 -1.037 . . . . 50.0 110.068 -179.457 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.613 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.6 t80 -92.12 98.79 11.76 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 118.984 -1.086 . . . . 50.0 109.497 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 3.1 t -96.11 69.76 2.77 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.318 -0.864 . . . . 50.0 110.028 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -118.46 132.22 9.63 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.631 -1.388 . . . . 99.99 109.631 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 45.3 m -83.95 18.5 2.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.231 -1.158 . . . . 99.99 110.317 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -99.92 -1.08 38.17 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.241 -0.912 . . . . 99.99 110.225 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.6 -149.93 29.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.105 -1.598 . . . . 99.99 109.105 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.59 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.9 Cg_endo -73.35 150.67 47.19 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.916 1.482 . . . . 99.99 110.406 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.707 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -169.87 161.48 9.0 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.377 -0.827 . . . . 50.0 109.96 -179.487 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.653 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 24.0 mmtt -75.61 111.03 10.51 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.018 -1.051 . . . . 50.0 109.229 178.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.014 HD11 HG23 ' A' ' 70' ' ' VAL . 2.2 mt -72.29 110.66 8.5 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.966 . . . . 50.0 110.423 -179.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 50.3 Cg_endo -84.54 97.67 0.7 Allowed 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 124.026 1.54 . . . . 50.0 110.652 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.824 ' CD1' HG22 ' A' ' 46' ' ' ILE . 24.2 mt -133.33 153.76 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 50.0 110.243 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.738 ' O ' HG13 ' A' ' 49' ' ' VAL . 11.2 p -125.78 110.97 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 50.0 110.23 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.456 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -91.52 100.74 13.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 50.0 109.751 179.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.656 HG23 HG22 ' A' ' 49' ' ' VAL . 24.8 t -122.2 155.2 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.235 -0.916 . . . . 50.0 110.223 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.544 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -60.92 164.36 4.97 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.204 -0.935 . . . . 50.0 109.208 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.65 ' N ' ' HA ' ' A' ' 90' ' ' SER . 16.8 t -71.53 101.27 2.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.721 -1.237 . . . . 50.0 108.936 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.553 ' HB2' ' O ' ' A' ' 53' ' ' SER . 5.0 tp 170.68 -61.67 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 C-N-CA 118.071 -1.451 . . . . 50.0 111.661 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 58' ' ' THR . 60.4 m-20 -92.92 149.92 20.93 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.904 -1.123 . . . . 50.0 110.273 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -106.12 -20.61 13.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.226 -0.921 . . . . 50.0 110.187 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 15.9 ttp -126.55 31.31 5.38 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.282 -0.886 . . . . 50.0 110.27 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.536 ' O ' ' CG1' ' A' ' 51' ' ' VAL . 59.6 m -126.87 120.62 22.81 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.225 -0.922 . . . . 50.0 110.171 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.5 126.0 11.16 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.968 1.509 . . . . 50.0 110.212 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 24.4 t -135.02 -47.77 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.91 . . . . 50.0 110.05 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.43 158.8 49.45 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.133 -1.587 . . . . 50.0 109.133 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.444 ' O ' ' HB2' ' A' ' 83' ' ' MET . 21.4 mtm180 -132.6 154.76 49.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.138 -1.213 . . . . 50.0 110.555 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.6 mt -94.15 129.67 40.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.383 -0.823 . . . . 50.0 109.866 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.527 HG23 ' HG2' ' A' ' 84' ' ' GLU . 24.2 t -80.84 -32.85 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.184 -0.948 . . . . 50.0 110.38 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' VAL . 15.2 t -79.33 168.35 19.64 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -0.964 . . . . 50.0 110.099 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.45 ' H ' HG13 ' A' ' 66' ' ' VAL . 7.3 m -50.99 179.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.191 -0.943 . . . . 50.0 110.057 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.64 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 14.1 m120 -46.96 143.62 4.34 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.204 -0.935 . . . . 50.0 110.058 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.873 ' C ' HD12 ' A' ' 46' ' ' ILE . 47.0 Cg_endo -73.56 66.42 4.65 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.963 1.507 . . . . 50.0 110.583 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.653 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 18.2 m-30 -118.3 121.84 41.42 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.895 . . . . 50.0 110.12 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.014 HG23 HD11 ' A' ' 46' ' ' ILE . 42.9 t -77.55 60.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.119 -0.988 . . . . 50.0 109.99 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.59 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -85.37 59.37 5.59 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.15 -0.969 . . . . 50.0 110.185 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -142.95 165.46 27.29 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 50.0 110.388 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -94.42 -4.4 48.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.308 -0.87 . . . . 50.0 110.005 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.62 7.91 11.16 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.304 -0.872 . . . . 99.99 110.204 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.985 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.05 8.58 3.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 99.99 110.102 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.8 m-80 -86.56 19.29 2.91 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.266 -0.896 . . . . 99.99 109.25 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.589 ' O ' ' HA ' ' A' ' 36' ' ' SER . 19.1 p -128.68 -172.36 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.463 -0.773 . . . . 99.99 109.41 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.529 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 4.6 mttp -62.91 88.72 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.467 -0.893 . . . . 99.99 109.283 179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.862 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.9 m -76.43 173.85 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.318 -0.864 . . . . 99.99 109.418 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.48 ' HG ' ' O ' ' A' ' 33' ' ' ILE . 5.7 tt -126.18 125.56 42.66 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.933 -1.104 . . . . 50.0 111.026 -179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.541 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.2 t -122.29 166.03 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.387 -0.821 . . . . 50.0 109.868 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.431 ' OE1' ' C ' ' A' ' 81' ' ' VAL . 3.1 pm0 -147.4 160.29 42.73 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.181 -0.949 . . . . 50.0 110.393 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.509 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 2.5 ptt? -157.07 158.98 37.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 50.0 110.202 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 64' ' ' VAL . 0.4 OUTLIER -115.86 57.05 1.31 Allowed Pre-proline 0 C--N 1.307 -1.247 0 O-C-N 121.111 -0.993 . . . . 50.0 110.746 -179.781 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.509 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.9 Cg_endo -71.44 170.48 18.35 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.936 1.493 . . . . 50.0 110.5 179.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -70.36 161.67 45.16 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.998 1.525 . . . . 50.0 110.439 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -74.88 144.67 43.25 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.272 -0.893 . . . . 50.0 110.155 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.38 178.87 16.62 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.285 -1.526 . . . . 50.0 109.285 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -67.85 131.21 45.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 50.0 110.102 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.65 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -120.28 140.71 50.82 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.25 -0.906 . . . . 50.0 110.351 -179.912 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.637 ' C ' HD13 ' A' ' 92' ' ' ILE . 3.8 m-30 -94.02 104.72 16.75 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.215 -0.928 . . . . 50.0 109.788 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.65 ' N ' HD13 ' A' ' 92' ' ' ILE . 3.2 mm -97.88 125.54 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.265 -0.897 . . . . 50.0 109.918 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.506 HG22 ' CB ' ' A' ' 102' ' ' ASN . 21.2 t -125.2 125.05 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.069 -1.02 . . . . 50.0 110.825 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 48' ' ' ILE . 95.4 t -106.87 105.01 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.858 . . . . 50.0 109.785 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.5 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.43 155.64 24.19 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.963 -1.255 . . . . 50.0 109.963 -179.549 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.503 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 3.7 ttm -111.17 -69.21 0.88 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.39 -1.065 . . . . 50.0 110.297 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -163.71 28.55 0.23 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.62 -1.392 . . . . 50.0 109.62 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -160.56 -50.91 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.173 -1.192 . . . . 50.0 110.241 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -126.16 149.34 49.05 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.301 -0.875 . . . . 50.0 110.164 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.599 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.99 148.92 42.59 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 110.481 -179.876 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.712 HD13 ' N ' ' A' ' 102' ' ' ASN . 0.0 OUTLIER -126.2 124.23 65.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.331 -0.856 . . . . 0.0 109.552 179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.712 ' N ' HD13 ' A' ' 101' ' ' ILE . 23.0 p-10 -111.26 134.83 52.55 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.073 -1.017 . . . . 0.0 110.843 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.707 ' CE1' HD11 ' A' ' 101' ' ' ILE . 0.1 OUTLIER -127.59 124.09 37.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.105 179.608 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 -78.9 98.44 6.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.375 -0.828 . . . . 0.0 110.337 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.556 ' CE3' ' HD2' ' A' ' 23' ' ' PRO . 8.1 m95 -94.51 160.99 14.4 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.266 -0.896 . . . . 0.0 110.477 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 32.5 p-80 -150.82 136.72 18.24 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.293 -0.88 . . . . 0.0 109.986 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . 0.401 ' O ' ' HG2' ' A' ' 107' ' ' LYS . 1.4 ttpm? -98.84 -9.02 24.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 -179.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -100.44 126.66 46.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.942 . . . . 0.0 110.301 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -90.74 96.28 2.18 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 11.3 m -111.1 -68.9 0.9 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 117.97 -1.014 . . . . 49.57 110.329 -179.91 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.401 ' OD2' ' O ' ' A' ' 1' ' ' ASP . 4.7 p-10 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.214 0.531 . . . . 50.0 110.248 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.0 tptm -129.24 152.74 48.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.211 -0.931 . . . . 50.0 110.181 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 5.0 mt -103.97 137.31 42.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 110.149 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.89 143.22 49.04 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.224 -0.922 . . . . 50.0 110.258 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -94.1 77.99 4.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 50.0 110.233 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 158.71 15.3 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.282 -0.886 . . . . 50.0 110.135 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -116.33 87.13 0.43 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.592 -1.403 . . . . 50.0 109.592 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -75.81 148.81 38.14 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.214 -1.168 . . . . 50.0 110.15 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 70.7 p -80.46 99.2 7.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 50.0 110.401 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 -153.47 157.66 40.19 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.231 -0.918 . . . . 50.0 109.993 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -91.41 139.63 14.85 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.759 -1.337 . . . . 50.0 109.759 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.615 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 10.4 mtp -73.31 109.33 6.75 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.305 -1.115 . . . . 50.0 110.045 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 9.7 p -148.95 107.35 3.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.994 -1.066 . . . . 99.99 111.196 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.67 HG23 ' CE1' ' A' ' 37' ' ' TYR . 2.6 m -161.58 53.95 0.26 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.731 -1.231 . . . . 99.99 110.549 179.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HB3' ' CB ' ' A' ' 96' ' ' MET . 18.7 pt-20 -75.29 4.72 6.61 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.089 -1.007 . . . . 99.99 110.181 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.541 ' HD2' ' CA ' ' A' ' 39' ' ' GLY . 6.3 mttp -92.36 61.31 3.8 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.216 -0.927 . . . . 50.0 110.397 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 1.018 ' CE2' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -96.65 145.87 25.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.05 -1.031 . . . . 50.0 109.926 179.647 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.584 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.1 OUTLIER -127.17 104.42 7.95 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.209 -0.932 . . . . 50.0 110.392 -179.743 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.591 ' CD1' HD23 ' A' ' 35' ' ' LEU . 22.6 m-85 -60.97 96.87 0.05 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.248 -0.908 . . . . 50.0 110.39 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.516 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.67 -29.21 25.84 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.221 -0.924 . . . . 50.0 110.01 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.522 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 14.4 mttm -144.68 147.03 32.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 50.0 110.091 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -73.79 162.12 75.57 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 50.0 110.163 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.616 ' HG2' ' CD2' ' A' ' 105' ' ' TRP . 44.8 Cg_endo -72.44 131.8 18.13 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 124.023 1.538 . . . . 50.0 110.222 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -126.25 147.86 49.6 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.183 -0.948 . . . . 50.0 110.358 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -77.81 113.76 16.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.314 -0.866 . . . . 50.0 110.186 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 32' ' ' VAL . 0.2 OUTLIER -79.19 -14.22 59.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 50.0 110.343 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.74 -106.58 0.22 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.513 -1.435 . . . . 50.0 109.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . 0.465 ' O ' ' ND1' ' A' ' 28' ' ' HIS . 9.4 p80 -121.98 102.67 8.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.255 -1.144 . . . . 50.0 110.264 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 81.92 23.93 56.47 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.654 -1.378 . . . . 50.0 109.654 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 30.5 p -129.88 107.89 9.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.168 -1.195 . . . . 50.0 110.338 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.552 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -111.22 135.32 50.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 O-C-N 121.291 -0.881 . . . . 50.0 109.793 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 80' ' ' LEU . 1.4 t -114.65 136.75 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 50.0 110.542 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.03 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -141.89 133.2 26.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.459 -0.775 . . . . 50.0 109.499 179.784 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.574 ' N ' HD13 ' A' ' 33' ' ' ILE . 34.0 tt0 -112.21 117.52 32.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.141 -0.974 . . . . 50.0 111.274 -179.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.03 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.76 143.77 51.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.363 -0.836 . . . . 50.0 108.969 178.945 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -95.61 132.42 40.78 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.98 -1.075 . . . . 50.0 110.209 -179.525 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.688 ' CD2' HG11 ' A' ' 70' ' ' VAL . 6.9 t80 -95.02 99.6 11.58 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.253 -0.979 . . . . 50.0 109.731 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.1 t -95.93 69.82 2.86 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.202 -0.936 . . . . 50.0 110.144 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.541 ' CA ' ' HD2' ' A' ' 16' ' ' LYS . . . -120.72 118.08 3.71 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.51 -1.436 . . . . 99.99 109.51 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.8 p -85.39 21.81 1.67 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.238 -1.154 . . . . 99.99 110.419 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.87 -0.52 50.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 99.99 110.024 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.69 -172.54 26.11 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.435 -1.466 . . . . 99.99 109.435 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.561 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 42.8 Cg_endo -70.82 152.69 64.04 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.893 1.47 . . . . 99.99 110.195 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.73 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.04 161.59 8.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.223 -0.923 . . . . 50.0 109.902 -179.385 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.615 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 0.7 OUTLIER -77.29 129.18 35.54 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.159 -0.963 . . . . 50.0 109.583 179.373 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.049 HG22 ' CD1' ' A' ' 48' ' ' ILE . 10.0 mt -84.01 112.36 40.14 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.188 -0.945 . . . . 50.0 110.39 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.822 ' C ' HD12 ' A' ' 48' ' ' ILE . 50.0 Cg_endo -77.41 74.9 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 124.001 1.527 . . . . 50.0 110.306 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.049 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.4 mp -115.41 151.04 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.146 -0.971 . . . . 50.0 110.294 -179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 23.8 m -128.32 147.15 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.439 -0.788 . . . . 50.0 110.09 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -122.25 100.76 7.13 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.362 -0.836 . . . . 50.0 109.654 179.673 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.838 HG12 ' HA ' ' A' ' 59' ' ' PRO . 25.4 m -114.99 160.86 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.234 -0.916 . . . . 50.0 110.421 -179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.63 ' HB2' HG11 ' A' ' 60' ' ' VAL . . . -60.25 164.63 4.06 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.42 -0.8 . . . . 50.0 109.927 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.7 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 3.4 t -66.64 120.49 13.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.181 -0.949 . . . . 50.0 109.805 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.7 ' CB ' ' O ' ' A' ' 53' ' ' SER . 10.1 tp 87.18 29.27 0.03 OUTLIER 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.658 -0.652 . . . . 50.0 110.725 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.493 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 66.9 m-80 -144.18 84.81 1.78 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.114 -0.991 . . . . 50.0 110.182 179.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.22 6.24 42.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.197 -0.939 . . . . 50.0 110.111 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.2 mmt -107.83 -14.59 14.75 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.26 -0.9 . . . . 50.0 110.081 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.3 p -133.14 119.83 15.82 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 50.0 110.04 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.838 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.84 125.85 10.83 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.942 1.496 . . . . 50.0 110.245 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.63 HG11 ' HB2' ' A' ' 52' ' ' ALA . 3.4 p -131.45 -33.72 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.14 -0.975 . . . . 50.0 110.025 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.534 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.91 143.45 34.95 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.697 -1.761 . . . . 50.0 108.697 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.469 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -126.62 156.27 41.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.055 -1.262 . . . . 50.0 110.794 -179.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.2 mp -93.84 129.8 40.11 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.808 . . . . 50.0 109.927 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.636 HG11 ' HB2' ' A' ' 82' ' ' GLU . 4.0 p -54.07 -26.11 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.158 -0.964 . . . . 50.0 110.209 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 7.5 t -114.56 176.05 5.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.285 -0.885 . . . . 50.0 110.117 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 69' ' ' PHE . 15.5 m -59.15 -170.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.162 -0.961 . . . . 50.0 110.225 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.623 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 15.2 t30 -46.79 140.3 6.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 50.0 109.987 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.559 ' O ' ' HB ' ' A' ' 46' ' ' ILE . 47.7 Cg_endo -74.84 78.07 2.93 Favored 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 123.989 1.521 . . . . 50.0 110.557 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.623 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 10.3 p90 -105.4 136.06 45.64 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.137 -0.977 . . . . 50.0 110.402 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.006 ' CG2' HD11 ' A' ' 46' ' ' ILE . 85.7 t -91.66 60.65 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.277 -0.889 . . . . 50.0 109.976 179.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.561 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -82.13 57.79 3.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.324 -0.86 . . . . 50.0 110.017 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 169.11 18.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.315 -0.865 . . . . 50.0 110.177 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -100.2 -5.59 27.43 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.242 -0.911 . . . . 50.0 109.977 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 29.8 t -121.25 10.12 10.56 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 99.99 110.507 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.827 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -80.77 10.43 4.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.018 -1.051 . . . . 99.99 110.004 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.519 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 96.6 m-20 -84.51 16.81 2.94 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.325 -0.859 . . . . 99.99 109.314 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.683 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.44 -172.42 2.36 Favored 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.441 -0.787 . . . . 99.99 109.347 -179.983 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.541 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.2 OUTLIER -62.79 87.94 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.354 -0.938 . . . . 99.99 109.006 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.999 HG22 ' O ' ' A' ' 35' ' ' LEU . 13.4 m -77.18 175.97 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.356 -0.84 . . . . 99.99 109.685 -179.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -127.93 142.01 51.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.918 -1.114 . . . . 50.0 110.705 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.605 HG23 ' CD1' ' A' ' 35' ' ' LEU . 0.0 OUTLIER -134.54 166.66 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.423 -0.798 . . . . 50.0 109.867 179.745 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.636 ' HB2' HG11 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -145.11 152.45 40.07 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.289 -0.882 . . . . 50.0 110.266 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.525 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 9.7 ptt? -155.3 144.96 21.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 50.0 110.302 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -106.93 74.87 0.39 Allowed Pre-proline 0 C--N 1.305 -1.369 0 O-C-N 121.286 -0.884 . . . . 50.0 110.397 -179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.552 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.4 Cg_endo -72.88 167.71 26.57 Favored 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.914 1.481 . . . . 50.0 110.5 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.43 154.32 60.68 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.947 1.498 . . . . 50.0 110.584 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.94 134.26 48.6 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.237 -0.914 . . . . 50.0 110.04 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 119.87 -168.54 13.68 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.379 -1.489 . . . . 50.0 109.379 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.578 ' OD2' ' CG ' ' A' ' 106' ' ' HIS . 7.2 m-20 -82.91 153.16 25.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -1.16 . . . . 50.0 110.116 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -136.96 138.61 40.77 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.284 -0.885 . . . . 50.0 110.296 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.593 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 2.7 m-30 -99.23 124.3 44.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.097 -1.002 . . . . 50.0 109.797 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.672 ' N ' HD12 ' A' ' 92' ' ' ILE . 4.9 mp -111.0 132.35 59.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.249 -0.907 . . . . 50.0 110.159 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.658 HG22 ' CB ' ' A' ' 102' ' ' ASN . 20.9 t -125.16 120.81 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.822 -1.174 . . . . 50.0 111.365 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 1.015 HG22 HG13 ' A' ' 48' ' ' ILE . 94.9 t -98.19 106.56 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.342 -0.849 . . . . 50.0 109.436 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.492 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -139.42 142.99 13.34 Favored Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.568 -1.301 . . . . 50.0 110.093 -179.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.545 ' CB ' ' HB3' ' A' ' 15' ' ' GLU . 25.8 ttp -115.74 70.07 0.74 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.428 -1.042 . . . . 50.0 109.957 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 56.03 18.9 20.89 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.559 -1.416 . . . . 50.0 109.559 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 64.2 m-20 -149.36 -88.1 0.08 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -1.104 . . . . 50.0 110.098 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.446 ' O ' ' HA2' ' A' ' 95' ' ' GLY . 0.9 OUTLIER -79.76 155.18 28.04 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.244 -0.91 . . . . 50.0 110.322 -179.876 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.675 ' O ' ' HG2' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -140.75 87.74 2.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.182 -0.949 . . . . 0.0 110.695 179.768 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.705 ' O ' HG23 ' A' ' 101' ' ' ILE . 1.1 tp -85.32 116.45 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.015 -1.053 . . . . 0.0 109.781 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.658 ' CB ' HG22 ' A' ' 93' ' ' VAL . 22.5 p30 -106.77 151.94 24.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.853 . . . . 0.0 110.963 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.484 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.2 OUTLIER -129.67 156.94 43.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.5 -0.75 . . . . 0.0 109.573 179.787 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.567 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 5.7 m170 -114.27 80.83 1.45 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.314 -0.867 . . . . 0.0 110.581 -179.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.616 ' CD2' ' HG2' ' A' ' 23' ' ' PRO . 10.4 t-105 -61.98 106.97 0.78 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.298 -0.877 . . . . 0.0 110.027 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.578 ' CG ' ' OD2' ' A' ' 89' ' ' ASP . 0.5 OUTLIER -104.86 139.27 39.86 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.266 -0.896 . . . . 0.0 110.367 -179.887 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . 0.44 ' O ' ' HB2' ' A' ' 108' ' ' ALA . 0.1 OUTLIER -61.82 -11.59 13.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.231 -0.918 . . . . 0.0 110.244 179.95 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.44 ' HB2' ' O ' ' A' ' 107' ' ' LYS . . . -178.02 156.24 1.03 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 110.134 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -155.75 147.06 15.3 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -174.7 -33.79 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -1.185 . . . . 0.0 110.19 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.41 ' O ' HG22 ' A' ' 111' ' ' THR . 16.8 m . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 118.031 -0.985 . . . . 49.57 110.183 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.263 0.554 . . . . 50.0 110.259 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -169.57 174.84 5.67 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.251 -0.906 . . . . 50.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.8 mt -88.94 141.94 28.06 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 50.0 110.121 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.07 159.12 23.04 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.319 -0.863 . . . . 50.0 110.279 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.3 tp -110.95 62.58 0.61 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.284 -0.885 . . . . 50.0 110.193 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 4.5 tptp -132.14 124.39 29.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.936 . . . . 50.0 110.324 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -161.01 131.36 2.58 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.541 -1.423 . . . . 50.0 109.541 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.5 m -53.81 166.61 0.32 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.31 -1.112 . . . . 50.0 110.288 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.7 t -52.6 163.52 0.44 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.285 -0.884 . . . . 50.0 110.203 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -166.16 178.03 6.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.192 -0.942 . . . . 50.0 110.275 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.425 ' O ' ' HG2' ' A' ' 45' ' ' LYS . . . -106.16 160.13 14.79 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.638 -1.385 . . . . 50.0 109.638 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.535 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -111.0 120.47 42.49 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.279 -1.13 . . . . 50.0 109.952 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.678 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -141.15 106.64 5.06 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.216 -0.927 . . . . 99.99 110.848 -179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.891 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -161.98 35.63 0.12 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.003 -1.061 . . . . 99.99 110.288 179.029 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.446 ' HB2' ' HB3' ' A' ' 96' ' ' MET . 6.9 tm-20 -68.25 3.51 1.66 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.214 -0.929 . . . . 99.99 110.422 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.18 60.55 0.68 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.085 -1.01 . . . . 50.0 110.836 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.762 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -92.81 142.39 27.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.114 -0.991 . . . . 50.0 109.499 179.074 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.597 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 7.0 t -127.4 98.38 5.23 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.117 -0.989 . . . . 50.0 110.608 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.693 ' CD1' HD23 ' A' ' 35' ' ' LEU . 17.8 m-85 -56.02 97.1 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.23 -0.919 . . . . 50.0 109.857 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.06 -29.85 26.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.249 -0.907 . . . . 50.0 110.491 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.485 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 26.9 mttm -143.11 145.43 32.84 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.098 -1.001 . . . . 50.0 110.397 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.442 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 10.8 p30 -66.74 163.79 39.42 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 50.0 109.922 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.531 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.4 Cg_endo -71.78 134.59 24.15 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.903 1.475 . . . . 50.0 110.288 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -128.17 160.86 30.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.209 -0.932 . . . . 50.0 110.194 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -94.46 143.16 26.64 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.226 -0.921 . . . . 50.0 110.253 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -109.83 -39.66 5.02 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.223 -0.923 . . . . 50.0 110.157 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -142.72 -105.12 0.53 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.405 -1.478 . . . . 50.0 109.405 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -129.61 97.91 4.67 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.135 -1.215 . . . . 50.0 110.25 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.38 30.31 10.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 45.4 p -134.62 114.91 13.24 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.252 -1.146 . . . . 50.0 110.366 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.531 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 43.7 t -111.29 124.93 68.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.307 -0.871 . . . . 50.0 109.907 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.92 ' CG1' HD21 ' A' ' 80' ' ' LEU . 2.1 t -108.18 151.76 10.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.231 -0.918 . . . . 50.0 110.489 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.558 ' CG2' ' HB ' ' A' ' 81' ' ' VAL . 7.4 tt -150.45 166.96 2.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.448 -0.782 . . . . 50.0 109.515 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.74 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 6.4 tp10 -136.66 104.15 5.44 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.116 -0.99 . . . . 50.0 110.711 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.949 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.4 OUTLIER -114.28 137.02 52.32 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.256 -0.903 . . . . 50.0 109.536 179.338 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 77' ' ' SER . 4.7 m -86.46 126.4 34.38 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.079 -1.013 . . . . 50.0 109.769 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.686 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.9 t80 -93.32 102.42 14.68 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.028 -1.069 . . . . 50.0 109.554 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -96.34 70.07 2.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.309 -0.869 . . . . 50.0 110.149 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -115.91 123.26 5.83 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.533 -1.427 . . . . 99.99 109.533 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.99 12.4 4.17 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.245 -1.15 . . . . 99.99 110.355 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.423 ' N ' ' OD1' ' A' ' 41' ' ' ASP . 0.8 OUTLIER -97.6 -1.73 43.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 99.99 110.016 179.837 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 91.15 -156.61 24.4 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.476 -1.45 . . . . 99.99 109.476 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.569 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.5 Cg_endo -71.47 150.89 58.62 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 124.035 1.545 . . . . 99.99 110.358 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.678 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.8 OUTLIER -170.73 162.69 7.81 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.269 -0.895 . . . . 50.0 110.036 -179.522 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.614 ' HD2' ' CG ' ' A' ' 69' ' ' PHE . 44.9 mmtt -72.89 131.74 42.62 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.103 -0.998 . . . . 50.0 110.045 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.086 HG22 ' CD1' ' A' ' 48' ' ' ILE . 2.4 mt -89.62 109.32 31.15 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.204 -0.935 . . . . 50.0 110.624 -179.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.69 ' C ' HD12 ' A' ' 48' ' ' ILE . 51.9 Cg_endo -79.13 68.44 8.28 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.087 1.572 . . . . 50.0 110.14 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.086 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -111.59 145.62 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.161 -0.962 . . . . 50.0 110.25 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 34.1 m -118.14 139.13 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.334 -0.854 . . . . 50.0 110.108 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.495 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -119.9 100.66 7.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.326 -0.859 . . . . 50.0 109.806 179.855 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.7 m -124.0 159.82 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.306 -0.871 . . . . 50.0 110.284 -179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -56.51 163.88 1.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.392 -0.818 . . . . 50.0 109.766 179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.829 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 2.2 m -73.57 104.27 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -0.993 . . . . 50.0 110.034 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.829 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 117.69 19.61 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.318 0 CA-C-O 121.113 0.482 . . . . 50.0 110.509 179.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.416 ' ND2' ' HB ' ' A' ' 58' ' ' THR . 0.2 OUTLIER -138.01 84.67 2.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.969 -1.082 . . . . 50.0 110.324 179.42 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -96.57 14.74 23.71 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.242 -0.911 . . . . 50.0 109.727 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.7 ttt -126.22 -12.99 6.25 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.327 -0.858 . . . . 50.0 110.383 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.416 ' HB ' ' ND2' ' A' ' 55' ' ' ASN . 3.6 m -128.58 129.78 23.53 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.913 . . . . 50.0 110.23 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.471 ' HA ' HG12 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -72.57 132.48 18.98 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 O-C-N 124.044 1.55 . . . . 50.0 110.182 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 6.9 t -137.86 -42.32 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.125 -0.984 . . . . 50.0 110.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -76.09 135.4 17.62 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.055 -1.618 . . . . 50.0 109.055 179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.519 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 2.9 mtm180 -119.43 152.27 37.15 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.099 -1.236 . . . . 50.0 110.626 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 1.1 mt -94.08 124.36 38.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.268 -0.895 . . . . 50.0 110.074 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.519 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 94.1 t -81.16 -38.8 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.218 -0.926 . . . . 50.0 110.364 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.6 t -65.84 172.73 3.35 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.186 -0.946 . . . . 50.0 110.095 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.436 ' H ' HG22 ' A' ' 66' ' ' VAL . 4.3 m -53.4 179.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.219 -0.926 . . . . 50.0 110.007 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.65 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 1.0 OUTLIER -46.84 144.22 3.85 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.159 -0.963 . . . . 50.0 110.154 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.445 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 46.5 Cg_endo -73.59 66.52 4.67 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.999 1.526 . . . . 50.0 110.961 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.65 ' CD2' ' HB3' ' A' ' 67' ' ' ASN . 19.9 m-30 -126.31 122.37 35.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.317 -0.864 . . . . 50.0 110.07 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.914 HG23 HD11 ' A' ' 46' ' ' ILE . 41.1 t -70.31 61.19 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.047 -1.033 . . . . 50.0 109.879 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.569 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -96.07 66.35 2.54 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.166 -0.959 . . . . 50.0 110.212 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.67 169.44 17.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.297 -0.877 . . . . 50.0 110.292 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.08 -14.56 31.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.223 -0.923 . . . . 50.0 110.184 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 75.1 m -121.16 23.2 10.65 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.226 -0.921 . . . . 99.99 110.332 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.765 ' HB1' HG13 ' A' ' 70' ' ' VAL . . . -80.56 9.94 5.4 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.126 -0.984 . . . . 99.99 110.31 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -88.05 18.01 4.58 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.222 -0.924 . . . . 99.99 109.188 179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.524 ' O ' ' HA ' ' A' ' 36' ' ' SER . 18.1 t -133.01 -171.91 2.8 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.554 -0.716 . . . . 99.99 109.551 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.54 ' O ' ' CG ' ' A' ' 78' ' ' LYS . 0.4 OUTLIER -62.86 90.48 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.367 -0.833 . . . . 99.99 109.187 179.539 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.949 HG22 ' O ' ' A' ' 35' ' ' LEU . 31.4 m -76.19 172.01 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.286 -0.884 . . . . 99.99 109.555 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.92 HD21 ' CG1' ' A' ' 32' ' ' VAL . 7.8 tt -117.14 119.75 36.18 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.055 -1.028 . . . . 50.0 111.005 -179.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.731 HG21 HD13 ' A' ' 35' ' ' LEU . 2.9 t -108.58 169.91 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.33 -0.857 . . . . 50.0 109.571 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HB3' ' HB ' ' A' ' 64' ' ' VAL . 2.6 mt-10 -151.17 151.29 31.71 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.046 -1.034 . . . . 50.0 110.58 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.518 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 8.3 ptt? -160.36 153.3 21.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.315 -0.865 . . . . 50.0 110.18 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.519 ' HG3' ' HB2' ' A' ' 62' ' ' ARG . 2.2 pt-20 -114.46 59.3 1.0 Allowed Pre-proline 0 C--N 1.306 -1.292 0 O-C-N 121.152 -0.967 . . . . 50.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HD3' ' C ' ' A' ' 83' ' ' MET . 44.1 Cg_endo -71.34 170.24 18.83 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.859 1.452 . . . . 50.0 110.331 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.14 163.19 39.47 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.035 1.545 . . . . 50.0 110.363 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -72.33 144.15 48.4 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.172 -0.955 . . . . 50.0 110.168 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 118.32 -160.42 13.9 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.306 -1.517 . . . . 50.0 109.306 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.531 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 3.2 m-20 -90.45 146.98 23.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -1.151 . . . . 50.0 110.255 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.54 ' HA ' ' N ' ' A' ' 53' ' ' SER . 78.8 p -130.33 143.75 50.96 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 50.0 110.078 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' A' ' 104' ' ' HIS . 0.1 OUTLIER -91.48 108.34 19.83 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.161 -0.962 . . . . 50.0 110.173 -179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.707 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.0 mp -101.22 125.75 55.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.281 -0.887 . . . . 50.0 109.355 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.866 HG22 ' CB ' ' A' ' 102' ' ' ASN . 26.3 t -124.7 117.41 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.893 -1.13 . . . . 50.0 111.268 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.923 HG13 HD11 ' A' ' 48' ' ' ILE . 15.0 t -95.25 105.98 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.321 -0.862 . . . . 50.0 109.34 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.48 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -133.91 140.11 11.49 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.683 -1.246 . . . . 50.0 110.064 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.566 ' HG3' ' HA ' ' A' ' 13' ' ' CYS . 10.0 tmm? -131.32 -26.28 2.1 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.368 -1.078 . . . . 50.0 110.239 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 166.73 -24.39 0.13 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.778 -1.329 . . . . 50.0 109.778 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -81.39 -70.16 0.56 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -1.163 . . . . 50.0 110.343 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -150.53 136.54 18.45 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.285 -0.885 . . . . 50.0 110.022 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.568 ' N ' ' NE2' ' A' ' 100' ' ' GLN . 0.5 OUTLIER -78.47 108.06 11.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.283 -0.886 . . . . 0.0 110.547 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.48 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 4.1 mt -94.88 110.75 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.308 -0.87 . . . . 0.0 110.131 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.866 ' CB ' HG22 ' A' ' 93' ' ' VAL . 15.3 p30 -106.4 130.03 54.28 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.245 -0.909 . . . . 0.0 110.422 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -132.93 134.72 44.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.369 -0.832 . . . . 0.0 110.187 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.62 ' NE2' ' CZ ' ' A' ' 91' ' ' TYR . 1.7 m-70 -72.32 140.91 48.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.255 -0.903 . . . . 0.0 110.073 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.707 ' HB2' HD13 ' A' ' 92' ' ' ILE . 2.4 m95 -134.22 137.66 44.53 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.158 -0.963 . . . . 0.0 110.4 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.466 ' CD2' ' N ' ' A' ' 106' ' ' HIS . 6.7 p80 -159.9 131.98 6.31 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 110.144 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.28 -10.19 59.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.232 -0.917 . . . . 0.0 110.205 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -98.33 111.22 23.63 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.21 -0.931 . . . . 0.0 110.279 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -98.13 -168.81 31.89 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.428 ' C ' ' OG1' ' A' ' 111' ' ' THR . 3.3 m -111.68 -57.68 2.22 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.202 -1.175 . . . . 0.0 110.126 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 110' ' ' SER . 4.1 p . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 117.999 -1.001 . . . . 49.57 110.138 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.284 0.564 . . . . 50.0 110.22 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.43 162.82 28.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.258 -0.901 . . . . 50.0 110.208 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.6 tp -113.34 146.68 39.05 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.247 -0.908 . . . . 50.0 110.13 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.59 155.55 17.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.27 -0.893 . . . . 50.0 110.265 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 5' ' ' LEU . 0.5 OUTLIER -106.16 86.89 2.44 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.282 -0.886 . . . . 50.0 110.245 179.933 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -104.41 137.35 42.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.217 -0.927 . . . . 50.0 110.121 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.3 127.28 6.56 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.53 -1.428 . . . . 50.0 109.53 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.467 ' O ' ' N ' ' A' ' 10' ' ' TYR . 44.5 p -59.6 168.0 1.81 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -1.124 . . . . 50.0 110.274 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -45.44 95.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.272 -0.893 . . . . 50.0 110.279 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.467 ' N ' ' O ' ' A' ' 8' ' ' THR . 1.2 m-85 -110.29 167.98 9.79 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.171 -0.955 . . . . 50.0 110.214 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -106.94 123.35 7.28 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.622 -1.391 . . . . 50.0 109.622 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.583 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -83.16 121.54 27.2 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.215 -1.168 . . . . 50.0 110.192 -179.913 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.793 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.83 105.58 3.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.021 -1.05 . . . . 99.99 111.507 -179.779 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.874 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.93 19.54 0.08 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.922 -1.112 . . . . 99.99 110.427 178.392 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.455 ' HB3' ' HB2' ' A' ' 96' ' ' MET . 1.1 pp20? -57.77 -11.87 2.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.09 -1.007 . . . . 99.99 110.42 -179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 4.3 mptt -80.15 60.71 3.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 50.0 110.382 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.496 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -93.75 149.36 21.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.249 -0.907 . . . . 50.0 109.917 179.581 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.685 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 t -127.43 136.34 51.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.178 -0.951 . . . . 50.0 109.799 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.855 ' HZ ' HG21 ' A' ' 101' ' ' ILE . 0.4 OUTLIER -83.48 115.14 21.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.068 -1.02 . . . . 50.0 110.185 -179.769 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.71 -35.8 7.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.35 -0.844 . . . . 50.0 109.953 179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.532 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 16.5 mttm -147.53 153.57 39.66 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.212 -0.93 . . . . 50.0 110.188 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 23' ' ' PRO . 29.6 p-10 -68.26 165.16 36.37 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.273 -0.892 . . . . 50.0 109.875 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 22' ' ' ASN . 44.6 Cg_endo -71.8 141.58 37.6 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.854 1.449 . . . . 50.0 110.199 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -137.68 165.64 25.89 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.191 -0.943 . . . . 50.0 110.321 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -90.49 159.08 16.7 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 50.0 110.136 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.593 HG23 HG21 ' A' ' 32' ' ' VAL . 0.1 OUTLIER -134.24 -45.55 0.77 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.326 -0.859 . . . . 50.0 110.217 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -133.38 -111.51 1.26 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.496 -1.442 . . . . 50.0 109.496 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -128.68 91.39 3.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -1.124 . . . . 50.0 110.211 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.492 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 95.4 31.0 7.77 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.506 -1.438 . . . . 50.0 109.506 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.736 HG22 HG11 ' A' ' 64' ' ' VAL . 0.2 OUTLIER -137.04 110.24 7.81 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.238 -1.154 . . . . 50.0 110.42 -179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 41.3 t -95.94 149.19 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.273 -0.892 . . . . 50.0 110.059 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 26' ' ' THR . 0.0 OUTLIER -124.06 148.5 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 50.0 110.577 -179.761 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.907 HG23 HD11 ' A' ' 35' ' ' LEU . 0.5 OUTLIER -147.36 142.3 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.42 -0.8 . . . . 50.0 109.776 179.818 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.908 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 0.0 OUTLIER -109.53 101.98 10.87 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.199 -0.938 . . . . 50.0 110.309 -179.736 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.016 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.3 OUTLIER -120.86 137.71 54.43 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.327 -0.858 . . . . 50.0 109.45 179.525 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -91.44 132.73 36.03 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.081 -1.012 . . . . 50.0 110.064 -179.691 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.509 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 33.4 t80 -96.1 95.51 8.22 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.843 -1.143 . . . . 50.0 109.761 179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.66 69.64 2.52 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.336 -0.852 . . . . 50.0 109.725 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -110.07 135.13 12.65 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.691 -1.364 . . . . 99.99 109.691 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 95.2 p -86.12 13.52 7.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.223 -1.163 . . . . 99.99 110.27 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 7.0 t0 -98.48 -20.0 17.34 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.264 -0.898 . . . . 99.99 110.134 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.64 -165.63 14.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.364 -1.494 . . . . 99.99 109.364 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.442 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 44.3 Cg_endo -73.28 140.42 30.59 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 123.868 1.457 . . . . 99.99 110.563 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.793 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -167.53 162.13 14.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.585 -0.697 . . . . 50.0 109.131 -179.887 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.583 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 9.9 mmtm -59.84 138.28 57.84 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.947 -1.095 . . . . 50.0 110.49 -179.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.874 HG23 ' HB ' ' A' ' 14' ' ' THR . 1.5 mt -93.11 109.11 37.64 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.442 -0.786 . . . . 50.0 110.545 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 48.0 Cg_endo -75.55 96.06 1.03 Allowed 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.154 1.607 . . . . 50.0 110.219 179.817 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.913 HG12 HG22 ' A' ' 94' ' ' VAL . 10.2 mt -132.38 145.57 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.881 . . . . 50.0 110.356 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 93' ' ' VAL . 4.6 m -115.96 130.93 69.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.324 -0.86 . . . . 50.0 109.912 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.566 ' O ' ' N ' ' A' ' 61' ' ' GLY . 13.3 m -114.71 101.27 8.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.18 -0.95 . . . . 50.0 109.81 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.612 HG12 ' HA ' ' A' ' 59' ' ' PRO . 33.9 m -131.12 159.7 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.285 -0.885 . . . . 50.0 110.236 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -56.13 163.92 1.43 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 50.0 109.898 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 29.3 t -63.47 122.54 16.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.156 -0.965 . . . . 50.0 110.484 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.627 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 78.72 30.24 0.37 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.513 -0.742 . . . . 50.0 110.579 179.785 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.451 ' O ' ' HB ' ' A' ' 51' ' ' VAL . 49.8 m-80 -136.23 84.64 2.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 50.0 110.086 179.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -105.43 8.6 33.62 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.245 -0.909 . . . . 50.0 110.187 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 2.9 ttt -103.75 -18.29 14.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 50.0 109.921 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.2 m -136.08 128.51 17.59 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.508 -0.745 . . . . 50.0 109.911 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.612 ' HA ' HG12 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.46 132.31 20.41 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 123.931 1.49 . . . . 50.0 110.396 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.1 t -135.12 -43.66 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.342 -0.849 . . . . 50.0 109.771 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -71.78 149.4 44.75 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.685 -1.766 . . . . 50.0 108.685 179.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG2' ' O ' ' A' ' 61' ' ' GLY . 9.5 mtp85 -141.07 157.03 45.87 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.85 -1.382 . . . . 50.0 110.908 -179.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.557 ' N ' HD12 ' A' ' 63' ' ' LEU . 6.6 mp -94.32 129.54 40.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 50.0 109.845 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.736 HG11 HG22 ' A' ' 30' ' ' THR . 43.9 t -79.87 7.3 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.234 -0.916 . . . . 50.0 110.329 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.483 ' CG2' ' HB2' ' A' ' 82' ' ' GLU . 68.9 p -115.5 167.05 11.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.136 -0.978 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' A' ' 65' ' ' THR . 16.7 m -52.87 -170.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 O-C-N 121.225 -0.922 . . . . 50.0 110.089 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -46.41 149.95 1.26 Allowed Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.128 -0.982 . . . . 50.0 110.044 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 46' ' ' ILE . 45.5 Cg_endo -72.16 91.03 0.75 Allowed 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 124.006 1.529 . . . . 50.0 110.691 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 1.117 ' CZ ' ' HB2' ' A' ' 71' ' ' ALA . 1.2 t80 -155.12 121.51 5.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.345 -0.847 . . . . 50.0 109.932 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.82 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.5 p -95.43 60.84 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.252 -0.905 . . . . 50.0 110.166 -179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 1.117 ' HB2' ' CZ ' ' A' ' 69' ' ' PHE . . . -73.9 82.44 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 50.0 110.235 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.74 148.88 37.97 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.229 -0.92 . . . . 50.0 110.359 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.2 t -68.45 -15.57 63.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 50.0 109.874 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -121.09 23.31 10.66 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.301 -0.874 . . . . 99.99 110.373 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.673 ' CB ' HG22 ' A' ' 70' ' ' VAL . . . -72.32 1.34 7.94 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.099 -1.0 . . . . 99.99 110.397 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.509 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 57.8 m-80 -87.2 24.12 1.66 Allowed 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.174 -0.954 . . . . 99.99 109.397 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.647 ' O ' HG13 ' A' ' 79' ' ' VAL . 2.3 p -128.7 -173.08 2.87 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.476 -0.765 . . . . 99.99 109.268 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.433 ' HA ' ' CA ' ' A' ' 36' ' ' SER . 0.7 OUTLIER -63.44 88.83 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.334 -0.854 . . . . 99.99 109.186 179.478 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 1.016 HG22 ' O ' ' A' ' 35' ' ' LEU . 15.9 m -76.52 176.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.449 -0.782 . . . . 99.99 109.695 -179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.433 HD23 ' N ' ' A' ' 81' ' ' VAL . 2.5 tt -127.57 128.36 45.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.888 -1.132 . . . . 50.0 111.054 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.47 ' HB ' ' CG2' ' A' ' 33' ' ' ILE . 3.2 t -115.45 172.19 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.354 -0.841 . . . . 50.0 110.024 179.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.483 ' HB2' ' CG2' ' A' ' 65' ' ' THR . 2.6 mt-10 -148.1 140.79 24.6 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.169 -0.957 . . . . 50.0 110.195 179.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.468 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 6.7 ptt? -151.52 146.75 26.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.122 -0.987 . . . . 50.0 110.62 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.705 ' HG2' HG22 ' A' ' 64' ' ' VAL . 0.9 OUTLIER -109.34 75.55 0.74 Allowed Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.408 -0.808 . . . . 50.0 110.132 179.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 83' ' ' MET . 46.1 Cg_endo -73.26 159.43 47.08 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 124.044 1.549 . . . . 50.0 110.536 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -71.02 148.44 56.93 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 O-C-N 124.079 1.568 . . . . 50.0 110.685 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -58.82 137.23 57.84 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.295 -0.878 . . . . 50.0 110.203 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.78 -125.96 6.43 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.526 ' HB3' ' CB ' ' A' ' 53' ' ' SER . 19.9 t0 -120.51 146.03 46.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -1.147 . . . . 50.0 110.213 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.562 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -141.7 137.57 31.81 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -0.894 . . . . 50.0 110.247 -179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.59 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 1.9 m-30 -98.98 117.28 33.14 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.109 -0.994 . . . . 50.0 109.952 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.689 HD13 ' HB2' ' A' ' 105' ' ' TRP . 3.2 mp -109.5 133.2 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 50.0 110.139 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.57 ' HB ' HG22 ' A' ' 49' ' ' VAL . 11.5 t -124.8 121.39 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.051 -1.03 . . . . 50.0 110.734 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.913 HG22 HG12 ' A' ' 48' ' ' ILE . 24.5 t -106.9 101.67 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.279 -0.888 . . . . 50.0 109.747 179.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.32 168.31 33.09 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.793 -1.323 . . . . 50.0 109.793 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.48 ' HG3' ' HG3' ' A' ' 47' ' ' PRO . 6.4 ttm -107.13 -55.15 2.37 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.395 -1.062 . . . . 50.0 110.175 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -166.37 -40.72 0.02 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.6 -85.26 0.22 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -1.172 . . . . 50.0 110.031 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 8.6 mmtm -79.72 128.87 33.95 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.262 -0.898 . . . . 50.0 110.061 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.654 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -132.53 149.75 52.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.894 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.855 HG21 ' HZ ' ' A' ' 19' ' ' PHE . 49.4 mm -122.81 122.5 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.117 -0.989 . . . . 0.0 110.258 -179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -109.99 136.57 49.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.349 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -124.43 164.54 19.48 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.886 . . . . 0.0 109.917 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.0 m170 -113.78 88.55 2.87 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.285 -0.884 . . . . 0.0 110.563 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 92' ' ' ILE . 1.7 t90 -59.78 109.52 0.95 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.321 -0.862 . . . . 0.0 110.227 179.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . . . . . . . . . 1.7 t-160 -147.41 120.66 8.93 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 0.0 110.318 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.91 -7.46 14.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.269 -0.894 . . . . 0.0 110.373 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -135.13 131.85 37.36 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.161 -0.962 . . . . 0.0 110.451 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -136.19 -141.86 4.39 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 57.17 101.48 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.157 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 70.7 p . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.042 -0.98 . . . . 49.57 110.229 -179.917 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.305 0.574 . . . . 50.0 110.164 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 4.3 mtpp -106.79 172.38 6.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.212 -0.93 . . . . 50.0 110.238 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.5 116.88 29.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.316 -0.865 . . . . 50.0 110.096 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.527 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . . . -81.93 159.54 23.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.895 . . . . 50.0 110.276 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.466 ' CG ' ' O ' ' A' ' 5' ' ' LEU . 0.7 OUTLIER -105.71 81.67 1.7 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.331 -0.856 . . . . 50.0 110.268 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.527 ' HE2' ' CB ' ' A' ' 4' ' ' ALA . 33.3 mttm -104.7 -179.37 3.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.311 -0.868 . . . . 50.0 110.22 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.21 35.84 3.8 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.639 -1.384 . . . . 50.0 109.639 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -52.68 144.0 14.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.238 -1.154 . . . . 50.0 110.162 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.579 ' O ' ' CG ' ' A' ' 10' ' ' TYR . 0.8 OUTLIER -44.64 156.37 0.08 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.286 -0.884 . . . . 50.0 110.199 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.579 ' CG ' ' O ' ' A' ' 9' ' ' THR . 0.8 OUTLIER -177.77 167.88 2.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.202 -0.936 . . . . 50.0 110.216 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.61 101.16 2.34 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.452 -1.459 . . . . 50.0 109.452 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 23.0 mtm -82.8 111.47 18.74 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.378 -1.072 . . . . 50.0 110.442 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.676 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 7.2 p -148.74 108.84 4.09 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.173 -0.954 . . . . 99.99 110.538 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.85 HG21 HG12 ' A' ' 46' ' ' ILE . 1.2 m -160.27 50.37 0.29 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.93 -1.106 . . . . 99.99 110.264 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.606 ' CB ' ' CB ' ' A' ' 96' ' ' MET . 3.8 pt-20 -77.88 28.18 0.17 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.297 -0.877 . . . . 99.99 110.743 -179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.446 ' HG2' ' C ' ' A' ' 15' ' ' GLU . 0.1 OUTLIER -129.24 60.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.89 -1.131 . . . . 50.0 110.878 -179.87 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.829 ' CE1' HD13 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -91.98 143.69 26.22 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.136 -0.978 . . . . 50.0 109.743 179.328 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.632 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 5.0 m -127.33 103.85 7.61 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 50.0 110.466 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -61.24 98.38 0.08 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.153 -0.967 . . . . 50.0 110.0 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.589 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -84.88 -32.96 22.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.22 -0.925 . . . . 50.0 109.879 179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.483 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 0.1 OUTLIER -142.54 145.23 33.41 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.352 -0.842 . . . . 50.0 110.187 -179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.482 ' HB2' ' CZ3' ' A' ' 105' ' ' TRP . 24.6 p30 -67.37 161.14 67.18 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.288 -0.883 . . . . 50.0 110.013 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.609 ' HG2' ' CD1' ' A' ' 105' ' ' TRP . 44.5 Cg_endo -71.55 126.07 11.79 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.909 1.479 . . . . 50.0 110.347 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -123.06 152.72 40.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 50.0 110.282 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.452 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.5 p30 -90.87 130.03 36.86 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.269 -0.894 . . . . 50.0 110.078 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.21 -0.69 22.49 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.18 -0.95 . . . . 50.0 110.151 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -174.59 -129.46 1.19 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.77 98.43 7.4 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.225 -1.162 . . . . 50.0 110.225 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 88.29 28.23 23.18 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.6 -1.4 . . . . 50.0 109.6 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 3.8 p -130.15 107.55 9.39 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -1.206 . . . . 50.0 110.182 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.544 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 57.8 t -111.22 114.89 48.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 O-C-N 121.255 -0.903 . . . . 50.0 110.086 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.427 ' H ' HG22 ' A' ' 32' ' ' VAL . 5.2 m -94.56 139.45 18.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.208 -0.932 . . . . 50.0 110.522 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.087 HG23 HD11 ' A' ' 35' ' ' LEU . 0.1 OUTLIER -143.57 137.38 25.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.4 -0.812 . . . . 50.0 109.678 179.68 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.898 ' N ' HD13 ' A' ' 33' ' ' ILE . 18.5 tt0 -113.08 117.24 31.44 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.078 -1.014 . . . . 50.0 110.883 -179.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.087 HD11 HG23 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -128.15 141.54 51.45 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.306 -0.871 . . . . 50.0 109.407 179.233 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.0 OUTLIER -86.84 123.66 32.21 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.072 -1.017 . . . . 50.0 109.753 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.707 ' CE1' HG23 ' A' ' 14' ' ' THR . 4.9 t80 -91.52 101.66 14.32 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 118.932 -1.107 . . . . 50.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.421 ' O ' ' HB3' ' A' ' 16' ' ' LYS . 0.2 OUTLIER -96.24 69.64 2.71 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.239 -0.913 . . . . 50.0 109.877 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.448 ' HA3' ' CE1' ' A' ' 37' ' ' TYR . . . -111.31 127.69 8.32 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.476 -1.45 . . . . 99.99 109.476 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 8.1 p -77.29 6.09 7.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.296 -1.12 . . . . 99.99 110.488 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.53 -3.7 42.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.215 -0.928 . . . . 99.99 109.925 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 81.42 -137.65 17.89 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.437 -1.465 . . . . 99.99 109.437 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.609 ' CB ' ' HA ' ' A' ' 71' ' ' ALA . 43.3 Cg_endo -70.91 142.42 42.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.968 1.509 . . . . 99.99 110.327 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.676 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.1 OUTLIER -170.13 162.42 8.87 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.349 -0.844 . . . . 50.0 110.078 -179.403 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HA ' ' CD1' ' A' ' 69' ' ' PHE . 25.7 mmtt -74.67 113.34 11.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 50.0 109.906 179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.999 HG22 ' CD1' ' A' ' 48' ' ' ILE . 3.2 mt -74.51 117.08 59.29 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.112 -0.993 . . . . 50.0 110.072 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.835 ' C ' HD12 ' A' ' 48' ' ' ILE . 48.7 Cg_endo -81.79 70.13 7.35 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 124.087 1.572 . . . . 50.0 110.158 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.999 ' CD1' HG22 ' A' ' 46' ' ' ILE . 1.7 mp -118.13 146.96 21.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 50.0 110.226 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.602 HG21 ' HB3' ' A' ' 59' ' ' PRO . 6.2 p -127.13 140.36 49.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.394 -0.816 . . . . 50.0 110.143 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.464 ' OG ' ' HG2' ' A' ' 83' ' ' MET . 75.2 m -107.32 100.5 9.94 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 50.0 109.8 179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.94 HG22 ' HA ' ' A' ' 59' ' ' PRO . 59.4 t -107.72 157.0 8.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.313 -0.867 . . . . 50.0 110.127 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -71.94 164.23 26.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.297 -0.877 . . . . 50.0 109.215 179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.621 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 29.6 t -70.79 100.86 1.98 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.74 -1.225 . . . . 50.0 109.321 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 173.19 -71.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 C-N-CA 118.52 -1.272 . . . . 50.0 111.382 -179.725 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.474 ' HB3' ' OG1' ' A' ' 58' ' ' THR . 80.8 m-20 -84.15 155.12 22.74 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.135 -0.978 . . . . 50.0 110.287 -179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -106.24 -23.5 12.55 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 50.0 110.118 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.38 37.09 4.38 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.268 -0.895 . . . . 50.0 110.267 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.502 ' O ' HG13 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -134.9 103.23 10.9 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.176 -0.952 . . . . 50.0 110.322 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.94 ' HA ' HG22 ' A' ' 51' ' ' VAL . 48.9 Cg_endo -73.72 125.84 10.31 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.063 1.559 . . . . 50.0 110.601 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.537 HG22 HG13 ' A' ' 51' ' ' VAL . 12.0 m -135.22 -28.07 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.338 -0.851 . . . . 50.0 110.271 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.432 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.82 170.78 48.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.895 -1.682 . . . . 50.0 108.895 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' O ' ' HG3' ' A' ' 83' ' ' MET . 14.8 mtt180 -140.36 155.91 46.6 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.045 -1.268 . . . . 50.0 110.602 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.593 HD22 ' HD3' ' A' ' 68' ' ' PRO . 2.2 mp -92.21 115.95 28.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.258 -0.901 . . . . 50.0 109.651 179.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.727 HG11 ' HG2' ' A' ' 82' ' ' GLU . 7.5 p -77.69 -34.54 20.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.087 -1.008 . . . . 50.0 110.352 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.544 ' HB ' ' HB3' ' A' ' 82' ' ' GLU . 7.3 t -82.58 173.28 12.1 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.087 -1.008 . . . . 50.0 109.821 179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.458 ' C ' ' O ' ' A' ' 65' ' ' THR . 47.2 t -41.23 159.78 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.212 -0.93 . . . . 50.0 109.789 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.63 ' HB3' ' CE2' ' A' ' 69' ' ' PHE . 8.7 m120 -46.58 158.59 0.39 Allowed Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 50.0 109.709 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.593 ' HD3' HD22 ' A' ' 63' ' ' LEU . 46.2 Cg_endo -73.61 65.83 4.72 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 O-C-N 123.882 1.464 . . . . 50.0 110.511 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.663 ' CD1' ' HA ' ' A' ' 45' ' ' LYS . 16.4 m-30 -126.23 121.68 33.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 50.0 110.034 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.857 HG13 HD11 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -86.97 60.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.013 -1.055 . . . . 50.0 109.589 179.487 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HA ' ' CB ' ' A' ' 43' ' ' PRO . . . -71.75 59.35 0.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.415 -0.803 . . . . 50.0 110.158 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.443 ' HB ' ' HB2' ' A' ' 75' ' ' ALA . 0.3 OUTLIER -142.84 158.25 43.81 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.245 -0.91 . . . . 50.0 110.361 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 19.3 m -85.98 -10.64 54.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.372 -0.83 . . . . 50.0 109.698 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.99 14.59 16.13 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 99.99 110.124 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.443 ' HB2' ' HB ' ' A' ' 72' ' ' THR . . . -80.26 10.99 3.84 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -0.885 . . . . 99.99 109.964 179.702 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 1.1 m-80 -85.84 16.16 4.3 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.286 -0.883 . . . . 99.99 109.435 179.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.583 ' O ' ' HA ' ' A' ' 36' ' ' SER . 60.3 p -121.91 -172.75 2.5 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 121.496 -0.752 . . . . 99.99 109.299 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.467 ' HG3' ' HB3' ' A' ' 36' ' ' SER . 0.6 OUTLIER -63.14 88.65 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.177 -0.952 . . . . 99.99 109.077 179.506 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.908 HG22 ' O ' ' A' ' 35' ' ' LEU . 28.0 m -76.35 176.08 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.33 -0.856 . . . . 99.99 109.603 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -126.76 127.15 44.62 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.945 -1.097 . . . . 50.0 110.759 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.8 t -118.43 169.72 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -0.918 . . . . 50.0 110.251 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.727 ' HG2' HG11 ' A' ' 64' ' ' VAL . 2.3 tt0 -138.23 135.7 35.83 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.288 -0.882 . . . . 50.0 110.065 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.486 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 1.6 mpp? -138.02 149.26 45.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.123 -0.986 . . . . 50.0 110.53 -179.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.476 ' HG2' ' HB ' ' A' ' 64' ' ' VAL . 2.0 pt-20 -115.33 66.24 2.2 Favored Pre-proline 0 C--N 1.305 -1.352 0 O-C-N 121.118 -0.989 . . . . 50.0 110.357 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.486 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.9 Cg_endo -73.09 164.62 34.96 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.026 1.54 . . . . 50.0 110.411 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.58 152.27 64.98 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.048 1.552 . . . . 50.0 110.405 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.501 ' CD1' ' N ' ' A' ' 87' ' ' PHE . 0.9 OUTLIER -52.76 142.67 18.19 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 50.0 110.263 -179.855 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.39 161.75 14.67 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.345 -1.502 . . . . 50.0 109.345 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.552 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 74.9 m-20 -52.78 163.1 0.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -1.188 . . . . 50.0 109.777 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.576 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -142.37 135.85 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.1 -1.0 . . . . 50.0 110.828 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.621 ' CD1' ' HA ' ' A' ' 53' ' ' SER . 5.4 m-30 -96.11 108.21 20.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.245 -0.91 . . . . 50.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 92' ' ' ILE . 3.6 mp -90.29 137.86 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.224 -0.922 . . . . 50.0 109.789 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.542 ' HB ' HG12 ' A' ' 49' ' ' VAL . 22.0 t -125.59 108.33 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 120.882 -1.136 . . . . 50.0 111.421 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.682 HG13 HD11 ' A' ' 48' ' ' ILE . 59.5 t -85.36 107.44 16.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.173 -0.955 . . . . 50.0 108.896 178.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.517 ' HA2' ' HB3' ' A' ' 100' ' ' GLN . . . -90.3 170.23 35.49 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.783 -1.198 . . . . 50.0 110.254 -178.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.606 ' CB ' ' CB ' ' A' ' 15' ' ' GLU . 0.0 OUTLIER -153.54 13.89 0.49 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.431 -1.041 . . . . 50.0 110.166 -179.811 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 136.36 -86.6 0.24 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.235 -1.546 . . . . 50.0 109.235 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -99.44 -68.71 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -1.154 . . . . 50.0 109.971 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.89 151.66 30.04 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.201 -0.937 . . . . 50.0 110.04 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.615 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -140.07 148.6 42.0 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.088 -1.008 . . . . 0.0 110.349 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 93' ' ' VAL . 11.0 mt -90.94 146.72 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.152 -0.968 . . . . 0.0 109.638 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.0 p-10 -132.83 132.02 41.68 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.108 -0.995 . . . . 0.0 110.845 -179.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.498 ' O ' ' HA ' ' A' ' 91' ' ' TYR . 0.0 OUTLIER -118.71 152.92 35.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.391 -0.818 . . . . 0.0 109.518 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.597 ' HA ' ' CD1' ' A' ' 91' ' ' TYR . 16.8 p-80 -116.23 83.1 1.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.554 -179.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.609 ' CD1' ' HG2' ' A' ' 23' ' ' PRO . 10.1 t-105 -58.51 93.89 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.206 -0.934 . . . . 0.0 109.943 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.851 ' CE1' ' HB3' ' A' ' 108' ' ' ALA . 6.8 t60 -124.79 112.0 16.19 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.318 -0.863 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.7 -6.9 23.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.296 -0.877 . . . . 0.0 110.396 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.851 ' HB3' ' CE1' ' A' ' 106' ' ' HIS . . . -56.7 138.84 52.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.14 -0.975 . . . . 0.0 110.225 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 110' ' ' SER . . . -116.38 23.85 10.19 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 109' ' ' GLY . 25.8 m -43.44 -58.09 2.76 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.231 -1.158 . . . . 0.0 110.312 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.557 HG23 ' OXT' ' A' ' 111' ' ' THR . 8.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 118.002 -0.999 . . . . 49.57 110.193 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.22 0.533 . . . . 50.0 110.217 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.445 ' O ' HD22 ' A' ' 3' ' ' LEU . 5.8 pttt -140.19 172.16 13.15 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.317 -0.865 . . . . 50.0 110.163 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.469 HD13 ' HA ' ' A' ' 3' ' ' LEU . 2.1 mm? -117.28 154.17 31.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.291 -0.881 . . . . 50.0 110.268 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -111.74 102.17 10.48 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.937 . . . . 50.0 110.214 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.427 HD23 ' ND2' ' A' ' 67' ' ' ASN . 3.9 mp -111.16 166.74 10.83 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.211 -0.931 . . . . 50.0 110.01 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.68 -171.14 2.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.322 -0.861 . . . . 50.0 110.148 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -138.55 59.07 0.61 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.584 -1.406 . . . . 50.0 109.584 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.416 ' O ' ' C ' ' A' ' 9' ' ' THR . 10.4 p -72.11 161.09 31.38 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.216 -1.167 . . . . 50.0 110.14 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' THR . 0.8 OUTLIER -43.35 115.29 0.75 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.271 -0.893 . . . . 50.0 110.112 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CD1' ' C ' ' A' ' 10' ' ' TYR . 12.1 p90 -129.23 155.42 45.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.215 -0.928 . . . . 50.0 110.39 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.457 ' O ' ' SG ' ' A' ' 44' ' ' CYS . . . -107.57 122.21 6.73 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.387 -1.485 . . . . 50.0 109.387 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.613 ' HA ' ' HB2' ' A' ' 45' ' ' LYS . 0.3 OUTLIER -83.55 85.36 7.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.243 -1.151 . . . . 50.0 110.343 -179.807 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.741 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 4.0 p -149.07 107.17 3.72 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.13 -0.981 . . . . 99.99 111.006 179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.671 ' HB ' HG23 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -162.25 28.9 0.11 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.643 -1.286 . . . . 99.99 110.505 179.289 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 -11.31 3.13 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.12 -0.988 . . . . 99.99 110.236 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.45 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 0.0 OUTLIER -71.0 61.05 0.26 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 50.0 110.429 -179.908 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.748 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.4 OUTLIER -105.62 141.4 37.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.155 -0.966 . . . . 50.0 109.859 179.564 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.602 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.8 OUTLIER -125.09 119.86 29.8 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.189 -0.944 . . . . 50.0 110.198 -179.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.61 ' CE2' ' NE2' ' A' ' 103' ' ' HIS . 7.3 m-85 -63.13 115.25 4.3 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.21 -0.931 . . . . 50.0 110.027 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.59 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -104.3 -28.34 11.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.241 -0.912 . . . . 50.0 110.103 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HG3' ' HB3' ' A' ' 34' ' ' GLU . 19.0 mttm -146.14 151.94 38.46 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 50.0 110.171 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -71.88 164.04 61.78 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 50.0 110.218 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.504 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 45.9 Cg_endo -72.87 128.09 12.89 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 O-C-N 123.997 1.525 . . . . 50.0 110.206 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.654 ' O ' HG22 ' A' ' 32' ' ' VAL . . . -125.23 152.84 44.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.913 . . . . 50.0 110.369 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.454 ' HA ' ' O ' ' A' ' 30' ' ' THR . 11.3 t70 -85.72 145.43 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.337 -0.852 . . . . 50.0 110.108 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -135.8 33.97 2.92 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.252 -0.905 . . . . 50.0 110.186 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 161.59 -109.87 0.41 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -128.02 88.99 2.85 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -1.155 . . . . 50.0 110.132 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 84' ' ' GLU . . . 87.11 -7.59 79.96 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.719 -1.352 . . . . 50.0 109.719 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.584 ' HA ' ' HG2' ' A' ' 84' ' ' GLU . 41.4 p -80.37 114.14 19.06 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -1.176 . . . . 50.0 110.194 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.566 ' CG2' ' HD2' ' A' ' 85' ' ' PRO . 21.6 t -106.47 141.46 21.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 O-C-N 121.224 -0.923 . . . . 50.0 110.326 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.654 HG22 ' O ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -112.41 142.4 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.269 -0.894 . . . . 50.0 110.334 -179.803 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.615 HG12 HD11 ' A' ' 35' ' ' LEU . 0.4 OUTLIER -141.37 140.26 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.348 -0.845 . . . . 50.0 109.706 179.695 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.59 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 18.3 tt0 -121.79 117.03 25.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -0.975 . . . . 50.0 110.535 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.102 ' O ' HG22 ' A' ' 79' ' ' VAL . 0.5 OUTLIER -126.38 139.53 53.2 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.307 -0.871 . . . . 50.0 109.529 179.413 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.638 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.2 OUTLIER -87.77 126.94 35.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.059 -1.026 . . . . 50.0 109.704 -179.75 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.553 ' O ' ' HA ' ' A' ' 76' ' ' ASN . 32.2 t80 -90.47 95.72 10.3 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.77 -1.172 . . . . 50.0 109.71 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.4 t -94.58 70.02 3.55 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.246 -0.909 . . . . 50.0 110.032 -179.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -121.75 126.76 6.61 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.515 -1.434 . . . . 99.99 109.515 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.44 25.31 1.23 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.227 -1.161 . . . . 99.99 110.36 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -99.76 -0.96 38.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.203 -0.935 . . . . 99.99 110.051 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.4 -163.28 31.23 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.391 -1.484 . . . . 99.99 109.391 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.62 ' HB2' ' HA ' ' A' ' 71' ' ' ALA . 43.8 Cg_endo -72.71 151.6 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 124.019 1.536 . . . . 99.99 110.515 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.741 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 3.7 t -170.22 161.71 8.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.391 -0.818 . . . . 50.0 109.666 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 12' ' ' MET . 25.1 mmtt -77.23 121.5 23.76 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.009 -1.057 . . . . 50.0 110.047 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.005 HG22 HD11 ' A' ' 48' ' ' ILE . 2.8 mt -83.92 110.3 24.67 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.367 -0.833 . . . . 50.0 110.585 -179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 45' ' ' LYS . 51.2 Cg_endo -80.47 106.29 1.84 Allowed 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.009 1.531 . . . . 50.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.005 HD11 HG22 ' A' ' 46' ' ' ILE . 3.0 mp -123.2 142.94 37.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.163 -0.961 . . . . 50.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 93' ' ' VAL . 5.9 m -120.71 96.62 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.357 -0.84 . . . . 50.0 109.724 179.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.451 ' HA ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -87.95 104.08 16.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.287 -0.883 . . . . 50.0 110.309 -179.625 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.718 HG12 ' H ' ' A' ' 60' ' ' VAL . 16.8 m -130.42 162.07 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.231 -0.918 . . . . 50.0 110.073 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 90' ' ' SER . . . -68.18 164.02 21.39 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.29 -0.882 . . . . 50.0 109.304 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.607 ' N ' ' HA ' ' A' ' 90' ' ' SER . 2.2 t -67.61 99.9 0.83 Allowed 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 118.529 -1.268 . . . . 50.0 108.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.592 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 172.06 -67.15 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.264 -1.374 . . . . 50.0 111.458 -179.688 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -99.64 122.03 42.08 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.087 -1.008 . . . . 50.0 110.299 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -106.18 19.45 20.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.176 -0.952 . . . . 50.0 110.074 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.19 -7.15 6.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.29 -0.881 . . . . 50.0 110.37 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.67 ' O ' HG11 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -134.44 140.88 37.05 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.19 -0.944 . . . . 50.0 110.288 -179.869 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.577 ' HA ' ' CG1' ' A' ' 51' ' ' VAL . 46.5 Cg_endo -73.07 136.13 24.21 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 124.072 1.564 . . . . 50.0 110.443 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.718 ' H ' HG12 ' A' ' 51' ' ' VAL . 52.8 t -147.18 10.41 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.216 -0.927 . . . . 50.0 110.381 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -110.08 170.78 14.39 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.271 -1.532 . . . . 50.0 109.271 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.544 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 5.1 mmt180 -107.07 145.13 32.78 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.101 -1.235 . . . . 50.0 110.218 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.486 ' HG ' ' SD ' ' A' ' 83' ' ' MET . 0.1 OUTLIER -116.99 110.34 18.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 50.0 110.065 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.804 ' O ' HG12 ' A' ' 64' ' ' VAL . 73.5 t -100.07 42.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.168 -0.958 . . . . 50.0 110.124 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.494 ' OG1' ' N ' ' A' ' 82' ' ' GLU . 1.6 m -130.71 144.89 51.75 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.868 . . . . 50.0 110.096 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.468 ' O ' ' O ' ' A' ' 65' ' ' THR . 26.0 m -52.72 -171.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.217 -0.927 . . . . 50.0 110.052 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB3' ' CD2' ' A' ' 69' ' ' PHE . 2.3 m-20 -46.83 115.46 3.34 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.128 -0.982 . . . . 50.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.625 ' O ' ' CD1' ' A' ' 69' ' ' PHE . 45.0 Cg_endo -71.89 66.27 3.23 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.964 1.507 . . . . 50.0 110.136 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.625 ' CD1' ' O ' ' A' ' 68' ' ' PRO . 13.5 m-85 -135.76 123.62 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.474 -0.766 . . . . 50.0 110.054 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.99 HG23 HD11 ' A' ' 46' ' ' ILE . 53.4 t -71.97 60.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.038 -1.039 . . . . 50.0 109.84 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.62 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -86.63 57.47 4.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 50.0 109.828 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.3 169.13 18.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.328 -0.857 . . . . 50.0 110.337 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.25 -7.34 35.79 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 50.0 109.999 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 14.6 p -121.06 13.18 11.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.312 -0.868 . . . . 99.99 110.313 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.962 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -76.99 5.45 8.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 99.99 109.958 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 40.2 m-20 -83.42 20.41 1.35 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.313 -0.867 . . . . 99.99 109.391 179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.661 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.6 OUTLIER -122.51 -172.91 2.57 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.363 -0.835 . . . . 99.99 109.444 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.16 89.03 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.731 -0.788 . . . . 99.99 109.118 179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 1.102 HG22 ' O ' ' A' ' 35' ' ' LEU . 10.4 m -76.23 175.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.406 -0.809 . . . . 99.99 109.663 -179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 81' ' ' VAL . 0.8 OUTLIER -131.47 139.97 49.46 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.879 -1.138 . . . . 50.0 111.028 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.438 ' N ' HD23 ' A' ' 80' ' ' LEU . 0.2 OUTLIER -131.21 172.26 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.452 -0.78 . . . . 50.0 109.991 179.963 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.494 ' N ' ' OG1' ' A' ' 65' ' ' THR . 37.9 mt-10 -135.41 142.41 45.64 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.155 -0.966 . . . . 50.0 110.084 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.522 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 0.0 OUTLIER -153.02 142.37 21.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.108 -0.995 . . . . 50.0 110.234 -179.71 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.642 ' HG3' HG21 ' A' ' 64' ' ' VAL . 1.5 mm-40 -110.79 67.89 0.56 Allowed Pre-proline 0 C--N 1.304 -1.37 0 O-C-N 121.022 -1.049 . . . . 50.0 110.619 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.566 ' HD2' ' CG2' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.26 155.78 55.79 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.978 1.515 . . . . 50.0 110.528 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.22 163.28 39.17 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.105 1.582 . . . . 50.0 110.463 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -73.54 138.46 45.01 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.201 -0.937 . . . . 50.0 110.172 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 121.43 -150.14 17.17 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.362 -1.495 . . . . 50.0 109.362 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.409 ' HB3' ' HB2' ' A' ' 53' ' ' SER . 8.6 m-20 -92.3 137.11 32.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.234 -1.156 . . . . 50.0 110.0 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.607 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -130.23 133.4 46.51 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.23 -0.919 . . . . 50.0 110.247 179.984 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.522 ' O ' ' CG2' ' A' ' 51' ' ' VAL . 0.2 OUTLIER -91.65 97.08 10.81 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.159 -0.963 . . . . 50.0 109.996 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 50' ' ' SER . 1.7 pt -102.56 116.95 47.18 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.271 -0.893 . . . . 50.0 109.839 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.643 HG22 ' HA ' ' A' ' 102' ' ' ASN . 42.5 t -118.57 131.07 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 50.0 110.556 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.821 HG13 HG13 ' A' ' 48' ' ' ILE . 14.7 t -107.28 96.66 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.278 -0.888 . . . . 50.0 109.86 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.536 ' HA3' ' CB ' ' A' ' 100' ' ' GLN . . . -155.42 165.42 32.39 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.623 -1.391 . . . . 50.0 109.623 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.529 ' HG3' ' N ' ' A' ' 97' ' ' GLY . 10.8 ptp -107.48 -33.41 7.36 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.282 -1.129 . . . . 50.0 110.316 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . 0.529 ' N ' ' HG3' ' A' ' 96' ' ' MET . . . 176.36 -63.21 0.1 OUTLIER Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.478 -1.449 . . . . 50.0 109.478 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -63.75 -107.59 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.204 -1.174 . . . . 50.0 110.132 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -79.29 123.35 27.37 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.111 -0.993 . . . . 50.0 110.161 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.781 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 1.7 pp0? -131.41 150.17 52.25 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 110.064 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 46.0 mt -102.88 106.7 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.996 -1.065 . . . . 0.0 110.136 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.643 ' HA ' HG22 ' A' ' 93' ' ' VAL . 7.6 p-10 -97.4 130.8 44.5 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 110.196 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.61 ' NE2' ' CE2' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -126.99 160.45 31.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.34 -0.85 . . . . 0.0 110.238 179.976 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.403 ' CD2' ' H ' ' A' ' 104' ' ' HIS . 7.3 p80 -123.26 86.53 2.59 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 110.131 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.501 ' CH2' ' HA ' ' A' ' 107' ' ' LYS . 0.1 OUTLIER -51.76 99.38 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 110.042 179.988 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.472 ' N ' ' CE3' ' A' ' 105' ' ' TRP . 0.9 OUTLIER -104.55 106.47 16.98 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.326 -0.859 . . . . 0.0 110.194 -179.879 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . 0.501 ' HA ' ' CH2' ' A' ' 105' ' ' TRP . 0.0 OUTLIER -81.34 -10.36 59.57 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.309 -0.869 . . . . 0.0 110.274 179.956 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -118.09 -174.49 2.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.24 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -158.08 -73.84 0.02 OUTLIER Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -91.22 143.07 27.04 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.282 -1.128 . . . . 0.0 110.186 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 118.051 -0.976 . . . . 49.57 110.214 -179.972 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.31 0.576 . . . . 50.0 110.107 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.3 pttm -136.94 151.93 49.6 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 50.0 110.057 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 3' ' ' LEU . 0.5 OUTLIER -107.18 98.95 8.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.197 -0.94 . . . . 50.0 110.224 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.21 133.85 54.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.246 -0.909 . . . . 50.0 110.342 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.439 HD13 ' HA ' ' A' ' 5' ' ' LEU . 1.4 mm? -111.23 170.23 8.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 50.0 109.749 179.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 3.3 ttpt -100.97 142.99 31.65 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.129 -0.982 . . . . 50.0 110.334 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 122.84 -36.84 2.98 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.38 -1.488 . . . . 50.0 109.38 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 3.0 p -132.92 99.29 4.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.346 -1.091 . . . . 50.0 110.102 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.468 ' O ' ' O ' ' A' ' 10' ' ' TYR . 5.1 t -173.76 170.13 4.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.258 -0.901 . . . . 50.0 110.27 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.468 ' O ' ' O ' ' A' ' 9' ' ' THR . 0.6 OUTLIER -48.07 179.06 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.413 -0.804 . . . . 50.0 110.171 179.823 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -70.97 168.95 49.59 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.671 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 2.0 ptt? -112.3 127.96 56.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.269 -1.136 . . . . 50.0 110.299 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.705 ' O ' ' HB3' ' A' ' 44' ' ' CYS . 0.0 OUTLIER -147.13 105.88 3.83 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.111 -0.993 . . . . 99.99 111.151 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.908 HG21 HG12 ' A' ' 46' ' ' ILE . 0.2 OUTLIER -162.22 25.09 0.11 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.115 -0.991 . . . . 99.99 109.938 178.458 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 96' ' ' MET . 17.9 tt0 -49.78 -18.67 0.51 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.316 -0.865 . . . . 99.99 110.375 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 37' ' ' TYR . 1.2 mmtt -76.2 61.43 1.61 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.136 -0.978 . . . . 50.0 110.411 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.919 ' CZ ' HG21 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -99.0 138.68 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.926 . . . . 50.0 109.94 179.524 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 12.7 t -128.29 97.47 4.76 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.205 -0.934 . . . . 50.0 110.621 -179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.521 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 6.7 p90 -56.5 117.95 4.34 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.993 -1.067 . . . . 50.0 109.836 179.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' HB1' ' HE2' ' A' ' 78' ' ' LYS . . . -107.34 -19.64 13.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.919 . . . . 50.0 110.651 -179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.512 ' CE ' ' OE1' ' A' ' 34' ' ' GLU . 25.9 mttm -140.79 150.79 43.8 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.14 -0.975 . . . . 50.0 110.684 -179.753 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -67.64 165.44 30.4 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.447 -0.783 . . . . 50.0 110.145 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 45.5 Cg_endo -72.75 142.89 36.39 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 124.012 1.533 . . . . 50.0 110.305 -179.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . . . -133.5 152.52 51.92 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.218 -0.926 . . . . 50.0 110.249 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 30' ' ' THR . 3.6 p30 -92.55 130.94 38.06 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.29 -0.881 . . . . 50.0 110.338 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.401 HG23 HG21 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -100.66 -80.84 0.48 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.29 -0.881 . . . . 50.0 110.035 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.41 -109.14 0.61 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.431 -1.467 . . . . 50.0 109.431 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -129.73 97.32 4.48 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.276 -1.132 . . . . 50.0 110.145 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 96.84 8.8 56.8 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.56 -1.416 . . . . 50.0 109.56 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 82.5 p -103.2 128.22 50.25 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -1.084 . . . . 50.0 110.263 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 82' ' ' GLU . 39.2 t -109.74 137.71 40.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.366 -0.834 . . . . 50.0 109.906 179.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.083 ' CG1' HD21 ' A' ' 80' ' ' LEU . 1.5 t -117.57 143.43 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 50.0 110.436 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.791 HG12 HD11 ' A' ' 35' ' ' LEU . 3.6 tt -142.93 145.11 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.262 -0.899 . . . . 50.0 109.759 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.564 ' HA ' ' O ' ' A' ' 79' ' ' VAL . 17.7 tt0 -116.46 102.55 9.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.16 -0.962 . . . . 50.0 110.721 -179.59 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 1.081 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.0 OUTLIER -113.56 136.77 52.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.259 -0.9 . . . . 50.0 109.536 179.45 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.624 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.4 OUTLIER -86.36 129.85 34.71 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.155 -0.966 . . . . 50.0 109.92 -179.57 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.617 ' CD2' HG11 ' A' ' 70' ' ' VAL . 10.7 t80 -95.59 99.6 11.45 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 118.983 -1.087 . . . . 50.0 109.869 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -96.27 72.29 2.83 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.116 -0.99 . . . . 50.0 110.135 -179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -124.67 124.03 5.27 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.532 -1.427 . . . . 99.99 109.532 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.65 29.45 2.62 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.212 -1.17 . . . . 99.99 110.265 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.421 ' OD1' ' C ' ' A' ' 41' ' ' ASP . 2.1 p30 -102.99 0.39 32.1 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.291 -0.881 . . . . 99.99 110.155 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.67 174.67 25.88 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.273 -1.531 . . . . 99.99 109.273 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.548 ' CB ' ' O ' ' A' ' 70' ' ' VAL . 45.0 Cg_endo -72.81 149.74 48.52 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.001 1.527 . . . . 99.99 110.599 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.705 ' HB3' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -167.47 162.66 14.64 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.439 -0.788 . . . . 50.0 109.56 -179.813 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.671 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 23.2 mmtt -67.5 141.44 56.91 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.968 -1.082 . . . . 50.0 109.745 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.054 HG22 ' CD1' ' A' ' 48' ' ' ILE . 7.1 mt -90.78 108.81 30.21 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.299 -0.875 . . . . 50.0 110.649 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.562 ' HG2' ' O ' ' A' ' 95' ' ' GLY . 49.9 Cg_endo -75.48 96.48 1.04 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 124.152 1.606 . . . . 50.0 110.955 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 1.054 ' CD1' HG22 ' A' ' 46' ' ' ILE . 0.5 OUTLIER -131.64 115.79 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 50.0 109.992 179.462 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.749 ' O ' HG23 ' A' ' 49' ' ' VAL . 18.0 m -93.07 107.44 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.852 . . . . 50.0 109.932 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -86.18 100.88 12.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.276 -0.89 . . . . 50.0 109.765 179.869 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.567 ' O ' ' N ' ' A' ' 91' ' ' TYR . 95.7 t -118.71 150.56 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.313 -0.867 . . . . 50.0 110.468 -179.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.465 ' C ' ' HA ' ' A' ' 90' ' ' SER . . . -67.51 164.73 18.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.373 -0.83 . . . . 50.0 109.62 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.639 ' N ' ' HA ' ' A' ' 90' ' ' SER . 5.4 t -70.05 101.84 1.9 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.834 -1.166 . . . . 50.0 109.424 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.498 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.2 OUTLIER 171.0 -64.12 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.057 -1.457 . . . . 50.0 111.703 -179.906 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.537 ' CB ' ' HB ' ' A' ' 58' ' ' THR . 41.4 m-80 -88.05 164.99 15.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.094 . . . . 50.0 110.315 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 56' ' ' ASP . 49.9 t0 -105.9 -37.87 6.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 50.0 110.238 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 3.0 ttm -123.85 30.39 6.19 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 50.0 110.217 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.537 ' HB ' ' CB ' ' A' ' 55' ' ' ASN . 17.3 m -111.85 120.62 41.74 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.256 -0.902 . . . . 50.0 110.049 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.416 ' HA ' HG22 ' A' ' 51' ' ' VAL . 44.4 Cg_endo -72.58 130.05 15.47 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.989 1.52 . . . . 50.0 110.414 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.413 HG23 HG13 ' A' ' 51' ' ' VAL . 10.5 t -142.3 -36.35 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.259 -0.901 . . . . 50.0 110.26 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 50' ' ' SER . . . -77.54 164.74 52.37 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.138 -1.585 . . . . 50.0 109.138 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.434 ' HG2' ' C ' ' A' ' 61' ' ' GLY . 10.5 mtt180 -138.49 156.45 47.52 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.095 -1.238 . . . . 50.0 110.445 -179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.665 HD13 ' HD3' ' A' ' 68' ' ' PRO . 2.5 mt -97.97 122.4 41.06 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.209 -0.932 . . . . 50.0 109.776 179.613 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.711 HG22 ' HG2' ' A' ' 84' ' ' GLU . 30.6 t -63.33 -13.5 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.217 -0.927 . . . . 50.0 110.12 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 66' ' ' VAL . 34.6 m -124.77 163.21 22.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.295 -0.878 . . . . 50.0 109.955 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.528 HG12 ' N ' ' A' ' 67' ' ' ASN . 74.1 t -44.09 168.93 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 50.0 109.959 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.628 ' O ' ' CD2' ' A' ' 69' ' ' PHE . 18.2 t-20 -46.68 142.73 4.56 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.196 -0.94 . . . . 50.0 110.11 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.665 ' HD3' HD13 ' A' ' 63' ' ' LEU . 49.8 Cg_endo -76.22 98.56 1.21 Allowed 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.927 1.488 . . . . 50.0 110.452 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.628 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 9.2 p90 -120.51 138.49 53.81 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.225 -0.922 . . . . 50.0 110.346 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.982 HG13 ' CB ' ' A' ' 75' ' ' ALA . 73.6 t -91.01 60.94 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.198 -0.939 . . . . 50.0 110.181 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.532 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -89.76 57.44 3.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 50.0 110.346 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.7 m -143.43 169.12 18.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.215 -0.928 . . . . 50.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.7 p -94.23 -6.83 43.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 50.0 109.92 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.14 17.74 11.6 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.895 . . . . 99.99 110.41 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.982 ' CB ' HG13 ' A' ' 70' ' ' VAL . . . -79.79 7.29 8.95 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.15 -0.969 . . . . 99.99 110.066 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.535 ' HA ' ' O ' ' A' ' 37' ' ' TYR . 53.6 m-20 -85.17 18.78 2.44 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.234 -0.917 . . . . 99.99 109.341 179.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.684 ' O ' HG13 ' A' ' 79' ' ' VAL . 0.1 OUTLIER -122.68 -172.73 2.54 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.404 -0.81 . . . . 99.99 109.277 179.97 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.487 ' HE2' ' HB1' ' A' ' 20' ' ' ALA . 40.0 mttt -62.98 88.47 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.327 -0.858 . . . . 99.99 109.168 179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 1.081 HG22 ' O ' ' A' ' 35' ' ' LEU . 11.4 m -76.68 176.48 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.376 -0.827 . . . . 99.99 109.392 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 1.083 HD21 ' CG1' ' A' ' 32' ' ' VAL . 8.0 tt -135.23 133.92 39.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.781 -1.2 . . . . 50.0 111.212 -179.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 82' ' ' GLU . 1.9 t -119.98 178.31 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.483 -0.76 . . . . 50.0 109.829 179.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 61.7 mt-10 -148.52 139.24 22.86 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.996 -1.065 . . . . 50.0 110.546 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.492 ' HA ' ' HA ' ' A' ' 63' ' ' LEU . 14.2 ptt? -155.81 139.03 15.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.268 -0.895 . . . . 50.0 110.245 179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.711 ' HG2' HG22 ' A' ' 64' ' ' VAL . 1.3 pt-20 -109.24 76.62 0.81 Allowed Pre-proline 0 C--N 1.305 -1.327 0 O-C-N 121.183 -0.948 . . . . 50.0 110.619 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 83' ' ' MET . 47.5 Cg_endo -73.86 170.34 20.3 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.02 1.537 . . . . 50.0 110.344 179.627 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.33 161.94 42.95 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.061 1.559 . . . . 50.0 110.42 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -67.13 145.35 55.38 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.171 -0.956 . . . . 50.0 110.154 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 110.28 158.62 16.74 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.189 -1.564 . . . . 50.0 109.189 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.496 ' OD2' ' CD2' ' A' ' 106' ' ' HIS . 1.0 OUTLIER -52.41 148.55 6.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -1.22 . . . . 50.0 109.928 -179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.639 ' HA ' ' N ' ' A' ' 53' ' ' SER . 83.4 p -130.49 138.77 50.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.118 -0.989 . . . . 50.0 110.705 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.567 ' N ' ' O ' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -90.65 104.35 16.94 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.16 -0.963 . . . . 50.0 109.415 179.334 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.422 HG23 ' O ' ' A' ' 92' ' ' ILE . 3.3 tt -103.43 135.02 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.155 -0.966 . . . . 50.0 110.341 -179.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 100' ' ' GLN . 10.7 t -125.15 114.52 40.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.089 -1.007 . . . . 50.0 110.863 -179.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.853 HG13 ' CD1' ' A' ' 48' ' ' ILE . 17.6 t -103.97 104.14 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.195 -0.941 . . . . 50.0 109.444 179.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -155.27 169.92 33.29 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.614 -1.279 . . . . 50.0 110.195 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.434 ' HB2' ' HB2' ' A' ' 15' ' ' GLU . 19.7 ttm -111.72 -51.35 2.86 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.355 -1.085 . . . . 50.0 110.597 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . -106.85 -145.14 12.18 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.845 -1.302 . . . . 50.0 109.845 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.403 ' O ' ' HG3' ' A' ' 100' ' ' GLN . 2.3 p30 -63.52 -36.11 82.68 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.219 -1.165 . . . . 50.0 110.384 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.37 116.56 19.68 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.207 -0.933 . . . . 50.0 110.184 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.606 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -139.45 148.69 43.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.323 -0.861 . . . . 0.0 110.114 -179.808 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.734 ' O ' HG23 ' A' ' 101' ' ' ILE . 3.5 tp -94.87 110.32 23.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.258 -0.901 . . . . 0.0 110.012 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.418 ' OD1' ' N ' ' A' ' 102' ' ' ASN . 32.8 p-10 -101.93 131.82 48.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.1 -1.0 . . . . 0.0 110.475 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -121.12 171.36 8.74 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.38 -0.825 . . . . 0.0 110.146 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 1.4 p80 -119.34 79.92 1.49 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 110.471 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.433 ' HZ2' HD11 ' A' ' 33' ' ' ILE . 0.1 OUTLIER -52.43 134.74 34.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.983 179.781 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.496 ' CD2' ' OD2' ' A' ' 89' ' ' ASP . 0.2 OUTLIER -110.52 98.75 7.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.179 -0.951 . . . . 0.0 110.412 -179.803 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.36 -9.75 13.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.333 -0.855 . . . . 0.0 110.036 179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -47.49 154.72 0.42 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.301 -0.874 . . . . 0.0 110.082 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -154.54 142.36 8.98 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.3 p -66.46 -177.22 0.53 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -1.145 . . . . 0.0 110.141 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . 0.556 HG22 ' O ' ' A' ' 111' ' ' THR . 22.0 m . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.042 -0.98 . . . . 49.57 110.263 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 45.8 m-20 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.263 0.554 . . . . 50.0 110.313 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -150.41 155.77 40.2 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 50.0 110.228 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 3' ' ' LEU . 0.7 OUTLIER -83.82 155.95 22.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 50.0 110.206 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.98 168.97 9.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.273 -0.892 . . . . 50.0 110.201 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.5 mp -89.91 61.69 5.4 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.24 -0.913 . . . . 50.0 110.142 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 4.1 tttt -97.27 149.32 22.18 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.338 -0.851 . . . . 50.0 110.171 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.92 -53.26 0.81 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.658 -1.377 . . . . 50.0 109.658 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 38.7 p -141.8 127.59 19.26 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.23 -1.159 . . . . 50.0 110.345 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -51.17 173.87 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.25 -0.906 . . . . 50.0 110.196 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -138.41 161.02 38.04 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.233 -0.917 . . . . 50.0 110.27 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -72.28 117.38 6.27 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.47 -1.452 . . . . 50.0 109.47 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.546 ' CB ' ' HB2' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -111.87 102.79 11.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -1.177 . . . . 50.0 110.248 -179.948 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.658 ' O ' ' SG ' ' A' ' 13' ' ' CYS . 11.6 p -148.69 107.35 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.204 -0.935 . . . . 99.99 110.415 179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 1.019 HG21 ' CD1' ' A' ' 46' ' ' ILE . 1.3 m -161.5 62.8 0.26 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.674 -1.266 . . . . 99.99 110.549 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.488 ' HG3' ' HE3' ' A' ' 16' ' ' LYS . 1.5 pp20? -84.63 25.18 0.93 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.156 -0.965 . . . . 99.99 110.117 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.514 ' HD3' ' HA3' ' A' ' 39' ' ' GLY . 1.8 mptt -123.47 61.02 1.06 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.177 -0.952 . . . . 50.0 110.782 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.816 ' CB ' HG11 ' A' ' 94' ' ' VAL . 0.0 OUTLIER -99.11 146.88 25.64 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.054 -1.029 . . . . 50.0 109.8 179.429 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.675 ' O ' ' HA ' ' A' ' 35' ' ' LEU . 0.4 OUTLIER -128.11 145.41 51.02 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.124 -0.985 . . . . 50.0 110.294 -179.898 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.738 ' CZ ' HD12 ' A' ' 101' ' ' ILE . 1.2 m-85 -85.32 104.28 15.01 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.962 -1.086 . . . . 50.0 109.617 179.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.929 ' HB3' ' O ' ' A' ' 34' ' ' GLU . . . -93.2 -34.53 13.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.128 -0.983 . . . . 50.0 110.648 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.512 ' HG2' ' O ' ' A' ' 20' ' ' ALA . 13.6 mttm -145.09 166.71 24.6 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.06 -1.025 . . . . 50.0 110.614 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.59 165.16 39.36 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 50.0 110.09 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.512 ' HB2' ' CG1' ' A' ' 31' ' ' VAL . 46.0 Cg_endo -72.71 136.75 26.15 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.969 1.51 . . . . 50.0 110.46 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 31' ' ' VAL . . . -125.44 167.53 14.85 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.251 -0.906 . . . . 50.0 110.346 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -105.81 132.31 52.08 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 50.0 110.37 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 1.1 p -108.78 -23.17 11.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.298 -0.876 . . . . 50.0 110.136 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.46 -114.64 0.59 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.468 -1.453 . . . . 50.0 109.468 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' HIS . . . . . 0.513 ' O ' ' CD2' ' A' ' 28' ' ' HIS . 11.5 p-80 -130.17 88.87 2.71 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -1.163 . . . . 50.0 110.296 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.484 ' O ' ' HB3' ' A' ' 84' ' ' GLU . . . 105.1 14.94 21.37 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.611 -1.396 . . . . 50.0 109.611 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.8 p -121.73 111.53 17.28 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.311 -1.111 . . . . 50.0 110.186 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.512 ' CG1' ' HB2' ' A' ' 23' ' ' PRO . 18.3 t -104.61 150.56 7.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.218 -0.926 . . . . 50.0 110.313 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.758 HG12 HD21 ' A' ' 80' ' ' LEU . 0.0 OUTLIER -128.19 135.09 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.244 -0.91 . . . . 50.0 110.271 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.944 HG23 HD11 ' A' ' 35' ' ' LEU . 8.0 tt -134.28 150.3 30.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.317 -0.864 . . . . 50.0 109.518 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.929 ' O ' ' HB3' ' A' ' 20' ' ' ALA . 2.4 tt0 -119.84 103.78 9.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.023 -1.048 . . . . 50.0 110.767 -179.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.961 ' O ' HG22 ' A' ' 79' ' ' VAL . 1.2 mp -110.89 137.36 48.63 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.226 -0.921 . . . . 50.0 109.691 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.549 ' HA ' ' O ' ' A' ' 77' ' ' SER . 0.8 OUTLIER -84.68 124.78 31.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.058 -1.026 . . . . 50.0 109.696 179.954 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.518 ' HB3' ' O ' ' A' ' 75' ' ' ALA . 6.3 t80 -92.34 97.84 11.12 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.904 -1.118 . . . . 50.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 21.9 t -95.14 72.09 3.34 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.391 -0.818 . . . . 50.0 110.163 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.514 ' HA3' ' HD3' ' A' ' 16' ' ' LYS . . . -125.57 126.68 5.96 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.574 -1.41 . . . . 99.99 109.574 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -83.55 16.85 2.42 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.244 -1.151 . . . . 99.99 110.201 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -92.4 -22.47 19.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.217 -0.927 . . . . 99.99 110.149 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.76 -163.31 12.31 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.641 -1.384 . . . . 99.99 109.641 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.536 ' HB3' ' O ' ' A' ' 70' ' ' VAL . 44.7 Cg_endo -73.5 150.31 45.78 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 O-C-N 123.966 1.509 . . . . 99.99 110.418 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.628 ' CB ' ' O ' ' A' ' 13' ' ' CYS . 0.0 OUTLIER -170.55 161.87 7.87 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.309 -0.87 . . . . 50.0 109.851 -179.531 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HB2' ' CB ' ' A' ' 12' ' ' MET . 13.7 mmtt -69.0 117.53 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.067 -1.021 . . . . 50.0 109.382 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 1.092 HD11 ' CG2' ' A' ' 70' ' ' VAL . 4.4 mm -71.4 112.83 15.19 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.058 -1.026 . . . . 50.0 110.372 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.508 ' CG ' ' HA ' ' A' ' 96' ' ' MET . 51.8 Cg_endo -80.26 91.87 1.13 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.061 1.558 . . . . 50.0 110.171 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.791 HG12 HG22 ' A' ' 94' ' ' VAL . 63.3 mt -133.11 149.98 32.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.128 -0.982 . . . . 50.0 110.541 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.564 ' CG2' ' HB ' ' A' ' 93' ' ' VAL . 26.1 m -124.14 159.66 29.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.382 -0.824 . . . . 50.0 109.661 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.455 ' O ' ' HA3' ' A' ' 61' ' ' GLY . 0.3 OUTLIER -134.76 107.66 7.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.217 -0.927 . . . . 50.0 110.066 -179.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' A' ' 91' ' ' TYR . 27.5 m -125.2 156.76 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.284 -0.885 . . . . 50.0 110.203 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.675 ' HB3' ' OD1' ' A' ' 55' ' ' ASN . . . -55.93 163.64 1.42 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.355 -0.841 . . . . 50.0 110.012 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.609 ' O ' ' CB ' ' A' ' 54' ' ' LEU . 0.4 OUTLIER -59.5 121.21 10.98 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.211 -0.931 . . . . 50.0 110.649 -179.556 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.609 ' CB ' ' O ' ' A' ' 53' ' ' SER . 0.1 OUTLIER 78.58 30.55 0.38 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.565 -0.709 . . . . 50.0 110.976 179.549 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.675 ' OD1' ' HB3' ' A' ' 52' ' ' ALA . 30.1 m120 -128.0 84.28 2.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.21 -0.931 . . . . 50.0 110.068 179.066 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.49 9.6 31.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.234 -0.917 . . . . 50.0 110.211 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.4 mtt -113.85 -15.65 12.35 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -0.863 . . . . 50.0 110.111 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -136.37 121.01 12.85 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.334 -0.854 . . . . 50.0 110.246 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.461 ' HA ' HG12 ' A' ' 51' ' ' VAL . 46.3 Cg_endo -72.98 133.66 20.2 Favored 'Trans proline' 0 C--N 1.305 -1.755 0 O-C-N 123.989 1.52 . . . . 50.0 110.16 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.435 ' CG2' ' H ' ' A' ' 52' ' ' ALA . 31.3 m -142.31 -31.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.223 -0.923 . . . . 50.0 110.429 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 50' ' ' SER . . . -71.41 144.79 37.94 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 108.397 -1.881 . . . . 50.0 108.397 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.471 ' HB2' ' HG3' ' A' ' 84' ' ' GLU . 11.7 mtp180 -123.6 157.0 34.71 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.851 -1.382 . . . . 50.0 110.892 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.42 ' HG ' ' HG3' ' A' ' 83' ' ' MET . 0.2 OUTLIER -96.82 124.91 40.93 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.299 -0.876 . . . . 50.0 109.86 179.627 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.486 ' HB ' ' CB ' ' A' ' 82' ' ' GLU . 17.9 t -50.76 -21.45 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.177 -0.952 . . . . 50.0 110.248 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.46 ' O ' ' O ' ' A' ' 66' ' ' VAL . 5.8 t -136.33 170.68 15.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 50.0 110.153 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 65' ' ' THR . 27.7 m -52.23 -172.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.237 -0.915 . . . . 50.0 110.157 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.552 ' O ' ' CE2' ' A' ' 69' ' ' PHE . 6.7 p30 -46.88 131.04 8.74 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.142 -0.973 . . . . 50.0 110.003 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.52 ' O ' HG12 ' A' ' 46' ' ' ILE . 46.8 Cg_endo -72.58 123.24 8.91 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.941 1.495 . . . . 50.0 110.559 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 67' ' ' ASN . 0.2 OUTLIER -135.14 157.07 47.86 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.286 -0.884 . . . . 50.0 110.069 -179.942 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 1.092 ' CG2' HD11 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -116.29 60.43 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.179 -0.951 . . . . 50.0 109.6 179.292 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 43' ' ' PRO . . . -73.55 58.91 0.6 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 50.0 110.347 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.0 m -142.59 155.2 44.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.32 -0.863 . . . . 50.0 110.233 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.61 -4.9 53.65 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.334 -0.854 . . . . 50.0 109.857 179.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.5 p -115.45 17.31 16.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.319 -0.863 . . . . 99.99 110.255 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.83 ' HB1' ' CG1' ' A' ' 70' ' ' VAL . . . -79.91 8.61 6.58 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.182 -0.949 . . . . 99.99 109.966 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -87.63 19.55 3.35 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.226 -0.921 . . . . 99.99 109.243 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.549 ' O ' ' HA ' ' A' ' 36' ' ' SER . 96.5 p -128.96 -172.56 2.75 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.536 -0.728 . . . . 99.99 109.346 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.428 ' HD2' ' OE2' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -63.35 88.82 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.263 -0.898 . . . . 99.99 109.291 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.961 HG22 ' O ' ' A' ' 35' ' ' LEU . 35.3 m -76.16 176.28 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 O-C-N 121.352 -0.843 . . . . 99.99 109.21 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.758 HD21 HG12 ' A' ' 32' ' ' VAL . 2.8 tt -134.02 132.93 40.66 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.884 -1.135 . . . . 50.0 111.239 -179.487 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 1.4 t -122.64 178.08 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.435 -0.791 . . . . 50.0 109.681 179.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.486 ' CB ' ' HB ' ' A' ' 64' ' ' VAL . 22.8 mt-10 -132.85 142.65 49.05 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.021 -1.049 . . . . 50.0 110.479 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.481 ' C ' ' HD3' ' A' ' 85' ' ' PRO . 0.0 OUTLIER -147.78 142.22 26.39 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.281 -0.887 . . . . 50.0 110.234 179.995 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.484 ' HB3' ' O ' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -114.69 66.38 1.75 Allowed Pre-proline 0 C--N 1.306 -1.296 0 O-C-N 121.151 -0.968 . . . . 50.0 110.563 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.481 ' HD3' ' C ' ' A' ' 83' ' ' MET . 47.6 Cg_endo -73.21 164.94 33.99 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.969 1.51 . . . . 50.0 110.28 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.51 140.83 33.74 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.92 1.484 . . . . 50.0 110.354 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -52.54 137.08 31.1 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.231 -0.918 . . . . 50.0 110.194 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 120.76 167.37 13.32 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.384 -1.486 . . . . 50.0 109.384 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ASP . . . . . 0.514 ' HB2' ' HB2' ' A' ' 53' ' ' SER . 23.1 m-20 -53.25 146.5 11.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.3 -1.118 . . . . 50.0 110.051 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.581 ' HA ' ' N ' ' A' ' 53' ' ' SER . 0.3 OUTLIER -141.43 141.37 33.71 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.21 -0.931 . . . . 50.0 110.604 -179.777 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 104' ' ' HIS . 1.0 OUTLIER -97.49 112.02 24.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 50.0 109.672 179.462 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.42 ' O ' HG23 ' A' ' 92' ' ' ILE . 5.0 tt -103.44 136.91 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.101 -0.999 . . . . 50.0 110.406 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.564 ' HB ' ' CG2' ' A' ' 49' ' ' VAL . 27.1 t -125.15 113.12 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.088 -1.007 . . . . 50.0 110.316 179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.816 HG11 ' CB ' ' A' ' 17' ' ' PHE . 42.1 t -105.13 100.54 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.259 -0.901 . . . . 50.0 110.065 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 47' ' ' PRO . . . -150.82 164.8 30.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.71 -1.356 . . . . 50.0 109.71 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' MET . . . . . 0.508 ' HA ' ' CG ' ' A' ' 47' ' ' PRO . 18.9 ttm -103.44 -29.71 11.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.32 -1.106 . . . . 50.0 110.319 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . 179.71 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.661 -1.376 . . . . 50.0 109.661 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.07 -67.9 0.4 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.27 -1.135 . . . . 50.0 110.422 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 12.1 tptt -79.47 109.38 13.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.208 -0.933 . . . . 50.0 110.109 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.652 ' O ' ' NE2' ' A' ' 100' ' ' GLN . 0.0 OUTLIER -134.82 149.73 50.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 110.111 -179.739 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.738 HD12 ' CZ ' ' A' ' 19' ' ' PHE . 5.6 pt -118.92 154.7 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.169 -0.957 . . . . 0.0 109.905 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.459 ' OD1' ' O ' ' A' ' 102' ' ' ASN . 14.4 p30 -143.1 136.35 28.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.164 -0.96 . . . . 0.0 110.429 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.491 ' HB3' ' CZ3' ' A' ' 105' ' ' TRP . 0.1 OUTLIER -120.78 168.25 11.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.24 -0.912 . . . . 0.0 110.28 179.887 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.588 ' HB3' ' CE1' ' A' ' 91' ' ' TYR . 8.8 p-80 -131.08 106.08 8.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.363 -0.836 . . . . 0.0 109.981 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' TRP . . . . . 0.491 ' CZ3' ' HB3' ' A' ' 103' ' ' HIS . 0.8 OUTLIER -87.69 112.84 22.79 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 110.629 -179.611 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' HIS . . . . . 0.593 ' CG ' ' O ' ' A' ' 106' ' ' HIS . 21.0 p80 -159.49 102.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.338 -0.851 . . . . 0.0 110.075 179.767 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -103.73 -10.89 17.97 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.204 -0.935 . . . . 0.0 110.381 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -79.63 123.97 28.12 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.28 -0.887 . . . . 0.0 110.259 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -146.69 70.46 0.35 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 13.6 m -148.3 98.17 2.87 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.268 -1.137 . . . . 0.0 110.154 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 35.2 p . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 118.048 -0.977 . . . . 49.57 110.174 -179.908 . . . . . . . . 0 0 . 1 stop_ save_